{"title": "Publikationen", "author": null, "url": null, "hostname": null, "description": "Publikationen - I. Medizinische Klinik und Poliklinik", "sitename": "UKE - I. Medizinische Klinik und Poliklinik - Publikationen", "date": "2021-05-22", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "- 2023\n- 2022\n- 2021\n- 2020\n- 2019\n- 2018\n- 2017\n- 2016\n- 2015\n- 2014\n- 2013\n- 2012\n- 2011\n- 2010\n- 2009\n- 2008\n- 2007\n- 2006\n- 2005\n- 2004\n- 2003\n- 2002\n- 2001\n- 2000\n- 1999\n- 1998\n- 1997\n- 1996\n- 1995\n- 1994\n- 1993\nAdequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal ALP level associated with complication-free survival gain?\nHEPATOLOGY. 2023 [Epub ahead of print].\nEVALUATION OF TOFACITINIB IN PRIMARY SCLEROSING CHOLANGITIS AND ASSOCIATED COLITIS: A MULTICENTER, RETROSPECTIVE STUDY\nCLIN GASTROENTEROL H. 2023 [Epub ahead of print].\nHLA-DPA1*02:01~B1*01:01 is a risk haplotype for primary sclerosing cholangitis mediating activation of NKp44+ NK cells\nGUT. 2023 [Epub ahead of print].\nQuantification of the hepatitis B virus cccDNA: evidence-based guidelines for monitoring the key obstacle of HBV cure\nAllweiss L, Testoni B, Yu M, Lucifora J, Ko C, Qu B, L\u00fctgehetmann M, Guo H, Urban S, Fletcher S, Protzer U, Levrero M, Zoulim F, Dandri-Petersen M\nGUT. 2023;72(5):972-983.\nCancer associated fibroblasts induce proliferation and therapeutic resistance to everolimus in neuroendocrine tumors through STAT3 activation\nAmin T, Viol F, Krause J, Fahl M, Eggers C, Awwad F, Schmidt B, Benten D, Ungefroren H, Fraune C, Clauditz T, Sauter G, Izbicki J, Lohse A, Huber S, Schrader J\nNEUROENDOCRINOLOGY. 2023;113(5):501-518.\nNomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report\nAndrade R, Aithal G, de Boer Y, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner D, De Martin E, Kullak-Ublick G, Stirnimann G, Devarbhavi H, Vierling J, Manns M, Sebode M, Londo\u00f1o M, Avigan M, Robles-Diaz M, Garc\u00eda-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi P, Hayashi P, Taubert R, Fontana R, Weber S, Oo Y, Zen Y, Licata A, Lucena M, Mieli-Vergani G, Vergani D, Bj\u00f6rnsson E\nJ HEPATOL. 2023;79(3):853-866.\nAlveolar echinococcosis in immunocompromised hosts\nAutier B, Gottstein B, Millon L, Ramharter M, Gruener B, Bresson-Hadni S, Dion S, Robert-Gangneux F\nCLIN MICROBIOL INFEC. 2023;29(5):593-599.\nProtective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC\nAwoniyi M, Wang J, Ngo B, Meadows V, Tam J, Viswanathan A, Lai Y, Montgomery S, Farmer M, Kummen M, Thingholm L, Schramm C, Bang C, Franke A, Lu K, Zhou H, Bajaj J, Hylemon P, Ting J, Popov Y, Hov J, Francis H, Sartor R\nGUT. 2023;72(4):671-685.\nShort-course versus long-course antibiotic treatment for uncomplicated vancomycin-resistant enterococcal bacteraemia: a retrospective multicentre cohort study\nBahrs C, Rieg S, Hennigs A, Hitzenbichler F, Brehm T, Rose N, Jacobi R, Heine V, Hornuss D, Huppertz G, Hagel S, Hanses F\nCLIN MICROBIOL INFEC. 2023;29(2):200-207.\nHLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis\nBaumdick M, Niehrs A, Degenhardt F, Schwerk M, Hinrichs O, Jordan-Paiz A, Padoan B, Wegner L, Schloer S, Zecher B, Malsy J, Joshi V, Illig C, Schr\u00f6der-Schwarz J, M\u00f6ller K, Martin M, Yuki Y, Ozawa M, Sauter J, Schmidt A, Perez D, Giannou A, Carrington M, Davis R, Schumacher U, Sauter G, Huber S, Puelles V, Melling N, Franke A, Altfeld M, Bunders M\nGASTROENTEROLOGY. 2023;165(4):946-962.e13.\nSex differences in the percentage of IRF5 positive B cells are associated with higher production of TNF-\u03b1 in women in response to TLR9 in humans\nBeisel C, Jordan-Paiz A, K\u00f6llmann S, Ahrenstorf A, Padoan B, Barkhausen T, Addo M, Altfeld M\nBIOL SEX DIFFER. 2023;14(1):11.\nImpact on follow-up strategies in patients with primary sclerosing cholangitis\nBergquist A, Weism\u00fcller T, Levy C, Rupp C, Joshi D, Nayagam J, Montano-Loza A, Lytvyak E, Wunsch E, Milkiewicz P, Zenouzi R, Schramm C, Cazzagon N, Floreani A, Liby I, Wiestler M, Wedemeyer H, Zhou T, Strassburg C, Rigopoulou E, Dalekos G, Narasimman M, Verhelst X, Degroote H, Vesterhus M, Kremer A, B\u00fcndgens B, Rorsman F, Nilsson E, J\u00f8rgensen K, von Seth E, Cornillet Jeannin M, Nyhlin N, Martin H, Kechagias S, Wiencke K, Werner M, Beretta-Piccoli B, Marzioni M, Isoniemi H, Arola J, Wefer A, S\u00f6derling J, F\u00e4rkkil\u00e4 M, Lenzen H\nLIVER INT. 2023;43(1):127-138.\nKidney-resident innate-like memory \u03b3\u03b4 T cells control chronic Staphylococcus aureus infection of mice\nBertram T, Reimers D, Lory N, Schmidt C, Schmid J, C Heinig L, Bradtke P, Rattay G, Zielinski S, Hellmig M, Bartsch P, Rohde H, Nu\u00f1ez S, Rosemblatt M, Bono M, Gagliani N, Sandrock I, Panzer U, Krebs C, Meyer-Schwesinger C, Prinz I, Mittr\u00fccker H\nP NATL ACAD SCI USA. 2023;120(1):e2210490120.\nComparison of the Diagnostic Accuracy of Three Real-Time PCR Assays for the Detection of Arcobacter butzleri in Human Stool Samples Targeting Different Genes in a Test Comparison without a Reference Standard\nBinder R, Hahn A, Eberhardt K, Hagen R, Rohde H, Loderst\u00e4dt U, Feldt T, Sarfo F, Di Cristanziano V, Kahlfuss S, Frickmann H, Zautner A\nMICROORGANISMS. 2023;11(5):.\nOrthopox simiae muscle abscess\nBrehm T, Hermanussen L, Schmiedel S\nINFECTION. 2023;51(3):799-800.\nFXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2\nBrevini T, Maes M, Webb G, John B, Fuchs C, Buescher G, Wang L, Griffiths C, Brown M, Scott W, Pereyra-Gerber P, Gelson W, Brown S, Dillon S, Muraro D, Sharp J, Neary M, Box H, Tatham L, Stewart J, Curley P, Pertinez H, Forrest S, Mlcochova P, Varankar S, Darvish-Damavandi M, Mulcahy V, Kuc R, Williams T, Heslop J, Rossetti D, Tysoe O, Galanakis V, Vila-Gonzalez M, Crozier T, Bargehr J, Sinha S, Upponi S, Fear C, Swift L, Saeb-Parsy K, Davies S, Wester A, Hagstr\u00f6m H, Melum E, Clements D, Humphreys P, Herriott J, Kijak E, Cox H, Bramwell C, Valentijn A, Illingworth C, , Dahman B, Bastaich D, Ferreira R, Marjot T, Barnes E, Moon A, Barritt A, Gupta R, Baker S, Davenport A, Corbett G, Gorgoulis V, Buczacki S, Lee J, Matheson N, Trauner M, Fisher A, Gibbs P, Butler A, Watson C, Mells G, Dougan G, Owen A, Lohse A, Vallier L, Sampaziotis F\nNATURE. 2023;615(7950):134-142.\nGenetic variation in TERT modifies the risk of hepatocellular carcinoma in alcohol-related cirrhosis: results from a genome-wide case-control study\nBuch S, Innes H, Lutz P, Nischalke H, Marquardt J, Fischer J, Weiss K, Rosendahl J, Marot A, Krawczyk M, Casper M, Lammert F, Eyer F, Vogel A, Marhenke S, von Felden J, Sharma R, Atkinson S, McQuillin A, Nattermann J, Schafmayer C, Franke A, Strassburg C, Rietschel M, Altmann H, Sulk S, Thangapandi V, Brosch M, Lackner C, Stauber R, Canbay A, Link A, Reiberger T, Mandorfer M, Semmler G, Scheiner B, Datz C, Romeo S, Ginanni Corradini S, Irving W, Morling J, Guha I, Barnes E, Ansari M, Quistrebert J, Valenti L, M\u00fcller S, Morgan M, Dufour J, Trebicka J, Berg T, Deltenre P, Mueller S, Hampe J, Stickel F\nGUT. 2023;72(2):381-391.\nHistological and serological features of acute liver injury after SARS-CoV-2 vaccination\nCodoni G, Kirchner T, Engel B, Villamil A, Efe C, St\u00e4ttermayer A, Weltzsch J, Sebode M, Bernsmeier C, Lleo A, Gevers T, Kup\u010dinskas L, Castiella A, Pinazo J, De Martin E, Bobis I, Sandahl T, Pedica F, Invernizzi F, Del Poggio P, Bruns T, Kolev M, Semmo N, Bessone F, Giguet B, Poggi G, Ueno M, Jang H, Elpek G, Soylu N, Cerny A, Wedemeyer H, Vergani D, Mieli-Vergani G, Lucena M, Andrade R, Zen Y, Taubert R, Terziroli Beretta-Piccoli B\nJHEP REP. 2023;5(1):100605.\nFrequency of IRF5+ dendritic cells is associated with the TLR7-induced inflammatory cytokine response in SARS-CoV-2 infection\nCords L, Woost R, Kummer S, Brehm T, Kluge S, Schmiedel S, Jordan S, Lohse A, Altfeld M, Addo M, Schulze Zur Wiesch J, Beisel C\nCYTOKINE. 2023;162:.\nAnti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial\nDenkinger C, Janssen M, Sch\u00e4kel U, Gall J, Leo A, Stelmach P, Weber S, Krisam J, Baumann L, Stermann J, Merle U, Weigand M, Nusshag C, Bullinger L, Schrezenmeier J, Bornh\u00e4user M, Alakel N, Witzke O, Wolf T, Vehreschild M, Schmiedel S, Addo M, Herth F, Kreuter M, Tepasse P, Hertenstein B, H\u00e4nel M, Morgner A, Kiehl M, Hopfer O, Wattad M, Schimanski C, Celik C, Pohle T, Ruhe M, Kern W, Schmitt A, Lorenz H, Souto-Carneiro M, Gaeddert M, Halama N, Meuer S, Kr\u00e4usslich H, M\u00fcller B, Schnitzler P, Parth\u00e9 S, Bartenschlager R, Gronkowski M, Klemmer J, Schmitt M, Dreger P, Kriegsmann K, Schlenk R, M\u00fcller-Tidow C\nNAT CANCER. 2023;4(1):96-107.\nFocussed Assessment with Sonography in acute Lassa Fever (FASLa): development of a point-of-care protocol and description of common ultrasound findings\nErameh C, Koch T, Edeawe O, Oestereich L, Omansen T, Jochum J, Adomeh D, Ikponwonsa O, Aire C, Pahlmann M, Asogun D, Ogbaini-Emovon E, Okogbenin S, G\u00fcnther S, Ramharter M, Akideno P, Kreuels B\nJ INFECTION. 2023;87(1):27-33.\nHigh burden of RSV and influenza in patients presenting with suspected pneumonia in the emergency room of a German tertiary hospital in fall of 2022\nEttemeyer M, Florey M, Tanida K, Jochum J, Schulze-Sturm U, L\u00fctgehetmann M, Baehr M, Addo M, Schmiedel S, Rohde H, Koch T\nINFECTION. 2023;51(5):1569-1575.\nScreening for Resistant Bacteria, Antimicrobial Resistance Genes, Sexually Transmitted Infections and Schistosoma spp. in Tissue Samples from Predominantly Vaginally Delivered Placentae in Ivory Coast and Ghana\nFranz R, Hahn A, Hagen R, Rohde H, Eberhardt K, Ehrhardt S, Baum J, Claussen L, Feldt T, Hinz R, Barthel D, Bindt C, Tagbor H, Nguah S, Koffi M, K\u00f6ller T, Warnke P, Pankok F, Taudien S, Frickmann H, Schoppen S\nPATHOGENS. 2023;12(8):.\nTissue resident iNKT17 cells facilitate cancer cell extravasation in liver metastasis via interleukin-22\nGiannou A, Kempski J, Shiri A, L\u00fccke J, Zhang T, Zhao L, Zazara D, Cortesi F, Riecken K, Amezcua Vesely M, Low J, Xu H, Kaffe E, Garcia-Perez L, Agalioti T, Yamada Y, Jungraithmayr W, Zigmond E, Karstens K, Steglich B, Wagner J, Konczalla L, Carambia A, Schulze K, von Felden J, May P, Briukhovetska D, Bedke T, Brockmann L, Starzonek S, Lange T, Koch C, Riethdorf S, Pelczar P, B\u00f6ttcher M, Sabihi M, Huber F, Reeh M, Grass J, Wahib R, Seese H, St\u00fcben B, Fard-Aghaie M, Dupr\u00e9e A, Scognamiglio P, Plitzko G, Meiners J, Soukou S, Wittek A, Manthey C, Maroulis I, Arck P, Perez D, Gao B, Zarogiannis S, Strowig T, Pasqualini R, Arap W, Gos\u00e1lvez J, Kobold S, Prinz I, Guse A, Tachezy M, Ghadban T, Heumann A, Li J, Melling N, Mann O, Izbicki J, Pantel K, Schumacher U, Lohse A, Flavell R, Gagliani N, Huber S\nIMMUNITY. 2023;56(1):125-142.e12.\nIL-22BP controls the progression of liver metastasis in colorectal cancer\nGiannou A, Kempski J, Zhang T, L\u00fccke J, Shiri A, Zazara D, Belios I, Machicote A, Seeger P, Agalioti T, Tintelnot J, Sagebiel A, Tomczak M, Bauditz L, Bedke T, Kocheise L, Mercanoglu B, Fard-Aghaie M, Giorgakis E, Lykoudis P, Pikouli A, Grass J, Wahib R, Bardenhagen J, Brunswig B, Heumann A, Ghadban T, Dupr\u00e9e A, Tachezy M, Melling N, Arck P, Stringa P, Gentilini M, Gondolesi G, Nakano R, Thomson A, Perez D, Li J, Mann O, Izbicki J, Gagliani N, Maroulis I, Huber S\nFRONT ONCOL. 2023;13:1170502.\nStrain-specific responsiveness of hepatitis D virus to interferon-alpha treatment\nGiersch K, Perez-Gonzalez P, Hendricks L, Goldmann N, Kolbe J, Hermanussen L, Bockmann J, Volz T, Volmari A, Allweiss L, Petersen J, Glebe D, L\u00fctgehetmann M, Dandri M\nJHEP REP. 2023;5(4):100673.\nEmergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients\nG\u00f6mer A, Kl\u00f6hn M, Jagst M, Nocke M, Pischke S, Horvatits T, Schulze Zur Wiesch J, M\u00fcller T, Hardtke S, Cornberg M, Wedemeyer H, Behrendt P, Steinmann E, Todt D\nHEPATOLOGY. 2023 [Epub ahead of print].\nECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease\nGordon H, Burisch J, Ellul P, Karmiris K, Katsanos K, Allocca M, Bamias G, Barreiro-de Acosta M, Braithwaite T, Greuter T, Harwood C, Juillerat P, Lobaton T, M\u00fcller-Ladner U, Noor N, Pellino G, Savarino E, Schramm C, Soriano A, Stein J, Uzzan M, van Rheenen P, Vavricka S, Vecchi M, Zuily S, Kucharzik T\nJ CROHNS COLITIS. 2023 [Epub ahead of print].\nTransition for adolescents with a rare disease: results of a nationwide German project\nGrasemann C, H\u00f6ppner J, Burgard P, Sch\u00fcndeln M, Matar N, M\u00fcller G, Krude H, Berner R, Lee-Kirsch M, Hauck F, Wainwright K, Baumgarten S, Atinga J, Bauer J, Manka E, K\u00f6rholz J, Kiewert C, Heinen A, Kretschmer T, Kurth T, Mittnacht J, Schramm C, Klein C, Graessner H, Hiort O, Muntau A, Gr\u00fcters A, Hoffmann G, Choukair D\nORPHANET J RARE DIS. 2023;18(1):93.\nPharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria\nGroger M, Akhideno P, Kleist C, Babatunde F, Edeawe O, Hinzmann J, Akhigbe T, Nwatuzor J, Eifediyi G, M\u00fcller J, Hinrichs M, Pahlmann M, Sarpong F, Wagner C, Thielebein A, Aihonwalan L, Koch T, Riedner M, Ogbaini-Emovon E, Okogbenin S, G\u00fcnther S, Wicha S, Ramharter M, Oestereich L, Duraffour S, Erameh C\nCLIN INFECT DIS. 2023;76(3):e841-e848.\nAnalysis of the humoral and cellular response after the third COVID-19 vaccination in patients with autoimmune hepatitis\nHartl J, R\u00fcther D, Duengelhoef P, Brehm T, Steinmann S, Weltzsch J, Glaser F, Sterneck M, Sebode M, Weiler-Normann C, L\u00fctgehetmann M, Schaub G, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A\nLIVER INT. 2023;43(2):393-400.\nLetter to the Editor: Living donor liver transplantation for people with PSC\nHeinemann M, Adam R, Karam V, Schramm C\nHEPATOLOGY. 2023;77(5):E95-E96.\nImpact of antibiotic intake on the incidence of extended-spectrum \u03b2-lactamase-producing Enterobacterales in sub-Saharan Africa\nHeinemann M, Kleinjohann L, Rolling T, Winter D, Hackbarth N, Ramharter M, Addo M, Eibach D, Phillips R, Owusu-Ofori A, Vinnemeier C\nCLIN MICROBIOL INFEC. 2023;29(3):340-345.\nSeroprevalence of arthropod-borne bacterial infections in homeless individuals in Hamburg in 2020\nHeinrich F, Rauch J, Bertram F, Kempf V, Besier S, Kuta P, Renn\u00e9 T, Ondruschka B, P\u00fcschel K, Tappe D\nINFECTION. 2023 [Epub ahead of print].\nDisseminated tuberculosis during TNF-\u03b1 inhibitor therapy diagnosed by positron emission tomography and mini-laparoscopy\nHermanussen L, Brehm T, Schmiedel S\nINFECTION. 2023;51(4):1181-1182.\nTecovirimat therapy for severe monkeypox infection: Longitudinal assessment of viral titers and clinical response pattern-A first case-series experience\nHermanussen L, Grewe I, Tang H, N\u00f6rz D, Bal L, Pfefferle S, Unger S, Hoffmann C, Berzow D, Kohsar M, Aepfelbacher M, Lohse A, Addo M, L\u00fctgehetmann M, Schulze zur Wiesch J, Schmiedel S\nJ MED VIROL. 2023;95(1):e28181.\nNon-organ-specific autoantibodies with unspecific patterns are a frequent para-infectious feature of chronic hepatitis D\nHermanussen L, Lampalzer S, Bockmann J, Ziegler A, Piecha F, Dandri M, Pischke S, Haag F, Lohse A, L\u00fctgehetmann M, Weiler-Normann C, Zur Wiesch J\nFRONT MED-LAUSANNE. 2023;10:1169096.\nClinical Outcomes of SARS-CoV-2 Breakthrough Infections in Liver Transplant Recipients during the Omicron Wave\nHerting A, Jahnke-Triankowski J, Harberts A, Schaub G, L\u00fctgehetmann M, Ruether D, Fischer L, Addo M, Lohse A, Schulze Zur Wiesch J, Sterneck M\nVIRUSES-BASEL. 2023;15(2):.\nMELD-Lactate Predicts Poor Outcome in Variceal Bleeding in Cirrhosis\nHorvatits T, Mahmud N, Serper M, Seiz O, Reher D, Drolz A, Sarnast N, Gu W, Erasmus H, Allo G, Ferstl P, Wittmann S, Piecha F, Groth S, Zeuzem S, Schramm C, Huber S, R\u00f6sch T, Lohse A, Trebicka J, Ogola G, Asrani S, Kluwe J\nDIGEST DIS SCI. 2023;68(3):1042-1050.\nDiscovery and systematic assessment of early biomarkers that predict progression to severe COVID-19 disease\nHufnagel K, Fathi A, Stroh N, Klein M, Skwirblies F, Girgis R, Dahlke C, Hoheisel J, Lowy C, Schmidt R, Griesbeck A, Merle U, Addo M, Schr\u00f6der C\nCommunications medicine. 2023;3(1):51.\nCXCR5+PD-1++ CD4+ T cells colonize infant intestines early in life and promote B cell maturation\nJordan-Paiz A, Martrus G, Steinert F, Kaufmann M, Sagebiel A, Schreurs R, Rechtien A, Baumdick M, Jung J, M\u00f6ller K, Wegner L, Gr\u00fcttner C, Richert L, Th\u00fcnauer R, Schroeder-Schwarz J, van Goudoever J, Geijtenbeek T, Altfeld M, Pals S, Perez D, Klarenbeek P, Tomuschat C, Sauter G, K\u00f6nigs I, Schumacher U, Friese M, Melling N, Reinshagen K, Bunders M\nCELL MOL IMMUNOL. 2023;20(2):201-213.\nPathogens associated with hospitalization due to acute lower respiratory tract infections in children in rural Ghana: a case-control study\nKrumkamp R, Kohsar M, Nolte K, Hogan B, Eibach D, Jaeger A, Akenten C, Drosten C, Boahen K, Sarpong N, Eckerle I, Binger T, Owusu-Dabo E, May J, Kreuels B\nSCI REP-UK. 2023;13(1):.\nCenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial\nKurth F, Helbig E, Lippert L, Thibeault C, Barbone G, Eckart M, Kluge M, Puengel T, Demir M, R\u00f6hle R, Keller T, Ruwwe-Gl\u00f6senkamp C, Witzenrath M, Suttorp N, von Kalle C, Sander L, Jochum C, Tacke F\nJ GLOB ANTIMICROB RE. 2023;32:44-47.\nExpansion-enhanced super-resolution radial fluctuations enable nanoscale molecular profiling of pathology specimens\nKylies D, Zimmermann M, Haas F, Schwerk M, Kuehl M, Brehler M, Czogalla J, Hernandez L, Konczalla L, Okabayashi Y, Menzel J, Edenhofer I, Mezher S, Aypek H, Dumoulin B, Wu H, Hofmann S, Kretz O, Wanner N, Tomas N, Krasemann S, Glatzel M, Kuppe C, Kramann R, Banjanin B, Schneider R, Urbschat C, Arck P, Gagliani N, van Zandvoort M, Wiech T, Grahammer F, S\u00e1ez P, Wong M, Bonn S, Huber T, Puelles V\nNAT NANOTECHNOL. 2023;18(4):336-342.\nLiquid biopsy-based protein biomarkers for risk prediction, early diagnosis and prognostication of cholangiocarcinoma\nLapitz A, Azkargorta M, Milkiewicz P, Olaizola P, Zhuravleva E, Grimsrud M, Schramm C, Arbelaiz A, O'Rourke C, La Casta A, Milkiewicz M, Pastor T, Vesterhus M, Jimenez-Ag\u00fcero R, Dill M, Lamarca A, Valle J, Macias R, Izquierdo-Sanchez L, Casta\u00f1o Y, Caballero-Camino F, Ria\u00f1o I, Krawczyk M, Ibarra C, Bustamante J, Nova-Camacho L, Falcon-Perez J, Elortza F, Perugorria M, Andersen J, Bujanda L, Karlsen T, Folseraas T, Rodrigues P, Banales J\nJ HEPATOL. 2023;79(1):93-108.\nScreening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study\nLemoine M, Assoumou L, Girard P, Valantin M, Katlama C, De Wit S, Campa P, Rougier H, Meynard J, Necsoi C, Huefner A, Van Luzen J, Schulze Zur Wiesch J, Bastard J, Fellahi S, Mauss S, Stankov M, Baumgarten A, Post G, Serfaty L, Ratziu V, Menu Y, Schlue J, Bedossa P, Capeau J, Costagliola D, Behrens G, Ingiliz P\nCLIN GASTROENTEROL H. 2023;21(3):713-722.e3.\nEtiology and Outcome of Adult and Pediatric Acute Liver Failure in Europe\nLenz D, J\u00f8rgensen M, Kelly D, Cardinale V, Geerts A, Gon\u00e7alves Costa I, Fichtner A, Garbade S, Hegen B, Hilberath J, de Kleine R, Kup\u010dinskas L, McLin V, Niesert M, Prado Gonzalez V, Sturm E, Staufner C, Tjwa E, Willemse J, Zecher B, Larsen F, Sebode M, Ytting H\nJ PEDIATR GASTR NUTR. 2023;77(1):115-120.\nPathogen detection in RNA-seq data with Pathonoia\nLiebhoff A, Menden K, Laschtowitz A, Franke A, Schramm C, Bonn S\nBMC BIOINFORMATICS. 2023;24(1):.\nTREM2 Regulates the Removal of Apoptotic Cells and Inflammatory Processes during the Progression of NAFLD\nLiebold I, Meyer S, Heine M, Kuhl A, Witt J, Eissing L, Fischer A, Koop A, Kluwe J, Wiesch J, Wehmeyer M, Knippschild U, Scheja L, Heeren J, Bosurgi L, Worthmann A\nCELLS-BASEL. 2023;12(3):.\nA prospective pilot study of a gluten-free diet for primary sclerosing cholangitis and associated colitis\nLiwinski T, H\u00fcbener S, Henze L, H\u00fcbener P, Heinemann M, Tetzlaff M, Hiller M, Jagemann B, Surabattula R, Leeming D, Karsdal M, Monguzzi E, Schachschal G, R\u00f6sch T, Bang C, Franke A, Lohse A, Schuppan D, Schramm C\nALIMENT PHARM THER. 2023;57(2):224-236.\nUnderstanding illness experiences of patients with primary sclerosing cholangitis: a qualitative analysis within the SOMA.LIV study\nL\u00f6sken C, Maehder K, Buck L, Hartl J, L\u00f6we B, Schramm C, Toussaint A\nBMC GASTROENTEROL. 2023;23(1):.\nTNF\u03b1 aggravates detrimental effects of SARS-CoV-2 infection in the liver\nL\u00fccke J, Nawrocki M, Schnell J, Meins N, Heinrich F, Zhang T, Bertram F, Sabihi M, B\u00f6ttcher M, Blankenburg T, Pfaff M, Notz S, Kempski J, Reeh M, Wolter S, Mann O, Izbicki J, L\u00fctgehetmann M, Dupr\u00e9e A, Giannou A, Ondruschka B, Huber S\nFRONT IMMUNOL. 2023;14:1151937.\nOutcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry\nMarchetti M, Salmanton-Garc\u00eda J, El-Ashwah S, Verga L, Itri F, R\u00e1\u010dil Z, D\u00e1vila-Valls J, Mart\u00edn-P\u00e9rez S, Van Doesum J, Passamonti F, Abu-Zeinah G, Farina F, L\u00f3pez-Garc\u00eda A, Dragonetti G, Cattaneo C, Gomes Da Silva M, Bilgin Y, \u017d\u00e1k P, Petzer V, Glenth\u00f8j A, Espigado I, Buquicchio C, Bonuomo V, Prezioso L, Meers S, Duarte R, Bergantim R, Jaksic O, \u010colovi\u0107 N, Blennow O, Cernan M, Sch\u00f6nlein M, Samarkos M, Mitra M, Magliano G, Maertens J, Ledoux M, Jim\u00e9nez M, Demirkan F, Collins G, Cabirta A, Gr\u00e4fe S, Nordlander A, Wolf D, Arellano E, Cordoba R, Hanakova M, Zambrotta G, Nunes Rodrigues R, Limberti G, Marchesi F, Cornely O, Pagano L\nTHER ADV HEMATOL. 2023;14:.\nHistory of cerebrovascular disease but not dementia increases the risk for secondary vascular events during SARS-CoV-2 infection with presumed Omicron variant: a retrospective observational study\nMayer C, Woo M, Brehm T, Heyer A, Fischer M, Fischbach F, Bal L, Addo M, Kluge S, Thomalla G, Schweingruber N, Wiesch J\nEUR J NEUROL. 2023;30(8):2297-2304.\nExpanded ILC2s in human infant intestines promote tissue growth\nM\u00f6ller K, Wegner L, Malsy J, Baumdick M, Borggrewe M, Jordan-Paiz A, Jung J, Martrus G, Kretschmer P, Sagebiel A, Schreurs R, Hagen S, Burmester G, Clauditz T, Pals S, Boettcher M, Melling N, Sauter G, Tomuschat C, K\u00f6nigs I, Schumacher U, Altfeld M, Bernink J, Perez D, Reinshagen K, Bunders M\nMUCOSAL IMMUNOL. 2023;16(4):408-421.\nHirnabszess als Komplikation bei pulmonaler Manifestation einer HHT\nM\u00fcller M, Weiler-Normann C, Meyer M, Schramm C, Buescher G\nINNERE MED. 2023 [Epub ahead of print].\nPsychological distress of adult patients consulting a center for rare and undiagnosed diseases: a cross-sectional study\nMund M, Uhlenbusch N, Rillig F, Weiler-Normann C, Herget T, Kubisch C, L\u00f6we B, Schramm C\nORPHANET J RARE DIS. 2023;18(1):82.\nDiagnosis and management of autoimmune hepatitis\nMuratori L, Lohse A, Lenzi M\nBMJ-BRIT MED J. 2023;380:.\n\u03b2-Propiolactone (BPL)-inactivation of SARS-Co-V-2: In vitro validation with focus on saliva from COVID-19 patients for scent dog training\nPilchov\u00e1 V, Prajeeth C, Jendrny P, Twele F, Meller S, Pink I, Fathi A, Addo M, Volk H, Osterhaus A, von K\u00f6ckritz-Blickwede M, Schulz C\nJ VIROL METHODS. 2023;317:.\nHigh prevalence of periodontal disease in patients with NASH- possible association of poor dental health with NASH severity\nPischke S, Shiprov A, Peters U, Schulze Zur Wiesch J, Kluwe J, Westphal T, Fischer F, Mader M, Fr\u00fcndt T, Horvatits K, Horvatits T, Aarabi G, Beikler T\nANN HEPATOL. 2023;28(2):.\nDiagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study\nPoetter-Lang S, Messner A, Bastati N, Ringe K, Ronot M, Venkatesh S, Ambros R, Kristic A, Korajac A, Dovjak G, Zalaudek M, Hodge J, Schramm C, Halilbasic E, Trauner M, Ba-Ssalamah A\nEUR RADIOL. 2023 [Epub ahead of print].\nMonkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome\u2013Coronavirus Spike Protein\nRaadsen M, Dahlke C, Fathi A, Lamers M, van den Doel P, Zaeck L, van Royen M, de Bruin E, Sikkema R, Koopmans M, van Gorp E, Sutter G, de Vries R, Addo M, Haagmans B\nJ INFECT DIS. 2023;228(5):586-590.\nDeePSC: A Deep Learning Model for Automated Diagnosis of Primary Sclerosing Cholangitis at Two-dimensional MR Cholangiopancreatography\nRagab H, Westhaeusser F, Ernst A, Yamamura J, Fuhlert P, Zimmermann M, Sauerbeck J, Shenas F, \u00d6zden C, Weidmann A, Adam G, Bonn S, Schramm C\nRADIOL-ARTIF INTELL. 2023;5(3):e220160.\nSymptoms of illness during travel and risk factors for non-adherence to malaria prophylaxis-a cross-sectional study in travellers from Germany\nReinsberg F, Moehlmann M, Krumkamp R, Landsmann L, Heitkamp C, Jochum J, Addo M, Ramharter M, Radt C, Rothe C, Vinnemeier C, Kreuels B\nJ TRAVEL MED. 2023;30(3):taad055.\nValidation of 4D flow cardiovascular magnetic resonance in TIPS stent grafts using a 3D-printed flow phantom\nRiedel C, Ristow I, Lenz A, Schoennagel B, Hoffmann M, Piecha F, Adam G, Reeder S, Bannas P\nJ CARDIOVASC MAGN R. 2023;25(1):.\nAbsence of Malaria-Associated Coagulopathy in Asymptomatic Plasmodium falciparum Infection: Results From a Cross-sectional Study in the Ashanti Region, Ghana\nRolling C, Phillips R, Abass K, Ken Adu Poku J, Osei-Mireku S, Osei-Wusu B, Thompson W, Vinnemeier C, Huebl L, Langer F, Francke P, Kuta P, Konrath S, Renn\u00e9 T, Tannich E, Rolling T, Heinemann M\nOPEN FORUM INFECT DI. 2023;10(3):ofad074.\nRabies post-exposure prophylaxis of international travellers - Results from two major German travel clinics\nSaffar F, Heinemann M, Heitkamp C, Stelzl D, Ramharter M, Schunk M, Rothe C, B\u00fchler S\nTRAVEL MED INFECT DI. 2023;53:.\nNirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry\nSalmanton-Garc\u00eda J, Marchesi F, Gomes da Silva M, Farina F, D\u00e1vila-Valls J, Bilgin Y, Glenth\u00f8j A, Falces-Romero I, Van Doesum J, Labrador J, Buquicchio C, El-Ashwah S, Petzer V, Van Praet J, Sch\u00f6nlein M, Dargenio M, M\u00e9ndez G, Meers S, Itri F, Giordano A, Pincz\u00e9s L, Espigado I, Stojanoski Z, L\u00f3pez-Garc\u00eda A, Prezioso L, Jaksic O, Vena A, Fracchiolla N, Gonz\u00e1lez-L\u00f3pez T, Colovi\u0107 N, Delia M, Weinbergerov\u00e1 B, Marchetti M, Marques de Almeida J, Finizio O, Besson C, Biernat M, Valkovi\u0107 T, Lahmer T, Cuccaro A, Ormazabal-V\u00e9lez I, Batini\u0107 J, Fern\u00e1ndez N, De Jonge N, Tascini C, Anastasopoulou A, Dul\u00e9ry R, Del Principe M, Plantefeve G, Papa M, Nucci M, Jim\u00e9nez M, Aujayeb A, Hern\u00e1ndez-Rivas J, Merelli M, Cattaneo C, Blennow O, Nordlander A, Cabirta A, Varricchio G, Sacchi M, Cordoba R, Arellano E, Gr\u00e4fe S, Wolf D, Emarah Z, Ammatuna E, Hersby D, Mart\u00edn-P\u00e9rez S, Nunes Rodrigues R, Rahimli L, Pagano L, Cornely O\nECLINICALMEDICINE. 2023;58:101939.\nLongitudinal SARS-CoV-2 Seroprevalence among Employees in Outpatient Care Services in Hamburg\nSchablon A, Harth V, Tersch\u00fcren C, Kleinm\u00fcller O, Wohlert C, Schnabel C, Brehm T, Schulze zur Wiesch J, Kersten J, Nienhaus A\nINT J ENV RES PUB HE. 2023;20(8):.\nEfficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma\nScheiner B, Roessler D, Phen S, Lim M, Pomej K, Pressiani T, Cammarota A, Fr\u00fcndt T, von Felden J, Schulze K, Himmelsbach V, Finkelmeier F, Deibel A, Siebenh\u00fcner A, Shmanko K, Radu P, Schwacha-Eipper B, Ebert M, Teufel A, Djanani A, Hucke F, Balcar L, Philipp A, Hsiehchen D, Venerito M, Sinner F, Trauner M, D'Alessio A, Fulgenzi C, Pinato D, Peck-Radosavljevic M, Dufour J, Weinmann A, Kremer A, Singal A, De Toni E, Rimassa L, Pinter M\nJHEP REP. 2023;5(1):.\nDoes gamma-glutamyltransferase correlate with liver tumor burden in neuroendocrine tumors?\nSchmidt B, Leiderer M, Amin T, Viol F, Huber S, Henes F, Schrader J\nENDOCRINE. 2023 [Epub ahead of print].\nPulmonary impairment independently determines mortality in critically ill patients with acute-on-chronic liver failure\nSchulz M, Mengers J, Gu W, Drolz A, Ferstl P, Amoros A, Uschner F, Ackermann N, Guttenberg G, Queck A, Brol M, Graf C, Stoffers P, de la Vera A, Cremonese C, Erasmus H, Welker M, Gr\u00fcnewaldt A, Arroyo V, Bojunga J, Fernandez J, Zeuzem S, Kluwe J, Peiffer K, Welsch C, Fuhrmann V, Rohde G, Trebicka J\nLIVER INT. 2023;43(1):180-193.\nHuman \u03b3\u03b4 T cell Identification from Single-cell RNA Sequencing Datasets by Modular TCR Expression\nSong Z, Henze L, Casar C, Schwinge D, Schramm C, Fuss J, Tan L, Prinz I\nJ LEUKOCYTE BIOL. 2023 [Epub ahead of print].\nPotential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin\nStern L, Boehme L, Goetz M, Nitschke C, Giannou A, Zhang T, G\u00fcng\u00f6r C, Reeh M, Izbicki J, Fliegert R, Hausen A, Giese N, Hackert T, Niv M, Heinrich S, Gaida M, Ghadban T\nINT J ONCOL. 2023;62(1):.\nMicrobiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer\nTintelnot J, Xu Y, Lesker T, Sch\u00f6nlein M, Konczalla L, Giannou A, Pelczar P, Kylies D, Puelles V, Bielecka A, Peschka M, Cortesi F, Riecken K, Jung M, Amend L, Br\u00f6ring T, Trajkovic-Arsic M, Siveke J, Renn\u00e9 T, Zhang D, Boeck S, Strowig T, Uzunoglu F, G\u00fcng\u00f6r C, Stein A, Izbicki J, Bokemeyer C, Sinn M, Kimmelman A, Huber S, Gagliani N\nNATURE. 2023;615(7950):168-174.\nImproving quality of life in patients with rare autoimmune liver diseases by structured peer-delivered support (Q.RARE.LI): study protocol for a transnational effectiveness-implementation hybrid trial\nUhlenbusch N, Bal A, Balogh B, Braun A, Geerts A, Hirschfield G, Janik M, Lohse A, Milkiewicz P, Papp M, Poppe C, Schramm C, L\u00f6we B\nBMC PSYCHIATRY. 2023;23(1):193.\nTrends in the epidemiology of Clostridioides difficile infection in Germany\nVehreschild M, Schreiber S, von M\u00fcller L, Epple H, Weinke T, Manthey C, Oh J, Wahler S, Stallmach A\nINFECTION. 2023 [Epub ahead of print];1-8.\nImpact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma\nVithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Sch\u00f6nlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R\nHEPATOL INT. 2023;17(4):904-914.\nFatty acid-binding protein-4 (FABP4) and matrix metalloproteinase-9 (MMP9) as predictive values for nonalcoholic steatohepatitis (NASH)\nWagner J, Kumar Y, Lautenbach A, von Kroge P, Wolter S, Mann O, Izbicki J, Gagliani N, Dupr\u00e9e A\nLIPIDS HEALTH DIS. 2023;22(1):1.\nExtending Tempcyclegan for Virtual Augmentation of Gastrointestinal Endoscopy Training Simulators\nWallrodt M, Schulz-Alsen M, Ehlken H, R\u00f6sch T, Schmitz R, Werner R\n2023. Bildverarbeitung f\u00fcr die Medizin 2023. Deserno T, Handels H, Maier A, Maier-Hein K, Palm C, Tolxdorff T (Hrsg.). 1. Aufl. Springer Vieweg, 3-8.\nPatient-reported quality of care in primary sclerosing cholangitis\nWalmsley M, Tornai D, Cazzagon N, Leburgue A, Mrzljak A, Lenzen H, Carbone M, Madaleno J, Lleo A, Junge N, Schramm C, Bergquist A\nLIVER INT. 2023;43(8):1654-1662.\nSafety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial\nWedemeyer H, Sch\u00f6neweis K, Bogomolov P, Blank A, Voronkova N, Stepanova T, Sagalova O, Chulanov V, Osipenko M, Morozov V, Geyvandova N, Sleptsova S, Bakulin I, Khaertynova I, Rusanova M, Pathil A, Merle U, Bremer B, Allweiss L, Lempp F, Port K, Haag M, Schwab M, Zur Wiesch J, Cornberg M, Haefeli W, Dandri M, Alexandrov A, Urban S\nLANCET INFECT DIS. 2023;23(1):117-129.\nAutoimmune Hepatitis: Von Autoantik\u00f6rpern bis Zirrhose\nWeltzsch J, Ziegler A, Lohse A\nINNERE MED. 2023;64(7):655-667.\nKnowledge, attitudes, behaviors, and serological status related to Chagas disease among Latin American migrants in Germany: A cross-sectional study in six German cities\nWirth M, G\u00e1lvez R, Jochum J, Strauss R, Kristensen K, Stich A, Stegemann M, Stahl P, Puchner K, Strasen J, Parisi S, Braasch T, Bender M, H\u00f6rning A, Hanke M, St\u00f6rk S, Jacobs T, Pritsch M, Zoller T\nFRONT CELL INFECT MI. 2023;12:.\nMulticytokine-producing CD4+ T cells characterize the livers of patients with NASH\nWoestemeier A, Scognamiglio P, Zhao Y, Wagner J, Muscate F, Casar C, Siracusa F, Cortesi F, Agalioti T, M\u00fcller S, Sagebiel A, Konczalla L, Wahib R, Karstens K, Giannou A, Dupr\u00e9e A, Wolter S, Wong M, M\u00fchlig A, Bielecka A, Bansal V, Zhang T, Mann O, Puelles V, Huber T, Lohse A, Izbicki J, Palm N, Bonn S, Huber S, Gagliani N\nJCI INSIGHT. 2023;8(1):.\nHigher Risk of HEV Transmission and Exposure among Blood Donors in Europe and Asia in Comparison to North America: A Meta-Analysis\nWolski A, Pischke S, Ozga A, Addo M, Horvatits T\nPATHOGENS. 2023;12(3):425.\nSotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study\nWoo M, Brehm T, Fischer M, Heyer A, Wichmann D, Jordan S, N\u00f6rz D, L\u00fctgehetmann M, Addo M, Lohse A, Schmiedel S, Kluge S, Schulze Zur Wiesch J\nMICROBIOL SPECTR. 2023;11(1):.\nAbsence of self-reported neuropsychiatric and somatic symptoms after Omicron variant SARS-CoV-2 breakthrough infections\nWoo M, Mayer C, Brehm T, Andersen G, Weigel A, L\u00f6we B, Lohse A, Addo M, Gerloff C, Knobloch J, Schulze Zur Wiesch J, Friese M\nBRAIN COMMUN. 2023;5(2):fcad092.\nClinical surrogates of dysautonomia predict lethal outcome in COVID-19 on intensive care unit\nWoo M, Mayer C, Fischer M, Kluge S, Roedl K, Gerloff C, Czorlich P, Thomalla G, Schulze Zur Wiesch J, Schweingruber N\nNeurol Res Pract. 2023;5(1):17.\nConfidence in treatment is contributing to quality of life in autoimmune liver diseases. The results of ERN RARE-LIVER online survey\nWunsch E, Krause L, Gevers T, Schramm C, Janik M, Krawczyk M, Willemse J, Uhlenbusch N, L\u00f6we B, Lohse A, Milkiewicz P\nLIVER INT. 2023;43(2):381-392.\nTreatment responses and outcomes in patients with autoimmune hepatitis and concomitant features of non-alcoholic fatty liver disease\nZachou K, Azariadis K, Lytvyak E, Snijders R, Takahashi A, Gatselis N, Robles M, Andrade R, Schramm C, Lohse A, Tanaka A, Drenth J, Montano-Loza A, Dalekos G\nJHEP REP. 2023;5(8):.\nThe co-inhibitory receptor TIGIT regulates NK cell function and is upregulated in human intrahepatic CD56bright NK cells\nZiegler A, Fittje P, M\u00fcller L, Ahrenstorf A, Hagemann K, Hagen S, Hess L, Niehrs A, Poch T, Ravichandran G, L\u00f6bl S, Padoan B, Brias S, Hennesen J, Richard M, Richert L, Peine S, Oldhafer K, Fischer L, Schramm C, Martrus G, Bunders M, Altfeld M, Lunemann S\nFRONT IMMUNOL. 2023;14:.\nReply to: \"The time is ripe for a randomized controlled trial of oral vancomycin in Primary Sclerosing Cholangitis\"\nZigmond E, Schramm C\nCLIN GASTROENTEROL H. 2023;21(10):2700.\nBile duct colonization with Enterococcus sp. associates with disease progression in Primary Sclerosing Cholangitis\nZigmond E, Zecher B, Bartels A, Ziv-Baran T, R\u00f6sch T, Schachschal G, Lohse A, Ehlken H, Schramm C\nCLIN GASTROENTEROL H. 2023;21(5):1223-1232.e3.\nHaematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data\nBMC MED. 2022;20(1):.\nTemporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis\nMALARIA J. 2022;21(1):.\nPhosphatidylethanol in patients with liver diseases of different etiologies: analysis of six homologues and comparison with other alcohol markers\nAboutara N, Szewczyk A, Jungen H, Mosebach A, Rodriguez Lago M, Vettorazzi E, Iwersen-Bergmann S, M\u00fcller A, Sterneck M\nCLIN CHIM ACTA. 2022;524:171-178.\nCell and Molecular Biology for Non-Biologists: A short introduction into key biological concepts\nAdlung L\n2022. Cell and Molecular Biology for Non-Biologists. 1. Aufl. Berlin, Heidelberg: Springer-Verlag Berlin, Heidelberg, .\nHuman dental pulp cells modulate CD8+ T cell proliferation and efficiently degrade extracellular ATP to adenosine in vitro\nAhmadi P, Yan M, Bauche A, Smeets R, M\u00fcller C, Koch-Nolte F, Haag F, Fliegert R, Kluwe L, Schulze Zur Wiesch J, Hartjen P\nCELL IMMUNOL. 2022;380:.\nEarly and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies\nAkbil B, Meyer T, Stubbemann P, Thibeault C, Staudacher O, Niemeyer D, Jansen J, M\u00fchlemann B, Doehn J, Tabeling C, Nusshag C, Hirzel C, Sanchez D, Nieters A, Lother A, Duerschmied D, Schallner N, Lieberum J, August D, Rieg S, Falcone V, Hengel H, K\u00f6lsch U, Unterwalder N, H\u00fcbner R, Jones T, Suttorp N, Drosten C, Warnatz K, Spinetti T, Schefold J, D\u00f6rner T, Sander L, Corman V, Merle U, Kurth F, von Bernuth H, Meisel C, Goffinet C\nJ CLIN IMMUNOL. 2022;42(6):1111-1129.\nTherapeutic shutdown of HBV transcripts promotes reappearance of the SMC5/6 complex and silencing of the viral genome in vivo\nAllweiss L, Giersch K, Pirosu A, Volz T, Muench R, Beran R, Urban S, Javanbakht H, Fletcher S, L\u00fctgehetmann M, Dandri-Petersen M\nGUT. 2022;71(2):372-381.\nAdvances in genetic, epigenetic and environmental aspects of rare liver diseases\nAndersson E, Lohse A\nEUR J MED GENET. 2022;65(2):.\nHealth care workers' knowledge on identification, management and treatment of snakebite cases in rural Malawi: A descriptive study\nAron M, Kachimanga C, Kreuels B, Mailosi B, Sambani C, Matanje B, Blessmann J, Chunga M, Momba G, Ndarama E, Kambalame D, Connolly E, Rosenthal A, Munyaneza F\nPLOS NEGLECT TROP D. 2022;16(11):.\nTissue-resident memory T cells in the kidney\nAsada N, Ginsberg P, Gagliani N, Mittr\u00fccker H, Panzer U\nSEMIN IMMUNOPATHOL. 2022;44(6):801-811.\nMetabolic Syndrome Is Associated with Impaired Survival after Surgery for Pancreatic Neuroendocrine Tumors\nAwwad F, Ozga A, Amin T, Schlueter C, Kailani S, Perez D, Wolter S, Sauter G, Izbicki J, Lohse A, Schrader J\nNEUROENDOCRINOLOGY. 2022;112(12):1225-1236.\nPsychomotor development in two-year-old Ivorian and Ghanaian children - Psychometric properties of the Kilifi Developmental Inventory\nBarthel D, Kriston L, Yao E, Fordjour D, Armel K, Eberhardt K, Hinz R, Ehrhardt S, Bindt C\nBRIT J DEV PSYCHOL. 2022;40(4):471-486.\nTh17 cell plasticity towards a T-bet-dependent Th1 phenotype is required for bacterial control in Staphylococcus aureus infection\nBartsch P, Kilian C, Hellmig M, Paust H, Borchers A, Sivayoganathan A, Enk L, Zhao Y, Shaikh N, B\u00fcttner H, Wong M, Puelles V, Wiech T, Flavell R, Huber T, Turner J, Bonn S, Huber S, Gagliani N, Mittr\u00fccker H, Rohde H, Panzer U, Krebs C\nPLOS PATHOG. 2022;18(4):e1010430.\nNo link between the prevalence of hepatitis E virus infection and the diagnosis of schizophrenia\nBeisel C, Pischke S, Mader M, Moritz S, Sch\u00f6ttle D, L\u00fcdecke D\nINFECTION. 2022;50(6):1623-1624.\nRecommendations regarding screening, diagnosis, treatment, and clinical management of Chagas disease in Germany: AWMF-Register-Nr. 042-009\nBissinger A, Deneke T, Feldt T, Froeschl G, G\u00e1lvez R, Guertler L, Hoerauf A, H\u00fcbner M, Jacobs T, Jochum J, Kobbe R, Leuschner F, Pritsch M, Ramharter M, Richter J, Rieke B, Schmiedel S, Seeba H, Stich A, Strauss R, Weinauer F, Weizs\u00e4cker K, Wirth M, Zoller T\n2022.\nS3-Leitlinie: Diagnostik und Therapie bili\u00e4rer Karzinome: Langversion 2.0 \u2013 Juni 2021 \u2013 AWMF-Registernummer: 032-053OL\nBitzer M, Voesch S, Albert J, Bartenstein P, Bechstein W, Bl\u00f6dt S, Brunner T, Dombrowski F, Evert M, Follmann M, La Foug\u00e8re C, Freudenberger P, Geier A, Gkika E, G\u00f6tz M, Hammes E, Helmberger T, Hoffmann R, Hofmann W, Huppert P, Kautz A, Kn\u00f6tgen G, K\u00f6rber J, Krug D, Lammert F, Lang H, Langer T, Lenz P, Mahnken A, Meining A, Micke O, Nadalin S, Nguyen H, Ockenga J, Oldhafer K, Paprottka P, Paradies K, Pereira P, Persigehl T, Plauth M, Plentz R, Pohl J, Riemer J, Reimer P, Ringwald J, Ritterbusch U, Roeb E, Schellhaas B, Schirmacher P, Schmid I, Schuler A, von Schweinitz D, Seehofer D, Sinn M, Stein A, Stengel A, Steubesand N, Stoll C, Tannapfel A, Taubert A, Trojan J, van Thiel I, Tholen R, Vogel A, Vogl T, Vorwerk H, Wacker F, Waidmann O, Wedemeyer H, Wege H, Wildner D, Wittekind C, W\u00f6rns M, Galle P, Malek N\nZ GASTROENTEROL. 2022;60(2):219-238.\nMucha-Habermann disease: a pediatric case report and proposal of a risk score\nBlohm M, Ebenebe C, Rau C, Escherich C, Johannsen J, Escherich G, Driemeyer J, Nagel P, Kobbe R, L\u00fctgehetmann M, Lennartz M, Booken N, Schneider S, Singer D\nINT J DERMATOL. 2022;61(4):401-409.\nAssessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection\nBoettler T, Gill U, Allweiss L, Pollicino T, Tavis J, Zoulim F\nJHEP REP. 2022;4(6):.\nT cells expressing multiple co-inhibitory molecules in acute malaria are not exhausted but exert a suppressive function in mice\nBrandi J, Lehmann C, Kaminski L, Schulze Zur Wiesch J, Addo M, Ramharter M, Mackroth M, Jacobs T, Riehn M\nEUR J IMMUNOL. 2022;52(2):312-327.\nTIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis\nBrauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar P, Tsoka S, Bullinger L, Seubert E, Smit D, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W\nJ IMMUNOTHER CANCER. 2022;10(12):.\nSaisonale Influenza \u2013 Aktuelles zu Epidemiologie, Pr\u00e4vention und Therapie\nBrehm T, Hennigs A\nDEUT MED WOCHENSCHR. 2022;147(22):1456-1464.\nAttitudes, practices, and obstacles towards influenza vaccination for international travelers among travel health advisors in Germany: A questionnaire-based survey\nBrehm T, Jordan S, Addo M, Ramharter M, Kreuels B\nTRAVEL MED INFECT DI. 2022;45:.\nClinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants\nBrehm T, Pfefferle S, von Possel R, Karolyi M, Zoufaly A, Wichmann D, Kobbe R, Emmerich P, N\u00f6rz D, Aepfelbacher M, Schulze Zur Wiesch J, Addo M, Schmiedel S, L\u00fctgehetmann M\nJ MED VIROL. 2022;94(10):5038-5043.\nDiagnosis of abdominal tuberculosis by mini-laparoscopy\nBrehm T, Schmiedel S, Lohse A\nINFECTION. 2022;50(4):1049-1050.\nThree Separate Spike Antigen Exposures by COVID-19 Vaccination or SARS-CoV-2 Infection Elicit Strong Humoral Immune Responses in Healthcare Workers\nBrehm T, Ullrich F, Thompson M, K\u00fcchen J, Schwinge D, Spier A, Huber S, Knobloch J, Aepfelbacher M, Addo M, Lohse A, L\u00fctgehetmann M, Schulze Zur Wiesch J\nVACCINES-BASEL. 2022;10(7):.\nCutaneous and Mediastinal Emphysema Following Dental Cleaning\nBuescher G, Klose H, Schultze A\nDTSCH ARZTEBL INT. 2022;119(7):112.\nSARS-CoV-2 in Pediatric Liver Transplant Recipients: The European Experience\nBuescher G, Sebode M, Marjot T, Webb G, Moon A, Barnes E, Barritt A, Cananzi M, Lohse A, J\u00f8rgensen M, McLin V\nJ PEDIATR GASTR NUTR. 2022;74(2):e41-e42.\nTransabdominal Ultrasound and Magnetic Resonance Enterography in Inflammatory Bowel Disease: Results of an Observational Retrospective Single-Center Study\nCalavrezos L, Bannas P, Warncke M, Wiegard C, Huber S, Manthey C\nULTRASOUND INT OPEN. 2022;8(1):E22-E28.\nCanine insulinoma as a model for human malignant insulinoma research: Novel perspectives for translational clinical studies\nCapodanno Y, Altieri B, Elders R, Colao A, Faggiano A, Schrader J\nTRANSL ONCOL. 2022;15(1):.\nErythropoietin-driven dynamic proteome adaptations during erythropoiesis prevent iron overload in the developing embryo\nChakraborty S, Andrieux G, Kastl P, Adlung L, Altamura S, Boehm M, Schwarzm\u00fcller L, Abdullah Y, Wagner M, Helm B, Gr\u00f6ne H, Lehmann W, Boerries M, Busch H, Muckenthaler M, Schilling M, Klingm\u00fcller U\nCELL REP. 2022;40(12):111360.\nHigh and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4+ T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19\nCords L, Knapp M, Woost R, Schulte S, Kummer S, Ackermann C, Beisel C, Peine S, Johansson A, Kwok W, G\u00fcnther T, Fischer N, Wittner M, Addo M, Huber S, Schulze Zur Wiesch J\nVIRUSES-BASEL. 2022;14(6):.\nLiver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis\nCorpechot C, Carrat F, Gaouar F, Chau F, Hirschfield G, Gulamhusein A, Montano-Loza A, Lytvyak E, Schramm C, Pares A, Olivas I, Eaton J, Osman K, Dalekos G, Gatselis N, Nevens F, Cazzagon N, Zago A, Russo F, Abbas N, Trivedi P, Thorburn D, Saffioti F, Barkai L, Roccarina D, Calvaruso V, Fichera A, Delamarre A, Medina-Morales E, Bonder A, Patwardhan V, Rigamonti C, Carbone M, Invernizzi P, Cristoferi L, van der Meer A, de Veer R, Zigmond E, Yehezkel E, Kremer A, Deibel A, Dumortier J, Bruns T, Gro\u00dfe K, Pageaux G, Wetten A, Dyson J, Jones D, Chazouill\u00e8res O, Hansen B, de L\u00e9dinghen V\nJ HEPATOL. 2022;77(6):1545-1553.\nPreliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: a real-world study\nD'Alessio A, Fulgenzi C, Nishida N, Sch\u00f6nlein M, von Felden J, Schulze K, Wege H, Gaillard V, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Sharma R, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D\nHEPATOLOGY. 2022;76(4):1000-1012.\nMalaria-associated adhesion molecule activation facilitates the destruction of uninfected red blood cells\nDalimot J, Klei T, Beuger B, Dikmen Z, Bouwman S, Mombo-Ngoma G, Zoleko-Manego R, Ndzebe-Ndoumba W, Eg\u00e9e S, Kuijpers T, Grobusch M, van Bruggen R\nBLOOD ADV. 2022;6(21):5798-5810.\nIncreased Seroprevalence of Campylobacter jejuni, but not HEV, in healthcare workers in gastroenterological endoscopy\nDammermann W, von Menges A, Singethan K, Pischke S, Ritter O, L\u00fcth S, Ullrich S\nZ GASTROENTEROL. 2022;60(12):1763-1769.\nThe hepatitis delta virus and chronic hepatitis D\nDandri M, Volmari A, L\u00fctgehetmann M\nJ HEPATOL. 2022;77(5):1448-1450.\nDetailed stratified GWAS analysis for severe COVID-19 in four European populations\nDegenhardt F, Ellinghaus D, Juzenas S, Lerga-Jaso J, Wendorff M, Maya-Miles D, Uellendahl-Werth F, ElAbd H, R\u00fchlemann M, Arora J, \u00d6zer O, Lenning O, Myhre R, Vadla M, Wacker E, Wienbrandt L, Blandino Ortiz A, de Salazar A, Garrido Chercoles A, Palom A, Ruiz A, Garcia-Fernandez A, Blanco-Grau A, Mantovani A, Zanella A, Holten A, Mayer A, Bandera A, Cherubini A, Protti A, Aghemo A, Gerussi A, Ramirez A, Braun A, Nebel A, Barreira A, Lleo A, Teles A, Kildal A, Biondi A, Caballero-Garralda A, Ganna A, Gori A, Gl\u00fcck A, Lind A, Tanck A, Hinney A, Carreras Nolla A, Fracanzani A, Peschuck A, Cavallero A, Dyrhol-Riise A, Ruello A, Juli\u00e0 A, Muscatello A, Pesenti A, Voza A, Rando-Segura A, Solier A, Schmidt A, Cortes B, Mateos B, Nafria-Jimenez B, Schaefer B, Jensen B, Bellinghausen C, Maj C, Ferrando C, de la Horra C, Quereda C, Skurk C, Thibeault C, Scollo C, Herr C, Spinner C, Gassner C, Lange C, Hu C, Paccapelo C, Lehmann C, Angelini C, Cappadona C, Azuure C, Bianco C, Cea C, Sancho C, Hoff D, Galimberti D, Prati D, Haschka D, Jim\u00e9nez D, Pesta\u00f1a D, Toapanta D, Mu\u00f1iz-Diaz E, Azzolini E, Sandoval E, Binatti E, Scarpini E, Helbig E, Casalone E, Urrechaga E, Paraboschi E, Pontali E, Reverter E, Calder\u00f3n E, Navas E, Sollig\u00e5rd E, Contro E, Arana-Arri E, Aziz F, Garcia F, Garc\u00eda S\u00e1nchez F, Ceriotti F, Martinelli-Boneschi F, Peyvandi F, Kurth F, Blasi F, Malvestiti F, Medrano F, Mesonero F, Rodriguez-Frias F, Hanses F, M\u00fcller F, Hemmrich-Stanisak G, Bellani G, Grasselli G, Pezzoli G, Costantino G, Albano G, Cardamone G, Bellelli G, Citerio G, Foti G, Lamorte G, Matullo G, Baselli G, Kurihara H, Neb H, My I, Kurth I, Hern\u00e1ndez I, Pink I, de Rojas I, Galv\u00e1n-Femenia I, Holter J, Afset J, Heyckendorf J, K\u00e4ssens J, Dam\u00e5s J, Rybniker J, Altm\u00fcller J, Ampuero J, Mart\u00edn J, Erdmann J, Banales J, Badia J, Dopazo J, Schneider J, Bergan J, Barretina J, Walter J, Hern\u00e1ndez Quero J, Goikoetxea J, Delgado J, Guerrero J, Fazaal J, Kraft J, Schr\u00f6der J, Risnes K, Banasik K, M\u00fcller K, Gaede K, Garcia-Etxebarria K, Tonby K, Heggelund L, Izquierdo-Sanchez L, Bettini L, Sumoy L, Sander L, Lippert L, Terranova L, Nkambule L, Knopp L, Gustad L, Garbarino L, Santoro L, T\u00e9llez L, Roade L, Ostadreza M, Intxausti M, Kogevinas M, Riveiro-Barciela M, Berger M, Schaefer M, Niemi M, Guti\u00e9rrez-Stampa M, Carrabba M, Figuera Basso M, Valsecchi M, Hernandez-Tejero M, Vehreschild M, Manunta M, Acosta-Herrera M, D'Angi\u00f2 M, Baldini M, Cazzaniga M, Grimsrud M, Cornberg M, N\u00f6then M, Marqui\u00e9 M, Castoldi M, Cordioli M, Cecconi M, D'Amato M, Augustin M, Tomasi M, Boada M, Dreher M, Seilmaier M, Joannidis M, Wittig M, Mazzocco M, Ciccarelli M, Rodr\u00edguez-Gand\u00eda M, Bocciolone M, Miozzo M, Imaz Ayo N, Blay N, Chueca N, Montano N, Braun N, Ludwig N, Marx N, Mart\u00ednez N, Cornely O, Witzke O, Palmieri O, Faverio P, Preatoni P, Bonfanti P, Omodei P, Tentorio P, Castro P, Rodrigues P, Espa\u00f1a P, Hoffmann P, Rosenstiel P, Schommers P, Suwalski P, de Pablo R, Ferrer R, Bals R, Gualtierotti R, Gallego-Dur\u00e1n R, Nieto R, Carpani R, Morilla R, Badalamenti S, Haider S, Ciesek S, May S, Bombace S, Marsal S, Pigazzini S, Klein S, Pelusi S, Wilfling S, Bosari S, Volland S, Brunak S, Raychaudhuri S, Schreiber S, Heilmann-Heimbach S, Aliberti S, Ripke S, Dudman S, Wesse T, Zheng T, Bahmer T, Eggermann T, Illig T, Brenner T, Pumarola T, Feldt T, Folseraas T, Gonzalez Cejudo T, Landmesser U, Protzer U, Hehr U, Rimoldi V, Monzani V, Skogen V, Keitel V, Kopfnagel V, Friaza V, Andrade V, Moreno V, Albrecht W, Peter W, Poller W, Farre X, Yi X, Wang X, Khodamoradi Y, Karadeniz Z, Latiano A, Goerg S, Bacher P, Koehler P, Tran F, Zoller H, Schulte E, Heidecker B, Ludwig K, Fern\u00e1ndez J, Romero-G\u00f3mez M, Albillos A, Invernizzi P, Buti M, Duga S, Bujanda L, Hov J, Lenz T, Asselta R, de Cid R, Valenti L, Karlsen T, C\u00e1ceres M, Franke A\nHUM MOL GENET. 2022;31(23):3945-3966.\nSevere acute hepatitis and acute liver failure of unknown origin in children: a questionnaire-based study within 34 paediatric liver centres in 22 European countries and Israel, April 2022\nde Kleine R, Lexmond W, Buescher G, Sturm E, Kelly D, Lohse A, Lenz D, J\u00f8rgensen M\nEUROSURVEILLANCE. 2022;27(19):.\nPredictors of Loneliness among Homeless Individuals in Germany during the COVID-19 Pandemic\nDost K, Heinrich F, Graf W, Brennecke A, Kowalski V, Leider A, Kraus A, van R\u00fcth V, Ondruschka B, P\u00fcschel K, K\u00f6nig H, Bertram F, Hajek A\nINT J ENV RES PUB HE. 2022;19(19):.\nSARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease\nDuengelhoef P, Hartl J, R\u00fcther D, Steinmann S, Brehm T, Weltzsch J, Glaser F, Schaub G, Sterneck M, Sebode M, Weiler-Normann C, Addo M, L\u00fctgehetmann M, Haag F, Schramm C, Schulze Zur Wiesch J, Lohse A\nUNITED EUR GASTROENT. 2022;10(3):319-329.\nTherapeutic options for CTLA-4 Insufficiency\nEgg D, Rump I, Mitsuiki N, Rojas-Restrepo J, Maccari M, Schwab C, Gabrysch A, Warnatz K, Goldacker S, Pati\u00f1o V, Wolff D, Okada S, Hayakawa S, Shikama Y, Kanda K, Imai K, Sotomatsu M, Kuwashima M, Kamiya T, Morio T, Matsumoto K, Mori T, Yoshimoto Y, Dybedal I, Kanariou M, Kucuk Z, Chapdelaine H, Petruzelkova L, Lorenz H, Sullivan K, Heimall J, Moutschen M, Litzman J, Recher M, Albert M, Hauck F, Seneviratne S, Schmid J, Kolios A, Unglik G, Klemann C, Snapper S, Giulino-Roth L, Svaton M, Platt C, Hambleton S, Neth O, Gosse G, Reinsch S, Holzinger D, Kim Y, Bakhtiar S, Atschekzei F, Schmidt R, Sogkas G, Chandrakasan S, Rae W, Derfalvi B, Marquart H, Ozen A, Kiykim A, Karakoc-Aydiner E, Kr\u00e1l\u00ed\u010dkov\u00e1 P, de Bree G, Kiritsi D, Seidel M, Kobbe R, Dantzer J, Alsina L, Armangue T, Lougaris V, Agyeman P, Nystr\u00f6m S, Buchbinder D, Arkwright P, Grimbacher B\nJ ALLERGY CLIN IMMUN. 2022;149(2):736-746.\nPossible tumour cell reimplantation during curative endoscopic therapy of superficial Barrett's carcinoma\nEhlken H, Schmitz R, Riethdorf S, Riethdorf L, Krause J, Karstens K, Schrader J, Viol F, Giannou A, Sterlacci W, Vieth M, Clauditz T, K\u00e4hler C, Mann O, Izbicki J, Huber S, Pantel K, R\u00f6sch T\nGUT. 2022;71(2):277-286.\nSpannungsfeld endoskopische Resektionsverfahren bei GEP-NET // Endoscopic resection for GEP-NET\nEhlken H, Younis F, Wolter S, Schrader J\nZBL CHIR. 2022;147(3):256-263.\nSurvey uncovering variations in the management of primary sclerosing cholangitis across Europe\nEliasson J, Lo B, Scramm C, Chazouilleres O, Folseraas T, Beuers U, Ytting H\nJHEP REP. 2022;4(11):.\nRisk factors for worsening of somatic symptom burden in a prospective cohort during the COVID-19 pandemic\nEngelmann P, L\u00f6we B, Brehm T, Weigel A, Ullrich F, Addo M, Schulze zur Wiesch J, Lohse A, Toussaint A\nFRONT PSYCHOL. 2022;13:1022203.\nPredictors of somatic symptom burden in healthcare professionals during the COVID-19 pandemic: an 8-week follow-up study\nEngelmann P, Toussaint A, Addo M, Brehm T, Lohse A, Weigel A, Thompson M, L\u00f6we B\nJ MENT HEALTH. 2022 [Epub ahead of print];1-11.\nCreatine kinase-(MB) and hepcidin as candidate biomarkers for early diagnosis of pulmonary tuberculosis: a proof-of-concept study in Lambar\u00e9n\u00e9, Gabon\nEssone P, Adegbite B, Mbadinga M, Mbouna A, Lotola-Mougeni F, Alabi A, Edoa J, Lell B, Alabi A, Adegnika A, Ramharter M, Siawaya J, Grobusch M, Kremsner P, Agnandji S\nINFECTION. 2022;50(4):897-905.\nIncreased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome\nFathi A, Dahlke C, Kr\u00e4hling V, Kupke A, Okba N, Raadsen M, Heidepriem J, M\u00fcller M, Paris G, Lassen-Haartje S, Kl\u00fcver M, Volz A, Koch T, Ly M, Friedrich M, Fux R, Tscherne A, Kalodimou G, Schmiedel S, Corman V, Hesterkamp T, Drosten C, Loeffler F, Haagmans B, Sutter G, Becker S, Addo M\nNAT COMMUN. 2022;13(1):4182.\nHand, Foot, and Mouth Disease as Differential Diagnosis of Monkeypox, Germany, August 2022\nFathi A, Schmiedel S\nEMERG INFECT DIS. 2022;28(12):2586.\nDNA methyltransferase 3A controls intestinal epithelial barrier function and regeneration in the colon\nFazio A, Bordoni D, Kuiper J, Weber-Stiehl S, Stengel S, Arnold P, Ellinghaus D, Ito G, Tran F, Messner B, Henning A, Bernardes J, H\u00e4sler R, Luzius A, Imm S, Hinrichsen F, Franke A, Huber S, Nikolaus S, Aden K, Schreiber S, Sommer F, Natoli G, Mishra N, Rosenstiel P\nNAT COMMUN. 2022;13:.\nTargeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation\nFederici S, Kredo-Russo S, Vald\u00e9s-Mas R, Kviatcovsky D, Weinstock E, Matiuhin Y, Silberberg Y, Atarashi K, Furuichi M, Oka A, Liu B, Fibelman M, Weiner I, Khabra E, Cullin N, Ben-Yishai N, Inbar D, Ben-David H, Nicenboim J, Kowalsman N, Lieb W, Kario E, Cohen T, Geffen Y, Zelcbuch L, Cohen A, Rappo U, Gahali-Sass I, Golembo M, Lev V, Dori-Bachash M, Shapiro H, Moresi C, Cuevas-Sierra A, Mohapatra G, Kern L, Zheng D, Nobs S, Suez J, Stettner N, Harmelin A, Zak N, Puttagunta S, Bassan M, Honda K, Sokol H, Bang C, Franke A, Schramm C, Maharshak N, Sartor R, Sorek R, Elinav E\nCELL. 2022;185(16):2879-2898.e24.\nPotent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues\nFeng Z, He X, Zhang X, Wu Y, Xing B, Knowles A, Shan Q, Miller S, Hojnacki T, Ma J, Katona B, Gade T, Schrader J, Metz D, June C, Hua X\nNAT CANCER. 2022;3(5):581-594.\nClinical Features and Prognosis of Patients with Carcinoid Syndrome and Carcinoid Heart Disease: A Retrospective Multicentric Study of 276 Patients\nFijalkowski R, Reher D, Rinke A, Gress T, Schrader J, Baum R, Kaemmerer D, H\u00f6rsch D\nNEUROENDOCRINOLOGY. 2022;112(6):547-554.\nHIV-1 Nef-mediated downregulation of CD155 results in viral restriction by KIR2DL5+ NK cells\nFittje P, H\u00f6lzemer A, Garcia-Beltran W, Vollmers S, Niehrs A, Hagemann K, Martrus G, K\u00f6rner C, Kirchhoff F, Sauter D, Altfeld M\nPLOS PATHOG. 2022;18(6):.\nCorrection to: MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes\nFraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, B\u00fcscheck F, H\u00f6flmayer D, Blessin N, Mandelkow T, Li W, Perez D, Izbicki J, Wilczak W, Sauter G, Schrader J, Neipp M, Mofid H, Daniels T, Isbert C, Clauditz T, Steurer S\nANN SURG ONCOL. 2022;29(9):6048.\nEqual Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment\nFr\u00fcndt T, Casar C, von Felden J, Sch\u00f6ler U, Priebe M, Kraczyk J, Ahrend H, Salamon J, Adam G, Huber S, Lohse A, Wege H, Schulze K\nCANCERS. 2022;14(3):.\nLow incidence of colonic complications after severe Shiga toxin-producing E. coli O104:H4 infection\nFr\u00fcndt T, Leuffert J, Groth S, R\u00f6sch T, Steurer S, Lohse A, Ullrich S, L\u00fcth S\nZ GASTROENTEROL. 2022;60(7):1104-1110.\nPrevalence and risk factors of undiagnosed diabetes mellitus among gastroenterological patients: a HbA1c-based single center experience \u2013 Prevalence of undiagnosed diabetes in gastroenterological patients\nFr\u00fcndt T, Schr\u00f6der N, H\u00f6lzemer A, Pinnschmidt H, de Heer J, Behrends B, Renne T, Lautenbach A, Lohse A, Schrader J\nZ GASTROENTEROL. 2022;60(9):1306-1313.\nCirculating tumor cells as a preoperative risk marker for occult metastases in patients with resectable cholangiocarcinoma\nFr\u00fcndt T, von Felden J, Krause J, Heumann A, Li J, Riethdorf S, Pantel K, Huber S, Lohse A, Wege H, Schulze K\nFRONT ONCOL. 2022;12:.\nRisk-adjusted active tuberculosis case finding strategy in central Ethiopia\nFuchs A, Tufa T, Pf\u00e4fflin F, Sch\u00f6nfeld A, Nordmann T, Melaku F, Sorsa A, Orth H, H\u00e4ussinger D, Luedde T, Feldt T\nIJID Regions. 2022;3:196-203.\nReproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study\nFulgenzi C, Cheon J, D'Alessio A, Nishida N, Ang C, Marron T, Wu L, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Napolitano A, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Sch\u00f6nlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D\nEUR J CANCER. 2022;175:204-213.\nmRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant\nGarcia-Beltran W, St. Denis K, Hoelzemer A, Lam E, Nitido A, Sheehan M, Berrios C, Ofoman O, Chang C, Hauser B, Feldman J, Roederer A, Gregory D, Poznansky M, Schmidt A, Iafrate A, Naranbhai V, Balazs A\nCELL. 2022;185(3):457-466.e4.\nCirculating microbiome in patients with portal hypertension\nGedgaudas R, Bajaj J, Skieceviciene J, Varkalaite G, Jurkeviciute G, Gelman S, Valantiene I, Zykus R, Pranculis A, Bang C, Franke A, Schramm C, Kupcinskas J\nGUT MICROBES. 2022;14(1):.\nComplement activation induces excessive T cell cytotoxicity in severe COVID-19\nGeorg P, Astaburuaga-Garc\u00eda R, Bonaguro L, Brumhard S, Michalick L, Lippert L, Kostevc T, G\u00e4bel C, Schneider M, Streitz M, Demichev V, Gem\u00fcnd I, Barone M, Tober-Lau P, Helbig E, Hillus D, Petrov L, Stein J, Dey H, Paclik D, Iwert C, M\u00fclleder M, Aulakh S, Djudjaj S, B\u00fclow R, Mei H, Schulz A, Thiel A, Hippenstiel S, Saliba A, Eils R, Lehmann I, Mall M, Stricker S, R\u00f6hmel J, Corman V, Beule D, Wyler E, Landthaler M, Obermayer B, von Stillfried S, Boor P, Demir M, Wesselmann H, Suttorp N, Uhrig A, M\u00fcller-Redetzky H, Nattermann J, Kuebler W, Meisel C, Ralser M, Schultze J, Aschenbrenner A, Thibeault C, Kurth F, Sander L, Bl\u00fcthgen N, Sawitzki B\nCELL. 2022;185(3):493-512.e25.\nClinical features of hepatitis E infections in patients with hematologic disorders\nGhandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kr\u00f6ger N, Ayuk F, Adjall\u00e9 R, Modemann F\nHAEMATOLOGICA. 2022;107(12):2870-2883.\nA Critical Role of the IL-22-IL-22 Binding Protein Axis in Hepatocellular Carcinoma\nGiannou A, L\u00fccke J, Kleinschmidt D, Shiri A, Steglich B, Nawrocki M, Zhang T, Zazara D, Kempski J, Zhao L, Giannou O, Agalioti T, Brockmann L, Bertram F, Sabihi M, B\u00f6ttcher M, Ewald F, Schulze K, von Felden J, Machicote A, Maroulis I, Arck P, Gra\u00df J, Mercanoglu B, Reeh M, Wolter S, Tachezy M, Seese H, Theodorakopoulou M, Lykoudis P, Heumann A, Uzunoglu F, Ghadban T, Mann O, Izbicki J, Li J, Dupr\u00e9e A, Melling N, Gagliani N, Huber S\nCANCERS. 2022;14(24):.\nHarnessing the liver to induce antigen-specific immune tolerance\nGottwick C, Carambia A, Herkel J\nSEMIN IMMUNOPATHOL. 2022;44(4):475-484.\nGreen tea extract-associated acute liver injury: Case report and review\nGrajecki D, Ogica A, Boenisch O, H\u00fcbener P, Kluge S\nClin Liver Dis (Hoboken). 2022;20(6):181-187.\nRisk stratification of cirrhotic patients undergoing esophagectomy for esophageal cancer: A single-centre experience\nGrass J, K\u00fcsters N, Kemper M, Tintrup J, Piecha F, Izbicki J, Perez D, Melling N, Bockhorn M, Reeh M\nPLOS ONE. 2022;17(3):e0265093.\nLeishmania infantum reactivation with secondary IgA nephropathy\nGrewe I, Brehm T, Kreuels B, Steinmetz O, Dumoulin B, Asemissen A, Tappe D, Ramharter M, Schmiedel S\nJ TRAVEL MED. 2022;29(7):.\nEffectiveness of pyronaridine-artesunate against Plasmodium malariae, Plasmodium ovale spp, and mixed-Plasmodium infections: a post-hoc analysis of the CANTAM-Pyramax trial\nGroger M, Tona Lutete G, Mombo-Ngoma G, Ntamabyaliro N, Kahunu Mesia G, Muena Mujobu T, Dimessa Mbadinga L, Zoleko Manego R, Egger-Adam D, Borghini-Fuhrer I, Shin J, Miller R, Arbe-Barnes S, Duparc S, Ramharter M\nLANCET MICROBE. 2022;3(8):e598-e605.\nSARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns\nGruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, M\u00fcnn F, Janicki H, Augustin M, Schommers P, Sander L, Kurth F, Kreer C, Klein F\nCELL HOST MICROBE. 2022;30(9):1231-1241.e6.\nNeutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage\nGruell H, Vanshylla K, Tober-Lau P, Hillus D, Sander L, Kurth F, Klein F\nLANCET INFECT DIS. 2022;22(10):1422-1423.\nmRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant\nGruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander L, Klein F\nNAT MED. 2022;28(3):477-480.\nCombined Targeting of Pathogenetic Mechanisms in Pancreatic Neuroendocrine Tumors Elicits Synergistic Antitumor Effects\nGulde S, Foscarini A, April-Monn S, Genio E, Marangelo A, Satam S, Helbling D, Falconi M, Toledo R, Schrader J, Perren A, Marinoni I, Pellegata N\nCANCERS. 2022;14(22):.\nCorrection to: Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial\nHagel S, Bach F, Brenner T, Bracht H, Brinkmann A, Annecke T, Hohn A, Weigand M, Michels G, Kluge S, Nierhaus A, Jarczak D, K\u00f6nig C, Weismann D, Frey O, Witzke D, M\u00fcller C, Bauer M, Kiehntopf M, Neugebauer S, Lehmann T, Roberts J, Pletz M\nINTENS CARE MED. 2022;48(5):646-647.\nNatural killer cell-mediated ADCC in SARS-CoV-2-infected individuals and vaccine recipients\nHagemann K, Riecken K, Jung J, Hildebrandt H, Menzel S, Bunders M, Fehse B, Koch-Nolte F, Heinrich F, Peine S, Schulze Zur Wiesch J, Brehm T, Addo M, L\u00fctgehetmann M, Altfeld M\nEUR J IMMUNOL. 2022;52(8):1297-1307.\nHumoral and Cellular Immune Response After Third and Fourth SARS-CoV-2 mRNA Vaccination in Liver Transplant Recipients\nHarberts A, Schaub G, Ruether D, Duengelhoef P, Brehm T, Karsten H, Fathi A, Jahnke-Triankowski J, Fischer L, Addo M, Haag F, L\u00fctgehetmann M, Lohse A, Schulze zur Wiesch J, Sterneck M\nCLIN GASTROENTEROL H. 2022;20(11):2558-2566.e5.\nCorrection: Broadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19\nHeide J, Schulte S, Kohsar M, Brehm T, Herrmann M, Karsten H, Marget M, Peine S, Johansson A, Sette A, L\u00fctgehetmann M, Kwok W, Sidney J, Schulze Zur Wiesch J\nPLOS PATHOG. 2022;18(1):.\nLong-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry\nHeinemann M, Liwinski T, Adam R, Berenguer M, Mirza D, Malek-Hosseini S, Heneghan M, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Mehrabi A, Acarli K, Tokat Y, Coker A, Yilmaz S, Karam V, Duvoux C, Lohse A, Schramm C\nAM J TRANSPLANT. 2022;22(2):626-633.\nRespiratory muscle dysfunction in long-COVID patients\nHennigs J, Huwe M, Hennigs A, Oqueka T, Simon M, Harbaum L, K\u00f6rbelin J, Schmiedel S, Schulze Zur Wiesch J, Addo M, Kluge S, Klose H\nINFECTION. 2022;50(5):1391-1397.\nRemdesivir-induced emergence of SARS-CoV2 variants in patients with prolonged infection\nHeyer A, G\u00fcnther T, Robitaille A, L\u00fctgehetmann M, Addo M, Jarczak D, Kluge S, Aepfelbacher M, Schulze Zur Wiesch J, Fischer N, Grundhoff A\nCELL REP MED. 2022;3(9):.\nEngagement of TRAIL triggers degranulation and IFN\u03b3 production in human natural killer cells\nH\u00f6fle J, Trenkner T, Kleist N, Schwane V, Vollmers S, Barcelona B, Niehrs A, Fittje P, Huynh-Tran V, Sauter J, Schmidt A, Peine S, Hoelzemer A, Richert L, Altfeld M, K\u00f6rner C\nEMBO REP. 2022;23(8):.\nHepatische Granulome \u2013 eine diagnostische Herausforderung\nHorst L, Weidemann S, Lohse A, Sebode M\nZ RHEUMATOL. 2022;81(7):567-576.\nMicroplastics detected in cirrhotic liver tissue\nHorvatits T, Tamminga M, Liu B, Sebode M, Carambia A, Fischer L, P\u00fcschel K, Huber S, Fischer E\nEBIOMEDICINE. 2022;82:.\nPeptide microarrays coupled to machine learning reveal individual epitopes from human antibody responses with neutralizing capabilities against SARS-CoV-2\nHotop S, Reimering S, Shekhar A, Asgari E, Beutling U, Dahlke C, Fathi A, Khan F, L\u00fctgehetmann M, Ballmann R, Gerstner A, Tegge W, Cicin-Sain L, Bilitewski U, McHardy A, Br\u00f6nstrup M\nEMERG MICROBES INFEC. 2022;11(1):1037-1048.\nEvaluation of Eosinophilic Cationic Protein as a Marker of Alveolar and Cystic Echinococcosis\nHotz J, Kaczirek K, Stremitzer S, Waneck F, Auer H, Perkmann T, Kussmann M, Bauer P, Chen R, Kriz R, Burgmann H, Ramharter M, Lagler H\nPATHOGENS. 2022;11(2):.\nCharacteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals\nHowe A, Rodrigo C, Cunningham E, Douglas M, Dietz J, Grebely J, Popping S, Sfalcin J, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio V, Chulanov V, Pawlotsky J, Harrigan P, Ceccherini-Silberstein F, Garcia F\nJHEP REP. 2022;4(5):.\nAutopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5\u039432/\u039432 Donor Cells\nHuyveneers L, Bruns A, Stam A, Ellerbroek P, de Jong D, Nagy N, Gumbs S, Tesselaar K, Bosman K, Salgado M, H\u00fctter G, Brosens L, Kwon M, Diez Martin J, van der Meer J, de Kort T, S\u00e1ez-Ciri\u00f3n A, Schulze Zur Wiesch J, Boelens J, Martinez-Picado J, Kuball J, Wensing A, Nijhuis M\nVIRUSES-BASEL. 2022;14(9):.\nThe rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis\nInnes H, Nischalke H, Guha I, Weiss K, Irving W, Gotthardt D, Barnes E, Fischer J, Ansari M, Rosendahl J, Lin S, Marot A, Pedergnana V, Casper M, Benselin J, Lammert F, McLauchlan J, Lutz P, Hamill V, Mueller S, Morling J, Semmler G, Eyer F, von Felden J, Link A, Vogel A, Marquardt J, Sulk S, Trebicka J, Valenti L, Datz C, Reiberger T, Schafmayer C, Berg T, Deltenre P, Hampe J, Stickel F, Buch S\nHEPATOL COMMUN. 2022;6(5):1213-1226.\nThe miR-181 family regulates colonic inflammation through its activity in the intestinal epithelium\nJimenez M, Clark M, Wright J, Michieletto M, Liu S, Erickson I, Dohnalova L, Uhr G, Tello-Cajiao J, Joannas L, Williams A, Gagliani N, Bewtra M, Tomov V, Thaiss C, Henao-Mejia J\nJ EXP MED. 2022;219(12):.\nParasiten \u2013 wichtige endemische und importierte Erreger\nJordan S, Kreuels B\nDEUT MED WOCHENSCHR. 2022;147(11):687-696.\nChildren with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey\nJ\u00f8rgensen M, Cananzi M, Buescher G, Samyn M, de Bruyne R\nJ HEPATOL. 2022;77(2):551-553.\nThe EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality\nKarlsen T, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, Pryke R, Hutchinson S, Sangro B, Martin N, Cecchini M, Dirac M, Belloni A, Serra-Burriel M, Ponsioen C, Sheena B, Lerouge A, Devaux M, Scott N, Hellard M, Verkade H, Sturm E, Marchesini G, Yki-J\u00e4rvinen H, Byrne C, Targher G, Tur-Sinai A, Barrett D, Ninburg M, Reic T, Taylor A, Rhodes T, Treloar C, Petersen C, Schramm C, Flisiak R, Simonova M, Pares A, Johnson P, Cucchetti A, Graupera I, Lionis C, Pose E, Fabrellas N, Ma A, Mendive J, Mazzaferro V, Rutter H, Cortez-Pinto H, Kelly D, Burton R, Lazarus J, Gin\u00e8s P, Buti M, Newsome P, Burra P, Manns M\nLANCET. 2022;399(10319):61-116.\nHigh-resolution analysis of individual spike peptide-specific CD4+ T-cell responses in vaccine recipients and COVID-19 patients\nKarsten H, Cords L, Westphal T, Knapp M, Brehm T, Hermanussen L, Omansen T, Schmiedel S, Woost R, Ditt V, Peine S, L\u00fctgehetmann M, Huber S, Ackermann C, Wittner M, Addo M, Sette A, Sidney J, Schulze Zur Wiesch J\nCLIN TRANSL IMMUNOL. 2022;11(8):.\nDas Darmmikrobiom in der Pathogenese und Therapie chronisch-entz\u00fcndlicher Darmerkrankungen\nKempski J, Huber S\nINNERE MED. 2022;63(10):1022-1027.\nPathopysiologie: Insulinresistenz\nKluwe J\n2022. Nicht-alkoholische Fettlebererkrankung . Geier A, Canbay A, Lammert F (Hrsg.). 1. Aufl. Berlin, Heidelberg: Springer Heidelberg, 51-62.\nVertical anti-SARS-CoV-2 monoclonal antibody transfer from mothers to HIV-exposed and unexposed infants\nKobbe R, Schulze-Sturm U, Kurnaz P, Rau C, Tallarek A, L\u00fctgehetmann M, Jordan S, Schmiedel S\nAIDS. 2022;36(11):1613-1615.\nCorrection: Evidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma\nKoehne E, Zander N, Rodi M, Held J, Hoffmann W, Zoleko-Manego R, Ramharter M, Mombo-Ngoma G, Kremsner P, Kreidenweiss A\nPLOS NEGLECT TROP D. 2022;16(6):.\nInversed Ratio of CD39/CD73 Expression on \u03b3\u03b4 T Cells in HIV Versus Healthy Controls Correlates With Immune Activation and Disease Progression\nKolbe K, Wittner M, Hartjen P, H\u00fcfner A, Degen O, Ackermann C, Cords L, Stellbrink H, Haag F, Schulze Zur Wiesch J\nFRONT IMMUNOL. 2022;13:.\nIn-situ x-ray fluorescence imaging of the endogenous iodine distribution in murine thyroids\nK\u00f6rnig C, Staufer T, Schmutzler O, Bedke T, Machicote A, Liu B, Liu Y, Gargioni E, Feliu N, Parak W, Huber S, Gr\u00fcner F\nSCI REP-UK. 2022;12(1):2903.\nA roadmap for serum biomarkers for hepatitis B virus: current status and future outlook\nKramvis A, Chang K, Dandri M, Farci P, Glebe D, Hu J, Janssen H, Lau D, Penicaud C, Pollicino T, Testoni B, Van B\u00f6mmel F, Andrisani O, Beumont-Mauviel M, Block T, Chan H, Cloherty G, Delaney W, Geretti A, Gehring A, Jackson K, Lenz O, Maini M, Miller V, Protzer U, Yang J, Yuen M, Zoulim F, Revill P\nNAT REV GASTRO HEPAT. 2022;19(11):727-745.\nQuantitative analysis of submucosal excision depth in endoscopic resection for early Barrett's cancer\nKrause J, R\u00f6sch T, Steurer S, Clauditz T, Sehner S, Schumacher U, Neuhaus H, Messmann H, Schumacher B, Probst A, Schachschal G, Ehlken H, Vieth M, Schmitz R\nENDOSCOPY. 2022;54(6):565-570.\nLeitlinie: Diagnostik und Therapie der Am\u00f6biasis: AWMF\u2013Register-Nr. 04-002\nKreuels B, Denkinger C, Jochum J, Schneitler S, Bissinger A, K\u00f6hler C, Ramharter M\n2022.\nThe Patient's Point of View: COVID-19 and Neuroendocrine Tumor Disease\nKrug S, Khosravian M, Weissbach J, George K, Damm M, Garbe J, Walldorf J, Reuken P, Amin T, Siebenh\u00fcner A, Rosendahl J, Gress T, Michl P, Schrader J, Rinke A\nCANCERS. 2022;14(3):.\nUpdates on Diagnostic and Therapeutic Management of Gastrointestinal and Pancreatic NET\nKrug S, Schrader J, Rinke A\nCANCERS. 2022;14(11):2628.\nThe intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts\nLiwinski T, Heinemann M, Schramm C\nSEMIN IMMUNOPATHOL. 2022;44(4):485-507.\nEinf\u00fchrung \"Symposium Infektionen und Gesellschaft - was wir gelernt haben\"\nLohse A, Mettenleiter T\n2022. Infektionen und Gesellschaft. Lohse A, Mettenleiter T (Hrsg.). 1. Aufl. Berlin: Springer Spektrum, Berlin, Heidelberg, 3-8.\nConsensus recommendations for histological criteria of autoimmune hepatitis from the International AIH Pathology Group: Results of a workshop on AIH histology hosted by the European Reference Network on Hepatological Diseases and the European Society of Pathology\nLohse A, Sebode M, Bhathal P, Clouston A, Dienes H, Jain D, Gouw A, Guindi M, Kakar S, Kleiner D, Krech T, Lackner C, Longerich T, Saxena R, Terracciano L, Washington K, Weidemann S, H\u00fcbscher S, Tiniakos D\nLIVER INT. 2022;42(5):1058-1069.\nTRPM2 Is Not Required for T-Cell Activation and Differentiation\nLory N, Nawrocki M, Corazza M, Schmid J, Schumacher V, Bedke T, Menzel S, Koch-Nolte F, Guse A, Huber S, Mittr\u00fccker H\nFRONT IMMUNOL. 2022;12:.\nPersistent SOMAtic symptoms ACROSS diseases - from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211)\nL\u00f6we B, Andresen V, Van den Bergh O, Huber T, von dem Knesebeck O, Lohse A, Nestoriuc Y, Schneider G, Schneider S, Schramm C, St\u00e4nder S, Vettorazzi E, Zapf A, Shedden-Mora M, Toussaint A\nBMJ OPEN. 2022;12(1):.\nPersistence of gastrointestinal symptoms in irritable bowel syndrome and ulcerative colitis: study protocol for a three-arm randomised controlled trial (SOMA.GUT-RCT)\nL\u00f6we B, Nestoriuc Y, Andresen V, Vettorazzi E, Zapf A, H\u00fcbener S, Maehder K, Peters L, Lohse A\nBMJ OPEN. 2022;12(6):.\nAuthor Correction: Platelet GPIb\u03b1 is a mediator and potential interventional target for NASH and subsequent liver cancer\nMalehmir M, Pfister D, Gallage S, Szydlowska M, Inverso D, Kotsiliti E, Leone V, Peiseler M, Surewaard B, Rath D, Ali A, Wolf M, Drescher H, Healy M, Dauch D, Kroy D, Krenkel O, Kohlhepp M, Engleitner T, Olkus A, Sijmonsma T, Volz J, Deppermann C, Stegner D, Helbling P, Nombela-Arrieta C, Rafiei A, Hinterleitner M, Rall M, Baku F, Borst O, Wilson C, Leslie J, O'Connor T, Weston C, Chauhan A, Adams D, Sheriff L, Teijeiro A, Prinz M, Bogeska R, Anstee N, Bongers M, Notohamiprodjo M, Geisler T, Withers D, Ware J, Mann D, Augustin H, Vegiopoulos A, Milsom M, Rose A, Lalor P, Llovet J, Pinyol R, Tacke F, Rad R, Matter M, Djouder N, Kubes P, Knolle P, Unger K, Zender L, Nieswandt B, Gawaz M, Weber A, Heikenwalder M\nNAT MED. 2022;28(3):600.\nDisturbed lipid and amino acid metabolisms in COVID-19 patients\nMasoodi M, Peschka M, Schmiedel S, Haddad M, Frye M, Maas C, Lohse A, Huber S, Kirchhof P, Nofer J, Renn\u00e9 T\nJ MOL MED. 2022;100(4):555-568.\nPerformance of Field's Stain Compared with Conventional Giemsa Stain for the Rapid Detection of Blood Microfilariae in Gabon\nMbassi F, Mombo-Ngoma G, Ndoumba W, Yovo E, Eberhardt K, Mbassi D, Adegnika A, Agnandji S, Bouyou-Akotet M, Ramharter M, Zoleko-Manego R\nAM J TROP MED HYG. 2022;107(2):383-387.\nSARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia\nMellinghoff S, Mayer L, Robrecht S, Weskamm L, Dahlke C, Gruell H, Schlotz M, Vanshylla K, Schloser H, Thelen M, Fink A, Fischer K, Klein F, Addo M, Eichhorst B, Hallek M, Langerbeins P\nHAEMATOLOGICA. 2022;107(10):2480-2484.\nSARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia\nMellinghoff S, Robrecht S, Mayer L, Weskamm L, Dahlke C, Gruell H, Vanshylla K, Schl\u00f6sser H, Thelen M, Fink A, Fischer K, Klein F, Addo M, Eichhorst B, Hallek M, Langerbeins P\nLEUKEMIA. 2022;36(2):562-565.\nDebunking Misinformation and Communicating Critical Events in Vaccine Trials: Experimental Evidence on Vaccination Intentions in SARS-CoV-2 Pandemic\nMemenga P, Eitze S, Shamsrizi P, Addo M, Betsch C\nEuropean Journal of Health Communication. 2022;3(2):64-96.\nFatal outcome of SARS-CoV-2 infection (B1.1.7) in a 4-year-old child\nMenger J, Apostolidou S, Edler C, Kniep I, Kobbe R, Singer D, Sperhake J\nINT J LEGAL MED. 2022;136(1):189-192.\nNK Cells, Monocytes and Macrophages in HIV-1 Control: Impact of Innate Immune Responses\nMensching L, H\u00f6lzemer A\nFRONT IMMUNOL. 2022;13:.\nStabilized recombinant SARS-CoV-2 spike antigen enhances vaccine immunogenicity and protective capacity\nMeyer Zu Natrup C, Tscherne A, Dahlke C, Ciurkiewicz M, Shin D, Fathi A, Rohde C, Kalodimou G, Halwe S, Limpinsel L, Schwarz J, Klug M, Esen M, Schneiderhan-Marra N, Dulovic A, Kupke A, Brosinski K, Clever S, Sch\u00fcnemann L, Beythien G, Armando F, Mayer L, Weskamm L, Jany S, Freudenstein A, Tuchel T, Baumg\u00e4rtner W, Kremsner P, Fendel R, Addo M, Becker S, Sutter G, Volz A\nJ CLIN INVEST. 2022;132(24):.\nLong-term persistence of antibodies after diphtheria/tetanus vaccination in immunosuppressed patients with inflammatory rheumatic diseases and healthy controls\nMischlinger J, Jaeger V, Ciurea A, Gabay C, Hasler P, Mueller R, Siegrist C, Villiger P, Walker U, Hatz C, B\u00fchler S\nVACCINE. 2022;40(33):4897-4904.\nMalaria and its importance in travel medicine\nMischlinger J, Jochum J, Ramharter M, Kurth F\nDEUT MED WOCHENSCHR. 2022;147(12):745-755.\nCOVID-19 and Adult Acute Leukemia: Our Knowledge in Progress\nModemann F, Ghandili S, Schmiedel S, Weisel K, Bokemeyer C, Fiedler W\nCANCERS. 2022;14(15):.\nEfficacy of Tigecycline as Salvage Therapy in Multidrug-Resistant Febrile Neutropenia in Patients with Acute Leukemia-A Single Center Analysis\nModemann F, H\u00e4rterich S, Schulze Zur Wiesch J, Rohde H, Lindeman N, Bokemeyer C, Fiedler W, Ghandili S\nANTIBIOTICS-BASEL. 2022;11(2):.\nRisk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation\nMontano-Loza A, Ronca V, Ebadi M, Hansen B, Hirschfield G, Elwir S, Alsaed M, Milkiewicz P, Janik M, Marschall H, Burza M, Efe C, Cal\u0131\u015fkan A, Harputluoglu M, Kaba\u00e7am G, Terrabuio D, de Quadros Onofrio F, Selzner N, Bonder A, Par\u00e9s A, Llovet L, Aky\u0131ld\u0131z M, Arikan C, Manns M, Taubert R, Weber A, Schiano T, Haydel B, Czubkowski P, Socha P, O\u0142dak N, Akamatsu N, Tanaka A, Levy C, Martin E, Goel A, Sedki M, Jankowska I, Ikegami T, Rodriguez M, Sterneck M, Weiler-Normann C, Schramm C, Donato M, Lohse A, Andrade R, Patwardhan V, van Hoek B, Biewenga M, Kremer A, Ueda Y, Deneau M, Pedersen M, Mayo M, Floreani A, Burra P, Secchi M, Beretta-Piccoli B, Sciveres M, Maggiore G, Jafri S, Debray D, Girard M, Lacaille F, Lytvyak E, Mason A, Heneghan M, Oo Y\nJ HEPATOL. 2022;77(1):84-97.\nInflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis\nM\u00fcller A, Casar C, Preti M, Krzikalla D, Gottwick C, Averhoff P, Rosenstiel P, Gelderblom M, Altfeld M, Lohse A, Steinmann S, Sebode M, Krause J, Schwinge D, Schramm C, Carambia A, Herkel J\nJ HEPATOL. 2022;77(6):1532-1544.\nDrug-induced hypersensitivity to artemisinin-based therapies for malaria\nNordmann T, Borrmann S, Ramharter M\nTRENDS PARASITOL. 2022;38(2):136-146.\nClinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus\nN\u00f6rz D, Brehm T, Tang H, Grewe I, Hermanussen L, Matthews H, Pestel J, Degen O, G\u00fcnther T, Grundhoff A, Fischer N, Addo M, Jordan S, Hertling S, Unger S, Sch\u00e4fer G, Schewe K, Hoffmann C, Aepfelbacher M, Pfefferle S, Schulze Zur Wiesch J, Schmiedel S, L\u00fctgehetmann M\nJ CLIN VIROL. 2022;155:.\nEvidence of surface contamination in hospital rooms occupied by patients infected with monkeypox, Germany, June 2022\nN\u00f6rz D, Pfefferle S, Brehm T, Franke G, Grewe I, Knobling B, Aepfelbacher M, Huber S, Klupp E, Jordan S, Addo M, Schulze Zur Wiesch J, Schmiedel S, L\u00fctgehetmann M, Knobloch J\nEUROSURVEILLANCE. 2022;27(26):.\nRapid Adaptation of Established High-Throughput Molecular Testing Infrastructure for Monkeypox Virus Detection\nN\u00f6rz D, Tang H, Emmerich P, Giersch K, Fischer N, Schmiedel S, Addo M, Aepfelbacher M, Pfefferle S, L\u00fctgehetmann M\nEMERG INFECT DIS. 2022;28(9):1765-1769.\nTwo Cases of Lassa Fever Successfully Treated with Ribavirin and Adjunct Dexamethasone for Concomitant Infections\nOkogbenin S, Erameh C, Okoeguale J, Edeawe O, Ekuaze E, Iraoyah K, Agho J, Groger M, Kreuels B, Oestereich L, Babatunde F, Akhideno P, G\u00fcnther S, Ramharter M, Omansen T\nEMERG INFECT DIS. 2022;28(10):2060-2063.\nA standardised Phase III clinical trial framework to assess therapeutic interventions for Lassa fever\nOlayinka A, Bourner J, Akpede G, Okoeguale J, Abejegah C, Ajayi N, Akude C, Ayodeji O, Bausch D, de Clerck H, Dan-Nwafor C, Dunning J, Erameh C, Eze J, Formenty P, Gillesen A, Jalloh S, Jaspard M, Jegede T, Maikere J, Malvy D, Ogbaini-Emovon E, Ojo O, Okogbenin S, O'Neill K, Orji M, Owhin S, Ramharter M, Samuels R, Shehu N, Merson L, Salam A, Kayem N, Horby P, Ihekweazu C, Olliaro P\nPLOS NEGLECT TROP D. 2022;16(1):.\nSarkoidose als Paradebeispiel einer granulomat\u00f6sen Erkrankung\nOqueka T, Galow S, Simon M, Weidmann A, St\u00fcbiger N, Zengin-Sahm E, Sinning C, Krusche M, Ruffer N, Steurer S, Schick-Bengardt X, Sebode M, Horst L, Steinmetz O, Melderis S, Rosenkranz S, M\u00f6ller K, Jantke H, Klose H\nZ RHEUMATOL. 2022;81(7):535-548.\nEpidemiology of Plasmids in Escherichia coli and Klebsiella pneumoniae with Acquired Extended Spectrum Beta-Lactamase Genes Isolated from Chronic Wounds in Ghana\nPankok F, Taudien S, Dekker D, Thye T, Oppong K, Wiafe Akenten C, Lamsh\u00f6ft M, Jaeger A, Kaase M, Scheithauer S, Tanida K, Frickmann H, May J, Loderst\u00e4dt U\nANTIBIOTICS-BASEL. 2022;11(5):.\nSystematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group\nPape S, Snijders R, Gevers T, Chazouilleres O, Dalekos G, Hirschfield G, Lenzi M, Trauner M, Manns M, Vierling J, Montano-Loza A, Lohse A, Schramm C, Drenth J, Heneghan M\nJ HEPATOL. 2022;76(4):841-849.\nThe spatial transcriptomic landscape of the healing mouse intestine following damage\nParigi S, Larsson L, Das S, Ramirez Flores R, Frede A, Tripathi K, Diaz O, Selin K, Morales R, Luo X, Monasterio G, Engblom C, Gagliani N, Saez-Rodriguez J, Lundeberg J, Villablanca E\nNAT COMMUN. 2022;13(1):.\nSpecific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant\nPaul K, Sibbertsen F, Weiskopf D, L\u00fctgehetmann M, Barroso M, Danecka M, Glau L, Hecher L, Hermann K, Kohl A, Oh J, Wiesch J, Sette A, Tolosa E, Vettorazzi E, Woidy M, Zapf A, Zazara D, Mir T, Muntau A, Gersting S, Dunay G\nFRONT IMMUNOL. 2022;13:867577.\nTargeting Cyclin-Dependent Kinase 7 - Association between CDK7 and pMED1 Expression in Prostate Cancer Tissue\nPaulsen F, Kang D, Becker F, Roth D, J\u00f6rg V, Dreyer E, Roesch M, Seidel C, Merseburger A, Kirfel J, Sailer V, Offermann A, Perner S\nCARCINOGENESIS. 2022;43(8):779-786.\nScreening for Monkeypox Infection in Asymptomatic High-Risk-Behaviour Men Having Sex with Men (MSM)\nPestel J, Matthews H, Schmiedel S, H\u00fcfner A, Jordan S, Scheiter R, L\u00fctgehetmann M, N\u00f6rz D, Degen O\nINFECT DIS REP. 2022;14(5):794-797.\nAktualisierte Empfehlungen zur infektiologischen Versorgung von Fl\u00fcchtlingen im Kindes- und Jugendalter in Deutschland (Stand 30. M\u00e4rz 2022), angemeldet als S1-Leitlinie (AWMF-Register Nr. 048-017): Stellungnahme der Deutschen Gesellschaft f\u00fcr P\u00e4diatrische Infektiologie e. V. (DGPI), der Gesellschaft f\u00fcr Tropenp\u00e4diatrie und Internationale Kindergesundheit e. V. (GTP), des Berufsverbandes der Kinder- und Jugend\u00e4rzte e. V. (BVKJ) und der Deutschen Gesellschaft f\u00fcr Kinder- und Jugendmedizin e. V. (DGKJ), unter Mitarbeit des Berufsverbands der \u00c4rztinnen und \u00c4rzte des \u00d6ffentlichen Gesundheitsdienstes e. V. (BV\u00d6GD), der Deutschen Gesellschaft f\u00fcr Kinderchirurgie e. V. (DGKCH), der Deutschen Gesellschaft f\u00fcr Gyn\u00e4kologie und Geburtshilfe e. V. (DGGG), Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (DEGAM), des B\u00fcndnis Kinder- und Jugendgesundheit e. V. (fr\u00fcher Deutsche Akademie f\u00fcr Kinder- und Jugendmedizin, DAKJ), der Deutschen Gesellschaft f\u00fcr Tropenmedizin, Reisemedizin und Globale Gesundheit e. V. (DTG), der Deutschen Gesellschaft f\u00fcr Globale und Tropenchirurgie e. V. (DTC) und der P\u00e4diatrisch Infektiologischen Gruppe Schweiz (PIGS)\nPfeil J, Assaad K, von Both U, Janda A, Kitz C, Kobbe R, Kunze M, Lindert J, Ritz N, Trapp S, Hufnagel M\nMONATSSCHR KINDERH. 2022;170(7):632-647.\nLiver damage promotes pro-inflammatory T-cell responses against apolipoprotein B-100\nPlochg B, Englert H, Rangaswamy C, Konrath S, Malle M, Lampalzer S, Beisel C, Wollin S, Frye M, Aberle J, Kluwe J, Renn\u00e9 T, Mailer R\nJ INTERN MED. 2022;291(5):648-664.\nBurden of malaria in pregnancy among adolescent girls compared to adult women in 5 sub-Saharan African countries: A secondary individual participant data meta-analysis of 2 clinical trials\nPons-Duran C, Mombo-Ngoma G, Macete E, Desai M, Kakolwa M, Zoleko-Manego R, Ou\u00e9dragou S, Briand V, Val\u00e1 A, Kabanywanyi A, Ouma P, Massougbodji A, Sevene E, Cot M, Aponte J, Mayor A, Slutsker L, Ramharter M, Men\u00e9ndez C, Gonz\u00e1lez R\nPLOS MED. 2022;19(9):.\nInflammatory cytokine profile and T cell responses in African tick bite fever patients\nRauch J, Jochum J, Eisermann P, Gisbrecht J, V\u00f6lker K, Hunstig F, Mehlhoop U, Muntau B, Tappe D\nMED MICROBIOL IMMUN. 2022;211(2-3):143-152.\nLocalization defines streptozotocin/5-FU response in primary pancreatic neuroendocrine tumours\nReher D, Fehrenbach U, Radiology D, Radiology D, Henes F, Cremer B, H\u00f6rsch D, Izbicki J, Lohse A, Rinke A, Schrader J\nNEUROENDOCRINOLOGY. 2022;112(6):595-605.\nChronisch-entz\u00fcndliche Darmerkrankungen: Therapiealgorithmus 2021\nReher D, Manthey C, Huber S\nt\u00e4gliche praxis. 2022;2022(66/3):373-389.\nCustomization of a dada2-based pipeline for fungal internal transcribed spacer 1 (ITS 1) amplicon datasets\nRolling T, Zhai B, Frame J, Hohl T, Taur Y\nJCI INSIGHT. 2022;7(1):.\nSARS-CoV2-specific humoral and T-cell immune response after second vaccination in liver cirrhosis and transplant patients\nRuether D, Schaub G, Duengelhoef P, Haag F, Brehm T, Fathi A, Wehmeyer M, Jahnke-Triankowski J, Mayer L, Hoffmann A, Fischer L, Addo M, L\u00fctgehetmann M, Lohse A, Schulze Zur Wiesch J, Sterneck M\nCLIN GASTROENTEROL H. 2022;20(1):162-172.e9.\nErratum zu: Imitation eines Felty-Syndroms durch eine viszerale Leishmaniasis bei rheumatoider Arthritis unter Therapie mit Methotrexat und Etanercept\nRuffer N, Tomas N, Schmiedel S, Jordan S, K\u00f6tter I\nZ RHEUMATOL. 2022;81(3):244.\nImitation eines Felty-Syndroms durch eine viszerale Leishmaniasis bei rheumatoider Arthritis unter Therapie mit Methotrexat und Etanercept\nRuffer N, Tomas N, Schmiedel S, Jordan S, K\u00f6tter I\nZ RHEUMATOL. 2022;81(3):240-243.\nAutoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care\nR\u00fcther D, Weltzsch J, Schramm C, Sebode M, Lohse A\nJ HEPATOL. 2022;77(1):250-251.\nS3-Leitlinie: Diagnostik und Therapie des hepatozellul\u00e4ren Karzinoms\nSabrina V, Michael B, J\u00f6rg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, J\u00fcrgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-J\u00fcrgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, J\u00fcrgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, J\u00f6rg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M\nZ GASTROENTEROL. 2022;60(1):e56-e130.\nS3-Leitlinie: Diagnostik und Therapie des hepatozellul\u00e4ren Karzinoms \u2013 Kurzversion 2.00 \u2013 Juni 2021, AWMF-Registernummer: 032-053OL\nSabrina V, Michael B, J\u00f6rg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian L, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, J\u00fcrgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-J\u00fcrgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, J\u00fcrgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich v, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, J\u00f6rg T, Ingo v, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M\nZ GASTROENTEROL. 2022;60(1):81-107.\nCorrigendum to: Molecular Epidemiology of Mansonella Species in Gabon\nSandri T, Kreidenweiss A, Cavallo S, Weber D, Juhas S, Rodi M, Woldearegai T, Gmeiner M, Veletzky L, Ramharter M, Tazemda-Kuitsouc G, Matsiegui P, Mordm\u00fcller B, Held J\nJ INFECT DIS. 2022;225(5):.\nA Multi\u2011Center, Open\u2011Label, Single\u2011Arm Trial to Evaluate the Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency\nSantamaria M, Neth O, Douglass J, Krivan G, Kobbe R, Bernatowska E, Grigoriadou S, Bethune C, Chandra A, Horneff G, Borte M, Sonnenschein A, Kralickova P, Ram\u00f3n S, Langguth D, Gonzalez-Granado L, Alsina L, Querolt M, Griffin R, Hames C, Mondou E, Price J, Sanz A, Lin J\nJ CLIN IMMUNOL. 2022;42(3):500-511.\nThe Clinical Features and Immunological Signature of Cyclospora cayetanensis Co-Infection among People Living with HIV in Ghana\nSarfo F, Dompreh A, Asibey S, Boateng R, Weinreich F, Kuffour E, Norman B, Di Cristanziano V, Frickmann H, Feldt T, Eberhardt K\nMICROORGANISMS. 2022;10(7):.\nPrognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score\nScheiner B, Pomej K, Kirstein M, Hucke F, Finkelmeier F, Waidmann O, Himmelsbach V, Schulze K, von Felden J, Fr\u00fcndt T, Stadler M, Heinzl H, Shmanko K, Spahn S, Radu P, Siebenh\u00fcner A, Mertens J, Rahbari N, K\u00fctting F, Waldschmidt D, Ebert M, Teufel A, De Dosso S, Pinato D, Pressiani T, Meischl T, Balcar L, M\u00fcller C, Mandorfer M, Reiberger T, Trauner M, Personeni N, Rimassa L, Bitzer M, Trojan J, Weinmann A, Wege H, Dufour J, Peck-Radosavljevic M, Vogel A, Pinter M\nJ HEPATOL. 2022;76(2):353-363.\nFeasibility and Efficacy of Adjuvant Chemotherapy With Gemcitabine After Liver Transplantation for Perihilar Cholangiocarcinoma - A Multi-Center, Randomized, Controlled Trial (pro-duct001)\nSchmelzle M, Benzing C, Fischer L, Herden U, Sterneck M, Settmacher U, Bauschke A, Neumann U, Pelzer U, M\u00fcller T, Strassburg C, Lang H, Becker T, K\u00f6nigsrainer A, Nadalin S, Quante M, Paul A, Friess H, Klempnauer J, Richter N, Vondran F, Pascher A, R\u00f6sch T, Sch\u00f6ning W, Krenzien F, \u00d6llinger R, Seehofer D, Neuhaus P, Pratschke J\nFRONT ONCOL. 2022;12:.\nRisk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients-COVIDOUT study\nSch\u00f6nlein M, Wrage V, Ghandili S, Mellinghoff S, Brehm T, Leypoldt L, Utz N, Schrader R, Alsdorf W, B\u00f6rschel N, Bu\u00dfmann L, Sch\u00f6nrock M, Perlick D, Sch\u00f6n G, Verpoort K, L\u00fctgehetmann M, Schulze Zur Wiesch J, Weisel K, Bokemeyer C, Schafhausen P, Sinn M\nCANCER CELL. 2022;40(6):581-583.\nThe German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics\nSchons M, Pilgram L, Reese J, Stecher M, Anton G, Appel K, Bahmer T, Bartschke A, Bellinghausen C, Bernemann I, Brechtel M, Brinkmann F, Br\u00fcnn C, Dhillon C, Fiessler C, Geisler R, Hamelmann E, Hansch S, Hanses F, Han\u00df S, Herold S, Heyder R, Hofmann A, Hopff S, Horn A, Jakob C, Jiru-Hillmann S, Keil T, Khodamoradi Y, Kohls M, Kraus M, Krefting D, Kunze S, Kurth F, Lieb W, Lippert L, Lorbeer R, Lorenz-Depiereux B, Maetzler C, Miljukov O, Nauck M, Pape D, P\u00fcntmann V, Reinke L, R\u00f6mmele C, Rudolph S, Sass J, Sch\u00e4fer C, Schaller J, Schattschneider M, Scheer C, Scherer M, Schmidt S, Schmidt J, Seibel K, Stahl D, Steinbeis F, St\u00f6rk S, Tauchert M, Tebbe J, Thibeault C, Toepfner N, Ungeth\u00fcm K, Vadasz I, Valentin H, Wiedmann S, Zoller T, Nagel E, Krawczak M, von Kalle C, Illig T, Schreiber S, Witzenrath M, Heuschmann P, Vehreschild J\nEUR J EPIDEMIOL. 2022;37(8):849-870.\nTolerance and autoimmunity in the liver\nSchramm C, Oo Y, Lohse A\nSEMIN IMMUNOPATHOL. 2022;44(4):393-395.\nFarnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis\nSchramm C, Wedemeyer H, Mason A, Hirschfield G, Levy C, Kowdley K, Milkiewicz P, Janczewska E, Malova E, Sanni J, Koo P, Chen J, Choudhury S, Klickstein L, Badman M, Jones D\nJHEP REP. 2022;4(11):.\nDeciphering the Plasmodium falciparum malaria-specific CD4+ T-cell response: ex vivo detection of high frequencies of PD-1+TIGIT+ EXP1-specific CD4+ T cells using a novel HLA-DR11-restricted MHC class II tetramer\nSchulte S, Heide J, Ackermann C, Peine S, Ramharter M, Mackroth M, Woost R, Jacobs T, Schulze Zur Wiesch J\nCLIN EXP IMMUNOL. 2022;207(2):227-236.\nB cells in autoimmune hepatitis: bystanders or central players?\nSchulthei\u00df C, Steinmann S, Lohse A, Binder M\nSEMIN IMMUNOPATHOL. 2022;44(4):411-427.\nThe IL-1\u03b2, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19\nSchulthei\u00df C, Willscher E, Paschold L, Gottschick C, Klee B, Henkes S, Bosurgi L, Dutzmann J, Sedding D, Frese T, Girndt M, H\u00f6ll J, Gekle M, Mikolajczyk R, Binder M\nCELL REP MED. 2022;3(6):100663.\nReinforcement learning-basierte Patchpriorisierung zur beschleunigten Segmentierung von hochaufl\u00f6senden Endoskopievideodaten\nSch\u00fcttler S, Madesta F, R\u00f6sch T, Werner R, Schmitz R\n2022. Informatik aktuell: Bildverarbeitung f\u00fcr die Medizin. Klaus M, Deserno T, Handels H, Maier A, Palm C, Tolxdorff T (Hrsg.). 1. Aufl. Wiesbaden: Springer Vieweg, 339-344.\nHistological spectrum of autoimmune hepatitis-reply to Fujiwara K. et al\nSebode M, Lohse A, H\u00fcbscher S, Tiniakos D\nLIVER INT. 2022;42(7):1704-1705.\nLiquid biopsy and preclinical tools for advancing diagnosis and treatment of patients with pancreatic neuroendocrine neoplasms\nSmolkova B, Kataki A, Earl J, Ruz-Caracuel I, Cihova M, Urbanova M, Buocikova V, Tamargo S, Rovite V, Niedra H, Schrader J, Kohl Y\nCRIT REV ONCOL HEMAT. 2022;180:.\nAttitude toward a mandatory COVID-19 vaccination policy and its determinants: Evidence from serial cross-sectional surveys conducted throughout the pandemic in Germany\nSprengholz P, Korn L, Eitze S, Felgendreff L, Siegers R, Goldhahn L, De Bock F, Huebl L, B\u00f6hm R, Betsch C\nVACCINE. 2022;40(51):7370-7377.\nFunctional limitations 12 months after SARS-CoV-2 infection correlate with initial disease severity: An observational study of cardiopulmonary exercise capacity testing in COVID-19 convalescents\nSteinbeis F, Knape P, Mittermaier M, Helbig E, Tober-Lau P, Thibeault C, Lippert L, Xiang W, M\u00fcller-Plathe M, Steinbrecher S, Meyer H, Ring R, Ruwwe-Gl\u00f6senkamp C, Alius F, Li Y, M\u00fcller-Redetzky H, Uhrig A, Lingscheid T, Grund D, Temmesfeld-Wollbr\u00fcck B, Suttorp N, Sander L, Kurth F, Witzenrath M, Zoller T\nRESP MED. 2022;202:.\nSeverity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months\nSteinbeis F, Thibeault C, Doellinger F, Ring R, Mittermaier M, Ruwwe-Gl\u00f6senkamp C, Alius F, Knape P, Meyer H, Lippert L, Helbig E, Grund D, Temmesfeld-Wollbr\u00fcck B, Suttorp N, Sander L, Kurth F, Penzkofer T, Witzenrath M, Zoller T\nRESP MED. 2022;191:.\nA clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission\nStockdale A, Kreuels B, Shawa I, Meiring J, Thindwa D, Silungwe N, Chetcuti K, Joekes E, Mbewe M, Mbale B, Patel P, Kachala R, Patel P, Malewa J, Finch P, Davis C, Shah R, Tong L, da Silva Filipe A, Thomson E, Geretti A, Gordon M\nJ VIRAL HEPATITIS. 2022;29(4):252-262.\nHepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi\nStockdale A, Meiring J, Shawa I, Thindwa D, Silungwe N, Mbewe M, Kachala R, Kreuels B, Patel P, Patel P, Henrion M, Bar-Zeev N, Swarthout T, Heyderman R, Gordon S, Geretti A, Gordon M\nJ INFECT DIS. 2022;226(5):871-880.\nIncreased concentrations of conjugated bile acids are associated with osteoporosis in PSC patients\nSt\u00fcrznickel J, Behler-Janbeck F, Baranowsky A, Schmidt T, Schwinge D, John C, Lohse A, Schramm C, Heeren J, Schinke T, Amling M\nSCI REP-UK. 2022;12(1):.\nS1-Leitlinie zur Versorgung von Lebertransplantierten w\u00e4hrend der COVID-19-Pandemie \u2013 AWMF-Registernummer: 021-031 \u2013 Stand 15. Juni 2022\nTacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein W, Berg T\nZ GASTROENTEROL. 2022;60(11):1678-1698.\nQuantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis\nTaubert R, Engel B, Diestelhorst J, Hupa-Breier K, Behrendt P, Baerlecken N, S\u00fchs K, Janik M, Zachou K, Sebode M, Schramm C, Londo\u00f1o M, Habes S, Oo Y, Lalanne C, Pape S, Schubert M, Hust M, D\u00fcbel S, Thevis M, Jonigk D, Beimdiek J, Buettner F, Drenth J, Muratori L, Adams D, Dyson J, Renand A, Graupera I, Lohse A, Dalekos G, Milkiewicz P, Stangel M, Maasoumy B, Witte T, Wedemeyer H, Manns M, Jaeckel E\nHEPATOLOGY. 2022;75(1):13-27.\nCross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections\nTober-Lau P, Gruell H, Vanshylla K, Koch W, Hillus D, Schommers P, Su\u00e1rez I, Suttorp N, Sander L, Klein F, Kurth F\nEMERG INFECT DIS. 2022;28(5):1050-1052.\nFactors associated with severity and persistence of fatigue in patients with primary biliary cholangitis: study protocol of a prospective cohort study with a mixed-methods approach (SOMA.LIV)\nToussaint A, Buck L, Hartl J, L\u00f6we B, Schramm C\nBMJ OPEN. 2022;12(12):.\nPrevalence and characterization of antimicrobial resistance among gram-negative bacteria isolated from febrile hospitalized patients in central Ethiopia\nTufa T, Mackenzie C, Orth H, Wienemann T, Nordmann T, Abdissa S, Hurissa Z, Sch\u00f6nfeld A, Bosselmann M, H\u00e4ussinger D, Pfeffer K, Luedde T, Fuchs A, Feldt T\nANTIMICROB RESIST IN. 2022;11(1):.\nDolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial\nTurkova A, Waalewijn H, Chan M, Bollen P, Bwakura-Dangarembizi M, Kekitiinwa A, Cotton M, Lugemwa A, Variava E, Ahimbisibwe G, Srirompotong U, Mumbiro V, Amuge P, Zuidewind P, Ali S, Kityo C, Archary M, Ferrand R, Violari A, Gibb D, Burger D, Ford D, Colbers A\nLANCET HIV. 2022;9(9):E627-E637.\nCross-tissue transcriptome-wide association studies identify susceptibility genes shared between schizophrenia and inflammatory bowel disease\nUellendahl-Werth F, Maj C, Borisov O, Juzenas S, Wacker E, J\u00f8rgensen I, Steiert T, Bej S, Krawitz P, Hoffmann P, Schramm C, Wolkenhauer O, Banasik K, Brunak S, Schreiber S, Karlsen T, Degenhardt F, N\u00f6then M, Franke A, Folseraas T, Ellinghaus D\nCOMMUN BIOL. 2022;5(1):.\nPsychosoziale Unterst\u00fctzung von Menschen mit Colitis ulcerosa und Reizdarmsyndrom: eine Machbarkeitsstudie zu Bedarf, Fokus und Durchf\u00fchrbarkeit\nUhlenbusch N, Manthey C, Nestoriuc Y, Andresen V, Lohse A, L\u00f6we B\nPSYCHOTHER PSYCH MED. 2022;72(11):481-490.\nCarboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas\nUhlig R, Contreras H, Weidemann S, Gorbokon N, Menz A, B\u00fcscheck F, Luebke A, Kluth M, Hube-Magg C, Hinsch A, H\u00f6flmayer D, Fraune C, M\u00f6ller K, Bernreuther C, Lebok P, Sauter G, Wilczak W, Izbicki J, Perez D, Schrader J, Steurer S, Burandt E, Krech R, Dum D, Krech T, Marx A, Simon R, Minner S, Jacobsen F, Clauditz T\nAM J SURG PATHOL. 2022;46(1):97-104.\nThe Use of PDX1 DNA Methylation to Distinguish Two Subtypes of Pancreatic Neuroendocrine Neoplasms with Different Prognoses\nUngefroren H, Konukiewitz B, Wellner U, Schrader J, Keck T\nCANCERS. 2022;15(1):.\nDifferential Effects of Somatostatin, Octreotide, and Lanreotide on Neuroendocrine Differentiation and Proliferation in Established and Primary NET Cell Lines: Possible Crosstalk with TGF-\u03b2 Signaling\nUngefroren H, K\u00fcnstner A, Busch H, Franzenburg S, Luley K, Viol F, Schrader J, Konukiewitz B, Wellner U, Meyh\u00f6fer S, Keck T, Marquardt J, Lehnert H\nINT J MOL SCI. 2022;23(24):.\nDurability of omicron-neutralising serum activity after mRNA booster immunisation in older adults\nVanshylla K, Tober-Lau P, Gruell H, M\u00fcnn F, Eggeling R, Pfeifer N, Le N, Landgraf I, Kurth F, Sander L, Klein F\nLANCET INFECT DIS. 2022;22(4):445-446.\nDistinct loiasis infection states and associated clinical and hematological manifestations in patients from Gabon\nVeletzky L, Eberhardt K, Hergeth J, Stelzl D, Zoleko Manego R, Mombo-Ngoma G, Kreuzmair R, Burger G, Adegnika A, Agnandji S, Matsiegui P, Boussinesq M, Mordm\u00fcller B, Ramharter M\nPLOS NEGLECT TROP D. 2022;16(9):.\nCorrection to: Reporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group\nVenkatesh S, L Welle C, H Miller F, Jhaveri K, Ringe K, Eaton J, Bungay H, Arriv\u00e9 L, Ba-Ssalamah A, Grigoriadis A, Schramm C, Fulcher A\nEUR RADIOL. 2022;32(4):2860.\nReporting standards for primary sclerosing cholangitis using MRI and MR cholangiopancreatography: guidelines from MR Working Group of the International Primary Sclerosing Cholangitis Study Group\nVenkatesh S, Welle C, Miller F, Jhaveri K, Ringe K, Eaton J, Bungay H, Arriv\u00e9 L, Ba-Ssalamah A, Grigoriadis A, Schramm C, Fulcher A\nEUR RADIOL. 2022;32(2):923-937.\nNovel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy\nViol F, Sipos B, Fahl M, Clauditz T, Amin T, Kriegs M, Nieser M, Izbicki J, Huber S, Lohse A, Schrader J\nCELL ONCOL. 2022;45(6):1401-1419.\nImpact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma\nVithayathil M, D'Alessio A, Fulgenzi C, Nishida N, Sch\u00f6nlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron T, Weinmann A, Galle P, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee P, Huang Y, Amara S, Muzaffar M, Naqash A, Cammarota A, Personeni N, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato D, Sharma R\nLIVER INT. 2022;42(11):2538-2547.\nDer Einsatz der immunonkologischen Therapie beim hepatozellul\u00e4ren Karzinom im Kontext der Lebertransplantation Eine interdisziplin\u00e4re Risiko-Nutzen-Abw\u00e4gung\nVogel A, Sterneck M, Vondran F, Waidmann O, Klein I, Lindig U, Nadalin S, Settmacher U, Tacke F, Schlitt H, Wege H\nZ GASTROENTEROL. 2022;60(2):184-191.\nHigh risk of complications and acute-on-chronic liver failure in cirrhosis patients with acute pancreatitis\nVogel M, Ehlken H, Kluge S, Roesch T, Lohse A, Huber S, Sterneck M, H\u00fcbener P\nEUR J INTERN MED. 2022;102:54-62.\nHost KIR/HLA-C Genotypes Determine HIV-Mediated Changes of the NK Cell Repertoire and Are Associated With Vpu Sequence Variations Impacting Downmodulation of HLA-C\nVollmers S, Lobermeyer A, Niehrs A, Fittje P, Indenbirken D, Nakel J, Virdi S, Brias S, Trenkner T, Sauer G, Peine S, Behrens G, Lehmann C, Meurer A, Pauli R, Postel N, Roider J, Scholten S, Spinner C, Stephan C, Wolf E, Wyen C, Richert L, Norman P, Sauter J, Schmidt A, H\u00f6lzemer A, Altfeld M, K\u00f6rner C\nFRONT IMMUNOL. 2022;13:.\nErratum zu: Milde COVID-19-Verl\u00e4ufe bei Mitarbeitenden einer Universit\u00e4tsklinik : Die \u201eerste Welle\u201c am Universit\u00e4tsklinikum Hamburg-Eppendorf\nvon Felden J, Brehm T, Schulze Zur Wiesch J, Addo M, Lohse A, Knobloch J, Koch T\nBUNDESGESUNDHEITSBLA. 2022;65(3):398.\nUnannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer\nvon Felden J, Garcia-Lezana T, Dogra N, Gonzalez-Kozlova E, Ahsen M, Craig A, Gifford S, Wunsch B, Smith J, Kim S, Diaz J, Chen X, Labgaa I, Haber P, Olsen R, Han D, Restrepo P, D'Avola D, Hernandez-Meza G, Allette K, Sebra R, Saberi B, Tabrizian P, Asgharpour A, Dieterich D, Llovet J, Cordon-Cardo C, Tewari A, Schwartz M, Stolovitzky G, Losic B, Villanueva A\nGUT. 2022;71(10):2069-2080.\nTissue Sampling and Homogenization with NIRL Enables Spatially Resolved Cell Layer Specific Proteomic Analysis of the Murine Intestine\nVo\u00df H, Moritz M, Pelczar P, Gagliani N, Huber S, Nippert V, Schl\u00fcter H, Hahn J\nINT J MOL SCI. 2022;23(11):.\nImmune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles\nWalker A, Schwarz T, Brinkmann-Paulukat J, Wisskirchen K, Menne C, Alizei E, Kefalakes H, Theissen M, Hoffmann D, Schulze Zur Wiesch J, Maini M, Cornberg M, Kraft A, Keitel V, Bock H, Horn P, Thimme R, Wedemeyer H, Heinemann F, Luedde T, Neumann-Haefelin C, Protzer U, Timm J\nFRONT IMMUNOL. 2022;13:.\nA multiplex protein panel assay for severity prediction and outcome prognosis in patients with COVID-19: An observational multi-cohort study\nWang Z, Cryar A, Lemke O, Tober-Lau P, Ludwig D, Helbig E, Hippenstiel S, Sander L, Blake D, Lane C, Sayers R, Mueller C, Zeiser J, Townsend S, Demichev V, M\u00fclleder M, Kurth F, Sirka E, Hartl J, Ralser M\nECLINICALMEDICINE. 2022;49:.\nMolecular consequences of SARS-CoV-2 liver tropism\nWanner N, Andrieux G, Badia-I-Mompel P, Edler C, Pfefferle S, Lindenmeyer M, Schmidt-Lauber C, Czogalla J, Wong M, Okabayashi Y, Braun F, L\u00fctgehetmann M, Meister E, Lu S, Noriega M, G\u00fcnther T, Grundhoff A, Fischer N, Br\u00e4uninger H, Lindner D, Westermann D, Haas F, Roedl K, Kluge S, Addo M, Huber S, Lohse A, Reiser J, Ondruschka B, Sperhake J, Saez-Rodriguez J, Boerries M, Hayek S, Aepfelbacher M, Scaturro P, Puelles V, Huber T\nNAT METAB. 2022;4(3):310-319.\nStop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial\nWehmeyer M, Horvatits T, Buchholz A, Krause L, Walter S, Zapf A, Lohse A, Kluwe J\nTRIALS. 2022;23(1):302.\nFrequent detection of functional hyposplenism via assessment of pitted erythrocytes in patients with advanced liver cirrhosis\nWehmeyer M, Sekhri H, Wroblewski R, Galante A, Meyer T, Lohse A, Schulze Zur Wiesch J\nPLOS ONE. 2022;17(7):.\nEinstellungen gegen\u00fcber der COVID-19-Impfung im Vergleich zur Grippeschutzimpfung bei Krankenhauspersonal\nWeigel A, Brehm T, Schulze zur Wiesch J, Vogt B, Lohse A, L\u00f6we B\nPSYCHOTHER PSYCH MED. 2022;72(8):382-385.\nComparative Evaluation of Real-Time Screening PCR Assays for Giardia duodenalis and of Assays Discriminating the Assemblages A and B\nWeinreich F, Hahn A, Eberhardt K, Kann S, Feldt T, Sarfo F, Di Cristanziano V, Frickmann H, Loderst\u00e4dt U\nMICROORGANISMS. 2022;10(7):.\nMulticentric Evaluation of SeeGene Allplex Real-Time PCR Assays Targeting 28 Bacterial, Microsporidal and Parasitic Nucleic Acid Sequences in Human Stool Samples\nWeinreich F, Hahn A, Eberhardt K, Kann S, K\u00f6ller T, Warnke P, Dupke S, Dekker D, May J, Frickmann H, Loderst\u00e4dt U\nDIAGNOSTICS. 2022;12(4):.\nScreening for Schistosoma spp. and Leishmania spp. DNA in Serum of Ghanaian Patients with Acquired Immunodeficiency\nWeinreich F, Weinreich F, Hahn A, Hagen R, Rohde H, Sarfo F, Feldt T, Dompreh A, Asibey S, Boateng R, Frickmann H, Eberhardt K\nPATHOGENS. 2022;11(7):.\nReal-World Data for Lenvatinib in Hepatocellular Carcinoma (ELEVATOR): A Retrospective Multicenter Study\nWelland S, Leyh C, Finkelmeier F, Jefremow A, Shmanko K, Gonzalez-Carmona M, Kandulski A, Jeliazkova P, Best J, Fr\u00fcndt T, Djanani A, Pangerl M, Maieron A, Greil R, Fricke C, Sookthai D, G\u00fcnther R, Schmiderer A, Wege H, Venerito M, Ehmer U, M\u00fcller M, Strassburg C, Weinmann A, Siebler J, Waidmann O, Lange C, Saborowski A, Vogel A\nLIVER CANCER. 2022;11(3):219-232.\nFlow cytometric protocol to characterize human memory B cells directed against SARS-CoV-2 spike protein antigens\nWeskamm L, Dahlke C, Addo M\nSTAR protocols. 2022;3(4):.\nPersistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine\nWeskamm L, Fathi A, Raadsen M, Mykytyn A, Koch T, Spohn M, Friedrich M, , Haagmans B, Becker S, Sutter G, Dahlke C, Addo M\nCELL REP MED. 2022;3(7):.\nLack of Evidence of Hepatitis E Virus Infections in a Cohort of Boars and Deer Species in a Game Reserve in Northern Germany\nWestphal T, Delling M, Mader M, Ackermann C, Horvatits T, L\u00fctgehetmann M, Schulze zur Wiesch J, Pischke S, Beisel C\nZoonotic Diseases. 2022;2(4):228-233.\nTranscriptional Pattern Analysis of Virus-Specific CD8+ T Cells in Hepatitis C Infection: Increased Expression of TOX and Eomesodermin During and After Persistent Antigen Recognition\nWildner N, Walker A, Brauneck F, Ditt V, Peine S, Huber S, Haag F, Beisel C, Timm J, Schulze Zur Wiesch J\nFRONT IMMUNOL. 2022;13:.\nNeutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab\nWu Y, Fulgenzi C, D'Alessio A, Cheon J, Nishida N, Saeed A, Wietharn B, Cammarota A, Pressiani T, Personeni N, Pinter M, Scheiner B, Balcar L, Huang Y, Phen S, Naqash A, Vivaldi C, Salani F, Masi G, Bettinger D, Vogel A, Sch\u00f6nlein M, von Felden J, Schulze K, Wege H, Galle P, Kudo M, Rimassa L, Singal A, Sharma R, Cortellini A, Gaillard V, Chon H, Pinato D, Ang C\nCANCERS. 2022;14(23):.\nTreatment Failure in Vertebral Osteomyelitis: Is it All About Staphylococcus aureus ?\nYagdiran A, Jochimsen D, Kernich N, Herden J, Eysel P, Eberhardt K, Jung N\nSPINE. 2022;47(20):E607-E614.\nCD4+ T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival\nYogev N, Bedke T, Kobayashi Y, Brockmann L, Lukas D, Regen T, Croxford A, Nikolav A, H\u00f6velmeyer N, von Stebut E, Prinz M, Ubeda C, Maloy K, Gagliani N, Flavell R, Waisman A, Huber S\nCELL REP. 2022;38(13):.\nTissue-resident immunity in the lung: a first-line defense at the environmental interface\nZazara D, Belios I, L\u00fccke J, Zhang T, Giannou A\nSEMIN IMMUNOPATHOL. 2022;44(6):827-854.\nEffectiveness of antimalarial drug combinations in treating concomitant urogenital schistosomiasis in malaria patients in Lambar\u00e9n\u00e9, Gabon: A non-randomised event-monitoring study\nZoleko-Manego R, Okwu D, Handrich C, Dimessa-Mbadinga L, Akinosho M, Ndzebe-Ndoumba W, Davi S, Stelzl D, Veletzky L, Kreidenweiss A, Nordmann T, Adegnika A, Lell B, Kremsner P, Ramharter M, Mombo-Ngoma G\nPLOS NEGLECT TROP D. 2022;16(10):.\nHepatitis E, Schistosomiasis and Echinococcosis-Prevalence in a Cohort of Pregnant Migrants in Germany and Their Influence on Fetal Growth Restriction\nZ\u00f6llkau J, Ankert J, Pletz M, Mishra S, Seliger G, Lobmaier S, Prazeres Da Costa C, Seidel V, Weizs\u00e4cker K, Jablonka A, Dopfer C, Baier M, Horvatits T, Reiter-Owona I, Groten T, Schleenvoigt B\nPATHOGENS. 2022;11(1):.\nCOVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study\nINFECTION. 2021;49(5):889-905.\nGuidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1\nAUTOPHAGY. 2021;17(1):1-382.\nAnalysis of six different homologues of phosphatidylethanol from dried blood spots using liquid chromatography-tandem mass spectrometry\nAboutara N, Jungen H, Szewczyk A, Sterneck M, M\u00fcller A, Iwersen-Bergmann S\nDRUG TEST ANAL. 2021;13(1):140-147.\nCell-to-cell variability in JAK2/STAT5 pathway components and cytoplasmic volumes defines survival threshold in erythroid progenitor cells\nAdlung L, Stapor P, T\u00f6nsing C, Schmiester L, Schwarzm\u00fcller L, Postawa L, Wang D, Timmer J, Klingm\u00fcller U, Hasenauer J, Schilling M\nCELL REP. 2021;36(6):109507.\nA transient early HBV DNA increase during PEG-IFN\u03b1 therapy of hepatitis D indicates loss of infected cells and is associated with HDV RNA and HBsAg reduction\nAnastasiou O, Yurdaydin C, Maasoumy B, Hardtke S, Alexandru Caruntu F, Curescu M, Yalcin K, Akarca U, G\u00fcrel S, Zeuzem S, Erhardt A, L\u00fcth S, Papatheodoridis G, Radu M, Liebig S, Bantel H, Bremer B, Manns M, Cornberg M, Wedemeyer H\nJ VIRAL HEPATITIS. 2021;28(2):410-419.\nLeptomeningeal Carcinomatosis: A Clinical Dilemma in Neuroendocrine Neoplasms\nApostolidis L, Schrader J, Jann H, Rinke A, Krug S\nBIOLOGY-BASEL. 2021;10(4):.\nFatal COVID-19 in a Child with Persistence of SARS-CoV-2 Despite Extensive Multidisciplinary Treatment: A Case Report\nApostolidou S, Harbauer T, Lasch P, Biermann D, Hempel M, L\u00fctgehetmann M, Pfefferle S, Herrmann J, R\u00fcffer A, Reinshagen K, Kozlik-Feldmann R, Gieras A, Kniep I, Oh J, Singer D, Ebenebe C, Kobbe R\nCHILDREN-BASEL. 2021;8(7):.\nEZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs)\nApril-Monn S, Andreasi V, Schiavo Lena M, Sadowski M, Kim-Fuchs C, Buri M, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I\nCANCERS. 2021;13(19):.\nAuthor Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials\nAxfors C, Schmitt A, Janiaud P, Van't Hooft J, Abd-Elsalam S, Abdo E, Abella B, Akram J, Amaravadi R, Angus D, Arabi Y, Azhar S, Baden L, Baker A, Belkhir L, Benfield T, Berrevoets M, Chen C, Chen T, Cheng S, Cheng C, Chung W, Cohen Y, Cowan L, Dalgard O, de Almeida E Val F, de Lacerda M, de Melo G, Derde L, Dubee V, Elfakir A, Gordon A, Hernandez-Cardenas C, Hills T, Hoepelman A, Huang Y, Igau B, Jin R, Jurado-Camacho F, Khan K, Kremsner P, Kreuels B, Kuo C, Le T, Lin Y, Lin W, Lin T, Lyngbakken M, McArthur C, McVerry B, Meza-Meneses P, Monteiro W, Morpeth S, Mourad A, Mulligan M, Murthy S, Naggie S, Narayanasamy S, Nichol A, Novack L, O'Brien S, Okeke N, Perez L, Perez-Padilla R, Perrin L, Remigio-Luna A, Rivera-Martinez N, Rockhold F, Rodriguez-Llamazares S, Rolfe R, Rosa R, R\u00f8sj\u00f8 H, Sampaio V, Seto T, Shahzad M, Soliman S, Stout J, Thirion-Romero I, Troxel A, Tseng T, Turner N, Ulrich R, Walsh S, Webb S, Weehuizen J, Velinova M, Wong H, Wrenn R, Zampieri F, Zhong W, Moher D, Goodman S, Ioannidis J, Hemkens L\nNAT COMMUN. 2021;12(1):3001.\nDigital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues\nBadbaran A, Mailer R, Dahlke C, Woens J, Fathi A, Mellinghoff S, Renn\u00e9 T, Addo M, Riecken K, Fehse B\nMOL THER-METH CLIN D. 2021;23:418-423.\nHEV-Associated Neuralgic Amyotrophy : A Multicentric Case Series\nBannasch J, Berger B, Schwartkopp C, Berning M, Goetze O, Panning M, Fritz-Weltin M, Trendelenburg G, Gelderblom M, L\u00fctgehetmann M, Stute F, Horvatits T, Dirks M, Antoni C, Behrendt P, Pischke S\nPATHOGENS. 2021;10(6):.\nPsychometric properties of the Brief Infant-Toddler Social and Emotional Assessment (BITSEA) in two-year-old Ivorian and Ghanaian children\nBarthel D, Kriston L, Guo N, Yao E, Jean Armel K, Fordjour D, Mohammed Y, Bony Kotchi C, Eberhardt K, Hinz R, Ehrhardt S, Bindt C\nAPPL DEV SCI. 2021;1-11.\nReal-world Effectiveness of Glecaprevir/Pibrentasvir (GLE/PIB) for Chronic Hepatitis C Infection: Evidence From a German Single-center Cohort Study\nBeisel C, Herrmann M, Piecha F, Lampalzer S, Buescher G, Pischke S, Schulze zur Wiesch J\nHEPAT MON. 2021;21(1):e110077.\nOne liver, two samples and two diagnoses-An example of how multiple samples by laparoscopically guided liver biopsy can be decisive\nBeisel C, Weidemann S, Sebode M\nLIVER INT. 2021;41(11):2786-2787.\nThe four weeks before lockdown during the COVID-19 pandemic in Germany: a weekly serial cross-sectional survey on risk perceptions, knowledge, public trust and behaviour, 3 to 25 March 2020\nBetsch C, Korn L, Burgard T, Gaissmaier W, Felgendreff L, Eitze S, Sprengholz P, B\u00f6hm R, Stollorz V, Ramharter M, Promies N, De Bock F, Schmid P, Renner B, Wieler L, Bosnjak M\nEUROSURVEILLANCE. 2021;26(42):.\nRefining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival\nBettinger D, Sturm L, Pfaff L, Hahn F, Kloeckner R, Volkwein L, Praktiknjo M, Lv Y, Han G, Huber J, Boettler T, Reincke M, Klinger C, Caca K, Heinzow H, Seifert L, Weiss K, Rupp C, Piecha F, Kluwe J, Zipprich A, Luxenburger H, Neumann-Haefelin C, Schmidt A, Jansen C, Meyer C, Uschner F, Brol M, Trebicka J, R\u00f6ssle M, Thimme R, Schultheiss M\nJ HEPATOL. 2021;74(6):1362-1372.\nSkin-resident innate lymphoid cells converge on a pathogenic effector state\nBielecki P, Riesenfeld S, H\u00fctter J, Torlai Triglia E, Kowalczyk M, Ricardo-Gonzalez R, Lian M, Amezcua Vesely M, Kroehling L, Xu H, Slyper M, Muus C, Ludwig L, Christian E, Tao L, Kedaigle A, Steach H, York A, Skadow M, Yaghoubi P, Dionne D, Jarret A, McGee H, Porter C, Licona-Lim\u00f3n P, Bailis W, Jackson R, Gagliani N, Gasteiger G, Locksley R, Regev A, Flavell R\nNATURE. 2021;592(7852):128-132.\nHigh Rates of Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Metabolic and Cardiovascular Comorbidities\nBockmann J, Kohsar M, Murray J, Hamed V, Dandri-Petersen M, L\u00fcth S, Lohse A, Schulze-Zur-Wiesch J\nMICROORGANISMS. 2021;9(5):.\nManagement of cell death in parasitic infections\nBosurgi L, Rothlin C\nSEMIN IMMUNOPATHOL. 2021;43(4):481-492.\nIncreased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML\nBrauneck F, Haag F, Woost R, Wildner N, Tolosa E, Rissiek A, Vohwinkel G, Wellbrock J, Bokemeyer C, Schulze Zur Wiesch J, Ackermann C, Fiedler W\nONCOIMMUNOLOGY. 2021;10(1):1930391.\nCombined Blockade of TIGIT and CD39 or A2AR Enhances NK-92 Cell-Mediated Cytotoxicity in AML\nBrauneck F, Seubert E, Wellbrock J, Schulze Zur Wiesch J, Duan Y, Magnus T, Bokemeyer C, Koch-Nolte F, Menzel S, Fiedler W\nINT J MOL SCI. 2021;22(23):.\nBone Marrow-Resident V\u03b41 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma\nBrauneck F, Weimer P, Schulze zur Wiesch J, Weisel K, Leypoldt L, Vohwinkel G, Fritzsche B, Bokemeyer C, Wellbrock J, Fiedler W\nFRONT MED-LAUSANNE. 2021;8:763773.\nHeatwave-associated Vibrio infections in Germany, 2018 and 2019\nBrehm T, Berneking L, Sena Martins M, Dupke S, Jacob D, Drechsel O, Bohnert J, Becker K, Kramer A, Christner M, Aepfelbacher M, Schmiedel S, Rohde H\nEUROSURVEILLANCE. 2021;26(41):2002041.\nNicht-Cholera-Vibrionen \u2013 derzeit noch seltene, aber wachsende Infektionsgefahr in Nord- und Ostsee\nBrehm T, Dupke S, Hauk G, Fickenscher H, Rohde H, Berneking L\nINTERNIST. 2021;62(8):876-886.\nPatient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020\nBrehm T, Heyer A, Roedl K, Jarczak D, Nierhaus A, Nentwich M, van der Meirschen M, Schultze A, Christner M, Fiedler W, Kr\u00f6ger N, Huber T, Klose H, Sterneck M, Jordan S, Kreuels B, Schmiedel S, Addo M, Huber S, Lohse A, Kluge S, Schulze Zur Wiesch J\nJ CLIN MED. 2021;10(11):.\nLower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A\nBrehm T, Mazaheri O, Horvatits T, L\u00fctgehetmann M, Schulze Zur Wiesch J, Lohse A, Polywka S, Pischke S\nPATHOGENS. 2021;10(1):60.\nSARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies\nBrehm T, Pfefferle S, von Possel R, Kobbe R, N\u00f6rz D, Schmiedel S, Grundhoff A, Olearo F, Emmerich P, Robitaille A, G\u00fcnther T, Braun P, Andersen G, Knobloch J, Addo M, Lohse A, Aepfelbacher M, Fischer N, Schulze Zur Wiesch J, L\u00fctgehetmann M\nVIRUSES-BASEL. 2021;13(4):.\nSeroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study\nBrehm T, Schwinge D, Lampalzer S, Schlicker V, K\u00fcchen J, Thompson M, Ullrich F, Huber S, Schmiedel S, Addo M, L\u00fctgehetmann M, Knobloch J, Schulze Zur Wiesch J, Lohse A\nINT J HYG ENVIR HEAL. 2021;232:.\nLow SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic\nBrehm T, Thompson M, Ullrich F, Schwinge D, Addo M, Spier A, Knobloch J, Aepfelbacher M, Lohse A, L\u00fctgehetmann M, Schulze Zur Wiesch J\nINT J HYG ENVIR HEAL. 2021;238:.\nComparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza\nBrehm T, van der Meirschen M, Hennigs A, Roedl K, Jarczak D, Wichmann D, Frings D, Nierhaus A, Oqueka T, Fiedler W, Christopeit M, Kraef C, Schultze A, L\u00fctgehetmann M, Addo M, Schmiedel S, Kluge S, Schulze Zur Wiesch J\nSCI REP-UK. 2021;11(1):.\nResidual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study\nBremer B, Anastasiou O, Hardtke S, Caruntu F, Curescu M, Yalcin K, Akarca U, G\u00fcrel S, Zeuzem S, Erhardt A, L\u00fcth S, Papatheodoridis G, Radu M, Idilman R, Manns M, Cornberg M, Yurdaydin C, Wedemeyer H\nLIVER INT. 2021;41(2):295-299.\nHepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis\nBuescher G, Ozga A, Lorenz E, Pischke S, May J, Addo M, Horvatits T\nLIVER INT. 2021;41(3):449-455.\nCross-talk among MEN1, p53 and Notch regulates the proliferation of pancreatic neuroendocrine tumor cells by modulating INSM1 expression and subcellular localization\nCapodanno Y, Chen Y, Schrader J, Tomosugi M, Sumi S, Yokoyama A, Hiraoka N, Ohki R\nNEOPLASIA. 2021;23(9):979-992.\nNanoparticle-mediated targeting of autoantigen peptide to cross-presenting liver sinusoidal endothelial cells protects from CD8 T-cell-driven autoimmune cholangitis\nCarambia A, Gottwick C, Schwinge D, Stein S, Digigow R, \u015eeleci M, Mungalpara D, Heine M, Schuran F, Corban C, Lohse A, Schramm C, Heeren J, Herkel J\nIMMUNOLOGY. 2021;162(4):452-463.\nCdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors\nCarter A, Kumar N, Herring B, Tan C, Guenter R, Telange R, Howse W, Viol F, McCaw T, Bickerton H, Gupta P, Gillardon F, Woltering E, Dhall D, Totenhagen J, Banerjee R, Kurian E, Reddy S, Chen H, Schrader J, Bart Rose J, Mukhtar M, Bibb J\nONCOGENESIS. 2021;10(12):83.\nPI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors\nChow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Townsend C, Anthony L, Wasilchenko C, Melton M, Schrader J, Evers B, Rychahou P\nCELLS-BASEL. 2021;10(5):.\nS3-Leitlinie der Deutschen Gesellschaft f\u00fcr Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion \u2013 (AWMF-Register-Nr. 021-11)\nCornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, H\u00f6ner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J\nZ GASTROENTEROL. 2021;59(7):691-776.\nPhylogenomics of Mycobacterium africanum reveals a new lineage and a complex evolutionary history\nCoscolla M, Gagneux S, Menardo F, Loiseau C, Ruiz-Rodriguez P, Borrell S, Otchere I, Asante-Poku A, Asare P, S\u00e1nchez-Bus\u00f3 L, Gehre F, Sanoussi C, Antonio M, Affolabi D, Fyfe J, Beckert P, Niemann S, Alabi A, Grobusch M, Kobbe R, Parkhill J, Beisel C, Fenner L, B\u00f6ttger E, Meehan C, Harris S, de Jong B, Yeboah-Manu D, Brites D\nMICROB GENOMICS. 2021;7(2):.\nGuidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)\nCossarizza A, Chang H, Radbruch A, Abrignani S, Addo R, Akdis M, Andr\u00e4 I, Andreata F, Annunziato F, Arranz E, Bacher P, Bari S, Barnaba V, Barros-Martins J, Baumjohann D, Beccaria C, Bernardo D, Boardman D, Borger J, B\u00f6ttcher C, Brockmann L, Burns M, Busch D, Cameron G, Cammarata I, Cassotta A, Chang Y, Chirdo F, Christakou E, \u010ci\u010din-\u0160ain L, Cook L, Corbett A, Cornelis R, Cosmi L, Davey M, De Biasi S, De Simone G, Del Zotto G, Delacher M, Di Rosa F, Santo J, Diefenbach A, Dong J, D\u00f6rner T, Dress R, Dutertre C, Eckle S, Eede P, Evrard M, Falk C, Feuerer M, Fillatreau S, Fiz-Lopez A, Follo M, Foulds G, Fr\u00f6bel J, Gagliani N, Galletti G, Gangaev A, Garbi N, Garrote J, Geginat J, Gherardin N, Gibellini L, Ginhoux F, Godfrey D, Gruarin P, Haftmann C, Hansmann L, Harpur C, Hayday A, Heine G, Hern\u00e1ndez D, Herrmann M, Hoelsken O, Huang Q, Huber S, Huber J, Huehn J, Hundemer M, Hwang W, Iannacone M, Ivison S, J\u00e4ck H, Jani P, Keller B, Kessler N, Ketelaars S, Knop L, Knopf J, Koay H, Kobow K, Kriegsmann K, Kristyanto H, Krueger A, Kuehne J, Kunze-Schumacher H, Kvistborg P, Kwok I, Latorre D, Lenz D, Levings M, Lino A, Liotta F, Long H, Lugli E, MacDonald K, Maggi L, Maini M, Mair F, Manta C, Manz R, Mashreghi M, Mazzoni A, McCluskey J, Mei H, Melchers F, Melzer S, Mielenz D, Monin L, Moretta L, Multhoff G, Mu\u00f1oz L, Mu\u00f1oz-Ruiz M, Muscate F, Natalini A, Neumann K, Ng L, Niedobitek A, Niemz J, Almeida L, Notarbartolo S, Ostendorf L, Pallett L, Patel A, Percin G, Peruzzi G, Pinti M, Pockley A, Pracht K, Prinz I, Pujol-Autonell I, Pulvirenti N, Quatrini L, Quinn K, Radbruch H, Rhys H, Rodrigo M, Romagnani C, Saggau C, Sakaguchi S, Sallusto F, Sanderink L, Sandrock I, Schauer C, Scheffold A, Scherer H, Schiemann M, Schildberg F, Schober K, Schoen J, Schuh W, Sch\u00fcler T, Schulz A, Schulz S, Schulze J, Simonetti S, Singh J, Sitnik K, Stark R, Starossom S, Stehle C, Szelinski F, Tan L, Tarnok A, Tornack J, Tree T, van Beek J, van de Veen W, van Gisbergen K, Vasco C, Verheyden N, von Borstel A, Ward-Hartstonge K, Warnatz K, Waskow C, Wiedemann A, Wilharm A, Wing J, Wirz O, Wittner J, Yang J, Yang J\nEUR J IMMUNOL. 2021;51(12):2708-3145.\nTranscriptomic characterization of cancer-testis antigens identifies MAGEA3 as a driver of tumor progression in hepatocellular carcinoma\nCraig A, Garcia-Lezana T, Ruiz de Galarreta M, Villacorta-Martin C, Kozlova E, Martins-Filho S, von Felden J, Ahsen M, Bresnahan E, Hernandez-Meza G, Labgaa I, D'Avola D, Schwartz M, Llovet J, Sia D, Thung S, Losic B, Lujambio A, Villanueva A\nPLOS GENET. 2021;17(6):.\nAnalysis of Human Gut Microbiota Composition Associated to the Presence of Commensal and Pathogen Microorganisms in C\u00f4te d\u2019Ivoire\ncristanziano v, Farowski F, FEDERICA B, Santoro M, Cave D, Gl\u00e9 C, Daeumer M, Thielen A, Wirtz M, Kaiser R, Eberhardt K, Vehreschild M, D\u2019Alfonso R\nMICROORGANISMS. 2021;9(8):1763.\nInnate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition\nDandri M, Bertoletti A, L\u00fctgehetmann M\nSEMIN IMMUNOPATHOL. 2021;43(4):535-548.\nA time-resolved proteomic and prognostic map of COVID-19\nDemichev V, Tober-Lau P, Lemke O, Nazarenko T, Thibeault C, Whitwell H, R\u00f6hl A, Freiwald A, Szyrwiel L, Ludwig D, Correia-Melo C, Aulakh S, Helbig E, Stubbemann P, Lippert L, Gr\u00fcning N, Blyuss O, Vernardis S, White M, Messner C, Joannidis M, Sonnweber T, Klein S, Pizzini A, Wohlfarter Y, Sahanic S, Hilbe R, Schaefer B, Wagner S, Mittermaier M, Machleidt F, Garcia C, Ruwwe-Gl\u00f6senkamp C, Lingscheid T, Bosquillon de Jarcy L, Stegemann M, Pfeiffer M, J\u00fcrgens L, Denker S, Zickler D, Enghard P, Zelezniak A, Campbell A, Hayward C, Porteous D, Marioni R, Uhrig A, M\u00fcller-Redetzky H, Zoller H, L\u00f6ffler-Ragg J, Keller M, Tancevski I, Timms J, Zaikin A, Hippenstiel S, Ramharter M, Witzenrath M, Suttorp N, Lilley K, M\u00fclleder M, Sander L, Ralser M, Kurth F\nCELL SYST. 2021;12(8):780-794.e7.\nEfficacy of a Brief, Peer-Delivered Self-management Intervention for Patients With Rare Chronic Diseases: A Randomized Clinical Trial\nDepping M, Uhlenbusch N, H\u00e4rter M, Schramm C, L\u00f6we B\nJAMA PSYCHIAT. 2021;78(6):607-615.\nCK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission\nDerben F, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, Dalekos G, Manns M, Jaeckel E, Taubert R\nLIVER INT. 2021;41(1):123-127.\nDetection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia\nDi Cristanziano V, Meyer-Schwickerath C, Eberhardt K, Rybniker J, Heger E, Knops E, Hallek M, Klein F, Holtick U, Jung N\nBONE MARROW TRANSPL. 2021;56(3):716-719.\nFailure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy\nDietz J, Di Maio V, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer A, Lara M, Pardo M, Zoller H, Degasperi E, Peiffer K, Sighinolfi L, T\u00e9llez F, Graf C, Ghisetti V, Schreiber J, Fern\u00e1ndez-Fuertes E, Boglione L, Mu\u00f1oz-Medina L, Stauber R, Gennari W, Figueruela B, Santos J, Lampertico P, Zeuzem S, Ceccherini-Silberstein F, Garc\u00eda F, Sarrazin C\nJ HEPATOL. 2021;74(4):801-810.\nEfficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections\nDietz J, Spengler U, M\u00fcllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer K, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C\nCLIN GASTROENTEROL H. 2021;19(1):195-198.e2.\nKlinisches Bild der Blutung bei kritisch kranken Patienten auf der Intensivstation: Organsysteme und klinische Implikationen\nDrolz A, Fuhrmann V\nMED KLIN-INTENSIVMED. 2021;116(6):482-490.\nRisk factors associated with bleeding after prophylactic endoscopic variceal ligation in cirrhosis\nDrolz A, Schramm C, Seiz O, Groth S, Vettorazzi E, Horvatits T, Wehmeyer M, Schramm C, Goeser T, Roesch T, Lohse A, Kluwe J\nENDOSCOPY. 2021;53(3):226-234.\nPerformance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity\nDrolz A, Wolter S, Wehmeyer M, Piecha F, Horvatits T, Schulze Zur Wiesch J, Lohse A, Mann O, Kluwe J\nINT J OBESITY. 2021;45(10):2197-2204.\nAuthor Correction: Auto-aggressive CXCR6+CD8 T cells cause liver immune pathology in NASH\nDudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, Hartmann D, H\u00fcser N, Meiser P, Bayerl F, Inverso D, Wigger J, Sebode M, \u00d6llinger R, Rad R, Hegenbarth S, Anton M, Guillot A, Bowman A, Heide D, M\u00fcller F, Ramadori P, Leone V, Garcia-Caceres C, Gruber T, Seifert G, Kabat A, Mallm J, Reider S, Effenberger M, Roth S, Billeter A, M\u00fcller-Stich B, Pearce E, Koch-Nolte F, K\u00e4ser R, Tilg H, Thimme R, Boettler T, Tacke F, Dufour J, Haller D, Murray P, Heeren R, Zehn D, B\u00f6ttcher J, Heikenw\u00e4lder M, Knolle P\nNATURE. 2021;593(7860):E14.\nAuto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH\nDudek M, Pfister D, Donakonda S, Filpe P, Schneider A, Laschinger M, Hartmann D, Meiser P, Bayerl F, Inverso D, Wigger J, Sebode M, \u00d6llinger R, Rad R, Hegenbarth S, Anton M, Guillot A, Bowman A, Heide D, M\u00fcller F, Ramadori P, Leone V, Garcia-Caceres C, Gruber T, Seifert G, Kabat A, Malm J, Reider S, Effenberger M, Roth S, Billeter A, M\u00fcller-Stich B, Pearce E, Koch-Nolte F, K\u00e4ser R, Tilg H, Thimme R, B\u00f6ttler T, Tacke F, Dufour J, Haller D, Murray P, Heeren R, Zehn D, B\u00f6ttcher J, Heikenw\u00e4lder M, Knolle P\nNATURE. 2021;592(7854):444-449.\nEvaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG\nEberhardt K, Dewald F, Heger E, Gieselmann L, Vanshylla K, Wirtz M, Kleipass F, Johannis W, Schommers P, Gruell H, Brensing K, M\u00fcller R, Augustin M, Lehmann C, Koch M, Klein F, Cristanziano V\nMICROORGANISMS. 2021;9(4):.\nIntestinal Colonization with Tropheryma whipplei\u2014Clinical and Immunological Implications for HIV Positive Adults in Ghana\nEberhardt K, Sarfo F, Klupp E, Dompreh A, Cristanziano V, Kuffour E, Boateng R, Norman B, Phillips R, Aepfelbacher M, Feldt T\nMICROORGANISMS. 2021;9(8):1781.\nGenetic aspects of adult and pediatric autoimmune hepatitis: A concise review\nEngel B, Laschtowitz A, Janik M, Junge N, Baumann U, Milkiewicz P, Taubert R, Sebode M\nEUR J MED GENET. 2021;64(6):104214.\nOxysterol 7-\u03b1 Hydroxylase (CYP7B1) Attenuates Metabolic-Associated Fatty Liver Disease in Mice at Thermoneutrality\nEvangelakos I, Schwinge D, Worthmann A, John C, Roeder N, Pertzborn P, Behrens J, Schramm C, Scheja L, Heeren J\nCELLS-BASEL. 2021;10(10):2656.\nWeniger ist mehr \u2026 in der Infektiologie\nFathi A, Hennigs A, Addo M\nINTERNIST. 2021;62(4):373-378.\nFacharzt-Training Innere Medizin \u2013 Das vierte Sonderheft ist da!\nFathi A, Hundertmark M, Raspe M\nINTERNIST. 2021;62(Suppl 5):497-498.\nImpfstoffe gegen COVID-19\nFathi A, Mellinghoff S\nINTERNIST. 2021;62(11):1191-1201.\nCabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort\nFinkelmeier F, Scheiner B, Leyh C, Best J, Fr\u00fcndt T, Czauderna C, Beutel A, Bettinger D, Wei\u00df J, Meischl T, K\u00fctting F, Waldschmidt D, Radu P, Schulthei\u00df M, Peiffer K, Ettrich T, Weinmann A, Wege H, Venerito M, Dufour J, Lange C, Pinter M, Waidmann O\nLIVER CANCER. 2021;10(4):360-369.\nBreakdown in membrane asymmetry regulation leads to monocyte recognition of P. falciparum-infected red blood cells\nFraser M, Jing W, Br\u00f6er S, Kurth F, Sander L, Matuschewski K, Maier A\nPLOS PATHOG. 2021;17(2):.\nGenetic Analysis of a Cohort of 275 Patients with Hyper-IgE Syndromes and/or Chronic Mucocutaneous Candidiasis\nFrede N, Rojas-Restrepo J, Caballero Garcia de Oteyza A, Buchta M, H\u00fcbscher K, G\u00e1mez-D\u00edaz L, Proietti M, Saghafi S, Chavoshzadeh Z, Soler-Palacin P, Galal N, Adeli M, Aldave-Becerra J, Al-Ddafari M, Ardenyz \u00d6, Atkinson T, Kut F, \u00c7elmeli F, Rees H, Kilic S, Kirovski I, Klein C, Kobbe R, Korganow A, Lilic D, Lunt P, Makwana N, Metin A, \u00d6zg\u00fcr T, Karakas A, Seneviratne S, Sherkat R, Sousa A, Unal E, Patiroglu T, Wahn V, von Bernuth H, Whiteford M, Doffinger R, Jouhadi Z, Grimbacher B\nJ CLIN IMMUNOL. 2021;41(8):1804-1838.\nT cell cytokines in the diagnostic of early-onset sepsis\nFroeschle G, Bedke T, Boettcher M, Huber S, Singer D, Ebenebe C\nPEDIATR RES. 2021;90(1):191-196.\nVariation of vital signs with potential to influence the performance of qSOFA scoring in the Ethiopian general population at different altitudes of residency: A multisite cross-sectional study\nFr\u00fch J, Fuchs A, Tufa T, Fr\u00fch L, Hurissa Z, Orth H, Bode J, Eberhardt K, H\u00e4ussinger D, Feldt T\nPLOS ONE. 2021;16(2):e0245496.\nDiagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients\nFr\u00fcndt T, Krause L, Hussey E, Steinbach B, K\u00f6hler D, von Felden J, Schulze K, Lohse A, Wege H, Schwarzenbach H\nCANCERS. 2021;13(10):2484.\nLow incidence of COVID-19 in a prospective cohort of patients with liver cirrhosis and hepatocellular carcinoma treated at a tertiary medical center during the 2020 pandemic\nFr\u00fcndt T, Kuballa L, L\u00fctgehetman M, N\u00f6rz D, Arend H, Brehm T, Schulze Zur Wiesch J, Horvatits T, Horvatits K, Huber S, Wege H, Kluwe J\nPLOS ONE. 2021;16(12):e0258450.\nA call to caution when hydroxychloroquine is given to elderly patients with COVID-19\nGabor J, Kreidenweiss A, Weber S, Salama M, Sulyok M, Sulyok Z, Koehne E, Esen M, Kreuels B, Shamsrizi P, Biecker E, Mordm\u00fcller B, Berg C, Fusco S, K\u00f6hler C, Kubicka S, Leitlein J, Addo M, Ramharter M, Schwab M, Bissinger A, Velavan T, Krishna S, Kremsner P\nINT J INFECT DIS. 2021;106:265-268.\nFusobacterium nucleatum CbpF Mediates Inhibition of T Cell Function Through CEACAM1 Activation\nGalaski J, Shhadeh A, Uma\u00f1a A, Yoo C, Arpinati L, Isaacson B, Berhani O, Singer B, Slade D, Bachrach G, Mandelboim O\nFRONT CELL INFECT MI. 2021;11:692544.\nUpdate of the simplified criteria for autoimmune hepatitis: evaluation of the methodology for immunoserological testing\nGalaski J, Weiler-Normann C, Schakat M, Zachou K, Muratori P, Lampalzer S, Haag F, Schramm C, Lenzi M, Dalekos G, Lohse A\nJ HEPATOL. 2021;74(2):312-320.\nThe genetic architecture of primary biliary cholangitis\nGerussi A, Carbone M, Corpechot C, Schramm C, Asselta R, Invernizzi P\nEUR J MED GENET. 2021;64(9):104292.\nPost-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment\nGhandili S, Sch\u00f6nlein M, L\u00fctgehetmann M, Wiesch J, Becher H, Bokemeyer C, Sinn M, Weisel K, Leypoldt L\nCANCERS. 2021;13(15):.\nLymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma\nGhandili S, Sch\u00f6nlein M, Wiessner C, Becher H, L\u00fctgehetmann M, Brehm T, Wiesch J, Bokemeyer C, Sinn M, Weisel K, Leypoldt L\nJ CLIN MED. 2021;10(23):.\nIn Vivo Models of HDV Infection: Is Humanizing NTCP Enough?\nGiersch K, Dandri M\nVIRUSES-BASEL. 2021;13(4):588.\nMurine hepatocytes do not support persistence of Hepatitis D Virus mono-infection in vivo\nGiersch K, Hermanussen L, Volz T, Kah J, Allweiss L, Casey J, Sureau C, Dandri M, L\u00fctgehetmann M\nLIVER INT. 2021;41(2):410-419.\nStrong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice\nGiersch K, Hermanussen L, Volz T, Volmari A, Allweiss L, Sureau C, Casey J, Huang J, Fischer N, L\u00fctgehetmann M, Dandri M\nFRONT MICROBIOL. 2021;12:671466.\nEvaluation of the safety and efficacy of dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria in HIV-infected pregnant women: protocol of a multicentre, two-arm, randomised, placebo-controlled, superiority clinical trial (MAMAH project)\nGonz\u00e1lez R, Nhampossa T, Mombo-Ngoma G, Mischlinger J, Esen M, Tchouatieu A, Pons-Duran C, Dimessa L, Lell B, Lagler H, Garcia-Otero L, Zoleko Manego R, El Gaaloul M, Sanz S, Piqueras M, Sevene E, Ramharter M, Saute F, Menendez C\nBMJ OPEN. 2021;11(11):.\nLiver transplantation for acute\u2010on\u2010chronic liver failure predicts post\u2010transplant mortality and impaired long\u2010term quality of life\nGoosmann L, Buchholz A, Bangert K, Fuhrmann V, Kluge S, Lohse A, Huber S, Fischer L, Sterneck M, H\u00fcbener P\nLIVER INT. 2021;41(3):574-584.\nClinical presentation and disease course of 37 consecutive cases of progressive multifocal leukoencephalopathy (PML) at a German tertiary-care hospital: a retrospective observational study\nGraf L, Rosenkranz S, H\u00f6lzemer A, Hagel C, Goebell E, Jordan S, Friese M, Addo M, Schulze zur Wiesch J, Beisel C\nFRONT NEUROL. 2021;12:632535.\nVoriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study\nGrensemann J, Pfaffendorf C, Wicha S, Koenig C, Roedl K, Jarczak D, Iwersen-Bergmann S, Manthey C, Kluge S, Fuhrmann V\nMICROORGANISMS. 2021;9(10):2087.\nSociodemographic characteristics determine download and use of a Corona contact tracing app in Germany-Results of the COSMO surveys\nGrill E, Eitze S, De Bock F, Dragano N, Huebl L, Schmich P, Wieler L, Betsch C\nPLOS ONE. 2021;16(9):.\nValidation of a Prospective Urinalysis-Based Prediction Model for ICU Resources and Outcome of COVID-19 Disease: A Multicenter Cohort Study\nGross O, Moerer O, Rauen T, B\u00f6ckhaus J, Hoxha E, J\u00f6rres A, Kamm M, Elfanish A, Windisch W, Dreher M, Floege J, Kluge S, Schmidt-Lauber C, Turner J, Huber S, Addo M, Scheithauer S, Friede T, Braun G, Huber T, Blaschke S\nJ CLIN MED. 2021;10(14):.\nDual NADPH oxidases DUOX1 and DUOX2 synthesize NAADP and are necessary for Ca2+ signaling during T cell activation\nGu F, Kr\u00fcger A, Roggenkamp H, Alpers R, Lodygin D, Jaquet V, M\u00f6ckl F, Hernandez C L, Winterberg K, Bauche A, Rosche A, Grasberger H, Kao J, Schetelig D, Werner R, Schr\u00f6der K, Carty M, Bowie A, Huber S, Meier C, Mittr\u00fccker H, Heeren J, Krause K, Fl\u00fcgel A, Diercks B, Guse A\nSCI SIGNAL. 2021;14(709):.\nTissue Sampling and Homogenization in the Sub-Microliter Scale with a Nanosecond Infrared Laser (NIRL) for Mass Spectrometric Proteomics\nHahn J, Moritz M, Vo\u00df H, Pelczar P, Huber S, Schl\u00fcter H\nINT J MOL SCI. 2021;22(19):.\nDeterminants of Postponed Cancer Screening During the COVID-19 Pandemic: Evidence from the Nationally Representative COVID-19 Snapshot Monitoring in Germany (COSMO)\nHajek A, De Bock F, H\u00fcbl L, Kretzler B, K\u00f6nig H\nRISK MANAG HEALTHC P. 2021;14:3003-3011.\nPostponed Dental Visits during the COVID-19 Pandemic and their Correlates. Evidence from the Nationally Representative COVID-19 Snapshot Monitoring in Germany (COSMO)\nHajek A, De Bock F, Huebl L, Kretzler B, K\u00f6nig H\nHEALTHCARE-BASEL. 2021;9(1):50.\nA simple, sensitive, and low-cost FACS assay for detecting antibodies against the native SARS-CoV-2 spike protein\nHambach J, St\u00e4hler T, Eden T, Wendt D, Tode N, Haag F, Tolosa E, Altfeld M, Fathi A, Dahlke C, Addo M, Menzel S, Koch-Nolte F\nIMMUN INFLAMM DIS. 2021;9(3):905-917.\nToward Tailoring the Degradation Rate of Magnesium-Based Biomaterials for Various Medical Applications: Assessing Corrosion, Cytocompatibility and Immunological Effects\nHartjen P, Wegner N, Ahmadi P, Matthies L, Nada O, Fuest S, Yan M, Knipfer C, Gosau M, Walther F, Smeets R\nINT J MOL SCI. 2021;22(2):971.\nBroadly directed SARS-CoV-2-specific CD4+ T cell response includes frequently detected peptide specificities within the membrane and nucleoprotein in patients with acute and resolved COVID-19\nHeide J, Schulte S, Kohsar M, Brehm T, Herrmann M, Karsten H, Marget M, Peine S, Johansson A, Sette A, L\u00fctgehetmann M, Kwok W, Sidney J, Schulze Zur Wiesch J\nPLOS PATHOG. 2021;17(9):.\nLongitudinal development of antibody responses in covid-19 patients of different severity with elisa, peptide, and glycan arrays: An immunological case series\nHeidepriem J, Dahlke C, Kobbe R, Santer R, Koch T, Fathi A, Seco B, Ly M, Schmiedel S, Schwinge D, Serna S, Sellrie K, Reichardt N, Seeberger P, Addo M, Loeffler F\nPATHOGENS. 2021;10(4):.\nPain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence\nHeinemann M, Hoffmann C, Hardes J, Guder W, Streitb\u00fcrger A, G\u00f6tte M, Welz T, J\u00fcrgens H, Ranft A, Vieth V, Weckesser M, Sch\u00e4fers M, Stegger L, Dirksen U\nPEDIATR BLOOD CANCER. 2021;68(3):.\nPolymicrobial enteric infections in african infants with diarrhoea - Results from a longitudinal prospective case-control study\nHeinemann M, Strauchs C, L\u00fctgehetmann M, Aepfelbacher M, Klupp E, Owusu-Dabo E, Rolling T, Cramer J, Vinnemeier C\nCLIN MICROBIOL INFEC. 2021;27(12):1792-1798.\nA single-center, open-label, randomized cross-over study to evaluate the pharmacokinetics and bioavailability of once-daily prolonged-release formulations of tacrolimus in de novo liver transplant recipients\nHerden U, Sterneck M, Buchholz B, Achilles E, Ott A, Fischer L\nIMMUN INFLAMM DIS. 2021;9(4):1771-1780.\nMediators of liver inflammation and carcinogenesis\nHerkel J, Schmidt-Arras D\nSEMIN IMMUNOPATHOL. 2021;43(4):477-479.\nDNA methylation profiling of human hepatocarcinogenesis\nHernandez-Meza G, von Felden J, Gonzalez-Kozlova E, Garcia-Lezana T, Peix J, Portela A, Craig A, Sayols S, Schwartz M, Losic B, Mazzaferro V, Esteller M, Llovet J, Villanueva A\nHEPATOLOGY. 2021;74(1):183-199.\nPrediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model\nHeyckendorf J, Marwitz S, Reimann M, Avsar K, DiNardo A, G\u00fcnther G, Hoelscher M, Ibraim E, Kalsdorf B, Kaufmann S, Kontsevaya I, van Leth F, Mandalakas A, Maurer F, M\u00fcller M, Nitschkowski D, Olaru I, Popa C, Rachow A, Rolling T, Rybniker J, Salzer H, Sanchez-Carballo P, Schuhmann M, Schaub D, Spinu V, Su\u00e1rez I, Terhalle E, Unnewehr M, Weiner J, Goldmann T, Lange C\nEUR RESPIR J. 2021;58(3):2003492.\nPathogen-free diagnosis of tuberculosis\nHeyckendorf J, Reimann M, Marwitz S, Lange C\nLANCET INFECT DIS. 2021;21(8):.\nA Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting\nHicks S, Pohl K, Neeman T, McNamara H, Parsons K, He J, Ali S, Nazir S, Rowntree L, Nguyen T, Kedzierska K, Doolan D, Vinuesa C, Cook M, Coatsworth N, Myles P, Kurth F, Sander L, Mann G, Gruen R, George A, Gardiner E, Cockburn I\nJ INFECT DIS. 2021;223(1):10-14.\nSafety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study\nHillus D, Schwarz T, Tober-Lau P, Vanshylla K, Hastor H, Thibeault C, Jentzsch S, Helbig E, Lippert L, Tscheak P, Schmidt M, Riege J, Solarek A, von Kalle C, Dang-Heine C, Gruell H, Kopankiewicz P, Suttorp N, Drosten C, Bias H, Seybold J, Klein F, Kurth F, Corman V, Sander L\nLANCET RESP MED. 2021;9(11):1255-1265.\nHepatitis E: vom akut-auf-chronischen Leberversagen bis zur chronischen Hepatitis E\nHorvatits T\nGASTROENTEROLOGE. 2021;2021:.\nImprovement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival\nHorvatits T, H\u00fcbener P, Touma M, Horvatits K, Fischer L, Lohse A, Sterneck M\nANN HEPATOL. 2021;26:.\nHepatitis E virus persists in the ejaculate of chronically infected men\nHorvatits T, Wi\u00dfmann J, Johne R, Groschup M, Gadicherla A, Wiesch J, Eiden M, Todt D, Reimer R, D\u00e4hnert L, Sch\u00f6bel A, Horvatits K, L\u00fcbke R, Wolschke C, Ayuk F, Rybczynski M, Lohse A, Addo M, Herker E, L\u00fctgehetmann M, Steinmann E, Pischke S\nJ HEPATOL. 2021;75(1):55-63.\nRecurrent Swelling and Microfilaremia Caused by Dirofilaria repens Infection after Travel to India\nHuebl L, Tappe D, Giese M, Mempel S, Tannich E, Kreuels B, Ramharter M, Veletzky L, Jochum J\nEMERG INFECT DIS. 2021;27(6):1701-1704.\nExtensive Antibiotic and Antimalarial Prescription Rate among Children with Acute Febrile Diseases in the Lake Victoria Region, Tanzania\nHuth P, Addo M, Daniel T, Groendahl B, Hokororo A, Koliopoulos P, Mshana S, Pretsch L, Schmidt C, Zuechner A, Gehring S, Kayange N\nJ TROP PEDIATRICS. 2021;67(1):fmaa135.\nScent dog identification of SARS-CoV-2 infections in different body fluids\nJendrny P, Twele F, Meller S, Schulz C, von K\u00f6ckritz-Blickwede M, Osterhaus A, Ebbers H, Ebbers J, Pilchov\u00e1 V, Pink I, Welte T, Manns M, Fathi A, Addo M, Ernst C, Sch\u00e4fer W, Engels M, Petrov A, Marquart K, Schotte U, Schalke E, Volk H\nBMC INFECT DIS. 2021;21(1):.\nMalaria in the Time of COVID-19: Do Not Miss the Real Cause of Illness\nJochum J, Kreuels B, Tannich E, Huber S, Schulze Zur Wiesch J, Schmiedel S, Ramharter M, Addo M\nTROP MED INFECT DIS. 2021;6(2):.\nEstimating infectiousness throughout SARS-CoV-2 infection course\nJones T, Biele G, M\u00fchlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, Bleicker T, Tesch J, Schmidt M, Sander L, Kurth F, Menzel P, Schwarzer R, Zuchowski M, Hofmann J, Krumbholz A, Stein A, Edelmann A, Corman V, Drosten C\nSCIENCE. 2021;373(6551):.\nKIR3DS1 directs NK cell-mediated protection against human adenovirus infections\nJung J, Ching W, Baumdick M, Hofmann-Sieber H, Bosse J, Koyro T, M\u00f6ller K, Wegner L, Niehrs A, Russu K, Ohms M, Zhang W, Ehrhardt A, Duisters K, Spierings E, H\u00f6lzemer A, K\u00f6rner C, Jansen S, Peine S, K\u00f6nigs I, L\u00fctgehetmann M, Perez D, Reinshagen K, Lindemans C, Altfeld M, Belderbos M, Dobner T, Bunders M\nSCI IMMUNOL. 2021;6(63):.\nA Genome-Wide CRISPR/Cas9-Based Screen Identifies Heparan Sulfate Proteoglycans as Ligands of Killer-Cell Immunoglobulin-Like Receptors\nKlein K, H\u00f6lzemer A, Wang T, Kim T, Dugan H, Jost S, Altfeld M, Garcia-Beltran W\nFRONT IMMUNOL. 2021;12:.\nConvalescent plasma treatment for early post-kidney-transplant acquired COVID-19\nKluger M, Czogalla J, Schmidt-Lauber C, Peine S, Schmiedel S, Bangert K, Kluge S, Huber S, Puelles V, Fischer L, Huber T, Grahammer F\nTRANSPL INFECT DIS. 2021;23(4):e13685.\nThe COVID-19 Vaccine Landscape\nKoch T, Fathi A, Addo M\nADV EXP MED BIOL. 2021;1318:549-573.\nCorrelates of Vaccine-Induced Protection against SARS-CoV-2\nKoch T, Mellinghoff S, Shamsrizi P, Addo M, Dahlke C\nVACCINES-BASEL. 2021;9(3):.\nDevelopment and design of the Hantavirus registry - HantaReg - for epidemiological studies, outbreaks and clinical studies on hantavirus disease\nKoehler F, Blomberg L, Brehm T, B\u00fcttner S, Cornely O, Degen O, Di Cristanziano V, Dolff S, Eberwein L, Hoxha E, Hoyer-Allo K, Rudolf S, Sp\u00e4th M, Wanken M, M\u00fcller R, Burst V\nCLIN KIDNEY J. 2021;14(11):2365-2370.\nIn vitro activity of eravacycline, a novel synthetic halogenated tetracycline, against the malaria parasite Plasmodium falciparum\nKoehne E, Kreidenweiss A, Adegbite B, Manego R, McCall M, Mombo-Ngoma G, Adegnika A, Agnandji S, Mordm\u00fcller B, Held J\nJ GLOB ANTIMICROB RE. 2021;24:93-97.\nEvidence for in vitro and in vivo activity of the antimalarial pyronaridine against Schistosoma\nKoehne E, Zander N, Rodi M, Held J, Hoffmann W, Zoleko-Manego R, Ramharter M, Mombo-Ngoma G, Kremsner P, Kreidenweiss A\nPLOS NEGLECT TROP D. 2021;15(6):.\nFr\u00fcherkennung von psychischer Komorbidit\u00e4t in der station\u00e4ren dermatologischen und internistischen Versorgung: Darstellung eines neuen Versorgungskonzeptes\nKohlmann S, K\u00f6ster F, Braunschneider L, Meier A, Lohse A, Schneider S, Loeper S, L\u00f6we B\nPSYCHOTHER PSYCH MED. 2021;71(9-10):406-411.\nHuman hepatitis D virus-specific T cell epitopes\nKohsar M, Landahl J, Neumann-Haefelin C, Schulze Zur Wiesch J\nJHEP REP. 2021;3(4):100294.\nMultiplex-RT-PCR-ELISA panel for detecting mosquito-borne pathogens: Plasmodium sp. preserved and eluted from dried blood spots on sample cards\nKoliopoulos P, Kayange N, Daniel T, Huth F, Gr\u00f6ndahl B, Medina-Monta\u00f1o G, Pretsch L, Kl\u00fcber J, Schmidt C, Z\u00fcchner A, Ulbert S, Mshana S, Addo M, Gehring S\nMALARIA J. 2021;20(1):.\nImpact of Dose, Duration, and Immune Status on Efficacy of Ultrashort Telacebec Regimens in Mouse Models of Buruli Ulcer\nKomm O, Almeida D, Converse P, Omansen T, Nuermberger E\nANTIMICROB AGENTS CH. 2021;65(11):.\nUpregulation of HLA-F expression by BK polyomavirus infection induces immune recognition by KIR3DS1-positive natural killer cells\nKoyro T, Kraus E, Lunemann S, H\u00f6lzemer A, Wulf S, Jung J, Fittje P, Henseling F, K\u00f6rner C, Huber T, Grundhoff A, Wiech T, Panzer U, Fischer N, Altfeld M\nKIDNEY INT. 2021;99(5):1140-1148.\nDevelopment and characterization of an indirect ELISA to detect SARS-CoV - 2 spike protein-specific antibodies\nKr\u00e4hling V, Halwe S, Rohde C, Becker D, Bergh\u00f6fer S, Dahlke C, Eickmann M, Ercanoglu M, Gieselmann L, Herwig A, Kupke A, M\u00fcller H, Neubauer-R\u00e4del P, Klein F, Keller C, Becker S\nJ IMMUNOL METHODS. 2021;490:.\nLeitlinie: Diagnostik und Therapie der Malaria: AWMF Register-Nr. 042-001\nKreuels B, Bissinger A, Boecken G, Burchard G, Feldt T, Grobusch M, Jochum J, Kroidl I, L\u00f6bermann M, L\u00f6scher T, Rothe C, Schmiedel S, Schneitler S, Steiner F, Stich A, Stojkovic M, Wiemer D, Belard S, Kurth F, Tannich E, Kobbe R, Wichmann D, Ramharter M\n2021.\nPsychosocial situation, adherence, and utilization of video consultation in young adult long-term pediatric liver transplant recipients during COVID-19 pandemic\nKr\u00f6ncke S, Lund L, Buchholz A, Lang M, Briem-Richter A, Grabhorn E, Sterneck M\nPEDIATR TRANSPLANT. 2021;25(8):e14121.\nFinding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality\nKrug S, Damm M, Garbe J, K\u00f6nig S, Schmitz R, Michl P, Schrader J, Rinke A\nJ CLIN MED. 2021;10(14):.\nRamucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial\nKrug S, Kegel T, Gress T, Rinke A, Apostolidis L, Jann H, K\u00f6nig A, H\u00f6rsch D, Schrader J, Ettrich T, Richter M, Steighardt J, Michl P\nBMC CANCER. 2021;21(1):.\nNegative SARS-CoV-2 PCR or rapid antigen test result and the subsequent risk of being infectious: a mathematical simulation study\nKrumkamp R, Kreuels B, Jaeger V, May J, Mikolajczyk R, Karch A\nBMC MED RES METHODOL. 2021;21(1):.\nAltered gut microbial metabolism of essential nutrients in primary sclerosing cholangitis\nKummen M, Thingholm L, R\u00fchlemann M, Holm K, Hansen S, Moitinho-Silva L, Liwinski T, Zenouzi R, Storm-Larsen C, Midttun \u00d8, McCann A, Ueland P, H\u00f8ivik M, Vesterhus M, Tr\u00f8seid M, Laudes M, Lieb W, Karlsen T, Bang C, Schramm C, Franke A, Hov J\nGASTROENTEROLOGY. 2021;160(5):1784-1798.e0.\nExperimental Models of Liquid Biopsy in Hepatocellular Carcinoma Reveal Clone-Dependent Release of Circulating Tumor DNA\nLabgaa I, von Felden J, Craig A, Martins-Filho S, Villacorta-Martin C, Demartines N, Dormond O, D'Avola D, Villanueva A\nHEPATOL COMMUN. 2021;5(6):1095-1105.\nHistological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis\nLaschtowitz A, Zachou K, Lygoura V, Pape S, Derben F, Jaeckel E, Oller-Moreno S, Weidemann S, Krech T, Piecha F, Sch\u00f6n G, Liebhoff A, Al Tarrah M, Heneghan M, Drenth J, Dalekos G, Taubert R, Lohse A, Schramm C\nJHEP REP. 2021;3(4):100321.\nApoptotic cell signals and heterogeneity in macrophage function: Fine-tuning for a healthy liver\nLiebold I, Al Jawazneh A, Hamley M, Bosurgi L\nSEMIN CELL DEV BIOL. 2021;119:72-81.\nDiagnostic point-of-care ultrasound in medical inpatients at Queen Elizabeth Central Hospital, Malawi: an observational study of practice and evaluation of implementation\nLimani F, Dula D, Keeley A, Joekes E, Phiri T, Tembo E, Gadama L, Nnensa V, Jordan S, Mallewa J, Kreuels B\nT ROY SOC TROP MED H. 2021;115(8):863-869.\nGastric NET Subtypes: Do We Need An Additional One?\nLock G, Oelckers M, Clauditz T, Schrader J\nZ GASTROENTEROL. 2021;59(3):255-258.\nInfektionen und Gesellschaft\nLohse A, Addo M\n2021. Infektionen und Gesellschaft. Lohse A (Hrsg.). 1. Aufl. Hamburg: Springer, 3-4; 135-147.\nDas Schweigen der Leber\nLohse A, Goettges U\n2021. Das Schweigen der Leber. 1. Aufl. Stuttgart: Georg Thieme Verlag, 1-271.\nMagen-Darm-Mittel und Lebertherapeutika\nLohse A, Huber S\n2021. Arzneiverordnungs-Report 2021. Ludwig W, M\u00fchlbauer B, Seifert R (Hrsg.). 1. Aufl. Berlin: Springer-Verlag, Berlin, 523-550.\nReply to: \"Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis\"\nLohse A, Sebode M, Vesterhus M\nJ HEPATOL. 2021;74(3):755-756.\nCross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination\nLoyal L, Braun J, Henze L, Kruse B, Dingeldey M, Reimer U, Kern F, Schwarz T, Mangold M, Unger C, D\u00f6rfler F, Kadler S, Rosowski J, G\u00fcrcan K, Uyar-Aydin Z, Frentsch M, Kurth F, Schnatbaum K, Eckey M, Hippenstiel S, Hocke A, M\u00fcller M, Sawitzki B, Miltenyi S, Paul F, Mall M, Wenschuh H, Voigt S, Drosten C, Lauster R, Lachman N, Sander L, Corman V, R\u00f6hmel J, Meyer-Arndt L, Thiel A, Giesecke-Thiel C\nSCIENCE. 2021;374(6564):eabh1823.\nThe good and the bad about separation anxiety: roles of IL-22 and IL-22BP in liver pathologies\nL\u00fccke J, Sabihi M, Zhang T, Bauditz L, Shiri A, Giannou A, Huber S\nSEMIN IMMUNOPATHOL. 2021;43(4):591-607.\nRationalizing heptadecaphobia: TH 17 cells and associated cytokines in cancer and metastasis\nL\u00fccke J, Shiri A, Zhang T, Kempski J, Giannou A, Huber S\nFEBS J. 2021;288(24):6942-6971.\nA distinct CD38+CD45RA+ population of CD4+, CD8+, and double-negative T cells is controlled by FAS\nMaccari M, Fuchs S, Kury P, Andrieux G, V\u00f6lkl S, Bengsch B, Lorenz M, Heeg M, Rohr J, J\u00e4gle S, Castro C, Gro\u00df M, Warthorst U, K\u00f6nig C, Fuchs I, Speckmann C, Thalhammer J, Kapp F, Seidel M, D\u00fcckers G, Sch\u00f6nberger S, Sch\u00fctz C, F\u00fchrer M, Kobbe R, Holzinger D, Klemann C, Smisek P, Owens S, Horneff G, Kolb R, Naumann-Bartsch N, Miano M, Staniek J, Rizzi M, Kalina T, Schneider P, Erxleben A, Backofen R, Ekici A, Niemeyer C, Warnatz K, Grimbacher B, Eibel H, Mackensen A, Frei A, Schwarz K, Boerries M, Ehl S, Rensing-Ehl A\nJ EXP MED. 2021;218(2):e20192191.\nPhysical Activity during COVID-19 in German Adults: Analyses in the COVID-19 Snapshot Monitoring Study (COSMO)\nMaertl T, De Bock F, Huebl L, Oberhauser C, Coenen M, Jung-Sievers C\nINT J ENV RES PUB HE. 2021;18(2):.\nPharmakotherapie der Reisediarrh\u00f6\nManthey C, Malsy J\nInternistische Praxis. 2021;64(2):329-340.\nWas ist gesichert in der Therapie chronisch-entz\u00fcndlicher Darmerkrankungen\nManthey C, Reher D, Huber S\nINTERNIST. 2021;62(12):1269-1279.\nSARS-CoV-2 infection in patients with autoimmune hepatitis\nMarjot T, Buescher G, Sebode M, Barnes E, Barritt A, Armstrong M, Baldelli L, Kennedy J, Mercer C, Ozga A, Casar C, Schramm C, Moon A, Webb G, Lohse A\nJ HEPATOL. 2021;74(6):1335-1343.\nSARS-CoV-2 vaccination in patients with liver disease: responding to the next big question\nMarjot T, Webb G, Barritt A, Gin\u00e8s P, Lohse A, Moon A, Pose E, Trivedi P, Barnes E\nLANCET GASTROENTEROL. 2021;6(3):156-158.\nMulticenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease\nMatrood S, Apostolidis L, Schrader J, Krug S, Lahner H, Ramaswamy A, Librizzi D, Kender Z, Kr\u00f6cher A, Kreutzfeldt S, Gress T, Rinke A\nFRONT ENDOCRINOL. 2021;12:.\nUngew\u00f6hnliche Ursache einer Hyperkalz\u00e4mie in der Schwangerschaft\nMehl L, Schrader J, Winterberg T, Daniels T, Gross A, Weidner U, Clauditz T, Lock G\nZ GASTROENTEROL. 2021;59(2):143-148.\nCase Report - Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19\nMellinghoff S, Vanshylla K, Dahlke C, Addo M, Cornely O, Klein F, Persigehl T, Rybniker J, Gruell H, Br\u00f6ckelmann P\nFRONT IMMUNOL. 2021;12:.\nUltra-fast proteomics with Scanning SWATH\nMessner C, Demichev V, Bloomfield N, Yu J, White M, Kreidl M, Egger A, Freiwald A, Ivosev G, Wasim F, Zelezniak A, J\u00fcrgens L, Suttorp N, Sander L, Kurth F, Lilley K, M\u00fclleder M, Tate S, Ralser M\nNAT BIOTECHNOL. 2021;39(7):846-854.\nPredictive Performance of Rapid Diagnostic Tests for Falciparum Malaria and Its Modeled Impact on Integrated Community Case Management of Malaria in Sub-Saharan African Febrile Children\nMischlinger J, Dudek V, Ramharter M\nCLIN INFECT DIS. 2021;73(5):e1158-e1167.\nDiagnostic performance of capillary and venous blood samples in the detection of Loa loa and Mansonella perstans microfilaraemia using light microscopy\nMischlinger J, Manego R, Mombo-Ngoma G, Ekoka Mbassi D, Hackbarth N, Ekoka Mbassi F, Davi S, Kreuzmair R, Veletzky L, Hergeth J, Ndoumba W, Pitzinger P, Groger M, Matsiegui P, Adegnika A, Agnandji S, Lell B, Ramharter M\nPLOS NEGLECT TROP D. 2021;15(8):.\nImpact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study\nM\u00fchlemann B, Thibeault C, Hillus D, Helbig E, Lippert L, Tober-Lau P, Schwarz T, M\u00fcller M, Witzenrath M, Suttorp N, Sander L, Drosten C, Jones T, Corman V, Kurth F\nCLIN MICROBIOL INFEC. 2021;27(10):1520.e7-1520.e10.\nAssessing the impact of COVID-19 on liver cancer management (CERO-19)\nMu\u00f1oz-Mart\u00ednez S, Sapena V, Forner A, Nault J, Sapisochin G, Rimassa L, Sangro B, Bruix J, Sanduzzi-Zamparelli M, Ho\u0142\u00f3wko W, El Kassas M, Mocan T, Bouattour M, Merle P, Hoogwater F, Alqahtani S, Reeves H, Pinato D, Giorgakis E, Meyer T, Villadsen G, Wege H, Salati M, M\u00ednguez B, Di Costanzo G, Roderburg C, Tacke F, Varela M, Galle P, Alvares-da-Silva M, Trojan J, Bridgewater J, Cabibbo G, Toso C, Lachenmayer A, Casadei-Gardini A, Toyoda H, L\u00fcdde T, Villani R, Matilla Pe\u00f1a A, Guedes Leal C, Ronzoni M, Delgado M, Perell\u00f3 C, Pascual S, Lled\u00f3 J, Argemi J, Basu B, da Fonseca L, Acevedo J, Siebenh\u00fcner A, Braconi C, Meyers B, Granito A, Sala M, Rodr\u00edguez Lope C, Blaise L, Romero-G\u00f3mez M, Pi\u00f1ero F, Gomez D, Mello V, Pinheiro Alves R, Fran\u00e7a A, Branco F, Brandi G, Pereira G, Coll S, Guarino M, Ben\u00edtez C, Anders M, Bandi J, Vergara M, Calvo M, Peck-Radosavljevic M, Garc\u00eda-Ju\u00e1rez I, Cardinale V, Lozano M, Gambato M, Okolicsanyi S, Arraez D, Elvevi A, Mu\u00f1oz A, Lu\u00e9 A, Iavarone M, Reig M\nJHEP REP. 2021;3(3):.\nFunctional heterogeneity of CD4+ T cells in liver inflammation\nMuscate F, Woestemeier A, Gagliani N\nSEMIN IMMUNOPATHOL. 2021;43(4):549-561.\nTrans-Ned 19-Mediated Antagonism of Nicotinic Acid Adenine Nucleotide\u2014Mediated Calcium Signaling Regulates Th17 Cell Plasticity in Mice\nNawrocki M, Lory N, Bedke T, Stumme F, Diercks B, Guse A, Meier C, Gagliani N, Mittr\u00fccker H, Huber S\nCELLS-BASEL. 2021;10(11):.\nLate presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B\nNhlane R, Kreuels B, Mallewa J, Chetcuti K, Gordon M, Stockdale A\nLANCET. 2021;398(10318):.\nQuantification of the Proportion of Unfavorable Clinical Outcomes among Imported Malaria Patients According to the Degree of Semi-Immunity on Population Level: An Ecological Study\nNordmann T, Davi S, Ramharter M, Mischlinger J\nAM J TROP MED HYG. 2021;105(2):477-479.\nTIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis-A case series and review of the literature\nNordmann T, Schlabe S, Feldt T, Gobbi F, Krieg A, Bode J, Fuchs A, Kraef C, Praktiknjo M, Trebicka J, Ramharter M, Addo M, Strassburg C, Lohse A, Luedde T, Schmiedel S, Orth H\nPLOS NEGLECT TROP D. 2021;15(12):.\nHandling and accuracy of four rapid antigen tests for the diagnosis of SARS-CoV-2 compared to RT-qPCR\nOlearo F, N\u00f6rz D, Heinrich F, Sutter J, Roedl K, Schultze A, Wiesch J, Braun P, Oestereich L, Kreuels B, Wichmann D, Aepfelbacher M, Pfefferle S, L\u00fctgehetmann M\nJ CLIN VIROL. 2021;137:.\nBilateral Hematothorax without Hematemesis - an unusual Presentation of Variceal Bleeding\nPaparoupa M, Schrader J, Jung C, Boenisch O, Lohse A, Kluge S\nHEPATOLOGY. 2021;73(3):1233-1235.\nRisk factors for and management of metronidazole-refractory giardiasis in international travellers: A retrospective analysis\nPeters T, Kreuels B, Addo M, Tannich E, Rothe C\nTRAVEL MED INFECT DI. 2021;43:.\nSARS Coronavirus-2 variant tracing within the first Coronavirus Disease 19 clusters in northern Germany\nPfefferle S, G\u00fcnther T, Kobbe R, Czech-Sioli M, N\u00f6rz D, Santer R, Oh J, Kluge S, Oestereich L, Peldschus K, Indenbirken D, Huang J, Grundhoff A, Aepfelbacher M, Knobloch J, L\u00fctgehetmann M, Fischer N\nCLIN MICROBIOL INFEC. 2021;27(1):130.e5-130.e8.\nNASH limits anti-tumour surveillance in immunotherapy-treated HCC\nPfister D, N\u00fa\u00f1ez N, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, M\u00fcller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber P, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg J, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly A, Scheiner B, Pomej K, Kirstein M, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, R\u00f6ssler F, Siebenh\u00fcner A, De Dosso S, Mallm J, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin H, Billeter A, M\u00fcller-Stich B, Kikuchi H, Duda D, K\u00fctting F, Waldschmidt D, Ebert M, Rahbari N, Mei H, Schulz A, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour J, Marron T, Kaseb A, Kudo M, Huang Y, Djouder N, Wolter K, Zender L, Marche P, Decaens T, Pinato D, Rad R, Mertens J, Weber A, Unger K, Meissner F, Roth S, Jilkova Z, Claassen M, Anstee Q, Amit I, Knolle P, Becher B, Llovet J, Heikenwalder M\nNATURE. 2021;592(7854):450-456.\nClinical establishment of a laboratory developed quantitative HDV PCR assay on the cobas6800 high-throughput system\nPfl\u00fcger L, N\u00f6rz D, Volz T, Giersch K, Giese A, Goldmann N, Glebe D, Bockmann J, Pfefferle S, Dandri M, Schulze Zur Wiesch J, L\u00fctgehetmann M\nJHEP REP. 2021;3(6):.\nHepatitis delta virus propagation enabled by hepatitis C virus - scientifically intriguing; but is it relevant to clinical practice?\nPfl\u00fcger L, Schulze Zur Wiesch J, Polywka S, L\u00fctgehetmann M\nJ VIRAL HEPATITIS. 2021;28(1):213-216.\nEvolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era\nPiecha F, G\u00e4n\u00dfler J, Ozga A, Wehmeyer M, Kluwe J, Lampalzer S, Creutzfeldt A, Buescher G, Horvatits T, Sterneck M, Pischke S, Lohse A, Schulze Zur Wiesch J\nSCAND J GASTROENTERO. 2021;56(7):840-848.\nInterleukin-10 improves stroke outcome by controlling the detrimental Interleukin-17A response\nPiepke M, Clausen B, Ludewig P, Vienhues J, Bedke T, Javidi E, Rissiek B, Jank L, Brockmann L, Sandrock I, Degenhardt K, Jander A, Roth V, Sch\u00e4dlich I, Prinz I, Flavell R, Kobayashi Y, Renn\u00e9 T, Gerloff C, Huber S, Magnus T, Gelderblom M\nJ NEUROINFLAMM. 2021;18(1):.\nChromatin Extraction from Frozen Chimeric Liver Tissue for Chromatin Immunoprecipitation Analysis\nPirosu A, Allweiss L, Dandri-Petersen M\nJOVE-J VIS EXP. 2021;2021(169):.\nLack of Evidence for an Association between Previous HEV Genotype-3 Exposure and Glomerulonephritis in General\nPischke S, Tamanaei S, Mader M, Wiesch J, Petersen-Benz C, Haddad M, Addo M, Schmidt T, Huber T, Krebs C, Steinmetz O, Turner J, Hoxha E, Horvatits T\nPATHOGENS. 2021;11(1):.\nSingle-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis\nPoch T, Krause J, Casar C, Liwinski T, Glau L, Kaufmann M, Ahrenstorf A, Hess L, Ziegler A, Martrus G, Lunemann S, Sebode M, Li J, Schwinge D, Krebs C, Franke A, Friese M, Oldhafer K, Fischer L, Altfeld M, Lohse A, Huber S, Tolosa E, Gagliani N, Schramm C\nJ HEPATOL. 2021;75(2):414-423.\nFailure of thymic deletion and instability of autoreactive Tregs drive autoimmunity in immune-privileged liver\nPreti M, Schlott L, L\u00fcbbering D, Krzikalla D, M\u00fcller A, Schuran F, Poch T, Schakat M, Weidemann S, Lohse A, Weiler-Normann C, Sebode M, Schwinge D, Schramm C, Carambia A, Herkel J\nJCI INSIGHT. 2021;6(6):141462.\nCardiovascular magnetic resonance demonstrates structural cardiac changes following transjugular intrahepatic portosystemic shunt\nRadunski U, Kluwe J, Klein M, Galante A, Lund G, Sinning C, Bohnen S, Tahir E, Starekova J, Bannas P, Stehning C, Adam G, Lohse A, Blankenberg S, Muellerleile K, Benten D\nSCI REP-UK. 2021;11(1):.\nDevelopment of sustainable research excellence with a global perspective on infectious diseases: Centre de Recherches M\u00e9dicales de Lambar\u00e9n\u00e9 (CERMEL), Gabon\nRamharter M, Agnandji S, Adegnika A, Lell B, Mombo-Ngoma G, Grobusch M, McCall M, Kreidenweiss A, Muranaka R, Velavan T, Esen M, Schaumburg F, Alabi A, Druml C, Mordm\u00fcller B, K\u00f6hler C, Kremsner P\nWIEN KLIN WOCHENSCHR. 2021;133(9-10):500-508.\nMalaria im Kindesalter: Status quo, State-of-the-Art-Management und k\u00fcnftige Entwicklungen\nRamharter M, Hunstig F, Jochum J\n2021. Infektionen und Infektionskrankheiten bei Kindern und Jugendlichen. 67-71.\nHigh Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients\nRamirez J, Smit D, Viol F, Schrader J, Ghadban T, Pantel K, Izbicki J, Reeh M\nCANCERS. 2021;13(19):.\nRemdesivir, Sinus Bradycardia and Therapeutic Drug Monitoring in Children With Severe COVID-19\nRau C, Apostolidou S, Singer D, Avataneo V, Kobbe R\nPEDIATR INFECT DIS J. 2021;40(12):e528-e529.\nDownregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis\nReich M, Spomer L, Klindt C, Fuchs K, Stindt J, Deutschmann K, H\u00f6hne J, Liaskou E, Hov J, Karlsen T, Beuers U, Verheij J, Ferreira-Gonzalez S, Hirschfield G, Forbes S, Schramm C, Esposito I, Nierhoff D, Fickert P, Fuchs C, Trauner M, Garc\u00eda-Beccaria M, Gabernet G, Nahnsen S, Mallm J, Vogel M, Schoonjans K, Lautwein T, K\u00f6hrer K, H\u00e4ussinger D, Luedde T, Heikenwalder M, Keitel V\nJ HEPATOL. 2021;75(3):634-646.\nDrug-induced liver injury at a tertiary care centre in Germany: Model for End-stage Liver Disease is the best predictor of outcome\nReike-Kunze M, Zenouzi R, Hartl J, Krech T, Weidemann S, Sterneck M, Weiler-Normann C, Lohse A, Schramm C, Sebode M\nLIVER INT. 2021;41(10):2383-2395.\nPerceived Access to Health Care Services and Relevance of Telemedicine during the COVID-19 Pandemic in Germany\nReitzle L, Schmidt C, F\u00e4rber F, Huebl L, Wieler L, Ziese T, Heidemann C\nINT J ENV RES PUB HE. 2021;18(14):.\nAdaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma\nRennert C, Tauber C, Fehrenbach P, Heim K, Bettinger D, Sogukpinar \u00d6, Schuch A, Zecher B, Bengsch B, Lang S, Bronsert P, Bj\u00f6rkstr\u00f6m N, Fichtner-Feigl S, Schultheiss M, Thimme R, Hofmann M\nCELLS-BASEL. 2021;10(6):1369.\nAbdominal Applications of 4D Flow MRI\nRiedel C, Lenz A, Fischer L, Li J, Piecha F, Kluwe J, Adam G, Bannas P\nROFO-FORTSCHR RONTG. 2021;193(4):388-398.\nSevere liver dysfunction complicating course of COVID-19 in the critically ill: multifactorial cause or direct viral effect?\nRoedl K, Jarczak D, Drolz A, Wichmann D, Boenisch O, de Heer G, Burdelski C, Frings D, Sensen B, Nierhaus A, L\u00fctgehetmann M, Kluge S, Fuhrmann V\nANN INTENSIVE CARE. 2021;11(1):.\nEstablishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study\nRojas-Restrepo J, Caballero-Oteyza A, Huebscher K, Haberstroh H, Fliegauf M, Keller B, Kobbe R, Warnatz K, Ehl S, Proietti M, Grimbacher B\nFRONT IMMUNOL. 2021;12:.\nHaematopoietic cell transplantation outcomes are linked to intestinal mycobiota dynamics and an expansion of Candida parapsilosis complex species\nRolling T, Zhai B, Gjonbalaj M, Tosini N, Yasuma-Mitobe K, Fontana E, Amoretti L, Wright R, Ponce D, Perales M, Xavier J, van den Brink M, Markey K, Peled J, Taur Y, Hohl T\nNAT MICROBIOL. 2021;6(12):1505-1515.\nClinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy\nRolvien T, Jandl N, St\u00fcrznickel J, Beil F, K\u00f6tter I, Oheim R, Lohse A, Barvencik F, Amling M\nCALCIFIED TISSUE INT. 2021;108(2):219-230.\nInduction of IL-22-Producing CD4+ T Cells by Segmented Filamentous Bacteria Independent of Classical Th17 Cells\nRoy U, de Oliveira R, Galvez E, Gronow A, Basic M, Perez L, Gagliani N, Bleich A, Huber S, Strowig T\nFRONT IMMUNOL. 2021;12:671331.\nMobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER\nR\u00fcther D, Sebode M, Lohse A, Wernicke S, B\u00f6ttinger E, Casar C, Braun F, Schramm C\nCLIN RES HEPATOL GAS. 2021;45(6):.\nHookworm infection in returning travellers and migrants: a 10-year case series at a German center for tropical medicine\nSaffar F, Kurth F, Tannich E, Ramharter M, Jochum J\nJ TRAVEL MED. 2021;28(1):taaa183.\nX-ray-Based Techniques to Study the Nano-Bio Interface\nSanchez-Cano C, Alvarez-Puebla R, Abendroth J, Beck T, Blick R, Cao Y, Caruso F, Chakraborty I, Chapman H, Chen C, Cohen B, Concei\u00e7\u00e3o A, Cormode D, Cui D, Dawson K, Falkenberg G, Fan C, Feliu N, Gao M, Gargioni E, Gl\u00fcer C, Gr\u00fcner F, Hassan M, Hu Y, Huang Y, Huber S, Huse N, Kang Y, Khademhosseini A, Keller T, K\u00f6rnig C, Kotov N, Koziej D, Liang X, Liu B, Liu S, Liu Y, Liu Z, Liz-Marz\u00e1n L, Ma X, Machicote A, Maison W, Mancuso A, Megahed S, Nickel B, Otto F, Palencia C, Pascarelli S, Pearson A, Pe\u00f1ate-Medina O, Qi B, R\u00e4dler J, Richardson J, Rosenhahn A, Rothkamm K, R\u00fcbhausen M, Sanyal M, Schaak R, Schlemmer H, Schmidt M, Schmutzler O, Schotten T, Schulz F, Sood A, Spiers K, Staufer T, Stemer D, Stierle A, Sun X, Tsakanova G, Weiss P, Weller H, Westermeier F, Xu M, Yan H, Zeng Y, Zhao Y, Zhao Y, Zhu D, Zhu Y, Parak W\nACS NANO. 2021;15(3):3754-3807.\nMolecular epidemiology of Mansonella species in Gabon\nSandri T, Kreidenweiss A, Cavallo S, Weber D, Juhas S, Rodi M, Woldearegai T, Gmeiner M, Veletzky L, Ramharter M, Tazemda-Kuitsouc G, Matsiegui P, Mordm\u00fcller B, Held J\nJ INFECT DIS. 2021;223(2):287-296.\nTFEB-deficiency attenuates mitochondrial degradation upon brown adipose tissue whitening at thermoneutrality\nSass F, Schlein C, Jaeckstein M, Pertzborn P, Schweizer M, Schinke T, Ballabio A, Scheja L, Heeren J, Fischer A\nMOL METAB. 2021;47:101173.\nContrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study\nSchellhaas B, Bernatik T, Bohle W, Borowitzka F, Chang J, Dietrich C, Dirks K, Donoval R, Drube K, Friedrich-Rust M, Gall C, Gittinger F, Gutermann M, Haenle M, von Herbay A, Ho C, Hochdoerffer R, Hoffmann T, H\u00fcttig M, Janson C, Jung E, Jung N, Karlas T, Klinger C, Kornmehl A, Kratzer W, Krug S, Kunze G, Leitlein J, Link A, Lottspeich C, Marano A, Mauch M, Moleda L, Neesse A, Petzold G, Potthoff A, Praktiknjo M, R\u00f6sner K, Schanz S, Schulthei\u00df M, Sivanathan V, Stock J, Thomsen T, Vogelpohl J, Vogt C, Wagner S, Wiegard C, Wiesinger I, Will U, Ziesch M, Zimmermann P, Strobel D\nULTRASCHALL MED. 2021;42(2):178-186.\nBone microarchitecture in patients with autoimmune hepatitis\nSchmidt C, St\u00fcrznickel J, Strahl A, Oheim R, Weiler-Normann C, Sebode M, Barvencik F, Lohse A, Schinke T, Amling M, Schramm C, Rolvien T\nJ BONE MINER RES. 2021;36(7):1316-1325.\nIL-17 receptor c signaling controls CD4+TH17 immune responses and tissue injury in immune-mediated kidney diseases\nSchmidt T, Luebbe J, Kilian C, Riedel J, Hiekmann S, Asada N, Ginsberg P, Robben L, Song N, Kaffke A, Peters A, Borchers A, Flavell R, Gagliani N, Pelzcar P, Huber S, Huber T, Turner J, Paust H, Krebs C, Panzer U\nJ AM SOC NEPHROL. 2021;32(12):3081-3098.\nMulti-scale fully convolutional neural networks for histopathology image segmentation: From nuclear aberrations to the global tissue architecture\nSchmitz R, Madesta F, Nielsen M, Krause J, Steurer S, Werner R, R\u00f6sch T\nMED IMAGE ANAL. 2021;70:101996.\nTargeting HDACs in Pancreatic Neuroendocrine Tumor Models\nSchmitz R, Weissbach J, Kleilein J, Bell J, H\u00fcttelmaier S, Viol F, Clauditz T, Grabowski P, Laumen H, Rosendahl J, Michl P, Schrader J, Krug S\nCELLS-BASEL. 2021;10(6):1408.\nCD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression\nSchneider E, Winzer R, Rissiek A, Ricklefs I, Meyer-Schwesinger C, Ricklefs F, Bauche A, Behrends J, Reimer R, Brenna S, Wasielewski H, Lauten M, Rissiek B, Puig B, Cortesi F, Magnus T, Fliegert R, M\u00fcller C, Gagliani N, Tolosa E\nNAT COMMUN. 2021;12(1):5911.\nNext-generation immunosequencing reveals pathological T cell architecture in autoimmune hepatitis\nSchulthei\u00df C, Germany D, Willscher E, Oberle A, Fanchi L, Bonzanni N, Wildner N, Schulze-Zur-Wiesch J, Weiler-Normann C, Lohse A, Binder M\nHEPATOLOGY. 2021;73(4):1436-1448.\nMaturation trajectories and transcriptional landscape of plasmablasts and autoreactive B cells in COVID-19\nSchulthei\u00df C, Paschold L, Willscher E, Simnica D, W\u00f6stemeier A, Muscate F, Wass M, Eisenmann S, Dutzmann J, Key\u00dfer G, Gagliani N, Binder M\nISCIENCE. 2021;24(11):.\nEarly Detection of Hepatocellular Carcinoma Since the Introduction of the German Clinical Practice Guideline in 2013\nSchulze K, Felden J, Fr\u00fcndt T, Krause J, Werner T, Casar C, Jung C, Ittrich H, Sterneck M, Li J, Heumann A, Fischer L, Adam G, Lohse A, Wege H\nDTSCH ARZTEBL INT. 2021;118(31-32):540-541.\nEurop\u00e4isches Referenznetzwerk f\u00fcr seltene Lebererkrankungen (ERN RARE-LIVER)\nSchulz L, Sebode M, Schramm C, Lohse A\nINTERNIST. 2021;62(4):441-448.\nCell-autonomous hepatocyte-specific GP130 signaling is sufficient to trigger a robust innate immune response in mice\nSchumacher N, Yan K, Gandra\u00df M, M\u00fcller M, Krisp C, H\u00e4sler R, Carambia A, Nofer J, Bernardes J, Khouja M, Thomsen I, Chalupsky K, Bolik J, H\u00f6lscher C, Wunderlich T, Herkel J, Rosenstiel P, Schramm C, Schl\u00fcter H, Renn\u00e9 T, Mittr\u00fccker H, Rose-John S, Schmidt-Arras D\nJ HEPATOL. 2021;74(2):407-418.\nA Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease\nSchuppan D, M\u00e4ki M, Lundin K, Isola J, Friesing-Sosnik T, Taavela J, Popp A, Koskenpato J, Langhorst J, Hovde \u00d8, L\u00e4hdeaho M, Fusco S, Schumann M, T\u00f6r\u00f6k H, Kupcinskas J, Zopf Y, Lohse A, Scheinin M, Kull K, Biedermann L, Byrnes V, Stallmach A, Jahnsen J, Zeitz J, Mohrbacher R, Greinwald R\nNEW ENGL J MED. 2021;385(1):35-45.\nAryl Hydrocarbon Receptor Activity in Hepatocytes Sensitizes to Hyperacute Acetaminophen-Induced Hepatotoxicity in Mice\nSchuran F, Lommetz C, Steudter A, Ghallab A, Wieschendorf B, Schwinge D, Zuehlke S, Reinders J, Heeren J, Lohse A, Schramm C, Herkel J, Carambia A\nCELL MOL GASTROENTER. 2021;11(2):371-388.\nDelayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany\nSchwarz T, Tober-Lau P, Hillus D, Helbig E, Lippert L, Thibeault C, Koch W, Landgraf I, Michel J, Bergfeld L, Niemeyer D, M\u00fchlemann B, Conrad C, Dang-Heine C, Kasper S, M\u00fcnn F, Kappert K, Nitsche A, Tauber R, Schmidt S, Kopankiewicz P, Bias H, Seybold J, von Kalle C, Jones T, Suttorp N, Drosten C, Sander L, Corman V, Kurth F\nEMERG INFECT DIS. 2021;27(8):2174-2178.\nCharacterization of Individuals Interested in Participating in a Phase I SARS-CoV-2 Vaccine Trial\nShamsrizi P, Kramer F, Addo M, Fathi A\nVACCINES-BASEL. 2021;9(10):1208.\nLandscape of T-cell repertoires with public COVID-19-associated T-cell receptors in pre-pandemic risk cohorts\nSimnica D, Schulthei\u00df C, Mohme M, Paschold L, Willscher E, Fitzek A, P\u00fcschel K, Matschke J, Ciesek S, Sedding D, Zhao Y, Gagliani N, Maringer Y, Walz J, Heide J, Schulze-Zur-Wiesch J, Binder M\nCLIN TRANSL IMMUNOL. 2021;10(9):e1340.\nHealth-related quality of life in autoimmune hepatitis\nSnijders R, Milkiewicz P, Schramm C, Gevers T\nWORLD J HEPATOL. 2021;13(11):1642-1652.\nPro-cachectic factors link experimental and human chronic kidney disease to skeletal muscle wasting programs\nSolagna F, Tezze C, Lindenmeyer M, Lu S, Wu G, Liu S, Zhao Y, Mitchell R, Meyer C, Omairi S, Kilic T, Paolini A, Ritvos O, Pasternack A, Matsakas A, Kylies D, Wiesch J, Turner J, Wanner N, Nair V, Eichinger F, Menon R, Martin I, Klinkhammer B, Hoxha E, Cohen C, Tharaux P, Boor P, Ostendorf T, Kretzler M, Sandri M, Kretz O, Puelles V, Patel K, Huber T\nJ CLIN INVEST. 2021;131(11):.\nCombination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis\nSoret P, Lam L, Carrat F, Smets L, Berg T, Carbone M, Invernizzi P, Leroy V, Trivedi P, Cazzagon N, Weiler-Normann C, Alric L, Rosa-Hezode I, Heurgu\u00e9 A, Cervoni J, Dumortier J, Potier P, Roux O, Silvain C, Bureau C, Anty R, Larrey D, Levy C, Pares A, Schramm C, Nevens F, Chazouill\u00e8res O, Corpechot C\nALIMENT PHARM THER. 2021;53(10):1138-1146.\nT cell plasticity in renal autoimmune disease\nSoukou S, Huber S, Krebs C\nCELL TISSUE RES. 2021;385(2):323-333.\nCharacterization and outcome of invasive infections due to Paecilomyces variotii: analysis of patients from the FungiScope\u00ae registry and literature reports\nSprute R, Salmanton-Garc\u00eda J, Sal E, Malaj X, Falces-Romero I, Hatvani L, Heinemann M, Klimko N, L\u00f3pez-Soria L, Meletiadis J, Shruti M, Steinmann J, Seidel D, Cornely O, Stemler J\nJ ANTIMICROB CHEMOTH. 2021;76(3):765-774.\nIL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression\nStein S, Henze L, Poch T, Carambia A, Krech T, Preti M, Schuran F, Reich M, Keitel V, Fiorotto R, Strazzabosco M, Fischer L, Li J, M\u00fcller L, Wagner J, Gagliani N, Herkel J, Schwinge D, Schramm C\nJ HEPATOL. 2021;74(4):919-930.\nDiagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi\nStockdale A, Silungwe N, Shawa I, Kreuels B, Gordon M, Geretti A\nBMC INFECT DIS. 2021;21(1):.\nPresence of donor specific HLA class 2 antibodies (DSA class 2) is associated with development of graft fibrosis more than 10 years after liver transplantation-a retrospective single center study\nSultani B, Marget M, Briem-Richter A, Herrmann J, Meisner S, Grabhorn E, Ozga A, Weidemann S, Herden U, Fischer L, Sterneck M\nCLIN TRANSPLANT. 2021;35(7):.\nS1-Leitlinie zur Versorgung von Lebertransplantierten w\u00e4hrend der COVID-19-Pandemie \u2013 AWMF-Register Nr. 021-031 \u2013 Stand: 07.01.21\nTacke F, Cornberg M, Sterneck M, Trebicka J, Settmacher U, Bechstein W, Berg T\nZ GASTROENTEROL. 2021;59(4):345-359.\nComparative Assessment of In-House Real-Time PCRs Targeting Enteric Disease-Associated Microsporidia in Human Stool Samples\nTanida K, Hahn A, Eberhardt K, Tannich E, Landt O, Kann S, Feldt T, Sarfo F, Cristanziano V, Frickmann H, Loderst\u00e4dt U\nPATHOGENS. 2021;10(6):656.\nCharacteristics and management of asymptomatic SARS-CoV-2 infections\nTanriover M, Fathi A, Raspe M, Novais A, Uyaro\u011flu O\nJournal of basic and clinical physiology and pharmacology. 2021;33(1):1-7.\nDiscrimination of SARS-CoV-2 Infections From Other Viral Respiratory Infections by Scent Detection Dogs\nTen Hagen N, Twele F, Meller S, Jendrny P, Schulz C, von K\u00f6ckritz-Blickwede M, Osterhaus A, Ebbers H, Pink I, Welte T, Manns M, Illig T, Fathi A, Addo M, Nitsche A, Puyskens A, Michel J, Krause E, Ehmann R, von Brunn A, Ernst C, Zwirglmaier K, W\u00f6lfel R, Nau A, Philipp E, Engels M, Schalke E, Volk H\nFRONT MED-LAUSANNE. 2021;8:.\nInitial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations\nThalhammer J, Kindle G, Nieters A, Rusch S, Sepp\u00e4nen M, Fischer A, Grimbacher B, Edgar D, Buckland M, Mahlaoui N, Ehl S\nJ ALLERGY CLIN IMMUN. 2021;148(5):1332-1341.e5.\nClinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study\nThibeault C, M\u00fchlemann B, Helbig E, Mittermaier M, Lingscheid T, Tober-Lau P, Meyer-Arndt L, Meiners L, Stubbemann P, Haenel S, Bosquillon de Jarcy L, Lippert L, Pfeiffer M, Stegemann M, Roehle R, Wiebach J, Hippenstiel S, Zoller T, M\u00fcller-Redetzky H, Uhrig A, Balzer F, von Kalle C, Suttorp N, Jones T, Drosten C, Witzenrath M, Sander L, Corman V, Kurth F\nINFECTION. 2021;49(4):703-714.\nOutbreak of SARS-CoV-2 B.1.1.7 Lineage after Vaccination in Long-Term Care Facility, Germany, February-March 2021\nTober-Lau P, Schwarz T, Hillus D, Spieckermann J, Helbig E, Lippert L, Thibeault C, Koch W, Bergfeld L, Niemeyer D, M\u00fchlemann B, Conrad C, Kasper S, M\u00fcnn F, Kunitz F, Jones T, Suttorp N, Drosten C, Sander L, Kurth F, Corman V\nEMERG INFECT DIS. 2021;27(8):2169-2173.\nLong-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers\nTober-Lau P, Schwarz T, Vanshylla K, Hillus D, Gruell H, Suttorp N, Landgraf I, Kappert K, Seybold J, Drosten C, Klein F, Kurth F, Sander L, Corman V\nLANCET RESP MED. 2021;9(11):e104-e105.\nPyronaridine-artesunate real-world safety, tolerability, and effectiveness in malaria patients in 5 African countries: A single-arm, open-label, cohort event monitoring study\nTona Lutete G, Mombo-Ngoma G, Assi S, Bigoga J, Koukouikila-Koussounda F, Ntamabyaliro N, Ntoumi F, Agnandji S, Groger M, Shin J, Borghini-Fuhrer I, Arbe-Barnes S, Allen S, Kremsner P, Miller R, Duparc S, Ramharter M\nPLOS MED. 2021;18(6):.\nLess than you'd think-a prospective study on MRSA-colonization in healthy travellers\nTran D, Winter D, Christner M, Ramharter M, Addo M, Rolling T, Vinnemeier C, Koch T\nJ TRAVEL MED. 2021;28(3):.\nHypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19\nTrump S, Lukassen S, Anker M, Chua R, Liebig J, Th\u00fcrmann L, Corman V, Binder M, Loske J, Klasa C, Krieger T, Hennig B, Messingschlager M, Pott F, Kazmierski J, Twardziok S, Albrecht J, Eils J, Hadzibegovic S, Lena A, Heidecker B, B\u00fcrgel T, Steinfeldt J, Goffinet C, Kurth F, Witzenrath M, V\u00f6lker M, M\u00fcller S, Liebert U, Ishaque N, Kaderali L, Sander L, Drosten C, Laudi S, Eils R, Conrad C, Landmesser U, Lehmann I\nNAT BIOTECHNOL. 2021;39(6):705-716.\nDolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children\nTurkova A, White E, Mujuru H, Kekitiinwa A, Kityo C, Violari A, Lugemwa A, Cressey T, Musoke P, Variava E, Cotton M, Archary M, Puthanakit T, Behuhuma O, Kobbe R, Welch S, Bwakura-Dangarembizi M, Amuge P, Kaudha E, Barlow-Mosha L, Makumbi S, Ramsagar N, Ngampiyaskul C, Musoro G, Atwine L, Liberty A, Musiime V, Bbuye D, Ahimbisibwe G, Chalermpantmetagul S, Ali S, Sarfati T, Wynne B, Shakeshaft C, Colbers A, Klein N, Bernays S, Sa\u00efdi Y, Coelho A, Grossele T, Compagnucci A, Giaquinto C, Rojo P, Ford D, Gibb D\nNEW ENGL J MED. 2021;385(27):2531-2543.\nKinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans\nVanshylla K, Cristanziano V, Kleipass F, Dewald F, Schommers P, Gieselmann L, Gruell H, Schlotz M, Ercanoglu M, Stumpf R, Mayer P, Zehner M, Heger E, Johannis W, Horn C, Su\u00e1rez I, Jung N, Salomon S, Eberhardt K, Gathof B, F\u00e4tkenheuer G, Pfeifer N, Eggeling R, Augustin M, Lehmann C, Klein F\nCELL HOST MICROBE. 2021;29(6):917-929.e4.\nLongitudinal monitoring of laboratory markers characterizes hospitalized and ambulatory COVID-19 patients\nVelavan T, Kuk S, Linh L, Lamsfus Calle C, Lalremruata A, Pallerla S, Kreidenweiss A, Held J, Esen M, Gabor J, Neurohr E, Shamsrizi P, Fathi A, Biecker E, Berg C, Ramharter M, Addo M, Kreuels B, Kremsner P\nSCI REP-UK. 2021;11(1):.\nPsittacosis in a traveller\nVeletzky L, Huebl L, Schulze Zur Wiesch J, Schmiedel S\nJ TRAVEL MED. 2021;28(6):.\nThe Supposedly Innocuous Eye Worm: Or, What Could Make You Put Chili in Your Eye?\nVeletzky L, Mombo-Ngoma G, Ramharter M\nAM J TROP MED HYG. 2021;105(6):1448-1449.\nLeukocyte-Derived High-Mobility Group Box 1 Governs Hepatic Immune Responses to Listeria monocytogenes\nVolmari A, Foelsch K, Zierz E, Yan K, Qi M, Bartels K, Kondratowicz S, Boettcher M, Reimers D, Nishibori M, Liu K, Schwabe R, Lohse A, Huber S, Mittruecker H, H\u00fcbener P\nHEPATOL COMMUN. 2021;5(12):2104-2120.\nUpdate 2021: COVID-19 aus Sicht der internistischen Schwerpunkte\nvon Bergwelt-Baildon M, Addo M\nDEUT MED WOCHENSCHR. 2021;146(13-14):.\nMilde COVID-19-Verl\u00e4ufe bei Mitarbeitenden einer Universit\u00e4tsklinik: Die \u201eerste Welle\u201c am Universit\u00e4tsklinikum Hamburg-Eppendorf\nvon Felden J, Brehm T, Schulze-Zur-Wiesch J, Addo M, Lohse A, Knobloch J, Koch T\nBUNDESGESUNDHEITSBLA. 2021;64(9):1165-1168.\nMutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma\nvon Felden J, Craig A, Garcia-Lezana T, Labgaa I, Haber P, D'Avola D, Asgharpour A, Dieterich D, Bonaccorso A, Torres-Martin M, Sia D, Sung M, Tabrizian P, Schwartz M, Llovet J, Villanueva A\nONCOGENE. 2021;40(1):140-151.\nSequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort\nvon Felden J, Karkmann K, Ittrich H, Gil-Ibanez I, Fr\u00fcndt T, Krause J, Lohse A, Wege H, Schulze K\nVISC MED. 2021;37(2):87-93.\nHeyde syndrome: prevalence and outcomes in patients undergoing transcatheter aortic valve implantation\nWaldschmidt L, Drolz A, Heimburg P, Go\u00dfling A, Ludwig S, Voigtl\u00e4nder L, Linder M, Schofer N, Reichenspurner H, Blankenberg S, Westermann D, Conradi L, Kluwe J, Seiffert M\nCLIN RES CARDIOL. 2021;110(12):1939-1946.\nPresent and future role of endoscopic retrograde cholangiography in primary sclerosing cholangitis\nWaldthaler A, Schramm C, Bergquist A\nEUR J MED GENET. 2021;64(6):104231.\nRare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas\nWege H, Schulze K, von Felden J, Calderaro J, Reig M\nEUR J MED GENET. 2021;64(11):.\nEditorial: only steps away from prime time? Hepatitis B virus RNA as routine marker to guide HBV treatment decisions\nWehmeyer M, Schulze zur Wiesch J\nALIMENT PHARM THER. 2021;54(7):970-971.\nAutoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation\nWeiler-Normann C, Lohse A\nCURR OPIN GASTROEN. 2021;37(2):86-90.\nSARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis\nWendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra I, Mittermaier M, Mache C, Chua R, Knoll R, Timm S, Brumhard S, Krammer T, Zauber H, Hiller A, Pascual-Reguant A, Mothes R, B\u00fclow R, Schulze J, Leipold A, Djudjaj S, Erhard F, Geffers R, Pott F, Kazmierski J, Radke J, Pergantis P, Ba\u00dfler K, Conrad C, Aschenbrenner A, Sawitzki B, Landthaler M, Wyler E, Horst D, Hippenstiel S, Hocke A, Heppner F, Uhrig A, Garcia C, Machleidt F, Herold S, Elezkurtaj S, Thibeault C, Witzenrath M, Cochain C, Suttorp N, Drosten C, Goffinet C, Kurth F, Schultze J, Radbruch H, Ochs M, Eils R, M\u00fcller-Redetzky H, Hauser A, Luecken M, Theis F, Conrad C, Wolff T, Boor P, Selbach M, Saliba A, Sander L\nCELL. 2021;184(26):6243-6261.e27.\nCorrection to: Prevention of coronary obstruction in patients at risk undergoing transcatheter aortic valve implantation: the Hamburg BASILICA experience\nWestermann D, Ludwig S, Kalbacher D, Spink C, Linder M, Bhadra O, Nikorowitsch J, Waldschmidt L, Demal T, Voigtl\u00e4nder L, Schaefer A, Seiffert M, Pecha S, Schofer N, Greenbaum A, Reichenspurner H, Blankenberg S, Conradi L, Schirmer J\nCLIN RES CARDIOL. 2021;110(10):.\nCommon virulence gene expression in adult first-time infected malaria patients and severe cases\nWichers J, Tonkin-Hill G, Thye T, Krumkamp R, Kreuels B, Strauss J, von Thien H, Scholz J, Smedegaard Hansson H, Weisel Jensen R, Turner L, Lorenz F, Sch\u00f6llhorn A, Bruchhaus I, Tannich E, Fendel R, Otto T, Lavstsen T, Gilberger T, Duffy M, Bachmann A\nELIFE. 2021;10:.\nB cell analysis in SARS\u2010CoV\u20102 versus malaria: Increased frequencies of plasmablasts and atypical memory B cells in COVID\u201019\nWildner N, Ahmadi P, Schulte S, Brauneck F, Kohsar M, L\u00fctgehetmann M, Beisel C, Addo M, Haag F, Schulze zur Wiesch J\nJ LEUKOCYTE BIOL. 2021;109(1):77-90.\nUntimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells\nWitkowski M, Tizian C, Ferreira-Gomes M, Niemeyer D, Jones T, Heinrich F, Frischbutter S, Angermair S, Hohnstein T, Mattiola I, Nawrath P, McEwen S, Zocche S, Viviano E, Heinz G, Maurer M, K\u00f6lsch U, Chua R, Aschman T, Meisel C, Radke J, Sawitzki B, Roehmel J, Allers K, Moos V, Schneider T, Hanitsch L, Mall M, Conrad C, Radbruch H, Duerr C, Trapani J, Marcenaro E, Kallinich T, Corman V, Kurth F, Sander L, Drosten C, Treskatsch S, Durek P, Kruglov A, Radbruch A, Mashreghi M, Diefenbach A\nNATURE. 2021;600(7888):295-301.\nMulti-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19\nWoo M, Haag F, Nierhaus A, Jarczak D, Roedl K, Mayer C, Brehm T, van der Meirschen M, Hennigs A, Christopeit M, Fiedler W, Karagiannis P, Burdelski C, Schultze A, Huber S, Addo M, Schmiedel S, Friese M, Kluge S, Schulze Zur Wiesch J\nISCIENCE. 2021;24(7):102752.\nControl of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients\nWoo M, Steins D, H\u00e4u\u00dfler V, Kohsar M, Haag F, Elias-Hamp B, Heesen C, L\u00fctgehetmann M, Schulze Zur Wiesch J, Friese M\nJ NEUROL. 2021;268(1):5-7.\nAnti-glycoprotein 2 (anti-GP2) IgA and anti-neutrophil cytoplasmic antibodies to serine proteinase 3 (PR3-ANCA): antibodies to predict severe disease, poor survival and cholangiocarcinoma in primary sclerosing cholangitis\nWunsch E, Norman G, Milkiewicz M, Krawczyk M, Bentow C, Shums Z, Mahler M, Lopens S, Reinhold D, Franke A, Schramm C, Roggenbuck D, Milkiewicz P\nALIMENT PHARM THER. 2021;53(2):302-313.\nR\u00e4tselhafte B-Symptomatik bei einem 61-J\u00e4hrigen unter Therapie einer rheumatoiden Arthritis\nW\u00fcstenberg R, Christner M, Schmiedel S, Tariparast A, Wichmann D, Lennartz M, Klose H, Kluge S\nINTERNIST. 2021;62(11):1231-1236.\nProteotranscriptomic classification and characterization of pancreatic neuroendocrine neoplasms\nYang K, Kalloger S, Aird J, Lee M, Rushton C, Mungall K, Mungall A, Gao D, Chow C, Xu J, Karasinska J, Colborne S, Jones S, Schrader J, Morin R, Loree J, Marra M, Renouf D, Morin G, Schaeffer D, Gorski S\nCELL REP. 2021;37(2):.\nPrevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey\nZecher B, Buescher G, Willemse J, Walmsley M, Taylor A, Leburgue A, Schramm C, Lohse A, Sebode M\nUNITED EUR GASTROENT. 2021;9(7):797-808.\nSchwere sekund\u00e4r sklerosierende Cholangitis als Manifestation einer sehr seltenen Grunderkrankung\nZecher B, Zenouzi R, Lang M, Karagiannis P, Clauditz T, Fischer L, Sterneck M, Schramm C, Lohse A, Sebode M\nINTERNIST. 2021;62(12):1349-1353.\nEfferocytosis fuels malignant pleural effusion through TIMP1\nZhao L, Giannou A, Xu Y, Shiri A, Liebold I, Steglich B, Bedke T, Zhang T, L\u00fccke J, Scognamiglio P, Kempski J, Woestemeier A, Chen J, Agalioti T, Zazara D, Lindner D, Janning M, Hennigs J, Jagirdar R, Kotsiou O, Zarogiannis S, Kobayashi Y, Izbicki J, Ghosh S, Rothlin C, Bosurgi L, Huber S, Gagliani N\nSCI ADV. 2021;7(33):.\nClonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients\nZhao Y, Kilian C, Turner J, Bosurgi L, Roedl K, Bartsch P, Gnirck A, Cortesi F, Schulthei\u00df C, Hellmig M, Enk L, Hausmann F, Borchers A, Wong M, Paust H, Siracusa F, Scheibel N, Herrmann M, Rosati E, Bacher P, Kylies D, Jarczak D, L\u00fctgehetmann M, Pfefferle S, Steurer S, Zur Wiesch J, Puelles V, Sperhake J, Addo M, Lohse A, Binder M, Huber S, Huber T, Kluge S, Bonn S, Panzer U, Gagliani N, Krebs C\nSCI IMMUNOL. 2021;6(56):.\nBirth weight, growth, nutritional status and mortality of infants from Lambar\u00e9n\u00e9 and Fougamou in Gabon in their first year of life\nZoleko-Manego R, Mischlinger J, Dejon-Agob\u00e9 J, Basra A, Mackanga J, Akerey Diop D, Adegnika A, Agnandji S, Lell B, Kremsner P, Matsiegui P, Gonz\u00e1lez R, Menendez C, Ramharter M, Mombo-Ngoma G\nPLOS ONE. 2021;16(2):e0246694.\nTwo simple and inexpensive methods for preparing DNA suitable for digital PCR from a small number of cells in 96-well plates\nZou Z, Guo L, Ahmadi P, Hartjen P, Gosau M, Smeets R, Kluwe L\nJ CLIN LAB ANAL. 2021;35(1):e23513.\nAntibiotikatherapie richtig gemacht\nAddo M, Thimme R\nDEUT MED WOCHENSCHR. 2020;145(23):1657.\nDefining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73- Phenotype Identifies Polyfunctional Cytotoxic Lymphocytes\nAhmadi P, Hartjen P, Kohsar M, Kummer S, Schmiedel S, Bockmann J, Fathi A, Huber S, Haag F, Schulze Zur Wiesch J\nCELLS-BASEL. 2020;9(8):.\nIn-vitro and in-vivo models for hepatitis B cure research\nAllweiss L, Strick-Marchand H\nCURR OPIN HIV AIDS. 2020;15(3):173-179.\nNK cell receptor NKG2D enforces proinflammatory features and pathogenicity of Th1 and Th17 cells\nBabic M, Dimitropoulos C, Hammer Q, Stehle C, Heinrich F, Sarsenbayeva A, Eisele A, Durek P, Mashreghi M, Lisnic B, Van Snick J, L\u00f6hning M, Fillatreau S, Withers D, Gagliani N, Huber S, Flavell R, Polic B, Romagnani C\nJ EXP MED. 2020;217(8):.\nIgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants\nBartsch Y, Eschweiler S, Leliavski A, Lunding H, Wagt S, Petry J, Lilienthal G, Rahm\u00f6ller J, de Haan N, H\u00f6lscher A, Erapaneedi R, Giannou A, Aly L, Sato R, de Neef L, Winkler A, Braumann D, Hobusch J, Kuhnigk K, Kr\u00e9mer V, Steinhaus M, Blanchard V, Gemoll T, Habermann J, Collin M, Salinas G, Manz R, Fukuyama H, Korn T, Waisman A, Yogev N, Huber S, Germany I, Rose-John S, Busch H, Berberich-Siebelt F, H\u00f6lscher C, Netherlands C, Ehlers M\nJ ALLERGY CLIN IMMUN. 2020;146(3):652-666.e11.\nSeroconversion of HBsAG coincides with hepatitis A super-infection: A case report\nBeisel C, Addo M, Zur Wiesch J\nWORLD J CLIN CASES. 2020;8(9):1651-1655.\nPaediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children\nB\u00e9lard S, Ramharter M, Kurth F\nCOCHRANE DB SYST REV. 2020;12:CD009568.\nMicrobiota-Propelled T Helper 17 Cells in Inflammatory Diseases and Cancer\nBellone M, Brevi A, Huber S\nMICROBIOL MOL BIOL R. 2020;84(2):.\nGALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis\nBest J, Bechmann L, Sowa J, Sydor S, Dech\u00eane A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg J, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Sch\u00fctte K, Weiss K, Toyoda H, Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson P, Canbay A\nCLIN GASTROENTEROL H. 2020;18(3):728-735.e4.\nHas Increased Rollout of Direct Acting Antiviral Therapy Decreased the Burden of Late Presentation and Advanced Liver Disease in Patients Starting Hepatitis C Virus Therapy in Germany?\nBischoff J, Boesecke C, Ingiliz P, Berger F, Simon K, Lutz T, Schewe C, Schulze Zur Wiesch J, Hueppe D, Christensen S, Mauss S, Baumgarten A, Rockstroh J\nJ CLIN GASTROENTEROL. 2020;54(2):192-199.\nHigh rates of cirrhosis and severe clinical events in patients with HBV/HDV co-infection:longitudinal analysis of a German cohort:longitudinal analysis of a German cohort\nBockmann J, Grube M, Hamed V, von Felden J, Landahl J, Wehmeyer M, Giersch K, Hall M, Murray J, Dandri M, L\u00fcth S, Lohse A, L\u00fctgehetmann M, Schulze Zur Wiesch J\nBMC GASTROENTEROL. 2020;20(1):24.\nThe early preclinical and clinical development of cipargamin (KAE609), a novel antimalarial compound\nBouwman S, Zoleko-Manego R, Renner K, Schmitt E, Mombo-Ngoma G, Grobusch M\nTRAVEL MED INFECT DI. 2020;36:101765.\nSARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19\nBraun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, Hippenstiel S, Dingeldey M, Kruse B, Fauchere F, Baysal E, Mangold M, Henze L, Lauster R, Mall M, Beyer K, R\u00f6hmel J, Voigt S, Schmitz J, Miltenyi S, Demuth I, M\u00fcller M, Hocke A, Witzenrath M, Suttorp N, Kern F, Reimer U, Wenschuh H, Drosten C, Corman V, Giesecke-Thiel C, Sander L, Thiel A\nNATURE. 2020;587(7833):270-274.\nWound infection with Vibrio harveyi following a traumatic leg amputation after a motorboat propeller injury in Mallorca, Spain:a case report and review of literature\nBrehm T, Berneking L, Rohde H, Chistner M, Schlickewei C, Sena Martins M, Schmiedel S\nBMC INFECT DIS. 2020;20(1):104.\nRisk factors for different intestinal pathogens among patients with traveler's diarrhea: A retrospective analysis at a German travel clinic (2009-2017)\nBrehm T, L\u00fctgehetmann M, Tannich E, Addo M, Lohse A, Rolling T, Vinnemeier C\nTRAVEL MED INFECT DI. 2020;37:101706.\nHigh effectiveness of multimodal infection control interventions in preventing SARS\u2212CoV\u22122 infections in healthcare professionals: a prospective longitudinal seroconversion study\nBrehm T, Schwinge D, Lampalzer S, Schlicker V, K\u00fcchen J, Thompson M, Ullrich F, Huber S, Schmiedel S, Addo M, L\u00fctgehetmann M, Knobloch J, Schulze zur Wiesch J, Lohse A\nmedRxiv BMJ. 2020.\nThe duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data\nBretscher M, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, D'Alessandro U, Djimde A, Dorsey G, Espi\u00e9 E, Fofana B, Gonz\u00e1lez R, Juma E, Karema C, Lasry E, Lell B, Lima N, Men\u00e9ndez C, Mombo-Ngoma G, Moreira C, Nikiema F, Ou\u00e9draogo J, Staedke S, Tinto H, Valea I, Yeka A, Ghani A, UK C, Okell L\nBMC MED. 2020;18(1):47.\nLong-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals\nBurkhard J, Ciurea A, Gabay C, Hasler P, M\u00fcller R, Niedrig M, Fehr J, Villiger P, Visser L, de Visser A, Walker U, Hatz C, B\u00fchler S\nVACCINE. 2020;38(19):3610-3617.\nCOVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis\nChua R, Lukassen S, Trump S, Hennig B, Wendisch D, Pott F, Debnath O, Th\u00fcrmann L, Kurth F, V\u00f6lker M, Kazmierski J, Timmermann B, Twardziok S, Schneider S, Machleidt F, M\u00fcller-Redetzky H, Maier M, Krannich A, Schmidt S, Balzer F, Liebig J, Loske J, Suttorp N, Eils J, Ishaque N, Liebert U, von Kalle C, Hocke A, Witzenrath M, Goffinet C, Drosten C, Laudi S, Lehmann I, Conrad C, Sander L, Eils R\nNAT BIOTECHNOL. 2020;38(8):970-979.\nSofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E - The HepNet SofE pilot study\nCornberg M, Pischke S, M\u00fcller T, Behrendt P, Piecha F, Benckert J, Todt D, Steinmann E, Papkalla A, von Karpowitz M, Koch A, Lohse A, Hardtke S, Manns M, Wedemeyer H\nJ HEPATOL. 2020;73(3):696-699.\nLong-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis\nCorpechot C, Chazouill\u00e8res O, Belnou P, Montano-Loza A, Mason A, Ebadi M, Eurich D, Chopra S, Jacob D, Schramm C, Sterneck M, Bruns T, Reuken P, Rauchfuss F, Roccarina D, Thorburn D, Gerussi A, Trivedi P, Hirschfield G, McDowell P, Nevens F, Boillot O, Bosch A, Giostra E, Conti F, Poupon R, Par\u00e9s A, Reig A, Donato M, Malinverno F, Floreani A, Russo F, Cazzagon N, Verhelst X, Goet J, Harms M, van Buuren H, Hansen B, Carrat F, Dumortier J\nJ HEPATOL. 2020;73(3):559-565.\nTumour evolution in hepatocellular carcinoma\nCraig A, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A\nNAT REV GASTRO HEPAT. 2020;17(3):139-152.\nLong-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?\nCreutzfeldt A, Piecha F, Schattenberg J, Schramm C, Lohse A\nJ HEPATOL. 2020;73(5):1285-1287.\nSex Differences in Immunity: Implications for the Development of Novel Vaccines Against Emerging Pathogens\nDahlke C, Fathi A, Addo M\nFRONT IMMUNOL. 2020;11(11):601170.\nDistinct early IgA profile may determine severity of COVID-19 symptoms: an immunological case series\nDahlke C, Heidepriem J, Kobbe R, Santer R, Koch T, Fathi A, Ly M, Schmiedel S, Seeberger P, , Addo M, Loeffler F\nmedRxiv. 2020.\nEpigenetic modulation in chronic hepatitis B virus infection\nDandri M\nSEMIN IMMUNOPATHOL. 2020;42(2):173-185.\ncccDNA Maintenance in Chronic Hepatitis B - Targeting the Matrix of Viral Replication\nDandri M, Petersen J\nINFECT DRUG RESIST. 2020;13:3873-3886.\nEpidemiology of schistosomiasis and soil-transmitted helminth coinfections among schoolchildren living in Lambar\u00e9n\u00e9, Gabon\nDejon-Agob\u00e9 J, Honkpehedji Y, Zinsou J, Edoa J, Ad\u00e9gbit\u00e8 B, Mangaboula A, Agnandji S, Mombo-Ngoma G, Ramharter M, Kremsner P, Lell B, Grobusch M, Adegnika A\nAM J TROP MED HYG. 2020;103(1):325-333.\nMolecular Characterization and Clinical Description of Non-Polio Enteroviruses Detected in Stool Samples from HIV-Positive and HIV-Negative Adults in Ghana\nDi Cristanziano V, Weimer K, B\u00f6ttcher S, Sarfo F, Dompreh A, Cesar L, Knops E, Heger E, Wirtz M, Kaiser R, Norman B, Phillips R, Feldt T, Eberhardt K\nVIRUSES-BASEL. 2020;12(2):221.\nCharacterization of the immune cell landscape of patients with NAFLD\nDiedrich T, Kummer S, Galante A, Drolz A, Schlicker V, Lohse A, Kluwe J, Eberhard J, Schulze Zur Wiesch J\nPLOS ONE. 2020;15(3):e0230307.\nResistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection\nDietz J, Kalinina O, Vermehren J, Peiffer K, Matschenz K, Buggisch P, Niederau C, Schattenberg J, M\u00fcllhaupt B, Yerly S, Ringelhan M, Schmid R, Antoni C, M\u00fcller T, Schulze Zur Wiesch J, Piecha F, Moradpour D, Deterding K, Wedemeyer H, Moreno C, Berg T, Berg C, Zeuzem S, Welsch C, Sarrazin C\nJ VIRAL HEPATITIS. 2020;27(10):974-986.\nTreatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions\nDietz J, Vermehren J, Matschenz K, Buggisch P, Klinker H, Schulze Zur Wiesch J, Hinrichsen H, Peiffer K, Graf C, Discher T, Trauth J, Schattenberg J, Piecha F, Mauss S, Niederau C, M\u00fcller T, Neumann-Haefelin C, Berg C, Zeuzem S, Sarrazin C\nLIVER INT. 2020;40(11):2660-2671.\nKlinische Relevanz von Laktat bei kritisch kranken Patienten mit Leberzirrhose\nDrolz A, Fuhrmann V\nIntensiv News. 2020;2020(1):24-26.\nIntegrin alpha E (CD103) limits virus-induced IFN-I production in conventional dendritic cells\nDuhan V, Khairnar V, Kitanovski S, Hamdan T, Klein A, Lang J, Ali M, Adomati T, Bhat H, Friedrich S, Li F, Krebs P, Futerman A, Addo M, Hardt C, Hoffmann D, Lang P, Lang K\nFRONT IMMUNOL. 2020;11:607889.\nVulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1\nEberhard J, Angin M, Passaes C, Salgado M, Monceaux V, Knops E, Kobbe G, Jensen B, Christopeit M, Kr\u00f6ger N, Vandekerckhove L, Badiola J, Bandera A, Raj K, van Lunzen J, H\u00fctter G, Kuball J, Martinez-Laperche C, Balsalobre P, Kwon M, D\u00edez-Mart\u00edn J, Nijhuis M, Wensing A, Martinez-Picado J, Schulze Zur Wiesch J, S\u00e1ez-Ciri\u00f3n A\nSCI TRANSL MED. 2020;12(542):.\nRNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients\nEberhardt K, Meyer-Schwickerath C, Heger E, Knops E, Lehmann C, Rybniker J, Schommers P, Eichenauer D, Kurth F, Ramharter M, Kaiser R, Holtick U, Klein F, Jung N, Di Cristanziano V\nVIRUSES-BASEL. 2020;12(9):.\nPrevention and Management of CMV Infections after Liver Transplantation: Current Practice in German Transplant Centers\nEngelmann C, Sterneck M, Weiss K, Templin S, Zopf S, Denk G, Eurich D, Pratschke J, Weiss J, Braun F, Welker M, Zimmermann T, Knipper P, Nierhoff D, Lorf T, J\u00e4ckel E, Hau H, Tsui T, Perrakis A, Schlitt H, Herzer K, Tacke F\nJ CLIN MED. 2020;9(8):.\nProspective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria\nErameh C, Edeawe O, Akhideno P, Eifediyi G, Omansen T, Wagner C, Sarpong F, Koch T, Wicha S, Kurth F, Duraffour S, Oestereich L, Pahlmann M, Okogbenin S, Ogbaini-Emovon E, G\u00fcnther S, Ramharter M, Groger M\nBMJ OPEN. 2020;10(4):e036936.\nMMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes\nFraune C, Burandt E, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, B\u00fcscheck F, H\u00f6flmayer D, Blessin N, Mandelkow T, Li W, Perez D, Izbicki J, Wilczak W, Sauter G, Schrader J, Neipp M, Mofid H, Daniels T, Isbert C, Clauditz T, Steurer S\nANN SURG ONCOL. 2020;27(10):3997-4006.\nHomogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas\nFraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kluth M, B\u00fcscheck F, Amin T, Viol F, Fehrle W, Dum D, H\u00f6flmayer D, Burandt E, Clauditz T, Perez D, Izbicki J, Wilczak W, Sauter G, Steurer S, Schrader J\nENDOCR PATHOL. 2020;31(2):182-189.\nProgrammed Cell Death Ligand (PD-L)-1 Contributes to the Regulation of CD4+ T Effector and Regulatory T Cells in Cutaneous Leishmaniasis\nFreitas e Silva R, G\u00e1lvez R, Pereira V, de Brito M, Choy S, Lotter H, Bosurgi L, Jacobs T\nFRONT IMMUNOL. 2020;11:.\nUsp18 Expression in CD169+ Macrophages is Important for Strong Immune Response after Vaccination with VSV-EBOV\nFriedrich S, Schmitz R, Bergerhausen M, Lang J, Cham L, Duhan V, H\u00e4ussinger D, Hardt C, Addo M, Prinz M, Asano K, Lang P, Lang K\nVACCINES-BASEL. 2020;8(1):.\nAdvanced organ support (ADVOS) in the critically ill: first clinical experience in patients with multiple organ failure\nFuhrmann V, Weber T, Roedl K, Motaabbed J, Tariparast A, Jarczak D, de Garibay A, Kluwe J, Boenisch O, Herkner H, Kellum J, Kluge S\nANN INTENSIVE CARE. 2020;10(1):96.\nAutoantibodies to intracellular \"rods and rings\" structures in two patients with autoimmune hepatitis treated with azathioprine\nGalaski J, Koop A, L\u00fctgehetmann M, Lohse A, Weiler-Normann C\nAUTOIMMUNITY. 2020;53(6):362-365.\nChallenges in treatment of patients with acute leukemia and COVID-19: a series of 12 patients\nGhandili S, Pfefferle S, Roedl K, Sonnemann P, Karagiannis P, Boenisch O, Kluge S, Schmiedel S, Ittrich H, Rohde H, L\u00fctgehetmann M, Weisel K, Bokemeyer C, Wichmann D, Fiedler W, Jarczak D, Modemann F\nBLOOD ADV. 2020;4(23):5936-5941.\nGenomic Characterization of Cholangiocarcinoma in Primary Sclerosing Cholangitis Reveals Therapeutic Opportunities\nGoeppert B, Folseraas T, Roessler S, Kloor M, Volckmar A, Endris V, Buchhalter I, Stenzinger A, Grzyb K, Grimsrud M, Gornicka B, von Seth E, Reynolds G, Franke A, Gotthardt D, Mehrabi A, Cheung A, Verheij J, Arola J, M\u00e4kisalo H, Eide T, Weidemann S, Cheville J, Mazza G, Hirschfield G, Ponsioen C, Bergquist A, Milkiewicz P, Lazaridis K, Schramm C, Manns M, F\u00e4rkkil\u00e4 M, Vogel A, Boberg K, Schirmacher P, Karlsen T\nHEPATOLOGY. 2020;72(4):1253-1266.\nUnreported Missense Mutation in the Dimerization Domain of ADA2 Leads to ADA2 Deficiency Associated with Severe Oral Ulcers and Neutropenia in a Female Somalian Patient\u2014Addendum to the Genotype-Phenotype Puzzle\nG\u00f6schl L, Winkler S, Dmytrus J, Heredia R, Lagler H, Ramharter M, Scheinecker C, Bonelli M, Schmetterer K, Pickl W, Grabmeier-Pfistershammer K, Hershfield M, Boztug K, F\u00f6rster-Waldl E, Gualdoni G\nJ CLIN IMMUNOL. 2020;40(1):223-226.\nAcute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study\nGrensemann J, Busse D, K\u00f6nig C, Roedl K, J\u00e4ger W, Jarczak D, Iwersen-Bergmann S, Manthey C, Kluge S, Kloft C, Fuhrmann V\nANN INTENSIVE CARE. 2020;10(1):48.\nTravel-related infections presenting in Europe: A 20-year analysis of EuroTravNet surveillance data\nGrobusch M, Weld L, Goorhuis A, Hamer D, Schunk M, Jordan S, Mockenhaupt F, Chappuis F, Asgeirsson H, Caumes E, Jensenius M, van Genderen P, Dastelli F, Lopez-Velez R, Field V, Bottieau E, Molina I, Rapp C, Diaz Menendez M, Gkrania-Klotsas E, Larsen C, Malvy D, Lalloo D, Gobbi F, Florescu S, Gautret P, Schlagenhauf P\nLANCET REG HEALTH-EU. 2020;1(100001):.\nReply to Lin et al\nGroger M, Ramharter M\nCLIN INFECT DIS. 2020;70(9):2019-2020.\nDescribing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 - 2018\nGuggenb\u00fchl Noller J, Froeschl G, Eisermann P, Jochum J, Theuring S, Reiter-Owona I, Bissinger A, Hoelscher M, Bakuli A, von Sonnenburg F, Rothe C, Bretzel G, Albajar-Vi\u00f1as P, Grout L, Pritsch M\nBMC INFECT DIS. 2020;20(1):919.\nErratum: Author Correction: Humoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients\nHarrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle J, Stiasny K, Greinix H, Rabitsch W, Kalhs P, Ramharter M, Burgmann H, Forstner C\nNPJ VACCINES. 2020;5(1):79.\nHumoral immune response to tick-borne encephalitis vaccination in allogeneic blood and marrow graft recipients\nHarrison N, Grabmeier-Pfistershammer K, Graf A, Schwarzinger I, Aberle J, Stiasny K, Greinix H, Rabitsch W, Kalhs P, Ramharter M, Burgmann H, Forstner C\nNPJ VACCINES. 2020;5(1):67.\nFeatures and outcome of AIH patients without elevation of IgG\nHartl J, Miquel R, Zachou K, Wong G, Asghar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech T, Weiler-Normann C, Drenth J, Oo Y, Dalekos G, Heneghan M, Schramm C, Lohse A\nJHEP REP. 2020;2(3):100094.\nEffects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis\nHedin C, Sado G, Ndegwa N, Lytvyak E, Mason A, Montano-Loza A, Gerussi A, Saffioti F, Thorburn D, Nilsson E, Larsson G, Moum B, van Munster K, Ponsioen C, Levy C, Nogueira N, Bowlus C, Gotlieb N, Shibolet O, Lynch K, Chapman R, Rupp C, Vesterhus M, J\u00f8rgensen K, Rorsman F, Schramm C, Sabino J, Vermeire S, Zago A, Cazzagon N, Marschall H, Ytting H, Ben Belkacem K, Chazouilleres O, Almer S, Bergquist A\nCLIN GASTROENTEROL H. 2020;18(10):2295-2304.e2.\nDetection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute Plasmodium falciparum Malaria\nHeide J, Wildner N, Ackermann C, Wittner M, Marget M, Sette A, Sidney J, Jacobs T, Schulze Zur Wiesch J\nFRONT IMMUNOL. 2020;10:3037.\nSelbst eingesch\u00e4tzte medizinische Versorgung im Verlauf der SARS-CoV-2-Pandemie in Deutschland: Ergebnisse der COSMO-Studie\nHeidemann C, Paprott R, H\u00fcbl L, Scheidt-Nave C, Reitzle L\nEpidemiologisches Bulletin. 2020;2020(46):3-10.\nEpitopes of Naturally Acquired and Vaccine-Induced Anti-Ebola Virus Glycoprotein Antibodies in Single Amino Acid Resolution\nHeidepriem J, Kr\u00e4hling V, Dahlke C, Wolf T, Klein F, Addo M, Becker S, Loeffler F\nBIOTECHNOL J. 2020;15(9):e2000069.\nLong-term survival after liver transplantation for autoimmune hepatitis - results from the European Liver Transplant Registry\nHeinemann M, Adam R, Berenguer M, Mirza D, Malek-Hosseini S, O'Grady J, Lodge P, Pratschke J, Boudjema K, Paul A, Zieniewicz K, Fronek J, Weiss K, Karam V, Duvoux C, Lohse A, Schramm C\nLIVER TRANSPLANT. 2020;26(7):866-877.\nCase Report: Acute Vision Loss in a Young Returning Traveler with Dengue Fever\nHeinemann M, Bigdon E, Veletzky L, Jordan S, Jochum J, Knospe V, Schmiedel S, Ramharter M\nAM J TROP MED HYG. 2020;103(5):2026-2028.\nRelapsing cutaneous leishmaniasis in a patient requiring TNF-\u03b1-inhibitor Infliximab for Takayasu-arteritis: Case report and review of the literature\nHeinemann M, Omansen T, Hennigs A, V\u00f6lker K, Menz A, Addo M, Schmiedel S\nTRAVEL MED INFECT DI. 2020;37:101700.\nHigh prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018\nHeinemann M, Phillips R, Vinnemeier C, Rolling C, Tannich E, Rolling T\nMALARIA J. 2020;19(1):366.\nRapid Response to Pandemic Threats: Immunogenic Epitope Detection of Pandemic Pathogens for Diagnostics and Vaccine Development Using Peptide Microarrays\nHeiss K, Heidepriem J, Fischer N, Weber L, Dahlke C, Jaenisch T, Loeffler F\nJ PROTEOME RES. 2020;19(11):4339-4354.\nRabies exposure in travellers to Asia, the Middle East, Africa, South and Central America-a German Airport study\nHeitkamp C, Stelzl D, Ramharter M, B\u00fchler S\nJ TRAVEL MED. 2020;27(7):taaa058.\nAntibiotikatherapie im klinischen Alltag\nHennigs A, Jochum J\nDEUT MED WOCHENSCHR. 2020;145(23):1673-1682.\nThe Effects of Androgens on T Cells: Clues to Female Predominance in Autoimmune Liver Diseases?\nHenze L, Schwinge D, Schramm C\nFRONT IMMUNOL. 2020;11:.\nAutoimmune hepatitis: Possible triggers, potential treatments\nHerkel J, Carambia A, Lohse A\nJ HEPATOL. 2020;73(2):446-448.\nAnalysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease\nHerrmann M, Schulte S, Wildner N, Wittner M, Brehm T, Ramharter M, Woost R, Lohse A, Jacobs T, Schulze zur Wiesch J\nFRONT IMMUNOL. 2020;11:1870.\nA cross-sectional study on risk factors for infection with Parvovirus B19 and the association with anaemia in a febrile paediatric population in Ghana\nHerr W, Krumkamp R, Hogan B, Dekker D, Gyau K, Owusu-Dabo E, Sarpong N, Jaeger A, Loag W, Winter D, Akenten C, Eibach D, Fickenscher H, Eis-H\u00fcbinger A, May J, Kreuels B\nSCI REP-UK. 2020;10(1):15695.\nCurrent Challenges in the Post-Transplant Care of Liver Transplant Recipients in Germany\nHerzer K, Sterneck M, Welker M, Nadalin S, Kirchner G, Braun F, Malessa C, Herber A, Pratschke J, Weiss K, Jaeckel E, Tacke F\nJ CLIN MED. 2020;9(11):.\nThe Transcription Factor Promyelocytic Leukemia Zinc Finger Protein Is Associated With Expression of Liver-Homing Receptors on Human Blood CD56bright Natural Killer Cells\nHess L, Martrus G, Ziegler A, Langeneckert A, Salzberger W, Goebels H, Sagebiel A, Hagen S, Poch T, Ravichandran G, Koch M, Schramm C, Oldhafer K, Fischer L, Tiegs G, Richert L, Bunders M, Lunemann S, Altfeld M\nHEPATOL COMMUN. 2020;4(3):409-424.\nSignificance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection\nHorvatits T, Schulze Zur Wiesch J, Polywka S, Buescher G, L\u00fctgehetmann M, Hussey E, Horvatits K, Peine S, Haag F, Addo M, Lohse A, Weiler-Normann C, Pischke S\nPATHOGENS. 2020;9(9):.\nNo link between male infertility and HEV genotype 3 infection\nHorvatits T, Varwig-Janssen D, Schulze Zur Wiesch J, L\u00fcbke R, Reucher S, Frerk S, Addo M, Schneider S, Lohse A, Luetgehetmann M, Pischke S\nGUT. 2020;69(6):1150-1151.\nDrittlinientherapie mit Quinacrin und Metronidazol bei refrakt\u00e4rer Giardiasis\nHunstig F, Jochum J, Tannich E, Kreuels B\nFLUGMEDIZIN TROPENME. 2020;2020(5):216-218.\nReinfection with the hepatitis C virus in men who have sex with men after successful treatment with direct-acting antivirals in Germany: Current incidence rates compared with rates during the interferon era\nIngiliz P, Wehmeyer M, Boesecke C, Schulze Zur Wiesch J, Schewe K, Lutz T, Baumgarten A, Simon K, Hueppe D, Rockstroh J, Mauss S, Christensen S\nCLIN INFECT DIS. 2020;71(5):1248-1254.\nSOP Transarterielle Chemoembolisation zur Tumortherapie\nIttrich H, Wege H, Schrader J\nGastroenterologie up2date. 2020;2020(16):201-208.\nScent dog identification of samples from COVID-19 patients - a pilot study\nJendrny P, Schulz C, Twele F, Meller S, von K\u00f6ckritz-Blickwede M, Osterhaus A, Ebbers J, Pilchov\u00e1 V, Pink I, Welte T, Manns M, Fathi A, Ernst C, Addo M, Schalke E, Volk H\nBMC INFECT DIS. 2020;20(1):536.\nClinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope\u00ae registry\nJenks J, Seidel D, Cornely O, Chen S, van Hal S, Kauffman C, Miceli M, Heinemann M, Christner M, Jover S\u00e1enz A, Burchardt A, Kemmerling B, Herbrecht R, Steinmann J, Shoham S, Gr\u00e4ber S, Pagano L, Deeren D, Slavin M, Hoenigl M\nMYCOSES. 2020;63(5):437-442.\nVoriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope\u00ae registry 2008-2019\nJenks J, Seidel D, Cornely O, Chen S, van Hal S, Kauffman C, Miceli M, Heinemann M, Christner M, S\u00e1enz A, Burchardt A, Kemmerling B, Herbrecht R, Steinmann J, Shoham S, Gr\u00e4ber S, Pagano L, Deeren D, Aslam S, Taplitz R, Revankar S, Baddley J, Mehta S, Reed S, Slavin M, Hoenigl M\nCLIN MICROBIOL INFEC. 2020;26(6):784.e1-784.e5.\nA 16-Year-Old Male Refugee from Somalia With High Fever and Slurred Speech\nJochum J\n2020. Clinical Cases in Tropical Medicine. Rothe C (Hrsg.). 2. Aufl. Elsevier Ltd., 286-288.\nAnthrax\nJochum J, Schmiedel S\n2020. Referenz Intensivmedizin. Marx G, Zacharowski K, Kluge S (Hrsg.). 1. Aufl. Georg Thieme Verlag KG Stuttgart \u00b7 New York, 774-784.\nBotulismus\nJochum J, Schmiedel S\n2020. Referenz Intensivmedizin. Marx G, Zacharowski K, Kluge S (Hrsg.). 1. Aufl. Georg Thieme Verlag KG Stuttgart \u00b7 New York, 720-727.\nA 48-year-old woman from Thailand with fever and disseminated cutaneous abscesses\nJordan S\n2020. Clinical Cases in Tropical Medicine. 2. Aufl. Elsevier Ltd., 167-169.\nRibavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study\nKamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux G, Barbet C, Moal V, Couzi L, Horvatits T, De Man R, Cassuto E, Elsharkawy A, Riezebos-Brilman A, Scemla A, Hillaire S, Donnelly M, Radenne S, Sayegh J, Garrouste C, Dumortier J, Glowaki F, Matignon M, Coilly A, Figueres L, Mousson C, Minello A, Dharancy S, Rerolle J, Lebray P, Etienne I, Perrin P, Choi M, Marion O, Izopet J\nCLIN INFECT DIS. 2020;71(5):1204-1211.\nTargeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)\nKarakas M, Jarczak D, Becker M, Roedl K, Addo M, Hein F, Bergmann A, Zimmermann J, Simon T, Marx G, L\u00fctgehetmann M, Nierhaus A, Kluge S\nBIOMOLECULES. 2020;10(8):.\nSystemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas\nKarstens K, Kempski J, Giannou A, Freiwald E, Reeh M, Tachezy M, Izbicki J, Lohse A, Gagliani N, Huber S, Pelczar P\nPLOS ONE. 2020;15(4):e0231833.\nAnti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival\nKarstens K, Kempski J, Giannou A, Pelczar P, Steglich B, Steurer S, Freiwald E, Woestemeier A, Konczalla L, Tachezy M, Reeh M, Bockhorn M, Perez D, Mann O, Lohse A, Roesch T, Izbicki J, Gagliani N, Huber S\nCANCER IMMUNOL IMMUN. 2020;69(6):1043-1056.\nIL22BP Mediates the Anti-Tumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans\nKempski J, Giannou A, Riecken K, Zhao L, Steglich B, L\u00fccke J, Garcia-Perez L, Karstens K, W\u00f6stemeier A, Nawrocki M, Pelczar P, Witkowski M, Nilsson S, Konczalla L, Shiri A, Kempska J, Wahib R, Brockmann L, Huber P, Gnirck A, Turner J, Zazara D, Arck P, Stein A, Simon R, Daubmann A, Meiners J, Perez D, Strowig T, Koni P, Kruglov A, Sauter G, Izbicki J, Guse A, Roesch T, Lohse A, Flavell R, Gagliani N, Huber S\nGASTROENTEROLOGY. 2020;159(4):1417-1430.e3.\nMedizinische Mikrobiologie und Infektiologie S. Suerbaum, G.D. Burchard, S.H.E. Kaufmann, T.F. Schulz: Infektionen bei Immunsuppression, Infektionen bei prim\u00e4ren Immundefekten, Opportunistische Infektionen bei Patienten mit HIV-Infektion, Infektionen bei Organtransplantation, Infektionen nach h\u00e4matopoetischer Stammzelltransplantation, Infektionen bei Asplenie, Infektionen bei medikament\u00f6s induzierter Immunsuppression\nKobbe R\n2020.\nSafety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial\nKoch T, Dahlke C, Fathi A, Kupke A, Kr\u00e4hling V, Okba N, Halwe S, Rohde C, Eickmann M, Volz A, Hesterkamp T, Jambrecina A, Borregaard S, Ly M, Zinser M, Bartels E, Poetsch J, Neumann R, Fux R, Schmiedel S, Lohse A, Haagmans B, Sutter G, Becker S, Addo M\nLANCET INFECT DIS. 2020;20(7):827-838.\nEbola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins\nKoch T, Rottstegge M, Ruibal P, Gomez-Medina S, Nelson E, Escudero-P\u00e9rez B, Pillny M, Ly M, Koundouno F, Bore J, Magassouba N, Dahlke C, G\u00fcnther S, Carroll M, Addo M, Mu\u00f1oz-Fontela C\nVIRUSES-BASEL. 2020;12(9):.\nTherapeutic Targeting of Myeloperoxidase Attenuates NASH in Mice\nKoop A, Thiele N, Steins D, Micha\u00eblsson E, Wehmeyer M, Scheja L, Steglich B, Huber S, Schulze zur Wiesch J, Lohse A, Heeren J, Kluwe J\nHEPATOL COMMUN. 2020;4(10):1441-1458.\nDiagnostik und Therapie unklarer Gallengangsstenosen\nKrause J, Ehlken H, Schramm C\nDEUT MED WOCHENSCHR. 2020;145(5):306-312.\nHepatocellular carcinoma: Intratumoral EpCAM-positive cancer stem cell heterogeneity identifies high-risk tumor subtype\nKrause J, von Felden J, Casar C, Fr\u00fcndt T, Galaski J, Schmidt C, Jung C, Ittrich H, Weidemann S, Krech T, Heumann A, Li J, Fischer L, Sauter G, Lohse A, Wege H, Schulze K\nBMC CANCER. 2020;20(1):1130.\nPathogen-induced tissue-resident memory TH17 (TRM17) cells amplify autoimmune kidney disease\nKrebs C, Reimers D, Zhao Y, Paust H, Bartsch P, Nu\u00f1ez S, Rosemblatt M, Hellmig M, Kilian C, Borchers A, Enk L, Zinke M, Becker M, Schmid J, Klinge S, Wong M, Puelles V, Schmidt C, Bertram T, Stumpf N, Hoxha E, Meyer-Schwesinger C, Lindenmeyer M, Cohen C, Rink M, Kurts C, Franzenburg S, Koch-Nolte F, Turner J, Riedel J, Huber S, Gagliani N, Huber T, Wiech T, Rohde H, Bono M, Bonn S, Panzer U, Mittr\u00fccker H\nSCI IMMUNOL. 2020;5(50):.\nA Therapeutic Non-self-reactive SARS-CoV-2 Antibody Protects from Lung Pathology in a COVID-19 Hamster Model\nKreye J, Reincke S, Kornau H, S\u00e1nchez-Sendin E, Corman V, Liu H, Yuan M, Wu N, Zhu X, Lee C, Trimpert J, H\u00f6ltje M, Dietert K, St\u00f6ffler L, von Wardenburg N, van Hoof S, Homeyer M, Hoffmann J, Abdelgawad A, Gruber A, Bertzbach L, Vladimirova D, Li L, Barthel P, Skriner K, Hocke A, Hippenstiel S, Witzenrath M, Suttorp N, Kurth F, Franke C, Endres M, Schmitz D, Jeworowski L, Richter A, Schmidt M, Schwarz T, M\u00fcller M, Drosten C, Wendisch D, Sander L, Osterrieder N, Wilson I, Pr\u00fcss H\nCELL. 2020;183(4):1058-1069.e19.\nProfessional Assessment of the Impact of COVID-19 on Handling NET Patients\nKrug S, Garbe J, K\u00f6nig S, Ungewiss H, Michl P, Rinke A, Schrader J\nJ CLIN MED. 2020;9(11):3633.\nMonocytes as potential mediators of pathogen-induced Th17 differentiation in patients with primary sclerosing cholangitis (PSC)\nKunzmann L, Schoknecht T, Poch T, Henze L, Stein S, Kriz M, Grewe I, Preti M, Hartl J, Pannicke N, Peiseler M, Sebode M, Zenouzi R, Horvatits T, B\u00f6ttcher M, Petersen B, Weiler-Normann C, Hess L, Ahrenstorf A, Lunemann S, Martrus G, Fischer L, Li J, Carambia A, Kluwe J, Huber S, Lohse A, Franke A, Herkel J, Schramm C, Schwinge D\nHEPATOLOGY. 2020;72(4):1310-1326.\nBlood and Lymph Node Dissemination of Clonal Genome-Intact Human Immunodeficiency Virus 1 DNA Sequences During Suppressive Antiretroviral Therapy\nKuo H, Banga R, Lee G, Gao C, Cavassini M, Corpataux J, Blackmer J, Zur Wiesch S, Yu X, Pantaleo G, Perreau M, Lichterfeld M\nJ INFECT DIS. 2020;222(4):655-660.\nManagement of hepatic encephalopathy in Germany: a survey among physicians\nLabenz C, Adarkwah C, W\u00f6rns M, Miehlke S, Hofmann W, Buggisch P, Galle P, Frieling T, Labenz J\nZ GASTROENTEROL. 2020;58(1):49-56.\nRecombinase polymerase amplification and lateral flow assay for ultrasensitive detection of low-density Plasmodium falciparum infection from controlled human malaria infection studies and naturally acquired infections\nLalremruata A, Nguyen T, McCall M, Mombo-Ngoma G, Agnandji S, Adegnika A, Lell B, Ramharter M, Hoffman S, Kremsner P, Mordm\u00fcller B\nJ CLIN MICROBIOL. 2020;58(5):.\nDiagnosis and treatment of primary biliary cholangitis\nLaschtowitz A, de Veer R, Van der Meer A, Schramm C\nUNITED EUR GASTROENT. 2020;8(6):667-674.\nDecreased Frequency of Intestinal CD39+ \u03b3\u03b4+ T Cells With Tissue-Resident Memory Phenotype in Inflammatory Bowel Disease\nLibera J, Wittner M, Kantowski M, Woost R, Eberhard J, de Heer J, Reher D, Huber S, Haag F, Schulze Zur Wiesch J\nFRONT IMMUNOL. 2020;11:567472.\nOutpatient treatment of imported uncomplicated Plasmodium falciparum malaria: results from a survey among TropNet and GeoSentinel experts for tropical medicine\nLingscheid T, Kurth F, Stegemann M, Clerinx J, Calleri G, Rothe C, Angheben A, Gobbi F, Bisoffi Z, Hamer D, Libman M, Hatz C, Zoller T\nJ TRAVEL MED. 2020;27(4):taaa082.\nA disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis\nLiwinski T, Casar C, Ruehlemann M, Bang C, Sebode M, Hohenester S, Denk G, Lieb W, Lohse A, Franke A, Schramm C\nALIMENT PHARM THER. 2020;51(12):1417-1428.\nHarnessing the Microbiota for Therapeutic Purposes\nLiwinski T, Elinav E\nAM J TRANSPLANT. 2020;20(6):1482-1488.\nEditorial: gut microbiota profile in patients with autoimmune hepatitis-a clue for adjunctive probiotic therapy? Authors' reply\nLiwinski T, Schramm C\nALIMENT PHARM THER. 2020;52(2):394-395.\nAlterations of the bile microbiome in primary sclerosing cholangitis\nLiwinski T, Zenouzi R, John C, Ehlken H, R\u00fchlemann M, Bang C, Groth S, Lieb W, Kantowski M, Andersen N, Schachschal G, Karlsen T, Hov J, R\u00f6sch T, Lohse A, Heeren J, Franke A, Schramm C\nGUT. 2020;69(4):665-672.\nManagement of patients with autoimmune liver disease during COVID-19 pandemic\nLleo A, Invernizzi P, Lohse A, Aghemo A, Carbone M\nJ HEPATOL. 2020;73(2):453-455.\nSecond-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group\nLohse A, Sebode M, J\u00f8rgensen M, Ytting H, Karlsen T, Kelly D, Manns M, Vesterhus M\nJ HEPATOL. 2020;73(6):1496-1506.\nIntratumoral heterogeneity and clonal evolution in liver cancer\nLosic B, Craig A, Villacorta-Martin C, Martins-Filho S, Akers N, Chen X, Ahsen M, von Felden J, Labgaa I, D\u02b9Avola D, Allette K, Lira S, Furtado G, Garcia-Lezana T, Restrepo P, Stueck A, Ward S, Fiel M, Hiotis S, Gunasekaran G, Sia D, Schadt E, Sebra R, Schwartz M, Llovet J, Thung S, Stolovitzky G, Villanueva A\nNAT COMMUN. 2020;11(1):291.\nTAVR for low-flow, low-gradient aortic stenosis: Prognostic impact of aortic valve calcification\nLudwig S, Go\u00dfling A, Waldschmidt L, Linder M, Bhadra O, Voigtl\u00e4nder L, Sch\u00e4fer A, Deuschl F, Schirmer J, Reichenspurner H, Blankenberg S, Sch\u00e4fer U, Westermann D, Seiffert M, Conradi L, Schofer N\nAM HEART J. 2020;225:138-148.\nA Comprehensive Molecular Characterization of the Pancreatic Neuroendocrine Tumor Cell Lines BON-1 and QGP-1\nLuley K, Biedermann S, K\u00fcnstner A, Busch H, Franzenburg S, Schrader J, Grabowski P, Wellner U, Keck T, Brabant G, Schmid S, Lehnert H, Ungefroren H\nCANCERS. 2020;12(3):691.\nEffects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases.\nLynch K, Chapman R, Keshav S, Montano-Loza A, Mason A, Kremer A, Vetter M, de Krijger M, Ponsioen C, Trivedi P, Hirschfield G, Schramm C, Liu C, Bowlus C, Estes D, Pratt D, Hedin C, Bergquist A, de Vries A, Janneke van der Woude C, Yu L, Assis D, Boyer J, Ytting H, Hallibasic E, Trauner M, Marschall H, Daretti L, Marzioni M, Yimam K, Perin N, Floreani A, Beretta-Piccoli B, Rogers J, Levy C\nCLIN GASTROENTEROL H. 2020;18(1):179-187.e6.\nSustained response after remdesivir and convalescent plasma therapy in a B-cell depleted patient with protracted COVID-19\nMalsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, L\u00fctgehetmann M, Rosien U, Jasper D, Peine S, Hiller J, Haag F, Schmiedel S, Huber S, Jordan S, Addo M, Schulze Zur Wiesch J\nCLIN INFECT DIS. 2020;73(11):e4020\u2013e4024.\nVaccination in Patients with Inflammatory Bowel Diseases\nManser C, Maillard M, Rogler G, Schreiner P, Rieder F, B\u00fchler S\nDIGESTION. 2020;101 Suppl 1:58-68.\nAkute Gastroenteritis im Kindes- und Erwachsenenalter\nManthey C, Beime J, Schulz-J\u00fcrgensen S\nGastroenterologie up2date. 2020;16(4):367-385.\nNeuropathology of patients with COVID-19 in Germany: a post-mortem case series\nMatschke J, L\u00fctgehetmann M, Hagel C, Sperhake J, Schr\u00f6der A, Edler C, Mushumba H, Fitzek A, Allweiss L, Dandri M, Dottermusch M, Heinemann A, Pfefferle S, Schwabenland M, Sumner Magruder D, Bonn S, Prinz M, Gerloff C, P\u00fcschel K, Krasemann S, Aepfelbacher M, Glatzel M\nLANCET NEUROL. 2020;19(11):919-929.\nA randomized controlled trial comparing the effectiveness of individual versus household treatment for scabies in Lambar\u00e9n\u00e9, Gabon\nMatthewman J, Manego R, Mbadinga L, \u0160inkovec H, V\u00f6lker K, Akinosho M, Haedrich C, D\u2019hamonville J, Lell B, Adegnika A, Ramharter M, Mombo-Ngoma G\nPLOS NEGLECT TROP D. 2020;14(6):e0008423.\nEBV renders B cells susceptible to HIV-1 in humanized mice\nMcHugh D, Myburgh R, Caduff N, Spohn M, Kok Y, Keller C, Murer A, Chatterjee B, R\u00fchl J, Engelmann C, Chijioke O, Quast I, Shilaih M, Strouvelle V, Neumann K, Menter T, Dirnhofer S, Lam J, Hui K, Bredl S, Schlaepfer E, Sorce S, Zbinden A, Capaul R, L\u00fcnemann J, Aguzzi A, Chiang A, Kempf W, Trkola A, Metzner K, Manz M, Grundhoff A, Speck R, M\u00fcnz C\nLIFE SCI ALLIANCE. 2020;3(8):.\nNerve decompression according to A.L. Dellon in Morton's neuroma - A retrospective analysis\nMischitz M, Zeitlinger S, Mischlinger J, Rab M\nJ PLAST RECONSTR AES. 2020;73(6):1099-1104.\nMeasles, Vaccines, and Types of Perception Bias in Public Debates\nMischlinger J, Muranaka R, B\u00fchler S, Ramharter M\nCLIN INFECT DIS. 2020;70(6):1258-1259.\nImported Malaria in countries where malaria is not endemic A comparison of semi-immune and nonimmune travelers\nMischlinger J, R\u00f6nnberg C, \u00c1lvarez-Mart\u00ednez M, B\u00fchler S, Paul M, Schlagenhauf P, Petersen E, Ramharter M\nCLIN MICROBIOL REV. 2020;33(2):.\nInvestigational Drugs, Quality, and Drug Formulations for Malaria\nMombo-Ngoma G, Duparc S\n2020. Encyclopedia of Malaria. Springer New York, 1-16.\nImpaired diagnostic accuracy of hair ethyl glucuronide testing in patients with renal dysfunction\nMosebach A, Aboutara N, Lago M, M\u00fcller A, Lang M, Fischer L, Iwersen-Bergmann S, Sterneck M\nFORENSIC SCI INT. 2020;317:110518.\nDiagnostic techniques of soil-transmitted helminths: Impact on control measures\nNgwese M, Manouana G, Moure P, Ramharter M, Esen M, Ad\u00e9gnika A\nTROP MED INFECT DIS. 2020;5(2):.\nGastrointestinale und bili\u00e4re Parasitosen\nOmansen T, Jochum J, Ramharter M\nGastroenterologie up2date. 2020;2020(16):83 - 96.\nPerforation of the ascending colon during implantation of an indwelling peritoneal catheter: a case report\nPaparoupa M, Wege H, Creutzfeldt A, Sebode M, Uzunoglu F, Boenisch O, Nierhaus A, Izbicki J, Kluge S\nBMC GASTROENTEROL. 2020;20(1):345.\nRapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months\nPape S, Gevers T, Vrolijk J, van Hoek B, Bouma G, van Nieuwkerk C, Taubert R, Jaeckel E, Manns M, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener D, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse A, Drenth J, Heneghan M\nCLIN GASTROENTEROL H. 2020;18(7):1609-1617.e4.\nHigh discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation\nPape S, Gevers T, Vrolijk J, van Hoek B, Bouma G, van Nieuwkerk C, Taubert R, Jaeckel E, Manns M, Papp M, Sipeki N, Stickel F, Efe C, Ozaslan E, Purnak T, Nevens F, Kessener D, Kahraman A, Wedemeyer H, Hartl J, Schramm C, Lohse A, Heneghan M, Drenth J\nLIVER INT. 2020;40(9):2164-2171.\nInulin Supplementation Disturbs Hepatic Cholesterol and Bile Acid Metabolism Independent from Housing Temperature\nPauly M, Rohde J, John C, Evangelakos I, Koop A, Pertzborn P, T\u00f6dter K, Scheja L, Heeren J, Worthmann A\nNUTRIENTS. 2020;12(10):.\nRapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination\nPejoski D, de Rham C, Martinez-Murillo P, Santoro F, Auderset F, Medaglini D, Pozzi G, Vono M, Lambert P, Huttner A, Haks M, Ottenhoff T, Villard J, Siegrist C\nNPJ VACCINES. 2020;5(1):32.\nPublisher Correction: TGF-\u03b2 signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer\nPerez L, Kempski J, McGee H, Pelzcar P, Agalioti T, Giannou A, Konczalla L, Brockmann L, Wahib R, Xu H, Vesely M, Soukou S, Steglich B, Bedke T, Manthey C, Seiz O, Diercks B, Gnafakis S, Guse A, Perez D, Izbicki J, Gagliani N, Flavell R, Huber S\nNAT COMMUN. 2020.\nTGF-\u03b2 signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer\nPerez L, Kempski J, M McGee H, Pelzcar P, Agalioti T, Giannou A, Konczalla L, Brockmann L, Wahib R, Xu H, Vesely M, Soukou S, Steglich B, Bedke T, Manthey C, Seiz O, Diercks B, Gnafakis S, Guse A, Perez D, Izbicki J, Gagliani N, Flavell R, Huber S\nNAT COMMUN. 2020;11(1):.\nClinical evaluation of five different automated SARS-CoV-2 serology assays in a cohort of hospitalized COVID-19 patients\nPfl\u00fcger L, Bannasch J, Brehm T, Pfefferle S, Hoffmann A, N\u00f6rz D, van der Meirschen M, Kluge S, Haddad M, Pischke S, Hiller J, Addo M, Lohse A, Wiesch J, Peine S, Aepfelbacher M, L\u00fctgehetmann M\nJ CLIN VIROL. 2020;130:104549.\nRifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial\nPhillips R, Robert J, Abass K, Thompson W, Sarfo F, Wilson T, Sarpong G, Gateau T, Chauty A, Omollo R, Ochieng Otieno M, Egondi T, Ampadu E, Agossadou D, Marion E, Ganlonon L, Wansbrough-Jones M, Grosset J, Macdonald J, Treadwell T, Saunderson P, Paintsil A, Lehman L, Frimpong M, Sarpong N, Saizonou R, Tiendrebeogo A, Ohene S, Stienstra Y, Asiedu K, van der Werf T\nLANCET. 2020;395(10232):1259-1267.\nTreatment and re-treatment results of HCV patients in the DAA era\nPiecha F, G\u00e4n\u00dfler J, Ozga A, Wehmeyer M, Dietz J, Kluwe J, Laschtowitz A, von Felden J, Sterneck M, Jordan S, Pischke S, Lohse A, Schulze Zur Wiesch J\nPLOS ONE. 2020;15(5):e0232773.\nSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine\nPolack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez J, Perez Marc G, Moreira E, Zerbini C, Bailey R, Swanson K, Roychoudhury S, Koury K, Li P, Kalina W, Cooper D, Frenck Jr R, Hammitt L, T\u00fcreci \u00d6, Nell H, Schaefer A, \u00dcnal S, Tresnan D, Mather S, Dormitzer P, Sahin U, Jansen K, Gruber W\nNEW ENGL J MED. 2020;383(27):2603-2615.\nRisk estimation for air travel-induced malaria transmission in central Europe - A mathematical modelling study\nPondorfer S, Jaeger V, Scholz-Kreisel P, Horn J, Krumkamp R, Kreuels B, Mikolajczyk R, Karch A\nTRAVEL MED INFECT DI. 2020;36:101564.\nMultiorgan and Renal Tropism of SARS-CoV-2\nPuelles V, L\u00fctgehetmann M, Lindenmeyer M, Sperhake J, Wong M, Allweiss L, Chilla S, Heinemann A, Wanner N, Liu S, Braun F, Lu S, Pfefferle S, Schr\u00f6der A, Edler C, Gross O, Glatzel M, Wichmann D, Wiech T, Kluge S, Pueschel K, Aepfelbacher M, Huber T\nNEW ENGL J MED. 2020;383(6):590-592.\nVon den Toten lernen - neue Erkenntnisse zu Covid-19\nP\u00fcschel K, Kluge S, Addo M, Aepfelbacher M\nHamb \u00c4rztebl. 2020;73(06):34-36.\nSEAweb: the small RNA Expression Atlas web application\nRahman R, Liebhoff A, Bansal V, Fiosins M, Rajput A, Sattar A, Magruder D, Madan S, Sun T, Gautam A, Heins S, Liwinski T, Bethune J, Trenkwalder C, Fluck J, Mollenhauer B, Bonn S\nNUCLEIC ACIDS RES. 2020;48(D1):D204-D219.\nEvaluating case definitions for Ebola virus disease\nRamharter M, G\u00fcnther S\nJ CLEAN PROD. 2020;20(11):1224-1226.\nFocused Assessment with Sonography for Urinary Schistosomiasis (FASUS)-pilot evaluation of a simple point-of-care ultrasound protocol and short training program for detecting urinary tract morbidity in highly endemic settings\nRemppis J, Verheyden A, Bustinduy A, Heller T, Garc\u00eda-Tard\u00f3n N, Manouana G, Obiang R, Adegnika A, Grobusch M, Ramharter M, Joekes E, B\u00e9lard S\nT ROY SOC TROP MED H. 2020;114(1):38-48.\nComparison of acetylsalicylic acid and clopidogrel non-responsiveness assessed by light transmittance aggregometry and PFA-100\u00ae in patients undergoing neuroendovascular procedures\nRolling C, Tomada J, Fr\u00f6lich A, Holst B, Holstein K, Voigtl\u00e4nder M, Janjetovic S, Haddad M, Renn\u00e9 T, Fiehler J, Bokemeyer C, Rolling T, Langer F\nCLIN CHEM LAB MED. 2020;59(2):383-392.\nThe European Register of Cystic Echinococcosis, ERCE: State-of-the-art five years after its launch\nRossi P, Tamarozzi F, Galati F, Akhan O, Cretu C, Vutova K, Siles-Lucas M, Brunetti E, Casulli A\nPARASITE VECTOR. 2020;13(1):236.\nReiseimpfungen\nRothe C, Boecken G\nBUNDESGESUNDHEITSBLA. 2020;63(1):74-84.\nA Disheveled Man with Inflammatory Bowel Disease and Signs of Infection\nRuether D, Menz A, Manthey C\nGASTROENTEROLOGY. 2020;159(4):1247-1249.\nGut mycobiome of primary sclerosing cholangitis patients is characterised by an increase of Trichocladium griseum and Candida species\nR\u00fchlemann M, Solovjeva M, Zenouzi R, Liwinski T, Kummen M, Lieb W, Hov J, Schramm C, Franke A, Bang C\nGUT. 2020;69(10):1890-1892.\nMicrobiota-Dependent Effects of IL-22\nSabihi M, B\u00f6ttcher M, Pelczar P, Huber S\nCELLS-BASEL. 2020;9(10):2205.\nProphylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion: AWMF-Register-Nr.: 021/012\nSarrazin C, Zimmermann T, Berg T, Hinrichsen H, Mauss S, Wedemeyer H, Zeuzem S\nZ GASTROENTEROL. 2020;58(11):1110-1131.\nEpidemiologisches Update: Aktuelles zur epidemiologischen Situation der alveol\u00e4ren Echinokokkose und deren Erfassungs- und Meldestrukturen in \u00d6sterreich, der Schweiz und Deutschland: An Update on the Epidemiological Situation of Alveolar Echinococcosis: Recording and Reporting Structures in Austria, Switzerland and Germany\nSchmidberger J, Baumann S, Kratzer W, Schlingeloff P, Lachmann R, Stark K, Peters L, Gruener B, Ramharter M, Hoepffner P, Stroh\u00e4ker J, Blum A, M\u00fcllhaupt B, Lagler H\nGESUNDHEITSWESEN. 2020.\nTravel patterns, risk behaviour and health problems of travellers with rheumatic diseases compared to controls: A multi-centre, observational study\nSchmid N, Ciurea A, Gabay C, Hasler P, Fehr J, M\u00fcller R, Villiger P, Walker U, Hatz C, B\u00fchler S\nTRAVEL MED INFECT DI. 2020;38:101818.\nA System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis\nSchmidt T, Schmidt C, Strahl A, Mussawy H, Rolvien T, Jandl N, Casar C, Oheim R, Schinke T, Lohse A, Amling M, Schramm C, Barvencik F\nCLIN GASTROENTEROL H. 2020;18(1):226-233.e3.\nTetanus\nSchmiedel S, Jochum J\n2020. Referenz Intensivmedizin. Marx G, Zacharowski K, Kluge S (Hrsg.). 1. Aufl. Georg Thieme Verlag KG Stuttgart \u00b7 New York, 768-773.\nTollwut\nSchmiedel S, Jochum J\n2020. Referenz Intensivmedizin. Marx G, Zacharowski K, Kluge S (Hrsg.). 1. Aufl. Georg Thieme Verlag KG Stuttgart \u00b7 New York, 494-497.\nSevere COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment\nSchulte-Schrepping J, Reusch N, Paclik D, Germany L, Schlickeiser S, Zhang B, Kr\u00e4mer B, Krammer T, Brumhard S, Bonaguro L, De Domenico E, Wendisch D, Grasshoff M, Kapellos T, Beckstette M, Pecht T, Saglam A, Dietrich O, Mei H, Schulz A, Conrad C, Kunkel D, Vafadarnejad E, Xu C, Horne A, Herbert M, Drews A, Thibeault C, Pfeiffer M, Hippenstiel S, Hocke A, M\u00fcller-Redetzky H, Heim K, Machleidt F, Uhrig A, Bosquillon de Jarcy L, J\u00fcrgens L, Stegemann M, Gl\u00f6senkamp C, Volk H, Goffinet C, Landthaler M, Wyler E, Georg P, Schneider M, Dang-Heine C, Neuwinger N, Kappert K, Tauber R, Corman V, Raabe J, Kaiser K, Vinh M, Rieke G, Meisel C, Ulas T, Becker M, Geffers R, Witzenrath M, Drosten C, Suttorp N, von Kalle C, Kurth F, H\u00e4ndler K, Schultze J, Aschenbrenner A, Li Y, Nattermann J, Sawitzki B, Saliba A, Sander L\nCELL. 2020;182(6):1419-1440.e23.\nNext-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease\nSchulthei\u00df C, Paschold L, Simnica D, Mohme M, Willscher E, von Wenserski L, Scholz R, Wieters I, Dahlke C, Tolosa E, Sedding D, Ciesek S, Addo M, Binder M\nIMMUNITY. 2020;53(2):442-455.e4.\nPopulation-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment\nSebode M, Kloppenburg A, Aigner A, Lohse A, Schramm C, Linder R\nZ GASTROENTEROL. 2020;58(5):431-438.\nMetamizole Has Been Overlooked as a Trigger for Acute Liver Injury and Acute Liver Failure\nSebode M, Lohse A, Schramm C\nDTSCH ARZTEBL INT. 2020;117(37):610.\nMetamizole: An underrated agent causing severe idiosyncratic drug-induced liver injury\nSebode M, Reike-Kunze M, Weidemann S, Zenouzi R, Hartl J, Peiseler M, Liwinski T, Schulz L, Weiler-Normann C, Sterneck M, Lohse A, Schramm C\nBRIT J CLIN PHARMACO. 2020;86(7):1406-1415.\nTraveling into the Abyss: Risk Perception of German Travelers at the Onset of the COVID-19 Pandemic\nShamsrizi P, Jochum J, Kreuels B, Ramharter M\nAM J TROP MED HYG. 2020;103(4):1640-1641.\nGallengangs- und Gallenblasenkarzinome: auf dem Weg zur personalisierten Therapie\nSinn M, Wege H, Stein A\nDEUT MED WOCHENSCHR. 2020;145(7):442-446.\nPrevalence and Clinical Outcomes of Poor Immune Response Despite Virologically Suppressive Antiretroviral Therapy Among Children and Adolescents With Human Immunodeficiency Virus in Europe and Thailand: Cohort Study\nSmith C, Marques L, Klein N, Gullen S, Judd A, Thorne C, Goodall R, Koenigs C, Spoulou V, Prata F, Goetghebuer T, Chiappini E, Galli L, Naver L, Giaquinto C, Gibb D, Marczynska M, Okhonskaia L, Klimkait T, Lallernant M, Ngo-Giang-Huong N, Kiseleva G, Malyuta R, Volokha A\nCLIN INFECT DIS. 2020;70(3):404-415.\nIntegrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab\nSmith S, Conrad C, Ramharter M, Gottlieb A, Patel H, Xu W, Riedl E, Schuster C\nJ AM ACAD DERMATOL. 2020;83(1):261-263.\nMonitoring Therapy Efficiency in Cancer through Extracellular Vesicles\nStevic I, Buescher G, Ricklefs F\nCELLS-BASEL. 2020;9(1):.\nGenetic variation in HSD17B13 reduces the risk of developing cirrhosis and hepatocellular carcinoma in alcohol misusers\nStickel F, Lutz P, Buch S, Nischalke H, Silva I, Rausch V, Fischer J, Weiss K, Gotthardt D, Rosendahl J, Marot A, Elamly M, Krawczyk M, Casper M, Lammert F, Buckley T, McQuillin A, Spengler U, Eyer F, Vogel A, Marhenke S, von Felden J, Wege H, Sharma R, Atkinson S, Franke A, Nehring S, Moser V, Schafmayer C, Spahr L, Lackner C, Stauber R, Canbay A, Link A, Valenti L, Grove J, Aithal G, Marquardt J, Fateen W, Zopf S, Dufour J, Trebicka J, Datz C, Deltenre P, Mueller S, Berg T, Hampe J, Morgan M\nHEPATOLOGY. 2020;72(1):88-102.\nThe global prevalence of hepatitis D virus infection: Systematic review and meta-analysis\nStockdale A, Kreuels B, Henrion M, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti A\nJ HEPATOL. 2020;73(3):523-532.\nHepatitis D prevalence: problems with extrapolation to global population estimates\nStockdale A, Kreuels B, Henrion M, Giorgi E, Kyomuhangi I, Geretti A\nGUT. 2020;69(2):396-397.\nIntegration of microarray data and literature mining identifies a sex bias in DPP4+CD4+ T cells in HIV-1 infection\nStubbe H, Dahlke C, Rotheneder K, Stirner R, Roider J, Conca R, Seybold U, Bogner J, Addo M, Draenert R\nPLOS ONE. 2020;15(9):e0239399.\nA case for adoption of continuous albendazole treatment regimen for human echinococcal infections\nTamarozzi F, Horton J, Muhtarov M, Ramharter M, Siles-Lucas M, Gruener B, Vuitton D, Bresson-Hadni S, Manciulli T, Brunetti E\nPLOS NEGLECT TROP D. 2020;14(9):e0008566.\nPlacenta-Specific 8 Is Overexpressed and Regulates Cell Proliferation in Low-Grade Human Pancreatic Neuroendocrine Tumors\nTatura M, Schmidt H, Haijat M, Stark M, Rinke A, Diels R, Lawlor R, Scarpa A, Schrader J, Hackert T, Schimmack S, Gress T, Buchholz M\nNEUROENDOCRINOLOGY. 2020;110(1-2):23-34.\nHepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes\nTham C, Kah J, Tan A, Volz T, Chia A, Giersch K, Ladiges Y, Loglio A, Borghi M, Sureau C, Lampertico P, L\u00fctgehetmann M, Dandri-Petersen M, Bertoletti A\nCELL REP MED. 2020;1(4):100060.\nEctonucleoside triphosphate diphosphohydrolase 1 and 5'-nucleotidase ecto gene polymorphisms and acute cellular rejection after liver transplantation\nThude H, Onken L, Kappauf J, Dworak M, Sterneck M, Peine S, Nashan B, Koch M\nHLA. 2020;96(1):64-69.\nCD28 gene polymorphisms and acute cellular rejection after liver transplantation\nThude H, Tiede P, Sterneck M, Peine S, Nashan B, Koch M\nHUM IMMUNOL. 2020;81(12):675-678.\nDiet Diurnally Regulates Small Intestinal Microbiome-Epithelial-Immune Homeostasis and Enteritis\nTuganbaev T, Mor U, Bashiardes S, Liwinski T, Nobs S, Leshem A, Dori-Bachash M, Thaiss C, Pinker E, Ratiner K, Adlung L, Federici S, Kleimeyer C, Moresi C, Yamada T, Cohen Y, Zhang X, Massalha H, Massasa E, Kuperman Y, Koni P, Harmelin A, Gao N, Itzkovitz S, Honda K, Shapiro H, Elinav E\nCELL. 2020;182(6):1441-1459.e21.\nA novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance\nTu T, Zehnder B, Qu B, Ni Y, Main N, Allweiss L, Dandri M, Shackel N, George J, Urban S\nANTIVIR RES. 2020;181:104865.\nBurden of disease in Gabon caused by loiasis: a cross-sectional survey\nVeletzky L, Hergeth J, Stelzl D, Mischlinger J, Manego R, Mombo-Ngoma G, McCall M, Adegnika A, Agnandji S, Metzger W, Matsiegui P, Lagler H, Mordm\u00fcller B, Budke C, Ramharter M\nLANCET INFECT DIS. 2020;20(11):1339-1346.\nSofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)\nVermehren J, Serfert Y, Cornberg M, Stoehr A, Klinker H, Simon K, Teuber G, Deterding K, Schulze Zur Wiesch J, Jung M, Manns M, Zeuzem S, Wedemeyer H, Sarrazin C\nZ GASTROENTEROL. 2020;58(9):841-846.\nCOVID-19: Wo stehen wir heute?\nvon Bergwelt Baildon M, Addo M\nDEUT MED WOCHENSCHR. 2020;145(15):1019.\nNew systemic agents for hepatocellular carcinoma: an update 2020\nvon Felden J\nCURR OPIN GASTROEN. 2020;36(3):177-183.\nLiquid biopsy in the clinical management of hepatocellular carcinoma\nvon Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A\nGUT. 2020;69(11):2025-2034.\nRole of Molecular Biomarkers in Liver Transplantation for Hepatocellular Carcinoma\nvon Felden J, Villanueva A\nLIVER TRANSPLANT. 2020;26(6):823-831.\nElevated Aspartate Aminotransferase to Alanine Aminotransferase Ratio Predicts Poor Outcome in Hepatocellular Carcinoma\nvon Felden J, Wege H, Schulze K\nHEPATOL COMMUN. 2020;4(9):1382-1383.\nIntensivmedizinisches Back-up bei infektiologischen Katastrophen\nWichmann D, Matthews H, Nentwich M, Schmiedel S, Kluge S\nMED KLIN-INTENSIVMED. 2020;115(8):641-648.\nAutopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study\nWichmann D, Sperhake J, L\u00fctgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schr\u00f6der A, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen H, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo M, Aepfelbacher M, P\u00fcschel K, Kluge S\nANN INTERN MED. 2020;173(4):268-277.\nMolecular Characterization of Staphylococcus aureus Isolated from Chronic Infected Wounds in Rural Ghana\nWolters M, Frickmann H, Christner M, Both A, Rohde H, Oppong K, Akenten C, May J, Dekker D\nMICROORGANISMS. 2020;8(12):.\nFrequent neurocognitive deficits after recovery from mild COVID-19\nWoo M, Malsy J, P\u00f6ttgen J, Seddiq Zai S, Ufer F, Hadjilaou A, Schmiedel S, Addo M, Gerloff C, Heesen C, Schulze zur Wiesch J, Friese M\nBRAIN COMMUN. 2020;2(2):fcaa205.\nInterleukin-9 protects from early podocyte injury and progressive glomerulosclerosis in Adriamycin-induced nephropathy\nXiong T, Attar M, Gnirck A, Wunderlich M, Becker M, Rickassel C, Puelles V, Meyer-Schwesinger C, Wiech T, Nies J, Divivier M, Fuchs T, Schulze Zur Wiesch J, Taipaleenm\u00e4ki H, Hoxha E, Wirtz S, Huber T, Panzer U, Turner J\nKIDNEY INT. 2020;98(3):615-629.\nThe induction and function of the anti-inflammatory fate of TH17 cells\nXu H, Agalioti T, Zhao J, Steglich B, Wahib R, Vesely M, Bielecki P, Bailis W, Jackson R, Perez D, Izbicki J, Licona-Lim\u00f3n P, Kaartinen V, Geginat J, Esplugues E, Tolosa E, Huber S, Flavell R, Gagliani N\nNAT COMMUN. 2020;11(1):3334.\nPermanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar\nZachou K, Weiler-Normann C, Muratori L, Muratori P, Lohse A, Dalekos G\nLIVER INT. 2020;40(2):368-376.\nA prenatally disrupted airway epithelium orchestrates the fetal origin of asthma in mice\nZazara-Giannou D, Wegmann M, Giannou A, Hierweger A, Alawi M, Thiele K, Huber S, Pincus M, Muntau A, Solano M, Arck P\nJ ALLERGY CLIN IMMUN. 2020;145(6):1641-1654.\nDas Europ\u00e4ische Referenznetzwerk f\u00fcr seltene Lebererkrankungen (ERN RARE-LIVER): Betroffene Patienten besser versorgen, Konsilangebot f\u00fcr \u00e4rztliche Kollegen\nZecher B, Sebode M, Lohse A\nZ GASTROENTEROL. 2020;58(10):1006.\nHigh-resolution mycobiota analysis reveals dynamic intestinal translocation preceding invasive candidiasis\nZhai B, Ola M, Rolling T, Tosini N, Joshowitz S, Littmann E, Amoretti L, Fontana E, Wright R, Miranda E, Veelken C, Morjaria S, Peled J, van den Brink M, Babady N, Butler G, Taur Y, Hohl T\nNAT MED. 2020;26(1):59-64.\nHepatitis B Virus Particles Activate Toll-Like Receptor 2 Signaling Initially Upon Infection of Primary Human Hepatocytes\nZhang Z, Trippler M, Real C, Werner M, Luo X, Schefczyk S, Kemper T, Anastasiou O, Ladiges Y, Treckmann J, Paul A, Baba H, Allweiss L, Dandri M, Gerken G, Wedemeyer H, Schlaak J, Lu M, Broering R\nHEPATOLOGY. 2020;72(3):829-844.\nA global scientific strategy to cure hepatitis B\nLANCET GASTROENTEROL. 2019;4(7):545-558.\nCompeting risk events in antimalarial drug trials in uncomplicated Plasmodium falciparum malaria: a WorldWide Antimalarial Resistance Network individual participant data meta-analysis\nMALARIA J. 2019;18(1):225.\nSex differences in clinical presentation and prognosis in patients with primary biliary cholangitis\nAbdulkarim M, Zenouzi R, Sebode M, Schulz L, Quaas A, Lohse A, Schramm C, Weiler-Normann C\nSCAND J GASTROENTERO. 2019;54(11):1391-1396.\nPoisoning with paracetamol: Cases from Hamburg and the GIZ Nord Poison Center with Special respect to Legislation Change in 2009 concerning packsizes\nAboutara N, Jungen H, Schaper A, Sterneck M, P\u00fcschel K, Iwersen-Bergmann S\nRECHTSMEDIZIN. 2019;29(4):274-280.\nHCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules\nAckermann C, Smits M, Woost R, Eberhard J, Peine S, Kummer S, Marget M, Kuntzen T, Kwok W, Lohse A, Jacobs T, Boettler T, Schulze Zur Wiesch J\nSCI REP-UK. 2019;9(1):10624.\nMonitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambar\u00e9n\u00e9, Gabon: an open-label clinical trial\nAdegbite B, Edoa J, Honkpehedji Y, Zinsou F, Dejon-Agobe J, Mbong-Ngwese M, Lotola-Mougueni F, Koehne E, Lalremruata A, Kreidenweiss A, Nguyen T, Kun J, Agnandji S, Lell B, Safiou A, Obone Atome F, Mombo-Ngoma G, Ramharter M, Velavan T, Mordm\u00fcller B, Kremsner P, Adegnika A\nMALARIA J. 2019;18(1):.\nCaseload and Case Fatality of Lassa Fever in Nigeria, 2001-2018:A Specialist Center's Experience and Its Implications\nAkpede G, Asogun D, Okogbenin S, Dawodu S, Momoh M, Dongo A, Ike C, Tobin E, Akpede N, Ogbaini-Emovon E, Adewale A, Ochei O, Onyeke F, Okonofua M, Atafo R, Odia I, Adomeh D, Odigie G, Ogbeifun C, Muebonam E, Ihekweazu C, Ramharter M, Colubri A, Sarbeti P, Happi C, G\u00fcnther S, Agbonlahor D\nFRONT PUBLIC HEALTH. 2019;7:170.\nCorrigendum: Caseload and Case Fatality of Lassa Fever in Nigeria, 2001-2018: A Specialist Center's Experience and Its Implications\nAkpede G, Asogun D, Okogbenin S, Dawodu S, Momoh M, Dongo A, Ike C, Tobin E, Akpede N, Ogbaini-Emovon E, Adewale A, Ochei O, Onyeke F, Okonofua M, Atafo R, Odia I, Adomeh D, Odigie G, Ogbeifun C, Muoebonam E, Ihekweazu C, Ramharter M, Colubri A, Sabeti P, Happi C, G\u00fcnther S, Agbonlahor D\nFRONT PUBLIC HEALTH. 2019;7:251.\nEffector TH17 Cells Give Rise to Long-Lived TRM Cells that Are Essential for an Immediate Response against Bacterial Infection\nAmezcua Vesely M, Pallis P, Bielecki P, Low J, Zhao J, Harman C, Kroehling L, Jackson R, Bailis W, Licona-Lim\u00f3n P, Xu H, Iijima N, Pillai P, Kaplan D, Weaver C, Kluger Y, Kowalczyk M, Iwasaki A, Pereira J, Esplugues E, Gagliani N, Flavell R\nCELL. 2019;178(5):1176-1188.e15.\nEvaluation of direct costs associated with alveolar and cystic echinococcosis in Austria\nAustria D, Budke C, Auer H, Kaczirek K, Waneck F, Austria D, Ramharter M\nPLOS NEGLECT TROP D. 2019;13(1):.\nIL-10-producing T cells and their dual functions\nBedke T, Muscate F, Soukou S, Gagliani N, Huber S\nSEMIN IMMUNOL. 2019;44:101335.\nChronic Hepatitis E is associated with cholangitis\nBeer A, Holzmann H, Pischke S, Behrendt P, Wrba F, Schlue J, Drebber U, Neudert B, Halilbasic E, Kreipe H, Lohse A, Sterneck M, Wedemeyer H, Manns M, Dienes H\nLIVER INT. 2019;39(10):1876-1883.\nPosition statement on access to care in rare liver diseases: advancements of the European reference network (ERN) RARE-LIVER\nBernts L, Jones D, Kaatee M, Lohse A, Schramm C, Sturm E, Drenth J\nORPHANET J RARE DIS. 2019;14(1):169.\nComparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes\nBockmann J, Stadler D, Xia Y, Ko C, Wettengel J, Schulze Zur Wiesch J, Dandri M, Protzer U\nJ INFECT DIS. 2019;220(4):567-577.\nTNF-Producing Th1 Cells Are Selectively Expanded in Liver Infiltrates of Patients with Autoimmune Hepatitis\nBovensiepen C, Schakat M, Sebode M, Zenouzi R, Hartl J, Peiseler M, Li J, Henze L, Woestemeier A, Schramm C, Lohse A, Herkel J, Weiler-Normann C\nJ IMMUNOL. 2019;203(12):3148-3156.\nSafety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-na\u00efve and -experienced patients\nBrehm T, Franz M, H\u00fcfner A, Hertling S, Schmiedel S, Degen O, Kreuels B, Schulze Zur Wiesch J\nMEDICINE. 2019;98(32):e16721.\nSafety and immunogenicity of tetanus/diphtheria vaccination in patients with rheumatic diseases-a prospective multi-centre cohort study\nB\u00fchler S, Jaeger V, Adler S, Bannert B, Br\u00fcmmerhoff C, Ciurea A, Distler O, Franz J, Gabay C, Hagenbuch N, Herzog C, Hasler P, Kling K, Kyburz D, M\u00fcller R, Nissen M, Siegrist C, Villiger P, Walker U, Hatz C\nRHEUMATOLOGY. 2019;58(9):1585-1596.\nFlucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures\nB\u00fchler S, Ramharter M\nESMO OPEN. 2019;4(1):e000481.\nConserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification\nCzarnewski P, Parigi S, Sorini C, Diaz O, Das S, Gagliani N, Villablanca E\nNAT COMMUN. 2019;10(1):2892.\nLower prevalence of Blastocystis sp. infections in HIV positive compared to HIV negative adults in Ghana\nDi Cristanziano V, D'Alfonso R, Berrilli F, Sarfo F, Santoro M, Fabeni L, Knops E, Heger E, Kaiser R, Dompreh A, Phillips R, Norman B, Feldt T, Eberhardt K\nPLOS ONE. 2019;14(9):e0221968.\nLactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis\nDrolz A, Horvatits T, Rutter K, Landahl F, Roedl K, Meersseman P, Wilmer A, Kluwe J, Lohse A, Kluge S, Trauner M, Fuhrmann V\nHEPATOLOGY. 2019;69(1):258-269.\nReview article: unanswered clinical and research questions in autoimmune hepatitis-conclusions of the International Autoimmune Hepatitis Group Research Workshop.\nDyson J, De Martin E, Dalekos G, Drenth J, Herkel J, Hubscher S, Kelly D, Lenzi M, Milkiewicz P, Oo Y, Heneghan M, Lohse A\nALIMENT PHARM THER. 2019;49(5):528-536.\nRibavirin for the treatment of Lassa fever: A systematic review and meta-analysis\nEberhardt K, Mischlinger J, Jordan S, Groger M, G\u00fcnther S, Ramharter M\nINT J INFECT DIS. 2019;87:15-20.\nPolyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV\nEhrhardt S, Zehner M, Kr\u00e4hling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu M, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo M, Diskin R, Becker S, Klein F\nNAT MED. 2019;25(10):1589-1600.\nLiver fibrosis affects the targeting properties of drug delivery systems to macrophage subsets in vivo\nErgen C, Niemietz P, Heymann F, Baues M, Gremse F, Pola R, van Bloois L, Storm G, Kiessling F, Trautwein C, Luedde T, Lammers T, Tacke F\nBIOMATERIALS. 2019;2018(206):49-60.\nMetastasis of pancreatic cancer: An uninflamed liver micromilieu controls cell growth and cancer stem cell properties by oxidative phosphorylation in pancreatic ductal epithelial cells\nFabian A, Stegner S, Miarka L, Zimmermann J, Lenk L, Rahn S, Buttlar J, Viol F, Knaack H, Esser D, Sch\u00e4uble S, Gro\u00dfmann P, Marinos G, H\u00e4sler R, Mikulits W, Saur D, Kaleta C, Sch\u00e4fer H, Sebens S\nCANCER LETT. 2019;453:95-106.\nRecombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens\nFathi A, Dahlke C, Addo M\nHUM VACC IMMUNOTHER. 2019;15(10):2269-2285.\nVAR2CSA Serology to Detect Plasmodium falciparum Transmission Patterns in Pregnancy\nFonseca A, Gonz\u00e1lez R, Bardaj\u00ed A, Jairoce C, Rup\u00e9rez M, Jim\u00e9nez A, Quint\u00f3 L, Cister\u00f3 P, Vala A, Sacoor C, Gupta H, Hegewisch-Taylor J, Brew J, Ndam N, Kariuki S, L\u00f3pez M, Doba\u00f1o C, Chitnis C, Ouma P, Ramharter M, Abdulla S, Aponte J, Massougbodji A, Briand V, Mombo-Ngoma G, Desai M, Cot M, Nhacolo A, Sevene E, Macete E, Men\u00e9ndez C, Mayor A\nEMERG INFECT DIS. 2019;25(10):1851-1860.\nBrain magnetic resonance imaging in imported malaria\nFr\u00f6lich A, Tober-Lau P, Sch\u00f6nfeld M, Brehm T, Kurth F, Vinnemeier C, Addo M, Fiehler J, Rolling T\nMALARIA J. 2019;18(1):74.\nHepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo\nGiersch K, Bhadra O, Volz T, Allweiss L, Riecken K, Fehse B, Lohse A, Petersen J, Sureau C, Urban S, Dandri M, L\u00fctgehetmann M\nGUT. 2019;68(1):150-157.\nLiver infiltrating T cells regulate bile acid metabolism in experimental cholangitis\nGlaser F, John C, Engel B, H\u00f6h B, Weidemann S, Dieckhoff J, Stein S, Becker N, Casar C, Amrei Schuran F, Wieschendorf B, Preti M, Jessen F, Franke A, Carambia A, Lohse A, Ittrich H, Herkel J, Heeren J, Schramm C, Schwinge D\nJ HEPATOL. 2019;71(4):783-792.\nEndogenous IL-22 is dispensable for experimental glomerulonephritis\nGnirck A, Wunderlich M, Becker M, Xiong T, Weinert E, Meyer-Schwesinger C, Dumoutier L, Renauld J, Huber S, Panzer U, Turner J\nAM J PHYSIOL-RENAL. 2019;316(4):F712-F722.\nProspective Clinical and Molecular Evaluation of Potential Plasmodium ovale curtisi and wallikeri Relapses in a High-transmission Setting\nGroger M, Veletzky L, Lalremruata A, Cattaneo C, Mischlinger J, Manego Zoleko R, Kim J, Klicpera A, Meyer E, Blessborn D, Winterberg M, Adegnika A, Agnandji S, Kremsner P, Mordm\u00fcller B, Mombo-Ngoma G, Fuehrer H, Ramharter M\nCLIN INFECT DIS. 2019;69(12):2119-2126.\nHelminth Infections Suppress the Efficacy of Vaccination against Seasonal Influenza\nHartmann W, Brunn M, Stetter N, Gagliani N, Muscate F, Stanelle-Bertram S, Gabriel G, Breloer M\nCELL REP. 2019;29(8):2243-2256.e4.\nComprehensive Review of Human Plasmodium falciparum-Specific CD8+ T Cell Epitopes\nHeide J, Vaughan K, Sette A, Jacobs T, Schulze Zur Wiesch J\nFRONT IMMUNOL. 2019;10:397.\nUnklare Panzytopenie bei einem 52-j\u00e4hrigen Patienten\nHeidenreich S, van Randenbourgh A, Ayuk F, Kr\u00f6ger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C\nINTERNIST. 2019;60(8):867-870.\nRezidivierendes Erbrechen und Kopfschmerzen bei einem 26-j\u00e4hrigen Patienten\nHeinemann M, Galaski J, Mager A, Ittrich H, Addo M, Jordan S\nINTERNIST. 2019;60(7):756-760.\nEndoscopic retrograde cholangiography and percutaneous transhepatic cholangiodrainage in biliary strictures after liver transplantation: Long-term outcome predictors and influence on patient survival\nHeinemann M, Tafrishi B, Pischke S, Fischer L, R\u00f6sch T, Lohse A, Sterneck M, Denzer U\nLIVER INT. 2019;39(6):1155-1164.\nEinsatz von Protonenpumpenhemmern bei Patienten mit Leberzirrhose \u2013 eine Umfrage unter Hepatologen in Deutschland\nHorvatits T, Drolz A, Wehmeyer M, Steib C, Trebicka J, Lohse A, Kluwe J\nZ GASTROENTEROL. 2019;57(6):729-733.\nHEV in pregnancy: Understanding the crucial role of steroid hormones\nHorvatits T, Pischke S\nLIVER INT. 2019;39(4):621-622.\nThe Clinical Perspective on Hepatitis E\nHorvatits T, Schulze Zur Wiesch J, L\u00fctgehetmann M, Lohse A, Pischke S\nVIRUSES-BASEL. 2019;11(7):.\nEpithelial HMGB1 Delays Skin Wound Healing and Drives Tumor Initiation by Priming Neutrophils for NET Formation\nHoste E, Mauer\u00f6der C, van Hove L, Catrysse L, Vikkula H, Sze M, Maes B, Karjosukarso D, Martens L, Gon\u00e7alves A, Parthoens E, Roelandt R, Declercq W, Fuentes I, Palisson F, Gonzalez S, Salas-Alanis J, Boon L, Huebener P, Mulder K, Ravichandran K, Saeys Y, Schwabe R, van Loo G\nCELL REP. 2019;29(9):2689-2701.e4.\nZ\u00f6liakie und Weizensensitivit\u00e4t im Wandel - ein Update\nH\u00fcbener S, Manthey C\nGastroenterologie up2date. 2019;15(04):375-393.\nCounter-selection of antimalarial resistance polymorphisms by intermittent preventive treatment in pregnancy\nHuijben S, Macete E, Mombo-Ngoma G, Ramharter M, Kariuki S, Desai M, Shi Y, Mwangoka G, Massougbodji A, Cot M, Ndam N, Uberegui E, Gupta H, Cister\u00f3 P, Aponte J, Gonz\u00e1lez R, Men\u00e9ndez C, Mayor A\nJ NUTR. 2019;221(2):293-303.\nCardiac ultrasound in resource-limited settings (CURLS): towards a wider use of basic echo applications in Africa\nHuson M, Kaminstein D, Kahn D, Belard S, Ganesh P, Kandoole-Kabwere V, Wallrauch C, Phiri S, Kreuels B, Heller T\nULTRASOUND J. 2019;11(1):.\nTypisches Katayama-Syndrom kann auch ohne Ei-Ablage induziert werden: Katayama-Syndrom bei experimenteller Schistosomeninfektion ohne Ei-Ablage\nJochum J\nFLUGMEDIZIN TROPENME. 2019;2019(4):149.\nPeritoneal GATA6+ macrophages function as a portal for Staphylococcus aureus dissemination\nJorch S, Surewaard B, Hossain M, Peiseler M, Deppermann C, Deng J, Bogoslowski A, van der Wal F, Omri A, Hickey M, Kubes P\nJ CLIN INVEST. 2019;129(11):4643-4656.\nRate of Spleen Length Progression is a Marker of Outcome in Patients with Primary Sclerosing Cholangitis\nJung F, Cazzagon N, Vettorazzi E, Corpechot C, Chazouilleres O, Arriv\u00e9 L, Lohse A, Schramm C, Ehlken H\nCLIN GASTROENTEROL H. 2019;17(12):2613-2615.\nAcute and Persistent Hepatitis E Virus Genotype 3 and 4 Infection: Clinical Features, Pathogenesis, and Treatment\nKamar N, Pischke S\nCSH PERSPECT MED. 2019;9(7):.\nCytotoxic T Cell-Derived Granzyme B Is Increased in Severe Plasmodium Falciparum Malaria\nKaminski L, Riehn M, Abel A, Steeg C, Yar D, Addai-Mensah O, Aminkiah F, Owusu Dabo E, Jacobs T, Mackroth M\nFRONT IMMUNOL. 2019;10:2917.\nMutations in Hepatitis D Virus Allow It to Escape Detection by CD8+ T Cells and Evolve at the Population Level\nKarimzadeh H, Kiraithe M, Oberhardt V, Salimi Alizei E, Bockmann J, Schulze Zur Wiesch J, Budeus B, Hoffmann D, Wedemeyer H, Cornberg M, Krawczyk A, Rashidi-Alavijeh J, Rodr\u00edguez-Fr\u00edas F, Casillas R, Buti M, Smedile A, Alavian S, Heinold A, Emmerich F, Panning M, Gostick E, Price D, Timm J, Hofmann M, Raziorrouh B, Thimme R, Protzer U, Roggendorf M, Neumann-Haefelin C\nGASTROENTEROLOGY. 2019;156(6):1820-1833.\nProspective comparison of diffusion-weighted MRI and dynamic Gd-EOB-DTPA-enhanced MRI for detection and staging of hepatic fibrosis in primary sclerosing cholangitis\nKeller S, Sedlacik J, Schuler T, Buchert R, Avanesov M, Zenouzi R, Lohse A, Kooijman H, Fiehler J, Schramm C, Yamamura J\nEUR RADIOL. 2019;29(2):818-828.\nThe Challenge of Post-Mortem GHB Analysis: Storage Conditions and Specimen Types Are Both Important\nKietzerow J, Otto B, Wilke N, Rohde H, Iwersen-Bergmann S, Andresen-Streichert H\nINT J LEGAL MED. 2019;2019:205-215.\nClinical and Immunological Phenotype of Patients With Primary Immunodeficiency Due to Damaging Mutations in NFKB2\nKlemann C, Camacho-Ordonez N, Yang L, Eskandarian Z, Rojas-Restrepo J, Frede N, Bulashevska A, Heeg M, Al-Ddafari M, Premm J, Seidl M, Ammann S, Sherkat R, Radhakrishnan N, Warnatz K, Unger S, Kobbe R, H\u00fcfner A, Leahy T, Ip W, Burns S, Fliegauf M, Grimbacher B\nFRONT IMMUNOL. 2019;10:297.\nHistone deacetylase inhibitors with high in vitro activities against Plasmodium falciparum isolates collected from Gabonese children and adults\nKoehne E, Kreidenweiss A, Zoleko Manego R, McCall M, Mombo-Ngoma G, Mackwitz M, Hansen F, Held J\nSCI REP-UK. 2019;9(1):.\nTransjugular Intrahepatic Portosystemic Shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis\nKraef C, Arand J, Galaski J, Jordan S, Kluwe J, Lohse A, Addo M, Ramharter M, Schmiedel S\nTRAVEL MED INFECT DI. 2019;30:130-132.\nKardiale Beteiligung bei Tropenerkrankungen: Cardiac manifestations of tropical diseases\nKraef C, Ramharter M\nHERZ. 2019;44(1):83-91.\nManagement der saisonalen Influenza 2017/2018: Erfahrungen an einem deutschen Universit\u00e4tsklinikum\nKraef C, van der Meirschen M, Wichmann D, Kutza M, Restemeyer C, Addo M, Lohse A, Schmiedel S, Kluge S, Schulze Zur Wiesch J\nBUNDESGESUNDHEITSBLA. 2019;62(7):870-880.\nDetection of a Broad Range of Low-Level Major Histocompatibility Complex Class II-Restricted, Hepatitis Delta Virus (HDV)-Specific T-Cell Responses Regardless of Clinical Status\nLandahl J, Bockmann J, Scheurich C, Ackermann C, Matzat V, Heide J, Nuurei T, D'Antonio G, von Felden J, Sette A, Peine S, Lohse A, L\u00fctgehetmann M, Marget M, Sidney J, Schulze Zur Wiesch J\nJ INFECT DIS. 2019;219(4):568-577.\nCCL21-expression and accumulation of CCR7 NK cells in livers of patients with primary sclerosing cholangitis\nLangeneckert A, Lunemann S, Martrus G, Salzberger W, Hess L, Ziegler A, Poch T, Ravichandran G, Matschl U, Bosse J, Tiegs G, Fischer L, Koch M, Herkel J, Oldhafer K, Schramm C, Altfeld M\nEUR J IMMUNOL. 2019;49(5):758-769.\nEditorial: post-operative elevation of liver enzymes and modern volatile anaesthetics-guilty as charged?\nLaschtowitz A, Sebode M\nALIMENT PHARM THER. 2019;49(9):1245-1246.\nDiagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study\nLemoine M, Assoumou L, De Wit S, Girard P, Valantin M, Katlama C, Necsoi C, Campa P, Huefner A, Schulze Zur Wiesch J, Rougier H, Bastard J, Stocker H, Mauss S, Serfaty L, Ratziu V, Menu Y, Schlue J, Behrens G, Bedossa P, Capeau J, Ingiliz P, Costagliola D\nJAIDS-J ACQ IMM DEF. 2019;80(4):e86-e94.\nInfektionsausbr\u00fcche: Grenzen und Defizite im Risikomanagement: Kommentar zu: Ammon, A: Rapid Risk Assessments f\u00fcr akute Infektionsereignisse: Methoden und praktische Anwendung\nLohse A\n2019. Rationale Entscheidungen unter Unsicherheit. Fleischer B, Lauterbach R, Pawlik K (Hrsg.). 1. Aufl. Berlin: Walter de Gruyter GmbH, Berlin/Boston, 54-58.\nFDG-PET/MRI imaging for the management of alveolar echinococcosis: initial clinical experience at a reference centre in Austria\nL\u00f6tsch F, Waneck F, Groger M, Auer H, Kaczirek K, Rausch I, Wadsak W, Hacker M, Lagler H, Ramharter M, Karanikas G\nTROP MED INT HEALTH. 2019;24(6):663-670.\nHuman liver-derived CXCR6+ NK cells are predominantly educated through NKG2A and show reduced cytokine production\nLunemann S, Langeneckert A, Martrus G, Hess L, Salzberger W, Ziegler A, L\u00f6bl S, Poch T, Ravichandran G, Sauter J, Schmidt A, Schramm C, Oldhafer K, Altfeld M, K\u00f6rner C\nJ LEUKOCYTE BIOL. 2019;105(6):1331-1340.\nUnbestechlicher Streiter f\u00fcr die akademische Medizin: die nationale und internationale Gastroenterologie und Hepatologie trauert um Karl-Hermann Meyer zum B\u00fcschenfelde\nManns M, Lohse A\nZ GASTROENTEROL. 2019;2019(11):1418-1419.\nInitial therapy affects duration of diarrhoea in critically ill patients with Clostridioides difficile infection (CDI)\nManthey C, Dranova D, Christner M, Drolz A, Kluge S, Lohse A, Fuhrmann V\nCRIT CARE. 2019;23(1):399.\nCD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans\nMartrus G, Goebels H, Langeneckert A, Kah J, Flomm F, Ziegler A, Niehrs A, L\u00f6bl S, Russu K, Hess L, Salzberger W, Poch T, Nashan B, Schramm C, Oldhafer K, Dandri M, Koch M, Lunemann S, Altfeld M\nFRONT IMMUNOL. 2019;10:1247.\nDoxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): A phase 3 randomised controlled trial\nMerle P, Blanc J, Phelip J, Pelletier G, Bronowicki J, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad A, Colombo M, Abergel A, Richou C, Waked I, Yee N, Mol\u00e9 A, Attali P, Le Boulicaut J, Vasseur B\nLANCET GASTROENTEROL. 2019;4(6):454-465.\nVaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)\nMoehler M, Heo J, Lee H, Tak W, Chao Y, Paik S, Yim H, Byun K, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc J, Rosmorduc O, Lencioni R, Patt R, Leen A, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher J, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn D, Breitbach C, Burke J\nONCOIMMUNOLOGY. 2019;8(8):1615817.\nReducing Hematologic Toxicity With Short Course Postexposure Prophylaxis With Zidovudine for HIV-1 Exposed Infants With Low Transmission Risk\nNguyen T, Kobbe R, Schulze-Sturm U, Blohm M, Hollwitz B, Hertling S, Becker C, Oommen P, Laws H, Martignoni F, Ole Jensen B, Olah K, Schmidtke S, Kreuels B, Vasconcelos M, Neubert J\nPEDIATR INFECT DIS J. 2019;38(7):727-730.\nDNA recovery from archived RDTs for genetic characterization of Plasmodium falciparum in a routine setting in Lambar\u00e9n\u00e9, Gabon\nNguyen T, Nzigou Mombo B, Lalremruata A, Koehne E, Zoleko Manego R, Dimessa Mbadinga L, Adegnika A, Agnandji S, Lell B, Kremsner P, Velavan T, Ramharter M, Mordm\u00fcller B, Mombo-Ngoma G\nMALARIA J. 2019;18(1):.\nA subset of HLA-DP molecules serve as ligands for the natural cytotoxicity receptor NKp44\nNiehrs A, Garcia-Beltran W, Norman P, Watson G, H\u00f6lzemer A, Chapel A, Richert L, Pommerening-R\u00f6ser A, K\u00f6rner C, Ozawa M, Martrus G, Rossjohn J, Lee J, Berry R, Carrington M, Altfeld M\nNAT IMMUNOL. 2019;20(9):1129-1137.\nImport of community-associated, methicillin-resistant Staphylococcus aureus to Europe through skin and soft-tissue infection in intercontinental travellers, 2011-2016\nNurjadi D, Fleck R, Lindner A, Sch\u00e4fer J, Gertler M, Mueller A, Lagler H, Van Genderen P, Caumes E, Boutin S, Kuenzli E, Gascon J, Kantele A, Grobusch M, Heeg K, Zanger P\nCLIN MICROBIOL INFEC. 2019;25(6):739-746.\nGlobal Epidemiology of Buruli Ulcer, 2010-2017, and Analysis of 2014 WHO Programmatic Targets\nOmansen T, Erbowor-Becksen , Yotsu R, van der Werf T, Tiendrebeogo A, Grout L, Asiedu K\nEMERG INFECT DIS. 2019;25(12):2183-2190.\nFehlen des linken Leberlappens\nPaech D, Loi L, Piecha F, Bonekamp D, Delorme S, Schlemmer H, Mueller S\nRADIOLOGE. 2019;59(6):550-554.\nPredniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis\nPape S, Gevers T, Belias M, Mustafajev I, Vrolijk J, van Hoek B, Bouma G, van Nieuwkerk C, Hartl J, Schramm C, Lohse A, Taubert R, Jaeckel E, Manns M, Papp M, Stickel F, Heneghan M, Drenth J\nCLIN GASTROENTEROL H. 2019;17(10):2068-2075.e2.\nClinical management of autoimmune hepatitis\nPape S, Schramm C, Gevers T\nUNITED EUR GASTROENT. 2019;7(9):1156-1163.\nTransjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct-Acting Antiviral Treatment Failure in Patients With Hepatitis C?\nPiecha F, G\u00e4n\u00dfler J, Jordan S, Ergen C, Ittrich H, Kluwe J, Pischke S, Lohse A, Schulze Zur Wiesch J\nHEPATOL COMMUN. 2019;3(5):614-619.\nAscites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival\nPiecha F, Radunski U, Ozga A, Steins D, Drolz A, Horvatits T, Spink C, Ittrich H, Benten D, Lohse A, Sinning C, Kluwe J\nJHEP REP. 2019;1(2):90-98.\nBeurteilung der Leberfibrose\nPiecha F, Wiegard C\nGastroenterologie up2date. 2019;2019(15(04): 355-371):.\nChronic Hepatitis E in Rheumatology and Internal Medicine Patients: A Retrospective Multicenter European Cohort Study\nPischke S, Peron J, von Wulffen M, von Felden J, H\u00f6ner Zu Siederdissen C, Fournier S, L\u00fctgehetmann M, Iking-Konert C, Bettinger D, Par G, Thimme R, Cantagrel A, Lohse A, Wedemeyer H, de Man R, Mallet V\nVIRUSES-BASEL. 2019;11(2):.\nDetectable Vesicular Stomatitis Virus (VSV)-Specific Humoral and Cellular Immune Responses Following VSV-Ebola Virus Vaccination in Humans\nPoetsch J, Dahlke C, Zinser M, Kasonta R, Lunemann S, Rechtien A, Ly M, Stubbe H, Kr\u00e4hling V, Biedenkopf N, Eickmann M, Fehling S, Olearo F, Strecker T, Sharma P, Lang K, Lohse A, Schmiedel S, Becker S, Addo M\nJ INFECT DIS. 2019;219(4):556-561.\nPopulation Pharmacokinetics of Mefloquine Intermittent Preventive Treatment for Malaria in Pregnancy in Gabon\nRamharter M, Schwab M, Mombo-Ngoma G, Zoleko Manego R, Akerey-Diop D, Basra A, Mackanga J, W\u00fcrbel H, Wojtyniak J, Gonzalez R, Hofmann U, Geditz M, Matsiegui P, Kremsner P, Menendez C, Kerb R, Lehr T\nANTIMICROB AGENTS CH. 2019;63(2):e01113-18.\nPerspektiven f\u00fcr junge \u00c4rztinnen und \u00c4rzte in der Infektiologie\nRaspe M, Rolling T, Leisse C, Fischer J, Lehmann C\nDEUT MED WOCHENSCHR. 2019;144(11):764-769.\nInterferon-\u03b3-dependent immune responses contribute to the pathogenesis of sclerosing cholangitis in mice\nRavichandran G, Neumann K, Berkhout L, Weidemann S, Langeneckert A, Schwinge D, Poch T, Huber S, Schiller B, Hess L, Ziegler A, Oldhafer K, Barikbin R, Schramm C, Altfeld M, Tiegs G\nJ HEPATOL. 2019;71(4):773-782.\nPancreatitis due to pancreatic metastases of small bowel and lung neuroendocrine tumors\nReher D, Henes F, Clauditz T, Klutmann S, Izbicki J, Lohse A, Perez D, Schrader J\n2019. ENETS Conference Programm. 73.\nResponse of the primary tumor in patients with pNETs treated with streptozotocin / 5-FU \u2013 a preliminary retrospective study\nReher D, Henes F, Gress T, Lohse A, H\u00f6rsch D, Cremer B, Rinke A, Schrader J\n2019. 16th Annual ENETS Conference . 68.\nFast increase of postmortem fentanyl blood concentrations after transdermal application: A call to careful interpretation\nReiter A, Mueller A, Otto B, Anders S, Falckenberg M, Iwersen-Bergmann S, Andresen-Streichert H\nFORENSIC SCI INT. 2019;302:109896.\nRecommendations on the Use of Magnetic Resonance Imaging for Collaborative Multicenter Studies in Primary Sclerosing Cholangitis\nRinge K, Grigoriadis A, Halibasic E, Wacker F, Manns M, Schramm C, Lenzen H\nHEPATOLOGY. 2019;69(3):1358-1359.\nAtypical memory B-cells are associated with Plasmodium falciparum anemia through anti-phosphatidylserine antibodies\nRivera-Correa J, Mackroth M, Jacobs T, Schulze Zur Wiesch J, Rolling T, Rodriguez A\nELIFE. 2019;8:.\nParasitosen in der Hausarztpraxis\nRolling T, V\u00f6lker K, Jordan S, Ramharter M\nMMW Fortschr Med. 2019;161(2):51-57.\nStress fractures in systemic lupus erythematosus after long-term MTX use successfully treated by MTX discontinuation and individualized bone-specific therapy\nRolvien T, Creutzfeldt A, Lohse A, Amling M\nLUPUS. 2019;28(6):790-793.\nSolit\u00e4re Harnblasenmetastase eines Mammakarzinoms: Fallbericht einer seltenen Differenzialdiagnose in der Computertomografie\nRuether D, Weinrich J, Bannas P\nROFO-FORTSCHR RONTG. 2019;191(5):442-443.\nConsistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis\nR\u00fchlemann M, Liwinski T, Heinsen F, Bang C, Zenouzi R, Kummen M, Thingholm L, Tempel M, Lieb W, Karlsen T, Lohse A, Hov J, Denk G, Lammert F, Krawczyk M, Schramm C, Franke A\nALIMENT PHARM THER. 2019;50(5):580-589.\n\u03b2-Catenin Activation Promotes Immune Escape and Resistance to Anti-PD-1 Therapy in Hepatocellular Carcinoma\nRuiz de Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, Lindblad K, Maier B, Sia D, Puigvehi M, Miguela V, Casanova-Acebes M, Dhainaut M, Villacorta-Martin C, Singhi A, Moghe A, von Felden J, Tal Grinspan L, Wang S, Kamphorst A, Monga S, Brown B, Villanueva A, Llovet J, Merad M, Lujambio A\nCANCER DISCOV. 2019;9(8):1124-1141.\nAkutes Leberversagen: Zeitgerechte Diagnose und Therapie ist entscheidend f\u00fcr die Prognose\nRutter K, Horvatits T, Drolz A, Roedl K, Siedler S, Kluge S, Fuhrmann V\nWiener klinisches Magazin. 2019;22(1):38-47.\nTreatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver Transplantation: real-life data from five German transplant centers\nSandmann L, D\u00f6rge P, Wranke A, Vermehren J, Welzel T, Berg C, Grottenthaler J, Weiss K, Langel J, Sterneck M, von Wulffen M, Manns M, Wedemeyer H, Hardtke S, von Hahn T\nEUR J GASTROEN HEPAT. 2019;31(8):1049-1056.\nImmediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, Pneumocystis jirovecii-pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study)\nSch\u00e4fer G, Hoffmann C, Arasteh K, Sch\u00fcrmann D, Stephan C, Jensen B, Stoll M, Bogner J, Faetkenheuer G, Rockstroh J, Klinker H, H\u00e4rter G, St\u00f6hr A, Degen O, Bibiza-Freiwald E, H\u00fcfner A, Jordan S, Schulze Zur Wiesch J, Addo M, Lohse A, van Lunzen J, Schmiedel S\nAIDS RES THER. 2019;16(1):34.\nProgrammed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort\nScheiner B, Kirstein M, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs J, Waneck F, Waidmann O, Reiberger T, M\u00fcller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M\nALIMENT PHARM THER. 2019;49(10):1323-1333.\nDeterminants of post-malarial anemia in African children treated with parenteral artesunate\nScheu K, Adegnika A, Addo M, Ansong D, Cramer J, F\u00fcrst S, Kremsner P, Kurth F, Jacobs T, May J, Ramharter M, Sylverken J, Vinnemeier C, Agbenyega T, Rolling T\nSCI REP-UK. 2019;9(1):18134.\nT-cell repertoire profiling by next-generation sequencing reveals tissue migration dynamics of TRBV13-family clonotypes in a common experimental autoimmune encephalomyelitis mouse model\nSchliffke S, Carambia A, Aky\u00fcz N, Thiele B, Herkel J, Binder M\nJ NEUROIMMUNOL. 2019;332:49-56.\nTh17 cell frequency is associated with low bone mass in primary sclerosing cholangitis\nSchmidt T, Schwinge D, Rolvien T, Jeschke A, Schmidt C, Neven M, Butscheidt S, Kriz M, Kunzmann L, Mussawy H, Hubert J, Hawellek T, R\u00fcther W, Oheim R, Barvencik F, Lohse A, Schramm C, Schinke T, Amling M\nJ HEPATOL. 2019;70(5):941-953.\nSystemische Therapie bei neuroendokrinen Neoplasien des Darmes\nSchrader J\nVerdauungskrankheiten. 2019;37(1):17 - 24.\nExtended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors\nSchrader J, Henes F, Blaeker M, Zimmermann-Fraedrich K, Pace A, Perez D, Izbicki J, Lohse A, Benten D\nENDOCRINE. 2019;65(2):460-467.\nAutoimmune Hepatitis Beyond Steroids: Effective Trial Design and Attention to Quality of Life\nSchramm C\nClin Liver Dis (Hoboken). 2019;14(1):33-36.\nHuman Fetal TNF-\u03b1-Cytokine-Producing CD4 Effector Memory T Cells Promote Intestinal Development and Mediate Inflammation Early in Life\nSchreurs R, Baumdick M, Sagebiel A, Kaufmann M, Mokry M, Klarenbeek P, Schaltenberg N, Steinert F, van Rijn J, Drewniak A, The S, Bakx R, Derikx J, de Vries N, Corpeleijn W, Pals S, Gagliani N, Friese M, Middendorp S, Nieuwenhuis E, Reinshagen K, Geijtenbeek T, van Goudoever J, Bunders M\nIMMUNITY. 2019;50(2):462-476.e8.\nSex-related factors in autoimmune liver diseases\nSchwinge D, Schramm C\nSEMIN IMMUNOPATHOL. 2019;41(2):165-175.\nAutoimmune hepatitis: Is the autoimmunity in the family?\nSebode M, Lohse A\nLIVER INT. 2019;39(1):42-44.\nInflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis\nSebode M, Wigger J, Filpe P, Fischer L, Weidemann S, Krech T, Weiler-Normann C, Peiseler M, Hartl J, Tolosa E, Herkel J, Schramm C, Lohse A, Arrenberg P\nFRONT IMMUNOL. 2019;10:1065.\nAlcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide\nShah N, Ventura-Cots M, Abraldes J, Alboraie M, Alfadhli A, Argemi J, Badia-Aranda E, Soler E, Barritt A, Bessone F, Biryukova M, Carrilho F, Fern\u00e1ndez M, Guiridi Z, El Kassas M, Eng-Kiong T, Farias A, George J, Gui W, Harichander-Thurairajah P, Hsiang J, Husi\u0107-Selimovic A, Isakov V, Karoney M, Kim W, Kluwe J, Kochhar R, Dhaka N, Costa P, Nabeshima M, Ono S, Reis D, Rodil A, Domech C, S\u00e1ez-Royuela F, Scheurich C, Siow W, Sivac-Burina N, Dos Santos Traquino E, Some F, Spreckic S, Tan S, Vorobioff J, Wandera A, Wu P, Yakoub M, Yang L, Yu Y, Zahiragic N, Zhang C, Cortez-Pinto H, Bataller R\nCLIN GASTROENTEROL H. 2019;17(11):2320-2329.e12.\nDendritic Cell Accumulation in the Gut and Central Nervous System Is Differentially Dependent on \u03b14 Integrins\nSie C, Perez L, Kreutzfeldt M, Potthast M, Ohnmacht C, Merkler D, Huber S, Krug A, Korn T\nJ IMMUNOL. 2019;203(6):1417-1427.\nHigh-Throughput Immunogenetics Reveals a Lack of Physiological T Cell Clusters in Patients With Autoimmune Cytopenias\nSimnica D, Schliffke S, Schulthei\u00df C, Bonzanni N, Fanchi L, Aky\u00fcz N, G\u00f6sch B, Casar C, Thiele B, Schl\u00fcter J, Lohse A, Binder M\nFRONT IMMUNOL. 2019;10:1897.\nDietary Habits and Intestinal Immunity: From Food Intake to CD4(+) T-H Cells\nSiracusa F, Schaltenberg N, Villablanca E, Huber S, Gagliani N\nFRONT IMMUNOL. 2019;9:3177.\nMalaria in Eritrean migrants newly arrived in seven European countries, 2011 to 2016\nSond\u00e9n K, Rolling T, W\u00e5ngdahl A, Ydring E, Vygen-Bonnet S, Kobbe R, Douhan J, Hammar U, Duijster J, de Gier B, Freedman J, Gysin N, Stark K, Stevens F, Vestergaard L, Tegnell A, F\u00e4rnert A\nEUROSURVEILLANCE. 2019;24(5):.\nHeterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis\nStrnad P, Buch S, Hamesch K, Fischer J, Rosendahl J, Schmelz R, Brueckner S, Brosch M, Heimes C, Woditsch V, Scholten D, Nischalke H, Janciauskiene S, Mandorfer M, Trauner M, Way M, McQuillin A, Reichert M, Krawczyk M, Casper M, Lammert F, Braun F, von Sch\u00f6nfels W, Hinz S, Burmeister G, Hellerbrand C, Teufel A, Feldman A, Schattenberg J, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Ridinger M, Wodarz N, Soyka M, Rietschel M, Weber T, Marhenke S, Vogel A, Hinrichsen H, Canbay A, Schlattjan M, Sosnowsky K, Sarrazin C, von Felden J, Geier A, Deltenre P, Sipos B, Schafmayer C, Nothnagel M, Aigner E, Datz C, Stickel F, Morgan M, Hampe J, Berg T, Trautwein C\nGUT. 2019;68(6):1099-1107.\nEfficacy of rituximab in difficult-to-manage autoimmune hepatitis: Results from the International Autoimmune Hepatitis Group\nThan N, Hodson J, Schmidt-Martin D, Taubert R, Wawman R, Botter M, Gautam N, Bock K, Jones R, Appanna G, Godkin A, Montano-Loza A, Lammert F, Schramm C, Manns M, Swain M, Burak K, Adams D, Hirschfield G, Oo Y\nJHEP REP. 2019;1(6):437-445.\nA Prospective Study on the Impact and Out-of-Pocket Costs of Dengue Illness in International Travelers.\nTozan Y, Headley T, Sewe M, Schwartz E, Shemesh T, Cramer J, Eberhardt K, Ramharter M, Harrison N, Leder K, Angheben A, Hatz C, Switzerland S, Chen L, De Pijper C, Grobusch M, Wilder-Smith A\nAM J TROP MED HYG. 2019;100(6):1525-1533.\nNorursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial\nTraussnigg S, Schattenberg J, Demir M, Wiegand J, Geier A, Teuber G, Hofmann W, Kremer A, Spreda F, Kluwe J, Petersen J, Boettler T, Rainer F, Halilbasic E, Greinwald R, Pr\u00f6ls M, Manns M, Fickert P, Trauner M\nLANCET GASTROENTEROL. 2019;4(10):781-793.\nDepression and anxiety in patients with different rare chronic diseases: A cross-sectional study\nUhlenbusch N, L\u00f6we B, H\u00e4rter M, Schramm C, Weiler-Normann C, Depping M\nPLOS ONE. 2019;14(2):e0211343.\nThe Translational Landscape of the Human Heart\nvan Heesch S, Witte F, Schneider-Lunitz V, Schulz J, Adami E, Faber A, Kirchner M, Maatz H, Blachut S, Sandmann C, Kanda M, Worth C, Schafer S, Calviello L, Merriott R, Patone G, Hummel O, Wyler E, Obermayer B, M\u00fccke M, Lindberg E, Trnka F, Memczak S, Schilling M, Felkin L, Barton P, Quaife N, Vanezis K, Diecke S, Mukai M, Mah N, Oh S, Kurtz A, Schramm C, Schwinge D, Sebode M, Harakalova M, Asselbergs F, Vink A, de Weger R, Viswanathan S, Widjaja A, G\u00e4rtner-Rommel A, Milting H, Dos Remedios C, Knosalla C, Mertins P, Landthaler M, Vingron M, Linke W, Seidman J, Seidman C, Rajewsky N, Ohler U, Cook S, Hubner N\nCELL. 2019;178(1):242-260.e29.\nPrimary HIV-1 Strains Use Nef To Downmodulate HLA-E Surface Expression\nvan Stigt Thans T, Akko J, Niehrs A, Garcia-Beltran W, Richert L, St\u00fcrzel C, Ford C, Li H, Ochsenbauer C, Kappes J, Hahn B, Kirchhoff F, Martrus G, Sauter D, Altfeld M, H\u00f6lzemer A\nJ VIROL. 2019;93(20):.\nThe burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study\nvon Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani M, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse A, Cornelissen J, de Man R, Mallet V\nJ HEPATOL. 2019;71(3):465-472.\nThe Impact of Translational Research in Hepatology\nvon Felden J, Craig A, Villanueva A\nClin Liver Dis (Hoboken). 2019;13(1):29-33.\nReply to: \"Burden of hepatitis E infection and associated healthcare resource utilization among hematological malignancy-related hospitalizations: A national perspective in the United States, 2007-2014\"\nvon Felden J, Mallet V, Pischke S\nJ HEPATOL. 2019;71(6):1268-1269.\nLifestyle behaviour and prevalence of cardiovascular risk factors - a pilot study comparing Kiribati and European seafarers\nvon Katzler R, Zyriax B, Jagemann B, Westenhoefer J, Jensen H, Harth V, Oldenburg M\nBMC PUBLIC HEALTH. 2019;19(1):855.\nDNA Methyltransferase 1 Controls Nephron Progenitor Cell Renewal and Differentiation\nWanner N, Vornweg J, Combes A, Wilson S, Plappert J, Rafflenbeul G, Puelles V, Rahman R, Liwinski T, Lindner S, Grahammer F, Kretz O, Wlodek M, Romano T, Moritz K, Boerries M, Busch H, Bonn S, Little M, Bechtel-Walz W, Huber T\nJ AM SOC NEPHROL. 2019;30(1):63-78.\nPeginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): A randomised, placebo controlled, phase 2 trial\nWedemeyer H, Yurdaydin C, Hardtke S, Caruntu F, Curescu M, Yalcin K, Akarca U, G\u00fcrel S, Zeuzem S, Erhardt A, L\u00fcth S, Papatheodoridis G, Keskin O, Port K, Radu M, Celen M, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes H, Cornberg M, Koch A, Manns M\nLANCET INFECT DIS. 2019;19(3):275-286.\nSOP Spontan bakterielle Peritonitis bei Leberzirrhose\nWege H, Kluwe J\nGastroenterologie up2date. 2019;2019(15):321-325.\nTreatment Lines in Hepatocellular Carcinoma\nWege H, Li J, Ittrich H\nVISC MED. 2019;35(4):266-272.\nT cell receptor grafting allows virological control of Hepatitis B virus infection\nWisskirchen K, Kah J, Malo A, Asen T, Volz T, Allweiss L, Wettengel J, L\u00fctgehetmann M, Urban S, Bauer T, Dandri M, Protzer U\nJ CLIN INVEST. 2019;129(7):2932-2945.\nComparison of the integrin \u03b14\u03b27 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis\nWittner M, Schlicker V, Libera J, Bockmann J, Horvatits T, Seiz O, Kummer S, Manthey C, H\u00fcfner A, Kantowski M, R\u00f6sch T, Degen O, Huber S, Eberhard J, Schulze Zur Wiesch J\nPLOS ONE. 2019;14(7):e0220008.\nCharacterization of Plasmodium infections among inhabitants of rural areas in Gabon\nWoldearegai T, Lalremruata A, Nguyen T, Gmeiner M, Veletzky L, Tazemda-Kuitsouc G, Matsiegui P, Mordm\u00fcller B, Held J\nSCI REP-UK. 2019;9(1):9784.\nEffects of Pharmacological Thermogenic Adipocyte Activation on Metabolism and Atherosclerotic Plaque Regression\nWorthmann A, Schlein C, Berb\u00e9e J, Rensen P, Heeren J, Bartelt A\nNUTRIENTS. 2019;11(2):.\nDown-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection\nYan Y, Allweiss L, Yang D, Kang J, Wang J, Qian X, Zhang T, Liu H, Wang L, Liu S, Sui J, Chen X, Dandri M, Zhao J, Lu F\nEMERG MICROBES INFEC. 2019;8(1):879-894.\nObeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial\nYounossi Z, Ratziu V, Loomba R, Rinella M, Anstee Q, Goodman Z, Bedossa P, Geier A, Beckebaum S, Newsome P, Sheridan D, Sheikh M, Trotter J, Knapple W, Lawitz E, Abdelmalek M, Kowdley K, Montano-Loza A, Boursier J, Mathurin P, Bugianesi E, Mazzella G, Olveira A, Cortez-Pinto H, Graupera I, Orr D, Gluud L, Dufour J, Shapiro D, Campagna J, Zaru L, MacConell L, Shringarpure R, Harrison S, Sanyal A\nLANCET. 2019;394(10215):2184-2196.\nMagnetic Resonance Imaging in Primary Sclerosing Cholangitis-Current State and Future Directions\nZenouzi R, Welle C, Venkatesh S, Schramm C, Eaton J\nSEMIN LIVER DIS. 2019;39(3):369-380.\nDescription of Plasmodium falciparum infections in central Gabon demonstrating high parasite densities among symptomatic adolescents and adults\nZoleko Manego R, Koehne E, Kreidenweiss A, Nzigou Mombo B, Adegbite B, Dimessa Mbadinga L, Akinosho M, Matthewman J, Adegnika A, Ramharter M, Mombo-Ngoma G\nMALARIA J. 2019;18(1):.\nCould inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers.\nJ HUM GENET. 2018;63(5):621-626.\nS2k-Leitlinie Neuroendokrine Tumore\nZ GASTROENTEROL. 2018;56(6):583-681.\nAuthor Correction: Differential expression pattern of co-inhibitory molecules on CD4 T cells in uncomplicated versus complicated malaria.\nAbel A, Steeg C, Aminkiah F, Addai-Mensah O, Addo M, Gagliani N, Casar C, Yar D, Owusu-Dabo E, Jacobs T, Mackroth M\nSCI REP-UK. 2018;8(1):17587.\nDifferential expression pattern of co-inhibitory molecules on CD4(+) T cells in uncomplicated versus complicated malaria\nAbel A, Steeg C, Aminkiah F, Addai-Mensah O, Addo M, Gagliani N, Casar C, Yar D, Owusu-Dabo E, Jacobs T, Mackroth M\nSCI REP-UK. 2018;8(1):4789.\nIst die Welt ausreichend ger\u00fcstet f\u00fcr das n\u00e4chste unbekannte Virus?\nAddo M\nFrankfurter Allgemeine Zeitung. 2018.\nT17 cell plasticity: The role of dendritic cells and molecular mechanisms\nAgalioti T, Villablanca E, Huber S, Gagliani N\nJ AUTOIMMUN. 2018;87:50-60.\nGenetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis\nAlberts R, de Vries E, Goode E, Jiang X, Sampaziotis F, Rombouts K, B\u00f6ttcher K, Folseraas T, Weism\u00fcller T, Mason A, Wang W, Alexander G, Alvaro D, Bergquist A, Bj\u00f6rkstr\u00f6m N, Beuers U, Bj\u00f6rnsson E, Boberg K, Bowlus C, Bragazzi M, Carbone M, Chazouill\u00e8res O, Cheung A, Dalekos G, Eaton J, Eksteen B, Ellinghaus D, F\u00e4rkkil\u00e4 M, Festen E, Floreani A, Franceschet I, Gotthardt D, Hirschfield G, Hoek B, Holm K, Hohenester S, Hov J, Imhann F, Invernizzi P, Juran B, Lenzen H, Lieb W, Liu J, Marschall H, Marzioni M, Melum E, Milkiewicz P, M\u00fcller T, Pares A, Rupp C, Rust C, Sandford R, Schramm C, Schreiber S, Schrumpf E, Silverberg M, Srivastava B, Sterneck M, Teufel A, Vallier L, Verheij J, Vila A, Vries B, Zachou K, Chapman R, Manns M, Pinzani M, Rushbrook S, Lazaridis K, Franke A, Anderson C, Karlsen T, Ponsioen C, Weersma R\nGUT. 2018;67(8):1517-1524.\nIntestinal IFN-\u03b3-producing type 1 regulatory T cells coexpress CCR5 and programmed cell death protein 1 and downregulate IL-10 in the inflamed guts of patients with inflammatory bowel disease\nAlfen J, Larghi P, Facciotti F, Gagliani N, Bosotti R, Paroni M, Maglie S, Gruarin P, Vasco C, Ranzani V, Frusteri C, Iseppon A, Moro M, Crosti M, Gatti S, Pagani M, Caprioli F, Abrignani S, Flavell R, Geginat J\nJ ALLERGY CLIN IMMUN. 2018;142(5):1537-1547.e8.\nProliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo\nAllweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse A, Beninati C, Pollicino T, Urban S, L\u00fctgehetmann M, Dandri M\nGUT. 2018;67(3):542-552.\nCorticosteroid Therapy Improves the Outcome of Autoimmune Hepatitis-Induced Acute Liver Failure\nAnastasiou O, Dogan-Cavus B, Kucukoglu O, Baba H, Kahraman A, Gerken G, Schramm C, Canbay A\nDIGESTION. 2018;98(2):104-111.\nAlcohol Biomarkers in Clinical and Forensic Contexts\nAndresen-Streichert H, M\u00fcller A, Glahn A, Skopp G, Sterneck M\nDTSCH ARZTEBL INT. 2018;115(18):309-315.\nThe role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance\nAristizabal Prada E, Sp\u00f6ttl G, Maurer J, Lauseker M, Koziolek E, Schrader J, Grossman A, Pacak K, Beuschlein F, Auernhammer C, N\u00f6lting S\nENDOCR-RELAT CANCER. 2018;25(10):893-908.\nEarly heme oxygenase 1 induction delays tumour initiation and enhances DNA damage repair in liver macrophages of Mdr2 mice\nBarikbin R, Berkhout L, Bolik J, Schmidt-Arras D, Ernst T, Ittrich H, Adam G, Parplys A, Casar C, Krech T, Karimi K, Sass G, Tiegs G\nSCI REP-UK. 2018;8(1):16238.\nDSM265: a novel drug for single-dose cure of Plasmodium falciparum malaria\nB\u00e9lard S, Ramharter M\nLANCET INFECT DIS. 2018;18(8):819-820.\nEstablishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model\nBenten D, Behrang Y, Unrau L, Weissmann V, Wolters-Eisfeld G, Burdak-Rothkamm S, Stahl F, Anlauf M, Grabowski P, M\u00f6bs M, Dieckhoff J, Sipos B, Fahl M, Eggers C, Perez D, Bockhorn M, Izbicki J, Lohse A, Schrader J\nMOL CANCER RES. 2018;16(3):496-507.\nA humanized mouse model of liver fibrosis following expansion of transplanted hepatic stellate cells\nBenten D, Kluwe J, Wirth J, Thiele N, Follenzi A, Bhargava K, Palestro C, Koepke M, Tjandra R, Volz T, Lutgehetmann M, Gupta S\nLAB INVEST. 2018;98(4):525-536.\nRibavirin in Acute Hepatitis E Infection in Patients with Gynecological Cancer: A Case Series\nBettinger D, Schlabe S, Pischke S, Mallmann M, Keyver-Paik M, Kuhn W, Strassburg C, Thimme R, Spengler U\nJ CLIN TRANSL HEPATO. 2018;6(2):237-240.\nMucosal-associated invariant T-cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with advanced fibrosis\nBeudeker B, van Oord G, Arends J, Schulze Zur Wiesch J, van der Heide M, de Knegt R, Verbon A, Boonstra A, Claassen M\nLIVER INT. 2018;38(3):458-468.\nTuberculous Tenosynovitis\nBrehm T, Schmiedel S, Addo M\nDTSCH ARZTEBL INT. 2018;115(42):714.\nEpidemiology, clinical and laboratory features of 24 consecutive cases of leptospirosis at a German infectious disease center.\nBrehm T, Schulze zur Wiesch J, L\u00fctgehetmann M, Tappe D, Eisermann P, Lohse A, Addo M, Schmiedel S\nINFECTION. 2018;46(6):847-853.\nSevere Acute Liver Injury Following Therapeutic Doses of Acetaminophen in a Patient With Spinal Muscular Atrophy\nBrehm T, Wehmeyer M, Fuhrmann V, Sch\u00e4fer H, Kluwe J\nAM J THER. 2018;26(4):e528-e529.\nMolecular and functional heterogeneity of IL-10-producing CD4+ T cells\nBrockmann L, Soukou S, Steglich B, Czarnewski P, Zhao L, Wende S, Bedke T, Ergen C, Manthey C, Agalioti T, Geffken M, Seiz O, Parigi S, Sorini C, Geginat J, Fujio K, Jacobs T, Roesch T, Izbicki J, Lohse A, Flavell R, Krebs C, Gustafsson J, Antonson P, Roncarolo M, Villablanca E, Gagliani N, Huber S\nNAT COMMUN. 2018;9(1):5457.\nMicrobiota-driven interleukin-17-producing cells and eosinophils synergize to accelerate multiple myeloma progression\nCalcinotto A, Brevi A, Chesi M, Ferrarese R, Garcia Perez L, Grioni M, Kumar S, Garbitt V, Sharik M, Henderson K, Tonon G, Tomura M, Miwa Y, Esplugues E, Flavell R, Huber S, Canducci F, Rajkumar V, Bergsagel P, Bellone M\nNAT COMMUN. 2018;9:4832.\nDietary and metabolic modulators of hepatic immunity\nCarambia A, Herkel J\nSEMIN IMMUNOPATHOL. 2018;40(2):175 - 188.\nInterleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation\nCouturier-Maillard A, Froux N, Piotet-Morin J, Michaudel C, Brault L, Le B\u00e9richel J, S\u00e9n\u00e9chal A, Robinet P, Chenuet P, Jejou S, Dumoutier L, Renauld J, Iovanna J, Huber S, Quesniaux V, Sokol H, Ryffel B\nMUCOSAL IMMUNOL. 2018;11(4):1181-1190.\nHigh-density single cell mRNA sequencing to characterize circulating tumor cells in hepatocellular carcinoma\nD'Avola D, Villacorta-Martin C, Martins-Filho S, Craig A, Labgaa I, von Felden J, Kimaada A, Bonaccorso A, Tabrizian P, Hartmann B, Sebra R, Schwartz M, Villanueva A\nSCI REP-UK. 2018;8:11570.\nLevels of Cytokines in Serum Associate With Development of Hepatocellular Carcinoma in Patients With HCV Infection Treated With Direct-Acting Antivirals\nDebes J, van Tilborg M, Groothuismink Z, Hansen B, Schulze Zur Wiesch J, von Felden J, de Knegt R, Boonstra A\nGASTROENTEROLOGY. 2018;154(3):515-517.\nSchistosoma haematobium effects on Plasmodium falciparum infection modified by soil-transmitted helminths in school-age children living in rural areas of Gabon\nDejon-Agob\u00e9 J, Zinsou J, Honkpehedji Y, Ateba-Ngoa U, Edoa J, Adegbite B, Mombo-Ngoma G, Agnandji S, Ramharter M, Kremsner P, Lell B, Grobusch M, Adegnika A\nPLOS NEGLECT TROP D. 2018;12(8):e0006663.\nIL-10 Receptor Signaling Empowers Regulatory T Cells to Control Th17 Responses and Protect from GN\nDiefenhardt P, Nosko A, Kluger M, Richter J, Wegscheid C, Kobayashi Y, Tiegs G, Huber S, Flavell R, Stahl R, Steinmetz O\nJ AM SOC NEPHROL. 2018;29(7):1825-1837.\nPatterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals\nDietz J, Susser S, Vermehren J, Peiffer K, Grammatikos G, Berger A, Ferenci P, Buti M, M\u00fcllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, H\u00fcppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C\nGASTROENTEROLOGY. 2018;154(4):976-988.e4.\nKombination von NAFLD Fibrosis Score und transienter Elastografie zur Identifikation mittelgradiger Fibrosestadien (II/III) bei nicht-alkoholischer Fettlebererkrankung\nDrolz A, Wehmeyer M, Diedrich T, Piecha F, Schulze Zur Wiesch J, Kluwe J\nZ GASTROENTEROL. 2018;56(1):43-50.\nPrimary sclerosing cholangitis\nDyson J, Beuers U, Jones D, Lohse A, Hudson M\nLANCET. 2018;391(10139):2547-2559.\nInequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom\nDyson J, Wong L, Bigirumurame T, Hirschfield G, Kendrick S, Oo Y, Lohse A, Heneghan M, Jones D\nALIMENT PHARM THER. 2018;48(9):951-960.\nExtended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in local and imported poultry meat in Ghana\nEibach D, Dekker D, Gyau Boahen K, Wiafe Akenten C, Sarpong N, Belmar Campos C, Berneking L, Aepfelbacher M, Krumkamp R, Owusu-Dabo E, May J\nVET MICROBIOL. 2018;217:7-12.\nOxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation\nEmg\u00e5rd J, Kammoun H, Garc\u00eda-Cassani B, Chesn\u00e9 J, Parigi S, Jacob J, Cheng H, Evren E, Das S, Czarnewski P, Sleiers N, Melo-Gonzalez F, Kvedaraite E, Svensson M, Scandella E, Hepworth M, Huber S, Ludewig B, Peduto L, Villablanca E, Veiga-Fernandes H, Pereira J, Flavell R, Willinger T\nIMMUNITY. 2018;48(1):120-132.\nDynamic changes of circulating miRNAs induced by the Ebola virus vaccine VSV-EBOV\nFischer T, Spohn M, Olearo F, Zinser M, Kasonta R, Stubbe H, Rechtien A, Ly M, Schmiedel S, Lohse A, Grundhoff A, Addo M, Dahlke C\nVACCINE. 2018;36(46):7083-7094.\nA mobile phone based tool to identify symptoms of common childhood diseases in Ghana: development and evaluation of the integrated clinical algorithm in a cross-sectional study\nFranke K, Krumkamp R, Mohammed A, Sarpong N, Owusu-Dabo E, Brinkel J, Fobil J, Marinovic A, Asihene P, Boots M, May J, Kreuels B\nBMC MED INFORM DECIS. 2018;18:23.\nRetrospective clinical case series study in 2017 identifies as most frequent species in returning travellers from Thailand to Germany\nFroeschl G, Nothdurft H, von Sonnenburg F, Bretzel G, Polanetz R, Kroidl I, Seilmaier M, Orth H, Jordan S, Kremsner P, Vygen-Bonnet S, Pritsch M, Hoelscher M, Rothe C\nEUROSURVEILLANCE. 2018;23(29):14-20.\nHbA1c-basiertes Screening zur Erfassung eines unerkannten Diabetes mellitus bei gastroenterologischen Patienten in einer Klinik der Maximalversorgung\nFr\u00fcndt T, Schr\u00f6der N, Pinnschmidt H, H\u00f6lzemer A, Heer J, Lohse A, Schrader J\nZ GASTROENTEROL. 2018;56(08):e388-e389.\nDiscordance in steatosis classification between liver biopsy and transient elastography for high controlled attenuation parameter (CAP) values\nGalaski J, Schulz L, Krause J, Lohse A\nZ GASTROENTEROL. 2018;56(1):36-42.\nSudden Dyspnea in a Liver Transplant Recipient\nGil-Ibanez I, Laqmani A, Pischke S\nDTSCH ARZTEBL INT. 2018;115(18):323.\nProspective Clinical Trial Assessing Species-Specific Efficacy of Artemether-Lumefantrine for the Treatment of Plasmodium malariae, Plasmodium ovale, and Mixed Plasmodium Malaria in Gabon\nGroger M, Veletzky L, Lalremruata A, Cattaneo C, Mischlinger J, Zoleko-Manego R, Endamne L, Klicpera A, Kim J, Nguyen T, Flohr L, Remppis J, Matsiegui P, Adegnika A, Agnandji S, Kremsner P, Mordm\u00fcller B, Mombo-Ngoma G, Ramharter M\nANTIMICROB AGENTS CH. 2018;62(3):e01758-17.\nUsefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis\nHartl J, Ehlken H, Sebode M, Peiseler M, Krech T, Zenouzi R, von Felden J, Weiler-Normann C, Schramm C, Lohse A\nJ HEPATOL. 2018;68(4):754-763.\nRecurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?\nHeinemann M, Ranft A, Langer T, J\u00fcrgens H, Kreyer J, Vieth V, Sch\u00e4fers M, Weckesser M, Simon T, Hassenpflug W, Corbacioglu S, Bielack S, Mayer-Steinacker R, K\u00fchne T, van den Berg H, Gelderblom H, Bauer S, Stegger L, Dirksen U\nPEDIATR BLOOD CANCER. 2018;65(7):e27011.\nSchistosomiasis bei Fl\u00fcchtlingen und Migranten\nHennigs A, Hennigs J, Schmiedel S\nFLUGMEDIZIN TROPENME. 2018;25(01):19-22.\nHMGB1 links chronic liver injury to progenitor responses and hepatocarcinogenesis.\nHernandez C, Huebener P, Pradere J, Antoine D, Friedman R, Schwabe R\nJ CLIN INVEST. 2018;128(6):2436-2451.\nImpact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany\nHerzer K, Gerken G, Kroy D, Tacke F, Plewe J, Eurich D, Spengler U, Strassburg C, Welker M, Pischke S, Sterneck M, Mehrabi A, Weiss K, Herber A, Berg T, Zimmermann T, Galle P, Heinzow H, Schmidt H, Markova A, Serfert Y, Manns M, Zeuzem S, Wedemeyer H\nJ HEPATOL. 2018;69(4):982-984.\nTreatment responses in multidrug-resistant tuberculosis in Germany\nHeyckendorf J, van Leth F, Avsar K, Glattki G, G\u00fcnther G, Kalsdorf B, M\u00fcller M, Olaru I, Rolling T, Salzer H, Schuhmann M, Terhalle E, Lange C\nINT J TUBERC LUNG D. 2018;22(4):399-406.\nRelapse-free cure from multidrug-resistant tuberculosis in Germany\nHeyckendorf J, van Leth F, Kalsdorf B, Olaru I, G\u00fcnther G, Salzer H, Terhalle E, Rolling T, Glattki G, M\u00fcller M, Schuhmann M, Avsar K, Lange C\nEUR RESPIR J. 2018;51(2):.\nCarcinoembryonic antigen-related cell adhesion molecule 1 controls IL-2-dependent regulatory T-cell induction in immune-mediated hepatitis in mice\nHorst A, Wegscheid C, Schaefers C, Schiller B, Neumann K, Lunemann S, Langeneckert A, Oldhafer K, Weiler-Normann C, Lang K, Singer B, Altfeld M, Diehl L, Tiegs G\nHEPATOLOGY. 2018;68(1):200-214.\nResponse for letter \"Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countries\"\nHorvatits T, Ozga A, Lohse A, Dalton H, Pischke S\nLIVER INT. 2018;38(12):2341.\nHepatitis E seroprevalence in the Americas: A systematic review and meta-analysis\nHorvatits T, Ozga A, Westh\u00f6lter D, Hartl J, Manthey C, L\u00fctgehetmann M, Rauch G, Kriston L, Lohse A, Bendall R, Wedemeyer H, Dalton H, Pischke S\nLIVER INT. 2018;38(11):1951-1964.\nExtrahepatic manifestations and HEV, the genotype matters\nHorvatits T, Pischke S\nEBIOMEDICINE. 2018;36:3-4.\nOutcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation\nHorvatits T, Pischke S, Proske V, Fischer L, Scheidat S, Thaiss F, Fuhrmann V, Lohse A, Nashan B, Sterneck M\nUNITED EUR GASTROENT. 2018;6(1):104-111.\nLack of evidence for human serum albumin as major source of HEV infections\nHorvatits T, Westh\u00f6lter D, Peine S, Schulze Zur Wiesch J, Lohse A, L\u00fctgehetmann M, Pischke S\nTRANSFUSION MED. 2018;28(6):470-471.\nDas akut-auf-chronische Leberversagen als diagnostische und therapeutische Herausforderung der Intensivmedizin\nH\u00fcbener P, Braun G, Fuhrmann V\nMED KLIN-INTENSIVMED. 2018;113(8):649-657.\nStabilisation of acute-on-chronic liver failure patients before liver transplantation predicts post-transplant survival\nH\u00fcbener P, Sterneck M, Bangert K, Drolz A, Lohse A, Kluge S, Fischer L, Fuhrmann V\nALIMENT PHARM THER. 2018;47(11):1502-1510.\nEditorial: transplantation in the setting of acute-on-chronic liver failure-calculating chances. Authors' reply\nHuebener P, Sterneck M, Fuhrmann V\nALIMENT PHARM THER. 2018;48(1):100-101.\nDeterminants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study\nHuttner A, Agnandji S, Combescure C, Fernandes J, Bache E, Kabwende L, Ndungu F, Brosnahan J, Monath T, Lema\u00eetre B, Grillet S, Botto M, Engler O, Portmann J, Siegrist D, Bejon P, Silvera P, Kremsner P, Siegrist C\nLANCET INFECT DIS. 2018;18(7):738-748.\nAccess to care in rare liver diseases: New challenges and new opportunities\nJones D, Sturm E, Lohse A\nJ HEPATOL. 2018;68(3):577-585.\nAmino Acid Substitutions within HLA-B*27-Restricted T Cell Epitopes Prevent Recognition by Hepatitis Delta Virus-Specific CD8+ T Cells\nKarimzadeh H, Kiraithe M, Kosinska A, Glaser M, Fiedler M, Oberhardt V, Salimi Alizei E, Hofmann M, Mok J, Nguyen M, van Esch W, Budeus B, Grabowski J, Homs M, Olivero A, Keyvani H, Rodr\u00edguez-Fr\u00edas F, Tabernero D, Buti M, Heinold A, Alavian S, Bauer T, Schulze Zur Wiesch J, Raziorrouh B, Hoffmann D, Smedile A, Rizzetto M, Wedemeyer H, Timm J, Antes I, Neumann-Haefelin C, Protzer U, Roggendorf M\nJ VIROL. 2018;92(13):e01891-17.\nVersorgung bei kompensierter Leberzirrhose 2018 \u2013 Evidenzbasierte prophylaktische Ma\u00dfnahmen\nKarkmann K, Piecha F, R\u00fcnzi A, Schulz L, von Wulffen M, Benten D, Kluwe J, Wege H\nZ GASTROENTEROL. 2018;56(1):55-69.\nCarbapenem-resistant Gram-negative pathogens in a German university medical Center: Prevalence, clinical implications and the role of novel \u03b2-lactam/\u03b2-lactamase inhibitor combinations\nKatchanov J, Asar L, Klupp E, Both A, Rothe C, K\u00f6nig C, Rohde H, Kluge S, Maurer F\nPLOS ONE. 2018;13(4):e0195757.\nAssociation of gadolinium-enhanced magnetic resonance imaging with hepatic fibrosis and inflammation in primary sclerosing cholangitis.\nKeller S, Aigner A, Zenouzi R, Kim A, Meijer A, Weidemann S, Krech T, Lohse A, Adam G, Schramm C, Yamamura J\nPLOS ONE. 2018;13(3):e0193929.\nGadolinium-based relative contrast enhancement in primary sclerosing cholangitis: additional benefit for clinicians?\nKeller S, Venkatesh S, Avanesov M, Weinrich J, Zenouzi R, Schramm C, Adam G, Yamamura J\nCLIN RADIOL. 2018;73(7):677.e1-677.e6.\nTransarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease\nKirstein M, Voigtl\u00e4nder T, Schweitzer N, Hinrichs J, Marquardt J, W\u00f6rns M, Kloeckner R, Fr\u00fcndt T, Ittrich H, Wacker F, Rodt T, Manns M, Wege H, Weinmann A, Vogel A\nUNITED EUR GASTROENT. 2018;6(2):238-246.\nEfficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection\nKlumpp K, Shimada T, Allweiss L, Volz T, L\u00fctgehetmann M, Hartman G, Flores O, Lam A, Dandri-Petersen M\nGASTROENTEROLOGY. 2018;154(3):652-662.e8.\nLiver metastasis of pancreatic Cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells\nKnaack H, Lenk L, Philipp L, Miarka L, Rahn S, Viol F, Hauser C, Egberts J, Gundlach J, Will O, Tiwari S, Mikulits W, Schumacher U, Hengstler J, Sebens S\nONCOTARGET. 2018;9(60):31771-31786.\nNonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3\nKoh S, Kah J, Tham C, Yang N, Ceccarello E, Chia A, Chen M, Khakpoor A, Pavesi A, Tan A, Dandri M, Bertoletti A\nGASTROENTEROLOGY. 2018;155(1):180-193.e6.\nA randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis\nKowdley K, Luketic V, Chapman R, Hirschfield G, Poupon R, Schramm C, Vincent C, Rust C, Par\u00e9s A, Mason A, Marschall H, Shapiro D, Adorini L, Sciacca C, Beecher-Jones T, B\u00f6hm O, Pencek R, Jones D\nHEPATOLOGY. 2018;67(5):1890-1902.\nSchistosomiasis detected during appendectomy\nKraef C, Arand J, Veletzky L, Sch\u00e4fer H, Jordan S, Schmiedel S, Ramharter M\nLANCET. 2018;391(10139):2546.\nCourse of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors\nKraef C, Schlein C, Hiller J, Westh\u00f6lter D, Denzer U, Horvatits T, Peine S, Lohse A, L\u00fctgehetmann M, Polywka S, Pischke S\nJ CLIN VIROL. 2018;105:26-30.\nImpact of the Interdisciplinary Tumor Board of the Cooperative Ewing Sarcoma Study Group on local therapy and overall survival of Ewing sarcoma patients after induction therapy\nKreyer J, Ranft A, Timmermann B, Juergens H, Jung S, Wiebe K, Boelling T, Schuck A, Vieth V, Streitbuerger A, Hardes J, Heinemann M, Dirksen U\nPEDIATR BLOOD CANCER. 2018;65(12):e27384.\nEmergence of a dalbavancin induced glycopeptide/lipoglycopeptide non-susceptible Staphylococcus aureus during treatment of a cardiac device-related endocarditis\nKussmann M, Karer M, Obermueller M, Schmidt K, Barousch W, Moser D, Nehr M, Ramharter M, Poeppl W, Makristathis A, Winkler S, Thalhammer F, Burgmann H, Lagler H\nEMERG MICROBES INFEC. 2018;7(1):202.\nA pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma\nLabgaa I, Villacorta-Martin C, D'Avola D, Craig A, von Felden J, Martins-Filho S, Sia D, Stueck A, Ward S, Fiel M, Mahajan M, Tabrizian P, Thung S, Ang C, Friedman S, Llovet J, Schwartz M, Villanueva A\nONCOGENE. 2018;37(27):3740-3752.\nPrim\u00e4r sklerosierende Cholangitis: Aktuelle Diagnostik und Therapie\nLiwinski T, Schramm C\nINTERNIST. 2018;59(6):551-559.\nGASL 2018\nLohse A\nZ GASTROENTEROL. 2018;56(1):28.\nPreliminary Evidence for the Absence of Cystic Echinococcosis in Gabon: A Cross-Sectional Pilot Survey in Humans and Definitive Hosts\nL\u00f6tsch F, Mombo-Ngoma G, Mischlinger J, Groger M, Veletzky L, Adegnika A, Lell B, Agnandji S, Bouyou-Akotet M, Oberm\u00fcller M, Wassermann M, Schneider R, Auer H, Ramharter M\nAM J TROP MED HYG. 2018;99(1):97-101.\nControl of Listeria monocytogenes infection requires classical IL-6 signaling in myeloid cells\nL\u00fccke K, Yan I, Krohn S, Volmari A, Klinge S, Schmid J, Schumacher V, Steinmetz O, Rose-John S, Mittr\u00fccker H\nPLOS ONE. 2018;13(8):e0203395.\nInteractions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture\nLunemann S, Sch\u00f6bel A, Kah J, Fittje P, H\u00f6lzemer A, Langeneckert A, Hess L, Poch T, Martrus G, Garcia-Beltran W, K\u00f6rner C, Ziegler A, Richert L, Oldhafer K, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M\nGASTROENTEROLOGY. 2018;155(5):1366-1371.\nStool cultures at the ICU: get rid of it!\nManthey C, Dranova D, Christner M, Berneking L, Kluge S, Lohse A, Fuhrmann V\nANN INTENSIVE CARE. 2018;8(1):10.\nGastrointestinale Infektionen \u2013 Aktuelles\nManthey C, Lohse A, Stallmach A\nGastroenterologie up2date. 2018;14:1\u201317.\nColitis Promotes a Pathological Condition of the Liver in the Absence of Foxp3 Regulatory T Cells\nMathies F, Steffens N, Kleinschmidt D, Stuhlmann F, Huber F, Roy U, Meyer T, Luetgehetmann M, von Petersdorff M, Seiz O, Herkel J, Schramm C, Flavell R, Gagliani N, Krebs C, Panzer U, Abdullah Z, Strowig T, Bedke T, Huber S\nJ IMMUNOL. 2018;201(12):3558-3568.\nValidity and reliability of methods to microscopically detect and quantify malaria parasitaemia\nMischlinger J, Pitzinger P, Veletzky L, Groger M, Zoleko-Manego R, Adegnika A, Agnandji S, Lell B, Kremsner P, Mombo-Ngoma G, Mordm\u00fcller B, Ramharter M\nTROP MED INT HEALTH. 2018;23(9):980-991.\nUse of Capillary Blood Samples Leads to Higher Parasitemia Estimates and Higher Diagnostic Sensitivity of Microscopic and Molecular Diagnostics of Malaria Than Venous Blood Samples\nMischlinger J, Pitzinger P, Veletzky L, Groger M, Zoleko-Manego R, Adegnika A, Agnandji S, Lell B, Kremsner P, Tannich E, Mombo-Ngoma G, Mordm\u00fcller B, Ramharter M\nJ INFECT DIS. 2018;218(8):1296-1305.\nBehavioural and clinical predictors for Loiasis\nMischlinger J, Veletzky L, Tazemda-Kuitsouc G, Pitzinger P, Matsegui P, Gmeiner M, Lagler H, Gebru T, Held J, Mordm\u00fcller B, Ramharter M\nJ GLOB HEALTH. 2018;8(1):010413.\nFeasibility of Electronic Health Information and Surveillance System (eHISS) for disease symptom monitoring: A case of rural Ghana\nMohammed A, Franke K, Boakye Okyere P, Brinkel J, Bona\u010di\u0107 Marinovic A, Kreuels B, Krumkamp R, Fobil J, May J, Owusu-Dabo E\nPLOS ONE. 2018;13(5):e0197756.\nEfficacy and Safety of Fosmidomycin-Piperaquine as Nonartemisinin-Based Combination Therapy for Uncomplicated Falciparum Malaria: A Single-Arm, Age De-escalation Proof-of-Concept Study in Gabon\nMombo-Ngoma G, Remppis J, Sievers M, Zoleko Manego R, Endamne L, Kabwende L, Veletzky L, Nguyen T, Groger M, L\u00f6tsch F, Mischlinger J, Flohr L, Kim J, Cattaneo C, Hutchinson D, Duparc S, Moehrle J, Velavan T, Lell B, Ramharter M, Adegnika A, Mordm\u00fcller B, Kremsner P\nCLIN INFECT DIS. 2018;66(12):1823-1830.\nA Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression\nMueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, John Parrott N, Zhang J, Schmucki R, Racek T, Hoflack J, Kueng E, Point F, Zhou X, Steiner G, L\u00fctgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young J, Javanbakht H\nJ HEPATOL. 2018;68(3):412-420.\nHVEM and CD160: Regulators of Immunopathology During Malaria Blood-Stage\nMuscate F, Stetter N, Schramm C, Schulze Zur Wiesch J, Bosurgi L, Jacobs T\nFRONT IMMUNOL. 2018;9:2611.\nFast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasma-correlation with liver cancer and liver cirrhosis\nNagel T, Klaus F, Ibanez I, Wege H, Lohse A, Meyer B\nANAL BIOANAL CHEM. 2018;410(30):7965-7977.\nEndoscopy versus radiology in post-procedural monitoring after peroral endoscopic myotomy (POEM)\nNast J, Berliner C, R\u00f6sch T, von Renteln D, Noder T, Schachschal G, Groth S, Ittrich H, Kersten J, Adam G, Werner Y\nSURG ENDOSC. 2018;32(9):3956-3963.\nUp regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer\nNeubauer E, Latif M, Krause J, Heumann A, Armbrust M, Luehr C, Fraune C, Hube-Magg C, Kluth M, M\u00f6ller-Koop C, Sauter G, Simon R, Beyer B, Pompe R, Thederan I, Schlomm T, B\u00fcscheck F\nEXP MOL PATHOL. 2018;105(1):50-56.\nFlt3 ligand expands bona fide innate lymphoid cell precursors in vivo\nParigi S, Czarnewski P, Das S, Steeg C, Brockmann L, Fernandez-Gaitero S, Yman V, Forkel M, H\u00f6\u00f6g C, Mj\u00f6sberg J, Westerberg L, F\u00e4rnert A, Huber S, Jacobs T, Villablanca E\nSCI REP-UK. 2018;8(1):154.\nEfficacy and Limitations of Budesonide as a Second-line Treatment for Patients With Autoimmune Hepatitis\nPeiseler M, Liebscher T, Sebode M, Zenouzi R, Hartl J, Ehlken H, Pannicke N, Weiler-Normann C, Lohse A, Schramm C\nCLIN GASTROENTEROL H. 2018;16(2):260-267.e1.\nRisk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis\nPeiseler M, Reiners D, Pinnschmidt H, Sebode M, Jung F, Hartl J, Zenouzi R, Ehlken H, Groth S, Schachschal G, R\u00f6sch T, Weiler-Normann C, Lohse A, Schramm C\nPLOS ONE. 2018;13(8):.\nPersistierender Aszites nach TIPS-Implantation ist pr\u00e4diktiv f\u00fcr ein geringeres transplantationsfreies \u00dcberleben bei Patienten mit Leberzirrhose\nPiecha F, Steins D, Drolz A, Wehmeyer M, Horvatits T, Spink C, Ittrich H, Lohse A, Kluwe J\n2018. Abstractband GASL 2018. 2018. Aufl. Thieme Deutschlnad, .\nConcordance of three alternative gestational age assessments for pregnant women from four African countries: A secondary analysis of the MIPPAD trial\nRada S, Gamper J, Gonz\u00e1lez R, Mombo-Ngoma G, Ou\u00e9draogo S, Kakolwa M, Zoleko-Manego R, Sevene E, Kabanywanyi A, Accrombessi M, Briand V, Cot M, Vala A, Kremsner P, Abdulla S, Massougbodgi A, Nhacolo A, Aponte J, Macete E, Men\u00e9ndez C, Ramharter M\nPLOS ONE. 2018;13(8):e0199243.\nDiabetes mellitus und Impfungen\nRadt C, Salzberger B, Pletz M\n2018.\nDiabetes as risk factor for pancreatic cancer: Hyperglycemia promotes epithelial-mesenchymal-transition and stem cell properties in pancreatic ductal epithelial cells\nRahn S, Zimmermann V, Viol F, Knaack H, Stemmer K, Peters L, Lenk L, Ungefroren H, Saur D, Sch\u00e4fer H, Helm O, Sebens S\nCANCER LETT. 2018;415:129-150.\nArbeits- und Weiterbildungsbedingungen deutscher Assistenz\u00e4rztinnen und -\u00e4rzte in internistischer Weiterbildung - Ergebnisse einer zweiten bundesweiten Befragung durch die Nachwuchsgruppen von DGIM und BDI\nRaspe M, Vogelgesang A, Fendel J, Wei\u00df C, Schulte K, Rolling T\nDEUT MED WOCHENSCHR. 2018;143(7):e42-e50.\nA rare case of septic shock due to Neisseria meningitidis serogroup B infection despite prior vaccination in a young adult with paroxysmal nocturnal haemoglobinuria receiving eculizumab\nReher D, Fuhrmann V, Kluge S, Nierhaus A\nVACCINE. 2018;36(19):2507-2509.\nColitis Ulcerosa \u2013 Behandlung nach der aktuellen S3-Leitlinie\nReher D, Manthey C, Bl\u00e4ker M, Huber S\nHamb \u00c4rztebl. 2018;(11):22-24.\nImmunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature\nReher D, Schramm C, Brinkert F, Weidemann S, Plauth M, Lohse A, Weiler-Normann C\nGastroHep. 2018;1(1):33-44.\nImmunosuppression as efficient therapy for Eosinophilic Cholangitis: A case series and review of the literature\nReher D, Schramm C, Brinkert F, Weidemann S, Plauth M, Lohse A, Weiler-Normann C\n2018. Zeitschrift f\u00fcr Gastroenterologie. 01. Aufl. Georg Thieme Verlag KG, E2-E89.\nOutbreak of Crimean-Congo haemorrhagic fever with atypical clinical presentation in the Karak District of Khyber Pakhtunkhwa, Pakistan\nRehman K, Bettani M, Veletzky L, Afridi S, Ramharter M\nINFECT DIS POVERTY. 2018;7(1):116.\nLeishmaniasis in Northern Syria during Civil War\nRehman K, Walochnik J, Mischlinger J, Alassil B, Allan R, Ramharter M\nEMERG INFECT DIS. 2018;24(11):1973-1981.\nThe Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases\nRoncarolo M, Gregori S, Bacchetta R, Battaglia M, Gagliani N\nIMMUNITY. 2018;49(6):1004-1019.\nTissue-resident NK cells differ in their expression profile of the nutrient transporters Glut1, CD98 and CD71\nSalzberger W, Martrus G, Bachmann K, Goebels H, He\u00df L, Koch M, Langeneckert A, Lunemann S, Oldhafer K, Pfeifer C, Poch T, Richert L, Schramm C, Wahib R, Bunders M, Altfeld M\nPLOS ONE. 2018;13(7):e0201170.\nDiagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease\nSalzer H, Burchard G, Cornely O, Lange C, Rolling T, Schmiedel S, Libman M, Capone D, Le T, Dalcolmo M, Heyckendorf J\nRESPIRATION. 2018;96(3):283-301.\nEpidemiological aspects of travel-related systemic endemic mycoses: a GeoSentinel analysis, 1997-2017.\nSalzer H, Stoney R, Angelo K, Rolling T, Grobusch M, Libman M, L\u00f3pez-V\u00e9lez R, Duvignaud A, \u00c1sgeirsson H, Crespillo-And\u00fajar C, Schwartz E, Gautret P, Bottieau E, Jordan S, Lange C, Hamer D\nJ TRAVEL MED. 2018;25(1):.\nAutoimmune Hepatitis\nSanyal A, Boyer T, Lindor K, Terrault N, Lohse A, Weiler-Normann C\n2018. Zakim and Boyer's Hepatology. 7. Aufl. Philadelphia: Elsevier, .\nDisease duration and stage influence bone microstructure in patients with primary biliary cholangitis\nSchmidt T, Schmidt C, Schmidt F, Butscheidt S, Mussawy H, Hubert J, Hawellek T, Oehler N, Barvencik F, Lohse A, Schinke T, Schramm C, Amling M, Rolvien T\nJ BONE MINER RES. 2018;33(6):1011-1019.\nVirtual Endoscopy Based on 3-dimensional Reconstruction of Histopathology Features of Endoscopic Resection Specimens\nSchmitz R, Krause J, Krech T, R\u00f6sch T\nGASTROENTEROLOGY. 2018;154(5):1234-1236.e4.\nBile Acids, the Microbiome, Immunity, and Liver Tumors\nSchramm C\nNEW ENGL J MED. 2018;379(9):888-890.\nVariant syndromes of primary biliary cholangitis\nSchulz L, Sebode M, Weidemann S, Lohse A\nBEST PRACT RES CL GA. 2018;34-35:55-61.\nAutoimmune hepatitis: From current knowledge and clinical practice to future research agenda\nSebode M, Hartl J, Vergani D, Lohse A\nLIVER INT. 2018;38(1):15-22.\nAutoantibodies in Autoimmune Liver Disease-Clinical and Diagnostic Relevance\nSebode M, Weiler-Normann C, Liwinski T, Schramm C\nFRONT IMMUNOL. 2018;9:609.\nCommensal Bacteria-Specific CD4 T Cell Responses in Health and Disease\nSorini C, Cardoso R, Gagliani N, Villablanca E\nFRONT IMMUNOL. 2018;9:2667.\nRole of IL-10 Receptor Signaling in the Function of CD4+ T-Regulatory Type 1 cells: T-Cell Therapy in Patients with Inflammatory Bowel Disease\nSoukou S, Brockmann L, Bedke T, Gagliani N, Flavell R, Huber S\nCRIT REV IMMUNOL. 2018;38(5):415-431.\nMucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype\nSowa M, Kolenda R, Baumgart D, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos D, Mytilinaiou M, Hammermann J, Laass M, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P\nFRONT IMMUNOL. 2018;9:1959.\nCorrection: Genetic Variants in PNPLA3 and TM6SF2 Predispose to the Development of Hepatocellular Carcinoma in Individuals With Alcohol-Related Cirrhosis\nStickel F, Buch S, Nischalke H, Weiss K, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein M, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan M, Hampe J\nAM J GASTROENTEROL. 2018;113(7):1099.\nGenetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis\nStickel F, Buch S, Nischalke H, Weiss K, Gotthardt D, Fischer J, Rosendahl J, Marot A, Elamly M, Casper M, Lammert F, McQuillin A, Zopf S, Spengler U, Marhenke S, Kirstein M, Vogel A, Eyer F, von Felden J, Wege H, Buch T, Schafmayer C, Braun F, Deltenre P, Berg T, Morgan M, Hampe J\nAM J GASTROENTEROL. 2018;113(10):1475-1483.\nHistology and Serum Cytokine Responses in an Imported Infection, Germany\nTappe D, Booken N, B\u00f6er-Auer A, Rauch J, Schmiedel S, Reich K\nAM J TROP MED HYG. 2018;98(1):248-251.\nDalbavancin as Primary and Sequential Treatment for Gram-Positive Infective Endocarditis: 2-Year Experience at the General Hospital of Vienna\nTobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen M, Winkler S, Thalhammer F\nCLIN INFECT DIS. 2018;67(5):795-798.\nMolecular evidence for relapse of an imported Plasmodium ovale wallikeri infection\nVeletzky L, Groger M, Lagler H, Walochnik J, Auer H, Fuehrer H, Ramharter M\nMALARIA J. 2018;17:78.\nSpecific cholecystitis: An unusual presentation of extrapulmonary tuberculosis\nVeletzky L, \u00d6sterreicher Z, Mayer K, Ba-Ssalamah A, Ramharter M, Winkler S\nINT J INFECT DIS. 2018;77:16-17.\nProphylaxe und Therapie der Malaria: aktuelle Empfehlungen\nVinnemeier C, Rolling T\nDEUT MED WOCHENSCHR. 2018;143(7):472-475.\nRegulation of IL-22BP in psoriasis\nVoglis S, Moos S, Kloos L, Wanke F, Zayoud M, Pelczar P, Giannou A, Pezer S, Albers M, Luessi F, Huber S, Sch\u00e4kel K, Kurschus F\nSCI REP-UK. 2018;8:5085.\nSuccessful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn's disease and short bowel syndrome\nvon Felden J, Scheurich C, Yamamura J, Brainard D, Mogalian E, Lohse A, Schulze Zur Wiesch J\nJ VIRAL HEPATITIS. 2018;25(2):214-215.\nHigh efficacy of sofosbuvir/velpatasvir and impact of baseline resistance-associated substitutions in hepatitis C genotype 3 infection\nvon Felden J, Vermehren J, Ingiliz P, Mauss S, Lutz T, Simon K, Busch H, Baumgarten A, Schewe K, Hueppe D, Boesecke C, Rockstroh J, Daeumer M, Luebke N, Timm J, Schulze Zur Wiesch J, Sarrazin C, Christensen S\nALIMENT PHARM THER. 2018;47(9):1288-1295.\nEditorial: genotype 3 HCV-who still needs ribavirin in a pan-genotypic era? Authors' reply.\nvon Felden J, Vermehren J, Schulze Zur Wiesch J, Sarrazin C, Christensen S\nALIMENT PHARM THER. 2018;47(11):1550-1551.\nHepatitis E: Still Waters Run Deep\nvon Wulffen M, Westh\u00f6lter D, L\u00fctgehetmann M, Pischke S\nJ CLIN TRANSL HEPATO. 2018;6(1):40-47.\nComprehensive Molecular Approach for Characterization of Hepatitis E Virus Genotype 3 Variants\nWang B, Harms D, Papp C, Niendorf S, Jacobsen S, L\u00fctgehetmann M, Pischke S, Wedermeyer H, Hofmann J, Bock C\nJ CLIN MICROBIOL. 2018;56(5):e01686-17.\nNeue Optionen in der Systemtherapie des hepatozellul\u00e4ren Karzinoms\nWege H, Schulze K\nTUMORDIAGN THER. 2018;9(39):590-594.\nTime trend of reported cases and publications: hepatitis E in comparison to hepatitis A - D in Germany from 2001 to 2016\nWehmeyer M, Hartl J, von Wulffen M, Lohse A, Pischke S\nZ GASTROENTEROL. 2018;56(1):29-35.\nReal-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03)\nWehmeyer M, Ingiliz P, Christensen S, Hueppe D, Lutz T, Simon K, Schewe K, Boesecke C, Baumgarten A, Busch H, Rockstroh J, Schmutz G, Kimhofer T, Berger F, Mauss S, Schulze Zur Wiesch J\nJ MED VIROL. 2018;90(2):304-312.\nAcute hepatitis as a prequel to very severe aplastic anemia\nWeiler-Normann C, Hartl J, Weidemann S, von Pein U, Fiedler W, Schramm C, Brinkert F, Kr\u00f6ger N, Christopeit M\nZ GASTROENTEROL. 2018;56(1):51-54.\nCultural differences in food and shape related attitudes and eating behavior are associated with differences of Body Mass Index in the same food Environment cross-sectional results from the Seafarer Nutrition Study of Kiribati and European seafarers on merchant ships.\nWestenhoefer J, von Katzler R, Jensen H, Zyriax B, Jagemann B, Harth V, Oldenburg M\nBMC Obesity . 2018;5:1.\nHEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients\nWesth\u00f6lter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Bl\u00f6cker J, Schulze Zur Wiesch J, Fischer N, Addo M, Peine S, G\u00f6ke B, Lohse A, L\u00fctgehetmann M, Pischke S\nJ HEPATOL. 2018;69(1):36-42.\nCEACAM1 promotes melanoma metastasis and is involved in the regulation of the EMT associated gene network in melanoma cells\nWicklein D, Otto B, Suling A, Elies E, L\u00fcers G, Lange T, Feldhaus S, Maar H, Schr\u00f6der-Schwarz J, Brunner G, Wagener C, Schumacher U\nSCI REP-UK. 2018;8:11893.\nPreclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection\nWiner B, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low B, Johnson H, Huang T, Hrebikova G, Heller B, Sharon Y, Giersch K, Gerges S, Seneca K, Pais M, Frankel A, Chiriboga L, Cullen J, Nahass R, Lutgehetmann M, Toettcher J, Wiles M, Schwartz R, Ploss A\nSCI TRANSL MED. 2018;10(447):eaap9328.\nRecipe for IBD: can we use food to control inflammatory bowel disease\nWitkowski M, Witkowski M, Gagliani N, Huber S\nSEMIN IMMUNOPATHOL. 2018;40(2):145-156.\nCD32 Expression of Different Memory T Cell Subpopulations in the Blood and Lymph Nodal Tissue of HIV Patients and Healthy Controls Correlates With Immune Activation\nWittner M, Dunay G, Kummer S, Bockhorn M, H\u00fcfner A, Schmiedel S, Degen O, van Lunzen J, Eberhard J, Schulze Zur Wiesch J\nJAIDS-J ACQ IMM DEF. 2018;77(4):345-349.\nLoss of complex O-glycosylation impairs exocrine pancreatic function and induces MODY8-like diabetes in mice\nWolters-Eisfeld G, Mercanoglu B, Hofmann B, Wolpers T, Schnabel C, Harder S, Steffen P, Bachmann K, Steglich B, Schrader J, Gagliani N, Schl\u00fcter H, G\u00fcng\u00f6r C, Izbicki J, Wagener C, Bockhorn M\nEXP MOL MED. 2018;50(10):1-13.\nFollow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret\nZenouzi R, Liwinski T, Yamamura J, Weiler-Normann C, Sebode M, Keller S, Lohse A, Schramm C\nALIMENT PHARM THER. 2018;48(2):169-178.\nPatients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure\nZenouzi R, von der Gablentz J, Heldmann M, G\u00f6ttlich M, Weiler-Normann C, Sebode M, Ehlken H, Hartl J, Fellbrich A, Siemonsen S, Schramm C, M\u00fcnte T, Lohse A\nPLOS ONE. 2018;13(1):e0190005.\nIL-33 modulates inflammatory brain injury but exacerbates systemic immunosuppression following ischemic stroke\nZhang S, Piepke M, Chu H, Broughton B, Shim R, Wong C, Lee S, Evans M, Vinh A, Sakkal S, Arumugam T, Magnus T, Huber S, Gelderblom M, Drummond G, Sobey C, Kim H\nJCI INSIGHT. 2018;3(18):.\nStable Frequencies of HLA-C*03:04/Peptide-Binding KIR2DL2/3+ Natural Killer Cells Following Vaccination\nZiegler M, Gra\u00f1ana F, Garcia-Beltran W, Schulze Zur Wiesch J, Hoffmann C, Rechtien A, Lunemann S, Altfeld M\nFRONT IMMUNOL. 2018;9:2361.\nEbola-Impfstoff-Entwicklung: Im Krisenfall schnell, aber mit hohem Sicherheitsanspruch\nZinser M, Borregaard S, Dahlke C, Addo M\nDTSCH ARZTEBL INT. 2018;115(Supplement: Perspektiven der Infektiologie):27-28.\nFood offerings on board and dietary intake of European and Kiribati seafarers - cross-sectional data from the seafarer Nutrition study.\nZyriax B, von Katzler R, Jagemann B, Westenhoefer J, Jensen H, Harth V, Oldenburg M\nJ OCCUP MED TOXICOL. 2018;13:9.\nRole of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline\nJ HEPATOL. 2017;66(6):1265-1281.\nRole of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline\nAabakken L, Karlsen T, Albert J, Arvanitakis M, Chazouilleres O, Dumonceau J, F\u00e4rkkil\u00e4 M, Fickert P, Hirschfield G, Laghi A, Marzioni M, Fernandez M, Pereira S, Pohl J, Poley J, Ponsioen C, Schramm C, Swahn F, Tringali A, Hassan C\nENDOSCOPY. 2017;49(6):588-608.\nSafety and immunogenicity of rVSV\u0394G-ZEBOV-GP Ebola vaccine in adults and children in Lambar\u00e9n\u00e9, Gabon: A phase I randomised trial\nAgnandji S, Fernandes J, Bache E, Obiang Mba R, Brosnahan J, Kabwende L, Pitzinger P, Staarink P, Massinga-Loembe M, Kr\u00e4hling V, Biedenkopf N, Fehling S, Strecker T, Clark D, Staines H, Hooper J, Silvera P, Moorthy V, Kieny M, Adegnika A, Grobusch M, Becker S, Ramharter M, Mordm\u00fcller B, Lell B, Krishna S, , Kremsner P\nPLOS MED. 2017;14(10):e1002402.\nThe Role of cccDNA in HBV Maintenance\nAllweiss L, Dandri M\nVIRUSES-BASEL. 2017;9(6):.\nImmunofluorescent Staining for the Detection of the Hepatitis B Core Antigen in Frozen Liver Sections of Human Liver Chimeric Mice\nAllweiss L, L\u00fctgehetmann M, Dandri M\nMethods Mol Biol. 2017;1540:135-142.\nImproved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study\nAndresen-Streichert H, Beres Y, Weinmann W, Schr\u00f6ck A, M\u00fcller A, Skopp G, Pischke S, Vettorazzi E, Lohse A, Nashan B, Sterneck M\nTRANSPL INT. 2017;30(6):611-620.\nAcute HIV-1 infection is associated with increased plasma levels of heme oxygenase-1 and presence of heme oxygenase-1-specific regulatory T cells\nAngin M, Fathi A, King M, Ledoux M, Piechocka-Trocha A, Altfeld M, Addo M\nAIDS. 2017;31(5):635-641.\nExacerbation of hepatitis E virus infection during anti-TNF\u03b1 treatment\nBehrendt P, L\u00fcth S, Dammermann W, Drave S, Brown R, Todt D, Schnoor U, Steinmann E, Wedemeyer H, Pischke S, Iking-Konert C\nJOINT BONE SPINE. 2017;84(2):217-219.\nTLR7-mediated activation of XBP1 correlates with the IFN\u03b1 production in humans\nBeisel C, Ziegler S, Martrus Zapater G, Chapel A, Griesbeck M, Hildebrandt H, Lohse A, Altfeld M\nCYTOKINE. 2017;94:55-58.\nIL-6 trans-signaling is essential for the development of hepatocellular carcinoma in mice\nBergmann J, M\u00fcller M, Baumann N, Reichert M, Heneweer C, Bolik J, L\u00fccke K, Gruber S, Carambia A, Boretius S, Leuschner I, Becker T, Rabe B, Herkel J, Wunderlich F, Mittr\u00fccker H, Rose-John S, Schmidt-Arras D\nHEPATOLOGY. 2017;65(1):89-103.\nLong-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study\nBerg T, Simon K, Mauss S, Schott E, Heyne R, Klass D, Eisenbach C, Welzel T, Zachoval R, Felten G, Schulze-Zur-Wiesch J, Cornberg M, Op den Brouw M, Jump B, Reiser H, Gallo L, Warger T, Petersen J\nJ HEPATOL. 2017;67(5):918-924.\nScreening and contact precautions - A survey on infection control measures for multidrug-resistant bacteria in German university hospitals\nBiehl L, Bertz H, Bogner J, Dobermann U, Kessel J, Kr\u00e4mer C, Lemmen S, von Lilienfeld-Toal M, Peter S, Pletz M, Rohde H, Schmiedel S, Schubert S, Ullmann A, F\u00e4tkenheuer G, Vehreschild M\nANTIMICROB RESIST IN. 2017;6:37.\nLiver Cirrhosis as a Risk Factor for Direct-Acting Antiviral Therapy Failure in Real-Life Hepatitis C Virus/Human Immunodeficiency Virus Coinfection\nBoesecke C, Ingiliz P, Berger F, Lutz T, Schewe K, Schulze Zur Wiesch J, Baumgarten A, Christensen S, Rockstroh J, Mauss S\nOPEN FORUM INFECT DI. 2017;4(3):ofx158.\nHRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and migration in colorectal cancer\nBogoevska V, Wolters-Eisfeld G, Hofmann B, El Gammal A, Mercanoglu B, Gebauer F, Vashist Y, Bogoevski D, Perez D, Gagliani N, Izbicki J, Bockhorn M, G\u00fcng\u00f6r C\nONCOGENE. 2017;36(17):2394-2404.\nMacrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells\nBosurgi L, Cao Y, Cabeza-Cabrerizo M, Tucci A, Hughes L, Kong Y, Weinstein J, Licona-Limon P, Schmid E, Pelorosso F, Gagliani N, Craft J, Flavell R, Ghosh S, Rothlin C\nSCIENCE. 2017;356(6342):1072-1076.\nDeath begets a new beginning\nBosurgi L, Hughes L, Rothlin C, Ghosh S\nIMMUNOL REV. 2017;280(1):8-25.\nHIV und Malaria: Auswirkungen und Interaktionen zwischen Antimalariamedikamenten und antiretroviraler Therapie\nBrehm T, Schmiedel S\nFLUGMEDIZIN TROPENME. 2017;24(5):230-233.\nNotfallm\u00e4\u00dfige Selbstbehandlung f\u00fcr Reisende in Malariagebiete mit geringem Transmissionsrisiko\nBrehm T, Vinnemeier C, Rolling T\nFLUGMEDIZIN TROPENME. 2017;24(05):227-229.\nMobile phone-based interactive voice response as a tool for improving access to healthcare in remote areas in Ghana - an evaluation of user experiences\nBrinkel J, May J, Krumkamp R, Lamsh\u00f6ft M, Kreuels B, Owusu-Dabo E, Mohammed A, Bonacic Marinovic A, Dako-Gyeke P, Kr\u00e4mer A, Fobil J\nTROP MED INT HEALTH. 2017;22(5):622-630.\nIL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo\nBrockmann L, Gagliani N, Steglich B, Giannou A, Kempski J, Pelczar P, Geffken M, Mfarrej B, Huber F, Herkel J, Wan Y, Esplugues E, Battaglia M, Krebs C, Flavell R, Huber S\nJ IMMUNOL. 2017;198(3):1130-1141.\nRegulation of TH17 Cells and Associated Cytokines in Wound Healing, Tissue Regeneration, and Carcinogenesis\nBrockmann L, Giannou A, Gagliani N, Huber S\nINT J MOL SCI. 2017;18(5):.\nMetabolic Circuit Involving Free Fatty Acids, microRNA 122, and Triglyceride Synthesis in Liver and Muscle Tissues\nChai C, Rivkin M, Berkovits L, Simerzin A, Zorde-Khvalevsky E, Rosenberg N, Klein S, Yaish D, Durst R, Shpitzen S, Udi S, Tam J, Heeren J, Worthmann A, Schramm C, Kluwe J, Ravid R, Hornstein E, Giladi H, Galun E\nGASTROENTEROLOGY. 2017;153(5):1404-1415.\nPeptide-specific engagement of the activating NK cell receptor KIR2DS1\nChapel A, Garcia-Beltran W, H\u00f6lzemer A, Ziegler M, Lunemann S, Martrus G, Altfeld M\nSCI REP-UK. 2017;7(1):2414.\nMolecular profiling of liver cancer heterogeneity\nCraig A, von Felden J, Villanueva A\nDISCOV MED. 2017;24(131):117-125.\nDose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization\nDahlke C, Kasonta R, Lunemann S, Kr\u00e4hling V, Zinser M, Biedenkopf N, Fehling S, Ly M, Rechtien A, Stubbe H, Olearo F, Borregaard S, Jambrecina A, Stahl F, Strecker T, Eickmann M, L\u00fctgehetmann M, Spohn M, Schmiedel S, Lohse A, Becker S, Addo M\nEBIOMEDICINE. 2017;19:107-118.\nComprehensive characterization of cellular immune responses following Ebola virus infection\nDahlke C, Lunemann S, Kasonta R, Kreuels B, Schmiedel S, Ly M, Fehling S, Strecker T, Becker S, Altfeld M, Sow A, Lohse A, Mu\u00f1oz-Fontela C, Addo M\nJ INFECT DIS. 2017;215(2):287-292.\nAutoantibodies against \"rods and rings\"-related IMPDH2 in hepatitis C genotype 1 and DAA therapy in a \"real life\" cohort\nDammermann W, Polywka S, Dettmann I, Mindorf S, Komorowski L, Wehmeyer M, Schulze Zur Wiesch J, St\u00f6cker W, L\u00fcth S\nMED MICROBIOL IMMUN. 2017;206(5):379-382.\nAnimal models of HBV infection\nDandri M, Petersen J\nBEST PRACT RES CL GA. 2017;31(3):273-279.\nLedipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV) an open-label, single-arm, phase 2 study\nDeterding K, Spinner C, Schott E, Welzel T, Gerken G, Klinker H, Spengler U, Wiegand J, Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Z\u00f6llner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns M, Wedemeyer H\nLANCET INFECT DIS. 2017;17(2):215-222.\nIncreased frequency of CD39+ CD56 bright Natural Killer cells in HIV-1 infection correlates with immune activation and disease progression\nDierks P, Wroblewski R, Eberhard J, Martrus G, Degen O, Hertling S, Schmiedel S, Lunemann S, H\u00fcfner A, Lohse A, Altfeld M, van Lunzen J, Schulze Zur Wiesch J\nJAIDS-J ACQ IMM DEF. 2017;74(4):467-472.\nClostridium difficile - Infektionen an der Intensivstation\nDranova D, Manthey C, Fuhrmann V\n2017. DIVI-Jahrbuch 2017/2018. Kluge S, Markewitz A, Schwab S, Putensen C, Quintel M, Sybrecht G (Hrsg.). 1. Aufl. Mwv Medizinisch Wissenschaftliche Verlagsges, 413-423.\nHuman Leukocyte Antigen F Presents Peptides and Regulates Immunity through Interactions with NK Cell Receptors\nDulberger C, McMurtrey C, H\u00f6lzemer A, Neu K, Liu V, Steinbach A, Garcia-Beltran W, Sulak M, Jabri B, Lynch V, Altfeld M, Hildebrand W, Adams E\nIMMUNITY. 2017;46(6):1018-1029.e7.\nAssessment of the HIV-1 reservoir in CD4+ regulatory T cells by a Droplet Digital PCR based approach\nDunay G, Solomatina A, Kummer S, H\u00fcfner A, Bialek J, Eberhard J, Tolosa E, Hauber J, Wiesch J\nVIRUS RES. 2017;240:107-111.\nRisk of cholangiocarcinoma in patients with primary sclerosing cholangitis: diagnosis and surveillance\nEhlken H, Zenouzi R, Schramm C\nCURR OPIN GASTROEN. 2017;33(2):78-84.\nnorUrsodeoxycholic Acid Improves Cholestasis in Primary Sclerosing Cholangitis\nFickert P, Hirschfield G, Denk G, Marschall H, Altorjay I, F\u00e4rkkil\u00e4 M, Schramm C, Spengler U, Chapman R, Bergquist A, Schrumpf E, Nevens F, Trivedi P, Reiter F, Tornai I, Halilbasic E, Greinwald R, Pr\u00f6ls M, Manns M, Trauner M\nJ HEPATOL. 2017;67(3):549-558.\nBasic Aspects of T Helper Cell Differentiation\nGagliani N, Huber S\nMethods Mol Biol. 2017;1514:19-30.\nSerum HBV pgRNA as a clinical marker for cccDNA activity\nGiersch K, Allweiss L, Volz T, Dandri-Petersen M, L\u00fctgehetmann M\nJ HEPATOL. 2017;66(2):460-462.\nBoth interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice\nGiersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse A, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, L\u00fctgehetmann M\nSCI REP-UK. 2017;7(1):3757.\nGingival fibroblasts protect against experimental abdominal aortic aneurysm development and rupture through tissue inhibitor of metalloproteinase-1 production\nGiraud A, Zeboudj L, Vandestienne M, Joffre J, Esposito B, Potteaux S, Vilar J, Cabuzu D, Kluwe J, Seguier S, Tedgui A, Mallat Z, Lafont A, Ait-Oufella H\nCARDIOVASC RES. 2017;113(11):1364-1375.\nActivation of the Akt-CREB signalling axis by a proline-rich heptapeptide confers resistance to stress-induced cell death and inflammation\nHerkel J, Schrader J, Erez N, Lohse A, Cohen I\nIMMUNOLOGY. 2017;151(4):474-480.\nBurden of influenza among hospitalized febrile children in Ghana\nHogan B, Ammer L, Zimmermann M, Binger T, Krumkamp R, Sarpong N, Rettig T, Dekker D, Kreuels B, Reigl L, Boahen K, Wiafe C, Adu-Sarkodie Y, Owusu-Dabo E, May J, Eibach D\nINFLUENZA OTHER RESP. 2017;11(6):497-501.\nNatural Killer Cell Interactions with Classical and Non-Classical Human Leukocyte Antigen Class I in HIV-1 Infection\nH\u00f6lzemer A, Garcia-Beltran W, Altfeld M\nFRONT IMMUNOL. 2017;8:1496.\nCD4+ T Helper Cell Plasticity in Infection, Inflammation, and Autoimmunity\nHuber S, Gagliani N, O'Connor W, Geginat J, Caprioli F\nMEDIAT INFLAMM. 2017;2017:7083153.\nChronicles of Cell Death Foretold: Specificities in the Mechanism of Disposal\nHughes L, Bosurgi L, Ghosh S, Rothlin C\nFRONT IMMUNOL. 2017;8:1743.\nMedizinische Versorgung von Fl\u00fcchtlingen. Chancen und Herausforderungen in Hamburg \u2013 ein Praxisbericht\nJakubowski E, Rau C, Quellhorst S, Sothmann P, Plenge-B\u00f6nig A, Niessen J\nGESUNDHEITSWESEN. 2017;79(8-09):599-604.\nGenome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease\nJi S, Juran B, Mucha S, Folseraas T, Jostins L, Melum E, Kumasaka N, Atkinson E, Schlicht E, Liu J, Shah T, Gutierrez-Achury J, Boberg K, Bergquist A, Vermeire S, Eksteen B, Durie P, Farkkila M, M\u00fcller T, Schramm C, Sterneck M, Weism\u00fcller T, Gotthardt D, Ellinghaus D, Braun F, Teufel A, Laudes M, Lieb W, Jacobs G, Beuers U, Weersma R, Wijmenga C, Marschall H, Milkiewicz P, Pares A, Kontula K, Chazouill\u00e8res O, Invernizzi P, Goode E, Spiess K, Moore C, Sambrook J, Ouwehand W, Roberts D, Danesh J, Floreani A, Gulamhusein A, Eaton J, Schreiber S, Coltescu C, Bowlus C, Luketic V, Odin J, Chopra K, Kowdley K, Chalasani N, Manns M, Srivastava B, Mells G, Sandford R, Alexander G, Gaffney D, Chapman R, Hirschfield G, de Andrade M, Rushbrook S, Franke A, Karlsen T, Lazaridis K, Anderson C\nNAT GENET. 2017;49(2):269-273.\nSomalischer Fl\u00fcchtling mit Fieber und auff\u00e4lligem Blutausstrich\nJochum J, Tannich E, Tappe D, Schmiedel S\nINTERNIST. 2017;58(3):287-292.\nLymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection\nKah J, Koh S, Volz T, Ceccarello E, Allweiss L, L\u00fctgehetmann M, Bertoletti A, Dandri M\nJ CLIN INVEST. 2017;127(8):3177-3188.\nHeme oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice\nKah J, Volz T, L\u00fctgehetmann M, Groth A, Lohse A, Tiegs G, Sass G, Dandri-Petersen M\nLIVER INT. 2017;37(8):1128-1137.\nRisk factors for excessively prolonged meropenem use in the intensive care settinga case-contol study\nKatchanov J, Kreuels B, Maurer F, W\u00f6stmann K, Jochum J, K\u00f6nig C, Seoudy K, Rohde H, Lohse A, Wichmann D, Baehr M, Rothe C, Kluge S\nBMC INFECT DIS. 2017;17(1):131.\nTH17 Cell and Epithelial Cell Crosstalk during Inflammatory Bowel Disease and Carcinogenesis\nKempski J, Brockmann L, Gagliani N, Huber S\nFRONT IMMUNOL. 2017;8:1373.\nDown-regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression\nKim E, Ackermann C, T\u00f3th I, Dierks P, Eberhard J, Wroblewski R, Scherg F, Geyer M, Schmidt R, Beisel C, Bockhorn M, Haag F, Lunzen J, Schulze Zur Wiesch J\nJ LEUKOCYTE BIOL. 2017;101(5):1263-1271.\nA Protective Function of IL-22BP in Ischemia Reperfusion and Acetaminophen-Induced Liver Injury\nKleinschmidt D, Giannou A, McGee H, Kempski J, Steglich B, Huber F, Ernst T, Shiri A, Wegscheid C, Tasika E, H\u00fcbener P, Huber P, Bedke T, Steffens N, Agalioti T, Fuchs T, Noll J, Lotter H, Tiegs G, Lohse A, Axelrod J, Galun E, Flavell R, Gagliani N, Huber S\nJ IMMUNOL. 2017;199(12):4078-4090.\nProtein structure shapes immunodominance in the CD4 T cell response to yellow fever vaccination\nKoblischke M, Mackroth M, Schwaiger J, Fae I, Fischer G, Stiasny K, Heinz F, Aberle J\nSCI REP-UK. 2017;7(1):8907.\nHIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells\nK\u00f6rner C, Simoneau C, Schommers P, Granoff M, Ziegler M, H\u00f6lzemer A, Lunemann S, Chukwukelu J, Corleis B, Naranbhai V, Kwon D, Scully E, Jost S, Kirchhoff F, Carrington M, Altfeld M\nCELL HOST MICROBE. 2017;22(1):111-119.e4.\nThe ABCB4 p.T175A variant as potential modulator of hepatic fibrosis in patients with chronic liver diseases: Looking beyond the cholestatic realm\nKrawczyk M, Rau M, Gr\u00fcnhage F, Schattenberg J, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Geier A, Lammert F\nHEPATOLOGY. 2017;66(2):666-667.\nCombined effects of the TM6SF2 rs58542926, PNPLA3 rs738409 and MBOAT7 rs641738 variants on NAFLD severity: multicentre biopsy-based study\nKrawczyk M, Rau M, Schattenberg J, Bantel H, Pathil A, Demir M, Kluwe J, Boettler T, Lammert F, Geier A\nJ LIPID RES. 2017;58(1):247-255.\nSevere malaria in European 8-year multi-centre observational study\nKurth F, Develoux M, Mechain M, Malvy D, Clerinx J, Antinori S, Gj\u00f8rup I, Gascon J, M\u00f8rch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-N\u00fcbling G, Neumayr A, Hachfeld A, Schmid M, Antonini P, Lingscheid T, Kern P, Kapaun A, da Cunha J, Pongratz P, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T\nMALARIA J. 2017;16(1):57.\nCurrent meningitis outbreak in Ghana: Historical perspectives and the importance of diagnostics\nKwarteng A, Amuasi J, Annan A, Ahuno S, Opare D, Nagel M, Vinnemeier C, May J, Owusu-Dabo E\nACTA TROP. 2017;169:51-56.\nThe hepatic microenvironment essentially determines tumor cell dormancy and metastatic outgrowth of pancreatic ductal adenocarcinoma\nLenk L, Pein M, Will O, Gomez B, Viol F, Hauser C, Egberts J, Gundlach J, Helm O, Tiwari S, Weiskirchen R, Rose-John S, R\u00f6cken C, Mikulits W, Wenzel P, Schneider G, Saur D, Sch\u00e4fer H, Sebens S\nONCOIMMUNOLOGY. 2017;7(1):e1368603.\nExpert clinical management of autoimmune hepatitis in the real world\nLiberal R, de Boer Y, Andrade R, Bouma G, Dalekos G, Floreani A, Gleeson D, Hirschfield G, Invernizzi P, Lenzi M, Lohse A, Macedo G, Milkiewicz P, Terziroli B, van Hoek B, Vierling J, Heneghan M\nALIMENT PHARM THER. 2017;45(5):723-732.\nAutoimmune hepatitis - update on clinical management in 2017\nLiwinski T, Schramm C\nCLIN RES HEPATOL GAS. 2017;41(6):617-625.\nCorrection: Cerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography\nL\u00f6bel U, Forkert N, Schmitt C, Dohrmann T, Schroeder M, Magnus T, Kluge S, Weiler-Normann C, Bi X, Fiehler J, Sedlacik J\nPLOS ONE. 2017;12(2):e0172450.\nCan Understanding the Pathogenesis of Autoimmune Hepatitis Lead to Rational Therapy?\nLohse A, Herkel J, Weiler-Normann C\nDIGEST DIS. 2017;35(4):367-370.\nA randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria\nMacintyre F, Adoke Y, Tiono A, Duong T, Mombo-Ngoma G, Bouyou-Akotet M, Tinto H, Bassat Q, Issifou S, Adamy M, Demarest H, Duparc S, Leroy D, Laurijssens B, Biguenet S, Kibuuka A, Tshefu A, Smith M, Foster C, Leipoldt I, Kremsner P, Phuc B, Ouedraogo A, Ramharter M, , Groger M, Mischlinger J\nBMC MED. 2017;15(1):181.\nMonocytic PDGFR-\u03b1 expression is essential for protection against intestinal inflammation\nManthey C\nZ GASTROENTEROL. 2017.\nTherapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin?\nManthey C, Eckmann L, Fuhrmann V\nEXPERT REV CLIN PHAR. 2017;10(11):1239-1250.\nWichtige aktuelle Leitlinien - kurz erl\u00e4utert\nManthey C, Stallmach A, Lohse A\n2017. Gastroenterologische Infektiologie. L\u00fcbbert C, Vogelmann R (Hrsg.). 1. Aufl. Berlin: Walter de Gruyter GmbH & Co. KG, 505-514.\nCirculating CXCR5(+)CXCR3(+)PD-1(lo) Tfh-like cells in HIV-1 controllers with neutralizing antibody breadth\nMartin-Gayo E, Cronin J, Hickman T, Ouyang Z, Lindqvist M, Kolb K, Schulze Zur Wiesch J, Cubas R, Porichis F, Shalek A, Lunzen J, Haddad E, Walker B, Kaufmann D, Lichterfeld M, Yu X\nJCI INSIGHT. 2017;2(2):e89574.\nProliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells\nMartrus G, Kautz T, Lunemann S, Richert L, Glau L, Salzberger W, Goebels H, Langeneckert A, Hess L, Poch T, Schramm C, Oldhafer K, Koch M, Tolosa E, Nashan B, Altfeld M\nPLOS ONE. 2017;12(8):e0182532.\nEffect of antiviral therapy for HCV on lipid levels\nMauss S, Berger F, Wehmeyer M, Ingiliz P, Hueppe D, Lutz T, Simon K, Schewe K, Rockstroh J, Baumgarten A, Christensen S\nANTIVIR THER. 2017;21(1):81-88.\n3D Hepatic Ultrasonography-A Detailed Imaging Modality\nMeisner S, Pischke S\nDTSCH ARZTEBL INT. 2017;114(19):338.\nTumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours\nMills L, Drymousis P, Vashist Y, Burdelski C, Prachalias A, Srinivasan P, Menon K, Cotoi C, Khan S, Cave J, Armstrong T, Weickert M, Izbicki J, Schrader J, Frilling A, Ramage J, Srirajaskanthan R\nENDOCR CONNECT. 2017;6(8):876-885.\nBlood fibrinogen levels discriminate low- and high-risk intraductal papillary mucinous neoplasms (IPMNs)\nNentwich M, Menzel K, Reeh M, Uzunoglu F, Ghadban T, Bachmann K, Schrader J, Bockhorn M, Izbicki J, Perez D\nEJSO-EUR J SURG ONC. 2017;43(4):758-762.\nA Proinflammatory Role of Type 2 Innate Lymphoid Cells in Murine Immune-Mediated Hepatitis\nNeumann K, Karimi K, Meiners J, Voetlause R, Steinmann S, Dammermann W, L\u00fcth S, Asghari F, Wegscheid C, Horst A, Tiegs G\nJ IMMUNOL. 2017;198(1):128-137.\nThe selective PI3K\u03b1 inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models\nN\u00f6lting S, Rentsch J, Freitag H, Detjen K, Briest F, M\u00f6bs M, Weissmann V, Siegmund B, Auernhammer C, Aristizabal Prada E, Lauseker M, Grossman A, Exner S, Fischer C, Gr\u00f6tzinger C, Schrader J, Grabowski P\nPLOS ONE. 2017;12(8):e0182852.\nTH17 cells express ST2 and are controlled by the alarmin IL-33 in the small intestine\nPascual-Reguant A, Bayat Sarmadi J, Baumann C, Noster R, Cirera-Salinas D, Curato C, Pelczar P, Huber S, Zielinski C, L\u00f6hning M, Hauser A, Esplugues E\nMUCOSAL IMMUNOL. 2017;10(6):1431-1442.\nPotential impact of screening for fatty liver disease by transient elastography with liver stiffness and controlled attenuation parameter measurements: a pilot study\nPeiseler M, Creutzfeldt A, Cassens I, Glaubke C, Kroll C, Lohse A, Weiler-Normann C\nZ GASTROENTEROL. 2017;55(8):754-760.\nAre the benefits of beta blockers in cirrhotics only related to decreased portal Hypertension?\nPiecha F, Mueller S\nAME Medical Journal. 2017.\nVery Severe Secondary Sclerosing Cholangitis as a Sequela of Influenza\nPischke S, Fischer L, Lohse A\nDTSCH ARZTEBL INT. 2017;114(25):429.\nHepatitis E virus infection beyond the liver?\nPischke S, Hartl J, Pas S, Lohse A, Jacobs B, van der Eijk A\nJ HEPATOL. 2017;66(5):1082-1095.\nFactors associated with long-term survival after liver Transplantation, a retrospective cohort study\nPischke S, Lege M, von Wulffen M, Galante A, Otto B, Wehmeyer M, Herden U, Fischer L, Nashan B, Lohse A, Sterneck M\nWORLD J HEPATOL. 2017;9(8):427-435.\nHigh clinical manifestation rate in an imported outbreak of hepatitis E genotype 1 infection in a German group of travellers returning from India\nPischke S, Schulze zur Wiesch J, L\u00fctgehetmann M, Kreuels B, L\u00fcth S, Kapaun P, Benten D, Schmiedel S, Sterneck M, Lohse A, Polywka S\nANN HEPATOL. 2017;16(1):57-62.\nSystems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV\nRechtien A, Richert L, Lorenzo H, Martrus G, Hejblum B, Dahlke C, Kasonta R, Zinser M, Stubbe H, Matschl U, Lohse A, Kr\u00e4hling V, Eickmann M, Becker S, Thi\u00e9baut R, Altfeld M, Addo M\nCELL REP. 2017;20(9):2251-2261.\nReiser\u00fcckkehrer mit Melioidose aus Thailand\nRoggelin L, Jordan S, Ittrich H, Schmiedel S\nFLUGMEDIZIN TROPENME. 2017;24(2):60-63.\nPre-travel advice at a crossroad: Medical preparedness of travellers to South and Southeast-Asia - The Hamburg Airport Survey\nRolling T, M\u00fchlenpfordt M, Addo M, Cramer J, Vinnemeier C\nTRAVEL MED INFECT DI. 2017;18:41-45.\nDistinct Microbial Communities Trigger Colitis Development upon Intestinal Barrier Damage via Innate or Adaptive Immune Cells\nRoy U, G\u00e1lvez E, Iljazovic A, Lesker T, B\u0142a\u017cejewski A, Pils M, Heise U, Huber S, Flavell R, Strowig T\nCELL REP. 2017;21(4):994-1008.\nFaecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis\nR\u00fchlemann M, Heinsen F, Zenouzi R, Lieb W, Franke A, Schramm C\nGUT. 2017;66(4):753-754.\nHelminthic infections in returning travelers and migrants with eosinophilia: Diagnostic value of medical history, eosinophil count and IgE\nSalzer H, Rolling T, Vinnemeier C, Tannich E, Schmiedel S, Addo M, Cramer J\nTRAVEL MED INFECT DI. 2017;20:49-55.\nAkute und Chronische Cholangitis\nSchmiedel S, Sothmann P\n2017. Gastroenterologische Infektiologie. L\u00fcbbert C, Vogelmann R (Hrsg.). 1. Aufl. Berlin: Walter de Gruyter GmbH & Co. KG, 283-296.\nCD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood\nSchoknecht T, Schwinge D, Stein S, Weiler-Normann C, Sebode M, Mucha S, Otto B, Ellinghaus E, Stahl F, Franke A, Lohse A, Herkel J, Schramm C\nJ LEUKOCYTE BIOL. 2017;101(2):589-597.\nSuccessful mTOR inhibitor therapy for a metastastic neuroendocrine tumour in a patient with a germline TSC2 mutation\nSchrader J, Henes F, Perez D, Burdak-Rothkamm S, Stein A, Izbicki J, Lohse A\nANN ONCOL. 2017;28(4):904-905.\nRecommendations on the use of MRI in PSC-A position statement from the International PSC study group\nSchramm C, Eaton J, Ringe K, Venkatesh S, Yamamura J\nHEPATOLOGY. 2017;66(5):1675-1688.\nDie erste deutschsprachige Leitlinie zu autoimmunen Lebererkrankungen\nSchramm C, Strassburg C\nDEUT MED WOCHENSCHR. 2017;142(24):1850-1854.\nDysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related with IL-12 signaling\nSchwinge D, von Haxthausen F, Quaas A, Carambia A, Otto B, Glaser F, H\u00f6h B, Thiele N, Schoknecht T, Huber S, Steffens N, Lohse A, Herkel J, Schramm C\nJ HEPATOL. 2017;66(4):798-805.\n\"Autoimmune(-Like)\" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis: New Insights into Molecular Pathogenesis\nSebode M, Schulz L, Lohse A\nINT J MOL SCI. 2017;18(9):E1954.\nAnti-TNF-\u03b1 for necrotizing sarcoid granulomatosis of the liver\nSebode M, Weidemann S, Wehmeyer M, Lohse A, Schramm C\nHEPATOLOGY. 2017;65(4):1410-1412.\nRickettsia felis Infection in Febrile Children, Ghana\nSothmann P, Keller C, Krumkamp R, Kreuels B, Aldrich C, Sarpong N, Steierberg S, Winter D, Boahen K, Owusu-Dabo E, May J, Eibach D\nAM J TROP MED HYG. 2017;96(4):783-785.\nMigrationsassoziierte Erkrankungen in der Gastroenterologie\nSothmann P, Schmiedel S\n2017. Gastroenterologische Infektiologie. L\u00fcbbert C, Vogelmann R (Hrsg.). 1. Aufl. Berlin: Walter de Gruyter GmbH & Co. KG, 453-466.\nExtending laboratory automation to the wards: effect of an innovative pneumatic tube system on diagnostic samples and transport time\nSuchsland J, Winter T, Greiser A, Streichert T, Otto B, Mayerle J, Runge S, Kallner A, Nauck M, Petersmann A\nCLIN CHEM LAB MED. 2017;55(2):225-230.\nTIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice\nThiele N, Wirth J, Steins D, Koop A, Ittrich H, Lohse A, Kluwe J\nSCI REP-UK. 2017;7(1):714.\nMulti-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model\nThomaschewski M, Riecken K, Unrau L, Volz T, Cornils K, Ittrich H, Heim D, Wege H, Akg\u00fcn E, L\u00fctgehetmann M, Dieckhoff J, K\u00f6pke M, Dandri M, Benten D, Fehse B\nONCOTARGET. 2017;8(70):115582-115595.\nThe influence of PEEP and positioning on central venous pressure and venous hepatic hemodynamics in patients undergoing liver resection\nUkere A, Meisner S, Greiwe G, Opitz B, Benten D, Nashan B, Fischer L, Trepte C, Reuter D, Haas S, Behem C\nJ CLIN MONIT COMPUT. 2017;31(6):1221-1228.\nClinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy\nvan Eijk J, Dalton H, Ripellino P, Madden R, Jones C, Fritz M, Gobbi C, Melli G, Pasi E, Herrod J, Lissmann R, Ashraf H, Abdelrahim M, Masri O, Fraga M, Benninger D, Kuntzer T, Aubert V, Sahli R, Moradpour D, Blasco-Perrin H, Attarian S, G\u00e9rolami R, Colson P, Giordani M, Hartl J, Pischke S, Lin N, Mclean B, Bendall R, Panning M, Peron J, Kamar N, Izopet J, Jacobs B, van Alfen N, van Engelen B\nNEUROLOGY. 2017;89(9):909-917.\nResponse to fever and utilization of standby emergency treatment (SBET) for malaria in travellers to Southeast Asia: a questionnaire-based cohort study\nVinnemeier C, Rothe C, Kreuels B, Addo M, Vygen-Bonnet S, Cramer J, Rolling T\nMALARIA J. 2017;16(1):44.\nHigh expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection\nvon Felden J, Heim D, Schulze K, Krech T, Ewald F, Nashan B, Lohse A, Wege H\nBMC CANCER. 2017;17(1):60.\nCirculating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection\nvon Felden J, Schulze K, Krech T, Ewald F, Nashan B, Pantel K, Lohse A, Riethdorf S, Wege H\nONCOTARGET. 2017;8(52):89978-89987.\nP185 - Kardiovaskul\u00e4res Risiko von Seeleuten \u2013 ein Vergleich zwischen europ\u00e4ischen und kiribatischen Besatzungsmitgliedern: P185\nvon Katzler R, Zyriax B, Jagemann B, Westenh\u00f6fer J, Harth V, Oldenburg M\n2017. Deutsche Gesellschaft f\u00fcr Arbeits- und Umweltmedizin e.V.: Dokumentationsband zur 56. DGAUM-Jahrestagung. Schmitz-Spanke S (Hrsg.). 1. Aufl. 614-615.\nV232 Aktivit\u00e4ts- und Schlafmonitoring auf Kauffahrteischiffen - Ergebnisse aus der SeaNut Studie\nvon Katzler R, Zyriax B, Jagemann B, Westenh\u00f6fer J, Jensen H, Harth V, Oldenburg M\n2017. Dokumentationsband zur 57. DGAUM-Jahrestagung. Harth V, Heidrich J (Hrsg.). Gentner Verlag, 43.\nChronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation\nWehmeyer M, Dammermann W, Seiz O, Zinser M, Galante A, Lohse A, Sterneck M, Nashan B, Herden U, L\u00fcth S\nPANCREATOLOGY. 2017;17(6):898-904.\nPatient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis\nWeism\u00fcller T, Trivedi P, Bergquist A, Imam M, Lenzen H, Ponsioen C, Holm K, Gotthardt D, F\u00e4rkkil\u00e4 M, Marschall H, Thorburn D, Weersma R, Fevery J, Mueller T, Chazouill\u00e8res O, Schulze K, Lazaridis K, Almer S, Pereira S, Levy C, Mason A, Naess S, Bowlus C, Floreani A, Halilbasic E, Yimam K, Milkiewicz P, Beuers U, Huynh D, Pares A, Manser C, Dalekos G, Eksteen B, Invernizzi P, Berg C, Kirchner G, Sarrazin C, Zimmer V, Fabris L, Braun F, Marzioni M, Juran B, Said K, Rupp C, Jokelainen K, Benito de Valle M, Saffioti F, Cheung A, Trauner M, Schramm C, Chapman R, Karlsen T, Schrumpf E, Strassburg C, Manns M, Lindor K, Hirschfield G, Hansen B, Boberg K\nGASTROENTEROLOGY. 2017;152(8):1975-1984.e8.\nSynergistische Therapiewirkung der Kombination des Hsp90 Inhibitor AUY922 und des PI3K Inhibitors BYL719 mit Everolimus bei neuroendokrinen Tumoren\nWei\u00dfmann V, Benten D, Wolters-Eisfeld G, Perez D, Izbicki J, Lohse A, Schrader J\nZ GASTROENTEROL. 2017;55(08):KV 402.\nEarly adverse events of per-oral endoscopic myotomy\nWerner Y, von Renteln D, Noder T, Schachschal G, Denzer U, Groth S, Nast J, Kersten J, Petzoldt M, Adam G, Mann O, Repici A, Hassan C, R\u00f6sch T\nGASTROINTEST ENDOSC. 2017;85(4):708-718.\nV101 Kulturelle Unterschiede in der Einstellung zum Essen und zur Figur sowie im Essverhalten bei Seeleuten aus Kiribati und Europa - Ergebnisse aus der Seafarer Nutrition Study.\nWestenh\u00f6fer J, von Katzler R, Jagemann B, Zyriax B, Jensen H, Harth V, Oldenburg M\n2017. Dokumentationsband zur 57. DGAUM-Jahrestagung. Harth V, Heidrich J (Hrsg.). 1. Aufl. Gentner Verlag, 42-43.\nIntensivmedizinische Behandlung eines Patienten mit Ebola-Virusinfektion in Deutschland\nWichmann D, Kreuels B, Schmiedel S, Kluge S\nMED KLIN-INTENSIVMED. 2017;112(1):38-41.\nInfluence of Liver Disease on Perioperative Outcome After Bariatric Surgery in a Northern German Cohort\nWolter S, Dupr\u00e9e A, Coelius C, El Gammal A, Kluwe J, Sauer N, Mann O\nOBES SURG. 2017;27(1):90-95.\nCold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis\nWorthmann A, John C, R\u00fchlemann M, Baguhl M, Heinsen F, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C, Fischer M, Dandri M, Kremoser C, Scheja L, Franke A, Shaul P, Heeren J\nNAT MED. 2017;23(7):839-849.\nDer besondere Fall: Ein tierisch gef\u00e4hrlicher Kuss\nXiong T, Schnoor U, Jochum J, Janneck M\nHamb \u00c4rztebl. 2017;2017(5):30-31.\nIntestinal type 1 regulatory T cells migrate to periphery to suppress diabetogenic T cells and prevent diabetes development\nYu H, Gagliani N, Ishigame H, Huber S, Zhu S, Esplugues E, Herold K, Wen L, Flavell R\nP NATL ACAD SCI USA. 2017;114(39):10443-10448.\nHuman pDCs display sex-specific differences in type I interferon subtypes and interferon \u03b1/\u03b2 receptor expression\nZiegler S, Beisel C, Sutter K, Griesbeck M, Hildebrandt H, Hagen S, Dittmer U, Altfeld M\nEUR J IMMUNOL. 2017;47(2):251-256.\nV129 Erhebungen zu Ern\u00e4hrung, Anthropometrie und kardiovaskul\u00e4rem Risiko in der Seafarer Nutrition Study.\nZyriax B, von Katzler R, Jagemann B, Westenh\u00f6fer J, Jensen H, Harth V, Oldenburg M\n2017. Dokumentationsband zur 57. DGAUM-Jahrestagung . Harth V, Heidrich J (Hrsg.). 1. Aufl. Gentner Verlag, 42.\nViren \u00fcberlisten: Globale Virusinfektionen werden beherrschbar - aber neue Gefahren drohen\nAddo M, Lohse A\n2016. Erkenntnis, Wissenschaft und Gesellschaft. Buchm\u00fcller W, Jakobeit C (Hrsg.). 1. Aufl. Springer-Verlag GmbH and Co. KG, 101-118.\nPhase 1 Trials of rVSV Ebola Vaccine in Africa and Europe\nAgnandji S, Huttner A, Zinser M, Njuguna P, Dahlke C, Fernandes J, Yerly S, Dayer J, Kraehling V, Kasonta R, Adegnika A, Altfeld M, Auderset F, Bache E, Biedenkopf N, Borregaard S, Brosnahan J, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling S, Finckh A, Goncalves A, Grobusch M, Hooper J, Jambrecina A, Kabwende A, Kaya G, Kimani D, Lell B, Lema\u00eetre B, Lohse A, Massinga-Loembe M, Matthey A, Mordm\u00fcller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl F, Staines H, Strecker T, Stubbe H, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny M, Bejon P, Kremsner P, Addo M, Siegrist C\nNEW ENGL J MED. 2016;374(17):1647-60.\nDiagnosing Salmonella enterica Serovar Typhi Infections by Polymerase Chain Reaction Using EDTA Blood Samples of Febrile Patients From Burkina Faso\nAl-Emran H, Hahn A, Baum J, Cruz Espinoza L, Deerin J, Im J, Ibrango S, Kabore L, von Kalckreuth V, Konings F, Marks F, Sampo E, Panzner U, Park S, Pak G, Sch\u00fctt-Gerowitt H, Vinnemeier C, Warren M, Soura A\nCLIN INFECT DIS. 2016;62 (Suppl 1):S37-41.\nExperimental in vitro and in vivo models for the study of human hepatitis B virus infection\nAllweiss L, Dandri-Petersen M\nJ HEPATOL. 2016;64(1 Suppl):S17-31.\nHuman liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation\nAllweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T, Rapp G, Sch\u00f6bel A, Lohse A, Polywka S, Pischke S, Herker E, Dandri-Petersen M, L\u00fctgehetmann M\nJ HEPATOL. 2016;64(5):1033-1040.\nDeterminants and frequency of irritable bowel syndrome in a German sample\nAlthaus A, Broicher W, Wittkamp P, Andresen V, Lohse A, L\u00f6we B\nZ GASTROENTEROL. 2016;54(3):217-225.\nPost-infectious irritable bowel syndrome (PI-IBS) after infection with Shiga-like toxin-producing Escherichia coli (STEC) O104:H4: A cohort study with prospective follow-up\nAndresen V, L\u00f6we B, Broicher W, Riegel B, Zimmermann-Fraedrich K, von Wulffen M, Gappmayer K, Wegscheider K, Treszl A, Rose M, Layer P, Lohse A\nUNITED EUR GASTROENT. 2016;4(1):121-31.\nInfections complicating severe alcoholic Hepatitis: Enterococcus species represent the most frequently identified pathogen\nBeisel C, Blessin U, Schulze Zur Wiesch J, Wehmeyer M, Lohse A, Benten D, Kluwe J\nSCAND J GASTROENTERO. 2016;51(7):807-13.\nIncreased CD56(bright) NK cells in HIV-HCV co-infection and HCV mono-infection are associated with distinctive alterations of their phenotype\nBhardwaj S, Ahmad F, Wedemeyer H, Cornberg M, Schulze Zur Wiesch J, Lunzen J, Sarin S, Schmidt R, Meyer-Olson D\nJ VIROL. 2016;13:67.\nPrimary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer\nBierwolf J, Volz T, L\u00fctgehetmann M, Allweiss L, Riecken K, Warlich M, Fehse B, Kalff J, Dandri-Petersen M, Pollok J\nTISSUE ENG PT A. 2016;22(9-10):742-53.\nResminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study\nBitzer M, Horger M, Giannini E, Ganten T, W\u00f6rns M, Siveke J, Dollinger M, Gerken G, Scheulen M, Wege H, Zagonel V, Cillo U, Trevisani F, Santoro A, Montesarchio V, Malek N, Holzapfel J, Herz T, Ammendola A, Pegoraro S, Hauns B, Mais A, Lauer U, Henning S, Hentsch B\nJ HEPATOL. 2016;65(2):280-8.\nImmunology of hepatic diseases during pregnancy\nBremer L, Schramm C, Tiegs G\nSEMIN IMMUNOPATHOL. 2016;38(6):669-685.\nTwo Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis\nBrinkert F, Arrenberg P, Krech T, Grabhorn E, Lohse A, Schramm C\nPEDIATRICS. 2016;138(3):e20154245.\nEfficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation\nCiesek S, Proske V, Otto B, Pischke S, Costa R, L\u00fctgehetmann M, Polywka S, Klempnauer J, Nashan B, Manns M, von Hahn T, Lohse A, Wedemeyer H, Mix H, Sterneck M\nTRANSPL INFECT DIS. 2016;18(3):326-32.\nSystemic inflammation in decompensated cirrhosis Characterization and role in acute-on-chronic liver failure\nCl\u00e0ria J, Stauber R, Coenraad M, Moreau R, Jalan R, Pavesi M, Amor\u00f3s \u00c0, Titos E, Alcaraz-Quiles J, Oettl K, Morales-Ruiz M, Angeli P, Domenicali M, Alessandria C, Gerbes A, Wendon J, Nevens F, Trebicka J, Laleman W, Saliba F, Welzel T, Albillos A, Gustot T, Benten D, Durand F, Gin\u00e8s P, Bernardi M, Arroyo V\nHEPATOLOGY. 2016;64(4):1249-64.\nThe challenge of protecting without overprotecting the two sides of myeloid-derived suppressor cells in HBV infection\nDandri-Petersen M, Bockmann J\nHEPATOLOGY. 2016;63(3):1044-6.\nLatest developments in the treatment of hepatitis B\nDandri-Petersen M, Petersen J\nMinerva Gastroenterol Dietol. 2016;62(1):88-102.\nMechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential\nDandri-Petersen M, Petersen J\nCLIN INFECT DIS. 2016;62 Suppl 4:S281-8.\nEndoscopic ultrasound-guided drainage of abdominal fluid collections after pancreatic surgery: Efficacy and long-term follow-up\nDenzer U, Sioulas A, Abdulkarim M, Groth S, R\u00f6sch T, Busch C, Izbicki J, Ittrich H, Adam G, Schachschal G\nZ GASTROENTEROL. 2016;54(9):1047-53.\nParallel assessment of Th17 cell frequencies by surface marker co-expression versus ex vivo IL-17 production in HIV-1 infection\nDunay G, T\u00f3th I, Eberhard J, Degen O, Tolosa E, Lunzen J, Hauber J, Zur Wiesch J\nCYTOM PART B-CLIN CY. 2016;90(6):486-492.\nPartial recovery of senescence and differentiation disturbances in CD8(+) T cell effector-memory cells in HIV-1 nfection after initiation of anti-retroviral treatment.\nEberhard J, Ahmad F, Hong H, Bhatnagar N, Keudel P, Schulze zur Wiesch J, Schmidt R, Meyer-Olson D\nCLIN EXP IMMUNOL. 2016;186(2):227-238.\nReduced CD161(+) MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter?\nEberhard J, Kummer S, Hartjen P, H\u00fcfner A, Diedrich T, Degen O, Lohse A, Lunzen J, Schulze Zur Wiesch J\nJ HEPATOL. 2016;65(6):1261-1263.\nTravelers to the FIFA world cup 2014 in Brazil: Health risks related to mass gatherings/sports events and implications for the Summer Olympic Games in Rio de Janeiro in 2016\nEberhardt K, Vinnemeier C, Dehnerdt J, Rolling T, Steffen R, Cramer J\nTRAVEL MED INFECT DI. 2016;14(3):212-20.\nSpleen size for the prediction of clinical outcome in patients with primary sclerosing cholangitis\nEhlken H, Wroblewski R, Corpechot C, Arriv\u00e9 L, Lezius S, Hartl J, Denzer U, Lohse A, Chazouilleres O, Schramm C\nGUT. 2016;65(7):1230-1232.\nValidation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis\nEhlken H, Wroblewski R, Corpechot C, Arriv\u00e9 L, Rieger T, Hartl J, Lezius S, H\u00fcbener P, Schulze K, Zenouzi R, Sebode M, Peiseler M, Denzer U, Quaas A, Weiler-Normann C, Lohse A, Chazouilleres O, Schramm C\nPLOS ONE. 2016;11(10):e0164224.\nSaccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial\nEhrhardt S, Guo N, Hinz R, Schoppen S, May J, Reiser M, Schroeder M, Schmiedel S, Keuchel M, Reisinger E, Langeheinecke A, de Weerth A, Schuchmann M, Schaberg T, Ligges S, Eveslage M, Hagen R, Burchard G, Lohse A\nOPEN FORUM INFECT DI. 2016;3(1):ofw011.\nExtended spectrum beta-lactamase producing Enterobacteriaceae causing bloodstream infections in rural Ghana, 2007-2012\nEibach D, Campos C, Krumkamp R, Al-Emran H, Dekker D, Boahen K, Kreuels B, Adu-Sarkodie Y, Aepfelbacher M, Park S, Panzner U, Marks F, May J\nINT J MED MICROBIOL. 2016;306(4):249-54.\nMolecular Epidemiology and Antibiotic Susceptibility of Vibrio cholerae Associated with a Large Cholera Outbreak in Ghana in 2014\nEibach D, Herrera-Le\u00f3n S, Gil H, Hogan B, Ehlkes L, Adjabeng M, Kreuels B, Nagel M, Opare D, Fobil J, May J\nPLOS NEGLECT TROP D. 2016;10(5):e0004751.\nIL-10-producing forkhead box protein 3-negative regulatory T cells inhibit B-cell responses and are involved in systemic lupus erythematosus\nFacciotti F, Gagliani N, H\u00e4ringer B, Alfen J, Penatti A, Maglie S, Paroni M, Iseppon A, Moro M, Crosti M, St\u00f6lzel K, Romagnani C, Moroni G, Ingegnoli F, Torretta S, Pignataro L, Annoni A, Russo F, Pagani M, Abrignani S, Meroni P, Flavell R, Geginat J\nJ ALLERGY CLIN IMMUN. 2016;137(1):318-321.e5.\nSpatial heterogeneity of malaria in Ghana: a cross-sectional study on the association between urbanicity and the acquisition of immunity.\nFrank C, Krumkamp R, Sothmann P, May J, Sarpong N, Fobil J, Jaeger A, Ehlkes L, Owusu-Dabo E, Schumann R, Marks F, Adu-Sarkodie Y, Foli G, Kreuels B\nMALARIA J. 2016;15(84):.\nOpen conformers of HLA-F are high-affinity ligands of the activating NK-cell receptor KIR3DS1\nGarcia-Beltran W, H\u00f6lzemer A, Martrus G, Chung A, Pacheco Y, Simoneau C, Rucevic M, Lamothe-Molina P, Pertel T, Kim T, Dugan H, Alter G, Dechanet-Merville J, Jost S, Carrington M, Altfeld M\nNAT IMMUNOL. 2016;17(9):1067-74.\nArboviral and other illnesses in travellers returning from Brazil, June 2013 to May 2016: implications for the 2016 Olympic and Paralympic Games\nGautret P, Mockenhaupt F, Grobusch M, Rothe C, von Sonnenburg F, van Genderen P, Chappuis F, Asgeirsson H, Caumes E, Bottieau E, Malvy D, Lopez-V\u00e9lez R, Jensenius M, Larsen C, Castelli F, Rapp C, Field V, Molina I, Gkrania-Klotsas E, Florescu S, Lalloo D, Schlagenhauf P\nEUROSURVEILLANCE. 2016;21:27.\nSchistosomiasis Screening of Travelers to Corsica, France\nGautret P, Mockenhaupt F, von Sonnenburg F, Rothe C, Libman M, Van De Winkel K, Bottieau E, Grobusch M, Hamer D, Esposito D, Parola P, Schlagenhauf P\nEMERG INFECT DIS. 2016;22(1):160-1.\nThe light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer\nGeginat J, Larghi P, Paroni M, Nizzoli G, Penatti A, Pagani M, Gagliani N, Meroni P, Abrignani S, Flavell R\nCYTOKINE GROWTH F R. 2016;30:87-93.\nCross-genotype-specific T-cell responses in acute hepatitis E virus (HEV) infection\nGisa A, Suneetha P, Behrendt P, Pischke S, Bremer B, Falk C, Manns M, Cornberg M, Wedemeyer H, Kraft A\nJ VIRAL HEPATITIS. 2016;23(4):305-15.\nF\u00e4kaler Mikrobiota-Transfer bei rezidivierenden Clostridium-difficile-Infektionen: Eine retrospektive multizentrische Beobachtungsstudie des MicroTrans-Registers\nHagel S, Fischer A, Ehlermann P, Frank T, Tueffers K, Sturm A, Link A, Demir M, Siebenhaar A, Storr M, Glueck T, Siegel E, Solbach P, Goeser F, Koelbel C, Lohse A, Luebbert C, Kandzi U, Maier M, Schuerle S, Lerch M, Tacke D, Cornely O, Stallmach A, Vehreschild M, German Clinical Microbiome Study Group (GCMSG) o\nDTSCH ARZTEBL INT. 2016;113(35-36):583-9.\nSuperinfection of a Pericardial Hydatid Cyst Leading to Sepsis and Multi-Organ Failure\nHammel A, Bannas P, Henes F\nROFO-FORTSCHR RONTG. 2016;188(10):959-61.\nTransient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis\nHartl J, Denzer U, Ehlken H, Zenouzi R, Peiseler M, Sebode M, H\u00fcbener S, Pannicke N, Weiler-Normann C, Quaas A, Lohse A, Schramm C\nJ HEPATOL. 2016;65(4):769-75.\nHepatitis E Seroprevalence in Europe: A Meta-Analysis\nHartl J, Otto B, Madden R, Webb G, Woolson K, Kriston L, Vettorazzi E, Lohse A, Dalton H, Pischke S\nVIRUSES-BASEL. 2016;8(8):E211.\nAcute Hepatitis E: Two Sides of the Same Coin\nHartl J, Wehmeyer M, Pischke S\nVIRUSES-BASEL. 2016;8(11):E299.\nConstitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response\nHeim D, Gil-Ibanez I, Herden J, Parplys A, Borgmann K, Schmidt-Arras D, Lohse A, Rose-John S, Wege H\nONCOTARGET. 2016;7(34):55639-55648.\nEarly Initiation of Everolimus After Liver Transplantation: A Single-Center Experience\nHerden U, Galante A, Fischer L, Pischke S, Li J, Achilles E, Koch M, Nashan B, Sterneck M\nANN TRANSPL. 2016;21:77-85.\nDamage-associated molecular patterns in cancer a double-edged sword\nHernandez C, H\u00fcbener P, Schwabe R\nONCOGENE. 2016;35(46):5931-5941.\nBiliary strictures and recurrence after liver transplantation for primary sclerosing cholangitis - a retrospective multicenter analysis\nHildebrand T, Pannicke N, Dechene A, Gotthardt D, Kirchner G, Reiter F, Sterneck M, Herzer K, Lenzen H, Rupp C, Barg-Hock H, de Leuw P, Teufel A, Zimmer V, Lammert F, Sarrazin C, Spengler U, Rust C, Manns M, Strassburg C, Schramm C, Weism\u00fcller T\nLIVER TRANSPLANT. 2016;22(1):42-52.\nEfficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance\nH\u00fcbener S, Oo Y, Than N, H\u00fcbener P, Weiler-Normann C, Lohse A, Schramm C\nCLIN GASTROENTEROL H. 2016;14(3):445-453.\nReply to: Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance.\nH\u00fcbener S, Than N, Oo Y, Lohse A, Schramm C\nCLIN GASTROENTEROL H. 2016;14(7):1063-4.\nPersisting hepatitis E virus infection leading to liver cirrhosis despite recovery of the immune system in an HIV-infected patient\nIngiliz P, Mayr C, Obermeier M, Herbst H, Polywka S, Pischke S\nCLIN RES HEPATOL GAS. 2016;40(3):e23-5.\nDirect reprogramming of fibroblasts into renal tubular epithelial cells by defined transcription factors\nKaminski M, Tosic J, Kresbach C, Engel H, Klockenbusch J, M\u00fcller A, Pichler R, Grahammer F, Kretz O, Huber T, Walz G, Arnold S, Lienkamp S\nNAT CELL BIOL. 2016;18(12):1269-1280.\nNew findings in HCV genotype distribution in selected West European, Russian and Israeli regions\nKartashev V, D\u00f6ring M, Nieto L, Coletta E, Kaiser R, Sierra S\nJ CLIN VIROL. 2016;81:82-9.\nDiffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis a comparison study with dual-energy X-ray absorptiometry\nKeller S, Ittrich H, Schramm C, Lohse A, Amling M, Adam G, Yamamura J\nJPN J RADIOL. 2016;34(10):677-683.\nDolutegravir in breast milk and maternal and infant plasma during breastfeeding\nKobbe R, Schalkwijk S, Dunay G, Eberhard J, Schulze-Sturm U, Hollwitz B, Degen O, Teulen M, Colbers A, Burger D\nAIDS. 2016;30(17):2731-2733.\nInfektiologie und Tropendermatologie - Teil 58: Affenpocken bei Gefl\u00fcchtetem?\nKoch T, Rothe C\nderm Praktische Dermatologie. 2016;2016(4):294.\nMolecular Diagnosis of Human Taenia martis Eye Infection\nKoch T, Schoen C, Muntau B, Addo M, Ostertag H, Wiechens B, Tappe D\nAM J TROP MED HYG. 2016;94(5):1055-7.\nAttenuated viral hepatitis in Trem1-/- mice is associated with reduced inflammatory activity of neutrophils\nKozik J, Trautmann T, Carambia A, Preti M, L\u00fctgehetmann M, Krech T, Wiegard C, Heeren J, Herkel J\nSCI REP-UK. 2016;6:28556.\nAutoimmune Renal Disease Is Exacerbated by S1P-Receptor-1-Dependent Intestinal Th17 Cell Migration to the Kidney\nKrebs C, Paust H, Krohn S, Koyro T, Brix S, Riedel J, Bartsch P, Wiech T, Meyer-Schwesinger C, Huang J, Fischer N, Busch C, Mittr\u00fccker H, Steinhoff U, Stockinger B, Perez L, Wenzel U, Janneck M, Steinmetz O, Gagliani N, Stahl R, Huber S, Turner J, Panzer U\nIMMUNITY. 2016;45(5):1078-1092.\nPlasticity of Th17 Cells in Autoimmune Kidney Diseases\nKrebs C, Turner J, Paust H, Kapffer S, Koyro T, Krohn S, Ufer F, Friese M, Flavell R, Stockinger B, Steinmetz O, Stahl R, Huber S, Panzer U\nJ IMMUNOL. 2016;197(2):449-57.\nAssociation Between Malaria and Invasive Nontyphoidal Salmonella Infection in a Hospital Study: Accounting for Berkson's Bias\nKrumkamp R, Kreuels B, Sarpong N, Boahen K, Foli G, Hogan B, Jaeger A, Reigl L, Zeeb H, Marks F, Adu-Sarkodie Y, May J\nCLIN INFECT DIS. 2016;62 Suppl 1:S83-9.\nAcute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study\nLehmann M, Br\u00fcnahl C, Addo M, Becker S, Schmiedel S, Lohse A, Schramm C, L\u00f6we B\nJ PSYCHOSOM RES. 2016;83:69-74.\nCerebral Hemodynamics in Patients with Hemolytic Uremic Syndrome Assessed by Susceptibility Weighted Imaging and Four-Dimensional Non-Contrast MR Angiography\nL\u00f6bel U, Forkert N, Schmitt P, Dohrmann T, Schroeder M, Magnus T, Kluge S, Weiler-Normann C, Bi X, Fiehler J, Sedlacik J\nPLOS ONE. 2016;11(11):e0164863.\nReply to \"Further considerations in autoimmune hepatitis\"\nLohse A, Chazouilleres O, Dalekos G, Drenth J, Heneghan M, Hofer H, Lammert F, Lenzi M\nJ HEPATOL. 2016;64(6):1458-9.\nThe Development of Irritable Bowel Syndrome: A Prospective Community-Based Cohort Study\nL\u00f6we B, Lohse A, Andresen V, Vettorazzi E, Rose M, Broicher W\nAM J GASTROENTEROL. 2016;111(9):1320-9.\nSequence variations in HCV core-derived epitopes alter binding of KIR2DL3 to HLA-C\u221703:04 and modulate NK cell function\nLunemann S, Martrus G, H\u00f6lzemer A, Chapel A, Ziegler M, K\u00f6rner C, Garcia Beltran W, Carrington M, Wedemeyer H, Altfeld M\nJ HEPATOL. 2016;65(2):252-8.\nAcute Malaria Induces PD1+CTLA4+ Effector T Cells with Cell-Extrinsic Suppressor Function\nMackroth M, Abel A, Steeg C, Schulze Zur Wiesch J, Jacobs T\nPLOS PATHOG. 2016;12(11):e1005909.\nRapid-Antigen Test Negative Malaria in a Traveler Returning From Thailand, Molecularly Diagnosed as Plasmodium knowlesi\nMackroth M, Tappe D, Tannich E, Addo M, Rothe C\nOPEN FORUM INFECT DI. 2016;3(1):ofw039.\nManagement of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell Transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5)\nMallet V, van B\u00f6mmel F, Doerig C, Pischke S, Hermine O, Locasciulli A, Cordonnier C, Berg T, Moradpour D, Wedemeyer H, Ljungman P\nLANCET INFECT DIS. 2016;16(5):606-17.\nEinfluss der PDGF-Familie und ihrer Rezeptoren auf intestinale Inflammation\nManthey C\n2016. Influence of PDGFR on intestinal inflammation. .\nGastrointestinale Infektionen \u2013 Aktuelle Leitlinie und Empfehlungen\nManthey C, Stallmach A, Lohse A\nGastroenterologie up2date. 2016;12:39-49.\nKinetics of HIV-1 latency reversal quantified on the single cell level using a novel flow-based technique\nMartrus G, Niehrs A, Cornelis R, Rechtien A, Garc\u00eda-Beltran W, L\u00fctgehetmann M, Hoffmann C, Altfeld M\nJ VIROL. 2016;90(20):9018-9028.\nProfile of illness in Syrian refugees: A GeoSentinel analysis, 2013 to 2015\nMockenhaupt F, Barbre K, Jensenius M, Larsen C, Barnett E, Stauffer W, Rothe C, Asgeirsson H, Hamer D, Esposito D, Gautret P, Schlagenhauf P\nEUROSURVEILLANCE. 2016;21(10):7 - 11.\nChemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury\nMossanen J, Krenkel O, Ergen C, Govaere O, Liepelt A, Puengel T, Heymann F, Kalthoff S, Lefebvre E, Eulberg D, Luedde T, Marx G, Strassburg C, Roskams T, Trautwein C, Tacke F\nHEPATOLOGY. 2016;64(5):1667-1682.\nVariability in long-term hepatitis B virus dynamics under antiviral therapy\nMurray J, Stancevic O, L\u00fctgehetmann M, Wursthorn K, Petersen J, Dandri-Petersen M\nJ THEOR BIOL. 2016;391:74-80.\nIL-23 prevents IL-13-dependent tissue repair associated with Ly6C(lo) monocytes in Entamoeba histolytica-induced liver damage\nNoll J, Helk E, Fehling H, Bernin H, Marggraff C, Jacobs T, Huber S, Pelczar P, Ernst T, Ittrich H, Otto B, Mittr\u00fccker H, H\u00f6lscher C, Tacke F, Bruchhaus I, Tannich E, Lotter H\nJ HEPATOL. 2016;64(5):1147-57.\nA pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease\nPelczar P, Witkowski M, Perez L, Kempski J, Hammel A, Brockmann L, Kleinschmidt D, Wende S, Haueis C, Bedke T, Krasemann S, Steurer S, Booth C, Busch C, K\u00f6nig A, Rauch U, Benten D, Izbicki J, R\u00f6sch T, Lohse A, Strowig T, Gagliani N, Flavell R, Huber S\nSCIENCE. 2016;354(6310):358-362.\nArterial pressure suffices to increase liver stiffness\nPiecha F, Peccerella T, Bruckner T, Seitz H, Rausch V, Mueller S\nAM J PHYSIOL-GASTR L. 2016;311(5):G945-G953.\nLow Risk of Developing Chronic Hepatitis E in Heart Transplant Recipients: A Prospective 2-Year Follow-Up Study\nPischke S, Bara C, Behrendt P, Haverich A, Manns M, Wedemeyer H\nIntervirology. 2016;59(5-6):254-255.\nApolipoprotein E \u03b53 and \u03b54 are associated with a lower exposure to hepatitis E virus in American non-Hispanic blacks\nPischke S, Hartl J, Roque-Afonso A, Mallet V\nHEPATOLOGY. 2016;64(2):687-8.\nBlood-borne Hepatitis E Virus Transmission: A Relevant Risk for Immunosuppressed Patients\nPischke S, Hiller J, L\u00fctgehetmann M, Polywka S, Rybczynski M, Ayuketang F, Lohse A\nCLIN INFECT DIS. 2016;63(4):569-570.\nCourse of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting\nPischke S, Polywka S, Proske V, Lang M, Jordan S, Nashan B, Lohse A, Sterneck M\nTRANSPL INFECT DIS. 2016;18:141-145.\nNeuralgische Schulteramyotrophie: Eine extrahepatische Manifestation der Hepatitis E\nPischke S, Ryll U, De Weerth A, Ufer F, Gelderblom M\nDEUT MED WOCHENSCHR. 2016;141(17):1239-42.\nHepatitis A\nPischke S, Wedemeyer H\n2016. Hepatology . Mauss S, Berg T, J\u00fcrgen R, Sarrazin C, Wedemeyer H (Hrsg.). 7. Aufl. Koblenz: Medizin Fokus Verlag, 31-38.\nHepatitis A\nPischke S, Wedemeyer H\n2016. Praxis der Hepatologie. Manns M, Schneidewind S (Hrsg.). 1. Aufl. Springer, 45-48.\nHepatitis E\nPischke S, Wedemeyer H\n2016. Praxis der Hepatologie. Manns M, Schneidewind S (Hrsg.). 1. Aufl. Springer, 69-74.\nHepatitis E: a relevant disease with many aspects\nPischke S, Wedemeyer H\n2016. Hepatology . Mauss S, Berg T, J\u00fcrgen R, Sarrazin C, Wedemeyer H (Hrsg.). 7. Aufl. Koblenz: Medizin Fokus Verlag, 69-84.\nVirale Hepatiden: Andere virale Infektionen\nPischke S, Wedemeyer H\n2016. Praxis der Hepatologie. Manns M, Schneidewind S (Hrsg.). 1. Aufl. Springer, 75-80.\nCytokine and Chemokine Signature in Elite versus Viremic Controllers infected with HIV\nPlatten M, Jung N, Trapp S, Flo\u00dfdorf P, Meyer-Olson D, Schulze Zur Wiesch J, Stephan C, Mauss S, Wei\u00df V, von Bergwelt-Balidon M, Rockstroh J, F\u00e4tkenheuer G, Lehmann C\nAIDS RES HUM RETROV. 2016;32(6):579-87.\nSurrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process\nPonsioen C, Chapman R, Chazouill\u00e8res O, Hirschfield G, Karlsen T, Lohse A, Pinzani M, Schrumpf E, Trauner M, Gores G\nHEPATOLOGY. 2016;63(4):1357-67.\nExpert opinions and scientific evidence for colonoscopy key performance indicators\nRees C, Bevan R, Zimmermann-Fraedrich K, Rutter M, Rex D, Dekker E, Ponchon T, Bretthauer M, Regula J, Saunders B, Hassan C, Bourke M, R\u00f6sch T\nGUT. 2016;65(12):2045-2060.\nMultiple Abszesse nach S\u00fcdamerikakreuzfahrt\nReynolds K, Schofer N, Zengin E, Lohse A, Faiss S, Schmiedel S\nINTERNIST. 2016;57(3):284-8.\nInflammation-Induced Expression and Secretion of MicroRNA 122 Leads to Reduced Blood Levels of Kidney-derived Erythropoietin and Anemia\nRivkin M, Simerzin A, Zorde-Khvalevsky E, Chai C, Yuval J, Rosenberg N, Harari-Steinfeld R, Schneider R, Amir G, Condiotti R, Heikenwalder M, Weber A, Schramm C, Wege H, Kluwe J, Galun E, Giladi H\nGASTROENTEROLOGY. 2016;151(5):999-1010.e3.\nSharp increase of imported Plasmodium vivax malaria seen in migrants from Eritrea in Hamburg, Germany\nRoggelin L, Tappe D, Noack B, Addo M, Tannich E, Rothe C\nMALARIA J. 2016;2016(15):325.\nUnique human immune signature of Ebola virus disease in Guinea\nRuibal P, Oestereich L, L\u00fcdtke A, Becker-Ziaja B, Wozniak D, Kerber R, Korva M, Cabeza-Cabrerizo M, Bore J, Koundouno F, Duraffour S, Weller R, Thorenz A, Cimini E, Viola D, Agrati C, Repits J, Afrough B, Cowley L, Ngabo D, Hinzmann J, Mertens M, Vitoriano I, Logue C, Boettcher J, Pallasch E, Sachse A, Bah A, Nitzsche K, Kuisma E, Michel J, Holm T, Zekeng E, Garc\u00eda-Dorival I, W\u00f6lfel R, Stoecker K, Fleischmann E, Strecker T, Di Caro A, Av\u0161i\u010d-\u017dupanc T, Kurth A, Meschi S, M\u00e9ly S, Newman E, Bocquin A, Kis Z, Kelterbaum A, Molkenthin P, Carletti F, Portmann J, Wolff S, Castilletti C, Schudt G, Fizet A, Ottowell L, Herker E, Jacobs T, Kretschmer B, Severi E, Ouedraogo N, Lago M, Negredo A, Franco L, Anda P, Schmiedel S, Kreuels B, Wichmann D, Addo M, Lohse A, De Clerck H, Nanclares C, Jonckheere S, Van Herp M, Sprecher A, Xiaojiang G, Carrington M, Miranda O, Castro C, Gabriel M, Drury P, Formenty P, Diallo B, Koivogui L, Magassouba N, Carroll M, G\u00fcnther S, Mu\u00f1oz-Fontela C\nNATURE. 2016;533(7601):100-4.\nCharacterization of patients with chronic pulmonary aspergillosis according to the new ESCMID/ERS/ECMM and IDSA guidelines\nSalzer H, Heyckendorf J, Kalsdorf B, Rolling T, Lange C\nMYCOSES. 2016;60(2):136-142.\nSevere Community-Acquired Bloodstream Infection with Acinetobacter ursingii in Person who Injects Drugs\nSalzer H, Rolling T, Schmiedel S, Klupp E, Lange C, Seifert H\nEMERG INFECT DIS. 2016;22(1):134-7.\nPersonalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis\nSalzer H, Wassilew N, K\u00f6hler N, Olaru I, G\u00fcnther G, Herzmann C, Kalsdorf B, Sanchez-Carballo P, Terhalle E, Rolling T, Lange C, Heyckendorf J\nRESPIRATION. 2016;92(4):199-214.\nBCG-assoziierte Urogenitaltuberkulose nach Harnblasenkarzinom\nSauer M, Degen O, Beyersdorff D\nROFO-FORTSCHR RONTG. 2016;188(8):782-3.\nHigh proportion of HIV late presenters at an academic tertiary care center in northern Germany confirms the results of several cohorts in Germany: time to put better HIV screening efforts on the national agenda?\nSch\u00e4fer G, Kreuels B, Schmiedel S, Hertling S, H\u00fcfner A, Degen O, Lunzen J, Schulze Zur Wiesch J\nINFECTION. 2016;44(3):347-52.\nBreadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype\nScheurich C, Schulze Zur Wiesch J, Kim A, Lewis-Ximenez L, Meyer T, Polywka S, Chung R, Lauer G\nJ VIRAL HEPATITIS. 2016;23(10):831-2.\nSunitinib treatment reduces tumor growth and limits changes in microvascular properties after minor surgical intervention in an in vivo model of secondary breast cancer growth in bone\nSchroeder M, Viezens L, Wellbrock J, Fiedler W, Ruether W, Algenstaedt P, Hansen-Algenstaedt N, Sch\u00e4fer C\nJ SURG ONCOL. 2016;113(5):515-21.\nCT-P13 (Inflectra\u2122, Remsima\u2122) monitoring in patients with inflammatory bowel disease\nSchulze K, Koppka N, Lutter F, Brandhorst G, Helwig U\nBIOLOGICALS. 2016;44(5):463-6.\nGenetic profiling of hepatocellular carcinoma using next-generation sequencing\nSchulze K, Nault J, Villanueva A\nJ HEPATOL. 2016;65(5):1031-1042.\nA Slow Maturation Process Renders Hepatitis B Virus Infectious\nSeitz S, Iancu C, Volz T, Mier W, Dandri-Petersen M, Urban S, Bartenschlager R\nCELL HOST MICROBE. 2016;20(1):25-35.\nIL-22 dampens the T cell response in experimental malaria\nSellau J, Alvarado C, Hoenow S, Mackroth M, Kleinschmidt D, Huber S, Jacobs T\nSCI REP-UK. 2016;6:28058.\nMedizinische Versorgung von Fl\u00fcchtlingen: Eine Fallserie des Universit\u00e4tsklinikums Hamburg-Eppendorf\nSothmann P, Schmedt auf der G\u00fcnne N, Addo M, Lohse A, Schmiedel S\nDEUT MED WOCHENSCHR. 2016;141(1):34-37.\nMedizinische Versorgung von Fl\u00fcchtlingen \u2013 Eine Fallserie des Universit\u00e4tsklinikums Hamburg-Eppendorf\nSothmann P, Schmedt auf der G\u00fcnne N, Roggelin L, Kreuels B, Rothe C, Addo M, Lohse A, Schulze zur Wiesch J, Schmiedel S\nFLUGMEDIZIN TROPENME. 2016;23(1):45-49.\nLong-term follow-up of five yr shows superior renal function with everolimus plus early calcineurin inhibitor withdrawal in the PROTECT randomized liver transplantation study\nSterneck M, Kaiser G, Heyne N, Richter N, Rauchfuss F, Pascher A, Schemmer P, Fischer L, Klein C, Nadalin S, Lehner F, Settmacher U, Gotthardt D, Loss M, Ladenburger S, Wimmer P, Dworak M, Schlitt H\nCLIN TRANSPLANT. 2016;30(6):741-8.\nClinical features and laboratory findings of dengue fever in German travellers: A single-centre, retrospective analysis\nTavakolipoor P, Schmidt-Chanasit J, Burchard G, Jordan S\nTRAVEL MED INFECT DI. 2016;14(1):39-44.\nLong-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy\nThan N, Wiegard C, Weiler-Normann C, F\u00fcssel K, Mann J, Hodson J, Hirschfield G, Lohse A, Adams D, Schramm C, Oo Y\nSCAND J GASTROENTERO. 2016;51(3):329-336.\nIn vivo evidence for ribavirin-induced mutagenesis of the hepatitis E virus genome\nTodt D, Gisa A, Radonic A, Nitsche A, Behrendt P, Suneetha P, Pischke S, Bremer B, Brown R, Manns M, Cornberg M, Bock C, Steinmann E, Wedemeyer H\nGUT. 2016;65(10):1733-43.\nA309 The influence of peep and positioning on central venous pressure and venous hepatic hemodynamics in patients undergoing liver resection\nUkere A, Meisner S, Greiwe G, Opitz B, Benten D, Nashan B, Fischer L, Trepte C, Reuter D, Haas S, Behem C\nINTENS CARE MED EXP. 2016.\nClinical Management of Ebola Virus Disease in the United States and Europe\nUyeki T, Mehta A, Davey R, Liddell A, Wolf T, Vetter P, Schmiedel S, Gr\u00fcnewald T, Jacobs M, Arribas J, Evans L, Hewlett A, Brantsaeter A, Ippolito G, Rapp C, Hoepelman A, Gutman J\nNEW ENGL J MED. 2016;374(7):636-46.\nM-CSF and GM-CSF Receptor Signaling Differentially Regulate Monocyte Maturation and Macrophage Polarization in the Tumor Microenvironment\nVan Overmeire E, Stijlemans B, Heymann F, Keirsse J, Morias Y, Elkrim Y, Brys L, Abels C, Lahmar Q, Ergen C, Vereecke L, Tacke F, De Baetselier P, Van Ginderachter J, Laoui D\nCANCER RES. 2016;76(1):35-42.\nTropheryma whipplei in children with diarrhoea in rural Ghana\nVinnemeier C, Klupp E, Krumkamp R, Rolling T, Fischer N, Owusu-Dabo E, Addo M, Adu-Sarkodie Y, K\u00e4smaier J, Aepfelbacher M, Cramer J, May J, Tannich E\nCLIN MICROBIOL INFEC. 2016;22(1):65.e1 - 65.e3.\nFirst- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation\nvon Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H\nDIAGNOSTICS. 2016;6(4):E44.\nIndikationsstellung f\u00fcr operative Eingriffe und perioperatives Management bei Transplantierten und Immunsupprimierten\nWege H, Benten D, Sterneck M\nAllgemein- und Viszeralchirurgie up2date. 2016;10(06):453-464.\nNonalcoholic fatty liver disease is associated with excessive calorie intake rather than a distinctive dietary pattern\nWehmeyer M, Zyriax B, Jagemann B, Roth E, Windler E, Schulze Zur Wiesch J, Lohse A, Kluwe J\nMEDICINE. 2016;95(23):e3887.\nNonalcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis: Further Reason for Teeth GNASHing?\nWeiler-Normann C, Lohse A\nDIGEST DIS SCI. 2016;61(9):2462 - 64.\nVariant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management\nWeiler-Normann C, Lohse A\nDIGEST DIS. 2016;34(4):334-9.\nClinical response to peroral endoscopic myotomy in patients with idiopathic achalasia at a minimum follow-up of 2 years\nWerner Y, Costamagna G, Swanstr\u00f6m L, von Renteln D, Familiari P, Sharata A, Noder T, Schachschal G, Kersten J, R\u00f6sch T\nGUT. 2016;65(6):899-906.\nPOEM and Submucosal Tunneling\nWerner Y, R\u00f6sch T\nCurrent treatment options in gastroenterology. 2016;14(2):163-77.\nNeue Therapieoption bei Diabetes mellitus Typ 2: EMPA-REG-Studie\nWindler E, Nitschmann S\nINTERNIST. 2016;57(1):102-103.\nDifferent Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling\nWolf J, Waetzig G, Chalaris A, Reinheimer T, Wege H, Rose-John S, Garbers C\nJ BIOL CHEM. 2016;291(31):16186-96.\nOpposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice\nWroblewski R, Armaka M, Kondylis V, Pasparakis M, Walczak H, Mittr\u00fccker H, Schramm C, Lohse A, Kollias G, Ehlken H\nHEPATOLOGY. 2016;64(2):508-521.\nNo Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis\nZenouzi R, Weism\u00fcller T, J\u00f8rgensen K, Bubenheim M, Lenzen H, H\u00fcbener P, Schulze K, Weiler-Normann C, Sebode M, Ehlken H, Pannicke N, Hartl J, Peiseler M, H\u00fcbener S, Karlsen T, Boberg K, Manns M, Lohse A, Schramm C\nCLIN GASTROENTEROL H. 2016;14(12):1806-1812.\nEfficacy and safety of faldaprevir, deleobuvir, and ribavirin in Treatment-naive patients with chronic Hepatitis C Virus infection and advanced liver fibrosis or cirrhosis.\nJ ANTIMICROB CHEMOTH. 2015;59(2):1282-1291.\nDetermination of ethyl glucuronide in hair for detection of alcohol consumption in patients after livertransplantation.\nAndresen-Streichert H, von Rothkirch G, Vettorazzi E, M\u00fcller A, Lohse A, Frederking D, Seegers B, Nashan B, Sterneck M\nTHER DRUG MONIT. 2015;37(4):539-545.\nGeschlechtsunterschiede bei Infektionserkrankungen\nBeisel C, Lunzen J, Lohse A, Addo M, Altfeld M\nDEUT MED WOCHENSCHR. 2015;140(18):1385-90.\nCombined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure\nBockmann J, Dandri-Petersen M, L\u00fcth S, Pannicke N, Lohse A, Dandri-Petersen M\nWORLD J GASTROENTERO. 2015;21(7):2214-9.\nEbola and provision of critical care\nBrown C, Kreuels B, Baker P, Baker T, Boyles T, Lado M, Johnson O\nLANCET. 2015;385(9976):1392.\nNanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice\nCarambia A, Freund B, Schwinge D, Bruns O, Salmen S, Ittrich H, Reimer R, Heine M, Huber S, Waurisch C, Eychm\u00fcller A, Wraith D, Korn T, Nielsen P, Weller H, Schramm C, L\u00fcth S, Lohse A, Heeren J, Herkel J\nJ HEPATOL. 2015;62(6):1349-1356.\nDevelopment of a novel IGRA assay to test T cell responsiveness to HBV antigens in whole blood of chronic Hepatitis B patients\nDammermann W, Bentzien F, Stiel E, K\u00fchne C, Ullrich S, Schulze Zur Wiesch J, L\u00fcth S\nJ TRANSL MED. 2015;13(2015):Art. 157.\nExperimental Models: Cell Culture and Animal Models\nDandri-Petersen M, Volz T, L\u00fctgehetmann M\n2015. Hepatitis B Virus in Human Diseases . Liaw Y, Zoulim F (Hrsg.). 1. Aufl. Springer International Publishing, 35-62.\nSoluble plasma VE-cadherin concentrations are elevated in patients with STEC infection and haemolytic uraemic Syndrome: a case-control study\nDoulgere J, Otto B, Nassour M, Wolters-Eisfeld G, Rohde H, Magnus T, Wagener C, Streichert T\nBMJ OPEN. 2015;5(3):e005659.\nAssociation between a gain-of-function variant of PTPN22 and rejection in liver transplantation\nDullin R, Koch M, Sterneck M, Nashan B, Thude H\nTRANSPLANTATION. 2015;99(2):431-7.\nUnmet clinical need in autoimmune liver diseases\nDyson J, Webb G, Hirschfield G, Lohse A, Beuers U, Lindor K, Jones D\nJ HEPATOL. 2015;62(1):208-18.\nHow Should Cancer Surveillance in Primary Sclerosing Cholangitis Be Performed?\nEhlken H, Schramm C\nVISZERALMEDIZIN. 2015;31(3):173-7.\nLack of the protein tyrosine phosphatase PTPN22 strengthens transplant tolerance to pancreatic islets in mice\nFousteri G, Jofra T, Di Fonte R, Gagliani N, Morsiani C, Stabilini A, Battaglia M\nDIABETOLOGIA. 2015;58(6):1319-28.\nAll in (IL-) 1?\nGagliani N, Battaglia M\nTRANSPLANTATION. 2015;99(11):2235-6.\nIntestinal Regulatory CD4+ T cells\nGagliani N, Huber S, Flavell R\n2015. Mucosal Immunology. Mestecky J, Strober W, Russell M, Cheroutre H, Lambrecht B, Kelsall B (Hrsg.). 4. Aufl. Academic Press, 777-785.\nImmune Depletion in Combination with Allogeneic Islets Permanently Restores Tolerance to Self-Antigens in Diabetic NOD Mice\nGagliani N, Jofra T, Posgai A, Atkinson M, Battaglia M\nPLOS ONE. 2015;10(11):e0142318.\nTh17 cells transdifferentiate into regulatory T cells during resolution of inflammation\nGagliani N, Vesely M, Iseppon A, Brockmann L, Xu H, Palm N, de Zoete M, Licona-Lim\u00f3n P, Paiva R, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire L, Cotton M, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell R\nNATURE. 2015;523(7559):221-5.\nRelevance of chronic hepatitis E in liver transplant recipients: a real-life setting\nGalante A, Pischke S, Polywka S, L\u00fctgehetmann M, Suneetha P, Gisa A, Hiller J, Dienes H, Nashan B, Lohse A, Sterneck M\nTRANSPL INFECT DIS. 2015;17(4):617-22.\nLocal and International Implications of Schistosomiasis Acquired in Corsica, France\nGautret P, Mockenhaupt F, von Sonnenburg F, Rothe C, Libman M, Van De Winkel K, Bottieau E, Grobusch M, Hamer D, Esposito D, Parola P, Schlagenhauf P\nEMERG INFECT DIS. 2015;21(10):1865-8.\nHepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection\nGiersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse A, Pollok J, Petersen J, Dandri-Petersen M, L\u00fctgehetmann M\nJ HEPATOL. 2015;63(2):346-53.\nHepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte\nGiersch K, Dandri-Petersen M\nJ CLIN TRANSL HEPATO. 2015;3(3):220-229.\nSex Differences in Plasmacytoid Dendritic Cell Levels of IRF5 Drive Higher IFN-\u03b1 Production in Women\nGriesbeck M, Ziegler S, Laffont S, Smith N, Chauveau L, Tomezsko P, Sharei A, Kourjian G, Porichis F, Hart M, Palmer C, Sirignano M, Beisel C, Hildebrandt H, C\u00e9nac C, Villani A, Diefenbach T, Le Gall S, Schwartz O, Herbeuval J, Autran B, Gu\u00e9ry J, Chang J, Altfeld M\nJ IMMUNOL. 2015;195(11):5327-36.\n\u00d6konomische Auswirkungen einer Clostridium-difficile-Enterokoloitis in deutschen Krankenh\u00e4usern auf der Basis von DRG-Kostendaten\nGrube R, Heinlein W, Scheffer H, Rathmayer M, Schepp W, Lohse A\nZ GASTROENTEROL. 2015;53(5):391-397.\nClinical Course of acute-on-chronic liver failure syndrome and effects on prognosis\nGustot T, Fernandez J, Garcia E, Morando F, Caraceni P, Alessandria C, Laleman W, Trebicka J, Elkrief L, Hopf C, Sol\u00eds-Munoz P, Saliba F, Zeuzem S, Albillos A, Benten D, Montero-Alvarez J, Chivas M, Concepci\u00f3n M, C\u00f3rdoba J, McCormick A, Stauber R, Vogel W, de Gottardi A, Welzel T, Domenicali M, Risso A, Wendon J, Deulofeu C, Angeli P, Durand F, Pavesi M, Gerbes A, Jalan R, Moreau R, Gin\u00e9s P, Bernardi M, Arroyo V\nHEPATOLOGY. 2015;62(1):243-52.\nS2k-Leitlinie Gastrointestinale Infektionen und Morbus Whipple\nHagel S, Epple H, Feurle G, Kern W, Lynen-Jansen P, Malfertheiner P, Marth T, Meyer E, Mielke M, Moos V, von M\u00fcller L, Nattermann J, Nothacker M, Pox C, Reisinger E, Salzberger B, Salzer H, Weber M, Weinke T, Suerbaum S, Lohse A, Stallmach A\nZ GASTROENTEROL. 2015;53(05):418-459.\nNeuropeptide Y restores non-receptor-mediated vasoconstrictive action in superior mesenteric arteries in portal hypertension.\nHartl J, Dietrich P, Moleda L, M\u00fcller-Schilling M, Wiest R\nLIVER INT. 2015;35(12):2556-63.\nPatient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis\nHartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse A, Schramm C\nJ HEPATOL. 2015;62(3):642-6.\nComparison of autochthonous and imported cases of hepatitis A or hepatitis E\nHartl J, Kreuels B, Polywka S, Addo M, L\u00fctgehetmann M, Dandri-Petersen M, Dammermann W, Sterneck M, Lohse A, Pischke S\nZ GASTROENTEROL. 2015;53(7):639-643.\nLitomosoides sigmodontis induces TGF-\u03b2 receptor responsive, IL-10-producing T cells that suppress bystander T-cell proliferation in mice\nHartmann W, Schramm C, Breloer M\nEUR J IMMUNOL. 2015;45(9):2568-81.\nRetroviral insertional mutagenesis in telomerase-immortalized hepatocytes identifies RIPK4 as novel tumor suppressor in human hepatocarcinogenesis\nHeim D, Cornils K, Schulze K, Fehse B, Lohse A, Br\u00fcmmendorf T, Wege H\nONCOGENE. 2015;34(3):385-393.\nRegulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases\nHerkel J\nDIGEST DIS. 2015;33(Suppl 2):70-74.\nLong term intravital multiphoton microscopy imaging of immune cells in healthy and diseased liver using CXCR6.Gfp reporter mice\nHeymann F, Niemietz P, Peusquens J, Ergen C, Kohlhepp M, Mossanen J, Schneider C, Vogt M, Tolba R, Trautwein C, Martin C, Tacke F\nJOVE-J VIS EXP. 2015;(97):.\nLiver inflammation abrogates immunological tolerance induced by Kupffer cells\nHeymann F, Peusquens J, Ludwig-Portugall I, Kohlhepp M, Ergen C, Niemietz P, Martin C, van Rooijen N, Ochando J, Randolph G, Luedde T, Ginhoux F, Kurts C, Trautwein C, Tacke F\nHEPATOLOGY. 2015;62(1):279-91.\nSelection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa.\nH\u00f6lzemer A, Thobakgale C, Jimenez Cruz C, Garcia Beltran W, van Teijlingen N, Mann J, Jaggernath M, Chung A, Schafer J, Evans D, Alter G, Walker B, Goulder P, Carrington M, Hartmann P, Pertel T, Zhou R, Ndung'u T, Altfeld M\nPLOS MED. 2015;12(11):e1001900.\nComment on: HMGB1-dependent and -independent autophagy\nH\u00fcbener P, Gwak G, Schwabe R\nAUTOPHAGY. 2015;11(7):1187-1188.\nHMGB1 and injury amplification\nH\u00fcbener P, Hernandez C, Schwabe R\nONCOTARGET. 2015;6(27):23048-9.\nDer klinisch und wissenschaftlich t\u00e4tige Arzt\u2013 aktueller Stand und Perspektiven\nHuber S, Schramm C\nZ GASTROENTEROL. 2015;53(2):137-8.\nPrenatal acetaminophen induces liver toxicity in dams, reduces fetal liver stem cells, and increases airway inflammation in adult offspring\nKarimi K, Ke\u00dfler T, Thiele K, Ramisch K, Erhardt A, H\u00fcbener P, Barikbin R, Arck P, Tiegs G\nJ HEPATOL. 2015;62(5):1085-91.\nCRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X\nKarimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann J, Grundhoff A, L\u00fcth S, Buchholz F, Schulze zur Wiesch J, Hauber J\nSCI REP-UK. 2015;5:13734.\nIncreased Frequency of CD49b/LAG-3(+) Type 1 Regulatory T Cells in HIV-Infected Individuals\nKoch K, Koch N, Sandaradura de Silva U, Jung N, Schulze Zur Wiesch J, F\u00e4tkenheuer G, Hartmann P, Romerio F, Lehmann C\nAIDS RES HUM RETROV. 2015;31(12):1238-46.\nSevere Ebola virus infection complicated by gram-negative septicemia\nKreuels B, Addo M, Schmiedel S\nNEW ENGL J MED. 2015;372(14):1377.\nIntravenous Artesunate Reduces Parasite Clearance Time, Duration of Intensive Care, and Hospital Treatment in Patients With Severe Malaria in Europe: The TropNet Severe Malaria Study\nKurth F, Develoux M, Mechain M, Clerinx J, Antinori S, Gj\u00f8rup I, Gascon J, M\u00f8rch K, Nicastri E, Ramharter M, Bartoloni A, Visser L, Rolling T, Zanger P, Calleri G, Salas-Coronas J, Nielsen H, Just-N\u00fcbling G, Neumayr A, Hachfeld A, Schmid M, Antonini P, Pongratz P, Kern P, Saraiva da Cunha J, Soriano-Arandes A, Schunk M, Suttorp N, Hatz C, Zoller T\nCLIN INFECT DIS. 2015;61(9):1441-4.\nAcute and Chronic Inflammation of the Biliary System\nLankisch T, Bektas H, Dech\u00eane A, Ehlken H, Kirchner G, Lang H, Schramm C\nVISZERALMEDIZIN. 2015;31(3):200-3.\nEbola and psychological stress of health care professionals\nLehmann M, Br\u00fcnahl C, L\u00f6we B, Addo M, Schmiedel S, Lohse A, Schramm C\nEMERG INFECT DIS. 2015;21(5):913-914.\nPsychosoziale Belastungen von \u00c4rzten und Pflegepersonal bei der Behandlung eines mit dem Ebola-Virus infizierten Patienten am Universit\u00e4tsklinikum Hamburg Eppendorf im September 2014\nLehmann M, Br\u00fcnahl C, L\u00f6we B, Addo M, Schramm C, Schmiedel S, Lohse A\n2015. Psycho - Somatik. .\nDiagnostic Criteria for Autoimmune Hepatitis: Scores and More\nLohse A\nDIGEST DIS. 2015;33( Suppl. 2):47-52.\nClearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody\nMailly L, Xiao F, Lupberger J, Wilson G, Aubert P, Duong F, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, L\u00fctgehetmann M, Volz T, Davis C, Harris H, Mee C, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim M, Neunlist M, Zeisel M, Dandri-Petersen M, McKeating J, Robinet E, Baumert T\nNAT BIOTECHNOL. 2015;33(5):549-54.\nAutoimmune Hepatitis - Update 2015\nManns M, Lohse A, Vergani D\nJ HEPATOL. 2015;62(1 Suppl):S100-S111.\nAn Unusual Case of Esophageal Ulcer and Weight Loss\nManthey C, Badran A, Denzer U\nGASTROENTEROLOGY. 2015;148(7):e5-e6.\nNeue S2k-Leitlinie \"Gastrointestinale Infektionen und Morbus Whipple\"\nManthey C, Hagel S, Lohse A, Stallmach A\n\u00c4rzteblatt Th\u00fcringen. 2015;26(12):696-700.\nNeue Leitlinie: Wann eine Erregerdiagnostik sinnvoll ist.\nManthey C, Hagel S, Stallmach A, Lohse A\nHamb \u00c4rztebl. 2015;69(11):24-25.\nDefinition of Chronic Hepatitis E after Liver Transplantation Conforms to Convention\nMeisner S, Polywka S, Memmler M, Nashan B, Lohse A, Sterneck M, Pischke S\nAM J TRANSPLANT. 2015;15(11):3011-3012.\nEpithelial IL-18 Equilibrium Controls Barrier Function in Colitis\nNowarski R, Jackson R, Gagliani N, de Zoete M, Palm N, Bailis W, Low J, Harman C, Graham M, Elinav E, Flavell R\nCELL. 2015;163(6):1444-56.\nOptimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?\nPetersen J, Dandri-Petersen M\nLIVER INT. 2015;35 Suppl 1:114-20.\nHepatitis-E-Infektion in der Rheumatologie: Eine bisher untersch\u00e4tzte Infektionskrankheit?\nPischke S, Iking-Konert C\nZ RHEUMATOL. 2015;74(8):731-736.\nAssociation of hepatitis E virus and essential cryoglobulinemia?\nPischke S, Polywka S, Haag F, Iking-Konert C, Sterneck M, L\u00fctgehetmann M, Dammermann W, L\u00fcth S, Schirmer J\nJ CLIN VIROL. 2015;67:23-24.\nHepatitis E in Transplant Recipients: Why is This Not a Problem in Japan?\nPischke S, Wedemeyer H\nEBIOMEDICINE. 2015;2(11):1564-1565.\nQuality of life one year post-Shiga Toxin-producing Eschericia coli O104 infection - A prospective cohort study\nRiegel B, Broicher W, Wegscheider K, Andresen V, Br\u00e4hler E, Lohse A, L\u00f6we B\nNEUROGASTROENT MOTIL. 2015;27(3):370-378.\nDiverse expression patterns of the EMT suppressor grainyhead-like 2 (GRHL2) in normal and tumour tissues\nRiethdorf S, Frey S, Santjer S, Stoupiec M, Otto B, Riethdorf L, Koop C, Wilczak W, Simon R, Sauter G, Pantel K, Assmann V\nINT J CANCER. 2015;138:949-963.\nS2k-Leitlinie nicht alkoholische Fettlebererkrankungen\nRoeb E, Steffen H, Bantel H, Baumann U, Canbay A, Demir M, Drebber U, Geier A, Hampe J, Hellerbrand C, Pathil-Warth A, Schattenberg J, Schramm C, Seitz H, Stefan N, Tacke F, Tannapfel A, Lynen Jansen P, Bojunga J\nZ GASTROENTEROL. 2015;53(7):668-723.\nSerological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers\nRoggelin L, Vinnemeier C, Fischer-Herr J, Johnson-Weaver B, Rolling T, Burchard G, Staats H, Cramer J\nVACCINE. 2015;33(33):4141-5.\nA 2013/2014 northern hemisphere season surface antigen inactivated trivalent influenza vaccine - Assessing the immunogenicity and safety in an open label, uncontrolled study\nRoggelin L, Vinnemeier C, Meyer S, Witte K, Marx L, Thee\u00df W, Burchard G, Rolling T, Cramer J\nHUM VACC IMMUNOTHER. 2015;11(10):2370-5.\nDelayed haemolysis after artesunate treatment of severe malaria - Review of the literature and perspective\nRolling T, Agbenyega T, Krishna S, Kremsner P, Cramer J\nTRAVEL MED INFECT DI. 2015;13(2):143-149.\nLow SAMHD1 expression following T-cell activation and proliferation renders CD4+ T cells susceptible to HIV-1\nRuffin N, Brezar V, Ayinde D, Lefebvre C, Schulze Zur Wiesch J, Lunzen J, Bockhorn M, Schwartz O, Hocini H, Lelievre J, Banchereau J, Levy Y, Seddiki N\nAIDS. 2015;29(5):519-30.\nTim-3 blocking rescue macrophage and T cell function against Mycobacterium tuberculosis infection in HIV+ patients\nSada-Ovalle I, Oca\u00f1a-Guzman R, P\u00e9rez-Patrige\u00f3n S, Ch\u00e1vez-Gal\u00e1n L, Sierra-Madero J, Torre-Bouscoulet L, Addo M, Addo M\nJ INT AIDS SOC. 2015;18(1):20078.\nHematogenous dissemination of Candida dubliniensis causing spondylodiscitis and spinal abscess in a HIV-1 and HCV-coinfected patient\nSalzer H, Rolling T, Klupp E, Schmiedel S\nMed Mycol Case Rep. 2015;8:17-20.\nPrevalence of malaria parasitaemia in school children from two districts of Ghana earmarked for indoor residual spraying: a cross-sectional study\nSarpong N, Owusu-Dabo E, Kreuels B, Fobil J, Segbaya S, Amoyaw F, Hahn A, Kruppa T, May J\nMALARIA J. 2015;14:260.\nArginine and NASH--do macrophages deliver the first hit?\nScheja L, Kluwe J\nJ HEPATOL. 2015;62(2):260-1.\nTravel-associated infection presenting in Europe (2008-12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation\nSchlagenhauf P, Weld L, Goorhuis A, Gautret P, Weber R, von Sonnenburg F, Lopez-V\u00e9lez R, Jensenius M, Cramer J, Field V, Odolini S, Gkrania-Klotsas E, Chappuis F, Malvy D, van Genderen P, Mockenhaupt F, Jaur\u00e9guiberry S, Smith C, Beeching N, Ursing J, Rapp C, Parola P, Grobusch M\nLANCET INFECT DIS. 2015;15(1):55-64.\nEbolafieber in Westafrika und in Deutschland: Klinik, Management und Erfahrungen mit den bisher in Deutschland behandelten Patienten\nSchmiedel S, Kreuels B\nBUNDESGESUNDHEITSBLA. 2015;58(7):679-685.\nFasciola hepatica in a German Traveler Returning From Thailand\nSchmiedel S, Salzer H\nJ TRAVEL MED. 2015; 22( 4):285\u2013286.\nDifferential signaling by regulatory subunits of phosphoinositide-3-kinase influences cell survival in INS-1E insulinoma cells\nSchrader J, Niebel P, Rossi A, Archontidou-Aprin E, H\u00f6rsch D\nEXP CLIN ENDOCR DIAB. 2015;123(2):118-25.\nPrimary Biliary Cirrhosis: Time to Replace a Misnomer: Reply to Giovanni Battista Levi Sandri\nSchramm C, Wahl I, Lohse A\nHEPATOLOGY. 2015;61(4):1435.\nCriteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with PrimarCortico-Cerebellar Structural Connectivity Is Related to Residual Motor Output in Chronic Strokey Sclerosing Cholangitis\nSchulze K, Weism\u00fcller T, Bubenheim M, H\u00fcbener P, Zenouzi R, Lenzen H, Rupp C, Gotthardt D, de Leuw P, Teufel A, Zimmer V, Reiter F, Rust C, Tharun L, Quaas A, Weidemann S, Lammert F, Sarrazin C, Manns M, Lohse A, Schramm C\nPLOS ONE. 2015;10(10):Art. e0140525.\nThe elephant and the blind men: making sense of the seemingly multifaceted role of Blimp-1 in HIV-1 infection\nSchulze Zur Wiesch J, Beisel C\nAIDS. 2015;29(1):134-6.\nTestosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis\nSchwinge D, Carambia A, Quaas A, Krech T, Wegscheid C, Tiegs G, Prinz I, Lohse A, Herkel J, Schramm C\nJ IMMUNOL. 2015;194(6):2522-30.\nPhenotypic alterations of regulatory T cells in autoimmune hepatitis: causal or associated with treatment and remission?\nSebode M, Peiseler M, Weiler-Normann C, Schramm C, Lohse A, Herkel J\nHEPATOLOGY. 2015;61(2):736-737.\nAIH:Which Alternative for Difficult-to-Treat Patients?\nSebode M, Schramm C\nDIGEST DIS. 2015;33 Suppl 2:83-7.\nNatural killer T cells: Novel players in biliary disease?\nSebode M, Schramm C\nHEPATOLOGY. 2015;62(4):999-1000.\nAktuelle Therapiekonzepte f\u00fcr lokale Cholangiokarzinome\nSeehofer D, Brunner T, Wege H\nONKOLOGE. 2015;10:1054 - 1063.\nRight Atrial Volume is Increased in Corrected Tetralogy of Fallot and Correlates with the Incidence of Supraventricular Arrhythmia: A CMR Study\nSohns J, Rosenberg C, Zapf A, Unterberg-Buchwald C, Staab W, Schuster A, Kowallick J, H\u00f6sch O, Nguyen T, Fasshauer M, Paul T, Lotz J, Steinmetz M\nPEDIATR CARDIOL. 2015;36(6):1239-1247.\n24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis\nSombetzki M, Fuchs C, Fickert P, \u00d6sterreicher C, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, G\u00fcnther N, Schramm C, Mueller-Hilke B, Reisinger E, Trauner M\nJ HEPATOL. 2015;62(4):871-8.\nUrbanicity and Paediatric Bacteraemia in Ghana-A Case-Control Study within a Rural-Urban Transition Zone\nSothmann P, Krumkamp R, Kreuels B, Sarpong N, Frank C, Ehlkes L, Fobil J, Gyau K, Jaeger A, Bosu B, Marks F, Owusu-Dabo E, Salzberger B, May J\nPLOS ONE. 2015;10(9):e0139433.\nDetermination of the mutant allele frequency in patients with neurofibromatosis type 2 and somatic mosaicism by means of deep sequencing\nSpyra M, Otto B, Sch\u00f6n G, Kehrer-Sawatzki H, Mautner V\nGENE CHROMOSOME CANC. 2015;54(8):482-488.\nDiagnostik und Therapie infekti\u00f6ser Durchfallerkrankungen Was ist gesichert?\nStallmach A, Hagel S, Lohse A\nINTERNIST. 2015;56:1353-1360.\nAdjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial\nStein A, Arnold D, Bridgewater J, Goldstein D, Jensen L, Kl\u00fcmpen H, Lohse A, Nashan B, Primrose J, Schrum S, Shannon J, Vettorazzi E, Wege H\nBMC CANCER. 2015;15:Art. 564.\nPrenatal Acetaminophen Affects Maternal Immune and Endocrine Adaptation to Pregnancy, Induces Placental Damage, and Impairs Fetal Development in Mice\nThiele K, Solano M, Huber S, Flavell R, Kessler T, Barikbin R, Jung R, Karimi K, Tiegs G, Arck P\nAM J PATHOL. 2015;185(10):2805-2818.\nRole of the Fyn -93A>G polymorphism (rs706895) in acute rejection after liver transplantation\nThude H, Kramer K, Peine S, Sterneck M, Nashan B, Koch M\nHUM IMMUNOL. 2015;76(9):657-662.\nHeterogeneous CD3 expression levels in differing T cell subsets correlate with the in vivo anti-CD3-mediated T cell modulation\nValle A, Barbagiovanni G, Jofra T, Stabilini A, Perol L, Baeyens A, Anand S, Cagnard N, Gagliani N, Piaggio E, Battaglia M\nJ IMMUNOL. 2015;194(5):2117-27.\nGroup B Streptococci Serotype Distribution in Pregnant Women in Ghana Assessment of Potential Coverage Through Future Vaccines\nVinnemeier C, Brust P, Owusu-Dabo E, Sarpong N, Sarfo E, Bio Y, Rolling T, Dekker D, Adu-Sarkodie Y, Eberhardt K, May J, Cramer J\nTROP MED INT HEALTH. 2015;20(11):1516-24.\nTemoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study\nWagner A, Denzer U, Neureiter D, Kiesslich T, Puespoeck A, Rauws E, Emmanuel K, Degenhardt N, Frick U, Beuers U, Lohse A, Berr F, Wolkersd\u00f6rfer G\nHEPATOLOGY. 2015;62(5):1456-65.\nDer besondere Fall - Rippenprellung mit ungew\u00f6hnlichem Verlauf\nWagner H, Henes F, Li Y, Schmiedel S\nHamb \u00c4rztebl. 2015;(07/08):28-29.\nPrimary biliary \"cirrhosis\" time to replace a misnomer\nWahl I, Feige A, L\u00f6we B, Weiler-Normann C, Rose M, Lohse A, Schramm C\nHEPATOLOGY. 2015;61(3):1091.\nIn reply\nWedemeyer H, Pischke S\nDTSCH ARZTEBL INT. 2015;112(13):220.\nHigh Rate of Cardiac Abnormalities in a Postmortem Analysis of Patients Suffering From Liver Cirrhosis\nWehmeyer M, Heuer A, Benten D, P\u00fcschel K, Sydow K, Lohse A, L\u00fcth S\nJ CLIN GASTROENTEROL. 2015;49(10):866-872.\nEfficacy and safety of sofosbuvir-based triple therapy in hepatitis C genotype 4 infection.\nWehmeyer M, Jordan S, L\u00fcth S, Hartl J, Stoehr A, Ei\u00dfing C, Lohse A, Petersen J, Buggisch P, Schulze zur Wiesch J\nDIGEST LIVER DIS. 2015;47(9):811-814.\nFirst data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology\nWeiss J, Rau M, Bantel H, Bock H, Demir M, Kluwe J, Krawczyk M, Pathil-Warth A, Schattenberg J, Tacke F, Roeb E, Geier A\nZ GASTROENTEROL. 2015;53(6):562-7.\nIsolation in patients with Ebola virus disease\nWichmann D, Schmiedel S, Kluge S\nINTENS CARE MED. 2015;41(3):511-3.\nAuswirkungen des glyk\u00e4mischen Index auf kardiovaskul\u00e4re Risikofaktoren: The OmniCarb randomized clinical trial\nWindler E, Nitschmann S\nINTERNIST. 2015;56(8):949-952.\nSupplementierung von Phytosterinen: Perspektive oder Risiko?\nWindler E, Zyriax B, Beil F\nCardiovasc. 2015;46-51.\n73-j\u00e4hrige leber- und nierentransplantierte Patientin mit dumpfen Oberbauchschmerzen und rezidivierendem Nasenbluten\nZinser M, Salzer H, Stein A, von Petersdorff-Campen M, Koops A, Holzh\u00fcter J\nINTERNIST. 2015;56(5):566-72.\nAnti-HDV IgM as a marker of disease activity in hepatitis delta\nPLOS ONE. 2014;9(7):e101002.\nThe orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response\nAbramowski P, Otto B, Martin R\nPLOS ONE. 2014;9(3):e91970.\nSex-based differences in HIV type 1 pathogenesis\nAddo M, Altfeld M\nJ INFECT DIS. 2014;209 Suppl 3(Suppl 3):S86-92.\nImmune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration\nAllweiss L, Volz T, L\u00fctgehetmann M, Giersch K, Bornscheuer T, Lohse A, Petersen J, Ma H, Klumpp K, Fletcher S, Dandri M\nJ HEPATOL. 2014;60(3):500-7.\nRegulatory T cells expanded from HIV-1-infected individuals maintain phenotype, TCR repertoire and suppressive capacity\nAngin M, Klarenbeek P, King M, Sharma S, Moodley E, Rezai A, Piechocka-Trocha A, Toth I, Chan A, Goulder P, Ndung'u T, Kwon D, Addo M\nPLOS ONE. 2014;9(2):e86920.\nHIV-1 infection impairs regulatory T-cell suppressive capacity on a per-cell basis\nAngin M, Sharma S, King M, Murooka T, Ghebremichael M, Mempel T, Walker B, Bhasin M, Addo M\nJ INFECT DIS. 2014;210(6):899-903.\nGerman cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients\nBeisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, L\u00fcth S, Lunzen J, Schulze Zur Wiesch J\nAIDS RES THER. 2014;11:16.\nReduced expression of Blimp-1 in memory B cells in patients with HIV-1 infection suggests distinct roles of this molecule for B and T cell regulation\nBeisel C, Toth I, Lunzen J, Schulze Zur Wiesch J\nAIDS. 2014;28(16):2489-2491.\nAssociation of autoimmune hepatitis and systemic lupus erythematodes: a case series and review of the literature\nBeisel C, Weiler-Normann C, Teufel A, Lohse A\nWORLD J GASTROENTERO. 2014;20(35):12662-12667.\nTGF-\u03b2-dependent induction of CD4\u207aCD25\u207aFoxp3\u207a Tregs by liver sinusoidal endothelial cells\nCarambia A, Freund B, Schwinge D, Heine M, Laschtowitz A, Huber S, Wraith D, Korn T, Schramm C, Lohse A, Heeren J, Herkel J\nJ HEPATOL. 2014;61(3):594-9.\nDeciphering the highway code for lymphocyte traffic along the gut - liver axis.\nCarambia A, Herkel J\nJ HEPATOL. 2014;60(6):1110-1111.\nLiver sinusoidal cells collecting MHC-I molecules: You can't get enough of a good thing.\nCarambia A, Herkel J\nJ HEPATOL. 2014;61(3):464-465.\nOnce-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study\nClotet B, Feinberg J, van Lunzen J, Khuong-Josses M, Antinori A, Dumitru I, Pokrovskiy V, Fehr J, Ortiz R, Saag M, Harris J, Brennan C, Fujiwara T, Min S\nLANCET. 2014;383(9936):2222-2231.\nWeek 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults\nCohen C, Wohl D, Arribas J, Henry K, Van Lunzen J, Bloch M, Towner W, Wilkins E, Ebrahimi R, Porter D, White K, Walker I, Chuck S, De-Oertel S, Fralich T\nAIDS. 2014;28(7):989-997.\nTransduction of fetal mice with a feline lentiviral vector induces liver tumors which exhibit an E2F activation signature\nCondiotti R, Goldenberg D, Giladi H, Schnitzer-Perlman T, Waddington S, Buckley S, Heim D, Cheung W, Themis M, Coutelle C, Simerzin A, Osejindu E, Wege H, Themis M, Galun E\nMOL THER. 2014;22(1):59-68.\nMultiplexing clonality: combining RGB marking and genetic barcoding\nCornils K, Thielecke L, H\u00fcser S, Forgber M, Thomaschewski M, Kleist N, Hussein K, Riecken K, Volz T, Gerdes S, Glauche I, Dahl A, Dandri M, Roeder I, Fehse B\nNUCLEIC ACIDS RES. 2014;42(7):e56.\nDengue-Virus & Co.: Sind durch Stechm\u00fccken \u00fcbertragene Viren auf dem Vormarsch?\nCramer J, Schmidt-Chanasit J\nDEUT MED WOCHENSCHR. 2014;139(6):247-50.\nCMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists\nDammermann W, Bochmann D, Bentzien F, Komorowski L, Steinhagen K, Ullrich S, van Lunzen J, L\u00fcth S\nJ IMMUNOL METHODS. 2014;414:82-90.\nMouse models of hepatitis B and delta virus infection\nDandri M, L\u00fctgehetmann M\nJ IMMUNOL METHODS. 2014;410:39-49.\nGenome-wide association study identifies variants associated with autoimmune hepatitis type 1\nde Boer Y, van Gerven N, Zwiers A, Verwer B, van Hoek B, van Erpecum K, Beuers U, van Buuren H, Drenth J, den Ouden J, Verdonk R, Koek G, Brouwer J, Guichelaar M, Vrolijk J, Kraal G, Mulder C, van Nieuwkerk C, Fischer J, Berg T, Stickel F, Sarrazin C, Schramm C, Lohse A, Weiler-Normann C, Lerch M, Nauck M, V\u00f6lzke H, Homuth G, Bloemena E, Verspaget H, Kumar V, Zhernakova A, Wijmenga C, Franke L, Bouma G\nGASTROENTEROLOGY. 2014;147(2):443-452.\nCardioprotective effects of osteopontin-1 during development of murine ischemic cardiomyopathy\nDuerr G, Mesenholl B, Heinemann J, Zoerlein M, H\u00fcbener P, Schneider P, Feisst A, Ghanem A, Tiemann K, Dewald D, Welz A, Dewald O\nBIOMED RES INT . 2014;2014:124063.\nCD161+ MAIT cells are severely reduced in peripheral blood and lymph nodes of HIV-infected individuals independently of disease progression\nEberhard J, Hartjen P, Kummer S, Schmidt R, Bockhorn M, Lehmann C, Balagopal A, Hauber J, Lunzen J, Schulze zur Wiesch J\nPLOS ONE. 2014;9(11):e111323.\nLeishmaniasis acquired by travellers to endemic regions in Europe: a EuroTravNet multi-centre study\nEhehalt U, Schunk M, Jensenius M, van Genderen P, Gkrania-Klotsas E, Chappuis F, Schlagenhauf P, Castelli F, Lopez-Velez R, Parola P, Burchard G, Cramer J\nTRAVEL MED INFECT DI. 2014;12(2):167-72.\nDeath receptor-independent FADD signalling triggers hepatitis and hepatocellular carcinoma in mice with liver parenchymal cell-specific NEMO knockout\nEhlken H, Krishna-Subramanian S, Ochoa-Callejero L, Kondylis V, Nadi N, Straub B, Schirmacher P, Walczak H, Kollias G, Pasparakis M\nCELL DEATH DIFFER. 2014;21(11):1721-1732.\nTransient elastography in primary sclerosing cholangitis-the value as a prognostic factor and limitations\nEhlken H, Lohse A, Schramm C\nGASTROENTEROLOGY. 2014;147(2):542-543.\nPSC: Novel disease associations providing pathogenetic clues?\nEhlken H, Schramm C\nJ HEPATOL. 2014;60(4):687-688.\nGeographically weighted regression of land cover determinants of Plasmodium falciparum transmission in the Ashanti Region of Ghana\nEhlkes L, Krefis A, Kreuels B, Krumkamp R, Adjei O, Ayim-Akonor M, Kobbe R, Hahn A, Vinnemeier C, Loag W, Schickhoff U, May J\nINT J HEALTH GEOGR. 2014;13:35.\nSpecific genomic and transcriptomic aberrations in tumors induced by partial hepatectomy of a chronically inflamed murine liver\nElla E, Heim D, Stoyanov E, Harari-Steinfeld R, Steinfeld I, Pappo O, Perlman T, Nachmansson N, Rivkin L, Olam D, Abramovitch R, Wege H, Galun E, Goldenberg D\nONCOTARGET. 2014;5(21):10318-10331.\nTACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial\nErhardt A, Kolligs F, Dollinger M, Schott E, Wege H, Bitzer M, Gog C, Lammert F, Schuchmann M, Walter C, Blondin D, Ohmann C, H\u00e4ussinger D\nCANCER CHEMOTH PHARM. 2014;74(5):947-954.\nImaging of the murine biliopancreatic tract at 7 tesla: Technique and results in a model of primary sclerosing cholangitis\nErnst T, Schwinge D, Raabe N, Daubmann A, Kaul M, Adam G, Schramm C, Ittrich H\nJ MAGN RESON IMAGING. 2014;40(6):1355-1364.\nCharacterization of animal models for primary sclerosing cholangitis (PSC)\nFickert P, Pollheimer M, Beuers U, Lackner C, Hirschfield G, Housset C, Keitel V, Schramm C, Marschall H, Karlsen T, Melum E, Kaser A, Eksteen B, Strazzabosco M, Manns M, Trauner M\nJ HEPATOL. 2014;60(6):1290-1303.\nThe Fire Within: Microbes Inflame Tumors\nGagliani N, Hu B, Huber S, Elinav E, Flavell R\nCELL. 2014;157(4):776-783.\nPersistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection\nGiersch K, Helbig M, Volz T, Allweiss L, Mancke L, Lohse A, Polywka S, Pollok J, Petersen J, Taylor J, Dandri M, L\u00fctgehetmann M\nJ HEPATOL. 2014;60(3):538-44.\nA dead-end host: is there a way out? A position piece on the ebola virus outbreak by the international union of immunology societies\nGray C, Addo M, Schmidt R\nFRONT IMMUNOL. 2014;5:562.\nIncreased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis\nGrint D, Peters L, Rockstroh J, de Wit S, Mitsura V, Knysz B, Pedersen C, Kirk O, Lundgren J, Mocroft A\nAIDS. 2014;28(4):577-587.\nSafety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study\nHarrer T, Plettenberg A, Arast\u00e9h K, Van Lunzen J, F\u00e4tkenheuer G, Jaeger H, Janssens M, Burny W, Collard A, Roman F, Loeliger A, Koutsoukos M, Bourguignon P, Lavreys L, Voss G\nVACCINE. 2014;32(22):2657-2665.\nAn Unresectable Klatskin's Tumor?\nHartl J, Werner T, Schramm C\nGASTROENTEROLOGY. 2014;146(7):e3-e4.\nRelevance of a Full-Length Genomic RNA Standard and a Thermal-Shock Step for Optimal Hepatitis Delta Virus Quantification\nHoms M, Giersch K, Blasi M, L\u00fctgehetmann M, Buti M, Esteban R, Dandri M, Rodriguez-Frias F\nJ CLIN MICROBIOL. 2014;52(9):3334-8.\nChronic hepatitis E virus infection beyond transplantation or human immunodeficiency virus infection\nH\u00f6ner zu Siederdissen C, Pischke S, Schlue J, Deterding K, Hellms T, Schuler-L\u00fcttmann S, Schwarz A, Manns M, Cornberg M, Wedemeyer H\nHEPATOLOGY. 2014;60(3):1112-113.\nMolekulare Therapie neuroendokriner Neoplasien: Sunitinib (Sutent) und Everolimus (Afinetor).\nH\u00f6rsch D, Schrader J\nVerdauungskrankheiten. 2014;(32 (3)):147-150.\nDevelopment and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure\nJalan R, Saliba F, Pavesi M, Amoros A, Moreau R, Gin\u00e8s P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Mu\u00f1oz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V\nJ HEPATOL. 2014;61(5):1038-1047.\nDer besondere Fall: Anhaltendes Leberknarren: Seltene Diagnose: Eine 25-j\u00e4hrige stellte sich mit atemabh\u00e4ngigen Schmerzen und Reibeger\u00e4usch unter dem Rippenbogen in der Klinik vor. Grund war eine Komplikation einer Infektion.\nJochum J, Schmiedel S\nHamb \u00c4rztebl. 2014;(09):30-31.\nDevelopment of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study\nKamara D, Ryom L, Ross M, Kirk O, Reiss P, Morlat P, Moranne O, Fux C, Mocroft A, Sabin C, Lundgren J, Smith C\nBMC NEPHROL. 2014;15:51.\nRandomized, Placebo-Controlled Trial or Post Hoc Subgroup Analysis: The Importance of Standardized and Comprehensive Reporting\nKarch A, Krumkamp R, Kreuels B\nJ INFECT DIS. 2014;210(1):15-159.\nTuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors\nKaro B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L\nBMC INFECT DIS. 2014;14:148.\nPolymorphism in NFKBIA gene is associated with recurrent acute rejections in liver transplant recipients\nKramer K, Thye T, Treszl A, Peine S, Koch M, Sterneck M, Nashan B, Thude H\nTISSUE ANTIGENS. 2014;84(4):370-7.\nNeurocysticercosis in a European Traveler Returning From India, Primarily Suspected as Neoplasia Response\nKrause R, Salzer H\nJ TRAVEL MED. 2014;21(1):75.\nA case of severe Ebola virus infection complicated by gram-negative septicemia\nKreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, Heer G, Kluge S, Sow A, Renn\u00e9 T, G\u00fcnther S, Lohse A, Addo M, Schmiedel S\nNEW ENGL J MED. 2014;371(25):2394-401.\nPsychological Outcome, Fatigue, and Quality of Life After Infection With Shiga Toxin-Producing Escherichia coli O104\nL\u00f6we B, Andresen V, Zimmermann-Fraedrich K, Gappmayer K, Wegscheider K, Treszl A, Riegel B, Rose M, Lohse A, Broicher W\nCLIN GASTROENTEROL H. 2014.\nSpecific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA\nLucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl M, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou W, Thasler W, H\u00fcser N, Durantel D, Liang T, M\u00fcnk C, Heim M, Browning J, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U\nSCIENCE. 2014;343(6176):1221-1228.\nHepatitis C: Neues vom amerikanischen Leberkongress AASLD\nL\u00fcth S\nDEUT MED WOCHENSCHR. 2014;139(3):71-73.\nPrevention of hemolytic uremic syndrome with daily bowel lavage in patients with Shiga toxin-producing enterohemorrhagic Escherichia coli O104:H4 infection\nL\u00fcth S, Fr\u00fcndt T, R\u00f6sch T, Schlee C, Lohse A\nJAMA INTERN MED. 2014;174(6):1003-5.\nEntwicklung infekti\u00f6ser Durchfallerkrankungen zwischen den Jahren 2000 und 2012\nLynen Jansen P, Stallmach A, Lohse A, Lerch M\nZ GASTROENTEROL. 2014;52(6):549-57.\nGemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme\nMoehler M, Maderer A, Schimanski C, Kanzler S, Denzer U, Kolligs F, Ebert M, Distelrath A, Geissler M, Trojan J, Sch\u00fctz M, Berie L, Sauvigny C, Lammert F, Lohse A, Dollinger M, Lindig U, Duerr E, Lubomierski N, Zimmermann S, Wachtlin D, Kaiser A, Schadmand-Fischer S, Galle P, Woerns M, , Denzer U\nEUR J CANCER. 2014;50(18):3125-35.\nAnalysis of the power of common diagnostic tools in the management of acute pancreatitis\nNistal M, Zoltani M, Lohse A, Di Daniele N, Tesauro M, Pace A\nGASTROENT RES PRACT. 2014;2014:438697.\nSynergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines\nNitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kr\u00f6ger N, Ayuketang F\nANTICANCER RES. 2014;34(4):1779-84.\nBinding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism\nOehler N, Volz T, Bhadra O, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok J, Lohse A, Fehse B, Petersen J, Urban S, L\u00fctgehetmann M, Heeren J, Dandri M\nHEPATOLOGY. 2014.\nMolecular changes in pre-metastatic lymph nodes of esophageal cancer patients\nOtto B, Koenig A, Tolstonog G, Jeschke A, Kl\u00e4tschke K, Vashist Y, Wicklein D, Wagener C, Izbicki J, Streichert T\nPLOS ONE. 2014;9(7):e102552.\nSimplification to rilpivirine/emtricitabine/tenofovir disoproxil fumarate from ritonavir-boosted protease inhibitor antiretroviral therapy in a randomized trial of HIV-1 RNA-suppressed participants\nPalella F, Fisher M, Tebas P, Gazzard B, Ruane P, Van Lunzen J, Shamblaw D, Flamm J, Ebrahimi R, Porter D, White K, Hindman J, Elbert E, De-Oertel S, Fralich T\nAIDS. 2014;28(3):335-344.\nHepatitis E in Germany-an under-reported infectious disease\nPischke S, Behrendt P, Bock C, Jilg W, Manns M, Wedemeyer H\nDTSCH ARZTEBL INT. 2014;111(35-36):577-583.\nHepatitis A\nPischke S, Wedemeyer H\n2014. Hepatology a Clinical Textbook. 5. Aufl. Deutschland: Flying Publisher, 1-655.\nHepatitis E\nPischke S, Wedemeyer H\n2014. Hepatology a Clinical Textbook. 5. Aufl. Deutschland: Flying Publisher, 1-655.\nAge-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection\nRoeder C, Jordan S, Schulze Zur Wiesch J, Pfeiffer-Vornkahl H, Hueppe D, Mauss S, Zehnter E, Stoll S, Alshuth U, Lohse A, L\u00fcth S\nWORLD J GASTROENTERO. 2014;20(31):10984-10993.\nMalaria prevention in the pregnant traveller: a review\nRoggelin L, Cramer J\nTRAVEL MED INFECT DI. 2014;12(3):229-36.\nDisease-associated QT-shortage versus quinine associated QT-Prolongation: age dependent ECG-effects in Ghanaian children with severe malaria\nRoggelin L, Pelletier D, Hill J, Feldt T, Hoffmann S, Ansong D, Sylverken J, Burhenne J, Fischer-Herr J, Mehrfar P, Thiel C, Burchard G, Nguah S, Cramer J\nMALARIA J. 2014;13:219.\nDelayed Hemolysis After Treatment With Parenteral Artesunate in African Children With Severe Malaria-A Double-center Prospective Study\nRolling T, Agbenyega T, Issifou S, Adegnika A, Sylverken J, Spahlinger D, Ansong D, L\u00f6hr S, Burchard G, May J, Mordm\u00fcller B, Krishna S, Kremsner P, Cramer J\nJ INFECT DIS. 2014;209(12):1921-8.\nEosinophilie bei Reiser\u00fcckkehrern \u2013 Rationale Diagnostik\nRolling T, Cramer J\nFLUGMEDIZIN TROPENME. 2014;21(2):79-83.\nWichtige Blickdiagnose in den Tropen: Pellagra durch Mangelern\u00e4hrung - Verwirrtheit, Durchfall und Hautver\u00e4nderungen bei 42-j\u00e4hriger Malawierin\nRothe C\nFLUGMEDIZIN TROPENME. 2014;21(1):12-13.\nDer Fluch der Karibik: Chikungunya nach Kurzurlaub auf Barbados\nRothe C, Schmidt-Chanasit J, Tappe D\nFLUGMEDIZIN TROPENME. 2014;21(6):279-81.\nKrank nach Eskimorolle\nSalzer H, Ehehalt U, Schmiedel S\nHamb \u00c4rztebl. 2014;3:36-37.\nAutoimmune hepatitis on the rise\nSchramm C, Lohse A\nJ HEPATOL. 2014;60(3):478-479.\nHealth-related quality of life, depression, and anxiety in patients with autoimmune hepatitis\nSchramm C, Wahl I, Weiler-Normann C, Voigt K, Wiegard C, Glaubke C, Br\u00e4hler E, L\u00f6we B, Lohse A, Rose M\nJ HEPATOL. 2014;60(3):618-624.\nLeberzirrhose - Was bringen die neuen Substanzen?\nSchulze zur Wiesch J, L\u00fcth S\nHepatitis and more. 2014;1:25-28.\nAuthors reply: diagnosis of a single imported dengue case who had travelled to Japan - how serious is it for travellers?\nSchwarz N, Kreuels B, Stark K, Frank C, Schmidt-Chanasit J\nEUROSURVEILLANCE. 2014;19(8):31-32.\nFuture perspective: immunomodulatory therapy for autoimmune hepatitis\nSebode M, Lohse A\nDIGEST DIS. 2014;32(5):502-506.\nReduced FOXP3(+) regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms\nSebode M, Peiseler M, Franke B, Schwinge D, Schoknecht T, Wortmann F, Quaas A, Petersen B, Ellinghaus E, Baron U, Olek S, Wiegard C, Weiler-Normann C, Lohse A, Herkel J, Schramm C\nJ HEPATOL. 2014;60(5):1010-6.\nNew foe treated with old guns - supportive role of steroids in the treatment of acute severe hepatitis E\nSebode M, Pischke S, L\u00fctgehetmann M, Polywka S, Quaas A, Lohse A, Wege H\nBMC GASTROENTEROL. 2014;14(191):.\nMuskul\u00e4re Sarkozystose nach Malaysiareise: eine Fallserie aus Deutschland\nSlesak G, Tappe D, Keller C, Cramer J, G\u00fcthoff W, Zanger P, Frank M, Ernestus K, Rauthe S, Stich A, Sch\u00e4fer J\nDEUT MED WOCHENSCHR. 2014;139(19):990-5.\nImprovement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients\nSterneck M, Settmacher U, Ganten T, Sarrazin C, Speidel N, Broering D, Heyne N, Paulus E, Mertens M, Fischer L\nTRANSPL P. 2014;46(1):234-240.\nDetermination of ethyl glucuronide in hair for detection of alcohol consumption in patients after liver transplantation\nSterneck M, von Rothkirch G, Andresen-Streichert H, Vettorazzi E, Schulze K, Nashan B\n2014. AMERICAN JOURNAL OF TRANSPLANTATION. .\nLack of association between CD40 polymorphisms and acute rejection in German liver transplant recipients\nThude H, Kramer K, Koch M, Peine S, Sterneck M, Nashan B\nHUM IMMUNOL. 2014;75(11):1123-7.\nCD4+ T-cell help is required for effective CD8+ T cell-mediated resolution of acute viral hepatitis in mice\nTrautmann T, Kozik J, Carambia A, Richter K, Lischke T, Schwinge D, Mittr\u00fccker H, Lohse A, Oxenius A, Wiegard C, Herkel J\nPLOS ONE. 2014;9(1):e86348.\nImmunogenicity and safety of an inactivated 2012/2013 trivalent influenza vaccine produced in mammalian cell culture (Optaflu\u00ae): an open label, uncontrolled study\nVinnemeier C, Fischer-Herr J, Meyer S, Liebig K, Thee\u00df W, Burchard G, Cramer J\nHUM VACC IMMUNOTHER. 2014;10(2):441-8.\nThe diagnosis and treatment of cholangiocarcinoma\nVogel A, Wege H, Caca K, Nashan B, Neumann U\nDTSCH ARZTEBL INT. 2014;111(44):748-54.\nSafety and efficacy of protease inhibitor based combination therapy in a single-center \"real-life\" cohort of 110 patients with chronic hepatitis C genotype 1 infection\nWehmeyer M, Ei\u00dfing F, Jordan S, R\u00f6der C, Hennigs A, Degen O, H\u00fcfner A, Hertling S, Schmiedel S, Sterneck M, Lunzen J, Lohse A, Schulze Zur Wiesch J, L\u00fcth S\nBMC GASTROENTEROL. 2014;14:87.\nPrediction of spontaneous bacterial peritonitis in cirrhotic ascites by a simple scoring system\nWehmeyer M, Krohm S, Kastein F, Lohse A, L\u00fcth S\nSCAND J GASTROENTERO. 2014;49(5):595-603.\nReply to: \"Anti-TNF-induced autoimmune hepatitis\"\nWeiler-Normann C, Herkel J, Schramm C, Lohse A\nJ HEPATOL. 2014;61(1):170-171.\nEbolaviruserkrankung: Manifestationsformen der Infektion.\nWolf T, Kreuels B, Schmiedel S, Thomas G\nDeutsches \u00c4rzteblatt. 2014;111(43):A 1856\u20137.\nMatrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin\nW\u00fcstenberg A, Kah J, Singethan K, Sirma H, Keller A, Perez Rosal S, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse A, Tiegs G, Sass G\nPLOS ONE. 2014;9(5):e96533.\nDose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients\nXicoy B, Ribera J, M\u00fcller M, Garc\u00eda O, Hoffmann C, Oriol A, Hentrich M, Grande C, Wasmuth J, Esteve J, van Lunzen J, Del Potro E, Knechten H, Brunet S, Mayr C, Escoda L, Schommers P, Alonso N, Vall-Llovera F, P\u00e9rez M, Morgades M, Gonz\u00e1lez J, Fern\u00e1ndez A, Thoden J, G\u00f6kbuget N, Hoelzer D, F\u00e4tkenheuer G, Wyen C\nLEUKEMIA LYMPHOMA. 2014;55(10):2341-2348.\nAutoimmune Hepatitis - aktuelle Entwicklungen einer zunehmenden Erkrankung\nZenouzi R, Hartl J, Lohse A\nDEUT MED WOCHENSCHR. 2014;139(40):2020-2.\nLong-term outcome in PSC/AIH \"overlap syndrome\": does immunosuppression also treat the PSC component?\nZenouzi R, Lohse A\nJ HEPATOL. 2014;61(5):1189-1191.\nLow Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis\nZenouzi R, Weism\u00fcller T, H\u00fcbener P, Schulze K, Bubenheim M, Pannicke N, Weiler-Normann C, Lenzen H, Manns M, Lohse A, Schramm C\nCLIN GASTROENTEROL H. 2014.\nSeltene Gerinnungsst\u00f6rung oder ein Fall f\u00fcr den Psychiater\nZinser M, Holstein K, Langer F, Voigt P, Holzh\u00fcter J\nHamb \u00c4rztebl. 2014;2014(11):30-31.\nImmuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe\nZoufaly A, Cozzi-Lepri A, Reekie J, Kirk O, Lundgren J, Reiss P, Jevtovic D, Machala L, Zangerle R, Mocroft A, Van Lunzen J\nPLOS ONE. 2014;9(1):e87160.\nHigh HIV prevalence among children presenting for general consultation in rural Cameroon\nZoufaly A, Hammerl R, Sunjoh F, Jochum J, Nassimi N, Awasom C, Tayong G, Sauter F, Schmiedel S, van Lunzen J, Burchard G, Feldt T\nINT J STD AIDS. 2014;25(10):742-744.\nDeterminants of HIV-1 drug resistance in treatment-na\u00efve patients and its clinical implications in an antiretroviral treatment program in Cameroon\nZoufaly A, Jochum J, Hammerl R, Nassimi N, Raymond Y, Burchard G, Schmiedel S, Drexler J, Kay C, Taka N, Awasom C, Metzner K, Lunzen J, Feldt T\nJ INT AIDS SOC. 2014;17(4 Suppl 3):19615.\nImmune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals\nZoufaly A, Kiepe J, Hertling S, H\u00fcfner A, Degen O, Feldt T, Schmiedel S, Kurowski M, van Lunzen J\nHIV MED. 2014;15(8):449-457.\nSubacute liver failure following anakinra treatment for adult-onset Still disease\nAly L, Iking-Konert C, Quaas A, Benten D\nJ RHEUMATOL. 2013;40(10):1775-7.\nNew tools to expand regulatory T cells from HIV-1-infected individuals\nAngin M, King M, Addo M\nJOVE-J VIS EXP. 2013;(75):e50244.\nShiga toxin-producing E. coli O104:H4 outbreak 2011 in Germany: radiological features of enterohemorrhagic colitis\nBannas P, Zimmermann-Fraedrich K, Treszl A, Bley T, Herrmann J, Habermann C, Derlin T, Henes F, Wenzel U, Adam G, Yamamura J\nROFO-FORTSCHR RONTG. 2013;185(5):434-9.\nFulminant Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.\nBohne S, Kentouche K, Petersen I, Fritzenwanger M, Pletz M, Lehmberg K, Paul L, Guntinas-Lichius O\nLARYNGOSCOPE. 2013;123(2):362-365.\nParadoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer\nBosurgi L, Bernink J, Delgado Cuevas V, Gagliani N, Joannas L, Schmid E, Booth C, Ghosh S, Rothlin C\nP NATL ACAD SCI USA. 2013;110(32):13091-6.\nReisediarrhoe\nBurchard G, Hentschke M, Weinke T, Nothdurft H\nDEUT MED WOCHENSCHR. 2013;138(33):1673-83; quiz 1684-6.\nHepatocytes contribute to immune regulation in the liver by activation of the Notch signaling pathway in T cells\nBurghardt S, Erhardt A, Claass B, Huber S, Adler G, Jacobs T, Chalaris A, Schmidt-Arras D, Rose-John S, Karimi K, Tiegs G\nJ IMMUNOL. 2013;191(11):5574-82.\nInhibition of inflammatory CD4 T cell activity by murine liver sinusoidal endothelial cells\nCarambia A, Frenzel C, Bruns O, Schwinge D, Reimer R, Hohenberg H, Huber S, Tiegs G, Schramm C, Lohse A, Herkel J\nJ HEPATOL. 2013;58(1):112-8.\nT cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response\nCarrera Silva E, Chan P, Joannas L, Errasti A, Gagliani N, Bosurgi L, Jabbour M, Perry A, Smith-Chakmakova F, Mucida D, Cheroutre H, Burstyn-Cohen T, Leighton J, Lemke G, Ghosh S, Rothlin C\nIMMUNITY. 2013;39(1):160-70.\nDuodenale F\u00e4kalinfusion bei Rezidivinfektion mit Clostridium difficile? - Vielversprechende Intervention mit einigen Fragezeichen\nCramer J\nDEUT MED WOCHENSCHR. 2013;138(12):566.\nIncreased expression of complement regulators CD55 and CD59 on peripheral blood cells in patients with EAHEC O104:H4 infection\nDammermann W, Schipper P, Ullrich S, Zimmermann-Fraedrich K, Schulze Zur Wiesch J, Fr\u00fcndt T, Tiegs G, Lohse A, L\u00fcth S\nPLOS ONE. 2013;8(9):e74880.\nToll like receptor 2 agonists lipoteichoic acid and peptidoglycan are able to enhance antigen specific IFN\u03b3 release in whole blood during recall antigen responses\nDammermann W, Wollenberg L, Bentzien F, Lohse A, L\u00fcth S\nJ IMMUNOL METHODS. 2013;396(1-2):107-15.\nExperimental models and therapeutic approaches for HBV\nDandri M, L\u00fctgehetmann M, Petersen J\nSEMIN IMMUNOPATHOL. 2013;35(1):7-21.\nPrimary sclerosing cholangitis and cholangiocarcinoma: pathogenesis and modes of diagnostics\nEhlken H, Schramm C\nDIGEST DIS. 2013;31(1):118-25.\nGenome-wide association analysis in Primary sclerosing cholangitis and ulcerative colitis identifies risk loci at GPR35 and TCF4.\nEllinghaus D, Folseraas T, Holm K, Ellinghaus E, Melum E, Balschun T, Laerdahl J, Shiryaev A, Gotthardt D, Weism\u00fcller T, Schramm C, Wittig M, Bergquist A, Bj\u00f6rnsson E, Marschall H, Vatn M, Teufel A, Rust C, Gieger C, Wichmann H, Runz H, Sterneck M, Rupp C, Braun F, Weersma R, Wijmenga C, Ponsioen C, Mathew C, Rutgeerts P, Vermeire S, Schrumpf E, Hov J, Manns M, Boberg K, Schreiber S, Franke A, Karlsen T\nHEPATOLOGY. 2013;58(3):1074-1083.\nVedolizumab as induction and maintenance therapy for ulcerative colitis\nFeagan B, Rutgeerts P, Sands B, Hanauer S, Colombel J, Sandborn W, Van Assche G, Axler J, Kim H, Danese S, Fox I, Milch C, Sankoh S, Wyant T, Xu J, Parikh A\nNEW ENGL J MED. 2013;369(8):699-710.\nHepatitis E virus infections in HIV-infected patients in Ghana and Cameroon\nFeldt T, Sarfo F, Zoufaly A, Phillips R, Burchard G, van Lunzen J, Jochum J, Chadwick D, Awasom C, Claussen L, Drosten C, Drexler J, Eis-H\u00fcbinger A\nJ CLIN VIROL. 2013;58(1):18-23.\nEHEC-O104:H4-Ausbruch im Sommer 2011: Charakterisierung der Hamburger Todesf\u00e4lle\nFr\u00fcndt T, H\u00f6pker W, Hagel C, Sperhake J, Isenberg A, L\u00fcth S, Lohse A, Sauter G, Glatzel M, P\u00fcschel K\nRECHTSMEDIZIN. 2013;23:374\u2013382 .\nCoexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.\nGagliani N, Magnani C, Huber S, Gianolini M, Pala M, Licona-Limon P, Guo B, Herbert D, Bulfone A, Trentini F, Clelia D, Bacchetta R, Andreani M, Brockmann L, Gregori S, Flavell R, Roncarolo M\nNAT MED. 2013;19(6):739-746.\nDiagnostik und Therapie des hepatozellul\u00e4ren Karzinoms\nGreten T, Malek N, Schmidt S, Arends J, Bartenstein P, Bechstein W, Bernatik T, Bitzer M, Chavan A, Dollinger M, Domagk D, Drognitz O, D\u00fcx M, Farkas S, Folprecht G, Galle P, Gei\u00dfler M, Gerken G, Habermehl D, Helmberger T, Herfarth K, Hoffmann R, Holtmann M, Huppert P, Jakobs T, Keller M, Klempnauer J, Kolligs F, K\u00f6rber J, Lang H, Lehner F, Lordick F, Lubienski A, Manns M, Mahnken A, M\u00f6hler M, M\u00f6nch C, Neuhaus P, Niederau C, Ocker M, Otto G, Pereira P, Pott G, Riemer J, Ringe K, Ritterbusch U, Rummeny E, Schirmacher P, Schlitt H, Schlottmann K, Schmitz V, Schuler A, Schulze-Bergkamen H, von Schweinitz D, Seehofer D, Sitter H, Stra\u00dfburg C, Stroszczynski C, Strobel D, Tannapfel A, Trojan J, van Thiel I, Vogel A, Wacker F, Wedemeyer H, Wege H, Weinmann A, Wittekind C, W\u00f6rmann B, Zech C\nZ GASTROENTEROL. 2013;51(11):1269-326.\nEndothelial progenitor cells and plasma vascular endothelial growth factor and stromal cell-derived factor-1 during ranibizumab treatment for neovascular age-related macular degeneration\nGrierson R, Stemplewitz B, Kunst F, Berna M, Richard G, Berna-Thill M\nJ OCUL PHARMACOL TH. 2013;29(6):530-8.\nStability of hepatitis C virus (HCV) RNA levels among interferon-na\u00efve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy\nGrint D, Peters L, Reekie J, Soriano V, Kirk O, Knysz B, Suetnov O, Lazzarin A, Ledergerber B, Rockstroh J, Mocroft A\nHIV MED. 2013;14(6):370-8.\nTemporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA\nGrint D, Peters L, Schwarze-Zander C, Beniowski M, Pradier C, Battegay M, Jevtovic D, Soriano V, Lundgren J, Rockstroh J, Kirk O, Mocroft A\nHIV MED. 2013;14(10):614-23.\nAbdominal pain in a patient with a complex history (case report)\nGuthoff A, Schulze zur Wiesch C, Berliner C, Quaas A, Lange M, Bockhorn M\nULTRASCHALL MED. 2013;34(S 01):PS3_07.\nAberrant ZNF423 impedes B cell differentiation and is linked to adverse outcome of ETV6-RUNX1 negative B precursor acute lymphoblastic leukemia\nHarder L, Eschenburg G, Zech A, Kriebitzsch N, Otto B, Streichert T, Behlich A, Dierck K, Klingler B, Hansen A, Stanulla M, Zimmermann M, Kremmer E, Stocking C, Horstmann M\nJ EXP MED. 2013;210(11):2289-304.\nThe NTPase/helicase domain of hepatitis C virus nonstructural protein 3 inhibits protein kinase C independently of its NTPase activity\nHartjen P, H\u00f6chst B, Heim D, von der Kammer H, Lucke J, Reinholz M, Baier A, Smeets R, Wege H, Borowski P, Schulze Zur Wiesch J\nCELL MOL BIOL LETT. 2013;18(3):447-58.\nV\u03b32V\u03b42 T cells are skewed toward a terminal differentiation phenotype in untreated HIV infection\nHartjen P, Meyer-Olson D, Lehmann C, Stellbrink H, van Lunzen J, Schulze zur Wiesch J\nJ INFECT DIS. 2013;208(1):180-2.\nHighly significant antiviral activity of HIV-1 LTR-specific tre-recombinase in humanized mice\nHauber I, Hofmann-Sieber H, Chemnitz J, Dubrau D, Chusainow J, Stucka R, Hartjen P, Schambach A, Ziegler P, Hackmann K, Schr\u00f6ck E, Schumacher U, Lindner C, Grundhoff A, Baum C, Manz M, Buchholz F, Hauber J\nPLOS PATHOG. 2013;9(9):e1003587.\n44-j\u00e4hrige Patientin mit heredit\u00e4rem nichtpolyp\u00f6sem Kolonkarzinom: Vorsorgeuntersuchungen nichtkolonischer Tumoren\nHolzh\u00fcter J, R\u00f6sch T, Block A, Lohse A, L\u00fcth S\nINTERNIST. 2013;54(3):353-8.\nA 44-year-old woman with hereditary nonpolyposis colon carcinoma: screening examinations for non-colonic tumors.\nHolzh\u00fcter J, R\u00f6sch T, Block A, Lohse A, L\u00fcth S\nINTERNIST. 2013;54:353-358.\nMicrobiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer.\nHu B, Elinav E, Huber S, Strowig T, Hao L, Hafemann A, Jin C, Eisenbarth S, Flavell R\nP NATL ACAD SCI USA. 2013;110(24):9862-9867.\nDysregulated Tim-3 expression on natural killer cells is associated with increased Galectin-9 levels in HIV-1 infection\nJost S, Moreno-Nieves U, Garcia-Beltran W, Rands K, Reardon J, Toth I, Piechocka-Trocha A, Altfeld M, Addo M\nRETROVIROLOGY. 2013;10:74.\nThe causal effect of malaria on stunting - a Mendelian randomization and matching approach\nKang H, Kreuels B, Adjei O, Krumkamp R, May J, Small D\nINT J EPIDEMIOL. 2013;42(5):1390-8.\nBarriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs.\nKatlama C, Deeks S, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, Miller M, Vella S, Schmitz J, Ahlers J, Richman D, Sekaly R\nLANCET. 2013;381(9883):2109-2117.\nIncreased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis\nKatt J, Schwinge D, Schoknecht T, Quaas A, Sobottka I, Burandt E, Becker C, Neurath M, Lohse A, Herkel J, Schramm C\nHEPATOLOGY. 2013;58(3):1084-93.\nHealth care utilization and symptom severity in Ghanaian children--a cross-sectional study\nKrumkamp R, Sarpong N, Kreuels B, Ehlkes L, Loag W, Schwarz N, Zeeb H, Adu-Sarkodie Y, May J\nPLOS ONE. 2013;8(11):e80598.\nAntiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C\nLarrey D, Lohse A, Trepo C, Bronowicki J, Arast\u00e9h K, Bourli\u00e8re M, Calleja J, Stern J, Nehmiz G, Abdallah N, Berger K, Marquis M, Steffgen J, Kukolj G\nANTIMICROB AGENTS CH. 2013;57(10):4727-35.\nGeoSentinel surveillance of illness in returned travelers, 2007-2011\nLeder K, Torresi J, Libman M, Cramer J, Castelli F, Schlagenhauf P, Wilder-Smith A, Wilson M, Keystone J, Schwartz E, Barnett E, von Sonnenburg F, Brownstein J, Cheng A, Sotir M, Esposito D, Freedman D\nANN INTERN MED. 2013;158(6):456-68.\nFunctional characterization of HLA-G\u207a regulatory T cells in HIV-1 infection\nLi C, Toth I, Schulze Zur Wiesch J, Pereyra F, Rychert J, Rosenberg E, van Lunzen J, Lichterfeld M, Yu X\nPLOS PATHOG. 2013;9(1):e1003140.\nDense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis\nLiu J, Hov J, Folseraas T, Ellinghaus E, Rushbrook S, Doncheva N, Andreassen O, Weersma R, Weism\u00fcller T, Eksteen B, Invernizzi P, Hirschfield G, Gotthardt D, Pares A, Ellinghaus D, Shah T, Juran B, Milkiewicz P, Rust C, Schramm C, M\u00fcller T, Srivastava B, Dalekos G, N\u00f6then M, Herms S, Winkelmann J, Mitrovic M, Braun F, Ponsioen C, Croucher P, Sterneck M, Teufel A, Mason A, Saarela J, Leppa V, Dorfman R, Alvaro D, Floreani A, Onengut-Gumuscu S, Rich S, Thompson W, Schork A, N\u00e6ss S, Thomsen I, Mayr G, K\u00f6nig I, Hveem K, Cleynen I, Gutierrez-Achury J, Rica\u00f1o-Ponce I, van Heel D, Bj\u00f6rnsson E, Sandford R, Durie P, Melum E, Vatn M, Silverberg M, Duerr R, Padyukov L, Brand S, Sans M, Annese V, Achkar J, Boberg K, Marschall H, Chazouill\u00e8res O, Bowlus C, Wijmenga C, Schrumpf E, Vermeire S, Albrecht M, Rioux J, Alexander G, Bergquist A, Cho J, Schreiber S, Manns M, F\u00e4rkkil\u00e4 M, Dale A, Chapman R, Lazaridis K, Franke A, Anderson C, Karlsen T\nNAT GENET. 2013;45(6):670-5.\nNot all PBC is the same!\nLohse A, Weiler-Normann C\nGASTROENTEROLOGY. 2013;144(3):494-7.\nKomorbidit\u00e4t rheumatischer und hepatologischer Erkrankungen\nMayet W, Lohse A\nZ RHEUMATOL. 2013;72(6):547-54.\nCD4 cell count and viral load-specific rates of AIDS, non-AIDS and deaths according to current antiretroviral use\nMocroft A, Phillips A, Gatell J, Horban A, Ledergerber B, Zilmer K, Jevtovic D, Maltez F, Podlekareva D, Lundgren J\nAIDS. 2013;27(6):907-18.\nAcute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis\nMoreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V\nGASTROENTEROLOGY. 2013;144(7):1426-37, 1437.e1-9.\nAnalysis of cyclosporin a in hair samples from liver transplanted patients\nM\u00fcller A, Jungen H, Iwersen-Bergmann S, Sterneck M, Andresen-Streichert H\nTHER DRUG MONIT. 2013;35(4):450-8.\nHepatopulmonary syndrome caused by sarcoidosis of the liver treated with transjugular intrahepatic portosystemic shunt.\nNistal M, Pace A, Klose H, Benten D, Lohse A\nTHORAX. 2013;68(9):889-890.\nInnate immune cells in inflammation and cancer\nNowarski R, Gagliani N, Huber S, Flavell R\nCANCER IMMUNOL RES. 2013;1(2):77-84.\nRegulatory T Cell-Derived IL-10 Ameliorates Crescentic GN.\nOstmann A, Paust H, Panzer U, Wegscheid C, Kapffer S, Huber S, Flavell R, Erhardt A, Tiegs G\nJ AM SOC NEPHROL. 2013;24(6):930-942.\nLow-grade and high-grade mammary carcinomas in WAP-T transgenic mice are independent entities distinguished by Met expression.\nOtto B, Gruner K, Heinlein C, Wegwitz F, Nollau P, Ylstra B, Pantel K, Schumacher U, Baumbusch L, Martin-Subero J, Siebert R, Wagener C, Streichert T, Deppert W, Tolstonog G\nINT J CANCER. 2013;132(6):1300-1310.\nTranscription factors link mouse WAP-T mammary tumors with human breast cancer\nOtto B, Streichert T, Wegwitz F, Gevensleben H, Kl\u00e4tschke K, Wagener C, Deppert W, Tolstonog G\nINT J CANCER. 2013;132(6):1311-1322.\nHepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice\nPradere J, Kluwe J, De Minicis S, Jiao J, Gwak G, Dapito D, Jang M, G\u00fcnther N, Mederacke I, Friedman R, Dragomir A, Aloman C, Schwabe R\nHEPATOLOGY. 2013;58(4):1461-73.\nOnce-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study\nRaffi F, Rachlis A, Stellbrink H, Hardy W, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S\nLANCET. 2013;381(9868):735-43.\nAntibiotika-Forschung: Probleme und Perspektiven: Stellungnahme\nReinitzer H, Lohse A, Hacker J\n2013.\nInfiltration of peritumoural but tumour-free parenchyma with IgG4-positive plasma cells in hilar cholangiocarcinoma and pancreatic adenocarcinoma\nResheq Y, Quaas A, von Renteln D, Schramm C, Lohse A, L\u00fcth S\nDIGEST LIVER DIS. 2013;45(10):859-65.\nFurther research needed to support a policy of antiretroviral therapy as an HIV prevention initiative\nRodger A, Bruun T, Vernazza P, Collins S, Estrada V, Van Lunzen J, Corbelli G, Phillips A, Lundgren J\nANTIVIR THER. 2013;18(3):285-7.\nMalariaprophylaxe und Notfalltherapie in der Schwangerschaft \u2013 Aktuelle Datenlage und Empfehlungen\nRoggelin L, Cramer J\nFLUGMEDIZIN TROPENME. 2013;20(3):134-139.\nArtesunate versus quinine in the treatment of severe imported malaria: comparative analysis of adverse events focussing on delayed haemolysis\nRolling T, Wichmann D, Schmiedel S, Burchard G, Kluge S, Cramer J\nMALARIA J. 2013;12:241.\nParagonimiasis\nRothe C\n2013. Principles of Medicine in Africa. Mabey D, Gill G, Parry E, Whitty C (Hrsg.). 4. . Aufl. Cambridge University Press, 473-474.\nLymphatic Filariasis and Loa Loa\nRothe C, Whitty C\n2013. Principles of Medicine in Africa. Mabey D, Gill G, Parry E, Weber M, Whitty C (Hrsg.). 4. Aufl. Cambridge University Press, 453-455.\nAssociation between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study\nRyom L, Mocroft A, Kirk O, Worm S, Kamara D, Reiss P, Ross M, Fux C, Morlat P, Moranne O, Smith C, Lundgren J\nJ INFECT DIS. 2013;207(9):1359-69.\nAssociations between immune depression and cardiovascular events in HIV infection\nSabin C, Ryom L, De Wit S, Mocroft A, Phillips A, Worm S, Weber R, D'Arminio Monforte A, Reiss P, Kamara D, El-Sadr W, Pradier C, Dabis F, Law M, Lundgren J\nAIDS. 2013;27(17):2735-48.\nNeurocysticercosis in a European traveler returning from India primarily suspected as neoplasia\nSalzer H, Hoenigl M, Valentin T, Zollner-Schwetz I, Krause R\nJ TRAVEL MED. 2013;20(5):333-5.\nViral hepatitis in alcohol-dependent inpatients: prevalence, risk factors, and treatment uptake\nSchmidt C, Sch\u00f6n D, Schulte B, L\u00fcth S, Polywka S, Reimer J\nJ ADDICT MED. 2013;7(6):417-21.\nLaparoscopic Heller myotomy versus endoscopic balloon dilatation for the treatment of achalasia: a network meta-analysis\nSchoenberg M, Marx S, Kersten J, R\u00f6sch T, Belle S, K\u00e4hler G, Vassiliou M, L\u00fcth S, von Renteln D\nANN SURG. 2013;258(6):943-52.\nThe role of MDSCs in hepatocellular carcinoma--in vivo veritas?\nSchrader J\nJ HEPATOL. 2013;59(5):921-3.\nAngiogenic growth factors in rheumatoid arthritis.\nSchr\u00f6der M, Viezens L, Fuhrhop I, Ruether W, Sch\u00e4fer C, Schwarzloh B, Algenstaedt P, Fink B, Hansen-Algenstaedt N\nRHEUMATOL INT. 2013;33(2):523-527.\nChemokine profile of disc degeneration with acute or chronic pain.\nSchr\u00f6der M, Viezens L, Sch\u00e4fer C, Friedrichs B, Algenstaedt P, Ruether W, Wiesner L, Hansen-Algenstaedt N\nJ NEUROSURG-SPINE. 2013;18(5):496-503.\nPresence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma\nSchulze K, Gasch C, Staufer K, Nashan B, Lohse A, Pantel K, Riethdorf S, Wege H\nINT J CANCER. 2013;133(9):2165-71.\nImproved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis?\nSchulze Zur Wiesch J, van Lunzen J\nJ INFECT DIS. 2013;208(2):362-363.\nInflammatorische Erkrankungen mit Leber- und Gelenkbeteiligung. Eine differenzialdiagnostische Herausforderung\nSebode M, Schramm C, Lohse A\nINTERNIST. 2013;54(4):441-448.\nClinical relevance of different biomarkers in imported plasmodium falciparum malaria in adults: a case control study\nStauga S, Hahn A, Brattig N, Fischer-Herr J, Baldus S, Burchard G, Cramer J\nMALARIA J. 2013;12:246.\nEfficacy of a travelers' diarrhea vaccine system in travelers to India\nSteffen R, Cramer J, Burchard G, Jelinek T, Schwarz U, Ramdas P, Chatterjee S, Jiang Z, DuPont H, Dewasthaly S, Westritschnig K, Behrens R\nJ TRAVEL MED. 2013;20(6):374-9.\nDolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study\nStellbrink H, Reynes J, Lazzarin A, Voronin E, Pulido F, Felizarta F, Almond S, St Clair M, Flack N, Min S\nAIDS. 2013;27(11):1771-8.\nArmillifer armillatus pentastomiasis in African immigrant, Germany\nTappe D, Haeupler A, Sch\u00e4fer H, Racz P, Cramer J, Poppert S\nEMERG INFECT DIS. 2013;19(3):507-8.\nDissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?\nThimme R, Dandri M\nJ HEPATOL. 2013;58(2):205-209.\nDecreased frequency of CD73+CD8+ T cells of HIV-infected patients correlates with immune activation and T cell exhaustion\nT\u00f3th I, Le A, Hartjen P, Thomssen A, Matzat V, Lehmann C, Scheurich C, Beisel C, Busch C, Degen O, Lohse A, Eiermann T, F\u00e4tkenheuer G, Meyer-Olson D, Bockhorn M, Hauber J, Lunzen J, Schulze Zur Wiesch J\nJ LEUKOCYTE BIOL. 2013;94(4):551-61.\nTemporal effect of HLA-B*57 on viral control during primary HIV-1 infection\nVaidya S, Streeck H, Beckwith N, Ghebremichael M, Pereyra F, Kwon D, Addo M, Rychert J, Routy J, Jessen H, Kelleher A, Hecht F, Sekaly R, Carrington M, Walker B, Allen T, Rosenberg E, Altfeld M\nRETROVIROLOGY. 2013;10:139.\nNeisseria meningitidis \u2013 Verf\u00fcgbare Impfstoffe, neue Entwicklungen und Relevanz f\u00fcr die Reisemedizin\nVinnemeier C, Cramer J\nFLUGMEDIZIN TROPENME. 2013;20(5):228-233.\nThe entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus\nVolz T, Allweiss L, Ben MBarek M, Warlich M, Lohse A, Pollok J, Alexandrov A, Urban S, Petersen J, L\u00fctgehetmann M, Dandri M\nJ HEPATOL. 2013;58(5):861-7.\nDuration of fecal shedding of Shiga toxin-producing Escherichia coli O104:H4 in patients infected during the 2011 outbreak in Germany: a multicenter study\nVonberg R, H\u00f6hle M, Aepfelbacher M, Bange F, Belmar Campos C, Claussen K, Christner M, Cramer J, Haller H, Hornef M, Fickenscher H, Zimmermann-Fraedrich K, Knobloch J, K\u00fchbacher T, Manns M, Nitschke M, Peters G, Pulz M, Rohde H, Roseland R, Sayk F, Schaumburg F, Sch\u00f6cklmann H, Schubert S, Solbach W, Karch H, Suerbaum S\nCLIN INFECT DIS. 2013;56(8):1132-40.\nPeroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study\nVon Renteln D, Fuchs K, Fockens P, Bauerfeind P, Vassiliou M, Werner Y, Fried G, Breithaupt W, Heinrich H, Bredenoord A, Kersten J, Verlaan T, Trevisonno M, R\u00f6sch T\nGASTROENTEROLOGY. 2013;145(2):309-11.e1-3.\nA novel flexible cryoprobe for EUS-guided pancreatic biopsies\nvon Renteln D, Quaas A, R\u00f6sch T, Denzer U, Szyrach M, Enderle M, L\u00fcth S, Haas S, Trepte C, Reuter D, Schachschal G\nGASTROINTEST ENDOSC. 2013;77(5):784-92.\nAchalasie\nvon Renteln D, Schoenberg M, Werner Y, Mann O, R\u00f6sch T\nDEUT MED WOCHENSCHR. 2013;138(23):1240-3.\nPhotodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin\nWagner A, Kiesslich T, Neureiter D, Friesenbichler P, Puespoek A, Denzer U, Wolkersd\u00f6rfer G, Emmanuel K, Lohse A, Berr F\nPHOTOCH PHOTOBIO SCI. 2013;12(6):1065-73.\nA needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma\nWege H, Br\u00fcmmendorf T, Gambacorti-Passerini C\nHEPATOLOGY. 2013;57(4):1291-3.\nSome unusual cystic lesions of the liver\nWehmeyer M, Lohse A, Schramm C\nGASTROENTEROLOGY. 2013;145(6):e1-2.\nAutoimmune hepatitis: a life-long disease.\nWeiler-Normann C, Lohse A\nJ HEPATOL. 2013;58(1):5-7.\nReply to: \"Use of TNF\u03b1 antagonists in refractory AIH: revealing the unforeseen\"\nWeiler-Normann C, Schramm C, Lohse A\nJ HEPATOL. 2013;59(1):198-9.\nInfliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis.\nWeiler-Normann C, Schramm C, Quaas A, Wiegard C, Glaubke C, Pannicke N, H\u00fcbener S, Lohse A\nJ HEPATOL. 2013;58(3):529-534.\nAutoimmune hepatitis 2013 and beyond\nWeiler-Normann C, Sebode M, Lohse A\nMinerva Gastroenterol Dietol. 2013;59(2):133-41.\nEffectiveness and safety of minilaparoscopy-guided spleen biopsy: a retrospective series of 57 cases\nWerner T, Koch J, Denzer U\nSURG ENDOSC. 2013;27(12):4743.\nProspective European-wide multicentre study on a blood based real-time PCR for the diagnosis of acute schistosomiasis\nWichmann D, Poppert S, Von Thien H, Clerinx J, Dieckmann S, Jensenius M, Parola P, Richter J, Schunk M, Stich A, Zanger P, Burchard G, Tannich E\nBMC INFECT DIS. 2013;13:55.\nNon-AIDS defining cancers in the D:A:D Study--time trends and predictors of survival: a cohort study\nWorm S, Bower M, Reiss P, Bonnet F, Law M, F\u00e4tkenheuer G, d'Arminio Monforte A, Abrams D, Grulich A, Fontas E, Kirk O, Furrer H, De Wit S, Phillips A, Lundgren J, Sabin C\nBMC INFECT DIS. 2013;13:471.\nIs fatigue in primary biliary cirrhosis cured by transplantation?\nZenouzi R, Weiler-Normann C, Lohse A\nJ HEPATOL. 2013;59(3):418-9.\nFaldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results\nZeuzem S, Asselah T, Angus P, Zarski J, Larrey D, M\u00fcllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki J, Roberts S, Arasteh K, Zoulim F, Heim M, Stern J, Nehmiz G, Kukolj G, B\u00f6cher W, Mensa F\nANTIVIR THER. 2013;18(8):1015-9.\nFaldaprevir and deleobuvir for HCV genotype 1 infection\nZeuzem S, Soriano V, Asselah T, Bronowicki J, Lohse A, M\u00fcllhaupt B, Schuchmann M, Bourli\u00e8re M, Buti M, Roberts S, Gane E, Stern J, Vinisko R, Kukolj G, Gallivan J, B\u00f6cher W, Mensa F\nNEW ENGL J MED. 2013;369(7):630-9.\nRisk factors for development of hemolytic uremic syndrome in a cohort of adult patients with STEC 0104:H4 infection.\nZoufaly A, Cramer J, Vettorazzi E, Sayk F, Bremer J, Koop I, de Weerth A, Schmiedel S, Jordan S, Zimmermann-Fraedrich K, Asselborn N, Nitschke M, Neumann-Grutzeck C, Magnus T, R\u00fcther C, Fellermann K, Stahl R, Wegscheider K, Lohse A\nPLOS ONE. 2013;8(3):e59209.\nPrevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional study\nZoufaly A, Fillekes Q, Hammerl R, Nassimi N, Jochum J, Drexler J, Awasom C, Sunjoh F, Burchard G, Burger D, van Lunzen J, Feldt T\nANTIVIR THER. 2013;18(5):681-90.\nThe association of genetic markers for type 2 diabetes with prediabetic status - cross-sectional data of a diabetes prevention trial\nZyriax B, Salazar R, Hoeppner W, Vettorazzi E, Herder C, Windler E\nPLOS ONE. 2013;8(9):e75807.\nIdentification of HIV-1-specific regulatory T-cells using HLA class II tetramers.\nAngin M, King M, Altfeld M, Walker B, Wucherpfennig K, Addo M\nAIDS. 2012;26(16):2112-2115.\nPreserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue.\nAngin M, Kwon D, Streeck H, Wen F, King M, Rezai A, Law K, Hongo T, Pyo A, Piechocka-Trocha A, Toth I, Pereyra F, Ghebremichael M, Rodig S, Milner D, Richter J, Altfeld M, Kaufmann D, Walker B, Addo M\nJ INFECT DIS. 2012;205(10):1495-1500.\nRegulatory T cell frequencies do not correlate with breadth or magnitude of HIV-1-specific T cell responses.\nAngin M, Streeck H, Wen F, King M, Pereyra F, Altfeld M, Walker B, Addo M\nAIDS RES HUM RETROV. 2012;28(8):749-751.\nInduction of heme oxygenase 1 prevents progression of liver fibrosis in Mdr2 knockout mice\nBarikbin R, Neureiter D, Wirth J, Erhardt A, Schwinge D, Kluwe J, Schramm C, Tiegs G, Sass G\nHEPATOLOGY. 2012;55(2):553-562.\nIFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.\nBelloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri-Petersen M, Levrero M\nJ CLIN INVEST. 2012;122(2):529-537.\nGut microbiome and intestinal barrier failure--the \"Achilles heel\" in hepatology?\nBenten D, Wiest R\nJ HEPATOL. 2012;56(6):1221-1223.\nPrimary human hepatocytes from metabolic-disordered children recreate highly differentiated liver-tissue-like spheroids on alginate scaffolds.\nBierwolf J, L\u00fctgehetmann M, Deichmann S, Erbes J, Volz T, Dandri-Petersen M, Cohen S, Nashan B, Pollok J\nTISSUE ENG PT A. 2012;18(13-14):1443-1453.\n[Intermittent fever under iatrogenic immunosuppression].\nB\u00f6nstrup M, Schmiedel S, Lohse A\nINTERNIST. 2012;53(2):213-217.\nTh17 cells bound for the liver: group tourists or private travellers?\nCarambia A, Herkel J\nJ HEPATOL. 2012;57(5):943-945.\nInfluenza A(H1N1)pdm09 antibodies after pandemic and trivalent seasonal influenza vaccination as well as natural infection in November 2010 in Hamburg, Germany.\nCramer J, Mac T, Hogan B, Stauga S, Eberhardt S, Wichmann O, Mertens T, Burchard G\nEUROSURVEILLANCE. 2012;17(2):.\nChimeric mouse model of hepatitis B virus infection.\nDandri M, Petersen J\nJ HEPATOL. 2012;56(2):493-495.\nNew insight in the pathobiology of hepatitis B virus infection.\nDandri-Petersen M, Locarnini S\nGUT. 2012;61 Suppl 1:6-17.\nPrimary HIV-1 infection is associated with increased plasma levels of heme-oxygenase-1 (HO-1) and presence of HO-1-specific regulatory T cells.\nFathi A, Angin M, King M, Piechocka-Trocha A, Altfeld M, Walker B, Addo M\n2012. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA. .\nExtended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci.\nFolseraas T, Melum E, Rausch P, Juran B, Ellinghaus E, Shiryaev A, Laerdahl J, Ellinghaus D, Schramm C, Weism\u00fcller T, Gotthardt D, Hov J, Clausen O, Weersma R, Janse M, Boberg K, Bj\u00f6rnsson E, Marschall H, Cleynen I, Rosenstiel P, Holm K, Teufel A, Rust C, Gieger C, Wichmann H, Bergquist A, Ryu E, Ponsioen C, Runz H, Sterneck M, Vermeire S, Beuers U, Wijmenga C, Schrumpf E, Manns M, Lazaridis K, Schreiber S, Baines J, Franke A, Karlsen T\nJ HEPATOL. 2012;57(2):366-375.\nTargeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.\nFraedrich K, Schrader J, Ittrich H, von Amsberg G, Gontarewicz A, Matzat V, Kromminga A, Pace A, Moll J, Bl\u00e4ker M, Lohse A, H\u00f6rsch D, Br\u00fcmmendorf T, Benten D\nCLIN CANCER RES. 2012;18(17):4621-4632.\nComplications and risk factors in 2731 diagnostic mini-laparoscopies in patients with liver disease.\nFrenzel C, Koch J, Lorenzen V, Werner T, Lohse A, Denzer U\nLIVER INT. 2012;32(6):970-976.\nBalancing pro- and anti-inflammatory CD4+ T helper cells in the intestine\nGagliani N, Huber S\n2012. Autoimmune Diseases - Contributing Factors, Specific Cases of Autoimmune Diseases, and Stem Cell and Other Therapies. Intech open Science: 51-76.\nThe Intestine: where amazing things happen.\nGagliani N, Huber S, Flavell R\nCELL RES. 2012;22(2):277-279.\nAssessment of the range of the HIV-1 infectivity enhancing effect of individual human semen specimen and the range of inhibition by EGCG.\nHartjen P, Frerk S, Hauber I, Matzat V, Thomssen A, Holstermann B, Hohenberg H, Schulze W, Schulze Zur Wiesch J, van Lunzen J\nAIDS RES THER. 2012;9(1):2.\nPancreatic neuroendocrine neoplasms.\nH\u00f6rsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum R\nMinerva Gastroenterol Dietol. 2012;58(4):401-426.\nIL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine\nHuber S, Gagliani N, Zenewicz L, Huber F, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W, Murphy A, Valenzuela D, Yancopoulos G, Booth C, Cho J, Ouyang W, Abraham C, Flavell R\nNATURE. 2012;491(7423):259-263.\nSelective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.\nKah J, W\u00fcstenberg A, Keller A, Sirma H, Montalbano R, Ocker M, Volz T, Dandri-Petersen M, Tiegs G, Sass G\nONCOL REP. 2012;28(3):1077-1083.\nAcute liver failure following minocycline treatment - a case report and review of the literature.\nKuhn A, Weiler-Normann C, Schramm C, Kluge S, Behne M, Lohse A, Benten D\nZ GASTROENTEROL. 2012;50(8):771-775.\nCD4+ CD25+ regulatory T cells impair HIV-1-specific CD4 T cell responses by upregulating interleukin-10 production in monocytes.\nKwon D, Angin M, Hongo T, Law K, Johnson J, Porichis F, Hart M, Pavlik D, Tighe D, Kavanagh D, Streeck H, Addo M, Kaufmann D\nJ VIROL. 2012;86(12):6586-6594.\nRapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.\nLarrey D, Lohse A, de Ledinghen V, Trepo C, Gerlach T, Zarski J, Tran A, Mathurin P, Thimme R, Arast\u00e9h K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim M, Gerken G, Stern J, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, B\u00f6cher W, Steffgen J\nJ HEPATOL. 2012;57(1):39-46.\nExpansion of HIV-specific T follicular helper cells in chronic HIV infection.\nLindqvist M, van Lunzen J, Soghoian D, Kuhl B, Ranasinghe S, Kranias G, Flanders M, Cutler S, Yudanin N, Muller M, Davis I, Farber D, Hartjen P, Haag F, Alter G, Schulze Zur Wiesch J, Streeck H\nJ CLIN INVEST. 2012;122(9):3271-3280.\nInduction of heme oxygenase 1 by HMG-CoA-Reductase inhibitors interferes with HCV replication\nLoscher C, W\u00fcstenberg A, Keller A, Lehmann E, Sirma H, Bartenschlager R, Lohmann V, Dandri-Petersen M, Tiegs G, Sass G\n2012. Zeitschrift f\u00fcr Gastroenterologie. .\nHumanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.\nL\u00fctgehetmann M, Mancke L, Volz T, Helbig M, Allweiss L, Bornscheuer T, Pollok J, Lohse A, Petersen J, Urban S, Dandri-Petersen M\nHEPATOLOGY. 2012;55(3):685-694.\nStereoselective synthesis of D- and L-carbocyclic nucleosides by enzymatically catalyzed kinetic resolution.\nMahler M, Reichardt B, Hartjen P, van Lunzen J, Meier C\nCHEM-EUR J. 2012;18(35):11046-11062.\nValidation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome:case-control study\nMenne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer J, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenm\u00fcller F, Haller H, Herget-Rosenthal S, Hertenstein B, Hofmann C, Lang M, Kielstein J, Klostermeier U, Knobloch J, Kuehbacher M, Kunzendorf U, Lehnert H, Manns M, Menne T, Meyer T, Michael C, M\u00fcnte T, Neumann-Grutzeck C, Nuernberger J, Pavenstaedt H, Ramazan L, Renders L, Repenthin J, Ries W, Rohr A, Rump L, Samuelsson O, Sayk F, Schmidt B, Schnatter S, Sch\u00f6cklmann H, Schreiber S, von Seydewitz C, Steinhoff J, Stracke S, Suerbaum S, van de Loo A, Vischedyk M, Weissenborn K, Wellh\u00f6ner P, Wiesner M, Zeissig S, B\u00fcning J, Schiffer M, Kuehbacher T\nBMJ-BRIT MED J. 2012;345:e4565.\nIncreased angiogenesis protects against adipose hypoxia and fibrosis in metabolic disease-resistant 11\u03b2-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice.\nMichailidou Z, Turban S, Miller E, Zou X, Schrader J, Ratcliffe P, Hadoke P, Walker B, Iredale J, Morton N, Seckl J\nJ BIOL CHEM. 2012;287(6):4188-4197.\nCardiac function in Ghanaian children with severe malaria.\nNguah S, Feldt T, Hoffmann S, Pelletier D, Ansong D, Sylverken J, Mehrfahr P, Herr J, Thiel C, Ehrhardt S, Burchard G, Cramer J\nINTENS CARE MED. 2012;38(12):2032-2041.\nTravel-related imported infections in Europe, EuroTravNet 2009.\nOdolini S, Parola P, Gkrania-Klotsas E, Caumes E, Schlagenhauf P, L\u00f3pez-V\u00e9lez R, Burchard G, Santos-O'Connor F, Weld L, von Sonnenburg F, Field V, de Vries P, Jensenius M, Loutan L, Castelli F\nCLIN MICROBIOL INFEC. 2012;18(5):468-474.\nHeparin-induced thrombocytopenia associated with acute liver graft failure.\nPannicke N, Pollok J, Kluge S, Petzoldt M\nBMJ CASE REP. 2012;2012:7323.\n[Autoimmune liver diseases].\nPannicke N, Schramm C, Lohse A\nINTERNIST. 2012;53(8):943-946.\nAutoimmunerkrankungen der Leber\nPannicke N, Schramm C, Lohse A\nINTERNIST. 2012;53(8):943-54; quiz 955-6.\nElevated \u03b3-glutamyltransferase\nPannicke N, Werner T, Schramm C\nGASTROENTEROLOGY. 2012;143(4):7-8.\nFOXP3+ regulatory T cells in autoimmune hepatitis are fully functional and not reduced in frequency\nPeiseler M, Sebode M, Franke B, Wortmann F, Schwinge D, Quaas A, Baron U, Olek S, Wiegard C, Lohse A, Weiler-Normann C, Schramm C, Herkel J\nJ HEPATOL. 2012;57(1):125-132.\nEntecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study.\nPetersen J, Ratziu V, Buti M, Janssen H, Brown A, Lampertico P, Schollmeyer J, Zoulim F, Wedemeyer H, Sterneck M, Berg T, Sarrazin C, L\u00fctgehetmann M, Buggisch P\nJ HEPATOL. 2012;56(3):520-526.\nc-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis.\nPiao X, Komazawa-Sakon S, Nishina T, Koike M, Piao J, Ehlken H, Kurihara H, Hara M, Nico V, Sch\u00fctz G, Ohmuraya M, Uchiyama Y, Yagita H, Okumura K, He Y, Nakano H\nSCI SIGNAL. 2012;5(255):93.\n[Prevention of nosocomial transmission of human immunodeficiency virus (HIV) from HIV-positive healthcare workers. Recommendations of the German Association for the Control of Viral Diseases (DVV) e.V. and the Society for Virology (GfV) e.V].\nRabenau H, Gottschalk R, G\u00fcrtler L, Haberl A, Hamouda O, Himmelreich H, Korn K, Mertens T, Schmidt K, Schmiedel S, Spickhoff A, Wirz G, Wutzler P, Wicker S\nBUNDESGESUNDHEITSBLA. 2012;55(8):937-943.\nBat3 promotes T cell responses and autoimmunity by repressing Tim-3\u2013mediated cell death and exhaustion.\nRangachari M, Zhu C, Sakuishi K, Xiao S, Karman J, Chen A, Angin M, Wakeham A, Greenfield E, Sobel R, Okada H, McKinnon P, Mak T, Addo M, Anderson A, Kuchroo V\nNAT MED. 2012;18(9):1394-1400.\nAn unusual cause of hypertriglyceridemic acute pancreatitis.\nResheq Y, Rinninger F, Lohse A, Schramm C\nAM J GASTROENTEROL. 2012;107(6):957-959.\nRGB marking with lentiviral vectors for multicolor clonal cell tracking.\nRiecken K, Thomaschewski M, Benten D, Fehse B\nNAT PHYS. 2012;7(5):839-849.\nRGB marking : Vielfarbige Zellmarkierung zur klonalen Analyse\nRiecken K, Thomaschewski M, Warlich M, Cornils K, Benten D, Fehse B\nLaborwelt. 2012;13(1):7-9.\nPartners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods.\nRodger A, Bruun T, Weait M, Vernazza P, Collins S, Estrada V, van Lunzen J, Corbelli G, Lampe F, Phillips A, Lundgren J, Group P\nBMC PUBLIC HEALTH. 2012;12:296.\nPost-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia.\nRolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard G, Cramer J\nMALARIA J. 2012;11:169.\nOutbreak of ciguatera fish poisoning on a cargo ship in the port of hamburg.\nSchlaich C, Hagelstein J, Burchard G, Schmiedel S\nJ TRAVEL MED. 2012;19(4):238-242.\nViruses acquired abroad: what does the primary care physician need to know?\nSchmidt-Chanasit J, Schmiedel S, Fleischer B, Burchard G\nDTSCH ARZTEBL INT. 2012;109(41):681-692.\nBackground morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.\nSchmidt C, Smith C, Barin B, Bakhtyari A, Bart P, Bekker L, Chomba E, Clumeck N, Ho D, Hoosen A, Jaoko W, Kaleebu P, Karita E, Keefer M, van Lunzen J, McMichael A, Mehendale S, Peters B, Ramanathan V, Robinson A, Rockstroh J, Vardas E, Vets E, Weber J, Graham B, Than S, Excler J, Kochhar S, Ho M, Heald A, Fast P\nHUM VACC IMMUNOTHER. 2012;8(5):630-638.\nChronic liver inflammation dominated by interferon-\u03b3 can prevent hepatocarcinogenesis.\nSchrader J, Herkel J\nONCOIMMUNOLOGY. 2012;1(2):222-223.\nGallbladder polyps in primary sclerosing cholangitis: indication for early intervention.\nSchramm C, Lohse A\nHEPATOLOGY. 2012;56(1):396.\n[Immune reconstitution inflammatory syndrome in cryptococcal meningitis: a rare phenomenon?].\nSchulze K, Schmiedel S, van Lunzen J\nDEUT MED WOCHENSCHR. 2012;137(16):834-837.\nBroadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence.\nSchulze Zur Wiesch J, Ciuffreda D, Lewis-Ximenez L, Kasprowicz V, Nolan B, Streeck H, Aneja J, Reyor L, Allen T, Lohse A, McGovern B, Chung R, Kwok W, Kim A, Lauer G\nJ EXP MED. 2012;209(1):61-75.\nAszites \u2013 Diagnostik, Therapie und Sekund\u00e4rkomplikationen\nSebode M, Benten D\nVISZERALMEDIZIN. 2012;28(2):142-148.\nAutoimmunerkrankungen mit Leberbeteiligung\nSebode M, Wiegard C, Lohse A\nGastroenterologie up2date. 2012;08(02):129-141.\nInoperable cerebral alveolar echinococcosis controlled with high dosages of albendazole adjusted with monitoring of blood levels.\nStauga S, Schmiedel S\nJ TRAVEL MED. 2012;19(3):198-201.\nReceptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].\nSzepeshazi K, Schally A, Keller G, Block N, Benten D, Halmos G, Szalontay L, Vidaurre I, Jaszberenyi M, Rick F\nONCOTARGET. 2012;3(7):686-699.\nThe indications for liver biopsy.\nTannapfel A, Dienes H, Lohse A\nDTSCH ARZTEBL INT. 2012;109(27-28):477-483.\nOnce daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.\nvan Lunzen J, Maggiolo F, Arribas J, Rakhmanova A, Yeni P, Young B, Rockstroh J, Almond S, Song I, Brothers C, Min S\nLANCET INFECT DIS. 2012;12(2):111-118.\nPredictive value of fever and palmar pallor for P. falciparum parasitaemia in children from an endemic area\nVinnemeier C, Schwarz N, Sarpong N, Loag W, Acquah S, Nkrumah B, Huenger F, Adu-Sarkodie Y, May J\nPLOS ONE. 2012;7(5):e36678.\nStrong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.\nVolz T, L\u00fctgehetmann M, Allweiss L, Warlich M, Bierwolf J, Pollok J, Petersen J, Matthes E, Dandri-Petersen M\nANTIVIR THER. 2012;17(4):623-631.\nPeroral endoscopic myotomy for the treatment of achalasia: a prospective single center study.\nvon Renteln D, Inoue H, Minami H, Werner Y, Pace A, Kersten J, Much C, Schachschal G, Mann O, Keller J, Fuchs K, R\u00f6sch T\nAM J GASTROENTEROL. 2012;107(3):411-417.\nSystemtherapie des Leberzellkarzinoms\nWege H, Arnold D\nONKOLOGE. 2012;18(7):602-610.\nTreatment adherence - room for improvement, not only in autoimmune hepatitis.\nWeiler-Normann C, Lohse A\nJ HEPATOL. 2012;57(6):1168-1170.\nMalaria prophylaxis in Latin America: a controversial topic.\nWeitzel T, Rolling T, Burchard G, Cramer J\nAM J TROP MED HYG. 2012;87(1):190-192.\nEffectiveness and safety of minilaparoscopy-guided spleen biopsy: a retrospective series of 57 cases.\nWerner T, Koch J, Frenzel C, Lohse A, Denzer U\nSURG ENDOSC. 2012;26(9):2416-2422.\nTreatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.\nWyen C, Jensen B, Hentrich M, Siehl J, Sabranski M, Esser S, Gillor D, M\u00fcller M, van Lunzen J, Wolf T, Bogner J, Wasmuth J, Christ H, F\u00e4tkenheuer G, Hoffmann C\nAIDS. 2012;26(4):457-464.\n[Pyogenic liver abscess: a retrospective patient study].\nZenouzi R, Schmiedel S, Lohse A\nZ GASTROENTEROL. 2012;50(6):578-584.\nLate presentation for HIV diagnosis and care in Germany.\nZoufaly A, An der Heiden M, Marcus U, Hoffmann C, Stellbrink H, Voss L, van Lunzen J, Hamouda O, Group C\nHIV MED. 2012;13(3):172-181.\nLack of detectable HIV-1-specific CD8(+) T cell responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individuals.\nAddo M, Altfeld M, Brainard D, Rathod A, Piechocka-Trocha A, Fideli U, Mulenga J, Shutes E, Alvino D, Hunter E, Allen S, Walker B\nJ INFECT DIS. 2011;203(2):258-262.\nA new experimental model to allow use of clinical-scale endoscopes in small-animal tumor models.\nAnders M, Frimberger E, Odau S, Wiedenmann B, R\u00f6sch T\nJ GASTROINTEST ONCOL. 2011;2(2):64-69.\nSulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice.\nArrenberg P, Maricic I, Kumar V\nGASTROENTEROLOGY. 2011;140(2):646-655.\nHighly co-ordinated var gene expression and switching in clinical Plasmodium falciparum isolates from non-immune malaria patients.\nBachmann A, Predehl S, May J, Harder S, Burchard G, Gilberger T, Tannich E, Bruchhaus I\nCELL MICROBIOL. 2011;13(9):1397-1409.\nThe transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).\nBenten D, Schulze Zur Wiesch J, Sydow K, Koops A, Buggisch P, B\u00f6ger R, Gaydos C, Won H, Franco V, Lohse A, Ray S, Balagopal A\nBMC GASTROENTEROL. 2011;11:107.\nExpression of CD133 and other putative stem cell markers in uveal melanoma.\nBerna-Thill M, Berna M, Grierson R, Reinhart I, Voelkel T, Piechaczek C, Galambos P, Jager M, Richard G, Lange C, Gehling U\nMELANOMA RES. 2011;21(5):405-416.\nSU5416 induces premature senescence in endothelial progenitor cells from patients with age-related macular degeneration.\nBerna-Thill M, Berna M, Kunst F, Wege H, Strunnikova N, Gordiyenko N, Grierson R, Richard G, Csaky K\nMOL VIS. 2011;17:85-98.\nPrimary rat hepatocyte culture on 3D nanofibrous polymer scaffolds for toxicology and pharmaceutical research.\nBierwolf J, L\u00fctgehetmann M, Feng K, Erbes J, Deichmann S, Toronyi E, Stieglitz C, Nashan B, Ma P, Pollok J\nBIOTECHNOL BIOENG. 2011;108(1):141-150.\nOverlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue.\nBoberg K, Chapman R, Hirschfield G, Lohse A, Manns M, Schrumpf E\nJ HEPATOL. 2011;54(2):374-385.\n[Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany].\nBoecken G, Sunderk\u00f6tter C, Bogdan C, Weitzel T, Fischer M, M\u00fcller A, L\u00f6bermann M, Anders G, von Stebut E, Schunk M, Burchard G, Grobusch M, Bialek R, Harms-Zwingenberger G, Fleischer B, Pietras M, Faulde M, Erkens K, Dermatology G, Medicine G, Chemotherapy G\nJ DTSCH DERMATOL GES. 2011;9 Suppl 8:1-51.\nAdjusting for heterogeneity of malaria transmission in longitudinal studies\nBousema T, Kreuels B, Gosling R\nJ INFECT DIS. 2011;204(1):1-3.\nFunctional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.\nBrassat U, Balabanov S, Bali D, Dierlamm J, Balabanov M, Hartmann U, Sirma H, G\u00fcnes C, Wege H, Fehse B, Gontarewicz A, Dikomey E, Borgmann K, Br\u00fcmmendorf T\nEXP HEMATOL. 2011;39(1):62-66.\nScavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells.\nBrundert M, Heeren J, Merkel M, Carambia A, Herkel J, Groitl P, Dobner T, Ramakrishnan R, Moore K, Rinninger F\nJ LIPID RES. 2011;52(4):745-758.\nBuruli-Ulkus - Diagnose und Therapie der infekti\u00f6sen tropischen Hauterkrankung\nBurchard G\nFLUGMEDIZIN TROPENME. 2011;18(2):80-82.\nDer Malariaimpfstoff RTS, S\nBurchard G\nKinder\u00e4rztliche Praxis. 2011;82:7.\n[Therapeutic management of malaria].\nBurchard G\nINTERNIST. 2011;52(12):1407-1413.\nCentral Africa\nBurchard G, Ehrhardt S\n2011. Infectious Diseases: A Geographic Guide. WileyBlackwell, London: 84-97.\nInfluenza nach der A/H1N1-Pandemie - Aktuelle Bedeutung und Impfungen f\u00fcr Reisende\nCramer J\nFLUGMEDIZIN TROPENME. 2011;18(3):132-136.\nJapanische Enzephalitis (JE)\nCramer J, Burchard G\nArzneiverordnung in der Praxis. 2011;38(1):11-12.\nManagement of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.\nCramer J, Burchard G, Sonnenburg F\nDeutsches \u00c4rzteblatt. 2011;108(48):2145.\nPolyarthritis in two travellers returning from Australia.\nCramer J, Kastenbauer U, L\u00f6scher T, Emmerich P, Schmidt-Chanasit J, Burchard G, von Sonnenburg F\nJ CLIN VIROL. 2011;52(1):1-3.\nTreatment of imported severe malaria with artesunate instead of quinine--more evidence needed?\nCramer J, L\u00f3pez-V\u00e9lez R, Burchard G, Grobusch M, Vries d, Peter J\nMALARIA J. 2011;10:256.\nHepatocyte IKK2 protects Mdr2-/- mice from chronic liver failure\nEhlken H, Kondylis V, Heinrichsdorff J, Ochoa-Callejero L, Roskams T, Pasparakis M\nPLOS ONE. 2011;6(10):e25942.\nCXCR3 deficiency exacerbates liver disease and abrogates tolerance in a mouse model of immune-mediated hepatitis.\nErhardt A, Wegscheid C, Claa\u00df B, Carambia A, Herkel J, Mittr\u00fccker H, Panzer U, Tiegs G\nJ IMMUNOL. 2011;186(9):5284-5293.\nControl of TH17 cells occurs in the small intestine.\nEsplugues E, Huber S, Gagliani N, Hauser A, Town T, Wan Y, O'Connor W, Rongvaux A, Nico V, Haberman A, Iwakura Y, Kuchroo V, Kolls J, Bluestone J, Herold K, Flavell R\nNATURE. 2011;475(7357):514-518.\nPatterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience.\nFlores-Figueroa J, Okhuysen P, von Sonnenburg F, DuPont H, Libman M, Keystone J, Hale D, Burchard G, Han P, Wilder-Smith A, Freedman D, Network G\nCLIN INFECT DIS. 2011;53(6):523-531.\nEpidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany.\nFrank C, Werber D, Cramer J, Askar M, Faber M, Matthias A, Bernard H, Fruth A, Prager R, Spode A, Wadl M, Zoufaly A, Jordan S, Kemper M, Follin P, M\u00fcller L, King L, Rosner B, Buchholz U, Stark K, Krause G, Team H\nNEW ENGL J MED. 2011;365(19):1771-1780.\nManagement of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany.\nG\u00fcnther S, Feldmann H, Geisbert T, Hensley L, Rollin P, Nichol S, Str\u00f6her U, Artsob H, Peters C, Ksiazek T, Becker S, Jan T, Olschl\u00e4ger S, Schmidt-Chanasit J, Sudeck H, Burchard G, Schmiedel S\nJ INFECT DIS. 2011;204 Suppl 3:785-790.\nDer besondere Fall \u00b7 Suizidversuch mit Knollenbl\u00e4tterpilz\nHarlandt O, Wichmann D, de Heer G, Fischer L, Nashan B, Reimer J, Benten D, Lohse A, Kluge S\nHamb \u00c4rztebl. 2011;65(5):34-35.\nLebensm\u00fcde ernten ihr Gift neuerdings im Wald ... Suizidversuch mit Knollenbl\u00e4tterpilz\nHarlandt O, Wichmann D, de Heer G, Fischer L, Nashan B, Reimer J, Benten D, Lohse A, Kluge S\nMedical Tribune. 2011;43(40):7.\nUnbiased screening of polymer libraries to define novel substrates for functional hepatocytes with inducible drug metabolism.\nHay D, Pernagallo S, Diaz-Mochon J, Medine C, Greenhough S, Hannoun Z, Schrader J, Black J, Fletcher J, Dalgetty D, Thompson A, Newsome P, Forbes S, Ross J, Bradley M, Iredale J\nSTEM CELL RES. 2011;6(2):92-102.\nThree-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.\nHeathcote E, Marcellin P, Buti M, Gane E, Man D, Robert A, Krastev Z, Germanidis G, Lee S, Flisiak R, Kaita K, Manns M, Kotzev I, Buggisch P, Buggisch P, Weilert F, Kurdas O, Shiffman M, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F\nGASTROENTEROLOGY. 2011;140(1):132-143.\nCharacterization of Enterobacter cloacae pneumonia: a single-center retrospective analysis.\nHennigs J, Baumann H, Schmiedel S, Tennstedt P, Sobottka I, Bokemeyer C, Kluge S, Klose H\nLUNG. 2011;189(6):475-483.\nMolecular basis of P2-receptor-mediated calcium signaling in activated pancreatic stellate cells.\nHennigs J, Seiz O, Spiro J, Berna M, Baumann H, Klose H, Pace A\nPANCREAS. 2011;40(5):740-746.\nLet it B in viral hepatitis?\nHerkel J, Carambia A\nJ HEPATOL. 2011;55(1):5-7.\nReduced cardiac output in imported Plasmodium falciparum malaria.\nHerr J, Mehrfahr P, Schmiedel S, Wichmann D, Brattig N, Burchard G, Cramer J\nMALARIA J. 2011;10:160.\nTh17 cells express interleukin-10 receptor and are controlled by Foxp3\u207b and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner\nHuber S, Gagliani N, Esplugues E, O'Connor W, Huber F, Chaudhry A, Kamanaka M, Kobayashi Y, Booth C, Rudensky A, Roncarolo M, Battaglia M, Flavell R\nIMMUNITY. 2011;34(4):554-565.\nRole of activin A in the induction of Foxp3+ and Foxp3- CD4+ regulatory T cells.\nHuber S, Schramm C\nCRIT REV IMMUNOL. 2011;31(1):53-60.\nThree ulcerative colitis susceptibility loci are associated with primary sclerosing cholangitis and indicate a role for IL2, REL, and CARD9.\nJanse M, Lamberts L, Franke L, Raychaudhuri S, Ellinghaus E, Kirsten M, Melum E, Folseraas T, Schrumpf E, Bergquist A, Bj\u00f6rnsson E, Fu J, Harm J, Groen H, Fehrmann R, Smolonska J, Berg v, Leonard H, Ophoff R, Porte R, Weism\u00fcller T, Schramm C, Sterneck M, Sterneck M, G\u00fcnther R, Braun F, Vermeire S, Henckaerts L, Wijmenga C, Ponsioen C, Schreiber S, Karlsen T, Franke A, Weersma R\nHEPATOLOGY. 2011;53(6):1977-1985.\nMemory/effector (CD45RB(lo)) CD4 T cells are controlled directly by IL-10 and cause IL-22-dependent intestinal pathology.\nKamanaka M, Huber S, Zenewicz L, Gagliani N, Rathinam C, O'Connor W, Wan Y, Nakae S, Iwakura Y, Hao L, Flavell R\nJ EXP MED. 2011;208(5):1027-1040.\nSpontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes.\nKim A, Kuntzen T, Timm J, Nolan B, Baca M, Reyor L, Berical A, Feller A, Johnson K, Schulze Zur Wiesch J, Robbins G, Chung R, Walker B, Carrington M, Allen T, Lauer G\nGASTROENTEROLOGY. 2011;140(2):681-686.\nMyeloperoxidase attracts neutrophils by physical forces.\nKlinke A, Nussbaum C, Kubala L, Friedrichs K, Rudolph T, Rudolph V, Paust H, Schr\u00f6der C, Benten D, Lau D, Sz\u00f6cs K, Furtm\u00fcller P, Heeringa P, Sydow K, Duchstein H, Ehmke H, Schumacher U, Meinertz T, Sperandio M, Baldus S\nBLOOD. 2011;117(4):1350-1358.\nAbsence of hepatic stellate cell retinoid lipid droplets does not enhance hepatic fibrosis but decreases hepatic carcinogenesis\nKluwe J, Wongsiriroj N, Troeger J, Gwak G, Dapito D, Pradere J, Jiang H, Siddiqi M, Piantedosi R, O'Byrne S, Blaner W, Schwabe R\nGUT. 2011;60(9):1260-8.\nFollow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants\nKobbe R, Hogan B, Adjei S, Klein P, Kreuels B, Loag W, Adjei O, May J\nJ INFECT DIS. 2011;203(4):556-60.\nRecognizing autoimmune hepatitis: scores help, but no more.\nLohse A\nJ HEPATOL. 2011;54(2):193-194.\nRolls Royce for everybody? Diagnosing liver disease by mini-laparoscopy.\nLohse A\nJ HEPATOL. 2011;54(3):584-585.\nReactivation of autoimmune hepatitis during budesonide monotherapy, and response to standard treatment.\nLohse A, Gil H\nJ HEPATOL. 2011;54(4):837-839.\nAutoimmune hepatitis.\nLohse A, Mieli-Vergani G\nJ HEPATOL. 2011;55(1):171-182.\nDiagnostic criteria for autoimmune hepatitis.\nLohse A, Wiegard C\nBEST PRACT RES CL GA. 2011;25(6):665-671.\nHepatitis B virus limits response of human hepatocytes to interferon-\u03b1 in chimeric mice.\nL\u00fctgehetmann M, Bornscheuer T, Volz T, Allweiss L, Bockmann J, Pollok J, Lohse A, Petersen J, Dandri-Petersen M\nGASTROENTEROLOGY. 2011;140(7):1-2, 2074-2083.\nChronic inflammatory IFN-\u03b3 signaling suppresses hepatocarcinogenesis in mice by sensitizing hepatocytes for apoptosis.\nL\u00fcth S, Schrader J, Zander S, Carambia A, Buchkremer J, Huber S, Reifenberg K, Yamamura K, Schirmacher P, Lohse A, Herkel J\nCANCER RES. 2011;71(11):3763-3771.\nHuman cord blood CD4+CD25hi regulatory T cells suppress prenatally acquired T cell responses to Plasmodium falciparum antigens\nMackroth M, Malhotra I, Mungai P, Koech D, Muchiri E, King C\nJ IMMUNOL. 2011;186(5):2780-91.\nCase report of aseptic meningitis in a patient with Crohn's disease under infliximab therapy.\nManthey C, Lohse A, Pace A\nINFLAMM BOWEL DIS. 2011;17(2):10.\nGenome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci.\nMelum E, Franke A, Schramm C, Weism\u00fcller T, Gotthardt D, Offner F, Juran B, Laerdahl J, Labi V, Bj\u00f6rnsson E, Weersma R, Henckaerts L, Teufel A, Rust C, Ellinghaus E, Balschun T, Boberg K, Ellinghaus D, Bergquist A, Sauer P, Ryu E, Hov J, Wedemeyer J, Lindkvist B, Wittig M, Porte R, Holm K, Gieger C, Wichmann H, Stokkers P, Ponsioen C, Runz H, Stiehl A, Wijmenga C, Sterneck M, Vermeire S, Beuers U, Villunger A, Schrumpf E, Lazaridis K, Manns M, Schreiber S, Karlsen T\nNAT GENET. 2011;43(1):17-19.\nPrevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-na\u00efve patients.\nMetzner K, Rauch P, Braun P, Knechten H, Ehret R, Korn K, Kaiser R, Sichtig N, Ranneberg B, van Lunzen J, Walter H\nJ CLIN VIROL. 2011;50(2):156-161.\nIL3 variant on chromosomal region 5q31-33 and protection from recurrent malaria attacks\nMeyer C, Calixto Fernandes M, Intemann C, Kreuels B, Kobbe R, Kreuzberg C, Ayim M, Ruether A, Loag W, Ehmen C, Adjei S, Adjei O, Horstmann R, May J\nHUM MOL GENET. 2011;20(6):1173-81.\nA randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data\nMoehler M, Schimanski C, Kanzler S, Woerns M, Denzer U, Kolligs F, Ebert M, Distelrath A, Geissler M, Zeuzem S, Lammert F, Lohse A, Dollinger M, Lindig U, Duerr E, Lubomierski N, Zimmermann S, Kabisch M, Schadmann-Fischer S, Galle P\nJ CLIN ONCOL. 2011;29(15_suppl):4077.\nAssociation of a common mineralocorticoid receptor gene polymorphism with salivary cortisol in healthy adults.\nMuhtz C, Zyriax B, Bondy B, Windler E, Otte C\nPSYCHONEUROENDOCRINO. 2011;36(2):298-301.\nDesperately seeking diarrhoea: outbreak of haemolytic uraemic syndrome caused by emerging sorbitol-fermenting shiga toxin-producing Escherichia coli O157:H-, Germany, 2009.\nNielsen S, Frank C, Fruth A, Spode A, Prager R, Graff A, Plenge-B\u00f6nig A, Loos S, L\u00fctgehetmann M, Kemper M, M\u00fcller-Wiefel D, Werber D\nZOONOSES PUBLIC HLTH. 2011;58(8):567-572.\n[Lack of data relevant for German transplantation medicine].\nOtto G, Lohse A\nZ GASTROENTEROL. 2011;49(12):1549-1552.\nPersistence of functional hepatocyte-like cells in immune-compromised mice.\nPayne C, Samuel K, Anne P, King J, Brownstein D, Schrader J, Medine C, Forbes S, Iredale J, Newsome P, Hay D\nLIVER INT. 2011;31(2):254-262.\nRGB marking facilitates multicolor clonal cell tracking.\nRiecken K, Thomaschewski M, Warlich M, Volz T, Cornils K, Niebuhr B, T\u00e4ger M, L\u00fctgehetmann M, Pollok J, Stocking C, Dandri-Petersen M, Benten D, Fehse B\nNAT MED. 2011;17(4):504-509.\nPKC\u03b8 activation in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors is needed for stimulation of numerous important cellular signaling cascades.\nSancho V, Berna M, Berna-Thill M, Jensen R\nBBA-MOL CELL RES. 2011;1813(12):2145-2156.\nImproved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks.\nSarrazin C, Schwendy S, M\u00f6ller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher W, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T\nGASTROENTEROLOGY. 2011;141(5):1656-1664.\nInhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.\nSass G, Klinger N, Sirma H, Hashemolhosseini S, Hellerbrand C, Neureiter D, Wege H, Ocker M, Tiegs G\nINT J ONCOL. 2011;39(2):433-442.\nMasernimpfung in der Reiseberatung - Wichtiger Schutz f\u00fcr Reisende und Gesamtbev\u00f6lkerung\nSch\u00e4fer G, Burchard G, Cramer J\nFLUGMEDIZIN TROPENME. 2011;18(5):235-239.\nMatrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells.\nSchrader J, Gordon-Walker T, Aucott R, van Deemter M, Quaas A, Walsh S, Benten D, Forbes S, Wells R, Iredale J\nHEPATOLOGY. 2011;53(4):1192-1205.\nThe inflammatory microenvironment of HCC - The plot becomes complex.\nSchrader J, Iredale J\nJ HEPATOL. 2011.\nPrim\u00e4r sklerosierende Cholangitis - Herausforderungen gemeinsam meistern. Die Deutsche PSC-Studiengruppe\nSchramm C, Gotthardt D, Spengler U, Schirmacher P, Weism\u00fcller T\nZ GASTROENTEROL. 2011;49(1):63-65.\n[Primary sclerosing cholangitis - challenges for all. The German Study Group PSC].\nSchramm C, Gotthardt D, Spengler U, Schirmacher P, Weism\u00fcller T\nZ GASTROENTEROL. 2011;49(1):63-65.\nRole of mycophenolate mofetil in the treatment of autoimmune hepatitis.\nSchramm C, Lohse A\nJ HEPATOL. 2011;55(3):510-511.\nRapid quantification of telomerase activity employing an improved real-time telomeric repeat amplification protocol in clinical tissue samples eliminates interference by PCR inhibitors\nSchriefer P, G\u00fcnes C, Wege H\nJ Cancer Sci Ther. 2011;3(8):176-180.\nLebererkrankungen in der Schwangerschaft\nSchulze K, L\u00fcth S\nGASTROENTEROLOGE. 2011;6(4):337-346.\nReal-Life comparison of pegylated-interferon 2a versus 2b combination therapy of chronic hepatitis C virus.\nSchulze Zur Wiesch J, Pudelski N, Hoepner L, Supplieth M, Buggisch P, Lohse A, L\u00fcth S\nHEPATOLOGY. 2011;53(4):1405-1407.\nComprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.\nSchulze Zur Wiesch J, Thomssen A, Hartjen P, Toth I, Lehmann C, Meyer-Olson D, Colberg K, Frerk S, Babikir D, Schmiedel S, Degen O, Mauss S, Rockstroh J, Staszewski S, Khaykin P, Strasak A, Lohse A, F\u00e4tkenheuer G, Hauber J, van Lunzen J\nJ VIROL. 2011;85(3):1287-1297.\nHide and seek... Can we eradicate HIV by treatment intensification?\nSchulze Zur Wiesch J, van Lunzen J\nJ INFECT DIS. 2011;203(7):894-897.\nThe induction of mild hypothermia improves systolic function of the resuscitated porcine heart at no further sympathetic activation\nSchwarzl M, Steendijk P, Huber S, Truschnig-Wilders M, Obermayer-Pietsch B, Maechler H, Pieske B, Post H\nACTA PHYSIOL. 2011;203(4):409-18.\nMCS-18, a novel natural plant product prevents autoimmune diabetes.\nSeifarth C, Littmann L, Resheq Y, R\u00f6ssner S, Goldwich A, Pangratz N, Kerek F, Steinkasserer A, Zinser E\nIMMUNOL LETT. 2011;139(1-2):58-67.\nAntibody dynamics and spontaneous viral clearance in patients with acute hepatitis C infection in Rio de Janeiro, Brazil.\nStrasak A, Kim A, Lauer G, Sousa d, Paulo S, Ginuino C, Fernandes C, Velloso C, Almeida d, Adilson J, Schulze Zur Wiesch J, Jaqueline M, Yoshida C, Julian S, Paranhos-Baccal\u00e1 G, Lang S, Brant L, Ulmer H, Strohmaier S, Kaltenbach L, Lampe E, Lewis-Ximenez L\nBMC INFECT DIS. 2011;11:15.\nPrimary human hepatocytes on biodegradable poly(l-lactic acid) matrices: a promising model for improving transplantation efficiency with tissue engineering.\nT\u00f6r\u00f6k-Pollok E, L\u00fctgehetmann M, Bierwolf J, Melbeck S, D\u00fcllmann J, Nashan B, Ma P, Pollok J\nLIVER TRANSPLANT. 2011;17(2):104-114.\nUbiquitin carboxyl-terminal hydrolase 1 (UCHL1) is a potential tumour suppressor in prostate cancer and is frequently silenced by promoter methylation.\nUmmanni R, Jost E, Balabanov M, Lohmann F, Mundt F, Barett C, Schlomm T, Sauter G, Senff T, Bokemeyer C, S\u00fcltmann H, Meyer-Schwesinger C, Br\u00fcmmendorf T, Balabanov S\nMOL CANCER. 2011;10:129.\nGene therapy strategies: can we eradicate HIV?\nvan Lunzen J, Fehse B, Hauber J\nCURR HIV-AIDS REP. 2011;8(2):78-84.\nForced activation of \u03b2-catenin signaling supports the transformation of hTERT-immortalized human fetal hepatocytes.\nWege H, Heim D, L\u00fctgehetmann M, Dierlamm J, Lohse A, Br\u00fcmmendorf T\nMOL CANCER RES. 2011;9(9):1222-1231.\nThe determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection.\nWeich V, Herrmann E, Chung T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Klinker H, Spengler U, Bergk A, Zeuzem S, Berg T\nJ GASTROENTEROL. 2011;46(12):1427-1436.\nDrug induced liver injury and its relationship to autoimmune hepatitis.\nWeiler-Normann C, Schramm C\nJ HEPATOL. 2011;55(4):747-749.\nPregnancy in primary sclerosing cholangitis.\nWellge B, Sterneck M, Teufel A, Rust C, Franke A, Schreiber S, Berg T, G\u00fcnther R, Kreisel W, Zu Eulenburg C, Braun F, Beuers U, Galle P, Lohse A, Schramm C\nGUT. 2011;60(8):1117-1121.\nEfficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.\nZeuzem S, Asselah T, Angus P, Zarski J, Larrey D, M\u00fcllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki J, Roberts S, Arasteh K, Zoulim F, Heim M, Stern J, Kukolj G, Nehmiz G, Haefner C, Boecher W\nGASTROENTEROLOGY. 2011;141(6):2014-2047.\nClinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy.\nZoufaly A, An der Heiden M, Kollan C, Bogner J, F\u00e4tkenheuer G, Wasmuth J, Stoll M, Hamouda O, van Lunzen J\nJ INFECT DIS. 2011;203(3):364-371.\nEntecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of na\u00efve patients with a partial virological response\nZoutendijk R, Reijnders J, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann W, Buti M, Santantonio T, van B\u00f6mmel F, Pradat P, Oo Y, L\u00fctgehetmann M, Berg T, Hansen B, Wedemeyer H, Janssen H\nHEPATOLOGY. 2011;54(2):443-51.\nIL-10 induces aberrant deletion of dendritic cells by natural killer cells in the context of HIV infection.\nAlter G, Kavanagh D, Rihn S, Luteijn R, Brooks D, Oldstone M, van Lunzen J, Altfeld M\nJ CLIN INVEST. 2010;120(6):1905-1913.\nOligoclonality and innate-like features in the TCR repertoire of type II NKT cells reactive to a beta-linked self-glycolipid.\nArrenberg P, Halder R, Dai Y, Maricic I, Kumar V\nP NATL ACAD SCI USA. 2010;107(24):10984-10989.\nSpecificity protein 2 (Sp2) is essential for mouse development and autonomous proliferation of mouse embryonic fibroblasts\nBaur F, Nau K, Sadic D, Allweiss L, Els\u00e4sser H, Gillemans N, de Wit T, Kr\u00fcger I, Vollmer M, Philipsen S, Suske G\nPLOS ONE. 2010;5(3):e9587.\nCCK1 and CCK2 receptors are expressed on pancreatic stellate cells and induce collagen production.\nBerna M, Seiz O, Nast J, Benten D, Bl\u00e4ker M, Koch J, Lohse A, Pace A\nJ BIOL CHEM. 2010;285(50):38905-38914.\nLebererkrankungen durch Parasiten, Bakterien und Pilze\nBurchard G, Cramer J, Krawinkel M\nMONATSSCHR KINDERH. 2010;158(11):1095-1101.\nNo evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment.\nBurhenne J, Matth\u00e9e A, Pas\u00e1kov\u00e1 I, R\u00f6der C, Heinrich T, Haefeli W, Mikus G, Weiss J\nANTIMICROB AGENTS CH. 2010;54(10):4185-4191.\nVaccination during pregnancy and lactation Few data on most of the vaccines available\nCramer J, Helling-Giese G\nFLUGMEDIZIN TROPENME. 2010;17(6):280-283.\nNecrotizing lymphadenitis: Kikuchi--Fujimoto disease alias lupus lymphadenitis?\nCramer J, Schmiedel S, Alegre N, Sch\u00e4fer H, Burchard G, Merz H\nLUPUS. 2010;19(1):89-92.\nOrthotopic Liver Transplantation: Is There a Risk for Listeria monocytogenes Infection?\nEhehalt U, Schmiedel S, Lohse A\nCASE REP MED. 2010;2010:901894.\nTravel and migration associated infectious diseases morbidity in Europe, 2008.\nField V, Gautret P, Schlagenhauf P, Burchard G, Caumes E, Jensenius M, Castelli F, Gkrania-Klotsas E, Weld L, Lopez-Velez R, de Vries P, von Sonnenburg F, Loutan L, Parola P, Network E\nBMC INFECT DIS. 2010;10:330.\nMobilization of hematopoietic progenitor cells in patients with liver cirrhosis.\nGehling U, Willems M, Schlagner K, Benndorf R, Dandri-Petersen M, Petersen J, Sterneck M, Pollok J, Hossfeld D, Rogiers X\nWORLD J GASTROENTERO. 2010;16(2):217-224.\nDifferences in clinical manifestations of imported versus autochthonous leptospirosis in Austria and Germany.\nHoffmeister B, Peyerl-Hoffmann G, Pischke S, Zollner-Schwetz I, Krause R, M\u00fcller M, Graf A, Kluge S, Burchard G, Kern W, Suttorp N, Cramer J\nAM J TROP MED HYG. 2010;83(2):326-335.\nMutational characterization of the bile acid receptor TGR5 in primary sclerosing cholangitis.\nHov J, Keitel V, Laerdahl J, Spomer L, Ellinghaus E, ElSharawy A, Melum E, Boberg K, Manke T, Balschun T, Schramm C, Bergquist A, Weism\u00fcller T, Gotthardt D, Rust C, Henckaerts L, Onnie C, Weersma R, Sterneck M, Teufel A, Runz H, Stiehl A, Ponsioen C, Wijmenga C, Vatn M, Stokkers P, Vermeire S, Mathew C, Lie B, Beuers U, Manns M, Schreiber S, Schrumpf E, H\u00e4ussinger D, Franke A, Karlsen T\nPLOS ONE. 2010;5(8):12403.\nInflammation-induced tumorigenesis in the colon is regulated by caspase-1 and NLRC4\nHu B, Elinav E, Huber S, Booth C, Strowig T, Jin C, Eisenbarth S, Flavell R\nP NATL ACAD SCI USA. 2010.\nInfrequent recovery of HIV from but robust exogenous infection of activated CD4(+) T cells in HIV elite controllers.\nJulg B, Pereyra F, Buz\u00f3n M, Piechocka-Trocha A, Clark M, Baker B, Lian J, Miura T, Martinez-Picado J, Addo M, Walker B\nCLIN INFECT DIS. 2010;51(2):233-238.\nGenome-wide association analysis in primary sclerosing cholangitis\nKarlsen T, Franke A, Melum E, Kaser A, Hov J, Balschun T, Lie B, Bergquist A, Schramm C, Weism\u00fcller T, Gotthardt D, Rust C, Philipp E, Fritz T, Henckaerts L, Weersma R, Stokkers P, Ponsioen C, Wijmenga C, Sterneck M, Nothnagel M, Hampe J, Teufel A, Runz H, Rosenstiel P, Stiehl A, Vermeire S, Beuers U, Manns M, Schrumpf E, Boberg K, Schreiber S\nGASTROENTEROLOGY. 2010;138(3):1102-1111.\nHepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution.\nKasprowicz V, Kang Y, Lucas M, Schulze Zur Wiesch J, Kuntzen T, Fleming V, Nolan B, Longworth S, Berical A, Bengsch B, Thimme R, Lewis-Ximenez L, Allen T, Kim A, Klenerman P, Lauer G\nJ VIROL. 2010;84(3):1656-1663.\nModulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.\nKluwe J, Pradere J, Gwak G, Mencin A, Samuele D, Osterreicher C, Colmenero J, Bataller R, Schwabe R\nGASTROENTEROLOGY. 2010;138(1):347-359.\nDiffering effects of HbS and HbC traits on uncomplicated falciparum malaria, anemia, and child growth.\nKreuels B, Kreuzberg C, Kobbe R, Ayim-Akonor M, Apiah-Thompson P, Thompson B, Ehmen C, Adjei S, Langefeld I, Adjei O, May J\nBLOOD. 2010;115(22):4551-4558.\nPlasmacytoid dendritic cells accumulate and secrete interferon alpha in lymph nodes of HIV-1 patients.\nLehmann C, Lafferty M, Garzino-Demo A, Jung N, Hartmann P, F\u00e4tkenheuer G, Wolf J, van Lunzen J, Romerio F\nPLOS ONE. 2010;5(6):11110.\nProspective follow-up of patients with acute hepatitis C virus infection in Brazil.\nLewis-Ximenez L, Lauer G, Schulze Zur Wiesch J, Sousa d, Fonseca P, Ginuino C, Paranhos-Baccal\u00e1 G, Ulmer H, Pfeiffer K, Goebel G, Pereira J, Jaqueline M, Yoshida C, Lampe E, Velloso C, Marcelo A, Coelho H, Almeida A, Fernandes C, Kim A, Strasak A\nCLIN INFECT DIS. 2010;50(9):1222-1230.\nImmune-mediated liver injury.\nLohse A, Weiler-Normann C, Tiegs G\nJ HEPATOL. 2010;52:136-144.\nWissensstand, Pr\u00e4ventionsverhalten und Therapieadh\u00e4renz von Patienten mit chronischer Hepatitis B in einem gro\u00dfen terti\u00e4ren Zentrum in Deutschland\nLutgehetmann M, Meyer F, Volz T, Lohse A, Fischer C, Dandri M, Petersen J\nZ GASTROENTEROL. 2010;48(9):1126-32.\n[Knowledge about HBV, prevention behaviour and treatment adherence of patients with chronic hepatitis B in a large referral centre in Germany].\nL\u00fctgehetmann M, Meyer F, Volz T, Lohse A, Fischer C, Dandri-Petersen M, Petersen J\nZ GASTROENTEROL. 2010;48(9):1126-1132.\nIn vivo proliferation of hepadnavirus-infected hepatocytes induces loss of covalently closed circular DNA in mice.\nL\u00fctgehetmann M, Volz T, K\u00f6pke A, Broja T, Tigges E, Lohse A, Fuchs E, Murray J, Petersen J, Dandri-Petersen M\nHEPATOLOGY. 2010;52(1):16-24.\nBudesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis.\nManns M, Woynarowski M, Kreisel W, Lurie Y, Rust C, Zuckerman E, Bahr M, G\u00fcnther R, Hultcrantz R, Spengler U, Lohse A, Szalay F, F\u00e4rkkil\u00e4 M, Pr\u00f6ls M, Strassburg C\nGASTROENTEROLOGY. 2010;139(4):1198-1206.\nElevated endogenous expression of the dominant negative basic helix-loop-helix protein ID1 correlates with significant centrosome abnormalities in human tumor cells.\nManthey C, Mern D, Gutmann A, Zielinski A, Herz C, Lassmann S, Hasskarl J\nBMC CELL BIOL. 2010;11(1):2.\nHealth risks in travelers to South Africa: the GeoSentinel experience and implications for the 2010 FIFA World Cup.\nMendelson M, Davis Xiaohong M, Jensenius M, Keystone Jay S, von Sonnenburg F, Hale Devon C, Burchard G, Field V, Vincent P, Freedman D, Network G\nAM J TROP MED HYG. 2010;82(6):991-995.\n[A rare cause of variceal bleeding].\nNaderi J, Lohse A, Galle P, Schramm C\nZ GASTROENTEROL. 2010;48(10):1215-1218.\nSeltene Ursache einer Fundusvarizenblutung\nNaderi J, Lohse A, Galle P, Schramm C\nZ GASTROENTEROL. 2010;48(10):1215-8.\nHuman SepSecS or SLA/LP: selenocysteine formation and autoimmune hepatitis.\nPalioura S, Herkel J, Simonovi M, Lohse A, S\u00f6ll D\nBIOL CHEM. 2010;391(7):771-776.\nOf guinea pigs and men--an unusual case of jaundice.\nPischke S, Ehmer U, Schedel I, Gratz W, Wedemeyer H, Ziesing S, Bange F, Burchard G, Manns M, Bahr M, Strassburg C\nZ GASTROENTEROL. 2010;48(1):33-37.\nHistory of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.\nReekie J, Mocroft A, Ledergerber B, Beniowski M, Clotet B, van Lunzen J, Chiesi A, Pradier C, Machala L, Lundgren J, Group E\nHIV MED. 2010;11(7):469-478.\nUngew\u00f6hnliche Anf\u00e4lle - Sibirisch-st\u00e4mmiger Patient mit zystischer Hirnerkrankung\nR\u00f6der C, Schmiedel S\nFLUGMEDIZIN TROPENME. 2010;17(6):270-271.\nRole and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis.\nSamuele D, Seki E, Paik Y, Osterreicher C, Kodama Y, Kluwe J, Torozzi L, Miyai K, Benedetti A, Schwabe R, Brenner D\nHEPATOLOGY. 2010;52(4):1420-1430.\nIs there Emergence of Clinical HBV Resistance Under Long-Term HBV Combination Therapy? A Challenging Case Report\nSchewe K, Noah C, Sirma H, Schmiedel S, van Lunzen J, Rockstroh J, Schildgen O\nVIRUSES-BASEL. 2010;2(8):1564-1570.\nHepatitis A auf einem Frachtschiff - Besonderheiten der reisemedizinischen Beratung in der Seeschifffahrt\nSchlaich C, Burchard G\nFLUGMEDIZIN TROPENME. 2010;17(2):62-64.\n[Plasmodium knowlesi: cause of naturally acquired malaria in humans].\nSchottelius J, Gilberger T, Ehrhardt S, Burchard G\nDEUT MED WOCHENSCHR. 2010;135(7):297-300.\nPrimary liver transplantation for autoimmune Hepatitis: A comparative analysis of the European Liver Transplant Registry\nSchramm C, Bubenheim M, Adam R, Karam V, Buckels J, O'Grady J, Jamieson N, Pollard S, Neuhaus P, Manns M, Porte R, Castaing D, Paul A, Traynor O, Garden J, Friman S, Ericzon B, Fischer L, Vitko S, Krawczyk M, Metselaar H, Foss A, Kilic M, Rolles K, Burra P, Rogiers X, Lohse A\nLIVER TRANSPLANT. 2010;16(4):461-469.\nTreatment response in patients with autoimmune hepatitis.\nSchramm C, Weiler-Normann C, Wiegard C, Hellweg S, M\u00fcller S, Lohse A\nHEPATOLOGY. 2010;52(6):2247-2248.\nGenomic Tandem Repeat Analysis Proves Laboratory-Acquired Brucellosis in Veterinary (Camel) Diagnostic Laboratory in the United Arab Emirates.\nSchulze Zur Wiesch J, Wichmann D, Sobottka I, Rohde H, Schmoock G, Wernery R, Schmiedel S, Burchard G, Melzer F\nZOONOSES PUBLIC HLTH. 2010;57(5):315-317.\nNerve growth factor enhances clara cell proliferation after lung injury.\nSonar S, Schwinge D, Kilic A, Yildirim A, Conrad M, Seidler K, M\u00fcller B, Renz H, Nockher W\nEUR RESPIR J. 2010;36(1):105-115.\nHIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008.\nStellbrink H, Baldus S, Behrens G, Bogner J, Harrer T, Hoffmann C, van Lunzen J, M\u00fcnch J, Racz P, Scheller C, Stoll M, Tenner-Racz K, Rockstroh J\nEUR J MED RES. 2010;15(1):1-12.\nThe major genetic determinants of HIV-1 control affect HLA class I peptide presentation.\nStudy I, Pereyra F, Jia X, McLaren P, Telenti A, Bakker d, Paul I, Walker B, Ripke S, Brumme C, Pulit S, Carrington M, Kadie C, Carlson J, Heckerman D, Graham R, Plenge R, Deeks S, Gianniny L, Crawford G, Sullivan J, Gonzalez E, Davies L, Camargo A, Moore J, Beattie N, Gupta S, Crenshaw A, Burtt N, Guiducci C, Gupta N, Gao X, Qi Y, Yuki Y, Piechocka-Trocha A, Cutrell E, Rosenberg R, Moss K, Lemay P, O'Leary J, Schaefer T, Verma P, Toth I, Block B, Baker B, Rothchild A, Lian J, Proudfoot J, Alvino D, Addo M, Addo M, Allen T, Altfeld M, Henn M, Sylvie L, Streeck H, Haas D, Kuritzkes D, Robbins G, Shafer R, Gulick R, Shikuma C, Haubrich R, Riddler S, Sax P, Daar E, Ribaudo H, Agan B, Agarwal S, Ahern R, Allen B, Altidor S, Altschuler E, Ambardar S, Anastos K, Anderson B, Anderson V, Andrady U, Antoniskis D, Bangsberg D, Barbaro D, Barrie W, Bartczak J, Barton S, Basden P, Basgoz N, Bazner S, Bellos N, Benson A, Berger J, Bernard N, Bernard A, Birch C, Bodner S, Bolan R, Boudreaux E, Bradley M, Braun J, Brndjar J, Brown S, Brown K, Brown S, Burack J, Bush L, Cafaro V, Campbell O, Campbell J, Carlson R, Carmichael J, Casey K, Cavacuiti C, Celestin G, Chambers S, Chez N, Chirch L, Cimoch P, Cohen D, Cohn L, Conway B, Cooper D, Cornelson B, Cox D, Cristofano M, Cuchural G, Czartoski J, Dahman J, Daly J, Davis B, Davis K, Davod S, DeJesus E, Dietz C, Dunham E, Dunn M, Ellerin T, Eron J, Fangman J, Farel C, Ferlazzo H, Fidler S, Fleenor-Ford A, Frankel R, Freedberg K, French N, Fuchs J, Fuller J, Gaberman J, Gallant J, Gandhi R, Garcia E, Garmon D, Gathe J, Gaultier C, Gebre W, Gilman F, Gilson I, Goepfert P, Gottlieb M, Goulston C, Groger R, Gurley T, Haber S, Hardwicke R, Hardy W, Harrigan P, Hawkins T, Heath S, Hecht F, Henry W, Hladek M, Hoffman R, Horton J, Hsu R, Huhn G, Hunt P, Hupert M, Illeman M, Jaeger H, Jellinger R, John M, Johnson J, Johnson K, Johnson H, Johnson K, Joly J, Jordan W, Kauffman C, Khanlou H, Killian R, Kim A, Kim D, Kinder C, Kirchner J, Kogelman L, Kojic E, Korthuis P, Kurisu W, Kwon D, LaMar M, Lampiris H, Lanzafame M, Lederman M, Lee D, Lee J, Lee M, Lee E, Lemoine J, Levy J, Llibre J, Liguori M, Little S, Liu A, Lopez A, Loutfy M, Loy D, Mohammed D, Man A, Mansour M, Marconi V, Markowitz M, Marques R, Martin J, Martin H, Mayer K, McElrath M, McGhee T, McGovern B, McGowan K, McIntyre D, Mcleod G, Menezes P, Mesa G, Metroka C, Meyer-Olson D, Miller A, Montgomery K, Mounzer K, Nagami E, Nagin I, Nahass R, Nelson M, Nielsen C, Norene D, O'Connor D, Ojikutu B, Okulicz J, Oladehin O, Oldfield E, Olender S, Ostrowski M, Owen W, Pae E, Parsonnet J, Pavlatos A, Perlmutter A, Pierce M, Pincus J, Pisani L, Price L, Proia L, Prokesch [\nSCIENCE. 2010;330(6010):1551-1557.\nConcurrent autoimmune diseases in patients with autoimmune hepatitis.\nTeufel A, Weinmann A, Kahaly G, Centner C, Piendl A, W\u00f6rns M, Lohse A, Galle P, Kanzler S\nJ CLIN GASTROENTEROL. 2010;44(3):208-213.\nImmune tolerance: what is unique about the liver.\nTiegs G, Lohse A\nJ AUTOIMMUN. 2010;34:1-6.\nLong-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.\nvan B\u00f6mmel F, Man d, Robert A, Wedemeyer H, Deterding K, Buggisch P, Buggisch P, Erhardt A, H\u00fcppe D, Stein K, Trojan J, Sarrazin C, B\u00f6cher W, Spengler U, Wasmuth H, Reinders J, M\u00f6ller B, Peter R, Feucht H, Wiedenmann B, Berg T\nHEPATOLOGY. 2010;51(1):73-80.\n[ALT screening for chronic liver diseases: scrutinizing the evidence].\nWedemeyer H, Hofmann W, L\u00fcth S, Malinski P, Thimme R, Tacke F, Wiegand J\nZ GASTROENTEROL. 2010;48(1):46-55.\nTelomere und Telomerase in Zellalterung und Karzinogenese\nWege H, Br\u00fcmmendorf T\nBIOspektrum. 2010;3:271-273.\nUnsung hero Robert C. Gallo.\nAbbadessa G, Accolla R, Aiuti F, Albini A, Aldovini A, Alfano M, Antonelli G, Bartholomew C, Bentwich Z, Bertazzoni U, Berzofsky J, Biberfeld P, Boeri E, Buonaguro L, Buonaguro F, Bukrinsky M, Burny A, Caruso A, Cassol S, Chandra P, Ceccherini-Nelli L, Chieco-Bianchi L, Clerici M, Colombini-Hatch S, de Giuli Morghen C, de Maria A, de Rossi A, Dierich M, Della-Favera R, Dolei A, Douek D, Erfle V, Felber B, Fiorentini S, Franchini G, Gershoni J, Gotch F, Green P, Greene W, Hall W, Haseltine W, Jacobson S, Kallings L, Kalyanaraman V, Katinger H, Khalili K, Klein G, Klein E, Klotman M, Klotman P, Kotler M, Kurth R, Lafeuillade A, Michelangelo L, Lewis J, Lillo F, Lisziewicz J, Lomonico A, Lopalco L, Lori F, Lusso P, Macchi B, Malim M, Margolis L, Markham P, McClure M, Miller N, Mingari M, Moretta L, Noonan D, O'Brien S, Okamoto T, Pal R, Palese P, Panet A, Pantaleo G, Pavlakis G, Pistello M, Plotkin S, Poli G, Pomerantz R, Radaelli A, Robertguroff M, Roederer M, Sarngadharan M, Schols D, Secchiero P, Shearer G, Siccardi A, Stevenson M, Svoboda J, Tartaglia J, Torelli G, Tornesello M, Tschachler E, Vaccarezza M, Vallbracht A, van Lunzen J, Varnier O, Vicenzi E, von Melchner H, Witz I, Zagury D, Zagury J, Zauli G, Zipeto D\nSCIENCE. 2009;323(5911):206-207.\nCross-regulation between distinct natural killer T cell subsets influences immune response to self and foreign antigens.\nArrenberg P, Halder R, Kumar V\nJ CELL PHYSIOL. 2009;218(2):246-250.\nAbsence of erythrocyte sequestration and lack of multicopy gene family expression in Plasmodium falciparum from a splenectomized malaria patient.\nBachmann A, Esser C, Petter M, Predehl S, Von Kalckreuth V, Schmiedel S, Bruchhaus I, Tannich E\nPLOS ONE. 2009;4(10):7459.\nHepatic targeting and biodistribution of human fetal liver stem/progenitor cells and adult hepatocytes in mice.\nBenten D, Cheng K, Bhargava K, Inada M, Joseph B, Palestro C, Gupta S\nHEPATOLOGY. 2009;50(4):1194-1203.\nAurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.\nBenten D, Keller G, Quaas A, Schrader J, Gontarewicz A, Balabanov S, Balabanov M, Wege H, Moll J, Lohse A, Br\u00fcmmendorf T\nNEOPLASIA. 2009;11(9):934-944.\nOrthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner.\nBenten D, Staufer K, Sterneck M\nNAT CLIN PRACT GASTR. 2009;6(1):23-36.\nIndividualized treatment strategy according to early viral kinetics in hepatitis C virus type 1-infected patients.\nBerg T, Weich V, Teuber G, Klinker H, M\u00f6ller B, Rasenack J, Hinrichsen H, Gerlach T, Spengler U, Buggisch P, Balk H, Zankel M, Neumann K, Sarrazin C, Zeuzem S\nHEPATOLOGY. 2009;50(2):369-377.\nGastrointestinal growth factors and hormones have divergent effects on Akt activation.\nBerna M, Tapia J, Sancho V, Berna-Thill M, Pace A, Hoffmann K, Gonzalez-Fernandez L, Jensen R\nCELL SIGNAL. 2009;21(4):622-638.\nHepatic stellate cell lipid droplets: a specialized lipid droplet for retinoid storage.\nBlaner W, O'Byrne S, Wongsiriroj N, Kluwe J, D'Ambrosio D, Jiang H, Schwabe R, Hillman E, Piantedosi R, Libien J\nBBA-MOL CELL BIOL L. 2009;1791(6):467-473.\nInfektionspatienten mit ansteckenden Krankheiten\nBurchard G\nNotfallmedizin up2date. 2009;4(1):69-81.\nCD4 T cells in hepatic immune tolerance.\nCarambia A, Herkel J\nJ AUTOIMMUN. 2009.\nRate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.\nCozzi-Lepri A, Phillips A, Losso M, Duran A, Vetter N, Karpov I, Vassilenko A, Clumeck N, De Wit S, Poll B, Colebunders R, Kostov K, Begovac J, Machala L, Rozsypal H, Sedlacek D, Nielsen J, Benfield T, Kirk O, Gerstoft J, Katzenstein T, Eg Hansen A, Skinh\u00f8j P, Pedersen C, Oestergaard L, Zilmer K, Smidt J, Ristola M, Katlama C, Viard J, Girard P, Livrozet J, Vanhems P, Pradier C, Dabis F, Rockstroh J, Schmidt R, van Lunzen J, Degen O, Stellbrink H, Staszewski S, Bogner J, F\u00e4tkenheuer G, Kosmidis J, Gargalianos P, Xylomenos G, Perdios J, Panos G, Filandras A, Karabatsaki E, Sambattakou H, Banhegyi D, Mulcahy F, Yust I, Turner D, Burke M, Pollack S, Hassoun G, Maayan S, Chiesi A, Vullo V, Lichtner M, Antonucci G, Iacomi F, Narciso P, Vlassi C, Zaccarelli M, Esposito R, Mazeu I, Mussini C, Arici C, Pristera R, Mazzotta F, Gabbuti A, Chirianni A, Montesarchio E, Gargiulo M, Lazzarin A, Finazzi R, Galli M, Ridolfo A, D'Arminio A, Rozentale B, Aldins P, Chaplinskas S, Hemmer R, Staub T, Reiss P, Bruun J, Maeland A, Ormaasen V, Knysz B, Gasiorowski J, Horban A, Prokopowicz D, Wiercinska-Drapalo A, Boron-Kaczmarska A, Pynka M, Beniowski M, Mularska E, Trocha H, Antunes F, Valadas E, Mansinho K, Maltez F, Duiculescu D, Babes V, Rakhmanova A, Vinogradova E, Buzunova S, Jevtovic D, Mokr\u00e1s M, Stanekov\u00e1 D, Gonz\u00e1lez-Lahoz J, Soriano V, Martin-Carbonero L, Labarga P, Clotet B, Ruiz L, Gatell J, Mir\u00f3 J, Domingo P, Gutierrez M, Mateo G, Sambeat M, Karlsson A, Persson P, Flamholc L, Ledergerber B, Weber R, Francioli P, Cavassini M, Hirschel B, Boffi E, Furrer H, Battegay M, Elzi L, Kravchenko E, Chentsova N, Barton S, Johnson A, Mercey D, Johnson M, Mocroft A, Murphy M, Weber J, Scullard G, Fisher M, Brettle R, Gatell J, Gazzard B, Monforte A, Lundgren J, Friis-M\u00f8ller N, Bannister W, Ellefson M, Borch A, Podlevkareva D, Kjaer J, Peters L, Reekie J\nJ INFECT DIS. 2009;200(5):687-697.\nJapanosche Enzephalitis, ein neuer Impfstoff.\nCramer J\nFLUGMEDIZIN TROPENME. 2009;16(3):125-130.\nLow N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation.\nCramer J, Lohse A, Burchard G, Fischer L, Nashan B, Zimmermann M, Marx A, Kluge S\nTRANSPL INT. 2009.\nNon-invasive diagnosis and monitoring of liver fibrosis and cirrhosis.\nDenzer U, L\u00fcth S\nBEST PRACT RES CL GA. 2009;23(3):453-460.\nThe German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection.\nDeterding K, Wiegand J, Gr\u00fcner N, Hahn A, J\u00e4ckel E, Jung M, Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H\nZ GASTROENTEROL. 2009;47(6):531-540.\nHepatic stem and progenitor cells in liver diseases and hepatocarcinogenesis.\nHeim D, Wege H\nMinerva Gastroenterol Dietol. 2009;55(2):111-121.\nTelaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection\nH\u00e9zode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki J, Bourli\u00e8re M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman R, Alam J, Pawlotsky J, Benhamou Y, Couzigou P, Grang\u00e9 J, Marcellin P, Mathurin P, Serfaty L, Tran A, Tr\u00e9po C, Zarski J, Berg T, Buggisch P, Buggisch P, Erhardt A, Gerken G, G\u00fcnther R, Rasenack J, Schmidt W, Spengler U, Wedemeyer H, Mutimer D, Zeuzem S\nNEW ENGL J MED. 2009;360(18):1839-1850.\nActivin a promotes the TGF-beta-induced conversion of CD4+CD25- T cells into Foxp3+ induced regulatory T cells.\nHuber S, Stahl F, Schrader J, L\u00fcth S, Presser K, Carambia A, Flavell R, Werner S, Blessing M, Herkel J, Schramm C\nJ IMMUNOL. 2009;182(8):4633-4640.\nMulticenter GeoSentinel analysis of rickettsial diseases in international travelers, 1996-2008.\nJensenius M, Davis X, von Sonnenburg F, Schwartz E, Keystone J, Leder K, Lop\u00e9z-V\u00e9l\u00e9z R, Caumes E, Cramer J, Chen L, Parola P\nEMERG INFECT DIS. 2009;15(11):1791-1798.\nImpaired CD4-cell immune reconstitution upon HIV therapy in patients with toxoplasmic encephalitis compared to patients with pneumocystis pneumonia as AIDS indicating disease\nKastenbauer U, Wolf E, Kollan C, Hamouda O, Arest\u00e9h K, Kowol S, Bergmann F, Warncke M, M\u00fchlb\u00e4cher N, Rockstroh J, Wasmuth J, Oette M, Blondin C, Esser S, Schenk-Westkamp P, Plettenberg A, Lorenzen T, Walther I, Adam A, Weitner L, Schewe K, Goey H, Fenske S, Buhk T, Stellbrink H, Gellerman H, van Lunzen J, Elshani D, Stoll M, Gerschmann S, Horst H, F\u00e4tkenheuer G, K\u00fcmmerle T, Gillor D, Brogner [, Sonntag B, Salzberger B, Fritzsche C, Kuehne A, Bogner J\nEUR J MED RES. 2009;14(6):244-249.\nTelomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.\nKeller G, Brassat U, Balabanov M, Heim D, Wege H, Br\u00fcmmendorf T\nHEMATOL ONCOL. 2009;27(3):123-129.\nChirurgische Gastroenterologie Interdisziplin\u00e4r wird zu Viszeralmedizin\nKlar E, M\u00f6ssner J, Lohse A\nVISZERALMEDIZIN. 2009;25(1):7-7.\nToll-like receptors, wound healing, and carcinogenesis.\nKluwe J, Mencin A, Schwabe R\nJ MOL MED. 2009;87(2):125-138.\nSickle cell trait (HbAS) and stunting in children below two years of age in an area of high malaria transmission.\nKreuels B, Ehrhardt S, Kreuzberg C, Adjei S, Kobbe R, Burchard G, Ehmen C, Ayim M, Adjei O, May J\nMALARIA J. 2009;8:16.\nPreferential upregulation of interferon-alpha subtype 2 expression in HIV-1 patients.\nLehmann C, Taubert D, Jung N, F\u00e4tkenheuer G, van Lunzen J, Hartmann P, Romerio F\nAIDS RES HUM RETROV. 2009;25(6):577-581.\nControl of cccDNA function in hepatitis B virus infection.\nLevrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri-Petersen M\nJ HEPATOL. 2009;51(3):581-592.\nAutoimmune hepatic diseases: Prognosis and management of autoimmune hepatitis\nLohse A, L\u00fcth S, Schramm C\n2009. Autoimmune Hepatic Diseases. Permanyer Publications: 115-122.\nCharacteristics and long-term prognosis of the autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome\nL\u00fcth S, Kanzler S, Frenzel C, Kasper H, Dienes H, Schramm C, Galle P, Herkel J, Lohse A\nJ CLIN GASTROENTEROL. 2009;43(1):75-80.\nPrognosis and management of autoimmune hepatitis\nL\u00fcth S, Schramm C, Lohse A\n2009. Autoimmune hepatic diseases. Permanyer Publications: 115-122.\n[Autoimmune liver diseases]\nL\u00fcth S, Weiler-Normann C, Schramm C, Lohse A\nINTERNIST. 2009;50(3):310-317.\nAutoimmunerkrankungen der Leber\nL\u00fcth S, Weiler-Normann C, Schramm C, Lohse A\nINTERNIST. 2009;50(3):310-7.\nToll-like receptors as targets in chronic liver diseases.\nMencin A, Kluwe J, Schwabe R\nGUT. 2009;58(5):704-720.\nDithiolethione modified valproate and diclofenac increase E-cadherin expression and decrease proliferation of non-small cell lung cancer cells.\nMoody T, Switzer C, Santana-Flores W, Ridnour L, Berna M, Berna-Thill M, Jensen R, Sparatore A, Piero D, Yeh G, Roberts D, Giaccone G, Wink D\nLUNG CANCER. 2009.\nDepressive symptoms and metabolic risk: effects of cortisol and gender.\nMuhtz C, Zyriax B, Kl\u00e4hn T, Windler E, Otte C\nPSYCHONEUROENDOCRINO. 2009;34(7):1004-1011.\nPlasminogen activator inhibitor type 1 up-regulation is associated with skeletal muscle atrophy and associated fibrosis.\nNaderi J, Bernreuther C, Grabinski N, Putman C, Henkel B, Bell G, Glatzel M, Sultan K\nAM J PATHOL. 2009;175(2):763-771.\nAngiotensin-converting-enzyme 2 inhibits liver fibrosis in mice.\nOsterreicher C, Taura K, Samuele D, Seki E, Penz-Osterreicher M, Kodama Y, Kluwe J, Schuster M, Oudit G, Penninger J, Brenner D\nHEPATOLOGY. 2009;50(3):929-938.\nPancreas and liver injury are associated in individuals with increased alcohol consumption.\nPace A, de Weerth A, Berna M, Hillbricht K, Tsokos M, Bl\u00e4ker M, P\u00fcschel K, Lohse A\nCLIN GASTROENTEROL H. 2009;7(11):1241-1246.\nNo evidence of chikungunya virus and antibodies shortly before the outbreak on Sri Lanka.\nPanning M, Wichmann D, Grywna K, Annan A, Wijesinghe S, Kularatne S, Drosten C\nMED MICROBIOL IMMUN. 2009;198(2):103-106.\nThe German NET-registry: an audit on the diagnosis and therapy of neuroendocrine tumors\nPloeckinger U, Kloeppel G, Wiedenmann B, Anzinger M, Auernhammer C, Hoffmann J, Begum N, Bihl H, Bl\u00e4ker M, Busse F, Daum S, Fottner C, Musholt T, Frilling A, Fuchs M, Haas S, Niedergethmann M, Isermann B, Lammert F, Zimmer V, M\u00f6nig H, Prinz C, Vogelsang H, Raffel A, Schmitt M, Rinke A, Schlamp A, Stier S, Ezziddin S, Trojan J, Pascher A, Lohmann R\nNEUROENDOCRINOLOGY. 2009;90(4):349-363.\nPeginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy\nPoynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, Moreno-Otero R, Carrilho F, Schmidt W, Berg T, McGarrity T, Heathcote E, Gon\u00e7ales F, Diago M, Craxi A, Silva M, Bedossa P, Mukhopadhyay P, Griffel L, Burroughs M, Brass C, Alberti A, Perez Alvarez R, Anderson F, Balart L, Barange K, Bodenheimer H, Bourliere M, Bronowicki J, Brunner H, Buggisch P, Buggisch P, Calleja J, Carvalho A, Caselmann W, Causse X, Cheng W, Coelho H, Colombato L, Crawford D, Curciarello J, Delwaide J, Serra Desfilis M, Dusheiko G, Enns R, Esteban-Mur R, Fainboim H, Feinman S, Ferraz M, Ferreira Filho R, Focaccia R, Gadano A, George J, Goncales F, Gordon S, Gutfreund K, Haussinger D, Hilzenrat N, Hinrichsen H, Horsmans Y, Hultcrantz R, Jacobson I, Jeffrey G, Kaita K, King P, Kwo P, Lai M, Leggett B, Lyra L, Maieron A, Manesis E, Manns M, Marcellin P, Marotta P, Marsano L, Mattos A, Mauad M, McCullough A, McHutchison J, Brandao Mello C, Millison L, Muellhaupt B, Muzzillo D, Ngu M, Niederau C, Pauly M, Peltekian K, Perrillo R, Picciotto A, Pinchuk L, Podda M, Poo J, Poordad F, Poupon R, Ramos-Gomez M, Reichen J, Reindollar R, Reymunde A, Rizzetto M, Roberts S, Rosa H, Rosenberg W, Routley D, Rumi M, Rustgi V, Sanchez-Tapias J, Shaikh O, Sherman K, Sievert W, Smith C, Spengler U, Sulkowski M, Tanno H, Teixeira R, Toro D, Torres E, Castellanos Tortajada G, Tran A, Trepo C, Tsai N, Vale A, Varon A, Planas Vila R, Villa E, Van Vlierberghe H, Wong F, Zachoval R, Zeuzem S, Zignego A, Albrecht J\nGASTROENTEROLOGY. 2009;136(5):1618-1628.\nSuccessful treatment of psychosis with infliximab in a patient with Crohn's disease.\nReimer J, Fink T, Bl\u00e4ker M, Sch\u00e4fer I, Otte C\nSCHIZOPHR RES. 2009;109(1-3):194-195.\nPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.\nRinke A, M\u00fcller H, Schade-Brittinger C, Klose K, Barth P, Wied M, Mayer C, Aminossadati B, Pape U, Bl\u00e4ker M, Harder J, Arnold C, Gress T, Arnold R\nJ CLIN ONCOL. 2009;27(28):4656-4663.\nAttenuated strains of influenza A viruses do not induce degradation of RNA polymerase II.\nRodriguez A, P\u00e9rez-Gonz\u00e1lez A, Hossain M, Chen L, Rolling T, P\u00e9rez-Bre\u00f1a P, Donis R, Kochs G, Nieto A\nJ VIROL. 2009;83(21):11166-11174.\nAdaptive mutations resulting in enhanced polymerase activity contribute to high virulence of influenza A virus in mice.\nRolling T, Koerner I, Zimmermann P, Holz K, Haller O, Staeheli P, Kochs G\nJ VIROL. 2009;83(13):6673-6680.\nImpaired gastric acidification negatively affects calcium homeostasis and bone mass.\nSchinke T, Schilling A, Baranowsky A, Seitz S, Marshall R, Linn T, Bl\u00e4ker M, Huebner A, Schulz A, Simon R, Gebauer M, Priemel M, Kornak U, Perkovic S, Barvencik F, Beil F, Andrea D, Frattini A, Streichert T, P\u00fcschel K, Villa A, Debatin K, Rueger J, Teti A, Zustin J, Sauter G, Amling M\nNAT MED. 2009;15(6):674-681.\nRestoration of contact inhibition in human glioblastoma cell lines after MIF knockdown.\nSchrader J, Deuster O, Rinn B, Schulz M, Kautz A, Dodel R, Meyer B, Al-Abed Y, Balakrishnan K, Reese J, Bacher M\nBMC CANCER. 2009;9:464.\nSenescence of activated stellate cells: not just early retirement.\nSchrader J, Fallowfield J, Iredale J\nHEPATOLOGY. 2009;49(3):1045-1047.\nEverolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options.\nSchrader J, Sterneck M, Klose H, Lohse A, Nashan B, Fischer L\nTRANSPL INT. 2009.\nResults of the IDEAL trial: \"Mirror, mirror on the wall ... which's the fairest peg-interferon of them all?\".\nSchulze Zur Wiesch J, Lohse A\nHEPATOLOGY. 2009;50(6):2034-2037.\nSustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection.\nSchulze Zur Wiesch J, Pieper D, Stahmer I, Eiermann T, Buggisch P, Lohse A, Hauber J, van Lunzen J\nCLIN INFECT DIS. 2009;49(3):466-472.\nCCR1 and CCR5 promote hepatic fibrosis in mice.\nSeki E, Samuele D, Gwak G, Kluwe J, Inokuchi S, Bursill C, Llovet J, Brenner D, Schwabe R\nJ CLIN INVEST. 2009;119(7):1858-1870.\nEpidemiologically linked transmission of HIV-1 illustrates the impact of host genetics on virological outcome.\nStreeck H, Jessen H, Kuecherer C, Li B, Jessen A, Dupke S, Baumgarten A, Stahmer I, van Lunzen J, Altfeld M, Walker B, Allen T\nAIDS. 2009;23(2):259-262.\nHepatocellular carcinoma in patients with autoimmune hepatitis.\nTeufel A, Weinmann A, Centner C, Piendl A, Lohse A, Galle P, Kanzler S\nWORLD J GASTROENTERO. 2009;15(5):578-582.\nPulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series.\nToussirot E, Berthelot J, Pertuiset E, Bouvard B, Gaudin P, Wendling D, Jos\u00e9 L, Lohse A, Lecuyer E, Cri L\nJ RHEUMATOL. 2009;36(11):2421-2427.\nThe replication cycle of hepatitis B virus.\nUrban S, Schulze A, Dandri-Petersen M, Petersen J\nJ HEPATOL. 2009.\n[Preliminary first steps are encouraging. Gene therapy against HIV? (interview by Waldtraud Paukstadt)]\nvan Lunzen J\nMMW Fortschr Med. 2009;151(18):83-84.\nTerlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.\nVon Kalckreuth V, Glowa F, Geibler M, Lohse A, Denzer U\nZ GASTROENTEROL. 2009;47(1):21-26.\nTelomerase-Inhibitoren\nWege H, Br\u00fcmmendorf T\n2009. Molekulare Therapie in der H\u00e4matologie/Onkologie. Bremen: Uni-Med, .\nA case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade.\nWeiler-Normann C, Wiegard C, Schramm C, Lohse A\nAM J GASTROENTEROL. 2009;104(11):2877-2878.\nCARDIAC INVOLVEMENT IN DENGUE VIRUS INFECTIONS DURING THE 2004/2005 DENGUE FEVER SEASON IN SRI LANKA\nWichmann D, Kularatne S, Ehrhardt S, Wijesinghe S, Brattig N, Abel W, Burchard G\nSEA J Trop Med Pub H. 2009;40(4):727-730.\nDiagnosing schistosomiasis by detection of cell-free parasite DNA in human plasma.\nWichmann D, Panning M, Quack T, Kramme S, Burchard G, Grevelding C, Drosten C\nPLOS NEGLECT TROP D. 2009;3(4):422.\nScoring systems for the diagnosis of autoimmune hepatitis: past, present, and future.\nWiegard C, Schramm C, Lohse A\nSEMIN LIVER DIS. 2009;29(3):254-261.\nTetrahydrobiopterin deficiency in human rabies.\nWilloughby R, Opladen T, Maier T, Rhead W, Schmiedel S, Hoyer J, Drosten C, Rupprecht C, Hyland K, Hoffmann G\nJ INHERIT METAB DIS. 2009;32(1):65-72.\nCumulative HIV viremia during highly active antiretroviral therapy is a strong predictor of AIDS-related lymphoma.\nZoufaly A, Stellbrink H, Heiden M, Kollan C, Hoffmann C, van Lunzen J, Hamouda O\nJ INFECT DIS. 2009;200(1):79-87.\nThe local cytokine and chemokine milieu within malignant effusions.\nAtanackovic D, Cao Y, Kim J, Brandl S, Thoem I, Faltz C, Hildebrandt Y, Bartels K, De Weerth A, Hegewisch-Becker S, Hossfeld D, Bokemeyer C\nTUMOR BIOL. 2008;29(2):93-104.\nIncidence of abacavir hypersensitivity reactions in euroSIDA.\nBannister W, Friis-M\u00f8ller N, Mocroft A, Viard J, van Lunzen J, Kirk O, Gargalianos P, B\u00e1nhegyi D, Chiesi A, Lundgren J\nANTIVIR THER. 2008;13(5):687-696.\nLow recurrence of preexisting extrahepatic malignancies after liver transplantation.\nBenten D, Sterneck M, Panse J, Rogiers X, Lohse A\nLIVER TRANSPLANT. 2008;14(6):789-798.\nA prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors.\nBerna M, Annibale B, Marignani M, Luong T, Corleto V, Pace A, Ito T, Liewehr D, Venzon D, Gianfranco D, Bordi C, Jensen R\nJ CLIN ENDOCR METAB. 2008;93(5):1582-1591.\nLate outgrowth endothelial progenitor cells in patients with age-related macular degeneration.\nBerna-Thill M, Strunnikova N, Berna M, Gordiyenko N, Schmid K, Cousins S, Thompson D, Csaky K\nINVEST OPHTH VIS SCI. 2008;49(6):2696-2708.\nActivation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.\nBiburger M, Tiegs G\nJ LEUKOCYTE BIOL. 2008;84(1):264-279.\nPlasmodium falciparum glycosylphosphatidylinositol toxin interacts with the membrane of non-parasitized red blood cells: a putative mechanism contributing to malaria anemia.\nBrattig N, Kowalsky K, Liu X, Burchard G, Kamena F, Seeberger P\nMICROBES INFECT. 2008;10(8):885-891.\n[Old dogmas and new perspectives in antibiotic-associated diarrhea]\nCramer J, Burchard G, Lohse A\nMED KLIN-INTENSIVMED. 2008;103(5):325-340.\nMyD88/IL-18-dependent pathways rather than TLRs control early parasitaemia in non-lethal Plasmodium yoelii infection.\nCramer J, Lepenies B, Kamena F, H\u00f6lscher C, Freudenberg M, Burchard G, Wagner H, Kirschning C, Liu X, Seeberger P, Jacobs T\nMICROBES INFECT. 2008;10(12-13):1259-1265.\nVirion half-life in chronic hepatitis B infection is strongly correlated with levels of viremia.\nDandri-Petersen M, Murray J, L\u00fctgehetmann M, Volz T, Lohse A, Petersen J\nHEPATOLOGY. 2008;48(4):1079-1086.\n[Mini laparoscopy].\nDenzer U, Lohse A\nDEUT MED WOCHENSCHR. 2008;133(30):1585-1588.\nEosinophilia in returning travelers and migrants.\nEhrhardt S, Burchard G\nDTSCH ARZTEBL INT. 2008;105(46):801-807.\nTransplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice.\nFollenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S\nJ CLIN INVEST. 2008;118(3):935-945.\nSimultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.\nGontarewicz A, Balabanov S, von Amsberg G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Br\u00fcmmendorf T\nBLOOD. 2008;111(8):4355-4364.\nLoss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors\nGrabowski P, Schrader J, Wagner J, H\u00f6rsch D, Arnold R, Arnold C, Georgieva I, Stein H, Zeitz M, Daniel P, Sturm I\nCLIN CANCER RES. 2008;14(22):7378-84.\nRabies vaccination and traffic accidents.\nGunther A, Burchard G, Schoenfeld C\nTRAVEL MED INFECT DI. 2008;6(5):326-327.\nEvaluation of complement factor 5 variants as genetic risk factors for the development of advanced fibrosis in chronic hepatitis C infection.\nHalangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, Klinker H, Hinrichsen H, Buggisch P, Landt O, Weich V, Bergk A, Wiedenmann B, Neuhaus P, Berg T, Witt H\nJ HEPATOL. 2008;49(3):339-345.\nTreatment of acute uncomplicated falciparum malaria with artemether-lumefantrine in nonimmune populations: a safety, efficacy, and pharmacokinetic study.\nHatz C, Soto J, Nothdurft H, Zoller T, Weitzel T, Loutan L, Bricaire F, Gay F, Burchard G, Andriano K, Lef\u00e8vre G, Palacios D, Ibarra P, Genton B\nAM J TROP MED HYG. 2008;78(2):241-247.\nMycophenolate mofetil as second line therapy in autoimmune hepatitis?\nHennes E, Oo Y, Schramm C, Denzer U, Buggisch P, Wiegard C, Kanzler S, Schuchmann M, Boecher W, Galle P, Adams D, Lohse A\nAM J GASTROENTEROL. 2008;103(12):3063-3070.\nSimplified criteria for the diagnosis of autoimmune hepatitis.\nHennes E, Zeniya M, Czaja A, Par\u00e9s A, Dalekos G, Krawitt E, Bittencourt P, Porta G, Boberg K, Hofer H, Bianchi F, Shibata M, Schramm C, Barbara E, Galle P, McFarlane I, Dienes H, Lohse A\nHEPATOLOGY. 2008;48(1):169-176.\nFalciparum malaria in a German tourist, acquired on Great Exuma, Bahamas, March 2008.\nHennigs A, Schmiedel S\nEUROSURVEILLANCE. 2008;13(18):.\n[Severe ileocolitis refractory to standard medical treatment. A diagnostic dilemma]\nHennigs A, Schmiedel S, Lohse A, Burchard G\nINTERNIST. 2008;49(9):1115-1119.\nSignificance of autoantibodies.\nHerkel J, Lohse A\nHEPATOLOGY. 2008;47(3):786-788.\nP38 MAP kinase signaling is required for the conversion of CD4+CD25- T cells into iTreg.\nHuber S, Schrader J, Fritz G, Presser K, Schmitt S, Waisman A, L\u00fcth S, Blessing M, Herkel J, Schramm C\nPLOS ONE. 2008;3(10):3302.\nPhenotype reversion in fetal human liver epithelial cells identifies the role of an intermediate meso-endodermal stage before hepatic maturation.\nInada M, Follenzi A, Cheng K, Surana M, Joseph B, Benten D, Bandi S, Qian H, Gupta S\nJ CELL SCI. 2008;121(7):1002-1013.\nEsophageal squamous cell carcinoma presenting with extensive skin lesions: a case report\nIwanski G, Block A, von Amsberg G, M\u00fcnch J, Claus S, Fiedler W, Bokemeyer C\nJ Med Case Rep. 2008;2:115.\nInherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies.\nJensen R, Berna M, Bingham D, Norton J\nCANCER-AM CANCER SOC. 2008;113(7):1807-1843.\nRelevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.\nJung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, Stellbrink H, Faetkenheuer G, Taubert D\nDRUG METAB DISPOS. 2008;36(8):1616-1623.\nHigh level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome.\nKasprowicz V, Schulze Zur Wiesch J, Kuntzen T, Nolan B, Longworth S, Berical A, Blum J, McMahon C, Reyor L, Elias N, Kwok W, McGovern B, Freeman G, Chung R, Klenerman P, Lewis-Ximenez L, Walker B, Allen T, Kim A, Lauer G\nJ VIROL. 2008;82(6):3154-3160.\nA randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children.\nKobbe R, Klein P, Adjei S, Amemasor S, Thompson W, Heidemann H, Nielsen M, Vohwinkel J, Hogan B, Kreuels B, B\u00fchrlen M, Loag W, Ansong D, May J\nMALARIA J. 2008;7:261.\nQ fever in young children, Ghana\nKobbe R, Kramme S, Kreuels B, Adjei S, Kreuzberg C, Panning M, Adjei O, Fleischer B, May J\nEMERG INFECT DIS. 2008;14(2):344-6.\nSpatial variation of malaria incidence in young children from a geographically homogeneous area with high endemicity\nKreuels B, Kobbe R, Adjei S, Kreuzberg C, von Reden C, B\u00e4ter K, Klug S, Busch W, Adjei O, May J\nJ INFECT DIS. 2008;197(1):85-93.\nNaturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-na\u00efve patients.\nKuntzen T, Timm J, Berical A, Lennon N, Berlin A, Young S, Lee B, Heckerman D, Carlson J, Reyor L, Kleyman M, McMahon C, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M, Kodira C, Roberts A, Lauer G, Rosen H, Bihl F, Cerny A, Spengler U, Liu Z, Kim A, Xing Y, Schneidewind A, Madey M, Fleckenstein J, Park V, Galagan J, Nusbaum C, Walker B, Lake-Bakaar G, Daar E, Jacobson I, Gomperts E, Edlin B, Donfield S, Chung R, Talal A, Marion T, Birren B, Henn M, Allen T\nHEPATOLOGY. 2008;48(6):1769-1778.\nIncreased interferon alpha expression in circulating plasmacytoid dendritic cells of HIV-1-infected patients.\nLehmann C, Harper J, Taubert D, Hartmann P, F\u00e4tkenheuer G, Jung N, van Lunzen J, Stellbrink H, Gallo R, Romerio F\nJAIDS-J ACQ IMM DEF. 2008;48(5):522-530.\nStructural basis for the binding of naproxen to human serum albumin in the presence of fatty acids and the GA module.\nLejon S, Cramer J, Nordberg P\nACTA CRYSTALLOGR F. 2008;64(2):64-69.\nInduction of experimental cerebral malaria is independent of TLR2/4/9.\nLepenies B, Cramer J, Burchard G, Wagner H, Kirschning C, Jacobs T\nMED MICROBIOL IMMUN. 2008;197(1):39-44.\nSorafenib in advanced hepatocellular carcinoma.\nLlovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, Oliveira d, Cosme A, Santoro A, Raoul J, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Buggisch P, Galle P, Seitz J, Borbath I, H\u00e4ussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J\nNEW ENGL J MED. 2008;359(4):378-390.\nSequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication.\nL\u00fctgehetmann M, Volz T, Quaas A, Zankel M, Fischer C, Dandri-Petersen M, Petersen J\nANTIVIR THER. 2008;13(1):57-66.\nSerologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis.\nL\u00fcth S, Herkel J, Kanzler S, Frenzel C, Galle P, Dienes H, Schramm C, Lohse A\nJ CLIN GASTROENTEROL. 2008;42(8):926-930.\nEctopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs\nL\u00fcth S, Huber S, Schramm C, Buch T, Zander S, Stadelmann C, Br\u00fcck W, Wraith D, Herkel J, Lohse A\nJ CLIN INVEST. 2008;118(10):3403-3410.\nC-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.\nMahner S, Baasch C, Schwarz J, Hein S, W\u00f6lber L, J\u00e4nicke F, Milde-Langosch K\nBRIT J CANCER. 2008;99(8):1269-1275.\nTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.\nMarcellin P, Heathcote E, Buti M, Gane E, Man d, Robert A, Krastev Z, Germanidis G, Lee S, Flisiak R, Kaita K, Manns M, Kotzev I, Buggisch P, Buggisch P, Weilert F, Kurdas O, Shiffman M, Trinh H, Washington M, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F\nNEW ENGL J MED. 2008;359(23):2442-2455.\nTherapeutic and prophylactic effect of intermittent preventive anti-malarial treatment in infants (IPTi) from Ghana and Gabon\nMay J, Adjei S, Busch W, Gabor J, Issifou S, Kobbe R, Kreuels B, Lell B, Schwarz N, Adjei O, Kremsner P, Grobusch M\nMALARIA J. 2008;7:198.\nA phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.\nMehendale S, van Lunzen J, Clumeck N, Rockstroh J, Vets E, Johnson P, Anklesaria P, Barin B, Boaz M, Kochhar S, Lehrman J, Schmidt C, Peeters M, Schwarze-Zander C, Kabamba K, Glaunsinger T, Sahay S, Thakar M, Paranjape R, Gilmour J, Excler J, Fast P, Heald A\nAIDS RES HUM RETROV. 2008;24(6):873-880.\nIdentification of CD4 T-cell epitopes in soluble liver antigen/liver pancreas autoantigen in autoimmune hepatitis.\nMix H, Weiler-Normann C, Thimme R, Ahlenstiel G, Shin E, Herkel J, David C, Lohse A, Rehermann B\nGASTROENTEROLOGY. 2008;135(6):2107-2118.\nHepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV.\nMizukoshi E, Eisenbach C, Edlin B, Newton K, Raghuraman S, Weiler-Normann C, Tobler L, Busch M, Carrington M, McKeating J, O'Brien T, Rehermann B\nJ INFECT DIS. 2008;198(2):203-212.\nProspective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.\nNorton J, Venzon D, Berna M, Alexander H, Fraker D, Libutti S, Marx S, Gibril F, Jensen R\nANN SURG. 2008;247(3):501-510.\nThe dual EGF/VEGF receptor tyrosine kinase inhibitor AEE788 inhibits growth of human hepatocellular carcinoma xenografts in nude mice.\nOkamoto K, Neureiter D, Alinger B, Meissnitzer M, Sass G, Schmitz V, Pietro D, Wissniowski T, Gahr S, Hohenstein B, Kaufmann B, Schl\u00f6sser A, Haus U, Hahn E, Herold C, Ocker M\nINT J ONCOL. 2008;33(4):733-742.\nEfficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.\nOrtiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade-Villanueva J, Fourie J, Sandra D, Martine D, Lefebvre E, Vangeneugden T, Spinosa-Guzman S\nAIDS. 2008;22(12):1389-1397.\nPrevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein.\nPetersen J, Dandri-Petersen M, Mier W, L\u00fctgehetmann M, Volz T, von Weizs\u00e4cker F, Haberkorn U, Fischer L, Pollok J, Erbes B, Seitz S, Urban S\nNAT BIOTECHNOL. 2008;26(3):335-341.\nCoexpression of TGF-beta1 and IL-10 enables regulatory T cells to completely suppress airway hyperreactivity\nPresser K, Schwinge D, Wegmann M, Huber S, Schmitt S, Quaas A, Maxeiner J, Finotto S, Lohse A, Blessing M, Schramm C\nJ IMMUNOL. 2008;181(11):7751-7758.\nDoes less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?\nReekie J, Mocroft A, Sambatakou H, Machala L, Chiesi A, van Lunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren J\nAIDS. 2008;22(17):2381-2390.\nHepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.\nRodr\u00edguez-Torres M, Govindarajan S, Sol\u00e1 R, Clumeck N, Lissen E, Pess\u00f4a M, Buggisch P, Main J, Depamphilis J, Dieterich D\nJ HEPATOL. 2008;48(5):756-764.\nInhibition of heme oxygenase 1 expression by small interfering RNA decreases orthotopic tumor growth in livers of mice.\nSass G, Leukel P, Schmitz V, Raskopf E, Ocker M, Neureiter D, Meissnitzer M, Tasika E, Tannapfel A, Tiegs G\nINT J CANCER. 2008;123(6):1269-1277.\nAdalimumab Could Suppress the Activity of Non Alcoholic Steatohepatitis (NASH).\nSchramm C, Schneider A, Marx A, Lohse A\nZ GASTROENTEROL. 2008;46(12):1369-1371.\nSorafenib-induced liver failure.\nSchramm C, Schuch G, Lohse A\nAM J GASTROENTEROL. 2008;103(8):2162-2163.\nPrimary HIV infection presenting as haemolytic crisis in a patient with previously undiagnosed glucose 6-phosphate dehydrogenase deficiency.\nSchulze Zur Wiesch J, Wichmann D, Hennigs A, van Lunzen J, Burchard G, Schmiedel S\nAIDS. 2008;22(14):1886-1888.\nCutting edge: a key pathogenic role of IL-27 in T cell- mediated hepatitis.\nSiebler J, Wirtz S, Frenzel C, Schuchmann M, Lohse A, Galle P, Neurath M\nJ IMMUNOL. 2008;180(1):30-33.\nAymptomatic CMV viremia is associated with increased levels of serum amyloid A in patients with advanced HIV-infection.\nSteininger C, Graninger W, Zoufaly A, Z\u00f6llner B, Feucht H, Kundi M, Stahmer I, Stellbrink H, van Lunzen J\nEUR J MED RES. 2008;13(6):304-308.\nDimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity.\nSydow K, Mondon C, Schrader J, Konishi H, Cooke J\nARTERIOSCL THROM VAS. 2008;28(4):692-697.\nSpontaneous hepatic fibrosis in transgenic mice overexpressing PDGF-A.\nThieringer F, Maass T, Czochra P, Klopcic B, Conrad I, Friebe D, Schirmacher P, Lohse A, Blessing M, Galle P, Teufel A, Kanzler S\nGENE. 2008;423(1):23-28.\n[Integrase inhibition--a new mode of action in HIV therapy]\nvan Lunzen J, Degen O\nMMW Fortschr Med. 2008;150(1):64-67.\nAutonomic renal denervation ameliorates experimental glomerulonephritis.\nVeelken R, Vogel E, Hilgers K, Amann K, Hartner A, Sass G, Neuhuber W, Tiegs G\nJ AM SOC NEPHROL. 2008;19(7):1371-1378.\nUnmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon.\nVon Kalckreuth V, Lohse A, Schramm C\nAM J GASTROENTEROL. 2008;103(8):2147-2148.\nPlacebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.\nvon Wagner M, Hofmann W, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S\nHEPATOLOGY. 2008;48(5):1404-1411.\nProphylactic immunisation against traveller's diarrhoea caused by enterotoxin-forming strains of Escherichia coli and against cholera: does it make sense and for whom?\nWeinke T, Liebold I, Burchard G, Fr\u00fchwein N, Grobusch M, Hatz C, Kollaritsch H, Nothdurft H, Reisinger E, Rieke B, Sch\u00f6nfeld C, Steffen R, Stich A\nTRAVEL MED INFECT DI. 2008;6(6):362-367.\nGlycosylphosphatidylinositol-induced cardiac myocyte death might contribute to the fatal outcome of Plasmodium falciparum malaria.\nWennicke K, Debierre-Grockiego F, Wichmann D, Brattig N, Pankuweit S, Maisch B, Schwarz R, Ruppert V\nAPOPTOSIS. 2008;13(7):857-866.\nIf the rumor is tumor, the issue is tissue.\nWichmann D, Scherpe S, Heese O, Schmiedel S, Burchard G, Ruckdeschel K, Sobottka I\nNEUROSURGERY. 2008;63(4):820.\nIncidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases.\nW\u00f6rns M, Teufel A, Kanzler S, Shrestha A, Victor A, Otto G, Lohse A, Galle P, H\u00f6hler T\nAM J GASTROENTEROL. 2008;103(1):138-146.\nImpact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.\nWyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer N, Bogner J, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, F\u00e4tkenheuer G, Khoo S, Egan D, Back D, Owen A\nJ ANTIMICROB CHEMOTH. 2008;61(4):914-918.\nFactors contributing to the risk of cardiovascular disease reflected by plasma adiponectin: data from the coronary risk factors for atherosclerosis in women (CORA) study.\nZyriax B, Algenstaedt P, Hess U, Sch\u00f6ffauer M, Bamberger C, Boeing H, Windler E\nATHEROSCLEROSIS. 2008;200(2):403-409.\nRemission of Philadelphia chromosome-positive central nervous system leukemia after dasatinib therapy.\nAbdelhalim A, Barcos M, Block A, Sait S, Starostik P, Wetzler M, Wang E\nLEUKEMIA LYMPHOMA. 2007;48(5):1053-1056.\nThe GNB3 C825T polymorphism affects response to HCV therapy with pegylated interferon in HCV/HIV co-infected but not in HCV mono-infected patients.\nAhlenstiel G, Nischalke H, Bueren K, Berg T, Vogel M, Biermer M, Gr\u00fcnhage F, Sauerbruch T, Rockstroh J, Spengler U, Nattermann J\nJ HEPATOL. 2007;47(3):348-355.\nCharacterization of isomeric 1,2,4-oxadiazolyl-N-methylpyridinium salts by electrospray ionization tandem mass spectrometry.\nAvellone G, Bongiorno D, Buscemi S, Ceraulo L, Indelicato S, Pace A, Pibiri I, Vivona N\nEUR J MASS SPECTROM. 2007;13(3):199-205.\naCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.\nBartos J, Gaile D, McQuaid D, Conroy J, Darbary H, Nowak N, Block A, Petrelli N, Mittelman A, Stoler D, Anderson G\nMUTAT RES-FUND MOL M. 2007;615(1-2):1-11.\nCCK causes PKD1 activation in pancreatic acini by signaling through PKC-delta and PKC-independent pathways.\nBerna M, Hoffmann K, Tapia J, Berna-Thill M, Pace A, Mantey S, Jensen R\nBBA-MOL CELL RES. 2007;1773(4):483-501.\nRole of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases.\nBerna M, Jensen R\nCURR TOP MED CHEM. 2007;7(12):1211-1231.\nProgress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential.\nBerna M, Tapia J, Sancho V, Jensen R\nCURR OPIN PHARMACOL. 2007;7(6):583-592.\nCosts and benefits of direct-to-consumer advertising: the case of depression.\nBlock A\nPHARMACOECONOMICS. 2007;25(6):511-521.\nThalamic-prefrontal cortical-ventral striatal circuitry mediates dissociable components of strategy set shifting.\nBlock A, Dhanji H, Thompson-Tardif S, Floresco S\nCEREB CORTEX. 2007;17(7):1625-1636.\nTropolone and its derivatives as inhibitors of the helicase activity of hepatitis C virus nucleotide triphosphatase/helicase.\nBorowski P, Lang M, Haag A, Baier A\nANTIVIR CHEM CHEMOTH. 2007;18(2):103-109.\nThe Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.\nCavaletti G, Frigeni B, Lanzani F, Piatti M, Rota S, Briani C, Zara G, Plasmati R, Pastorelli F, Caraceni A, Pace A, Manicone M, Lissoni A, Colombo N, Bianchi G, Zanna C\nJ PERIPHER NERV SYST. 2007;12(3):210-215.\nPulmonary infection with rapidly growing mycobacteria in a singer with achalasia: a case report.\nCramer J, Sudeck H, Burchard G\nJ INFECTION. 2007;54(4):219-221.\nProspective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications.\nDenzer U, Arnoldy A, Kanzler S, Galle P, Dienes H, Lohse A\nJ CLIN GASTROENTEROL. 2007;41(1):103-110.\nLarge-scale surveillance of Plasmodium falciparum crt(K76T) in northern Ghana.\nEhrhardt S, Eggelte T, Kaiser S, Adjei L, Burchard G, Anemana S, Bienzle U, Mockenhaupt F\nANTIMICROB AGENTS CH. 2007;51(9):3407-3409.\nIL-10, regulatory T cells, and Kupffer cells mediate tolerance in concanavalin A-induced liver injury in mice.\nErhardt A, Biburger M, Papadopoulos T, Tiegs G\nHEPATOLOGY. 2007;45(2):475-485.\nUsing the WWW to teach undergraduate nurses clinical communication.\nFarrell G, Cubit K, Bobrowski C, Salmon P\nNURS EDUC TODAY. 2007;27(5):427-435.\nBAC constructs in transgenic reporter mouse lines control efficient and specific LacZ expression in hypertrophic chondrocytes under the complete Col10a1 promoter.\nGebhard S, Hattori T, Bauer E, B\u00f6sl M, Schlund B, P\u00f6schl E, Adam N, de Crombrugghe B, von der Mark K\nHISTOCHEM CELL BIOL. 2007;127(2):183-194.\nExtracellular NAD and ATP: Partners in immune cell modulation.\nHaag F, Adriouch S, Brass A, Jung C, H\u00fcbener S, Scheuplein F, Bannas P, Seman M, Koch-Nolte F\nPURINERG SIGNAL. 2007;3(1-2):71-81.\nAbsence of oncogenic transformation despite acquisition of cytogenetic aberrations in long-term cultured telomerase-immortalized human fetal hepatocytes.\nHaker B, Fuchs S, Dierlamm J, Br\u00fcmmendorf T, Wege H\nCANCER LETT. 2007;256(1):120-127.\nTNF-alpha alters visfatin and adiponectin levels in human fat.\nHector J, Schwarzloh B, Goehring J, Strate T, Hess U, Deuretzbacher G, Hansen-Algenstaedt N, Beil F, Algenstaedt P\nHORM METAB RES. 2007;39(4):250-255.\n[Recurrent gastrointestinal bleeding and aortic valve stenosis (Heyde syndrome): need for valve replacement?]\nHenne S, Denzer U, Seitz U, G\u00f6ttsche J, Soehendra N, Lohse A\nZ GASTROENTEROL. 2007;45(3):245-249.\nSelenocysteine, soluble liver antigen/liver-pancreas, and autoimmune hepatitis.\nHerkel J, Manns M, Lohse A\nHEPATOLOGY. 2007;46(1):275-277.\n[Chronic lupoid leishmaniasis. A rare differential diagnosis in Germany for erythematous infiltrative facial plaques]\nHerrmann A, Wohlrab J, Sudeck H, Burchard G, Marsch W\nHAUTARZT. 2007;58(3):256-260.\nAdoptive transfer of syngeneic T cells in HIV-1 discordant twins indicates rapid regulation of T-cell homeostasis.\nHoffmann C, Stellbrink H, Dielschneider T, Degen O, Stoehr A, Knechten H, Wolf E, van Lunzen J\nBRIT J HAEMATOL. 2007;136(4):641-648.\nProlonged glial expression of Sox4 in the CNS leads to architectural cerebellar defects and ataxia.\nHoser M, Baader S, B\u00f6sl M, Ihmer A, Wegner M, Sock E\nJ NEUROSCI. 2007;27(20):5495-5505.\nMonitoring the expression of purinoceptors and nucleotide-metabolizing ecto-enzymes with antibodies directed against proteins in native conformation.\nH\u00fcbener S, Jung C, Adriouch S, Dubberke G, Seyfried F, Seman M, Haag F, Koch Nolte F\nPURINERG SIGNAL. 2007;3(4):359-366.\nImmunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection.\nJulian S, Lauer G, Timm J, Kuntzen T, Neukamm M, Berical A, Jones A, Nolan B, Longworth S, Kasprowicz V, McMahon C, Wurcel A, Lohse A, Lewis-Ximenez L, Chung R, Kim A, Allen T, Walker B\nBLOOD. 2007;110(5):1559-1569.\nRap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.\nKarhoff D, Sauer S, Schrader J, Arnold R, Fendrich V, Bartsch D, H\u00f6rsch D\nNEUROENDOCRINOLOGY. 2007;85(1):45-53.\nImmune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity.\nKempf K, Hector J, Strate T, Schwarzloh B, Rose B, Herder C, Martin S, Algenstaedt P\nHORM METAB RES. 2007;39(8):596-600.\nMalaria incidence and efficacy of intermittent preventive treatment in infants (IPTi)\nKobbe R, Adjei S, Kreuzberg C, Kreuels B, Thompson B, Thompson P, Marks F, Busch W, Tosun M, Schreiber N, Opoku E, Adjei O, Meyer C, May J\nMALARIA J. 2007;6:163.\nTravel-associated Coxiella burnetii infections: three cases of Q fever with different clinical manifestation.\nKobbe R, Kramme S, Gocht A, Werner M, Lippert U, May J, Burchard G\nTRAVEL MED INFECT DI. 2007;5(6):374-379.\nA randomized controlled trial of extended intermittent preventive antimalarial treatment in infants\nKobbe R, Kreuzberg C, Adjei S, Thompson B, Langefeld I, Thompson P, Abruquah H, Kreuels B, Ayim M, Busch W, Marks F, Amoah K, Opoku E, Meyer C, Adjei O, May J\nCLIN INFECT DIS. 2007;45(1):16-25.\nCurrent hemoglobin levels are more predictive of disease progression than hemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV type 1 infection.\nKowalska J, Mocroft A, Blaxhult A, Colebunders R, van Lunzen J, Podlekareva D, Hansen A, Machala L, Yust I, Benfield T\nAIDS RES HUM RETROV. 2007;23(10):1183-1188.\nEfficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-alpha and ribavirin: results from a randomized, placebo-controlled, double-blind trial.\nKronenberger B, Berg T, Herrmann E, Hinrichsen H, Gerlach T, Buggisch P, Spengler U, Goeser T, Nasser S, Wursthorn K, Pape G, Hopf U, Zeuzem S\nEUR J GASTROEN HEPAT. 2007;19(8):639-646.\nDiagnostic criteria for autoimmune hepatitis.\nLohse A, Hennes E\nHEPATOL RES. 2007;37(3):509.\nDe novo autoimmune hepatitis after liver transplantation.\nLohse A, Weiler-Normann C, Burdelski M\nHEPATOL RES. 2007;37(3):462.\nSecretin-receptor and secretin-receptor-variant expression in gastrinomas: correlation with clinical and tumoral features and secretin and calcium provocative test results.\nLong S, Berna M, Berna-Thill M, Pace A, Pradhan T, Hoffmann K, Serrano J, Jensen R\nJ CLIN ENDOCR METAB. 2007;92(11):4394-4402.\nFluoropolymer based on a polyaspartamide containing 1,2,4-oxadiazole units: a potential artificial oxygen (O2) carrier.\nMandracchia D, Piccionello A, Pitarresi G, Pace A, Buscemi S, Giammona G\nMACROMOL BIOSCI. 2007;7(6):836-845.\nMyD88-dependent immune activation mediated by human immunodeficiency virus type 1-encoded Toll-like receptor ligands.\nMeier A, Alter G, Frahm N, Sidhu H, Li B, Bagchi A, Teigen N, Streeck H, Stellbrink H, Hellman J, van Lunzen J, Altfeld M\nJ VIROL. 2007;81(15):8180-8191.\nA male infant with a 9.6 Mb terminal Xp deletion including the OA1 locus: Limit of viability of Xp deletions in males.\nMelichar V, Guth S, Hellebrand H, Meindl A, von der Hardt K, Kraus C, Trautmann U, Rascher W, Rauch A, Zenker M\nAM J MED GENET A. 2007;143(2):135-141.\nMurine CXCL14 is dispensable for dendritic cell function and localization within peripheral tissues.\nMeuter S, Schaerli P, Roos R, Brandau O, B\u00f6sl M, Andrian v, Ulrich H, Moser B\nMOL CELL BIOL. 2007;27(3):983-992.\nIntermittent preventive treatment in infants as a means of malaria control: a randomized, double-blind, placebo-controlled trial in northern Ghana.\nMockenhaupt F, Reither K, Zanger P, Roepcke F, Danquah I, Saad E, Ziniel P, Dzisi S, Frempong M, Agana-Nsiire P, Amoo-Sakyi F, Otchwemah R, Cramer J, Anemana S, Dietz E, Bienzle U\nANTIMICROB AGENTS CH. 2007;51(9):3273-3281.\nWeekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.\nNistic\u00f2 C, Bria E, Cuppone F, Fornier M, Sperduti I, Carpino A, Pace A, Cognetti F, Terzoli E\nANTI-CANCER DRUG. 2007;18(6):687-692.\nExperimental and DFT studies on competitive heterocyclic rearrangements. Part 2: a one-atom side-chain versus the classic three-atom side-chain (Boulton-Katritzky) ring rearrangement of 3-acylamino-1,2,4-oxadiazoles.\nPace A, Pibiri I, Piccionello A, Buscemi S, Vivona N, Barone G\nJ ORG CHEM. 2007;72(20):7656-7666.\nPhotooxidations of alkenes in fluorinated constrained media: fluoro-organically modified NaY as improved reactors for singlet oxygen \"Ene\" reactions.\nPace A, Pierro P, Buscemi S, Vivona N, Clennan E\nJ ORG CHEM. 2007;72(7):2644-2646.\n[Autoimmune pancreatitis with normal IgG4-Levels: 4 case reports and review of the literature]\nPace A, Topalidis T, Bl\u00e4ker M, Guthoff A, De Weerth A, Lohse A\nZ GASTROENTEROL. 2007;45(12):1245-1251.\nThe revised international autoimmune hepatitis score in chronic liver diseases including autoimmune hepatitis/overlap syndromes and autoimmune hepatitis with concurrent other liver disorders.\nPapamichalis P, Zachou K, Koukoulis G, Veloni A, Karacosta E, Kypri L, Mamaloudis I, Gabeta S, Rigopoulou E, Lohse A, Dalekos G\nJ Autoimmune Dis. 2007;4:3.\nProlonged Sox4 expression in oligodendrocytes interferes with normal myelination in the central nervous system.\nPotzner M, Griffel C, L\u00fctjen-Drecoll E, B\u00f6sl M, Wegner M, Sock E\nMOL CELL BIOL. 2007;27(15):5316-5326.\nAntiviral activity and hepatoprotection by heme oxygenase-1 in hepatitis B virus infection.\nProtzer U, Seyfried S, Quasdorff M, Sass G, Svorcova M, Webb D, Bohne F, H\u00f6sel M, Schirmacher P, Tiegs G\nGASTROENTEROLOGY. 2007;133(4):1156-1165.\nTemozolomide as salvage treatment in primary brain lymphomas.\nReni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, Bordonaro R, Ilariucci F, Faedi M, Corazzelli G, Manno P, Franceschi E, Pace A, Candela M, Abbadessa A, Stelitano C, Latte G, Ferreri A\nBRIT J CANCER. 2007;96(6):864-867.\nConsensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.\nSalzberger B, D\u00e4umer M, Gute P, Jaeger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink H, Stoll M, Sturmer M\nEUR J MED RES. 2007;12(3):93-102.\nGene expression profiles during hepatic stellate cell activation in culture and in vivo.\nSamuele D, Seki E, Uchinami H, Kluwe J, Zhang Y, Brenner D, Schwabe R\nGASTROENTEROLOGY. 2007;132(5):1937-1946.\nTNF pretreatment interferes with mitochondrial apoptosis in the mouse liver by A20-mediated down-regulation of Bax.\nSass G, Shembade N, Haimerl F, Lamoureux N, Hashemolhosseini S, Tannapfel A, Tiegs G\nJ IMMUNOL. 2007;179(10):7042-7049.\nCluster of trichinellosis cases in Germany, imported from Poland, June 2007.\nSchmiedel S, Kramme S\nEUROSURVEILLANCE. 2007;12(7):4.\nCase report on fatal human rabies infection in Hamburg, Germany, March 2007.\nSchmiedel S, Panning M, Lohse A, Kreymann K, Gerloff C, Burchard G, Drosten C\nEUROSURVEILLANCE. 2007;12(5):5.\nOmega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines.\nSchm\u00f6cker C, Weylandt K, Kahlke L, Wang J, Lobeck H, Tiegs G, Berg T, Kang J\nHEPATOLOGY. 2007;45(4):864-869.\nCytokine-induced osteoprotegerin expression protects pancreatic beta cells through p38 mitogen-activated protein kinase signalling against cell death.\nSchrader J, Rennekamp W, Niebergall U, Schoppet M, Jahr H, Brendel M, H\u00f6rsch D, Hofbauer L\nDIABETOLOGIA. 2007;50(6):1243-1247.\nHypomorphic Sox10 alleles reveal novel protein functions and unravel developmental differences in glial lineages.\nSchreiner S, Cossais F, Fischer K, Scholz S, B\u00f6sl M, Holtmann B, Sendtner M, Wegner M\nDEVELOPMENT. 2007;134(18):3271-3281.\nBiliary stent clogging solved by nanotechnology? In vitro study of inorganic-organic sol-gel coatings for teflon stents.\nSeitz U, Block A, Schaefer A, Wienhold U, Bohnacker S, Siebert K, Seewald S, Thonke F, Wulff H, De Weerth A, Soehendra N\nGASTROENTEROLOGY. 2007;133(1):65-71.\nTLR4 enhances TGF-beta signaling and hepatic fibrosis.\nSeki E, Samuele D, Osterreicher C, Kluwe J, Osawa Y, Brenner D, Schwabe R\nNAT MED. 2007;13(11):1324-1332.\nAntifolate pseudo-resistance due to elevated levels of thymidine and hypoxanthine in a commercial serum preparation.\nSimon M, Blatter J, Granzow C\nANTICANCER RES. 2007;27(2):769-773.\n[Extraction of management information from the national quality assurance program]\nStausberg J, Bartels C, Bobrowski C\nMED KLIN-INTENSIVMED. 2007;102(7):507-514.\nTreatment of chronic hepatitis C with consensus interferon in relapsers and non-responders to interferon-based therapy.\nSteffen M, Cornberg M, Buggisch P\nHEPATO-GASTROENTEROL. 2007;54(80):2368-2372.\nChikungunya fever in travelers: clinical presentation and course.\nTaubitz W, Cramer J, Kapaun A, Pfeffer M, Drosten C, Dobler G, Burchard G, L\u00f6scher T\nCLIN INFECT DIS. 2007;45(1):1-4.\nCellular and cytokine-mediated mechanisms of inflammation and its modulation in immune-mediated liver injury.\nTiegs G\nZ GASTROENTEROL. 2007;45(1):63-70.\nEffect of chronic Giardia lamblia infection on epithelial transport and barrier function in human duodenum.\nTroeger H, Epple H, Schneider T, Wahnschaffe U, Ullrich R, Burchard G, Jelinek T, Zeitz M, Fromm M, Schulzke J\nGUT. 2007;56(3):328-335.\nHow will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.\nvan Lunzen J\nEUR J MED RES. 2007;12(9):435-440.\nTransfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.\nvan Lunzen J, Glaunsinger T, Stahmer I, von Baehr V, Baum C, Schilz A, Kuehlcke K, Naundorf S, Martinius H, Hermann F, Giroglou T, Newrzela S, M\u00fcller I, Brauer F, Brandenburg G, Alexandrov A, von Laer D\nMOL THER. 2007;15(5):1024-1033.\nConcomitant use of gastric acid-reducing agents is frequent among HIV-1-infected patients receiving protease inhibitor-based highly active antiretroviral therapy.\nvan Lunzen J, Liess H, Arast\u00e9h K, Walli R, Daut B, Sch\u00fcrmann D\nHIV MED. 2007;8(4):220-225.\nImpaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients.\nVolz T, L\u00fctgehetmann M, Wachtler P, Jacob A, Quaas A, Murray J, Dandri-Petersen M, Petersen J\nGASTROENTEROLOGY. 2007;133(3):843-852.\nDiagnostic value of endoscopy for the diagnosis of giardiasis and other intestinal diseases in patients with persistent diarrhea from tropical or subtropical areas.\nWahnschaffe U, Ignatius R, Loddenkemper C, Liesenfeld O, Muehlen M, Jelinek T, Burchard G, Weinke T, Harms G, Stein H, Zeitz M, Ullrich R, Schneider T\nSCAND J GASTROENTERO. 2007;42(3):391-396.\nTelomerase activation in liver regeneration and hepatocarcinogenesis: Dr. Jekyll or Mr. Hyde?\nWege H, Br\u00fcmmendorf T\nCURR STEM CELL RES T. 2007;2(1):31-38.\nRegeneration in pig livers by compensatory hyperplasia induces high levels of telomerase activity.\nWege H, M\u00fcller A, M\u00fcller L, Petri S, Petersen J, Hillert C\nComp Hepatol. 2007;6:6.\nMouse models of liver fibrosis.\nWeiler-Normann C, Herkel J, Lohse A\nZ GASTROENTEROL. 2007;45(1):43-50.\nMultiple conserved regulatory elements with overlapping functions determine Sox10 expression in mouse embryogenesis.\nWerner T, Hammer A, Wahlbuhl M, B\u00f6sl M, Wegner M\nNUCLEIC ACIDS RES. 2007;35(19):6526-6538.\nPlasmodium falciparum glycosylphosphatidylinositol induces limited apoptosis in liver and spleen mouse tissue.\nWichmann D, Schwarz R, Ruppert V, Ehrhardt S, Cramer J, Burchard G, Maisch B, Debierre-Grockiego F\nAPOPTOSIS. 2007;12(6):1037-1041.\nFate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha2b therapy for acute hepatitis C.\nWiegand J, Cornberg M, Aslan N, Schlaphoff V, Sarrazin C, Kubitschke A, Buggisch P, Ciner A, Jaeckel E, Manns M, Wedemeyer H\nANTIVIR THER. 2007;12(3):303-316.\nDefective T helper response of hepatocyte-stimulated CD4 T cells impairs antiviral CD8 response and viral clearance.\nWiegard C, Wolint P, Frenzel C, Cheruti U, Schmitt E, Oxenius A, Lohse A, Herkel J\nGASTROENTEROLOGY. 2007;133(6):2010-2018.\nCloning and characterization of an adenoviral vector for highly efficient and doxycycline-suppressible expression of bioactive human single-chain interleukin 12 in colon cancer.\nWulff H, Krieger T, Kr\u00fcger K, Stahmer I, Thaiss F, Sch\u00e4fer H, Block A\nBMC BIOTECHNOL. 2007;7:35.\nEfficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.\nZimmermann T, B\u00f6cher W, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros A, Sprinzl M, W\u00f6rns M, Lohse A, M\u00f6nch C, Otto G, Galle P, Schuchmann M\nTRANSPL INT. 2007;20(7):583-590.\nIntestinal Kaposi's sarcoma may mimic gastrointestinal stromal tumor in HIV infection.\nZoufaly A, Schmiedel S, Lohse A, van Lunzen J\nWORLD J GASTROENTERO. 2007;13(33):4514-4516.\nSerum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features.\nBerna M, Hoffmann K, Long S, Serrano J, Gibril F, Jensen R\nMEDICINE. 2006;85(6):331-364.\nSerum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.\nBerna M, Hoffmann K, Serrano J, Gibril F, Jensen R\nMEDICINE. 2006;85(6):295-330.\nSmall animal model systems for studying hepatitis B virus replication and pathogenesis.\nDandri-Petersen M, L\u00fctgehetmann M, Volz T, Petersen J\nSEMIN LIVER DIS. 2006;26(2):181-191.\nMalaria, anemia, and malnutrition in african children--defining intervention priorities.\nEhrhardt S, Burchard G, Mantel C, Cramer J, Kaiser S, Kubo M, Otchwemah R, Bienzle U, Mockenhaupt F\nJ INFECT DIS. 2006;194(1):108-114.\nEvaluation of F-actin ELISA for the diagnosis of autoimmune hepatitis.\nFrenzel C, Herkel J, L\u00fcth S, Galle P, Schramm C, Lohse A\nAM J GASTROENTEROL. 2006;101(12):2731-2736.\nApplication of stable carbon isotope analysis to the detection of testosterone administration to cattle.\nHebestreit M, Flenker U, Buisson C, Andre F, Bruno L, Fry H, Lang M, Weigert A, Heinrich K, Hird S, Sch\u00e4nzer W\nJ AGR FOOD CHEM. 2006;54(8):2850-2858.\nInterleukin-4 differentially regulates osteoprotegerin expression and induces calcification in vascular smooth muscle cells\nHofbauer L, Schrader J, Niebergall U, Viereck V, Burchert A, H\u00f6rsch D, Preissner K, Schoppet M\nTHROMB HAEMOSTASIS. 2006;95(4):708-14.\nGastrointestinal hormones cause rapid c-Met receptor down-regulation by a novel mechanism involving clathrin-mediated endocytosis and a lysosome-dependent mechanism.\nHoffmann K, Tapia J, Berna M, Thill M, Braunschweig T, Mantey S, Moody T, Jensen R\nJ BIOL CHEM. 2006;281(49):37705-37719.\nTGF-beta and CD4+CD25+ regulatory T cells\nHuber S, Schramm C\nFRONT BIOSCI-LANDMRK. 2006;11(1):1014-1023.\nMultiplex neuritis in a patient with autoimmune hepatitis: a case report\nLuth S, Birklein F, Schramm C, Herkel J, Hennes E, Muller-Forell W, Galle P, Lohse A\nWORLD J GASTROENTERO. 2006;12(33):5396-8.\nToll-like receptor (TLR) polymorphisms in African children: Common TLR-4 variants predispose to severe malaria.\nMockenhaupt F, Cramer J, Hamann L, Stegemann M, Eckert J, Oh N, Otchwemah R, Dietz E, Ehrhardt S, Schr\u00f6der N, Bienzle U, Schumann R\nP NATL ACAD SCI USA. 2006;103(1):177-182.\nThe Src family kinase, Lyn, is activated in pancreatic acinar cells by gastrointestinal hormones/neurotransmitters and growth factors which stimulate its association with numerous other signaling molecules.\nPace A, Tapia J, Garcia-Marin L, Jensen R\nBBA-BIOMEMBRANES. 2006;1763(4):356-365.\nEmergence of multiple cytomegalovirus strains in blood and lung of lung transplant recipients.\nPuchhammer-St\u00f6ckl E, G\u00f6rzer I, Zoufaly A, Jaksch P, Bauer C, Klepetko W, Popow-Kraupp T\nTRANSPLANTATION. 2006;81(2):187-194.\nPregnancy in autoimmune hepatitisoutcome and risk factors\nSchramm C, Herkel J, Beuers U, Kanzler S, Galle P, Lohse A\nAM J GASTROENTEROL. 2006;101(3):556-60.\nMorphological and functional analysis of rat hepatocyte spheroids generated on poly(L-lactic acid) polymer in a pulsatile flow bioreactor.\nT\u00f6r\u00f6k E, Vogel C, L\u00fctgehetmann M, Ma P, Dandri-Petersen M, Petersen J, Burda M, Siebert K, D\u00fcllmann J, Rogiers X, Pollok J\nTISSUE ENG. 2006;12(7):1881-1890.\nMyeloradiculitis: a rare event in schistosoma infection.\nWichmann D, Hofmann C, Sudeck H, Burchard G, Moser A\nINFECTION. 2006;34(6):349-351.\nTemporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.\nWursthorn K, Buggisch P, L\u00fctgehetmann M, Zollner B, Petersen J\nANTIVIR THER. 2006;11(5):647-652.\nPeginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B.\nWursthorn K, L\u00fctgehetmann M, Dandri-Petersen M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J\nHEPATOLOGY. 2006;44(3):675-684.\nLimited influence of haptoglobin genotypes on severe malaria in Ghanaian children.\nBienzle U, Eggelte T, Adjei L, Dietz E, Ehrhardt S, Cramer J, Otchwemah R, Mockenhaupt F\nTROP MED INT HEALTH. 2005;10(7):668-671.\nAge-dependent effect of plasma nitric oxide on parasite density in Ghanaian children with severe malaria.\nCramer J, N\u00fcssler A, Ehrhardt S, Burkhardt J, Otchwemah R, Zanger P, Dietz E, Gellert S, Bienzle U, Mockenhaupt F\nTROP MED INT HEALTH. 2005;10(7):672-680.\nChronic infection with hepatitis B viruses and antiviral drug evaluation in uPA mice after liver repopulation with tupaia hepatocytes.\nDandri-Petersen M, Burda M, Zuckerman D, Wursthorn K, Matschl U, Pollok J, Rogiers X, Gocht A, K\u00f6ck J, Blum H, von Weizs\u00e4cker F, Petersen J\nJ HEPATOL. 2005;42(1):54-60.\nHepatitis B virus cccDNA clearance: killing for curing?\nDandri-Petersen M, Petersen J\nHEPATOLOGY. 2005;42(6):1453-1455.\nAnimal models for the study of HBV replication and its variants.\nDandri-Petersen M, Volz T, L\u00fctgehetmann M, Petersen J\nJ CLIN VIROL. 2005;34(1):54-62.\nHigh levels of circulating cardiac proteins indicate cardiac impairment in African children with severe Plasmodium falciparum malaria.\nEhrhardt S, Mockenhaupt F, Anemana S, Otchwemah R, Wichmann D, Cramer J, Bienzle U, Burchard G, Brattig N\nMICROBES INFECT. 2005;7(11-12):1204-1210.\nPartial hepatectomy induces mobilization of a unique population of haematopoietic progenitor cells in human healthy liver donors.\nGehling U, Willems M, Dandri-Petersen M, Petersen J, Berna M, Thill M, Wulf T, M\u00fcller L, Pollok J, Schlagner K, Faltz C, Hossfeld D, Rogiers X\nJ HEPATOL. 2005;43(5):845-853.\nA randomized, placebo-controlled, double-blind trial on sulfadoxine-pyrimethamine alone or combined with artesunate or amodiaquine in uncomplicated malaria.\nMockenhaupt F, Ehrhardt S, Dzisi S, Teun Bousema J, Wassilew N, Schreiber J, Anemana S, Cramer J, Otchwemah R, Sauerwein R, Eggelte T, Bienzle U\nTROP MED INT HEALTH. 2005;10(6):512-520.\nTumor growth-promoting cellular host response during liver atrophy after portal occlusion.\nMueller L, G\u00f6ttsche J, Abdulgawad A, Vashist Yogesh K, Meyer J, Wilms C, Hillert C, Rogiers X, Broering Dieter C\nLIVER INT. 2005;25(5):994-1001.\nAltered expression of TGF-beta receptors in hepatocellular carcinoma--effects of a constitutively active TGF-beta type I receptor mutant.\nMusch A, Rabe C, Paik M, Berna M, Schmitz V, Hoffmann P, Nischalke H, Sauerbruch T, Caselmann W\nDIGESTION. 2005;71(2):78-91.\nRisk and spectrum of diseases in travelers to popular tourist destinations.\nRack J, Wichmann O, Kamara B, G\u00fcnther M, Cramer J, Sch\u00f6nfeld C, Henning T, Schwarz U, M\u00fchlen M, Weitzel T, Friedrich-J\u00e4nicke B, Foroutan B, Jelinek T\nJ TRAVEL MED. 2005;12(5):248-253.\nDie prim\u00e4r sklerosierende Cholangitis als Pr\u00e4kanzerose\nSchramm C, Galle P\nZ GASTROENTEROL. 2005;43(6):607-11.\nOverlap syndromes of cholestatic liver diseases and auto-immune hepatitis.\nSchramm C, Lohse A\nCLIN REV ALLERG IMMU. 2005;28(2):105-14.\nThe liver stage of Plasmodium berghei inhibits host cell apoptosis.\nvan de Sand C, Horstmann S, Schmidt A, Sturm A, Bolte S, Krueger A, L\u00fctgehetmann M, Pollok J, Libert C, Heussler V\nMOL MICROBIOL. 2005;58(3):731-742.\nBI-1 protects cells from oxygen glucose deprivation by reducing the calcium content of the endoplasmic reticulum.\nWestphalen C, Wessig J, Leypoldt F, Arnold S, Methner A\nCELL DEATH DIFFER. 2005;12(3):304-306.\nMurine liver antigen presenting cells control suppressor activity of CD4+CD25+ regulatory T cells.\nWiegard C, Frenzel C, Herkel J, Kallen K, Schmitt E, Lohse A\nHEPATOLOGY. 2005;42(1):193-199.\nCharacterization of effusion-infiltrating T cells: benign versus malignant effusions.\nAtanackovic D, Block A, de Weerth A, Faltz C, Hossfeld D, Hegewisch-Becker S\nCLIN CANCER RES. 2004;10(8):2600-2608.\nVitamin B6 modulates glucocorticoid-dependent gene transcription in a promoter- and cell type-specific manner\nBamberger C, Else T, Ellebrecht I, Milde-Langosch K, Pankoke D, Beil F, Bamberger A\nEXP CLIN ENDOCR DIAB. 2004;112(10):595-600.\nAutoimmune Lebererkrankungen: Diagnostik und Therapie\nBayer E, Schramm C, Kanzler S, Lohse A\nZ GASTROENTEROL. 2004;42(1):19-30.\nThe cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT.\nBl\u00e4ker M, Arrenberg P, Stange I, Schulz M, Burghardt S, Michaelis H, Pace A, Greten H, von Schrenck T, de Weerth A\nREGUL PEPTIDES. 2004;118(1-2):111-117.\nDifferential expression of somatostatin receptor subtypes in hepatocellular carcinomas.\nBl\u00e4ker M, Schmitz M, Gocht A, Burghardt S, Schulz M, Br\u00f6ring D, Pace A, Greten H, Andreas D\nJ HEPATOL. 2004;41(1):112-118.\nSynthesis and evaluation of ATP-binding site directed potential inhibitors of nucleoside triphosphatases/helicases and polymerases of hepatitis C and other selected Flaviviridae viruses.\nBretner M, Schalinski S, Haag A, Lang M, Schmitz H, Baier A, Behrens S, Kulikowski T, Borowski P\nANTIVIR CHEM CHEMOTH. 2004;15(1):35-42.\niNOS promoter variants and severe malaria in Ghanaian children.\nCramer J, Mockenhaupt F, Ehrhardt S, Burkhardt J, Otchwemah R, Dietz E, Gellert S, Bienzle U\nTROP MED INT HEALTH. 2004;9(10):1074-1080.\nAllelic dimorphism of the erythrocyte binding antigen-175 (eba-175) gene of Plasmodium falciparum and severe malaria: Significant association of the C-segment with fatal outcome in Ghanaian children.\nCramer J, Mockenhaupt F, M\u00f6hl I, Dittrich S, Dietz E, Otchwemah R, Ehrhardt S, Bienzle U, Jelinek T\nMALARIA J. 2004;3:11.\nHumoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells\nEhlken H, Schadendorf D, Eichm\u00fcller S\nINT J CANCER. 2004;108(2):307-13.\nCirculating concentrations of cardiac proteins in complicated and uncomplicated Plasmodium falciparum malaria.\nEhrhardt S, Wichmann D, Hemmer C, Burchard G, Brattig N\nTROP MED INT HEALTH. 2004;9(10):1099-1103.\nLife after death: posttraumatic stress disorder in survivors of cardiac arrest--prevalence, associated factors, and the influence of sedation and analgesia.\nGamper G, Willeit M, Sterz F, Herkner H, Zoufaly A, Hornik K, Havel C, Laggner A\nCRIT CARE MED. 2004;32(2):378-383.\nManifestation and outcome of severe malaria in children in northern Ghana.\nMockenhaupt F, Ehrhardt S, Burkhardt J, Bosomtwe S, Laryea S, Anemana S, Otchwemah R, Cramer J, Dietz E, Gellert S, Bienzle U\nAM J TROP MED HYG. 2004;71(2):167-172.\nHemoglobin C and resistance to severe malaria in Ghanaian children.\nMockenhaupt F, Ehrhardt S, Cramer J, Otchwemah R, Anemana S, Goltz K, Mylius F, Dietz E, Eggelte T, Bienzle U\nJ INFECT DIS. 2004;190(5):1006-1009.\nTransplantation of human hepatocytes in immunodeficient UPA mice: a model for the study of hepatitis B virus.\nPetersen J, Burda M, Dandri-Petersen M, Rogler C\nMethods Mol Med. 2004;96:253-260.\nLimited specificity of promoter constructs for gene therapy in osteosarcoma.\nPollmann A, Kabisch H, Block A, M\u00fcller J, Hellwinkel O\nINT J MOL MED. 2004;14(4):737-742.\nDifferentiation of human and mouse embryonic stem cells along a hepatocyte lineage\nShirahashi H, Wu J, Yamamoto N, Catana A, Wege H, Wager B, Okita K, Zern M\nCELL TRANSPLANT. 2004;13(3):197-211.\nEvaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.\nSt\u00fcrenburg E, Lang M, Horstkotte Matthias A, Laufs R, Mack D\nJ ANTIMICROB CHEMOTH. 2004;54(5):870-875.\nUp-regulation of macrophage migration inhibitory factor gene and protein expression in glial tumor cells during hypoxic and hypoglycemic stress indicates a critical role for angiogenesis in glioblastoma multiforme\nBacher M, Schrader J, Thompson N, Kuschela K, Gemsa D, Waeber G, Schlegel J\nAM J PATHOL. 2003;162(1):11-7.\nTumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.\nBiermer M, Puro R, Schneider Robert J\nJ VIROL. 2003;77(7):4033-4042.\nHighly suppressible expression of single-chain interleukin-12 by doxycycline following adenoviral infection with a single-vector Tet-regulatory system.\nBlock A, Puls F, M\u00fcller J, Milasinovic D, Igelmann D, Sch\u00e4fer P, Kupfermann N, Schmoldt A, Ameis D, Greten H\nJ GENE MED. 2003;5(3):190-200.\nQuantitative gene expression analysis reveals transition of fetal liver progenitor cells to mature hepatocytes after transplantation in uPA/RAG-2 mice.\nCantz T, Zuckerman D, Burda M, Dandri-Petersen M, G\u00f6ricke B, Thalhammer S, Heckl W, Manns M, Petersen J, Ott M\nAM J PATHOL. 2003;162(1):37-45.\nSodium-dependent myo-inositol transporter 1 is a cellular receptor for Mus cervicolor M813 murine leukemia virus.\nHein S, Prassolov V, Zhang Y, Ivanov D, L\u00f6hler J, Ross S, Stocking C\nJ VIROL. 2003;77(10):5926-5932.\nMHC class II-expressing hepatocytes function as antigen-presenting cells and activate specific CD4 T lymphocyutes.\nHerkel J, Jagemann B, Wiegard C, Lazaro J, Lueth S, Kanzler S, Blessing M, Schmitt E, Lohse A\nHEPATOLOGY. 2003;37(5):1079-1085.\nA young woman with persistent hypoglycemia, rhabdomyolysis, and coma: recognizing fatty acid oxidation defects in adults.\nKluge S, K\u00fchnelt P, Block A, Merkel M, Gocht A, Lukacs Z, Kohlsch\u00fctter A, Kreymann G\nCRIT CARE MED. 2003;31(4):1273-1276.\nTransient expression of PU.1 commits multipotent progenitors to a myeloid fate whereas continued expression favors macrophage over granulocyte differentiation.\nMcIvor Z, Hein S, Fiegler H, Schroeder T, Stocking C, Just U, Cross M\nEXP HEMATOL. 2003;31(1):39-47.\nPhosphospecific site tyrosine phosphorylation of p125FAK and proline-rich kinase 2 is differentially regulated by cholecystokinin receptor type A activation in pancreatic acini.\nPace A, Garc\u00eda-Marin L, Tapia J, Bragado M, Jensen R\nJ BIOL CHEM. 2003;278(21):19008-19016.\nIn vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging\nWege H, Chui M, Le H, Strom S, Zern M\nCELL TRANSPLANT. 2003;12(8):897-906.\nSYBR Green real-time telomeric repeat amplification protocol for the rapid quantification of telomerase activity\nWege H, Chui M, Le H, Tran J, Zern M\nNUCLEIC ACIDS RES. 2003;31(2):E3-3.\nTelomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential\nWege H, Le H, Chui M, Liu L, Wu J, Giri R, Malhi H, Sappal B, Kumaran V, Gupta S, Zern M\nGASTROENTEROLOGY. 2003;124(2):432-44.\nHuman cytomegalovirus-mediated induction of MIF in fibroblasts\nBacher M, Eickmann M, Schrader J, Gemsa D, Heiske A\nVIROLOGY. 2002;299(1):32-7.\nAmplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors.\nBlock A, Milasinovic D, Mueller J, Schaefer P, Schaefer H, Greten H\nANTICANCER RES. 2002;22(6):3285-3292.\nCharacterization of imidazo[4,5-d]pyridazine nucleosides as modulators of unwinding reaction mediated by West Nile virus nucleoside triphosphatase/helicase: evidence for activity on the level of substrate and/or enzyme.\nBorowski P, Lang M, Haag A, Schmitz H, Choe J, Huan-Ming C, Hosmane Ramachandra S\nANTIMICROB AGENTS CH. 2002;46(5):1231-1239.\nIncrease in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation.\nDandri-Petersen M, Burda M, B\u00fcrkle A, Zuckerman D, Will H, Rogler C, Greten H, Petersen J\nHEPATOLOGY. 2002;35(1):217-223.\nAssociation between c135G/A genotype and RET proto-oncogene germline mutations and phenotype of Hirschsprung's disease.\nFitze G, Cramer J, Ziegler A, Schierz M, Schreiber M, Kuhlisch E, Roesner D, Schackert H\nLANCET. 2002;359(9313):1200-1205.\nThe induction of the immediate-early-genes Egr-1, PAI-1 and PRL-1 during liver regeneration in surgical models is related to increased portal flow.\nMueller L, Broering Dieter C, Meyer J, Vashist Y, G\u00f6ttsche J, Wilms C, Rogiers X\nJ HEPATOL. 2002;37(5):606-612.\nKeeping central venous lines open: a prospective comparison of heparin, vitamin C and sodium chloride sealing solutions in medical patients.\nRabe C, Gramann T, Sons X, Berna M, Gonz\u00e1lez-Carmona M, Klehr H, Sauerbruch T, Caselmann W\nINTENS CARE MED. 2002;28(8):1172-1176.\nHantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice.\nWichmann D, Gr\u00f6ne H, Frese M, Pavlovic J, Anheier B, Haller O, Klenk H, Feldmann H\nJ VIROL. 2002;76(17):8890-8899.\nStructural and functional heterogeneity of naturally occurring hepatitis B virus variants.\nBurda M, G\u00fcnther S, Dandri-Petersen M, Will H, Petersen J\nANTIVIR RES. 2001;52(2):125-138.\nWoodchuck hepatocytes remain permissive for hepadnavirus infection and mouse liver repopulation after cryopreservation.\nDandri-Petersen M, Burda M, Gocht A, T\u00f6r\u00f6k E, Pollok J, Rogler C, Will H, Petersen J\nHEPATOLOGY. 2001;34(4 Pt 1):824-833.\nRepopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus.\nDandri-Petersen M, Burda M, T\u00f6r\u00f6k E, Pollok J, Iwanska A, Sommer G, Rogiers X, Rogler C, Gupta S, Will H, Greten H, Petersen J\nHEPATOLOGY. 2001;33(4):981-988.\nMus cervicolor murine leukemia virus isolate M813 belongs to a unique receptor interference group.\nPrassolov V, Hein S, Ziegler M, Ivanov D, M\u00fcnk C, L\u00f6hler J, Stocking C\nJ VIROL. 2001;75(10):4490-4498.\nThe Mus cervicolor MuLV isolate M813 is highly fusogenic and induces a T-cell lymphoma associated with large multinucleated cells.\nPrassolov V, Ivanov D, Hein S, Rutter G, M\u00fcnk C, L\u00f6hler J, Stocking C\nVIROLOGY. 2001;290(1):39-49.\nClinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma.\nRabe C, Pilz T, Klostermann C, Berna M, Schild H, Sauerbruch T, Caselmann W\nWORLD J GASTROENTERO. 2001;7(2):208-215.\nOptimization of hepatocyte spheroid formation for hepatic tissue engineering on three-dimensional biodegradable polymer within a flow bioreactor prior to implantation.\nT\u00f6r\u00f6k E, Pollok J, Ma P, Kaufmann P, Dandri-Petersen M, Petersen J, Burda M, Kluth D, Perner F, Rogiers X\nCELLS TISSUES ORGANS. 2001;169(1):34-41.\nHepatic tissue engineering on 3-dimensional biodegradable polymers within a pulsatile flow bioreactor.\nT\u00f6r\u00f6k E, Pollok J, Ma P, Vogel C, Dandri-Petersen M, Petersen J, Burda M, Kaufmann P, Kluth D, Rogiers X\nDIGEST SURG. 2001;18(3):196-203.\nCationic lipid polymerization as a novel approach for constructing new DNA delivery agents\nWu J, Lizarzaburu M, Kurth M, Liu L, Wege H, Zern M, Nantz M\nBIOCONJUGATE CHEM. 2001;12(2):251-7.\nGene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase.\nBlock A, Freund C, Chen S, Nguyen K, Finegold M, Windler E, Woo S\nCANCER GENE THER. 2000;7(3):438-445.\nIncreased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA.\nDandri-Petersen M, Burda M, Will H, Petersen J\nHEPATOLOGY. 2000;32(1):139-146.\nAdenovirus-mediated suicide gene therapy for bladder cancer: comparison of the cytomegalovirus- and Rous sarcoma virus-promoter.\nFreund C, Tong X, Block A, Contant C, Kieback D, Rowley D, Lerner S\nANTICANCER RES. 2000;20(5):2811-2816.\nLack of evidence for an association between hantavirus infections and Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and giant cell arteritis.\nGerke P, Wichmann D, Sch\u00f6nermarck U, Sch\u00fctt M, Feldmann H, Ksiazek T, Rob P, Gross W\nRHEUMATOLOGY. 2000;39(12):1424-1425.\nExpression of stress protein gp96, a tumor rejection antigen, in human colorectal cancer.\nHeike M, Frenzel C, Meier D, Galle P\nINT J CANCER. 2000;86(4):489-493.\nCerebrocutaneous xanthoma disseminatum and disseminated demyelinating encephalomyelitis\nPfeiffer G, Hagel C, Eckert B, Zschaber R, Gross G, Bamberger C\nEUR NEUROL. 2000;44(2):123-4.\nLate endocytic compartments are major sites of annexin VI localization in NRK fibroblasts and polarized WIF-B hepatoma cells.\nPons M, Ihrke G, Koch S, Biermer M, Pol A, Grewal T, J\u00e4ckle S, Enrich C\nEXP CELL RES. 2000;257(1):33-47.\nIdentification and characterization of a histone binding site of the non-structural protein 3 of hepatitis C virus\nBorowski P, K\u00fchl R, Laufs R, Schulze zur Wiesch J, Heiland M\nJ CLIN VIROL. 1999;13(1-2):61-9.\nAdenovirus-mediated ex vivo immunogene and in vivo combination gene therapy strategies induce a systemic anti-tumor immune defense in the mouse B16 melanoma model.\nBonnekoh B, Greenhalgh D, Chen S, Bickenbach J, Block A, Rich S, Krieg T, Woo S, Roop D\nADV EXP MED BIOL. 1998;451:335-343.\nEx vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model.\nBonnekoh B, Greenhalgh D, Chen S, Block A, Rich S, Krieg T, Woo S, Roop D\nJ INVEST DERMATOL. 1998;110(6):867-871.\nMetabolic labeling of woodchuck hepatitis B virus X protein in naturally infected hepatocytes reveals a bimodal half-life and association with the nuclear framework.\nDandri-Petersen M, Petersen J, Stockert R, Harris T, Rogler C\nJ VIROL. 1998;72(11):9359-9364.\nGastrin/cholecystokinin type B receptors in the kidney: molecular, pharmacological, functional characterization, and localization.\nde Weerth A, Jonas L, Schade R, Sch\u00f6neberg T, Wolf G, Pace A, Kirchhoff F, Schulz M, Heinig T, Greten H, von Schrenck T\nEUR J CLIN INVEST. 1998;28(7):592-601.\nLiver repopulation with xenogenic hepatocytes in B and T cell-deficient mice leads to chronic hepadnavirus infection and clonal growth of hepatocellular carcinoma.\nPetersen J, Dandri-Petersen M, Gupta S, Rogler C\nP NATL ACAD SCI USA. 1998;95(1):310-315.\nAntisense downregulation of N-myc1 in woodchuck hepatoma cells reverses the malignant phenotype.\nWang H, Zhang L, Dandri-Petersen M, Rogler C\nJ VIROL. 1998;72(3):2192-2198.\nAdenoviral-mediated herpes simplex virus thymidine kinase gene transfer: regression of hepatic metastasis of pancreatic tumors.\nBlock A, Chen S, Kosai K, Finegold M, Woo S\nPANCREAS. 1997;15(1):25-34.\n[Adenovirus gene therapy for liver metastases of gastrointestinal tumors. Development status and future prospectives]\nBlock A, Windler E, Greten H, Woo S\nDEUT MED WOCHENSCHR. 1997;122(22):728-732.\n[Immunohistochemical localization of annexin VI in the endocytic compartment of rat liver hepatocytes]\nOrtega D, Pol A, Biermer M, J\u00e4ckle S, Enrich C\nGASTROENT HEPAT-BARC. 1997;20(8):391-397.\nIncrease in the frequency of hepadnavirus DNA integrations by oxidative DNA damage and inhibition of DNA repair.\nPetersen J, Dandri-Petersen M, B\u00fcrkle A, Zhang L, Rogler C\nJ VIROL. 1997;71(7):5455-5463.\nAdenovirus-mediated suicide gene therapy for experimental bladder cancer.\nSutton M, Berkman S, Chen S, Block A, Dang T, Kattan M, Wheeler T, Rowley D, Woo S, Lerner S\nUROLOGY. 1997;49(2):173-180.\nWoodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and woodchuck hepatocellular carcinomas which are permissive for viral replication.\nDandri-Petersen M, Schirmacher P, Rogler C\nJ VIROL. 1996;70(8):5246-5254.\nAnnexins in endocytosis.\nJ\u00e4ckle S, Rinninger F, Beisiegel U, Block A, Tauscher W, Biermer M, Greten H, Windler E\nZ GASTROENTEROL. 1996;34(3):81-82.\nIn vivo gene therapy of ovarian cancer by adenovirus-mediated thymidine kinase gene transduction and ganciclovir administration.\nTong X, Block A, Chen S, Contant C, Agoulnik I, Blankenburg K, Kaufman R, Woo S, Kieback D\nGYNECOL ONCOL. 1996;61(2):175-179.\nAdenovirus-mediated thymidine kinase gene transduction in human epithelial ovarian cancer cell lines followed by exposure to ganciclovir.\nTong X, Block A, Chen S, Woo S, Kieback D\nANTICANCER RES. 1996;16(4):1611-1617.\nImmunologische Selbsterkenntnis? Immunregulation der autoimmunen Hepatitis\nLohse A\nForschungsmagazin der Johannes Gutenberg-Universit\u00e4t Mainz. 1995;11(2):118-126.\nAnnexin VI, a marker protein of hepatocytic endosomes.\nJ\u00e4ckle S, Beisiegel U, Rinninger F, Buck F, Grigoleit A, Block A, Gr\u00f6ger I, Greten H, Windler E\nJ BIOL CHEM. 1994;269(2):1026-1032.\nTrans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product.\nMenzo S, Clementi M, Alfani E, Bagnarelli P, Iacovacci S, Manzin A, Dandri-Petersen M, Natoli G, Levrero M, Carloni G\nVIROLOGY. 1993;196(2):878-882.\nLetzte Aktualisierung aus dem FIS: 25.10.2023 - 00:32 Uhr\n- - -", "language": null, "image": null, "pagetype": null, "links": ["/allgemein/ueber-uns/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/index.html", "/allgemein/presse/index.html", "/allgemein/mediathek/index.html", "/allgemein/international/index.html", "/allgemein/qualitaet/index.html", "https://www.uke-stiftung.de", "/allgemein/spenden/index.html", "/patienten-besucher/leichte-sprache/index.html", "/orientierung", "/allgemein/login/index.html", "/english/departments-institutes/departments/i.-medical-clinic-and-polyclinic/index.html", "/index.html", "/english/departments-institutes/departments/i.-medical-clinic-and-polyclinic/index.html", "/allgemein/index.html", "/allgemein/ueber-uns/index.html", "/allgemein/ueber-uns/das-uke/index.html", "/allgemein/ueber-uns/das-uke/vorstand/index.html", "/allgemein/ueber-uns/das-uke/kuratorium/index.html", "/allgemein/ueber-uns/das-uke/medizinische-fakultaet/index.html", "/allgemein/ueber-uns/das-uke/kollegium/index.html", "/allgemein/ueber-uns/das-uke/zahlen-fakten/index.html", "/allgemein/ueber-uns/das-uke/strategie-wachstum/index.html", "/allgemein/ueber-uns/das-uke/nachhaltigkeit/index.html", "/allgemein/ueber-uns/historie/index.html", "/allgemein/ueber-uns/leitbild/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/ueber-uns/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/mitgliedschaft/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/aktuelles/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/newsarchiv/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/uke-alumni-verein/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/erika-haus/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/medizinhistorisches-museum/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/promotionspreise/index.html", "/allgemein/ueber-uns/freundes-und-foerderkreis/stipendien-studienbeihilfen/index.html", "/allgemein/ueber-uns/medizinhistorisches-museum/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/regionalwettbewerb-hamburg-eppendorf-2020/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/regionalwettbewerb-hamburg-eppendorf-2018/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/regionalwettbewerb-hamburg-eppendorf-2017/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/regionalwettbewerb-hamburg-eppendorf-2016/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/kooperation-besiegelt/index.html", "/allgemein/ueber-uns/jugend-forscht-im-uke/weitere-aktivitaeten/index.html", "/allgemein/presse/index.html", "/allgemein/presse/kontakt/index.html", "/allgemein/presse/pressemitteilungen/index.html", "/allgemein/presse/zahlen-fakten/index.html", "/allgemein/presse/mediathek/index.html", "/allgemein/presse/bilder/index.html", "/allgemein/presse/bilder/corona/index.html", "/allgemein/presse/bilder/bilder-download/index.html", "/allgemein/mediathek/index.html", "/allgemein/mediathek/aktuelles/index.html", "/allgemein/mediathek/aktuelles/2022-meldungen-startseite/index.html", "/allgemein/mediathek/aktuelles/2021-meldungen-startseite/index.html", "/allgemein/mediathek/aktuelles/2020-meldungen-startseite/index.html", "/allgemein/mediathek/aktuelles/2019-meldungen-startseite/index.html", "/allgemein/mediathek/aktuelles/2018-meldungen-startseite/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/patienten-berichten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/patienten-berichten/tausend-tage-bis-zum-letzten-atemzug/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/patienten-berichten/lebensqualitaet-steigt-mit-neuer-lunge-sprungartig/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/patienten-berichten/mit-yoga-zurueck-ins-leben/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/patienten-berichten/warnzeichen-ernst-nehmen/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/moin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/tschuess/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/lieblingsplatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/kinderreporter/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/reportage/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/was-macht-eigentlich/karriere/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/gesundheitsakademie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-herbst-2023/lieblingsrezept/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/patienten-berichten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/patienten-berichten/wieder-vertrauen-fassen/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/patienten-berichten/gemeinsam-gegen-brustkrebs/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/patienten-berichten/aufgeben-ist-keine-option/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/patienten-berichten/angriff-auf-die-weisse-substanz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/was-macht-eigentlich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/was-macht-eigentlich/moin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/was-macht-eigentlich/tschuess/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/was-macht-eigentlich/kinderreporter/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/was-macht-eigentlich/reportage/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/was-macht-eigentlich/karriere/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/gesundheitsakademie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/stadtpiraten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/stadtpiraten/lieblingsplatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/stadtpiraten/stadturlaub/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2023/lieblingsrezept/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/patienten-berichten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/patienten-berichten/seynabous-langer-weg/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/patienten-berichten/kleiner-schnitt-mit-grosser-wirkung/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/patienten-berichten/die-welt-mit-neuen-augen-sehen/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/patienten-berichten/die-kleinste-transplantation/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/was-macht-eigentlich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/was-macht-eigentlich/moin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/was-macht-eigentlich/tschuess/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/was-macht-eigentlich/kinderreporter/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/was-macht-eigentlich/reportage/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/was-macht-eigentlich/karriere/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/gesundheitsakademie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/stadtpiraten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/stadtpiraten/lieblingsplatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/stadtpiraten/stadturlaub/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-winter-2023/lieblingsrezept/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/patienten-berichten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/patienten-berichten/seit-16-jahren-chronisch-krank/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/patienten-berichten/mit-neuer-abwehr-gegen-ms/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/patienten-berichten/kein-weg-ist-zu-weit/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/patienten-berichten/verdeckten-krebszellen-auf-der-spur/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/was-macht-eigentlich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/was-macht-eigentlich/moin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/was-macht-eigentlich/tschuess/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/was-macht-eigentlich/kinderreporter/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/was-macht-eigentlich/reportage/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/was-macht-eigentlich/karriere/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/gesundheitsakademie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/stadtpiraten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/stadtpiraten/lieblingsplatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/stadtpiraten/stadturlaub/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2022/lieblingsrezept/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/patienten-berichten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/patienten-berichten/richtung-horizont/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/patienten-berichten/gefaehrliche-sonnenfalle/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/patienten-berichten/mein-blick-geht-nach-vorn/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/patienten-berichten/op-nicht-immer-noetig/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/was-macht-eigentlich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/was-macht-eigentlich/moin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/was-macht-eigentlich/tschuess/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/was-macht-eigentlich/kinderreporter/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/was-macht-eigentlich/reportage/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/was-macht-eigentlich/karriere/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/gesundheitsakademie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/stadtpiraten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/stadtpiraten/lieblingsplatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/stadtpiraten/stadturlaub/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2022/lieblingsrezept/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/patienten-berichten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/patienten-berichten/ueberall-eine-maske-aufgesetzt/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/patienten-berichten/ich-dachte-mein-leben-ist-vorbei/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/patienten-berichten/schmerz-und-sorgen/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/report/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/report/nichts-ist-alltaeglich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/report/jeder-alarm-kann-notfall-sein/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/moin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/tschuess/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/kinderreporter/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/hchs-gesundheitsstudie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/school-of-life-science/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/was-macht-eigentlich/ehemalige-patienten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/gesundheitsakademie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/stadtpiraten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/stadtpiraten/lieblingsplatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/stadtpiraten/stadturlaub/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fruehling-2022/lieblingsrezept/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/herz-und-gefaesszentrum-faehrt-langsam-hoch/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/ein-highlight-fuer-die-patienten/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/uke-aerztin-nach-covid-19-erkrankung-wieder-im-einsatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/zahnklinik-geoeffnet/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/das-virus-soll-lieber-angst-vor-mir-haben/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/telemedizin-eroeffnet-neue-wege-in-der-therapie/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/unterwegs-als-notaerztin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/%E2%80%9Ewir-sind-die-vermittlerinnen%E2%80%9C/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/ich-wuerde-es-wieder-machen/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/sicherheitsdienst-im-sondereinsatz/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/strategischer-einkauf-ordert-nachschub/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/wo-auf-covid-19-getestet-wird/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/pflege-auf-der-intensivstation/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/hygieneschulungen-f%C3%BCr-alle/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/suche-nach-dem-impfstoff/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/zweite-heimat-tansania/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/ambulanz-f%C3%BCr-akute-atemwegsinfekte/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/ambulanz-f%C3%BCr-akute-atemwegsinfekte/interview-mit-einer-%C3%A4rztin/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-fr%C3%BChjahr-2020/ambulanz-f%C3%BCr-akute-atemwegsinfekte/die-koordinatorin-berichtet/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/zweite-chance/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/neues-herz-f%C3%BCr-emilia/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/lieblingspl%C3%A4tze/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/umzug-ins-kinder-uke/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/ganz-sch%C3%B6n-schnell/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/moin-und-tsch%C3%BCss/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-herbst-2017/gesund-essen/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/life-sommer-2017/index.html", "/allgemein/mediathek/gesch%C3%A4ftsberichte-jahrb%C3%BCcher/index.html", "/allgemein/mediathek/wissen-forschen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/versorgungsforschung-und-public-health/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/pandemie-als-wendepunkt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/gemeinsam-allein/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/notaufnahmen-in-not/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/bruecken-bauen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/im-ungleichgewicht/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/recover-psychische-gesundheit-im-fokus/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/wer-wartet-wie-lange/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/warum-gehen-wir-zum-arzt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/in-virtueller-realitaet-zwaenge-behandeln/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/wenn-es-nicht-mehr-weiter-geht/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/hilfe-finden-huerden-meistern/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/damit-gesundheit-kein-fremdwort-bleibt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/nachdenken-ueber-das-eigene-denken/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2021/kurzbeitraege/wissen-aus-erster-hand/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/mit-sicherheit/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/experten-f%C3%BCr-schwere-f%C3%A4lle/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/ein-kraftakt-f%C3%BCr-kinder/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/vereint-gegen-den-erreger/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/hauptsache-gemeinsam/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/das-multiorganvirus-auch-nieren-befallen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/angriff-aufs-herz/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/sars-cov-2-greift-auch-das-gehirn-an/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/krebs-macht-keine-pause/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/von-herdenimmunit%C3%A4t-weit-entfernt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/das-leben-auf-den-kopf-gestellt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/forscherteams-mit-breitem-themenmix/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/corona-kompakt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/kurzbeitr%C3%A4ge/unikliniken-bilden-bundesweites-netzwerk/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2020/spenden-sie-gesundheit/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/wettlauf-gegen-die-zeit/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/taktgeber-f%C3%BCrs-gehirn/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/spielend-lernen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/doppelpass-gegen-multiple-sklerose/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/chaos-im-kopf/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/die-hightech-pioniere/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/erwartungen-ver%C3%A4ndern-schmerzen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/kurzbeitr%C3%A4ge/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/kurzbeitr%C3%A4ge/die-sprache-des-gehirns/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/kurzbeitr%C3%A4ge/ja-oder-nein-jein!/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/kurzbeitr%C3%A4ge/das-wachstum-verlangsamen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/kurzbeitr%C3%A4ge/eng-vernetzt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/spenden-f%C3%BCr-die-forschung/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2018/spenden-f%C3%BCr-die-forschung/die-chance-auf-heilung-erh%C3%B6hen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/genetischer-schl%C3%BCssel/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/entfesselte-abwehrkr%C3%A4fte/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/der-letzte-schritt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/starthilfe-in-ein-neues-leben/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/forschen-mit-farbe/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/krebsforschung-im-ucch/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/ucch-f%C3%B6rderer/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2017/kurzbeitr%C3%A4ge/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/gegen-das-vergessen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/zu-fr%C3%BCh/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/lebensqualit%C3%A4t-verbessern/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/aus-der-spur/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/leben-retten/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/beben-im-kopf/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/forschen-f%C3%BCr-die-seltenen/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/hier-entsteht-die-neue-kinderklinik/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/der-grundstein-ist-gelegt/index.html", "/allgemein/mediathek/wissen-forschen/wissen-forschen-2016/kurzbeitr%C3%A4ge/index.html", "/allgemein/mediathek/filme/index.html", "/allgemein/mediathek/125-jahre-uke/index.html", "/allgemein/spenden/index.html", "/allgemein/spenden/online-spende/index.html", "/allgemein/spenden/spendenkonto/index.html", "/allgemein/spenden/spendenprojekte-im-uke/index.html", "/allgemein/spenden/als-unternehmer-helfen/index.html", "/allgemein/spenden/spenden-im-trauerfall/index.html", "/allgemein/spenden/spenden-statt-schenken/index.html", "/allgemein/spenden/spendenaktion/index.html", "/allgemein/spenden/vererben/index.html", "https://www.uke-stiftung.de", "/allgemein/spenden/kontakt/index.html", "/allgemein/spenden/uke-benefizlauf/index.html", "/allgemein/spenden/uke-benefizlauf/startseite/index.html", "/allgemein/spenden/uke-benefizlauf/benefizlauf-onlinetool/index.html", "/allgemein/spenden/uke-benefizlauf/spendenprojekt/index.html", "/allgemein/spenden/uke-benefizlauf/spendenkonto/index.html", "/allgemein/spenden/uke-benefizlauf/prominente-botschafter/index.html", "/allgemein/spenden/uke-benefizlauf/laeufer-galerie/index.html", "/allgemein/spenden/uke-benefizlauf/sponsoren/index.html", "/allgemein/qualitaet/index.html", "/allgemein/international/index.html", "/allgemein/login/index.html", "/allgemein/kontakt/index.html", "/patienten-besucher/index.html", "/patienten-besucher/aufenthalt/index.html", "/patienten-besucher/aufenthalt/vorbereitung-aufnahme/index.html", "/patienten-besucher/aufenthalt/tagesablauf/index.html", "/patienten-besucher/aufenthalt/wahlleistung/index.html", "/patienten-besucher/aufenthalt/zimmer/index.html", "/patienten-besucher/aufenthalt/verpflegung/index.html", "/patienten-besucher/aufenthalt/patientenrechte/index.html", "/patienten-besucher/aufenthalt/angeh%C3%B6rige/index.html", "/patienten-besucher/aufenthalt/entlassung/index.html", "/patienten-besucher/aufenthalt/hausordnung-sicherheitsdienst/index.html", "/patienten-besucher/anreise/index.html", "/patienten-besucher/orientierung/index.html", "/patienten-besucher/dialog-beratung/index.html", "/patienten-besucher/dialog-beratung/%C3%A4ngste-sorgen/index.html", "/patienten-besucher/dialog-beratung/ombudspersonen/index.html", "/patienten-besucher/dialog-beratung/besuchsdienst/index.html", "/patienten-besucher/dialog-beratung/seelsorge-religion/index.html", "/patienten-besucher/dialog-beratung/patientenbefragung/index.html", "/patienten-besucher/dialog-beratung/sozial-pflegeberatung/index.html", "/patienten-besucher/dialog-beratung/klinische-ethik/index.html", "/patienten-besucher/qualit%C3%A4t/index.html", "/patienten-besucher/qualit%C3%A4t/patientensicherheit/index.html", "/patienten-besucher/qualit%C3%A4t/medizinische-ergebnisqualit%C3%A4t/index.html", "/patienten-besucher/qualit%C3%A4t/qualit%C3%A4tsberichte/index.html", "/patienten-besucher/qualit%C3%A4t/zufriedenheit/index.html", "/patienten-besucher/qualit%C3%A4t/krankenhaushygiene/index.html", "/patienten-besucher/qualit%C3%A4t/lob-beschwerdemanagement/index.html", "/patienten-besucher/qualit%C3%A4t/hinweisgebersystem/index.html", "/patienten-besucher/qualit%C3%A4t/risikomanagement/index.html", "/patienten-besucher/qualit%C3%A4t/zertifizierungen/index.html", "/patienten-besucher/einkaufen-service/index.html", "/patienten-besucher/einkaufen-service/gastronomie/index.html", "/patienten-besucher/einkaufen-service/merchandising/index.html", "/patienten-besucher/einkaufen-service/spectrum/index.html", "/patienten-besucher/veranstaltungen/index.html", "/patienten-besucher/veranstaltungen/ausstellung-kim-lewerenz/index.html", "/patienten-besucher/uke-international/index.html", "/patienten-besucher/patientenorientierung/index.html", "/patienten-besucher/leichte-sprache/index.html", "/patienten-besucher/leichte-sprache/was-machen-wir-im-uke/index.html", "/patienten-besucher/leichte-sprache/infos-f%C3%BCr-patienten/index.html", "/patienten-besucher/leichte-sprache/telefon/index.html", "/patienten-besucher/leichte-sprache/unsere-kliniken/index.html", "/patienten-besucher/leichte-sprache/wer-arbeitet-im-uke/index.html", "/patienten-besucher/leichte-sprache/der-weg-zum-uke/index.html", "/patienten-besucher/musik-mensch-medizin/index.html", "/patienten-besucher/musik-mensch-medizin/konzertreihe-im-uke/index.html", "/patienten-besucher/musik-mensch-medizin/kooperation-ndr-elbphilharmonie-orchester/index.html", "/patienten-besucher/musik-mensch-medizin/sprechstunde-f%C3%BCr-musikerinnen-und-musiker/index.html", "/patienten-besucher/musik-mensch-medizin/weihnachtsoratorium/index.html", "/patienten-besucher/musik-mensch-medizin/musikalisches-archiv/index.html", "/%C3%A4rzte-partner/index.html", "/%C3%A4rzte-partner/was-suchen-sie/index.html", "/%C3%A4rzte-partner/aktuelles/index.html", "/%C3%A4rzte-partner/dienstleistungen/index.html", "/%C3%A4rzte-partner/kooperationen/index.html", "/studium-lehre/index.html", "/studium-lehre/studienentscheidung/index.html", "/studium-lehre/studienentscheidung/warum-uke/index.html", "/studium-lehre/studienentscheidung/medizin/index.html", "/studium-lehre/studienentscheidung/zahnmedizin/index.html", "/studium-lehre/studienentscheidung/hebammenwissenschaft/index.html", "/studium-lehre/studienentscheidung/bewerbung/index.html", "/studium-lehre/studienentscheidung/auswahlverfahren/index.html", "/studium-lehre/modellstudiengang-medizin-imed/index.html", "/studium-lehre/modellstudiengang-medizin-imed/orientierungseinheit/index.html", "/studium-lehre/modellstudiengang-medizin-imed/studiengangorganisation/index.html", "/studium-lehre/modellstudiengang-medizin-imed/pr%C3%BCfungen/index.html", "/studium-lehre/modellstudiengang-medizin-imed/krankenpflegedienst-famulatur/index.html", "/studium-lehre/modellstudiengang-medizin-imed/praktisches-jahr/index.html", "/studium-lehre/modellstudiengang-medizin-imed/rechtsgrundlagen-formulare/index.html", "/studium-lehre/modellstudiengang-medizin-imed/qualit%C3%A4tssicherung/index.html", "/studium-lehre/modellstudiengang-medizin-imed/promotion-phd/index.html", "/studium-lehre/modellstudiengang-medizin-imed/beh%C3%B6rden-institutionen/index.html", "/studium-lehre/modellstudiengang-medizin-imed/h%C3%A4ufige-fragen-(faq)/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/orientierungseinheit/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/studiengangorganisation/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/pr%C3%BCfungen/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/krankenpflegedienst-famulatur/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/rechtsgrundlagen-formulare/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/qualit%C3%A4tssicherung/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/promotion-phd/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/beh%C3%B6rden-institutionen/index.html", "/studium-lehre/modellstudiengang-zahnmedizin-imed-dent/h%C3%A4ufige-fragen-(faq)/index.html", "/studium-lehre/zahnmedizin/index.html", "/studium-lehre/zahnmedizin/orientierungseinheit/index.html", "/studium-lehre/zahnmedizin/studiengangorganisation/index.html", "/studium-lehre/zahnmedizin/pr%C3%BCfungen/index.html", "/studium-lehre/zahnmedizin/zweitstudium-(mkg)/index.html", "/studium-lehre/zahnmedizin/rechtsgrundlagen-formulare/index.html", "/studium-lehre/zahnmedizin/qualit%C3%A4tssicherung/index.html", "/studium-lehre/zahnmedizin/promotion-phd/index.html", "/studium-lehre/zahnmedizin/beh%C3%B6rden-institutionen/index.html", "/studium-lehre/zahnmedizin/h%C3%A4ufige-fragen-(faq)/index.html", "/studium-lehre/hebammenwissenschaft/index.html", "/studium-lehre/hebammenwissenschaft/bewerbungs-verfahren/index.html", "/studium-lehre/hebammenwissenschaft/aufbau-des-studiengangs/index.html", "/studium-lehre/hebammenwissenschaft/orientierungseinheit/index.html", "/studium-lehre/hebammenwissenschaft/studiengangorganisation/index.html", "/studium-lehre/hebammenwissenschaft/pr%C3%BCfungen/index.html", "/studium-lehre/hebammenwissenschaft/rechtsgrundlagen/index.html", "", "/studium-lehre/hebammenwissenschaft/behoerden-und-institutionen/index.html", "/studium-lehre/hebammenwissenschaft/h%C3%A4ufige-fragen-faq/index.html", "/studium-lehre/hebammenwissenschaft/kontakt/index.html", "/studium-lehre/extracurriculares-lehrangebot/index.html", "/studium-lehre/weitere-studieng%C3%A4nge/index.html", "/studium-lehre/lernumgebung/index.html", "/studium-lehre/lernumgebung/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/index.html", "/studium-lehre/lernumgebung/meditreff/index.html", "/studium-lehre/lernumgebung/elearning/index.html", "/studium-lehre/lernumgebung/imed-textbook/index.html", "/studium-lehre/lernumgebung/imed-crashkurse/index.html", "/studium-lehre/lernumgebung/mentoring-programm/index.html", "/studium-lehre/lernumgebung/simulationspatientenprogramm/index.html", "/studium-lehre/lernumgebung/interprofessionelles-lernen/index.html", "/studium-lehre/international/index.html", "/studium-lehre/international/studieren-im-ausland/index.html", "/studium-lehre/international/studieren-im-uke/index.html", "/studium-lehre/international/praktikum-im-uke/index.html", "/studium-lehre/international/erasmus/index.html", "/studium-lehre/international/partneruniversit%C3%A4ten/index.html", "/studium-lehre/international/empfehlungsschreiben/index.html", "/studium-lehre/international/buddy-net/index.html", "/studium-lehre/international/usmle/index.html", "/studium-lehre/international/service-ehemalige-studierende/index.html", "/studium-lehre/campusleben/index.html", "/studium-lehre/campusleben/campus-rundgang/index.html", "/studium-lehre/campusleben/essen-trinken/index.html", "/studium-lehre/campusleben/uke-card/index.html", "/studium-lehre/campusleben/uke-mail-it/index.html", "/studium-lehre/campusleben/schlie%C3%9Ff%C3%A4cher/index.html", "/studium-lehre/qualitaet-und-lehrservice/index.html", "/studium-lehre/qualitaet-und-lehrservice/lehrauftraege/index.html", "/studium-lehre/qualitaet-und-lehrservice/uke-medizindidaktik/index.html", "/studium-lehre/qualitaet-und-lehrservice/lehrevaluation/index.html", "/studium-lehre/qualitaet-und-lehrservice/pruefungszentrum/index.html", "/studium-lehre/qualitaet-und-lehrservice/lehrforschung/index.html", "/studium-lehre/qualitaet-und-lehrservice/teacher-of-the-year/index.html", "/studium-lehre/qualitaet-und-lehrservice/lehrbudget/index.html", "/studium-lehre/qualitaet-und-lehrservice/lehrleistungspruefung/index.html", "/studium-lehre/studieren-mit-familie/index.html", "/studium-lehre/studieren-mit-familie/mutterschutz/index.html", "/studium-lehre/studieren-mit-familie/studienorganisation-f%C3%BCr-eltern/index.html", "https://www.uke.de/organisationsstruktur/zentrale-bereiche/personalbeauftragte/inklusion-im-uke/inklusion-studierende.html", "/studium-lehre/studentische-projekte/index.html", "/studium-lehre/kontakt-beratung/index.html", "/studium-lehre/kontakt-beratung/team-und-studienberatung/index.html", "/studium-lehre/kontakt-beratung/weitere-beratungsangebote/index.html", "/studium-lehre/kontakt-beratung/verbesserungs-beschwerdemanagement/index.html", "/forschung/index.html", "/forschung/aktuelles/index.html", "/forschung/aktuelles/paper-of-the-month/index.html", "/forschung/aktuelles/internationale-wissenschaftler/index.html", "/forschung/aktuelles/freiwilliges-soziales-jahr-in-der-wissenschaft/index.html", "/forschung/wissenschaftliche-leitlinien/index.html", "/forschung/wissenschaftliche-leitlinien/open-science/index.html", "/forschung/wissenschaftliche-leitlinien/3r/index.html", "/forschung/wissenschaftliche-leitlinien/gute-wissenschaftliche-praxis/index.html", "/forschung/wissenschaftliche-leitlinien/gute-klinische-praxis/index.html", "/forschung/wissenschaftliche-leitlinien/deklaration-von-helsinki/index.html", "/forschung/forschungsschwerpunkte/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/forschung/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/cvrc-aufsichtsrat/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/graduiertenkolleg/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/veranstaltungen/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/veranstaltungen/cvrc-seminare/index.html", "/forschung/forschungsschwerpunkte/cardiovascular-research-center-cvrc/veranstaltungen/cvrc-graduiertenkolleg/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/aktuelles/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/aktuelles/netzwerk/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/aktuelles/team/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/forschung/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/forschung/projekte/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/forschung/publikationen/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/imed-(2nd-track)/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/methodenkurse/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/nachwuchspreis/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/nachwuchstag/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/phd-programm/index.html", "/forschung/forschungsschwerpunkte/center-for-health-care-research-chcr/lehrangebote-fortbildungen/mentoring/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/startseite/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/c3i-board/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/netzwerk/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/institutionen/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/institutionen/kliniken-institute/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/institutionen/campus-forschung-i-ii-hcti/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/institutionen/uke-core-facilities/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/aktivitaeten/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/aktivitaeten/seminare/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/aktivitaeten/veranstaltungen/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/kooperationen/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/kooperationen/lokal/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/kooperationen/national/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/training/index.html", "/forschung/forschungsschwerpunkte/center-for-inflammation-infection-and-immunity-c3i/satzung/index.html", "/forschung/forschungsschwerpunkte/hamburg-center-of-neuroscience-hcns/index.html", "/forschung/forschungsschwerpunkte/universit%C3%A4res-cancer-center-hamburg-ucch/index.html", "/forschung/verb%C3%BCnde-programme/index.html", "/forschung/verb%C3%BCnde-programme/sonderforschungsbereiche/index.html", "/forschung/verb%C3%BCnde-programme/forschungsgruppen/index.html", "/forschung/verb%C3%BCnde-programme/graduiertenkollegs/index.html", "/forschung/verb%C3%BCnde-programme/deutsche-zentren-der-gesundheitsforschung/index.html", "/forschung/verb%C3%BCnde-programme/investigator-initiierte-trial/index.html", "/forschung/verb%C3%BCnde-programme/netzwerk-universit%C3%A4tsmedizin/index.html", "/forschung/verb%C3%BCnde-programme/eu-projekte/index.html", "/forschung/verb%C3%BCnde-programme/bmbf-projekte/index.html", "/forschung/verb%C3%BCnde-programme/landesforschungsf%C3%B6rderung/index.html", "/forschung/verb%C3%BCnde-programme/einzelf%C3%B6rderung/index.html", "/forschung/klinische-forschung/index.html", "/forschung/klinische-forschung/clinical-trial-office/index.html", "/forschung/klinische-forschung/qualitaetsmanagement-klinische-studien/index.html", "/forschung/klinische-forschung/registrierung-klinischer-studien/index.html", "/forschung/klinische-forschung/nationale-forschungsfoerderung/index.html", "/forschung/klinische-forschung/vertragsmanagement-drittmittel/index.html", "/forschung/klinische-forschung/kalkulation-controlling-klinischer-studien/index.html", "/forschung/klinische-forschung/epidemiologisches-studienzentrum/index.html", "/forschung/translation-technologietransfer/index.html", "/forschung/translation-technologietransfer/technologietransfer/index.html", "/forschung/translation-technologietransfer/wipano/index.html", "/forschung/translation-technologietransfer/hamburg-innovation/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/medizinische-fakult%C3%A4t/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/universit%C3%A4t-hamburg/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/externe-foerdermoeglichkeiten/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/forschen-im-ausland/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/eu-projekte/index.html", "/forschung/f%C3%B6rderm%C3%B6glichkeiten/gleichstellung/index.html", "/forschung/nachwuchsfoerderung/index.html", "/forschung/nachwuchsfoerderung/iprime/index.html", "/forschung/nachwuchsfoerderung/iprime/ueber-iprime/index.html", "/forschung/nachwuchsfoerderung/iprime/ueber-iprime/leitungsteam/index.html", "/forschung/nachwuchsfoerderung/iprime/ueber-iprime/iprime-ekfs/index.html", "/forschung/nachwuchsfoerderung/iprime/aktuelles/index.html", "/forschung/nachwuchsfoerderung/iprime/stipendien/index.html", "/forschung/nachwuchsfoerderung/iprime/ausbildungsprogramm/index.html", "/forschung/nachwuchsfoerderung/iprime/bewerbung/index.html", "/forschung/nachwuchsfoerderung/iprime/projekte/index.html", "/forschung/nachwuchsfoerderung/iprime/alumni/index.html", "/forschung/nachwuchsfoerderung/iprime-cs/index.html", "/forschung/nachwuchsfoerderung/clinician-scientist-programm/index.html", "/forschung/nachwuchsfoerderung/istar/index.html", "/forschung/nachwuchsfoerderung/mildred-scheel-nachwuchszentrum/index.html", "/forschung/nachwuchsfoerderung/idfellows/index.html", "/forschung/academy-of-biomedical-health-sciences/index.html", "/forschung/academy-of-biomedical-health-sciences/promovierende/index.html", "/forschung/academy-of-biomedical-health-sciences/postdocs/index.html", "/forschung/academy-of-biomedical-health-sciences/schools/index.html", "/forschung/promotion-phd-habilitation/index.html", "/forschung/promotion-phd-habilitation/promotion/index.html", "/forschung/promotion-phd-habilitation/promotion/wie-finde-ich-die-richtige-doktorarbeit-fuer-mich/index.html", "/forschung/promotion-phd-habilitation/phd-programm-medizin/index.html", "/forschung/promotion-phd-habilitation/phd-programm-nicht-medizin/index.html", "/forschung/habilitation/index.html", "/forschung/infrastruktur/index.html", "/forschung/infrastruktur/core-facilities/index.html", "/forschung/infrastruktur/campus-forschung/index.html", "/forschung/infrastruktur/biobanken/index.html", "/forschung/infrastruktur/forschungstierhaltung/index.html", "/forschung/infrastruktur/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/index.html", "/forschung/infrastruktur/forschungsinformationssystem-(fis)/index.html", "/forschung/infrastruktur/forschungsportal/index.html", "/kliniken-institute/index.html", "/kliniken-institute/zentren/index.html", "/kliniken-institute/zentren/adipositas-centrum/index.html", "/kliniken-institute/zentren/adipositas-centrum/%C3%BCber-das-centrum/index.html", "/kliniken-institute/zentren/adipositas-centrum/%C3%BCber-das-centrum/aktuelles/index.html", "/kliniken-institute/zentren/adipositas-centrum/%C3%BCber-das-centrum/team/index.html", "/kliniken-institute/zentren/adipositas-centrum/%C3%BCber-das-centrum/geschichte/index.html", "/kliniken-institute/zentren/adipositas-centrum/therapieangebot/index.html", "/kliniken-institute/zentren/adipositas-centrum/sprechstunden/index.html", "/kliniken-institute/zentren/adipositas-centrum/aufnahme/index.html", "/kliniken-institute/zentren/adipositas-centrum/aufenthalt/index.html", "/kliniken-institute/zentren/adipositas-centrum/forschung/index.html", "/kliniken-institute/zentren/adipositas-centrum/aus-weiterbildung/index.html", "/kliniken-institute/zentren/adipositas-centrum/kooperationspartner/index.html", "/kliniken-institute/zentren/ambulanzzentrum-medizinisches-versorgungszentrum-(mvz)/index.html", "/kliniken-institute/zentren/ambulanzzentrum-medizinisches-versorgungszentrum-(mvz)/%C3%BCber-das-ambulanzzentrum/index.html", "/kliniken-institute/zentren/ambulanzzentrum-medizinisches-versorgungszentrum-(mvz)/%C3%BCber-das-ambulanzzentrum/gesch%C3%A4ftsf%C3%BChrung/index.html", "/kliniken-institute/zentren/ambulanzzentrum-medizinisches-versorgungszentrum-(mvz)/%C3%BCber-das-ambulanzzentrum/zahlen-fakten/index.html", "/kliniken-institute/zentren/ambulanzzentrum-medizinisches-versorgungszentrum-(mvz)/%C3%BCber-das-ambulanzzentrum/forschung/index.html", "/kliniken-institute/zentren/ambulanzzentrum-medizinisches-versorgungszentrum-(mvz)/fachbereiche/index.html", "/kliniken-institute/zentren/brustzentrum/index.html", "/kliniken-institute/zentren/brustzentrum/%C3%BCber-das-zentrum/index.html", "/kliniken-institute/zentren/brustzentrum/%C3%BCber-das-zentrum/aktuelles/index.html", "/kliniken-institute/zentren/brustzentrum/%C3%BCber-das-zentrum/team/index.html", "/kliniken-institute/zentren/brustzentrum/%C3%BCber-das-zentrum/netzwerk/index.html", "/kliniken-institute/zentren/brustzentrum/%C3%BCber-das-zentrum/zahlen-fakten/index.html", "/kliniken-institute/zentren/brustzentrum/behandlungsangebot/index.html", "/kliniken-institute/zentren/brustzentrum/behandlungsangebot/anschlusstherapie/index.html", "/kliniken-institute/zentren/brustzentrum/behandlungsangebot/therapiebegleitende-angebote/index.html", "/kliniken-institute/zentren/brustzentrum/behandlungsangebot/selbsthilfegruppen/index.html", "/kliniken-institute/zentren/brustzentrum/behandlungsangebot/rehabilitation/index.html", "/kliniken-institute/zentren/brustzentrum/sprechstunden/index.html", "/kliniken-institute/zentren/brustzentrum/sprechstunden/brustsprechstunde/index.html", "/kliniken-institute/zentren/brustzentrum/sprechstunden/famili%C3%A4rer-brust-eierstockkrebs/index.html", "/kliniken-institute/zentren/brustzentrum/aufnahme/index.html", "/kliniken-institute/zentren/brustzentrum/aufenthalt/index.html", "/kliniken-institute/zentren/brustzentrum/nachsorge/index.html", "/kliniken-institute/zentren/brustzentrum/forschung/index.html", "/kliniken-institute/zentren/brustzentrum/forschung/arbeitsgruppen/index.html", "/kliniken-institute/zentren/brustzentrum/forschung/studien/index.html", "/kliniken-institute/zentren/brustzentrum/forschung/publikationen/index.html", "/kliniken-institute/zentren/brustzentrum/kooperationspartner/index.html", "/kliniken-institute/zentren/brustzentrum/spende/index.html", "/kliniken-institute/zentren/das-kinder-uke/index.html", "/kliniken-institute/zentren/das-kinder-uke/medizinische-angebote/index.html", "/kliniken-institute/zentren/das-kinder-uke/einladende-raeume/index.html", "/kliniken-institute/zentren/das-kinder-uke/rund-um-die-hainbuche/index.html", "/kliniken-institute/zentren/das-kinder-uke/geschichten-aus-dem-klinikalltag/index.html", "/kliniken-institute/zentren/das-kinder-uke/das-kinder-uke-in-zahlen/index.html", "/kliniken-institute/zentren/das-kinder-uke/arbeiten-im-kinder-uke/index.html", "/kliniken-institute/zentren/das-kinder-uke/die-foerderer-%E2%80%93-spenden/index.html", "/kliniken-institute/zentren/das-kinder-uke/f%C3%BCr-zuweisende-aerzte/index.html", "/kliniken-institute/zentren/das-kinder-uke/kontakt/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/aktuelles/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/team/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/netzwerk/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/zahlen-fakten/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/newsletter/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/ueber-das-zentrum/geschichte/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/therapieangebot/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/sprechstunden/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/aufnahme/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/aufenthalt/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/forschung/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/forschung/projekte/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/forschung/publikationen/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/aus-und-weiterbildung/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/aus-und-weiterbildung/fortbildung/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/aus-und-weiterbildung/studierende/index.html", "/kliniken-institute/zentren/deutsches-zentrum-fuer-suchtfragen-des-kindes-und-jugendalters/unterst%C3%BCtzung-spende/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/%C3%BCber-das-zentrum/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/team/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/erkrankungsspektrum/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/nachsorge/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/therapieverfahren/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/tumorkonferenz/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/untersuchungsmethoden/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/behandlungsangebot/zweitmeinung/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/sprechstunden/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/klinische-studien/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/forschung/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/veranstaltungen/index.html", "/kliniken-institute/zentren/hauttumorzentrum-hamburg/kontakt/index.html", "/kliniken-institute/zentren/kopf-neurozentrum/index.html", "/kliniken-institute/zentren/kopf-neurozentrum/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/kopf-neurozentrum/zentrumsleitung/index.html", "/kliniken-institute/zentren/leberzentrum/index.html", "/kliniken-institute/zentren/leberzentrum/leistungen-im-ueberblick/index.html", "/kliniken-institute/zentren/leberzentrum/mitglieder-des-leberzentrums/index.html", "/kliniken-institute/zentren/leberzentrum/das-interdisziplinaere-leberzentrums-board/index.html", "/kliniken-institute/zentren/leberzentrum/f%C3%BCr-zuweisende/index.html", "/kliniken-institute/zentren/leberzentrum/qualitaetssicherung/index.html", "/kliniken-institute/zentren/leberzentrum/team/index.html", "/kliniken-institute/zentren/leberzentrum/forschung/index.html", "/kliniken-institute/zentren/leberzentrum/kontakt/index.html", "/kliniken-institute/zentren/onkologisches-zentrum/index.html", "/kliniken-institute/zentren/onkologisches-zentrum/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/onkologisches-zentrum/zentrumsleitung/index.html", "/kliniken-institute/zentren/uke-athleticum/index.html", "/kliniken-institute/zentren/uke-athleticum/%C3%BCber-das-athleticum/index.html", "/kliniken-institute/zentren/uke-athleticum/%C3%BCber-das-athleticum/aktuelles/index.html", "/kliniken-institute/zentren/uke-athleticum/%C3%BCber-das-athleticum/team/index.html", "/kliniken-institute/zentren/uke-athleticum/diagnostik/index.html", "/kliniken-institute/zentren/uke-athleticum/therapien/index.html", "/kliniken-institute/zentren/uke-athleticum/kooperationen/index.html", "/kliniken-institute/zentren/uke-athleticum/forschung/index.html", "/kliniken-institute/zentren/uke-athleticum/forschung/studien/index.html", "/kliniken-institute/zentren/uke-athleticum/forschung/arbeitsgruppen/index.html", "/kliniken-institute/zentren/uke-athleticum/athleticum-am-volkspark/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/ueber-das-centrum/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/ueber-das-centrum/aktuelles/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/ueber-das-centrum/team/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/ueber-das-centrum/netzwerk/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/ueber-das-centrum/geschichte/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/behandlungsangebot/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/forschung/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/f%C3%BCr-zuweisende-aerzte/index.html", "/kliniken-institute/zentren/martin-zeitz-centrum/kompetenzcentren/index.html", "/kliniken-institute/zentren/perinatalzentrum/index.html", "/kliniken-institute/zentren/perinatalzentrum/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/perinatalzentrum/ueber-das-zentrum/team/index.html", "/kliniken-institute/zentren/perinatalzentrum/ueber-das-zentrum/zahlen-fakten/index.html", "/kliniken-institute/zentren/perinatalzentrum/ueber-das-zentrum/downloads/index.html", "/kliniken-institute/zentren/perinatalzentrum/unsere-angebote/index.html", "/kliniken-institute/zentren/speiseroehrenzentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/aktuelles/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/organigramm/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/team/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/organkrebszentren/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/patientenbeirat-forschung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/patientenkompetenzzentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/veranstaltungen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/zahlen-fakten/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/%C3%BCber-das-tumorzentrum/aus-und-weiterbildung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/netzwerkarbeit/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/mitglieder-im-uke/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/krankenh%C3%A4user/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/facharztpraxen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/selbsthilfegruppen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/palliativ-versorgung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/forschungseinrichtungen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/kooperationen/gesundheitskiosk/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/allgemeine-sprechstunde/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/gastrointestinale-tumoren/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/heredit%C3%A4re-tumoren/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/komplement%C3%A4rmedizin/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/lebertumoren-metastasen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/palliativmedizin/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/sarkomzentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/sprechstunden/leben-nach-krebs/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/therapie/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/zweitmeinung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/therapiebegleitende-angebote/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/ucch-lotsendienst/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/personalisierte-krebsmedizin/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/leben-nach-krebs/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/behandlungsangebot/ambulante-spezialfach%C3%A4rztliche-versorgung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/nachsorge/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/fr%C3%BCherkennung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/langzeitnebenwirkungen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/lebensstil/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/psychosoziales/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/leben-nach-krebs/junge-erwachsene-care-for-caya/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/forschungsprogramme/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/core-facilities/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/biobank/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/veranstaltungen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/hamburg-school-of-oncology/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/grk-innovative-technologien/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/forschung/publikationen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/ueber-uns/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/forschungsschwerpunkt/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/ausschreibungen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/aktuelles/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/gefoerderte-wissenschaftler/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/weiterbildung-karriere/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/netzwerk/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/mildred-scheel-nachwuchszentrum/nuetzliches-wissenswertes/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/epidemiologie-tumordokumentation/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/epidemiologie-tumordokumentation/klinisches-krebsregister/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/epidemiologie-tumordokumentation/genetische-tumorepidemiologie/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/epidemiologie-tumordokumentation/ethik-recht/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/epidemiologie-tumordokumentation/onkologische-versorgungsforschung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/f%C3%BCr-zuweisende-%C3%A4rzte/tumorboards/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/f%C3%BCr-zuweisende-%C3%A4rzte/patientenanmeldung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/studien/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/pr%C3%A4vention-und-bildung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/pr%C3%A4vention-und-bildung/pr%C3%A4vention/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/pr%C3%A4vention-und-bildung/bildungsma%C3%9Fnahmen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/pr%C3%A4vention-und-bildung/digitale-kultur-und-literaturempfehlung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-cancer-center-hamburg-(ucch)/spende/index.html", "/kliniken-institute/zentren/universitaeres-cardiac-arrest-center-hamburg-(ucach)/index.html", "/kliniken-institute/zentren/universitaeres-gesichtsschmerzzentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/zentrumsleitung/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/kardiologie/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/herz-und-gefaesschirurgie/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/gefae%C3%9Fmedizin/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/kinderherzmedizin-und-emah/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/deutsches-aortenzentrum-hamburg/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/patientenkoordination/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/kliniken-fachbereiche/stationen-funktionsbereiche/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/behandlungsangebote/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/%C3%BCber-das-zentrum/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/%C3%BCber-das-zentrum/news-presseberichte/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/%C3%BCber-das-zentrum/zahlen-fakten/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/veranstaltungen/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/herzjobs-wir-suchen-dich!/index.html", "/kliniken-institute/zentren/universit%C3%A4res-herzzentrum-(uhz)/f%C3%B6rderverein/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/ueber-das-centrum/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/ueber-das-centrum/aktuelles/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/ueber-das-centrum/patientenbeirat/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-erwachsenen/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-erwachsenen/lebertransplantation-erwachsene/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-erwachsenen/nierentransplantation-erwachsene/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-erwachsenen/bauchspeicheldr%C3%BCsentransplantation-erwachsene/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-erwachsenen/herztransplantation-erwachsene/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-erwachsenen/lungentransplantation-erwachsene/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-kindern/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-kindern/herztransplantation-kinder/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-kindern/nierentransplantation-kinder/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantation-bei-kindern/lebertransplantation-kinder/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/transplantationskoordination/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/lebendspende/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/sprechstunden/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/infothek-f%C3%BCr-patient-innen/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/aufenthalt/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/zentren/universitaeres-transplantations-centrum/kooperationspartner/index.html", "/kliniken-institute/zentren/universitaeres-zentrum-fuer-muskuloskelettale-medizin/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/ueber-das-zentrum/team/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/behandlungsangebot/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/sprechstunden/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/fuer-zuweisende-aerzte/studien/index.html", "/kliniken-institute/zentren/viszeralonkologisches-zentrum/forschung/index.html", "/kliniken-institute/zentren/wirbelsaeulenzentrum/index.html", "/kliniken-institute/zentren/wirbelsaeulenzentrum/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/wirbelsaeulenzentrum/ueber-das-zentrum/aktuelles/index.html", "/kliniken-institute/zentren/wirbelsaeulenzentrum/ueber-das-zentrum/netzwerk/index.html", "/kliniken-institute/zentren/wirbelsaeulenzentrum/zentrumsleitung/index.html", "/kliniken-institute/zentren/wirbelsaeulenzentrum/behandlungsangebot/index.html", "/kliniken-institute/zentren/zentrum-fuer-anaesthesiologie-und-intensivmedizin/index.html", "/kliniken-institute/zentren/zentrum-fuer-anaesthesiologie-und-intensivmedizin/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-anaesthesiologie-und-intensivmedizin/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-diagnostik/index.html", "/kliniken-institute/zentren/zentrum-fuer-diagnostik/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-diagnostik/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-diagnostik/dienstleistungen/index.html", "/kliniken-institute/zentren/zentrum-fuer-diagnostik/dienstleistungen/coall-studie/index.html", "/kliniken-institute/zentren/zentrum-fuer-diagnostik/dienstleistungen/zentrale-probenentnahme/index.html", "/kliniken-institute/zentren/zentrum-fuer-experimentelle-medizin/index.html", "/kliniken-institute/zentren/zentrum-fuer-experimentelle-medizin/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-experimentelle-medizin/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-geburtshilfe-kinder-jugendmedizin/index.html", "/kliniken-institute/zentren/zentrum-fuer-geburtshilfe-kinder-jugendmedizin/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-geburtshilfe-kinder-jugendmedizin/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-innere-medizin/index.html", "/kliniken-institute/zentren/zentrum-fuer-innere-medizin/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-innere-medizin/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/ueber-das-zentrum/aktuelles/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/ueber-das-zentrum/veranstaltungen/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/ueber-das-zentrum/geschichte/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/entwicklungsneurophysiologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/molekulare-neurogenetik/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/medizinische-systembiologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/molekulare-und-zellul%C3%A4re-kognition/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/neuroimmunologie-und-multiple-sklerose-(inims)/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/synaptische-physiologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/systemimmunologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/emeritusgruppe-biosynthese-neuraler-strukturen/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/emeritusgruppe-zellbiochemie-und-klinische-neurobiologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/molekulare-neuroonkologische-pathologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/neuronale-und-zellul%C3%A4re-signaltransduktion/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/synaptische-informationsverarbeitung/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/verhaltensbiologie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/forschungsgruppen/gastgruppen/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/zmnh-core-facilities/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/zmnh-core-facilities/bioanalytik/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/zmnh-core-facilities/morphologie-und-elektronenmikroskopie/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/zmnh-core-facilities/transgene-m%C3%A4use/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/zmnh-core-facilities/it-service-entwicklung/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/publikationen/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/lehre/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/lehre/aufbaustudium-molekularbiologie-(asmb)/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/lehre/zmnh-doktorandenprogramm/index.html", "/kliniken-institute/zentren/zentrum-f%C3%BCr-molekulare-neurobiologie-(zmnh)/kontakt/index.html", "/kliniken-institute/zentren/zentrum-fuer-operative-medizin/index.html", "/kliniken-institute/zentren/zentrum-fuer-operative-medizin/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-operative-medizin/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-psychosoziale-medizin/index.html", "/kliniken-institute/zentren/zentrum-fuer-psychosoziale-medizin/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-psychosoziale-medizin/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-radiologie-und-endoskopie/index.html", "/kliniken-institute/zentren/zentrum-fuer-radiologie-und-endoskopie/ueber-das-zentrum/index.html", "/kliniken-institute/zentren/zentrum-fuer-radiologie-und-endoskopie/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-zahn-mund-kieferheilkunde-(zmk)/index.html", "/kliniken-institute/zentren/zentrum-fuer-zahn-mund-kieferheilkunde-(zmk)/behandlung/index.html", "/kliniken-institute/zentren/zentrum-fuer-zahn-mund-kieferheilkunde-(zmk)/behandlung-durch-studierende/index.html", "/kliniken-institute/zentren/zentrum-fuer-zahn-mund-kieferheilkunde-(zmk)/zentrumsleitung/index.html", "/kliniken-institute/zentren/zentrum-fuer-zahn-mund-kieferheilkunde-(zmk)/kontakt_zmk/index.html", "/kliniken-institute/institute/index.html", "/kliniken-institute/institute/allgemeinmedizin/index.html", "/kliniken-institute/institute/allgemeinmedizin/aktuelles/index.html", "/kliniken-institute/institute/allgemeinmedizin/team/index.html", "/kliniken-institute/institute/allgemeinmedizin/behandlungsangebot/index.html", "/kliniken-institute/institute/allgemeinmedizin/forschung/index.html", "/kliniken-institute/institute/allgemeinmedizin/forschung/kopal/index.html", "/kliniken-institute/institute/allgemeinmedizin/publikationen/index.html", "/kliniken-institute/institute/allgemeinmedizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/allgemeinmedizin/kompetenzzentrum/index.html", "/kliniken-institute/institute/allgemeinmedizin/geschichte/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/team/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/forschung/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/forschung/projekte_institut_anatomie/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/publikationen/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/dienstleistungen/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/geschichte/index.html", "/kliniken-institute/institute/anatomie-und-experimentelle-morphologie/k%C3%B6rperspende/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/aktuelles/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/team/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/sfb-erc/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/graduiertenkollegs/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/forschergruppen/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/publikationen/index.html", "/kliniken-institute/institute/biochemie-und-molekulare-zellbiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/aktuelles/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/forschung/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/forschung/drittmittel/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/forschung/laborausstattung-methoden/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/team/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/team/alumni/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/f%C3%BCr-bewerber/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/publikationen/index.html", "/kliniken-institute/institute/biochemie-und-signaltransduktion/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/computational-neuroscience/index.html", "/kliniken-institute/institute/computational-neuroscience/aktuelles/index.html", "/kliniken-institute/institute/computational-neuroscience/team/index.html", "/kliniken-institute/institute/computational-neuroscience/forschung/index.html", "/kliniken-institute/institute/computational-neuroscience/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/computational-neuroscience/forschung/drittmittel/index.html", "/kliniken-institute/institute/computational-neuroscience/forschung/nachwuchsgruppen/index.html", "/kliniken-institute/institute/computational-neuroscience/publikationen/index.html", "/kliniken-institute/institute/computational-neuroscience/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/aktuelles/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/team/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/forschung/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/forschung/drittmittel/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/publikationen/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/experimentelle-herz-kreislaufforschung/geschichte/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/aktuelles/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/team/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/forschung/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/forschung/sfb-erc/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/forschung/graduiertenkollegs/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/publikationen/index.html", "/kliniken-institute/institute/experimentelle-immunologie-und-hepatologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/aktuelles/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/team/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/sfb-erc/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/graduiertenkollegs/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/forschung/studien/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/publikationen/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/dienstleistungen/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/experimentelle-pharmakologie-und-toxikologie/geschichte/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/aktuelles/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/team/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/forschung/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/forschung/drittmittel/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/publikationen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/klinische-ethik/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/dienstleistungen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/geschichte/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/objektsammlungen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/dokumentensammlung/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/team/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/geschichte/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/fritz-schumacher-haus/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/foerderer/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/raumvermietung/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/presseberichte/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/%C3%BCber-das-museum/pressematerial/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/ausstellungen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/ausstellungen/sonderausstellungen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/ausstellungen/r%C3%BCckblende/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/ausstellungen/lern-und-gedenkort/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/besucherinformationen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/veranstaltungsprogramm/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/veranstaltungsprogramm/veranstaltungen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/veranstaltungsprogramm/tagungen-workshops/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/fuehrungen-gruppenangebote/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/fuehrungen-gruppenangebote/fuehrungen-f%C3%BCr-erwachsene/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/fuehrungen-gruppenangebote/angebote-f%C3%BCr-schulklassen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/forschung/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/forschung/projekte/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/forschung/promotionen/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/newsletteranmeldung/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/spenden/index.html", "/kliniken-institute/institute/geschichte-und-ethik-der-medizin/medizinhistorisches-museum/institut-f%C3%BCr-geschichte-und-ethik-der-medizin/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/aktuelles/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/team/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/arbeitsgruppe-studiendaten-i/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/arbeitsgruppe-studiendaten-ii/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/arbeitsgruppe-studiendaten-iii/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/arbeitsgruppe-routinedaten-i/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/arbeitsgruppe-routinedaten-ii/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/forschung/professur-interdisziplinaere-versorgungsepidemiologie/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/publikationen/index.html", "/kliniken-institute/institute/gesundheits%C3%B6konomie-und-versorgungsforschung/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/humangenetik/index.html", "/kliniken-institute/institute/humangenetik/aktuelles/index.html", "/kliniken-institute/institute/humangenetik/team/index.html", "/kliniken-institute/institute/humangenetik/forschung/index.html", "/kliniken-institute/institute/humangenetik/forschung/ag-kubisch/index.html", "/kliniken-institute/institute/humangenetik/forschung/ag-kutsche/index.html", "/kliniken-institute/institute/humangenetik/forschung/ag-kindler/index.html", "/kliniken-institute/institute/humangenetik/forschung/ag-kreienkamp/index.html", "/kliniken-institute/institute/humangenetik/forschung/ag-rosenberger/index.html", "/kliniken-institute/institute/humangenetik/forschung/ag-schlein/index.html", "/kliniken-institute/institute/humangenetik/publikationen/index.html", "/kliniken-institute/institute/humangenetik/dienstleistungen/index.html", "/kliniken-institute/institute/humangenetik/dienstleistungen/humangenetische-beratung/index.html", "/kliniken-institute/institute/humangenetik/dienstleistungen/molekulargenetische-diagnostik/index.html", "/kliniken-institute/institute/humangenetik/dienstleistungen/zytogenetische-diagnostik/index.html", "/kliniken-institute/institute/humangenetik/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/humangenetik/geschichte/index.html", "/kliniken-institute/institute/immunologie/index.html", "/kliniken-institute/institute/immunologie/aktuelles/index.html", "/kliniken-institute/institute/immunologie/team/index.html", "/kliniken-institute/institute/immunologie/forschung/index.html", "/kliniken-institute/institute/immunologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/immunologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/immunologie/forschung/fuer-bewerber/index.html", "/kliniken-institute/institute/immunologie/diagnostiklabor/index.html", "/kliniken-institute/institute/immunologie/publikationen/index.html", "/kliniken-institute/institute/immunologie/dienstleistungen/index.html", "/kliniken-institute/institute/immunologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/immunologie/geschichte/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/aktuelles/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/team/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/klinische-studien/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/forschung/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/assoziierte-arbeitsgruppen/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/publikationen/index.html", "/kliniken-institute/institute/infektionsforschung-und-impfstoffentwicklung/drittmittel-und-kooperationen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/aktuelles/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/team/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/sfb-erc-eu/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/graduiertenkollegs/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/forschung/studien/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/publikationen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/dienstleistungen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/pharmakologie-f%C3%BCr-pharmazeuten/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/geschichte/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/%C3%BCber-decipher/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/kooperationspartner-netzwerk/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/projekte/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/veranstaltungen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/publikationen/index.html", "/kliniken-institute/institute/klinische-pharmakologie-und-toxiologie/decipher_de/kontakt/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/aktuelles/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/team/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/diagnostik/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/forschung/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/forschung/drittmittel/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/forschung/studien/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/forschung/spende/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/klinische-chemie-und-laboratoriumsmedizin/publikationen/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/aktuelles/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/veranstaltungen/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/team/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/forschung/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/forschung/statistische-methodenforschung/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/forschung/epidemiologische-forschung/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/forschung/klinische-forschung/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/forschung/versorgungsforschung/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/publikationen/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/fuer-uke-angeh%C3%B6rige/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/fuer-an-kooperation-interessierte/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/fuer-studierende-am-uke/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/fuer-studierende-anderer-f%C3%A4cher/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/fuer-bewerbende/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/wir-bieten-an/fuer-die-presse/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/geschichte/index.html", "/kliniken-institute/institute/medizinische-biometrie-und-epidemiologie/kontakt/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/aktuelles/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/team/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/forschung/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/forschung/publikationen/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/dienstleistungen/index.html", "/kliniken-institute/institute/medizinische-mikrobiologie-virologie-und-hygiene/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/medizinische-soziologie/index.html", "/kliniken-institute/institute/medizinische-soziologie/team/index.html", "/kliniken-institute/institute/medizinische-soziologie/forschung/index.html", "/kliniken-institute/institute/medizinische-soziologie/publikationen/index.html", "/kliniken-institute/institute/medizinische-soziologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/medizinische-soziologie/geschichte/index.html", "/kliniken-institute/institute/medizinische-systembiologie/index.html", "/kliniken-institute/institute/medizinische-systembiologie/aktuelles/index.html", "/kliniken-institute/institute/medizinische-systembiologie/team/index.html", "/kliniken-institute/institute/medizinische-systembiologie/forschung/index.html", "/kliniken-institute/institute/medizinische-systembiologie/f%C3%B6rderung/index.html", "/kliniken-institute/institute/medizinische-systembiologie/publikationen/index.html", "/kliniken-institute/institute/medizinische-systembiologie/lehrangebote-fortbildung/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/aktuelles/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/team/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/forschung/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/publikationen/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/behandlungsangebot/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/behandlungsangebot/anmeldung/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/behandlungsangebot/spezialambulanz-f%C3%BCr-psychoonkologie/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/behandlungsangebot/spezialambulanz-f%C3%BCr-transplantationspsychologie/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/behandlungsangebot/spezialambulanz-f%C3%BCr-hiv-aids-und-angeh%C3%B6rige/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/lehrangebote-fortbildungen/studierende/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/lehrangebote-fortbildungen/mitarbeitende/index.html", "/kliniken-institute/institute/institut-und-poliklinik-f%C3%BCr-medizinische-psychologie/geschichte/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/aktuelles/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/team/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/forschung/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/f%C3%B6rderung/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/publikationen/index.html", "/kliniken-institute/institute/molekulare-neurogenetik/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/molekulare-und-zellul%C3%A4re-kognition/index.html", "/kliniken-institute/institute/molekulare-und-zellul%C3%A4re-kognition/team/index.html", "/kliniken-institute/institute/molekulare-und-zellul%C3%A4re-kognition/forschung/index.html", "/kliniken-institute/institute/molekulare-und-zellul%C3%A4re-kognition/f%C3%B6rderung/index.html", "/kliniken-institute/institute/molekulare-und-zellul%C3%A4re-kognition/publikationen/index.html", "/kliniken-institute/institute/molekulare-und-zellul%C3%A4re-kognition/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/neuroanatomie/index.html", "/kliniken-institute/institute/neuroanatomie/aktuelles/index.html", "/kliniken-institute/institute/neuroanatomie/team/index.html", "/kliniken-institute/institute/neuroanatomie/forschung/index.html", "/kliniken-institute/institute/neuroanatomie/publikationen/index.html", "/kliniken-institute/institute/neuroanatomie/anatomische-sammlung/index.html", "/kliniken-institute/institute/neuroanatomie/lehre-der-humanmedizin-und-zahnmedizin/index.html", "/kliniken-institute/institute/neuroanatomie/geschichte/index.html", "/kliniken-institute/institute/neuroanatomie/k%C3%B6rperspende/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/aktuelles/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/team/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/forschung/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/publikationen/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/f%C3%B6rderung/index.html", "/kliniken-institute/institute/neuroimmunologie-und-mutiple-sklerose-(inims)/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/neuropathologie/index.html", "/kliniken-institute/institute/neuropathologie/aktuelles/index.html", "/kliniken-institute/institute/neuropathologie/team/index.html", "/kliniken-institute/institute/neuropathologie/bereiche/index.html", "/kliniken-institute/institute/neuropathologie/forschung/index.html", "/kliniken-institute/institute/neuropathologie/publikationen/index.html", "/kliniken-institute/institute/neuropathologie/dienstleistungen/index.html", "/kliniken-institute/institute/neuropathologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/neuropathologie/geschichte/index.html", "/kliniken-institute/institute/neuropathologie/spenden/index.html", "/kliniken-institute/institute/neurophysiologie-und-pathophysiologie/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/aktuelles/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/team/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/sprechstunden/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/behandlungsangebot/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/forschung/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/publikationen/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/national-center-for-bone-diseases/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/national-center-for-bone-diseases/national-bone-board/index.html", "/kliniken-institute/institute/osteologie-und-biomechanik/national-center-for-bone-diseases/hypophosphatasie-spezialambulanz/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/aktuelles/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/team/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/diagnostik/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/f%C3%BCr-einsender/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/forschung/index.html", "/kliniken-institute/institute/pathologie-mit-sektionen-molekularpathologie-und-zytopathologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/ueber-das-institut/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/ueber-das-institut/geschichte/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/behandlungsangebot/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/tiefenpsychologisch-fundierte-psychotherapie/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/tiefenpsychologisch-fundierte-psychotherapie/ausbildung-psychologinnen-psychologen/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/tiefenpsychologisch-fundierte-psychotherapie/weiterbildung-%C3%A4rztinnen-%C3%A4rzte/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/tiefenpsychologisch-fundierte-psychotherapie/studienplan/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/tiefenpsychologisch-fundierte-psychotherapie/vorlesungen/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/verhaltenstherapie/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/verhaltenstherapie/ausbildung-psychologinnen-psychologen/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/verhaltenstherapie/weiterbildung-aerztinnen-aerzte/index.html", "/kliniken-institute/institute/institut-fuer-psychotherapie/verhaltenstherapie/studienplan/index.html", "/kliniken-institute/institute/rechtsmedizin/index.html", "/kliniken-institute/institute/rechtsmedizin/aktuelles/index.html", "/kliniken-institute/institute/rechtsmedizin/team/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/forensische-pathologie/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/forensische-bildgebung/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/klinische-rechtsmedizin-untersuchungsstelle/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/forensische-molekularbiologie/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/forensische-toxikologie-alkohologie/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/postmortale-gewebespende/index.html", "/kliniken-institute/institute/rechtsmedizin/bereiche/lions-hornhautbank-am-uke/index.html", "/kliniken-institute/institute/rechtsmedizin/forschung/index.html", "/kliniken-institute/institute/rechtsmedizin/foerderprojekte/index.html", "/kliniken-institute/institute/rechtsmedizin/publikationen/index.html", "/kliniken-institute/institute/rechtsmedizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/rechtsmedizin/dienstleistungen/index.html", "/kliniken-institute/institute/rechtsmedizin/dienstleistungen/privatpersonen/index.html", "/kliniken-institute/institute/rechtsmedizin/dienstleistungen/polizei-justiz-beh%C3%B6rden/index.html", "/kliniken-institute/institute/rechtsmedizin/dienstleistungen/%C3%A4rzte-krankenh%C3%A4user/index.html", "/kliniken-institute/institute/rechtsmedizin/dienstleistungen/versicherungen-berufsgenossenschaften/index.html", "/kliniken-institute/institute/rechtsmedizin/akkreditierung/index.html", "/kliniken-institute/institute/rechtsmedizin/geschichte/index.html", "/kliniken-institute/institute/rechtsmedizin/forex-gutachten-gmbh/index.html", "/kliniken-institute/institute/rechtsmedizin/kontakt/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/ueber-uns/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/ueber-uns/team/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/ueber-uns/geschichte/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/behandlungsangebot/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/behandlungsangebot/spezialambulanz/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/behandlungsangebot/praeventionsambulanz/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/behandlungsangebot/privatambulanz/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/aktuelles/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/uebersicht-messzeitpunkte/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/studienteilnahme-fuer-cis-personen/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/team-kontakt/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/stimmen-zur-studie/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/projekte/transgender-in-transition/studienergebnisse/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/forschung/publikationen/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/gutachten/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/lehrangebote-fortbildungen/fortbildung/index.html", "/kliniken-institute/institute/institut-fuer-sexualforschung-sexualmedizin-und-forensische-psychiatrie/lehrangebote-fortbildungen/studierende/index.html", "/kliniken-institute/institute/struktur-und-systembiologie/index.html", "/kliniken-institute/institute/struktur-und-systembiologie/aktuelles/index.html", "/kliniken-institute/institute/struktur-und-systembiologie/team/index.html", "/kliniken-institute/institute/struktur-und-systembiologie/forschung/index.html", "/kliniken-institute/institute/struktur-und-systembiologie/publikationen/index.html", "/kliniken-institute/institute/struktur-und-systembiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/synaptische-physiologie/index.html", "/kliniken-institute/institute/synaptische-physiologie/aktuelles/index.html", "/kliniken-institute/institute/synaptische-physiologie/team/index.html", "/kliniken-institute/institute/synaptische-physiologie/forschung/index.html", "/kliniken-institute/institute/synaptische-physiologie/f%C3%B6rderung/index.html", "/kliniken-institute/institute/synaptische-physiologie/publikationen/index.html", "/kliniken-institute/institute/synaptische-physiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/aktuelles/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/team/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/neurowissenschaftliches-mrt/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/kopfschmerzambulanz/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/sfb-erc/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/graduiertenkollegs/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/forschergruppen/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/drittmittel/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/publikationen/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/systemische-neurowissenschaften/geschichte/index.html", "/kliniken-institute/institute/transfusionsmedizin/index.html", "/kliniken-institute/institute/transfusionsmedizin/aktuelles/index.html", "/kliniken-institute/institute/transfusionsmedizin/team/index.html", "/kliniken-institute/institute/transfusionsmedizin/forschung/index.html", "/kliniken-institute/institute/transfusionsmedizin/publikationen/index.html", "/kliniken-institute/institute/transfusionsmedizin/dienstleistungen/index.html", "/kliniken-institute/institute/transfusionsmedizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/transfusionsmedizin/blutspende/index.html", "/kliniken-institute/institute/transfusionsmedizin/hamburger-stammzelldatei/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/aktuelles/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/team/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/forschung/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/forschung/sfb-erc/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/forschung/studien/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/publikationen/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/patienteninformation/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/geschichte/index.html", "/kliniken-institute/institute/institut-f%C3%BCr-tumorbiologie/european-liquid-biopsy-society-elbs/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/%C3%BCber-das-institut/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/%C3%BCber-das-institut/team/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/%C3%BCber-das-institut/zahlen-fakten/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/%C3%BCber-das-institut/kooperationen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/%C3%BCber-das-institut/jahresberichte/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/aktuelles/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/cedef/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/cvderm/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/cetraf/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/cvcare/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/cvvasc/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/cwc/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/chcr/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/hche/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/bereiche/hebpraev/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/behandlungsangebot/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/sprechstunden/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/dienstleistungen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/forschung/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/forschung/forschungsgruppen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/forschung/drittmittel/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/forschung/studien/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/forschung/stipendien/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/publikationen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/lehrangebote-fortbildungen/studentische-lehre/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/lehrangebote-fortbildungen/trainee-programm/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/lehrangebote-fortbildungen/second-track-pr%C3%A4ventive-medizin/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/lehrangebote-fortbildungen/hospitationen-praktika/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/lehrangebote-fortbildungen/facharztweiterbildung/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/veranstaltungen/index.html", "/kliniken-institute/institute/versorgungsforschung-in-der-dermatologie-und-bei-pflegeberufen/veranstaltungen/veranstaltungsberichte/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/team/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/forschung/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/forschung/sfb-erc/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/forschung/forschergruppen/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/forschung/drittmittel/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/publikationen/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/zellul%C3%A4re-und-integrative-physiologie/geschichte/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/aktuelles/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/team/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/forschung/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/forschung/arbeitsgruppen/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/forschung/drittmittel/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/forschung/studien/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/publikationen/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/arbeitsmedizinische-diagnostik/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/labor/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/dienstleistungen/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/geschichte/index.html", "/kliniken-institute/institute/universit%C3%A4tsprofessur-f%C3%BCr-arbeitsmedizin/kontakt/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/aktuelles/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/team/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/forschung/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/foerderung/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/publikationen/index.html", "/kliniken-institute/institute/seniorgruppe-biosynthese-neuraler-strukturen/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/seniorgruppe-zellbiochemie-und-klinische-neurobiologie/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/aktuelles/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/team/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/forschung/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/f%C3%B6rderung/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/publikationen/index.html", "/kliniken-institute/institute/forschungsgruppe-neuronale-und-zellul%C3%A4re-signaltransduktion/lehrangebote-und-fortbildungen/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/aktuelles/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/team/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/forschung/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/f%C3%B6rderung/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/publikationen/index.html", "/kliniken-institute/institute/forschungsgruppe-verhaltensbiologie/lehrangebote-und-fortbildungen/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/aktuelles/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/team/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/forschung/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/f%C3%B6rderung/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/publikationen/index.html", "/kliniken-institute/institute/institut-fuer-entwicklungsneurophysiologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/aktuelles/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/team/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/forschung/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/f%C3%B6rderung/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/publikationen/index.html", "/kliniken-institute/institute/forschungsgruppe-synaptische-informationsverarbeitung/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/systemimmunologie/index.html", "/kliniken-institute/institute/systemimmunologie/aktuelles/index.html", "/kliniken-institute/institute/systemimmunologie/team/index.html", "/kliniken-institute/institute/systemimmunologie/forschung/index.html", "/kliniken-institute/institute/systemimmunologie/f%C3%B6rderung/index.html", "/kliniken-institute/institute/systemimmunologie/publikationen/index.html", "/kliniken-institute/institute/systemimmunologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/team/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/applied-ai/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/agile-systems/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/clinical-analytics/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/secondary-use-of-healthcare-data/index.html", "/kliniken-institute/institute/institut-fuer-angewandte-medizininformatik/kontakt/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/aktuelles/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/team/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/forschung/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/foerderung/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/publikationen/index.html", "/kliniken-institute/institute/forschungsgruppe-molekulare-neuroonkologische-pathologie/lehrangebote-und-fortbildungen/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/aktuelles/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/team/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/forschung/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/f%C3%B6rderung/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/publikationen/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/lehrangebote-und-fortbildungen/index.html", "/kliniken-institute/institute/exzellenz-abteilung-f%C3%BCr-neurale-informationsverarbeitung/stellenangebote/index.html", "/kliniken-institute/kliniken/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/aktuelles/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/behandlungsangebot/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/sprechstunden/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aufnahme/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aufenthalt/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/ern-rare-liver/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/studien/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/publikationen/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/pj-studenten/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/aktuelles/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/behandlungsangebot/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/behandlungsangebot/musiktherapie/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/behandlungsangebot/patienteninformationen/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/palliativmedizin/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/sprechstunden/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aufnahme/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aufenthalt/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rzte/laborleistungen/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/forschung/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/forschung/studien/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/forschung/publikationen/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/ii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/aktuelles/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/behandlungsangebot/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/behandlungsangebot/nephrologie/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/behandlungsangebot/rheumatologie/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/behandlungsangebot/endokrinologie/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/sprechstunden/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aufenthalt/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/forschung/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/studienarbeit/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/iii.-medizinische-klinik-und-poliklinik/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/%C3%BCber-die-klinik/veranstaltungen/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/sprechstunden/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/kontakt/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/haeufige-fragen-faq/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/haeufige-fragen-faq/bauchspeicheldr%C3%BCsentumor/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/haeufige-fragen-faq/zysten-der-bauchspeicheldr%C3%BCse/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/haeufige-fragen-faq/bauchspeicheldr%C3%BCsenentz%C3%BCndung/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/eras-programm/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/pankreas/welt-pankreaskrebstag/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/behandlungsangebot/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/behandlungsangebot/weichteil-und-knochentumore-der-extremitaeten/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/behandlungsangebot/weichteiltumore-des-bauchraums/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/behandlungsangebot/eras-programm/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/team/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/aufenthalt/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/forschung-und-studien/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/behandlungsangebot/sarkom/kontakt-und-zuweisende/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/forschung/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/forschung/studien/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/allgemein-viszeral-und-thoraxchirurgie/viszeralonkologisches-zentrum/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/%C3%BCber-die-klinik/veranstaltungen/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/behandlungsangebot/an%C3%A4sthesie/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/behandlungsangebot/an%C3%A4sthesie/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/behandlungsangebot/intensivmedizin/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/behandlungsangebot/notfallmedizin/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/behandlungsangebot/schmerzmedizin/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/behandlungsangebot/palliativmedizin/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/sprechstunden/pr%C3%A4medikationsambulanz/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/sprechstunden/pr%C3%A4medikationsambulanz/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/sprechstunden/schmerzambulanz/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/forschung/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/forschung/projekte/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/forschung/doktoranden/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/studierende/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/lehr-simulationszentrum/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/an%C3%A4sthesiologie/anaesthesie-pflege/index.html", "/kliniken-institute/kliniken/augenheilkunde/index.html", "/kliniken-institute/kliniken/augenheilkunde/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/augenheilkunde/%C3%BCber-die-klinik/unser-team/index.html", "/kliniken-institute/kliniken/augenheilkunde/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/katarakt-grauer-star/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/glaukom-gruener-star/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/hornhauterkrankungen-und-refraktive-chirurgie/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/netzhauterkrankungen/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/plastische-und-aesthetische-chirurgie/index.html", "/kliniken-institute/kliniken/augenheilkunde/unser-behandlungsspektrum/ple-und-orthoptik/index.html", "/kliniken-institute/kliniken/augenheilkunde/unsere-ambulanzen/index.html", "/kliniken-institute/kliniken/augenheilkunde/station%C3%A4re-aufnahme/index.html", "/kliniken-institute/kliniken/augenheilkunde/station%C3%A4rer-aufenthalt/index.html", "/kliniken-institute/kliniken/augenheilkunde/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/augenheilkunde/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/augendiagnostik-center-(adc)/index.html", "/kliniken-institute/kliniken/augenheilkunde/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/unsere-studien/index.html", "/kliniken-institute/kliniken/augenheilkunde/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/telemedizin/index.html", "/kliniken-institute/kliniken/augenheilkunde/forschung-studien/index.html", "/kliniken-institute/kliniken/augenheilkunde/forschung-studien/grundlagenforschung/index.html", "/kliniken-institute/kliniken/augenheilkunde/forschung-studien/klinische-forschung-(studien)/index.html", "/kliniken-institute/kliniken/augenheilkunde/forschung-studien/ag-imaging-ai/index.html", "/kliniken-institute/kliniken/augenheilkunde/forschung-studien/publikationen/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/veranstaltungen-fortbildungen/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/augenheilkunde/veranstaltungen-aus-weiterbildung/berufsfachschule-orthoptik/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/%C3%BCber-die-klinik/aktuelles-veranstaltungen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/sprechstunden/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/sprechstunden/tumorerkrankungen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/sprechstunden/operative-dermatologie/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/sprechstunden/allergie/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/sprechstunden/%C3%A4sthetische-dermatologie/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/aufenthalt/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/aufenthalt/aufnahme/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/f%C3%BCr-zuweisende-%C3%A4rzte/patientenanmeldung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/hauttumorzentrum/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/forschung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/forschung/studien/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/forschung/dienstleistungen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/tagesklinik/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/tagesklinik/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/laserabteilung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/laserabteilung/team/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/laserabteilung/behandlungsangebot/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/laserabteilung/sprechstunden/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/laserabteilung/forschung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/laserabteilung/h%C3%A4ufig-gestellte-fragen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/%C3%BCber-die-abteilung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/%C3%BCber-die-abteilung/team/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/sprechstunden/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aufnahme/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/f%C3%BCr-zuweisende-%C3%A4rzte/laborleistungen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/f%C3%BCr-zuweisende-%C3%A4rzte/telemedizin/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/forschung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/forschung/studien/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/dermatologie-und-venerologie/ergaenzende-schwerpunkte/andrologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/bild-ausgabe/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/anmeldung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/telemedizin/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/forschung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/forschung/publikationen/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/forschung/sektion-f%C3%BCr-experimentelle-biomedizinische-bildgebung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/forschung/studienkoordination/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/%C3%BCber-die-abteilung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/%C3%BCber-die-abteilung/team/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/bild-ausgabe/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/aufnahme/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-kinderradiologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/abteilung-f%C3%BCr-nuklearmedizin/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/%C3%BCber-das-centrum/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/%C3%BCber-das-centrum/team/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/behandlungsangebot/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/forschung/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/forschung/publikationen/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/forschung/studien/index.html", "/kliniken-institute/kliniken/diagnostische-und-interventionelle-radiologie-und-nuklearmedizin/centrum-f%C3%BCr-interdisziplin%C3%A4re-herzbildgebung/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/sprechstunden/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/aufnahme/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/aufenthalt/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/forschung/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/forschung/projekte-studien/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/forschung/publikationen/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/ttts-informationen/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/infoabend/index.html", "/kliniken-institute/kliniken/geburtshilfe-und-pr%C3%A4natalmedizin/infoabend/faq-h%C3%A4ufige-fragen/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/ueber-die-klinik/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/ueber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/sprechstunden/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/aufnahme/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/aufenthalt/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/forschung/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/forschung/publikationen/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/forschung/ag-translationale-wundforschung/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/aus-weiterbildung/studentische-lehre/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/gefae%C3%9Fmedizin/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/sprechstunden/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/aufnahme/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/aufenthalt/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/forschung/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/forschung/projekte/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/forschung/forschungslabor/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/gyn%C3%A4kologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/%C3%BCber-die-klinik/veranstaltungen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/otologie/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/cochlea-implantat-versorgung/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/rhinologie/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/kopf-hals-onkologie/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/schlafbezogene-atmungsst%C3%B6rungen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/erkrankungen-der-speicheldr%C3%BCsen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/sch%C3%A4delbasischirurgie/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/behandlungsangebot/kehlkopf-und-luftr%C3%B6hrenverengungen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/spezialsprechstunden/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aufnahme/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aufenthalt/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/forschung/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/forschung/klinische-studien/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/forschung/publikationen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aus-weiterbildung/pj-ausbildung/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aus-weiterbildung/famulaturen/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/hals-nasen-und-ohrenheilkunde/kontakt/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/forschung/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/forschung/schwerpunkte/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/herz-und-gef%C3%A4%C3%9Fchirurgie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/behandlungsangebot/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/sprechstunden/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/aufnahme/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/forschung/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/forschung/studien/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/forschung/publikationen/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/h%C3%B6r-stimm-und-sprachheilkunde/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/intensivmedizin/index.html", "/kliniken-institute/kliniken/intensivmedizin/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/intensivmedizin/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/intensivmedizin/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/intensivmedizin/%C3%BCber-die-klinik/spenden/index.html", "/kliniken-institute/kliniken/intensivmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/intensivmedizin/f%C3%BCr-patienten/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivstationen/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/stationen-intensivpflegepool/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/anp-(advanced-nursing-practice)/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/atmungstherapie/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/bzhi/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/klinische-ethik/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/pflegeentwicklung-kim/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/praxisanleitung/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/pflegeexpertinnen/wundmanagement/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/fort-und-weiterbildung/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/betriebliches-gesundheitsmanagement/index.html", "/kliniken-institute/kliniken/intensivmedizin/intensivpflege/hospitation/index.html", "/kliniken-institute/kliniken/intensivmedizin/forschung/index.html", "/kliniken-institute/kliniken/intensivmedizin/forschung/klinische-forschung/index.html", "/kliniken-institute/kliniken/intensivmedizin/forschung/studienzentrale/index.html", "/kliniken-institute/kliniken/intensivmedizin/forschung/publikationen/index.html", "/kliniken-institute/kliniken/intensivmedizin/forschung/forschungsf%C3%B6rderung/index.html", "/kliniken-institute/kliniken/intensivmedizin/lehrangebote-fortbildungen/index.html", "/kliniken-institute/kliniken/intensivmedizin/lehrangebote-fortbildungen/fortbildung/index.html", "/kliniken-institute/kliniken/intensivmedizin/lehrangebote-fortbildungen/pflege/index.html", "/kliniken-institute/kliniken/intensivmedizin/ards-zentrum/index.html", "/kliniken-institute/kliniken/intensivmedizin/universit%C3%A4res-cardiac-arrest-center-hamburg-(ucach)/index.html", "/kliniken-institute/kliniken/intensivmedizin/teleintensiv/index.html", "/kliniken-institute/kliniken/intensivmedizin/teleintensiv/startseite/index.html", "/kliniken-institute/kliniken/intensivmedizin/teleintensiv/ablauf-tele-intensivmedizin/index.html", "/kliniken-institute/kliniken/intensivmedizin/teleintensiv/spezial-kompetenzen/index.html", "/kliniken-institute/kliniken/intensivmedizin/teleintensiv/kontakt/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/sprechstunden/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/aufnahme/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/aufenthalt/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/f%C3%BCr-zuweisende-%C3%A4rzte/telemedizin/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/forschung/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/forschung/studien/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/interdisziplin%C3%A4re-endoskopie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/kardiologie/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/bereich-herzinsuffizienz/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/bereich-kardiovaskul%C3%A4re-bildgebung/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/bereich-rhythmologie/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/bereich-strukturelle-herzerkrankungen/index.html", "/kliniken-institute/kliniken/kardiologie/ueber-die-klinik/bereich-vaskul%C3%A4re-herzerkrankungen/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/chest-pain-unit/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/device-therapie/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/genetisch-bedingte-herzerkrankungen/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/herzinsuffizienz-transplantation/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/komplexe-therapien/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/interventionelle-elektrophysiologie/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/interventionelle-kardiologie/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/kardiale-bildgebung/index.html", "/kliniken-institute/kliniken/kardiologie/behandlungsangebot/strukturelle-herzerkrankungen/index.html", "/kliniken-institute/kliniken/kardiologie/sprechstunden/index.html", "/kliniken-institute/kliniken/kardiologie/f%C3%BCr-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/kardiologie/patienteninformationen/index.html", "/kliniken-institute/kliniken/kardiologie/forschung/index.html", "/kliniken-institute/kliniken/kardiologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/kardiologie/forschung/klinische-forschung/index.html", "/kliniken-institute/kliniken/kardiologie/forschung/molekulare-forschung/index.html", "/kliniken-institute/kliniken/kardiologie/forschung/klinisch-epidemiologische-forschung/index.html", "/kliniken-institute/kliniken/kardiologie/forschung/studienzentrale/index.html", "/kliniken-institute/kliniken/kardiologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/sprechstunden/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/aufnahme/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/forschung/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/forschung/posterbeitr%C3%A4ge/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/forschung/publikationen/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/kieferorthop%C3%A4die/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/kinderchirurgie/index.html", "/kliniken-institute/kliniken/kinderchirurgie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/kinderchirurgie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kinderchirurgie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/kinderchirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kinderchirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/kinderchirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/kinderchirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/klinische-studien/index.html", "/kliniken-institute/kliniken/kinderchirurgie/forschung/index.html", "/kliniken-institute/kliniken/kinderchirurgie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/kinderchirurgie/forschung/studien/index.html", "/kliniken-institute/kliniken/kinderchirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/kinderchirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/ueber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/ueber-die-klinik/bereich-kinderkardiolgie/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/ueber-die-klinik/bereich-kinderherzchirurgie-chirurgie-angeborener-herzfehler/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/ueber-die-klinik/bereich-erwachsene-mit-angeborenem-herzfehler-emah/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/asd-vorhofseptumdefekt/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/avsd-atrioventrikulaerer-septumdefekt/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/hypoplastisches-linksherzsyndrom-und-norwood-op/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/ista-aortenisthmusstenose/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/pda-persistierender-ductus-arteriosus/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/tac-truncus-arteriosus-communis/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/tga-transposition-gro%C3%9Fer-arterien/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/tof-fallotsche-tetralogie/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/behandlungsangebot/vsd-ventrikulaerer-septumdefekt/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/sprechstunden/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/patienteninformationen/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/patienteninformationen/anreise-ihr-weg-zu-uns/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/patienteninformationen/behandlungsablauf/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/patienteninformationen/familienbaumhaus/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/forschung/index.html", "/kliniken-institute/kliniken/kinderherzmedizin-und-emah/aus-und-weiterbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/ped-ucit-aktivit%C3%A4ten/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/ped-ucit-aktivit%C3%A4ten/aktuelle-studien/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/ped-ucit-aktivit%C3%A4ten/zugelassene-therapien/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/ped-ucit-aktivit%C3%A4ten/dienstleistungen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/aktuelles/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/behandlungsangebot/centrum-fuer-innovative-therapien-cit/kontakt/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/sprechstunden/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aufnahme/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aufenthalt/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/%C3%BCber-die-sektion/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/%C3%BCber-die-sektion/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/behandlungsangebot/neonatologie/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/behandlungsangebot/p%C3%A4diatrische-intensivmedizin/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/aufenthalt/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/forschung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/aus-weiterbildung/lehrvideos/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/paediatrische-intensivmedizin/informationen-f%C3%BCr-med.-fachpersonal/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/neonatologie-und-p%C3%A4diatrische-intensivmedizin/paediatrische-intensivmedizin/informationen-f%C3%BCr-med.-fachpersonal/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/kinderschutzgruppe/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/laborleistungen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/forschung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/forschung/publikationen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/kinder-und-jugendmedizin/unser-neubau-kinder-uke/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/transgender/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/behandlungsangebot/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/termine-kontakt/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/haeufige-fragen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/kooperation/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/sprechstunden/geschlechtsidentit%C3%A4t-transgender/forschung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aufnahme/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aufenthalt/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/child-public-health/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/child-public-health/aktuelles/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/child-public-health/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/child-public-health/forschung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/child-public-health/lehrangebote/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/child-public-health/publikationen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/aktuelles/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/team/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/ambulanz/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/forschung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/publikationen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/arbeitsgruppen/familienforschung-und-psychotherapie/lehrangebot/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/studien/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/forschung/publikationen/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/kinder-und-jugendpsychiatrie-psychotherapie-und-psychosomatik/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/%C3%BCber-die-abteilung/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/%C3%BCber-die-abteilung/team/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/%C3%BCber-die-abteilung/zahlen-fakten/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/behandlungsangebot/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/behandlungsangebot/erektionsstoerungen/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/behandlungsangebot/refertilisierung/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/behandlungsangebot/ejakulations-und-orgasmusstoerungen/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/behandlungsangebot/hormone-f%C3%BCr-den-mann/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/behandlungsangebot/praevention-und-vorsorge/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/sprechstunde/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/aufnahme/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/aufenthalt/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/forschung/index.html", "/kliniken-institute/kliniken/m%C3%A4nnergesundheit/aus-und-weiterbildung/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/behandlungsangebot/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/f%C3%BCr-patienten/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/aus-und-weiterbildung/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/fortbildung-kongresse/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/forschung/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/forschung/publikationen/index.html", "/kliniken-institute/kliniken/mund-kiefer-und-gesichtschirurgie-(mkg)/spenden/index.html", "/kliniken-institute/kliniken/neurochirurgie/index.html", "/kliniken-institute/kliniken/neurochirurgie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/neurochirurgie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/neurochirurgie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/neurochirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/neurochirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/neurochirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/neurochirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/neurochirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/neurochirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/labor-f%C3%BCr-hirntumorbiologie/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/studien/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/forschungsf%C3%B6rderung/index.html", "/kliniken-institute/kliniken/neurochirurgie/forschung/immuno-oncology-symposium/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/neurochirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/neurologie/index.html", "/kliniken-institute/kliniken/neurologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/neurologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/neurologie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/neurologie/%C3%BCber-die-klinik/geschichte/index.html", "/kliniken-institute/kliniken/neurologie/%C3%BCber-die-klinik/aktuelles-veranstaltungen/index.html", "/kliniken-institute/kliniken/neurologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/neurologie/sprechstunden-tageskliniken/index.html", "/kliniken-institute/kliniken/neurologie/aufnahme/index.html", "/kliniken-institute/kliniken/neurologie/aufenthalt/index.html", "/kliniken-institute/kliniken/neurologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/neurologie/f%C3%BCr-zuweisende-%C3%A4rzte/telemedizin/index.html", "/kliniken-institute/kliniken/neurologie/forschung/index.html", "/kliniken-institute/kliniken/neurologie/forschung/studien/index.html", "/kliniken-institute/kliniken/neurologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/pj-ler-famulanten/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/studierende/index.html", "/kliniken-institute/kliniken/neurologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/aneurysma/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/schlaganfall/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/verengung-der-gef%C3%A4%C3%9Fe/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/angiome-avm/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/mrt/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/ct/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/behandlungsangebot/angiographie/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/anmeldung/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/f%C3%BCr-zuweisende-%C3%A4rzte/telemedizin/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/forschung/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/forschung/studien/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/forschung/publikationen/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/studierende/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/neuroradiologische-diagnostik-und-intervention/aus-weiterbildung/mtra/index.html", "/kliniken-institute/kliniken/nuklearmedizin/index.html", "/kliniken-institute/kliniken/nuklearmedizin/%C3%BCber-die-abteilung/index.html", "/kliniken-institute/kliniken/nuklearmedizin/%C3%BCber-die-abteilung/team/index.html", "/kliniken-institute/kliniken/nuklearmedizin/%C3%BCber-die-abteilung/zahlen-fakten/index.html", "/kliniken-institute/kliniken/nuklearmedizin/behandlungsangebot/index.html", "/kliniken-institute/kliniken/nuklearmedizin/sprechstunden/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aufnahme/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aufenthalt/index.html", "/kliniken-institute/kliniken/nuklearmedizin/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/nuklearmedizin/forschung/index.html", "/kliniken-institute/kliniken/nuklearmedizin/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/nuklearmedizin/forschung/publikationen/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/nuklearmedizin/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/behandlungsangebot/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/sprechstunden/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aufnahme/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aufenthalt/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/forschung/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/forschung/publikationen/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/orthop%C3%A4die/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/%C3%BCber-die-klinik/aktuelles/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/%C3%BCber-die-klinik/kooperationspartner/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sprechstunden/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aufnahme/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aufenthalt/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/kinderschutzgruppe/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/%C3%BCber-die-sektion/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/%C3%BCber-die-sektion/team/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/%C3%BCber-die-sektion/zahlen-fakten/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/sprechstunden/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/aufnahme/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/aufenthalt/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/f%C3%BCr-zuweisende-%C3%A4rzte/laborleistungen/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/forschung/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/sektion-p%C3%A4diatrische-stammzelltransplantation-und-immunologie/unterstuetzung-und-spende/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/haemostaseologie-%E2%80%93-haemophiliezentrum/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/f%C3%BCr-zuweisende-%C3%A4rzte/laborleistungen/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/forschung/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/p%C3%A4diatrische-h%C3%A4matologie-und-onkologie/spende/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/%C3%BCber-die-abteilung/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/%C3%BCber-die-abteilung/team/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/rekonstruktive-chirurgie/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/%C3%A4sthetische-chirurgie/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/brustchirurgie/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/adipositas-chirurgie/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/fazialisparese-gesichtslaehmung/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/behandlungsangebot/geschlechtsangleichende-operationen/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/plastische-rekonstruktive-und-%C3%A4sthetische-chirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/%C3%BCber-die-klinik/aktuelles/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/%C3%BCber-die-klinik/veranstaltungen-kongresse/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/%C3%BCber-die-klinik/pflege/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/%C3%BCber-die-klinik/kooperationspartner/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/privatambulanz/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/notfallbehandlung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/fr%C3%BCherkennung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/ambulante-angebote/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/tagesklinische-angebote/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/station%C3%A4re-angebote/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/integrierte-versorgung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/weitere-angebote/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/behandlungsangebot/f%C3%BCr-angeh%C3%B6rige/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/therapiewegweiser/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aufnahme-aufenthalt/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/forschung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/forschung/verb%C3%BCnde/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/forschung/doktoranden/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/studierende-der-humanmedizin/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/studierende-der-psychologie/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/psychotherapeuten-in-ausbildung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/weiterbildung/index.html", "/kliniken-institute/kliniken/psychiatrie-und-psychotherapie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/ueber-die-klinik/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/ueber-die-klinik/geschichte/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/ueber-die-klinik/veranstaltungen-kongresse/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/ueber-die-klinik/anmeldung-newsletter/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/ambulantes-behandlungsangebot/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/tagesklinik/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/stationaeres-behandlungsangebot/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/selbstmanagement/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/nachwuchsgruppen/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/verbuende/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/projekt-1/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/projekt-2/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/projekt-3/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/projekt-4/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/projekt-5/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/projekt-6/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/forschung/studien/for-5211-somacross/z-projekt/index.html", "/kliniken-institute/kliniken/psychosomatische-medizin-und-psychotherapie/lehrangebote/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/%C3%BCber-die-klinik/aktuelles/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/behandlungsangebot/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/fuer-patienten/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/fuer-patienten/sprechstunden/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/fuer-patienten/aufnahme/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/fuer-patienten/aufenthalt/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/fuer-patienten/patienten-berichten/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/fuer-patienten/hilfreiche-links/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/forschung/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/forschung/studien/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/forschung/publikationen/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/stammzelltransplantation/unterstuetzung-spenden/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/aufenthalt/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlentherapie-radioonkologie/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/medizinphysik/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/team/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/ag1-homologe-rekombination/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/ag2-dsb-reparatur-in-tumoren/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/ag3-signaltransduktion/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/ag4-strahlenbiologie-von-kopf-hals-tumoren/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/ag5-strahlenbiologie-von-kindlichen-hirntumoren/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/projekte/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/projekte/bmbf-dsb-rep/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/publikationen/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/lehrangebote-fortbildungen/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/forschung/strahlenbiologie-experimentelle-radioonkologie/geschichte/index.html", "/kliniken-institute/kliniken/strahlentherapie-radioonkologie/lehre-fortbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/forschung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/%C3%BCber-die-abteilung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/%C3%BCber-die-abteilung/team/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/%C3%BCber-die-abteilung/zahlen-fakten/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/sprechstunde/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/forschung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/forschung/studien/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aus-und-weiterbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aus-und-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aus-und-weiterbildung/doktoranden/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aus-und-weiterbildung/pj-ler/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aus-und-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/unfall-hand-und-wiederherstellungschirurgie/wirbels%C3%A4ulenchirurgie/aus-und-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/urologie/index.html", "/kliniken-institute/kliniken/urologie/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/urologie/%C3%BCber-die-klinik/team/index.html", "/kliniken-institute/kliniken/urologie/%C3%BCber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/urologie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/urologie/sprechstunden/index.html", "/kliniken-institute/kliniken/urologie/aufnahme/index.html", "/kliniken-institute/kliniken/urologie/aufenthalt/index.html", "/kliniken-institute/kliniken/urologie/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/urologie/f%C3%BCr-zuweisende-%C3%A4rzte/studien/index.html", "/kliniken-institute/kliniken/urologie/forschung/index.html", "/kliniken-institute/kliniken/urologie/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/urologie/forschung/studien/index.html", "/kliniken-institute/kliniken/urologie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/urologie/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/urologie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/urologie/aus-weiterbildung/studierende/index.html", "/kliniken-institute/kliniken/urologie/aus-weiterbildung/fortbildung/index.html", "/kliniken-institute/kliniken/urologie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/urologie/spende/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/ueber-die-klinik/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/ueber-die-klinik/zahlen-fakten/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/behandlungsangebot/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/sprechstunden/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/aufnahme/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/aufenthalt/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/forschung/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/forschung/studien/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/forschung/publikationen/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/aus-weiterbildung/facharztweiterbildung/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/aus-weiterbildung/studenten/index.html", "/kliniken-institute/kliniken/klinik-fuer-viszerale-transplantationschirurgie/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/team/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/behandlungsangebot/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/sprechstunden/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/termin-besuch/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/forschung/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/forschung/studien-und-projekte/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/forschung/publikationen/index.html", "/kliniken-institute/kliniken/zahn%C3%A4rztliche-prothetik/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/ueber-die-klinik/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/ueber-die-klinik/team/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/behandlungsangebot/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/sprechstunden/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/fuer-zuweisende-aerzte/index.html", "/kliniken-institute/kliniken/parodontologie-praeventive-zahnmedizin-und-zahnerhaltung/aus-und-weiterbildung/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/%C3%BCber-die-zna/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/behandlungsangebot/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/f%C3%BCr-patienten/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/f%C3%BCr-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/f%C3%BCr-rettungsdienste/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/aus-weiterbildung/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/aus-weiterbildung/praktikanten/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/aus-weiterbildung/famulanten/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/aus-weiterbildung/pflege/index.html", "/kliniken-institute/kliniken/zentrale-notaufnahme/anfahrt-kontakt/index.html", "/kliniken-institute/kliniken/unfallchirurgie-und-orthopaedie/index.html", "/organisationsstruktur/index.html", "/organisationsstruktur/vorstand/index.html", "/organisationsstruktur/kuratorium/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/dekanat/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/fakultaetsservice-und-budget/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-akademische-verfahren/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-akademische-verfahren/promotionsverfahren/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-akademische-verfahren/phd-verfahren/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-forschung/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/qualitaetsmanagement-klinische-studien/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/clinical-trial-office/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/netzwerk-universitaetsmedizin/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/registrierung-klinische-studien/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/investigator-initiierte-trials/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-klinische-forschung-und-translation/kontakt-beratung/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/prodekanat-f%C3%BCr-lehre/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/team/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/aktuelles/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/geschlechtergerechte-sprache/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/gender/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/diversity/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/familie/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/f%C3%B6rderprogramme/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/geschichte/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/publikationen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/rechtliche-grundlagen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gleichstellungsreferat/rahel-liebesch%C3%BCtz-plaut-mentoringprogramm/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gremien-aussch%C3%BCsse/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gremien-aussch%C3%BCsse/fakult%C3%A4tsbeauftragte/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gremien-aussch%C3%BCsse/curriculumkommitees/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gremien-aussch%C3%BCsse/fakult%C3%A4tsrat-seine-aussch%C3%BCsse/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/gremien-aussch%C3%BCsse/wissenschaftliche-beir%C3%A4te/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/alumni/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/rechtliche-grundlagen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/%C3%A4rztliche-zentralbibliothek/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/medigate/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/ueber-uns/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/aktuelles/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierschutz/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierschutz/culture-of-care/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierschutz/haltung-der-tiere/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierschutz/informationen-f%C3%BCr-forschende/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierschutz/tierschutzma%C3%9Fnahmen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/qualifikation/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierexperimentelle-forschung/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierexperimentelle-forschung/forschungsvorhaben/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/tierexperimentelle-forschung/versuchstierzahlen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/3-r-forschung/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/3-r-forschung/replace-tierversuche-ersetzen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/3-r-forschung/reduce-tierversuche-reduzieren/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/3-r-forschung/refinement-in-der-tierhaltung/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/transparenzinitiative/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/forschungstierhaltung/kontakt/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/epidemiologisches-studienzentrum/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/epidemiologisches-studienzentrum/%C3%BCber-uns/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/epidemiologisches-studienzentrum/hchs/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/epidemiologisches-studienzentrum/nako/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/epidemiologisches-studienzentrum/h%C3%A4ufige-fragen-(faq)/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/epidemiologisches-studienzentrum/lehrangebote-fortbildungen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/voxel-man/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/voxel-man/team/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/voxel-man/publikationen/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/kindertagesst%C3%A4tte/index.html", "/organisationsstruktur/medizinische-fakult%C3%A4t/raumvermietung/index.html", "/organisationsstruktur/kollegium/index.html", "/organisationsstruktur/zentren/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/%C3%BCber-uns/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/magnet-krankenhaus/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/zentrumsleitungen/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/funktionsdienste/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/personalentwicklung-akademisierung/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/personalentwicklung-akademisierung/uke-kompetenzmodell/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/kooperationen-netzwerke/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflegeentwicklung-wissenschaft/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflegeentwicklung-wissenschaft/nursing-journal-club/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflegeentwicklung-wissenschaft/facharbeiten/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/drittmittelprojekte/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/drittmittelprojekte/pflashboard/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/einsatzbereiche/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/mzp-pflegepool/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/einarbeitung/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/pflegefachpersonen-aus-dem-ausland/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/fort-und-weiterbildung-studium/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/flexible-arbeitszeiten/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/verguetung/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/kinderbetreuung/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/wohnen-und-umzug/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-in-der-uke-pflege/bewerberberatung/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/arbeiten-5-0-pflege-gestalten/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/magnet-krankenhaus/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/magnet-krankenhaus/magnet4europe/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/magnet-krankenhaus/h%C3%A4ufig-gestellte-fragen-(faq)/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/pflegefachmann-frau/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/duales-studium-pflege/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/medizinische-fachangestellte-r/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/operationstechnische-assistenz/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/anaesthesietechnische-assistenz/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/medizinische-technologen-%E2%80%93-radiologie/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/medizinische-technologen-%E2%80%93-laboratoriumsanalytik/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/ausbildung-studium/weitere-ausbildungen-studieng%C3%A4nge-im-uke/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/hospitation/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/schuelerpraktikum/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/berufsorientierungspraktikum/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/pflegepraktikum-f%C3%BCr-medizinstudierende/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/pflichtpraktikum-weiterbildung-studium/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/hospitation-praktikum/fsj-bundesfreiwilligendienst/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/wissenschaft-akademisierung/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/wissenschaft-akademisierung/akademisierung-im-uke/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/wissenschaft-akademisierung/studierendenunterst%C3%BCtzung-f%C3%BCr-uke'ler/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/wissenschaft-akademisierung/uke-kompetenzmodell/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/wissenschaft-akademisierung/advanced-practice-nursing/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/direktion-f%C3%BCr-patienten-und-pflegemanagement/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/direktion-f%C3%BCr-patienten-und-pflegemanagement/team/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/direktion-f%C3%BCr-patienten-und-pflegemanagement/schwerpunktthemen/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/tag-der-pflegenden/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/tag-der-pflegenden/aktionstag-2023/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/tag-der-pflegenden/aktionstag-2022/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/f%C3%BCr-lieferanten/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/kontakt/strategischer-einkauf/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/einkauf/kontakt/operativer-dispositiver-einkauf/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/finanzen/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/finanzen/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/finanzen/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/finanzen/f%C3%BCr-patienten/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/finanzen/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/f%C3%B6rdererbetreuung-fundraising/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/f%C3%B6rdererbetreuung-fundraising/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/f%C3%B6rdererbetreuung-fundraising/testamentsspende/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/f%C3%B6rdererbetreuung-fundraising/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/f%C3%B6rdererbetreuung-fundraising/benefizlauf-2021/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/informationstechnologie/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/informationstechnologie/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/informationstechnologie/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/informationstechnologie/projekte/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/informationstechnologie/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/interne-revision/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/interne-revision/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/interne-revision/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/interne-revision/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/personal/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/personal/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/personal/%C3%BCber-uns/publikationen/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/personal/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/personal/karriere-im-uke/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/personal/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/projekt-und-changemanagement/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/projekt-und-changemanagement/ueber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/projekt-und-changemanagement/leistungen-im-ueberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/projekt-und-changemanagement/projekte/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/projekt-und-changemanagement/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/qualitaetsmanagement-patientensicherheit/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/qualitaetsmanagement-patientensicherheit/ueber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/qualitaetsmanagement-patientensicherheit/leistungen-im-ueberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/qualitaetsmanagement-patientensicherheit/projekte/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/qualitaetsmanagement-patientensicherheit/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/recht/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/recht/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/recht/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/recht/beihilfe/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/recht/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/sicherheit-compliance/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/sicherheit-compliance/ueber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/sicherheit-compliance/leistungen-im-ueberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/sicherheit-compliance/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/strategische-unternehmensentwicklung/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/strategische-unternehmensentwicklung/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/strategische-unternehmensentwicklung/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/strategische-unternehmensentwicklung/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/unternehmenskommunikation/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/unternehmenskommunikation/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/unternehmenskommunikation/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/unternehmenskommunikation/projekte/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/unternehmenskommunikation/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrale-entgeltabrechnung-und-patientenaufnahme/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrale-entgeltabrechnung-und-patientenaufnahme/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrale-entgeltabrechnung-und-patientenaufnahme/kontakt/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrales-controlling/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrales-controlling/%C3%BCber-uns/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrales-controlling/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrales-controlling/fuer-patienten/index.html", "/organisationsstruktur/gesch%C3%A4ftsbereiche/zentrales-controlling/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/aktuelles/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/aktuelles/abk-blog/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/aktuelles/abk-report/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/aktuelles/impulse/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/aktuelles/good-to-know/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/aktuelles/talent-campus/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/ausbildung/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/studium/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/praktikum/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/neue-mitarbeiterinnen-mitarbeiter/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/e-learning-it-training/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/ethik/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/fachweiterbildung/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/gesundheitsfoerderung-praevention/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/hygiene/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/klinische-forschung/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/kommunikation-persoenlichkeit/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/management-recht-ethik/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/patientenorientierung/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/pflege-therapie-forschung/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fort-weiterbildung/qualifizierung-fuer-mentoren/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fuehrung-karriere/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fuehrung-karriere/auswahlverfahren/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fuehrung-karriere/potenzialanalyse/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fuehrung-karriere/fuehrungstraining/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fuehrung-karriere/coaching-co/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/fuehrung-karriere/publikationen-vortraege/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/f%C3%BCr-zugewanderte-fachkraefte/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/f%C3%BCr-zugewanderte-fachkraefte/anpassungsqualifizierung-apq/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/f%C3%BCr-zugewanderte-fachkraefte/anpassungsqualifizierung-physiotherapie/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/f%C3%BCr-zugewanderte-fachkraefte/inga-pflege/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/weitere-leistungen/index.html", "/organisationsstruktur/zentrale-bereiche/uke-akademie-fuer-bildung-karriere/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/%C3%BCber-uns-apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/%C3%BCber-uns-apotheke/team_apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/%C3%BCber-uns-apotheke/zahlen-fakten-apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/%C3%BCber-uns-apotheke/self-assessment/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/%C3%BCber-uns-apotheke/auszeichnungen-preise/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/leistungen-im-%C3%BCberblick-apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/forschung-apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/aus-weiterbildung-apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/publikationen-apotheke/index.html", "/organisationsstruktur/zentrale-bereiche/apotheke/3d-druck-von-arzneimitteln/index.html", "/organisationsstruktur/zentrale-bereiche/baudienststelle/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/%C3%BCber-uns/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/%C3%BCber-uns/ansprechpartner/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/medien/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/medien/apps-und-mehr/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/medien/publikationen-am-uke/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/beratung-und-hilfe/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/dfg-publikationsfonds/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/uke-foerderung/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/open-access/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/rechtliche-informationen/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/publizieren/tools/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/beratung-hilfe/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/beratung-hilfe/online-statt-vor-ort/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/beratung-hilfe/kursangebote/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/beratung-hilfe/technik/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/beratung-hilfe/h%C3%A4ufige-fragen/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/elearning/mephisto-moodle/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/elearning/mephisto-moodle/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/elearning/imed-textbook/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/elearning/amboss/index.html", "/organisationsstruktur/zentrale-bereiche/%C3%A4rztliche-zentralbibliothek-(%C3%A4zb)/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/betriebs%C3%A4rztlicher-dienst/index.html", "/organisationsstruktur/zentrale-bereiche/betriebs%C3%A4rztlicher-dienst/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/zentrale-bereiche/betriebs%C3%A4rztlicher-dienst/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/international-office/index.html", "/organisationsstruktur/zentrale-bereiche/international-office/internationale-patienten/index.html", "/organisationsstruktur/zentrale-bereiche/international-office/internationale-patienten/ablaufverfahren/index.html", "/organisationsstruktur/zentrale-bereiche/international-office/dolmetscherdienst/index.html", "/organisationsstruktur/zentrale-bereiche/international-office/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/vorstandsbeauftragte-f%C3%BCr-klinische-ethik/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/klinisches-ethik-komitee-(kek)/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/klinisches-ethik-komitee-(kek)/mitglieder/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/klinisches-ethik-komitee-(kek)/satzung-gesch%C3%A4ftsordnung/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/ethische-fallberatung/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/patientenverfuegung-vorsorgevollmacht/index.html", "/organisationsstruktur/zentrale-bereiche/klinische-ethik-am-uke/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/krankenhaushygiene/index.html", "/organisationsstruktur/zentrale-bereiche/krankenhaushygiene/%C3%BCber-uns/index.html", "/organisationsstruktur/zentrale-bereiche/krankenhaushygiene/uke-hygienekampagne/index.html", "/organisationsstruktur/zentrale-bereiche/krankenhaushygiene/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/agg-beschwerdestelle/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/beauftragte-des-arbeitgebers-f%C3%BCr-die-belange-von-menschen-mit-behinderung/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/gleichstellungsbeauftragte-f%C3%BCr-das-nichtwissenschaftliche-personal/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/gleichstellungsbeauftragte-f%C3%BCr-das-wissenschaftliche-personal/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/inklusion-im-uke/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/integrationsbeauftragte-des-uke/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/psycho-soziale-beratung-und-suchtpr%C3%A4vention/index.html", "/organisationsstruktur/zentrale-bereiche/personalbeauftragte/schwerbehindertenvertretung-f%C3%BCr-das-nichtwissenschaftliche-personal/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/%C3%BCber-uns/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/praxis-fuer-physiotherapie/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/stationaere-leistungen/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/forschung/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/forschung/projekte/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/forschung/publikationen/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/forschung/team/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/spezialangebote/index.html", "/organisationsstruktur/zentrale-bereiche/physiotherapie/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/%C3%BCber-uns/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/sozialdienst/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/sozialdienst/leistungen/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/sozialdienst/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/sozialdienst-kinder-uke/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/sozialdienst-kinder-uke/kinderklinik/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/sozialdienst-kinder-uke/perinatalzentrum/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/psychosozialer-dienst/index.html", "/organisationsstruktur/zentrale-bereiche/sozial-pflegeberatung/pflegeexperte-demenz/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/ueber-uns/team/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/ueber-uns/team/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/ueber-uns/op-management/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/ueber-uns/op-pflege/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/ueber-uns/zahlen-fakten/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/bereiche/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/bereiche/sds-same-day-surgery/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-op-management/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-belegungsmanagement/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-belegungsmanagement/%C3%BCber-uns/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-belegungsmanagement/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/zentrale-bereiche/zentrales-belegungsmanagement/kontakt/index.html", "/organisationsstruktur/zentrale-bereiche/organspende/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/pflegepool/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/aushilfen-pflege/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/uke-studierendenpool/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/arbeitnehmerueberlassung/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/fsj-und-bfd/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/ehrenamt/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/aktuelles/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/team-mzp/index.html", "/organisationsstruktur/tochtergesellschaften/index.html", "/organisationsstruktur/tochtergesellschaften/altonaer-kinderkrankenhaus/index.html", "/organisationsstruktur/tochtergesellschaften/mvz-am-altonaer-kinderkrankenhaus/index.html", "/organisationsstruktur/tochtergesellschaften/ambulanzzentrum/index.html", "/organisationsstruktur/tochtergesellschaften/forex/index.html", "/organisationsstruktur/tochtergesellschaften/forex/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/tochtergesellschaften/forex/akkreditierung/index.html", "/organisationsstruktur/tochtergesellschaften/forex/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/%C3%BCber-das-janssen-haus/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/%C3%BCber-das-janssen-haus/team/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/%C3%BCber-das-janssen-haus/zahlen-fakten/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/%C3%BCber-das-janssen-haus/leitbild/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/behandlungsangebot/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/behandlungsangebot/tagesklinik/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/behandlungsangebot/ambulanz/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/aufnahme/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/aufenthalt/index.html", "/organisationsstruktur/tochtergesellschaften/janssen-haus/f%C3%BCr-zuweisende-%C3%A4rzte/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/zukunftsplan-2050/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/ausschreibungen/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/realisierte-neubauten/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/%C3%BCber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/neubauprojekte/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/%C3%BCber-das-baumanagement/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/infrastruktur-und-technische-instandhaltung/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/betriebsabteilungen/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/energiemanagement/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/liegenschaftsmanagement/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/die-kfe/nachhaltigkeit/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/jobs/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-facility-management-eppendorf/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/%C3%BCber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/die-kge-in-zahlen/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/patientenversorgung/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/health-kitchen/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/imbiss-fruits-und-mehr/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/event-catering/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/di%C3%A4t-und-ern%C3%A4hrungsberatung/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/jobs/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/unsere-%C3%B6ffnungszeiten/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-gastronomie-eppendorf/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-logistik-und-engineering/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-logistik-und-engineering/ueber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-logistik-und-engineering/team/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-logistik-und-engineering/leistungen-im-ueberblick/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-logistik-und-engineering/ausbildung-in-der-kle/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-logistik-und-engineering/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-service-eppendorf/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-service-eppendorf/%C3%BCber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-service-eppendorf/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-service-eppendorf/jobs/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-service-eppendorf/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-textilien-eppendorf/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-textilien-eppendorf/%C3%BCber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-textilien-eppendorf/leistungen-im-%C3%BCberblick/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-textilien-eppendorf/jobs/index.html", "/organisationsstruktur/tochtergesellschaften/klinik-textilien-eppendorf/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/martini-klinik/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/aktuelles/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ueber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ueber-uns/team/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ueber-uns/alumni/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ueber-uns/zahlen-fakten/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ueber-uns/leitbild-sls/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ueber-uns/beirat/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bta-ausbildung/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bta-ausbildung/ausbildung/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bta-ausbildung/labor/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bta-ausbildung/finanzierung/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bta-ausbildung/berufsinformation/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bta-ausbildung/schuelerpraktikum/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ausland/erasmus/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/ausland/erasmus/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/bewerbung/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/weiterbildung/index.html", "/organisationsstruktur/tochtergesellschaften/school-of-life-science/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/uke-consult-und-management-gmbh/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/%C3%BCber-uns/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/vertragsmanagement-drittmittel/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/kalkulation-controlling-klinischer-studien/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/nationale-forschungsf%C3%B6rderung/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/aktuelles-und-projekte/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/fuer-erfinder/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/fuer-gruender/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/fuer-firmen/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/patentstrategie/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/technologieangebote/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/technologietransfer/downloads/index.html", "/organisationsstruktur/tochtergesellschaften/medigate/kontakt/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/spenden/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/spenden/geldspende/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/spenden/spenden-im-trauerfall/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/spenden/spenden-statt-geschenke/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/spenden/benefizveranstaltung/index.html", "/organisationsstruktur/tochtergesellschaften/uke-ggmbh-foerdererbetreuung/kontakt/index.html", "/karriere/index.html", "/karriere/berufe-jobs-im-uke/index.html", "/karriere/berufe-jobs-im-uke/stellenangebote-und-bewerbung/index.html", "/karriere/berufe-jobs-im-uke/pflege-funktionsdienst/index.html", "/karriere/berufe-jobs-im-uke/gesundheitsfachberufe/index.html", "/karriere/berufe-jobs-im-uke/medizinisch-technische-berufe/index.html", "/karriere/berufe-jobs-im-uke/aerztlicher-dienst/index.html", "/karriere/berufe-jobs-im-uke/forschung-und-universitaere-lehre/index.html", "/karriere/berufe-jobs-im-uke/management-it-und-verwaltung/index.html", "/karriere/berufe-jobs-im-uke/therapeutische-und-paedagogische-berufe/index.html", "/karriere/berufe-jobs-im-uke/technik-service/index.html", "/karriere/berufe-jobs-im-uke/internationale-fachkraefte/index.html", "/karriere/ausbildung-und-studium/index.html", "/karriere/ausbildung-und-studium/pflegeberufe/index.html", "/karriere/ausbildung-und-studium/gesundheitsfachberufe/index.html", "/karriere/ausbildung-und-studium/naturwissenschaftliche-berufe/index.html", "/karriere/ausbildung-und-studium/technische-und-handwerkliche-berufe/index.html", "/karriere/ausbildung-und-studium/kaufmaennische-berufe/index.html", "/karriere/ausbildung-und-studium/studiengaenge-der-medizinischen-fakultaet/index.html", "/karriere/ausbildung-und-studium/berufsbegleitende-und-duale-studiengaenge/index.html", "/karriere/praktikum-fsj-und-bfd/index.html", "/karriere/praktikum-fsj-und-bfd/schueler-und-schuelerinnen-praktika/index.html", "/karriere/praktikum-fsj-und-bfd/kaufmaennische-praktika/index.html", "/karriere/praktikum-fsj-und-bfd/medizinische-praktika/index.html", "/karriere/praktikum-fsj-und-bfd/ausbildungspraktikum/index.html", "/karriere/praktikum-fsj-und-bfd/praktisches-jahr/index.html", "/karriere/praktikum-fsj-und-bfd/famulatur/index.html", "/karriere/praktikum-fsj-und-bfd/freiwilliges-soziales-jahr-und-bundesfreiwilligendienst/index.html", "/karriere/das-uke-als-arbeitgeber/index.html", "/karriere/das-uke-als-arbeitgeber/ueber-uns/index.html", "/karriere/das-uke-als-arbeitgeber/arbeitgebervorteile/index.html", "/karriere/das-uke-als-arbeitgeber/verguetung-tarifvertraege/index.html", "/karriere/das-uke-als-arbeitgeber/leitbild-und-fuehrungsverstaendnis/index.html", "/karriere/das-uke-als-arbeitgeber/nachhaltiges-klinikum/index.html", "/karriere/das-uke-als-arbeitgeber/diversity-im-uke/index.html", "/karriere/das-uke-als-arbeitgeber/leben-und-arbeiten-in-hamburg/index.html", "/karriere/aktuelles-zum-arbeitgeber/index.html", "/karriere/kontakt-ins-uke/index.html", "/karriere/haeufige-fragen-faq/index.html", "/karriere/unsere-klinikneubauten/index.html", "/index.html", "/kliniken-institute/index.html", "/kliniken-institute/kliniken/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/publikationen/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/%C3%BCber-die-klinik/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/behandlungsangebot/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/sprechstunden/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aufnahme/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aufenthalt/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/f%C3%BCr-zuweisende-%C3%A4rztinnen-%C3%A4rzte/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/arbeitsgruppen/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/studien/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/publikationen/index.html", "/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/aus-weiterbildung/index.html", "#top", "/allgemein/ueber-uns/index.html", "/organisationsstruktur/direktion-f%C3%BCr-patienten-pflegemanagement/pflege-im-uke/index.html", "/allgemein/presse/index.html", "/allgemein/mediathek/index.html", "/allgemein/international/index.html", "/allgemein/qualitaet/index.html", "https://www.uke-stiftung.de", "/allgemein/spenden/index.html", "/patienten-besucher/leichte-sprache/index.html", "/orientierung", "/allgemein/login/index.html", "javascript: window.print();", "mailto:?to=&body=http://www.uke.de/kliniken-institute/kliniken/i.-medizinische-klinik-und-poliklinik/forschung/publikationen/index.html&subject=Empfehlung", "#", "tel:112", "/kliniken-institute/kliniken/zentrale-notaufnahme/index.html", "tel:+494074100", "/kliniken-institute/kliniken/zentrale-notaufnahme/notfallpraxis-am-uke.html", "tel:+494074100", "/dateien/allgemeiner-bildpool/lageplan/lageplan_uke.pdf", "/orientierung", "https://www.uke.de/wegweiser/", "tel:+4940741055555", "/dateien/allgemeiner-bildpool/lageplan/lageplan_uke.pdf", "/dateien/allgemeiner-bildpool/lageplan/orientierungsplan-o10.pdf", "/patienten-besucher/anreise/index.html", "https://www.hvv.de/de", "https://stadtrad.hamburg.de/de", "https://www.hamburg-airport.de/de/", "/dateien/zielgruppen/patienten-angehoerige/dokumente/uke_patientenbroschuere_herzlich-willkommen_online.pdf", "/patienten-besucher/leichte-sprache/index.html", "/allgemein/mediathek/life-das-magazin-aus-dem-uke/index.html", "/corona-virus/index.html", "/kontakt-uke-hamburg-eppendorf.html", "https://pay.girocheckout.de/IgBGJ3-OKmFHK84idt05SQfWYHfhj9k4tST1seTOzD5BgXGu0CUAot7aXKE2TF6w1jpSt9zXxuk-ljG-xmqK9w", "https://www.uke-stiftung.de/spenden/", "/allgemein/spenden/index.html", "/kliniken-institute/institute/transfusionsmedizin/blutspende/index.html", "/organisationsstruktur/zentrale-bereiche/management-zeitarbeit-und-pool/ehrenamt/index.html", "tel:+494074100", "mailto:INFO@UKE.DE", "/allgemein/feedback-website-uke.html", "/allgemein/ueber-uns/index.html", "/allgemein/presse/index.html", "/allgemein/mediathek/index.html", "/karriere/index.html", "/allgemein/impressum/index.html", "/allgemein/datenschutzerklaerung-uke/index.html", "/allgemein/erklaerung-zur-barrierefreiheit.html", "https://www.instagram.com/uke_hamburg/", "https://twitter.com/UKEHamburg", "https://de.linkedin.com/company/universit-tsklinikum-hamburg-eppendorf", "https://www.xing.com/companies/universit%C3%A4tsklinikumhamburg-eppendorf%7Cuke", "https://www.youtube.com/user/UKEkanal", "/allgemein/sitemap/index.html", "/allgemein/datenschutzerklaerung-uke/datenschutzerklaerung-website/index.html", "/allgemein/impressum/index.html"]}